This	O
study	O
will	O
be	O
conducted	O
in	O
conjunction	O
with	O
two	O
parent	O
VA	O
Medical	O
Centers	O
within	O
a	O
single	O
region	O
or	O
Veterans	O
Integrated	O
Services	O
Network	O
(	O
VISN	O
)	O
in	O
the	O
southern	O
USA	O
.	O

Each	O
parent	O
VA	O
Medical	O
Center	O
will	O
identify	O
CBOCs	O
that	O
lack	O
on	O
-	O
site	O
full	O
-	O
time	O
psychiatrists	O
and	O
psychologists	O
or	O
report	O
a	O
major	O
unmet	O
need	O
for	O
PCMHI	O
services	O
.	O

Final	O
selection	O
will	O
be	O
based	O
on	O
recommendations	O
from	O
VISN	O
mental	O
health	O
leadership	O
and	O
VA	O
Medical	O
Center	O
leaders’	O
willingness	O
to	O
participate	O
.	O

All	O
sites	O
will	O
have	O
on	O
-	O
site	O
licensed	O
clinical	O
social	O
workers	O
(	O
LCSWs	O
)	O
,	O
mental	O
health	O
telephone	O
care	O
managers	O
,	O
and	O
interactive	O
video	O
equipment	O
available	O
.	O

The	O
study	O
will	O
provide	O
a	O
tele	O
-	O
psychologist	O
to	O
receive	O
warm	O
handoffs	O
and	O
provide	O
open	O
access	O
to	O
PCMHI	O
services	O
.	O

During	O
implementation	O
planning	O
(	O
see	O
below	O
)	O
,	O
we	O
will	O
work	O
with	O
mental	O
health	O
leaders	O
at	O
each	O
parent	O
facility	O
to	O
identify	O
psychiatrists	O
and	O
/	O
or	O
other	O
prescribing	O
providers	O
to	O
work	O
as	O
part	O
of	O
the	O
tele	O
-	O
PCMHI	O
team	O
.	O

Prior	O
to	O
adapting	O
PCMHI	O
,	O
we	O
will	O
conduct	O
an	O
expert	O
panel	O
comprised	O
of	O
clinical	O
providers	O
and	O
managers	O
who	O
are	O
applying	O
telemedicine	O
to	O
identify	O
core	O
components	O
of	O
a	O
tele	O
-	O
PCMHI	O
model	O
for	O
CBOCs	O
.	O

Next	O
,	O
we	O
will	O
create	O
an	O
implementation	O
checklist	O
for	O
clinics	O
to	O
use	O
to	O
develop	O
local	O
implementation	O
plans	O
.	O

This	O
checklist	O
will	O
be	O
reviewed	O
by	O
senior	O
VA	O
PCMHI	O
leadership	O
and	O
revised	O
based	O
on	O
their	O
input	O
to	O
ensure	O
that	O
it	O
addresses	O
national	O
VA	O
standards	O
.	O

The	O
CBOC	O
primary	O
care	O
director	O
at	O
each	O
site	O
will	O
be	O
asked	O
to	O
identify	O
a	O
champion	O
for	O
program	O
implementation	O
.	O

Local	O
champions	O
will	O
likely	O
be	O
mental	O
health	O
staff	O
who	O
will	O
be	O
involved	O
in	O
supporting	O
the	O
delivery	O
of	O
the	O
tele	O
-	O
PCMHI	O
model	O
or	O
supervisors	O
such	O
as	O
clinic	O
manager	O
.	O

As	O
part	O
of	O
initial	O
IF	O
activities	O
[	O
15	O
]	O
,	O
members	O
of	O
the	O
facilitation	O
team	O
will	O
conduct	O
pre	O
-	O
site	O
visit	O
phone	O
calls	O
with	O
the	O
CBOC	O
executive	O
director	O
,	O
on	O
-	O
site	O
mental	O
health	O
providers	O
,	O
and	O
the	O
site	O
champion	O
to	O
discuss	O
potential	O
barriers	O
to	O
and	O
facilitators	O
of	O
implementation	O
,	O
and	O
how	O
the	O
program	O
should	O
be	O
best	O
implemented	O
,	O
given	O
the	O
site’s	O
organizational	O
context	O
.	O

In	O
addition	O
,	O
we	O
will	O
request	O
that	O
each	O
informant	O
anonymously	O
complete	O
the	O
Organizational	O
Readiness	O
for	O
Change	O
scale	O
[	O
16	O
]	O
to	O
provide	O
additional	O
information	O
to	O
the	O
facilitators	O
and	O
the	O
site	O
champion	O
about	O
potential	O
implementation	O
barriers	O
and	O
facilitators	O
.	O

The	O
information	O
collected	O
in	O
the	O
pre	O
-	O
site	O
visit	O
phone	O
calls	O
will	O
be	O
reviewed	O
and	O
organized	O
for	O
each	O
site	O
to	O
inform	O
the	O
implementation	O
process	O
.	O

The	O
research	O
team	O
has	O
used	O
these	O
techniques	O
successfully	O
in	O
the	O
past	O
to	O
implement	O
innovations	O
in	O
VAs	O
[	O
17	O
]	O
.	O

The	O
two	O
facilitators	O
will	O
visit	O
each	O
CBOC	O
to	O
provide	O
academic	O
detailing	O
on	O
the	O
tele	O
-	O
PCMHI	O
model	O
and	O
meet	O
with	O
key	O
stakeholders	O
to	O
help	O
them	O
adapt	O
the	O
program	O
to	O
meet	O
local	O
needs	O
prior	O
to	O
implementation	O
.	O

Stakeholders	O
will	O
include	O
on	O
-	O
site	O
champions	O
,	O
mid	O
-	O
level	O
mental	O
health	O
providers	O
,	O
nursing	O
and	O
primary	O
care	O
leadership	O
as	O
well	O
as	O
off	O
-	O
site	O
telephone	O
nurse	O
care	O
managers	O
,	O
tele	O
-	O
psychiatrists	O
,	O
and	O
the	O
tele	O
-	O
PCMHI	O
clinician	O
.	O

The	O
IF	O
team	O
will	O
adapt	O
the	O
tele	O
-	O
PCMHI	O
model	O
for	O
each	O
participating	O
CBOC	O
while	O
retaining	O
the	O
core	O
elements	O
identified	O
by	O
the	O
expert	O
panel	O
.	O

The	O
tele	O
-	O
PCMHI	O
clinicians	O
will	O
be	O
trained	O
by	O
research	O
team	O
members	O
or	O
collaborators	O
with	O
expertise	O
in	O
PCMHI	O
.	O

Throughout	O
the	O
implementation	O
,	O
the	O
IF	O
team	O
will	O
continue	O
the	O
facilitation	O
activities	O
at	O
each	O
site	O
.	O

Throughout	O
all	O
phases	O
,	O
facilitators	O
will	O
track	O
their	O
activities	O
in	O
a	O
time	O
motion	O
tracking	O
log	O
[	O
17	O
]	O
and	O
report	O
on	O
key	O
facilitation	O
activities	O
and	O
implementation	O
status	O
during	O
implementation	O
team	O
meetings	O
,	O
and	O
participate	O
in	O
weekly	O
debriefing	O
calls	O
with	O
a	O
member	O
of	O
the	O
evaluation	O
team	O
(	O
qualitative	O
expert	O
and	O
implementation	O
scientist	O
,	O
KD	O
)	O
,	O
who	O
will	O
document	O
all	O
discussions	O
during	O
implementation	O
team	O
meetings	O
and	O
conduct	O
weekly	O
debriefings	O
with	O
the	O
facilitators	O
to	O
document	O
facilitation	O
and	O
adaptation	O

in	O
detail	O
.	O

The	O
proposed	O
study	O
is	O
a	O
hybrid	O
type	O
2	O
pragmatic	O
effectiveness	O
-	O
implementation	O
trial	O
of	O
tele	O
-	O
PCMHI	O
in	O
six	O
sites	O
over	O
24	O
months	O
.	O

Hybrid	O
type	O
2	O
research	O
trials	O
include	O
both	O
effectiveness	O
and	O
implementation	O
research	O
objectives	O
[	O
14	O
]	O
to	O
speed	O
the	O
process	O
of	O
gathering	O
and	O
translating	O
evidence	O
of	O
the	O
effectiveness	O
of	O
an	O
innovation	O
into	O
implementation	O
in	O
real	O
-	O
world	O
settings	O
.	O

Aim	O
2	O
will	O
evaluate	O
the	O
effectiveness	O
of	O
tele	O
-	O
PCMHI	O
in	O
rural	O
CBOCS	O
and	O
will	O
also	O
study	O
the	O
process	O
and	O
outcomes	O
of	O
the	O
implementation	O
strategy	O
,	O
IF	O
.	O

The	O
proposed	O
study	O
will	O
employ	O
a	O
cluster	O
-	O
randomized	O
,	O
stepped	O
-	O
wedge	O
design	O
in	O
which	O
study	O
sites	O
sequentially	O
begin	O
implementation	O
of	O
the	O
tele	O
-	O
PCMHI	O
model	O
in	O
three	O
waves	O
or	O
steps	O
at	O
6	O
-	O
month	O
intervals	O
[	O
18	O
]	O
.	O

Each	O
step	O
will	O
include	O
(	O
1	O
)	O
a	O
6	O
-	O
month	O
period	O
of	O
implementation	O
planning	O
,	O
followed	O
by	O
(	O
2	O
)	O
a	O
6	O
-	O
month	O
period	O
of	O
active	O
implementation	O
and	O
(	O
3	O
)	O
subsequent	O
stepped	O
-	O
down	O
implementation	O
facilitation—that	O
is	O
,	O
the	O
research	O
team	O
hands	O
off	O
skills	O
to	O
continue	O
the	O
innovation	O
to	O
site	O
personnel	O
to	O
enhance	O
sustainability	O
(	O
see	O
Fig	O
.	O

1	O
)	O
.	O

The	O
stepped	O
-	O
wedge	O
design	O
will	O
allow	O
us	O
to	O
(	O
1	O
)	O
extend	O
implementation	O
support	O
to	O
the	O
maximal	O
number	O
of	O
clinics	O
,	O
and	O
(	O
2	O
)	O
enhance	O
the	O
formative	O
evaluation	O
of	O
our	O
implementation	O
process	O
[	O
19	O
]	O
.	O

The	O
proposed	O
study	O
design	O
also	O
employs	O
many	O
core	O
elements	O
of	O
pragmatic	O
comparative	O
effectiveness	O
trials	O
including	O
(	O
1	O
)	O
comparing	O
the	O
innovation	O
to	O
a	O
commonly	O
used	O
active	O
treatment	O
,	O
(	O
2	O
)	O
applying	O
relatively	O
few	O
exclusion	O
criteria	O
,	O
(	O
3	O
)	O
enrolling	O
a	O
diverse	O
set	O
of	O
patients	O
,	O
(	O
4	O
)	O
delivering	O
the	O
innovation	O
using	O
clinical	O
staff	O
available	O
in	O
routine	O
care	O
settings	O
,	O
(	O
5	O
)	O
monitoring	O
,	O
but	O
not	O
controlling	O
fidelity	O
,	O
(	O
6	O
)	O
defining	O
clinical	O
outcomes	O
as	O
changes	O
in	O
patient	O
-	O
reported	O
symptoms	O
,	O
and	O
(	O
7	O
)	O
using	O
intent	O
-	O
to	O
-	O
treat	O

analyses	O
to	O
examine	O
group	O
differences	O
[	O
20	O
]	O
.	O

Fig	O
.	O

1	O
Study	O
timeline	O
and	O
stepped	O
-	O
wedge	O
design	O

Study	O
timeline	O
and	O
stepped	O
-	O
wedge	O
design	O

Patients	O
at	O
CBOCs	O
that	O
have	O
not	O
yet	O
implemented	O
the	O
tele	O
-	O
PCMHI	O
model	O
will	O
receive	O
usual	O
treatment	O
,	O
which	O
in	O
CBOCs	O
typically	O
consists	O
of	O
referral	O
of	O
patients	O
with	O
identified	O
or	O
suspected	O
mental	O
disorders	O
to	O
a	O
specialty	O
mental	O
health	O
care	O
provider	O
on	O
-	O
site	O
or	O
at	O
a	O
VA	O
Medical	O
Center	O
farther	O
away	O
or	O
through	O
telehealth	O
.	O

Once	O
the	O
adapted	O
tele	O
-	O
PCMHI	O
has	O
been	O
implemented	O
at	O
a	O
CBOC	O
(	O
Fig	O
.	O

1	O
)	O
,	O
patients	O
at	O
that	O
CBOC	O
will	O
have	O
access	O
to	O
PCMHI	O
services	O
,	O
including	O
warm	O
handoffs	O
and	O
same	O
-	O
day	O
access	O
to	O
mental	O
health	O
care	O
,	O
in	O
addition	O
to	O
the	O
availability	O
of	O
referral	O
to	O
specialty	O
mental	O
health	O
care	O
.	O

Evaluation	O
will	O
include	O
formative	O
and	O
summative	O
evaluation	O
activities	O
.	O

Formative	O
evaluation	O
is	O
designed	O
to	O
identify	O
potential	O
and	O
actual	O
influences	O
on	O
the	O
progress	O
and	O
effectiveness	O
of	O
implementation	O
efforts	O
and	O
may	O
be	O
done	O
before	O
(	O
developmental	O
FE	O
)	O
,	O
during	O
(	O
implementation	O
-	O
and	O
progress	O
-	O
focused	O
FE	O
)	O
,	O
and	O
/	O
or	O
after	O
(	O
interpretive	O
FE	O
)	O
active	O
implementation	O
efforts	O
depending	O
upon	O
study	O
needs	O
and	O
design	O
[	O
19	O
]	O
.	O

The	O
formative	O
evaluation	O
for	O
this	O
project	O
will	O
be	O
conducted	O
throughout	O
all	O
phases	O
of	O
facilitation	O
and	O
implementation	O
for	O
all	O
study	O
sites	O
.	O

Summative	O
evaluation	O
will	O
be	O
conducted	O
to	O
quantitatively	O
assess	O
the	O
effectiveness	O
of	O
tele	O
-	O
PCMHI	O
implementation	O
.	O

Six	O
CBOCs	O
will	O
participate	O
in	O
the	O
study	O
,	O
with	O
two	O
CBOCs	O
allocated	O
to	O
each	O
of	O
the	O
three	O
start	O
dates	O
.	O

Because	O
sites	O
may	O
differ	O
with	O
regard	O
to	O
organizational	O
/	O
program	O
characteristics	O
,	O
we	O
will	O
use	O
the	O
restricted	O
selection	O
method	O
of	O
randomization	O
to	O
balance	O
key	O
site	O
characteristics	O
over	O
time	O
.	O

For	O
example	O
,	O
if	O
somewhat	O
larger	O
CBOCs	O
(	O
serving	O
a	O
relatively	O
more	O
urban	O
population	O
)	O
were	O
randomized	O
to	O
participate	O
in	O
the	O
first	O
wave	O
of	O
implementation	O
and	O
the	O
smallest	O
sites	O
were	O
assigned	O
to	O
the	O
last	O
wave	O
,	O
fewer	O
rural	O
patients	O
would	O
likely	O
be	O
exposed	O
to	O
the	O
innovation	O
.	O

Following	O
the	O
methods	O
of	O
Bauer	O
and	O
colleagues	O
[	O
21	O
]	O
,	O
we	O
will	O
utilize	O
a	O
computer	O
-	O
based	O
algorithm	O
to	O
balance	O
site	O
characteristics	O
as	O
much	O
as	O
possible	O
using	O
key	O
site	O
characteristics	O
recommended	O
by	O
clinical	O
partners	O
,	O
including	O
the	O
following	O
:	O
CBOC	O
size	O
(	O
number	O
of	O
unique	O
patients	O
)	O
Parent	O
facility	O
Number	O
of	O
specialty	O
mental	O
health	O
providers	O
available	O
on	O
-	O
site	O
or	O
via	O
telehealth	O
Measures	O
of	O
access	O
to	O
mental	O
health	O
care	O

CBOC	O
size	O
(	O
number	O
of	O
unique	O
patients	O
)	O

Parent	O
facility	O

Number	O
of	O
specialty	O
mental	O
health	O
providers	O
available	O
on	O
-	O
site	O
or	O
via	O
telehealth	O

Measures	O
of	O
access	O
to	O
mental	O
health	O
care	O

The	O
small	O
number	O
of	O
sites	O
and	O
multiple	O
categories	O
of	O
site	O
characteristics	O
rule	O
out	O
perfect	O
balance	O
.	O

The	O
algorithm	O
provides	O
as	O
much	O
balance	O
as	O
possible	O
in	O
the	O
spirit	O
of	O
an	O
analysis	O
of	O
variance	O
(	O
ANOVA	O
)	O
balanced	O
incomplete	O
block	O
design	O
.	O

We	O
will	O
initiate	O
recruitment	O
for	O
primary	O
data	O
collection	O
at	O
all	O
sites	O
at	O
the	O
same	O
time	O
that	O
we	O
begin	O
implementation	O
planning	O
at	O
the	O
first	O
two	O
sites	O
.	O

Since	O
the	O
duration	O
of	O
the	O
implementation	O
period	O
may	O
vary	O
slightly	O
from	O
site	O
to	O
site	O
,	O
we	O
will	O
consider	O
a	O
site’s	O
first	O
referral	O
to	O
the	O
tele	O
-	O
PCMHI	O
model	O
as	O
the	O
index	O
date	O
with	O
all	O
patients	O
enrolled	O
prior	O
to	O
that	O
date	O
designated	O
as	O
controls	O
and	O
all	O
patients	O
enrolled	O
after	O
that	O
date	O
designated	O
as	O
innovation	O
participants	O
.	O

Patients	O
who	O
screen	O
positive	O
on	O
routinely	O
administered	O
mental	O
health	O
screens	O
(	O
i	O
.	O
e	O
.	O
,	O
depression	O
,	O
alcohol	O
,	O
PTSD	O
)	O
will	O
be	O
eligible	O
for	O
the	O
study	O
.	O

We	O
will	O
exclude	O
only	O
those	O
patients	O
receiving	O
specialty	O
mental	O
health	O
treatment	O
in	O
the	O
6	O
months	O
prior	O
to	O
recruitment	O
;	O
those	O
with	O
a	O
diagnosis	O
of	O
substance	O
dependence	O
;	O
and	O
those	O
with	O
a	O
psychotic	O
disorder	O
diagnosis	O
(	O
schizophrenia	O
,	O
bipolar	O
disorder	O
,	O
and	O
other	O
psychotic	O
disorders	O
)	O
.	O

Patients	O
enrolled	O
in	O
specialty	O
mental	O
health	O
care	O
are	O
already	O
receiving	O
a	O
higher	O
level	O
of	O
care	O
than	O
tele	O
-	O
PCMHI	O
and	O
would	O
not	O
be	O
expected	O
to	O
benefit	O
clinically	O
from	O
tele	O
-	O
PCMHI	O
.	O

The	O
justification	O
for	O
excluding	O
patients	O
with	O
substance	O
dependence	O
or	O
psychotic	O
disorder	O
diagnoses	O
is	O
that	O
currently	O
there	O
are	O
no	O
evidence	O
-	O
based	O
PCMHI	O
innovations	O
for	O
such	O
patients	O
.	O

We	O
aim	O
to	O
identify	O
and	O
enroll	O
patients	O
as	O
soon	O
as	O
possible	O
after	O
a	O
positive	O
mental	O
health	O
screen	O
is	O
recorded	O
so	O
that	O
research	O
assessments	O
will	O
capture	O
pre	O
-	O
treatment	O
severity	O
of	O
symptoms	O
and	O
functioning	O
.	O

Using	O
administrative	O
databases	O
,	O
we	O
will	O
identify	O
all	O
patients	O
at	O
study	O
clinics	O
who	O
have	O
an	O
upcoming	O
primary	O
care	O
appointment	O
within	O
30	O
days	O
and	O
send	O
them	O
information	O
about	O
the	O
study	O
.	O

Patients	O
who	O
do	O
not	O
opt	O
out	O
within	O
2	O
weeks	O
,	O
who	O
have	O
a	O
positive	O
screen	O
for	O
depression	O
,	O
alcohol	O
abuse	O
,	O
or	O
PTSD	O
recorded	O
in	O
the	O
administrative	O
database	O
,	O
and	O
who	O
meet	O
inclusion	O
/	O
exclusion	O
criteria	O
will	O
be	O
contacted	O
by	O
phone	O
.	O

Those	O
who	O
are	O
unable	O
to	O
understand	O
or	O
engage	O
in	O
the	O
informed	O
consent	O
process	O
(	O
e	O
.	O
g	O
.	O
,	O
cognitive	O
impairment	O
,	O
intoxication	O
)	O
will	O
be	O
excluded	O
.	O

Some	O
patients	O
who	O
were	O
not	O
identified	O
as	O
having	O
an	O
upcoming	O
appointment	O
may	O
visit	O
their	O
clinic	O
and	O
have	O
a	O
positive	O
mental	O
health	O
screen	O
recorded	O
.	O

These	O
patients	O
will	O
also	O
be	O
sent	O
opt	O
-	O
out	O
letters	O
and	O
contacted	O
in	O
2	O
weeks	O
if	O
they	O
do	O
not	O
opt	O
out	O
.	O

The	O
recruitment	O
phase	O
will	O
last	O
for	O
3	O
years	O
.	O

Developmental	O
,	O
implementation	O
-	O
focused	O
,	O
and	O
progress	O
-	O
focused	O
formative	O
evaluation	O
will	O
be	O
conducted	O
through	O
detailed	O
documentation	O
and	O
analysis	O
of	O
facilitation	O
activities	O
by	O
the	O
team’s	O
qualitative	O
expert	O
and	O
implementation	O
scientist	O
(	O
author	O
KD	O
)	O
,	O
who	O
will	O
(	O
1	O
)	O
attend	O
all	O
weekly	O
meetings	O
of	O
the	O
implementation	O
team	O
,	O
documenting	O
all	O
discussions	O
and	O
(	O
2	O
)	O
conduct	O
debriefings	O
with	O
the	O
two	O
study	O
facilitators	O
each	O
week	O
.	O

Notes	O
from	O
these	O
meetings	O
will	O
be	O
cleaned	O
,	O
organized	O
by	O
site	O
,	O
and	O
uploaded	O
into	O
Atlas	O
.	O
ti	O
qualitative	O
data	O
analysis	O
software	O
for	O
analysis	O
.	O

Data	O
analysis	O
will	O
include	O
a	O
hybrid	O
inductive	O
-	O
deductive	O
approach	O
,	O
with	O
deductive	O
codes	O
informed	O
by	O
the	O
Integrated	O
Promoting	O
Action	O
on	O
Research	O
Implementation	O
in	O
Health	O
Services	O
(	O
i	O
-	O
PARIHS	O
)	O
framework	O
[	O
22	O
]	O
and	O
inductive	O
codes	O
derived	O
from	O
emerging	O
themes	O
in	O
the	O
data	O
[	O
23	O
,	O
24	O
]	O
.	O

Findings	O
will	O
be	O
fed	O
back	O
to	O
the	O
implementation	O
team	O
periodically	O
during	O
implementation	O
team	O
meetings	O
in	O
order	O
to	O
inform	O
ongoing	O
facilitation	O
and	O
implementation	O
efforts	O
.	O

We	O
will	O
also	O
conduct	O
patient	O
interviews	O
for	O
our	O
progress	O
-	O
focused	O
formative	O
evaluation	O
[	O
19	O
]	O
.	O

We	O
will	O
interview	O
four	O
patients	O
at	O
each	O
site	O
during	O
early	O
implementation	O
to	O
assess	O
patient	O
perspectives	O
on	O
barriers	O
to	O
and	O
experiences	O
with	O
tele	O
-	O
PCMHI	O
(	O
N	O
=	O
24	O
)	O
.	O

Patients	O
will	O
be	O
identified	O
by	O
a	O
tele	O
-	O
PCMHI	O
provider	O
who	O
will	O
provide	O
names	O
and	O
contact	O
information	O
via	O
encrypted	O
e	O
-	O
mail	O
,	O
telephone	O
,	O
or	O
secure	O
research	O
website	O
to	O
the	O
evaluation	O
team	O
.	O

Potential	O
patient	O
participants	O
will	O
be	O
sent	O
an	O
opt	O
-	O
out	O
letter	O
and	O
recruited	O
by	O
phone	O
if	O
they	O
do	O
not	O
opt	O
-	O
out	O
within	O
2	O
weeks	O
.	O

Because	O
we	O
need	O
to	O
interview	O
patient	O
participants	O
soon	O
after	O
they	O
receive	O
their	O
mental	O
health	O
care	O
,	O
we	O
will	O
obtain	O
verbal	O
consent	O
over	O
the	O
phone	O
and	O
document	O
that	O
we	O
have	O
obtained	O
verbal	O
consent	O
in	O
the	O
research	O
record	O
.	O

The	O
evaluation	O
team’s	O
qualitative	O
expert	O
(	O
author	O
KD	O
)	O
will	O
conduct	O
these	O
interviews	O
using	O
a	O
semi	O
-	O
structured	O
interview	O
guide	O
covering	O
the	O
topics	O
of	O
patient	O
experience	O
with	O
the	O
telehealth	O
innovation	O
,	O
barriers	O
encountered	O
in	O
receiving	O
services	O
via	O
telehealth	O
,	O
and	O
preferences	O
for	O
receiving	O
care	O
via	O
telehealth	O
or	O
otherwise	O
.	O

These	O
results	O
will	O
be	O
fed	O
back	O
to	O
the	O
IF	O
team	O
to	O
further	O
refine	O
how	O
tele	O
-	O
PCMHI	O
is	O
being	O
implemented	O
and	O
improved	O
at	O
each	O
site	O
.	O

The	O
objective	O
of	O
the	O
interpretive	O
evaluation	O
is	O
to	O
obtain	O
stakeholder	O
perspectives	O
post	O
-	O
implementation	O
on	O
the	O
perceived	O
value	O
of	O
and	O
satisfaction	O
with	O
the	O
implementation	O
process	O
,	O
barriers	O
and	O
facilitators	O
encountered	O
,	O
unintended	O
consequences	O
,	O
and	O
any	O
needed	O
refinements	O
to	O
future	O
iterations	O
of	O
the	O
innovation	O
.	O

To	O
obtain	O
these	O
perspectives	O
,	O
evaluation	O
team	O
qualitative	O
expert	O
(	O
author	O
KD	O
)	O
will	O
also	O
conduct	O
qualitative	O
interviews	O
with	O
key	O
site	O
personnel	O
identified	O
by	O
the	O
facilitators	O
(	O
e	O
.	O
g	O
.	O
,	O
clinic	O
director	O
,	O
site	O
champion	O
)	O
following	O
implementation	O
to	O
obtain	O
their	O
feedback	O
on	O
implementation	O
processes	O
and	O
facilitation	O
efforts	O
[	O
19	O
,	O
21	O
]	O
.	O

These	O
data	O
will	O
be	O
collected	O
primarily	O
for	O
the	O
purposes	O
of	O
triangulating	O
with	O
our	O
quantitative	O
summative	O
evaluation	O
data	O
(	O
see	O
below	O
)	O
to	O
confirm	O
and	O
/	O
or	O
explain	O
summative	O
evaluation	O
findings	O
for	O
each	O
site	O
.	O

Finally	O
,	O
we	O
will	O
synthesize	O
qualitative	O
findings	O
with	O
quantitative	O
findings	O
to	O
develop	O
an	O
individual	O
descriptive	O
case	O
study	O
of	O
how	O
facilitators	O
helped	O
to	O
further	O
adapt	O
and	O
implement	O
Tele	O
-	O
PCMHI	O
at	O
each	O
study	O
site	O
(	O
see	O
Additional	O
file	O
1	O
)	O
.	O

The	O
hybrid	O
type	O
2	O
effectiveness	O
-	O
implementation	O
trial	O
will	O
be	O
evaluated	O
using	O
the	O
RE	O
-	O
AIM	O
Framework	O
[	O
25	O
–	O
28	O
]	O
.	O

The	O
study	O
timeline	O
will	O
not	O
allow	O
us	O
to	O
fully	O
study	O
the	O
maintenance	O
of	O
the	O
innovation	O
.	O

To	O
have	O
a	O
broad	O
public	O
health	O
impact	O
,	O
an	O
innovation	O
must	O
reach	O
a	O
large	O
proportion	O
of	O
the	O
targeted	O
patient	O
population	O
,	O
be	O
adopted	O
by	O
providers	O
,	O
be	O
implemented	O
with	O
high	O
fidelity	O
,	O
effectively	O
improve	O
clinical	O
outcomes	O
,	O
and	O
be	O
maintained	O
after	O
the	O
research	O
funds	O
are	O
withdrawn	O
.	O

By	O
measuring	O
the	O
innovation’s	O
Reach	O
and	O
Effectiveness	O
in	O
the	O
patient	O
population	O
of	O
interest	O
,	O
we	O
will	O
be	O
able	O
to	O
estimate	O
the	O
“population	O
level	O
impact”	O
of	O
PCMHI	O
[	O
29	O
]	O
.	O

We	O
are	O
planning	O
to	O
extend	O
traditional	O
measurements	O
of	O
implementation	O
by	O
evaluating	O
fidelity	O
to	O
the	O
innovation	O
,	O
implementation	O
process	O
,	O
and	O
the	O
implementation	O
strategy	O
using	O
multiple	O
measures	O
.	O

See	O
Additional	O
file	O
1	O
for	O
our	O
operational	O
definitions	O
of	O
RE	O
-	O
AIM	O
domains	O
.	O

We	O
will	O
use	O
methods	O
we	O
have	O
employed	O
previously	O
to	O
extract	O
and	O
analyze	O
administrative	O
and	O
clinical	O
data	O
from	O
the	O
VA	O
Corporate	O
Data	O
Warehouse	O
[	O
30	O
]	O
,	O
including	O
service	O
use	O
data	O
,	O
mental	B-phenotype
health	I-phenotype
diagnoses	I-phenotype
(	O
ICD	B-coding_system
-	I-coding_system
10	I-coding_system
)	O
,	O
mental	O
health	O
screening	O
results	O
,	O
age	O
,	O
gender	O
,	O
marital	O
status	O
,	O
percent	O
disability	O
,	O
and	O
zip	O
code	O
.	O

These	O
data	O
will	O
be	O
used	O
to	O
identify	O
patients	O
who	O
are	O
eligible	O
for	O
the	O
effectiveness	O
trial	O
and	O
to	O
assess	O
service	O
use	O
and	O
determine	O
RE	O
-	O
AIM	O
measures	O
at	O
the	O
patient	O
-	O
and	O
CBOC	O
-	O
levels	O
.	O

The	O
primary	O
measure	O
of	O
reach	O
into	O
the	O
patient	O
population	O
will	O
be	O
the	O
percentage	O
of	O
all	O
patients	O
with	O
positive	O
mental	O
health	O
screens	O
that	O
received	O
any	O
PCMHI	O
services	O
at	O
the	O
time	O
of	O
the	O
screening	O
visit	O
or	O
within	O
the	O
next	O
6	O
months	O
.	O

This	O
measure	O
will	O
indicate	O
how	O
much	O
the	O
innovation	O
is	O
reaching	O
the	O
intended	O
target	O
population	O
.	O

A	O
secondary	O
measure	O
will	O
be	O
a	O
national	O
VA	O
performance	O
measure	O
of	O
PCMHI	O
penetration	O
that	O
will	O
indicate	O
how	O
much	O
the	O
innovation	O
is	O
reaching	O
the	O
general	O
patient	O
population	O
:	O
the	O
percentage	O
of	O
assigned	O
primary	O
care	O
patients	O
who	O
receive	O
at	O
least	O
one	O
PCMHI	O
service	O
.	O

Both	O
measures	O
will	O
be	O
determined	O
using	O
administrative	O
data	O
.	O

We	O
will	O
administer	O
research	O
assessments	O
to	O
enrolled	O
patients	O
at	O
the	O
time	O
of	O
enrollment	O
and	O
at	O
6	O
-	O
month	O
follow	O
-	O
up	O
.	O

Assessments	O
will	O
be	O
administered	O
via	O
telephone	O
by	O
trained	O
research	O
assistants	O
using	O
a	O
computer	O
-	O
assisted	O
telephone	O
interviewing	O
system	O
.	O

Table	O
1	O
lists	O
the	O
instruments	O
.	O

Table	O
1	O
Effectiveness	O
assessment	O
instruments	O
Instrument	O
Construct	O
Administred	O
only	O
at	O
baseline	O
a	O
Socio	O
-	O
demographics	O
18	O
items	O
that	O
measure	O
socio	O
-	O
economic	O
and	O
military	O
characteristics	O
Hoge	O
barriers	O
assessment	O
14	O
-	O
item	O
measure	O
of	O
perceived	O
access	O
,	O
need	O
,	O
and	O
treatment	O
effectiveness	O
[	O
34	O
]	O
Perceived	O
access	O
inventory	O
b	O
43	O
items	O
that	O
perceived	O
access	O
to	O
mental	O
health	O
care	O
instrument	O
developed	O
in	O
a	O
preceding	O
research	O
project	O
Readiness	O
ruler	O
3	O
items	O
that	O
assess	O
perceived	O
readiness	O
to	O
seek	O
treatment	O
[	O
35	O
]	O
Administered	O

at	O
baseline	O
and	O
follow	O
-	O
up	O
SF	O
-	O
12V	O
c	O
12	O
items	O
addressing	O
overall	O
physical	O
and	O
mental	O
health	O
functioning	O
[	O
31	O
]	O
Patient	O
Health	O
Questionnaire	O
-	O
9	O
d	O
9	O
-	O
item	O
inventory	O
that	O
yields	O
a	O
continuous	O
and	O
dichotomous	O
assessment	O
of	O
depression	O
[	O
32	O
]	O
Alcohol	O
Use	O
Disorders	O
Identification	O
Test	O
(	O
AUDIT	O
-	O
C	O
)	O
d	O
3	O
items	O
that	O
yield	O
a	O
continuous	O
and	O
dichotomous	O
assessment	O
of	O
alcohol	O
use	O
[	O
33	O
]	O
Miklowitz	O
Adherence	O
Scale	O
2	O
-	O
item	O
medication	O
adherence	O
scale	O
[	O
36	O
]	O
Pain	O
scale	O
Single	O
-	O
item	O
participant	O
rating	O
of	O
the	O
average	O
overall	O
level	O

of	O
pain	O
for	O
the	O
past	O
week	O
rated	O
on	O
a	O
continuous	O
scale	O
from	O
0	O
to	O
10	O
Jenkins	O
Sleep	O
Scale	O
4	O
-	O
item	O
measure	O
that	O
assesses	O
trouble	O
falling	O
and	O
staying	O
asleep	O
,	O
and	O
feeling	O
tired	O
during	O
the	O
daytime	O
[	O
37	O
]	O
Prime	O
-	O
Screen	O
6	O
-	O
item	O
assessment	O
of	O
dietary	O
and	O
exercise	O
habits	O
/	O
behaviors	O
[	O
38	O
]	O
Generalized	O
anxiety	O
Disorder	O
7	O
-	O
item	O
7	O
-	O
item	O
inventory	O
that	O
yields	O
a	O
continuous	O
and	O
dichotomous	O
assessment	O
of	O
generalized	O
anxiety	O
disorder	O
[	O
39	O
]	O
American	O
Psychiatric	O
Association–Diagnostic	O
and	B-coding_system
Statistical	I-coding_system
Manual	I-coding_system
of	I-coding_system
Mental	I-coding_system
Disorders	I-coding_system

(	I-coding_system
DSM	I-coding_system
)	I-coding_system
Severity	O
Measure	O
for	O
Panic	O
-	O
Adult	O
10	O
-	O
item	O
inventory	O
that	O
yields	O
a	O
continuous	O
and	O
dichotomous	O
assessment	O
of	O
panic	B-phenotype
disorder	I-phenotype
[	O
40	O
]	O
PTSD	O
Checklist	O
for	O
DSM	B-coding_system
-	I-coding_system
5	I-coding_system
20	O
-	O
item	O
inventory	O
that	O
yields	O
a	O
continuous	O
and	O
dichotomous	O
assessment	O
of	O
posttraumatic	B-phenotype
stress	I-phenotype
disorder	I-phenotype
(	I-phenotype
PTSD	I-phenotype
)	I-phenotype
[	O
41	O
]	O
Behavioral	O
Risk	O
Factor	O
Surveillance	O
System	O
Tobacco	O
Use	O
5	O
items	O
to	O
assess	O
current	O
tobacco	O
use	O
Client	O
Satisfaction	O
Questionnaire	O
8	O
items	O
to	O
assess	O
client	O
satisfaction	O
with	O
MH	O
services	O
[	O
42	O
]	O
a	O
Constructs	O
assessed	O
via	O
these	O
instruments	O

will	O
be	O
used	O
for	O
case	O
-	O
mix	O
adjustment	O
b	O
The	O
Perceived	O
Access	O
Inventory	O
was	O
developed	O
in	O
2017	O
as	O
the	O
main	O
product	O
of	O
another	O
VA	O
research	O
project	O
[	O
43	O
]	O
c	O
Measures	O
for	O
primary	O
effectiveness	O
outcome	O
d	O
Measures	O
for	O
secondary	O
effectiveness	O
outcomes	O

Effectiveness	O
assessment	O
instruments	O

a	O
Constructs	O
assessed	O
via	O
these	O
instruments	O
will	O
be	O
used	O
for	O
case	O
-	O
mix	O
adjustment	O

b	O
The	O
Perceived	O
Access	O
Inventory	O
was	O
developed	O
in	O
2017	O
as	O
the	O
main	O
product	O
of	O
another	O
VA	O
research	O
project	O
[	O
43	O
]	O

c	O
Measures	O
for	O
primary	O
effectiveness	O
outcome	O

d	O
Measures	O
for	O
secondary	O
effectiveness	O
outcomes	O

We	O
will	O
assess	O
the	O
effectiveness	O
of	O
tele	O
-	O
PCMHI	O
regarding	O
improving	O
patient	O
outcomes	O
for	O
two	O
different	O
patient	O
subgroups	O
.	O

The	O
first	O
patient	O
subgroup	O
(	O
subgroup	O
A	O
)	O
will	O
consist	O
of	O
patients	O
who	O
screen	O
positive	O
for	O
only	O
depression	O
or	O
alcohol	O
misuse	O
in	O
primary	O
care—this	O
is	O
the	O
subgroup	O
for	O
whom	O
PCMHI	O
is	O
targeted	O
based	O
on	O
current	O
effectiveness	O
data	O
.	O

The	O
second	O
patient	O
subgroup	O
(	O
subgroup	O
B	O
)	O
will	O
consist	O
of	O
patients	O
who	O
screen	O
positive	O
for	O
posttraumatic	O
stress	O
disorder	O
(	O
PTSD	O
)	O
with	O
or	O
without	O
depression	O
or	O
alcohol	O
misuse	O
in	O
primary	O
care	O
.	O

The	O
effectiveness	O
of	O
PCMHI	O
has	O
not	O
been	O
documented	O
for	O
this	O
patient	O
subgroup	O
on	O
mental	O
health	O
symptom	O
outcomes	O
and	O
therefore	O
,	O
measures	O
of	O
PCMHI	O
effectiveness	O
will	O
be	O
explored	O
and	O
conceptualized	O
differently	O
for	O
subgroup	O
B	O
compared	O
to	O
subgroup	O
A	O
.	O

For	O
subgroup	O
A	O
patients	O
,	O
the	O
primary	O
measure	O
of	O
effectiveness	O
will	O
be	O
clinically	O
and	O
statistically	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
significant	O
reductions	O
in	O
symptoms	O
of	O
depression	O
and	O
alcohol	O
misuse	O
.	O

This	O
primary	O
analysis	O
attempts	O
to	O
replicate	O
current	O
findings	O
that	O
traditional	O
PCMHI	O
delivered	O
in	O
person	O
leads	O
to	O
significant	O
reductions	O
in	O
depression	O
[	O
44	O
–	O
47	O
]	O
and	O
alcohol	O
misuse	O
[	O
48	O
–	O
50	O
]	O
.	O

The	O
secondary	O
measure	O
of	O
effectiveness	O
for	O
subgroup	O
A	O
will	O
be	O
statistically	O
significant	O
reductions	O
in	O
other	O
psychosocial	O
symptoms	O
not	O
specific	O
to	O
mental	O
health	O
:	O
mental	O
health	O
functioning	O
,	O
physical	O
health	O
functioning	O
,	O
pain	O
,	O
sleep	O
,	O
dietary	O
and	O
exercise	O
behaviors	O
,	O
smoking	O
,	O
and	O
medication	O
adherence	O
.	O

These	O
outcomes	O
are	O
indicative	O
of	O
a	O
patient’s	O
whole	O
health	O
and	O
may	O
change	O
independently	O
of	O
,	O
or	O
in	O
addition	O
to	O
,	O
disease	O
-	O
specific	O
mental	O
health	O
symptoms	O
and	O
are	O
emphasized	O
as	O
important	O
markers	O
of	O
patient	O
health	O
by	O
the	O
VA	O
Office	O
of	O
Patient	O
-	O
Centered	O
Care	O
and	O
the	O
Institute	O
for	O
Healthcare	O
Improvement	O
[	O
51	O
]	O
.	O

For	O
subgroup	O
B	O
patients	O
,	O
the	O
primary	O
measure	O
of	O
effectiveness	O
will	O
be	O
the	O
percentage	O
of	O
patients	O
with	O
at	O
least	O
one	O
specialty	O
mental	O
health	O
care	O
visit	O
after	O
a	O
tele	O
-	O
PCMHI	O
visit	O
.	O

This	O
measure	O
is	O
conceptualized	O
as	O
successful	O
referral	O
management—that	O
is	O
,	O
a	O
patient	O
in	O
need	O
of	O
specialty	O
mental	O
health	O
for	O
PTSD	O
was	O
referred	O
to	O
and	O
attended	O
one	O
specialty	O
mental	O
health	O
care	O
visit	O
.	O

Referral	O
management	O
is	O
one	O
of	O
the	O
explicit	O
purposes	O
of	O
PCMHI	O
,	O
although	O
not	O
the	O
main	O
purpose	O
[	O
4	O
,	O
52	O
]	O
.	O

Two	O
other	O
exploratory	O
measures	O
of	O
effectiveness	O
for	O
subgroup	O
B	O
patients	O
will	O
be	O
changes	O
in	O
these	O
mental	O
health	O
symptoms	O
:	O
depression	O
,	O
alcohol	O
misuse	O
,	O
generalized	O
anxiety	O
disorder	O
,	O
panic	O
disorder	O
,	O
and	O
PTSD	O
;	O
and	O
also	O
changes	O
in	O
other	O
psychosocial	O
symptoms	O
not	O
specific	O
to	O
mental	O
health	O
:	O
mental	O
health	O
functioning	O
,	O
physical	O
health	O
functioning	O
,	O
pain	O
,	O
sleep	O
,	O
dietary	O
and	O
exercise	O
behaviors	O
,	O
smoking	O
,	O
and	O
medication	O
adherence	O
.	O

The	O
primary	O
measure	O
of	O
adoption	O
will	O
be	O
the	O
percentage	O
of	O
primary	O
care	O
providers	O
referring	O
at	O
least	O
one	O
patient	O
to	O
tele	O
-	O
PCMHI	O
per	O
site	O
.	O

This	O
will	O
determine	O
how	O
many	O
primary	O
care	O
providers	O
are	O
“adopters	O
.	O
”	O
The	O
secondary	O
measure	O
of	O
adoption	O
will	O
be	O
the	O
mean	O
percentage	O
of	O
primary	O
care	O
providers’	O
patients	O
who	O
are	O
referred	O
to	O
tele	O
-	O
PCMHI	O
.	O

This	O
will	O
assess	O
the	O
extent	O
of	O
adoption	O
.	O

We	O
will	O
use	O
VA	O
administrative	O
data	O
to	O
determine	O
each	O
primary	O
care	O
physician’s	O
patient	O
caseloads	O
.	O

We	O
will	O
classify	O
each	O
patient	O
as	O
having	O
received	O
tele	O
-	O
PCMHI	O
services	O
if	O
this	O
was	O
documented	O
by	O
stopcodes	O
in	O
the	O
electronic	O
medical	O
record	O
during	O
their	O
initial	O
encounter	O
or	O
during	O
the	O
6	O
-	O
month	O
follow	O
-	O
up	O
period	O
.	O

We	O
will	O
assess	O
implementation	O
fidelity	O
in	O
both	O
traditional	O
ways	O
(	O
i	O
.	O
e	O
.	O
,	O
fidelity	O
to	O
the	O
innovation	O
)	O
and	O
novel	O
ways	O
(	O
i	O
.	O
e	O
.	O
,	O
fidelity	O
to	O
the	O
implementation	O
process	O
and	O
strategy	O
)	O
.	O

Regarding	O
innovation	O
fidelity	O
,	O
we	O
will	O
assess	O
fidelity	O
at	O
the	O
program	O
-	O
level	O
by	O
assessing	O
whether	O
core	O
components	O
of	O
the	O
PCMHI	O
program	O
are	O
in	O
place	O
after	O
implementation	O
as	O
well	O
as	O
performance	O
of	O
the	O
PCMHI	O
program	O
on	O
same	O
-	O
day	O
access	O
measures	O
.	O

Same	O
-	O
day	O
access	O
is	O
a	O
critical	O
and	O
unique	O
component	O
of	O
PCMHI	O
that	O
provides	O
patients	O
with	O
access	O
to	O
PCMHI	O
the	O
same	O
day	O
they	O
also	O
have	O
a	O
primary	O
care	O
physician	O
appointment	O
.	O

We	O
will	O
also	O
assess	O
innovation	O
fidelity	O
at	O
the	O
clinical	O
encounter	O
or	O
visit	O
-	O
level	O
by	O
assessing	O
self	O
-	O
reported	O
behaviors	O
of	O
the	O
tele	O
-	O
PCMHI	O
mental	O
health	O
providers	O
to	O
evaluate	O
how	O
consistent	O
they	O
are	O
with	O
ideal	O
clinical	O
encounter	O
behaviors	O
.	O

Regarding	O
implementation	O
fidelity	O
,	O
we	O
will	O
assess	O
fidelity	O
to	O
the	O
process	O
of	O
implementing	O
tele	O
-	O
PCMHI	O
using	O
our	O
pre	O
-	O
established	O
implementation	O
checklist	O
.	O

We	O
will	O
also	O
assess	O
fidelity	O
to	O
the	O
implementation	O
strategy	O
(	O
i	O
.	O
e	O
.	O
,	O
implementation	O
facilitation	O
)	O
using	O
an	O
implementation	O
fidelity	O
monitoring	O
tool	O
currently	O
in	O
development	O
[	O
53	O
]	O
.	O

Analyses	O
of	O
reach	O
and	O
effectiveness	O
of	O
the	O
innovation	O
will	O
be	O
both	O
descriptive	O
and	O
inferential	O
,	O
comparing	O
dependent	O
variables	O
for	O
the	O
exposed	O
tele	O
-	O
PCMHI	O
model	O
innovation	O
period	O
(	O
innovation	O
phase	O
)	O
to	O
the	O
unexposed	O
observation	O
periods	O
(	O
control	O
phase	O
)	O
.	O

Analyses	O
of	O
adoption	O
and	O
implementation	O
will	O
be	O
descriptive	O
in	O
nature	O
.	O

Characteristics	O
of	O
the	O
patients	O
and	O
the	O
CBOCs	O
will	O
be	O
summarized	O
by	O
exposure	O
status	O
to	O
examine	O
potential	O
selection	O
bias	O
or	O
lack	O
of	O
balance	O
[	O
54	O
]	O
.	O

Because	O
we	O
have	O
a	O
small	O
number	O
(	O
3	O
)	O
of	O
randomization	O
steps	O
,	O
we	O
will	O
compare	O
numbers	O
of	O
patients	O
analyzed	O
,	O
cluster	O
(	O
CBOC	O
)	O
size	O
,	O
CBOC	O
characteristics	O
,	O
and	O
patient	O
characteristics	O
by	O
randomization	O
group	O
.	O

The	O
CBOC	O
-	O
level	O
analysis	O
will	O
examine	O
RE	O
-	O
AIM	O
measures	O
before	O
and	O
after	O
implementation	O
of	O
tele	O
-	O
PCMHI	O
-	O
based	O
care	O
.	O

At	O
each	O
facility	O
,	O
we	O
will	O
determine	O
the	O
index	O
start	O
date	O
at	O
which	O
the	O
first	O
utilization	O
of	O
the	O
telemedicine	O
-	O
based	O
service	O
began	O
.	O

This	O
will	O
allow	O
us	O
to	O
consider	O
the	O
differing	O
lengths	O
of	O
time	O
it	O
may	O
take	O
to	O
implement	O
the	O
innovation	O
at	O
various	O
CBOCs	O
.	O

Before	O
this	O
index	O
date	O
,	O
patients	O
participating	O
in	O
the	O
study	O
at	O
that	O
CBOC	O
will	O
be	O
considered	O
as	O
being	O
in	O
the	O
control	O
phase	O
and	O
those	O
participating	O
after	O
the	O
index	O
date	O
will	O
be	O
considered	O
in	O
the	O
innovation	O
phase	O
.	O

Analyses	O
comparing	O
before	O
to	O
after	O
implementation	O
outcomes	O
will	O
be	O
conducted	O
for	O
continuous	O
measures	O
using	O
linear	O
mixed	O
models	O
.	O

The	O
interaction	O
of	O
innovation	O
by	O
CBOC	O
will	O
test	O
whether	O
results	O
differ	O
by	O
CBOC	O
.	O

We	O
will	O
adjust	O
for	O
baseline	O
differences	O
among	O
CBOCs	O
in	O
the	O
model	O
[	O
55	O
]	O
.	O

The	O
patient	O
-	O
level	O
analysis	O
will	O
be	O
a	O
generalized	O
linear	O
mixed	O
model	O
which	O
includes	O
fixed	O
terms	O
for	O
innovation	O
(	O
usual	O
care	O
referral	O
model	O
versus	O
tele	O
-	O
PCMHI	O
care	O
)	O
and	O
time	O
(	O
6	O
-	O
month	O
time	O
periods	O
for	O
each	O
step	O
)	O
.	O

The	O
model	O
will	O
use	O
random	O
effects	O
to	O
model	O
the	O
correlation	O
of	O
patients	O
within	O
CBOCs	O
[	O
56	O
,	O
57	O
]	O
.	O

In	O
addition	O
,	O
we	O
may	O
consider	O
adjusting	O
the	O
analyses	O
to	O
deal	O
with	O
lags	O
in	O
the	O
innovation	O
effect	O
.	O

This	O
delayed	O
innovation	O
effect	O
occurs	O
if	O
the	O
innovation	O
does	O
not	O
become	O
fully	O
effective	O
during	O
the	O
step	O
in	O
which	O
it	O
is	O
introduced	O
[	O
58	O
]	O
.	O

If	O
,	O
for	O
example	O
,	O
we	O
expect	O
the	O
lag	O
in	O
the	O
innovation	O
effect	O
to	O
be	O
50	O
%	O
in	O
the	O
implementation	O
step	O
and	O
100	O
%	O
effective	O
within	O
6	O
months	O
,	O
we	O
could	O
follow	O
the	O
suggestion	O
of	O
Hussey	O
and	O
Hughes	O
of	O
using	O
fractional	O
values	O
for	O
the	O
treatment	O
indicator	O
[	O
56	O
]	O
.	O

Because	O
this	O
is	O
a	O
cross	O
-	O
sectional	O
design	O
in	O
which	O
different	O
patients	O
are	O
sampled	O
at	O
each	O
step	O
in	O
the	O
study	O
,	O
we	O
do	O
not	O
need	O
to	O
include	O
a	O
random	O
-	O
effects	O
term	O
for	O
repeated	O
measures	O
on	O
the	O
same	O
individuals	O
.	O

The	O
effect	O
size	O
adjusted	O
for	O
calendar	O
time	O
and	O
its	O
95	O
%	O
confidence	O
interval	O
will	O
be	O
calculated	O
to	O
assess	O
the	O
estimated	O
change	O
in	O
outcomes	O
after	O
the	O
introduction	O
of	O
the	O
innovation	O
.	O

Per	O
Hemming	O
et	O
al	O
.	O
[	O
54	O
]	O
,	O
we	O
will	O
report	O
the	O
estimated	O
intra	O
-	O
cluster	O
correlation	O
for	O
use	O
in	O
the	O
design	O
of	O
future	O
trials	O
.	O

In	O
addition	O
,	O
we	O
will	O
report	O
the	O
time	O
effect	O
from	O
the	O
fitted	O
model	O
to	O
allow	O
assessment	O
of	O
possible	O
confounding	O
effects	O
of	O
calendar	O
time	O
.	O

We	O
may	O
include	O
an	O
effect	O
modifier	O
term	O
in	O
the	O
model	O
representing	O
the	O
length	O
of	O
the	O
period	O
up	O
to	O
the	O
current	O
observation	O
during	O
which	O
the	O
CBOC	O
has	O
been	O
exposed	O
to	O
the	O
innovation	O
.	O

This	O
will	O
allow	O
examination	O
of	O
the	O
way	O
the	O
impact	O
of	O
the	O
tele	O
-	O
PCMHI	O
-	O
based	O
care	O
develops	O
over	O
time	O
once	O
introduced	O
into	O
the	O
CBOC	O
.	O

The	O
first	O
type	O
of	O
analysis	O
for	O
reach	O
will	O
be	O
descriptive	O
.	O

We	O
will	O
compare	O
the	O
primary	O
measure	O
of	O
PCMHI	O
reach	O
before	O
implementation	O
to	O
active	O
implementation	O
.	O

We	O
will	O
also	O
compare	O
the	O
secondary	O
measure	O
of	O
PCMHI	O
penetration	O
to	O
the	O
established	O
VA	O
performance	O
expectation	O
that	O
7	O
%	O
of	O
assigned	O
primary	O
care	O
patients	O
receive	O
at	O
least	O
one	O
PCMHI	O
service	O
.	O

The	O
second	O
analysis	O
for	O
reach	O
will	O
be	O
correlational	O
.	O

A	O
dummy	O
variable	O
representing	O
implementation	O
group	O
assignment	O
(	O
pre	O
-	O
implementation	O
control	O
or	O
active	O
implementation	O
)	O
will	O
be	O
specified	O
as	O
the	O
explanatory	O
variable	O
of	O
interest	O
for	O
reach	O
.	O

We	O
hypothesize	O
that	O
during	O
active	O
implementation	O
,	O
the	O
reach	O
of	O
PCMHI	O
will	O
be	O
greater	O
than	O
during	O
the	O
pre	O
-	O
implementation	O
period	O
.	O

An	O
alpha	O
significance	O
level	O
of	O
0	O
.	O
05	O
will	O
be	O
used	O
to	O
reject	O
/	O
accept	O
the	O
null	O
hypothesis	O
.	O

Significant	O
intra	O
-	O
class	O
correlation	O
violates	O
the	O
independence	O
assumption	O
of	O
standard	O
regression	O
models	O
and	O
may	O
cause	O
underestimation	O
of	O
coefficient	O
standard	O
errors	O
,	O
possibly	O
leading	O
to	O
incorrect	O
inferences	O
concerning	O
the	O
rejection	O
of	O
the	O
null	O
hypotheses	O
.	O

Therefore	O
,	O
the	O
first	O
step	O
of	O
the	O
statistical	O
analysis	O
will	O
be	O
to	O
test	O
for	O
lack	O
of	O
independence	O
among	O
observations	O
within	O
clusters	O
using	O
intra	O
-	O
class	O
correlation	O
coefficients	O
at	O
the	O
site	O
level	O
.	O

Specifically	O
,	O
using	O
a	O
likelihood	O
ratio	O
test	O
,	O
we	O
will	O
compare	O
the	O
−2log	O
likelihoods	O
for	O
an	O
unrestricted	O
model	O
to	O
a	O
model	O
that	O
restricts	O
the	O
intra	O
-	O
class	O
correlation	O
to	O
be	O
zero	O
.	O

Raudenbush	O
recommends	O
that	O
unconditional	O
models	O
(	O
i	O
.	O
e	O
.	O
,	O
without	O
explanatory	O
variables	O
)	O
should	O
be	O
estimated	O
prior	O
to	O
considering	O
conditional	O
models	O
(	O
i	O
.	O
e	O
.	O
,	O
with	O
explanatory	O
variables	O
)	O
[	O
59	O
]	O
.	O

If	O
it	O
turns	O
out	O
that	O
the	O
−2log	O
likelihoods	O
are	O
not	O
significantly	O
different	O
,	O
the	O
hypotheses	O
will	O
be	O
tested	O
using	O
a	O
standard	O
logistic	O
regression	O
model	O
.	O

The	O
following	O
case	O
-	O
mix	O
factors	O
will	O
be	O
included	O
in	O
the	O
regression	O
equation	O
:	O
mental	O
health	O
diagnostic	O
categories	O
,	O
age	O
,	O
gender	O
,	O
race	O
,	O
marital	O
status	O
,	O
percent	O
disability	O
,	O
and	O
rurality	O
.	O

Missing	O
race	O
data	O
will	O
be	O
handled	O
by	O
specifying	O
an	O
unknown	O
race	O
category	O
.	O

Conversely	O
,	O
if	O
the	O
results	O
of	O
the	O
likelihood	O
ratio	O
test	O
suggest	O
that	O
the	O
intra	O
-	O
class	O
correlation	O
is	O
significant	O
,	O
a	O
mixed	O
logistic	O
model	O
will	O
be	O
used	O
[	O
60	O
,	O
61	O
]	O
.	O

The	O
mixed	O
-	O
model	O
will	O
include	O
a	O
random	O
effect	O
for	O
the	O
intercept	O
and	O
fixed	O
effects	O
for	O
the	O
patient	O
-	O
level	O
variables	O
(	O
including	O
implementation	O
group	O
assignment	O
)	O
.	O

The	O
variance	O
-	O
covariance	O
matrix	O
will	O
be	O
specified	O
to	O
be	O
unstructured	O
.	O

For	O
patients	O
screening	O
positive	O
for	O
depression	O
or	O
alcohol	O
use	O
only	O
(	O
subgroup	O
A	O
)	O
,	O
we	O
will	O
calculate	O
change	O
scores	O
between	O
baseline	O
and	O
6	O
-	O
month	O
follow	O
-	O
up	O
for	O
(	O
a	O
)	O
depression	O
and	O
alcohol	O
misuse	O
and	O
(	O
b	O
)	O
whole	O
health	O
outcomes	O
(	O
i	O
.	O
e	O
.	O
,	O
mental	O
health	O
functioning	O
,	O
physical	O
health	O
functioning	O
,	O
pain	O
,	O
sleep	O
,	O
dietary	O
and	O
exercise	O
behaviors	O
,	O
smoking	O
,	O
and	O
medication	O
adherence	O
)	O
.	O

The	O
primary	O
outcome	O
of	O
interest	O
for	O
the	O
effectiveness	O
analysis	O
is	O
change	O
in	O
overall	O
mental	O
health	O
functioning	O
(	O
Short	O
Form	O
12–Veterans	O
Version	O
[	O
SF	O
-	O
12	O
V	O
]	O
Mental	O
Health	O
Composite	O
Scale	O
mental	O
health	O
composite	O
score	O
)	O
[	O
31	O
]	O
;	O
secondary	O
effectiveness	O
outcomes	O
are	O
changes	O
in	O
depressive	O
symptoms	O
(	O
PHQ	O
-	O
9	O
)	O
[	O
32	O
]	O
and	O
alcohol	O
use	O
(	O
AUDIT	O
-	O
C	O
)	O
[	O
33	O
]	O
.	O

See	O
Table	O
1	O
for	O
assessments	O
.	O

For	O
patients	O
screening	O
positive	O
for	O
PTSD	O
(	O
subgroup	O
B	O
)	O
,	O
we	O
will	O
examine	O
the	O
extent	O
of	O
referral	O
management	O
,	O
defined	O
as	O
the	O
proportion	O
of	O
patients	O
who	O
have	O
a	O
specialty	O
mental	O
health	O
encounter	O
following	O
a	O
tele	O
-	O
PCMHI	O
encounter	O
,	O
and	O
calculate	O
change	O
scores	O
between	O
baseline	O
and	O
6	O
-	O
month	O
follow	O
-	O
up	O
for	O
mental	O
health	O
symptom	O
measures	O
and	O
whole	O
health	O
measures	O
.	O

Hierarchical	O
models	O
will	O
be	O
run	O
in	O
which	O
patients	O
are	O
nested	O
within	O
the	O
CBOC	O
in	O
which	O
they	O
received	O
care	O
.	O

We	O
will	O
adjust	O
for	O
covariates	O
selected	O
a	O
priori	O
to	O
prevent	O
overfitting	O
[	O
61	O
]	O
.	O

We	O
hypothesize	O
there	O
will	O
be	O
a	O
significant	O
effect	O
of	O
tele	O
-	O
PCMHI	O
on	O
the	O
differences	O
between	O
baseline	O
and	O
6	O
-	O
month	O
follow	O
-	O
up	O
scores	O
on	O
all	O
the	O
aforementioned	O
effectiveness	O
measures	O
.	O

An	O
alpha	O
significance	O
level	O
of	O
0	O
.	O
05	O
will	O
be	O
used	O
for	O
all	O
analyses	O
.	O

Descriptive	O
analysis	O
will	O
determine	O
the	O
proportion	O
of	O
primary	O
care	O
providers	O
who	O
refer	O
at	O
least	O
one	O
patient	O
to	O
tele	O
-	O
PCMHI	O
after	O
implementation	O
,	O
and	O
the	O
mean	O
number	O
of	O
patients	O
referred	O
per	O
provider	O
.	O

Analyses	O
will	O
be	O
descriptive	O
.	O

Implementation	O
fidelity	O
at	O
the	O
program	O
(	O
CBOC	O
)	O
level	O
and	O
provider	O
level	O
[	O
62	O
]	O
and	O
fidelity	O
to	O
the	O
implementation	O
strategy	O
will	O
be	O
determined	O
as	O
described	O
in	O
Additional	O
file	O
1	O
.	O

We	O
calculated	O
the	O
sample	O
size	O
needed	O
given	O
the	O
stepped	O
-	O
wedge	O
design	O
to	O
test	O
the	O
primary	O
hypothesis	O
,	O
that	O
the	O
innovation	O
improves	O
the	O
primary	O
outcome	O
,	O
SF	O
-	O
12	O
V	O
Mental	O
Health	O
Composite	O
Scale	O
scores	O
,	O
following	O
the	O
approach	O
of	O
Woertman	O
et	O
al	O
.	O
[	O
63	O
]	O
,	O
which	O
has	O
been	O
corrected	O
by	O
Hemming	O
,	O
Girling	O
,	O
and	O
Taljaard	O
[	O
64	O
,	O
65	O
]	O
.	O

The	O
calculations	O
are	O
based	O
on	O
having	O
80	O
%	O
power	O
at	O
a	O
significance	O
level	O
of	O
0	O
.	O
05	O
to	O
detect	O
a	O
medium	O
effect	O
size	O
(	O
Cohen’s	O
d	O
=	O
0	O
.	O
50	O
)	O
between	O
the	O
usual	O
care	O
referral	O
model	O
and	O
the	O
tele	O
-	O
PCMHI	O
model	O
innovation	O
group	O
in	O
our	O
primary	O
outcome	O
measure	O
.	O

The	O
total	O
number	O
of	O
patients	O
to	O
be	O
selected	O
for	O
assessment	O
across	O
the	O
6	O
CBOCs	O
will	O
be	O
540	O
.	O

This	O
was	O
determined	O
after	O
adjusting	O
the	O
total	O
sample	O
size	O
required	O
under	O
individual	O
randomization	O
N	O
u	O
,	O
for	O
the	O
design	O
effect	O
,	O
multiplying	O
by	O
the	O
5	O
measurement	O
periods	O
,	O
and	O
accounting	O
for	O
a	O
20	O
%	O
attrition	O
rate	O
.	O

This	O
will	O
result	O
in	O
approximately	O
432	O
patients	O
providing	O
baseline	O
and	O
6	O
-	O
month	O
follow	O
-	O
up	O
data	O
for	O
analysis	O
.	O

Thus	O
,	O
we	O
aim	O
to	O
recruit	O
18	O
patients	O
in	O
each	O
of	O
the	O
5	O
6	O
-	O
month	O
periods	O
at	O
each	O
of	O
the	O
6	O
CBOCs	O
.	O

This	O
was	O
a	O
retrospective	O
,	O
cross	O
-	O
sectional	O
,	O
naturalistic	O
study	O
.	O

Our	O
psychiatry	O
clinical	O
hospital	O
database	O
was	O
screened	O
for	O
serum	O
thyroid	O
-	O
stimulating	O
hormone	O
(	O
TSH	O
)	O
level	O
.	O

Only	O
the	O
first	O
entry	O
for	O
each	O
patient	O
from	O
inpatient	O
care	O
units	O
were	O
used	O
for	O
analysis	O
.	O

Usually	O
the	O
first	O
blood	O
tests	O
are	O
done	O
next	O
day	O
after	O
admission	O
to	O
our	O
units	O
.	O

Thus	O
,	O
we	O
have	O
assumed	O
that	O
most	O
patients	O
that	O
we	O
included	O
in	O
the	O
study	O
were	O
in	O
acute	O
phase	O
of	O
their	O
disorder	O
.	O

We	O
focused	O
on	O
patients	O
with	O
schizophrenia	O
(	O
all	O
subtypes	O
)	O
,	O
bipolar	O
disorder	O
and	O
unipolar	O
depression	O
.	O

Patients	O
of	O
all	O
ages	O
were	O
included	O
in	O
the	O
study	O
.	O

Results	O
for	O
1	O
,	O
685	O
Caucasian	O
patients	O
were	O
included	O
in	O
the	O
study	O
.	O

Patients	O
were	O
grouped	O
under	O
diagnostic	O
criteria	O
as	O
schizophrenia	B-phenotype
(	O
F20	B-code
according	O
to	O
ICD	B-coding_system
-	I-coding_system
10	I-coding_system
,	O
295	B-code
according	O
to	O
DSM	B-coding_system
-	I-coding_system
IV	I-coding_system
)	O
,	O
unipolar	B-phenotype
depression	I-phenotype
(	O
F31	B-code
and	O
F32	B-code
according	O
to	O
ICD	B-coding_system
-	I-coding_system
10	I-coding_system
,	O
296	B-code
.	I-code
2	I-code
and	O
296	B-code
.	I-code
3	I-code
according	O
to	O
DSM	B-coding_system
-	I-coding_system
IV	I-coding_system
)	O
,	O
bipolar	B-phenotype
disorder	I-phenotype
(	O
F30	B-code
and	O
F31	B-code
according	O
to	O
ICD	B-coding_system
-	I-coding_system
10	I-coding_system
,	O
296	B-code
.	O
[	O
0	O
,	O
4	O
,	O
6	O
]	O
according	O
to	O
DSM	B-coding_system
-	I-coding_system
IV	I-coding_system
)	O
,	O
bipolar	B-phenotype
depression	I-phenotype
(	O
F31	B-code
.	I-code
3–F31	I-code
.	I-code
5	I-code
according	O
to	O
ICD	B-coding_system
-	I-coding_system
10	I-coding_system
,	O
296	B-code
.	I-code
6	I-code
according	O
to	O
DSM	B-coding_system
-	I-coding_system
IV	I-coding_system
)	O
and	O
bipolar	B-phenotype
mania	I-phenotype
(	O
F30	B-code
and	O
F31	B-code
.	I-code
0–F31	I-code
.	I-code
2	I-code
according	O
to	O
ICD	B-coding_system
-	I-coding_system
10	I-coding_system
,	O
296	B-code
.	I-code
0	I-code
and	O
296	B-code
.	I-code
4	I-code
according	O
to	O
DSM	B-coding_system
-	I-coding_system
IV	I-coding_system
)	O
.	O

In	O
our	O
unit	O
diagnosis	O
is	O
based	O
on	O
the	O
ICD	B-coding_system
-	I-coding_system
10	I-coding_system
criteria	O
,	O
DSM	B-coding_system
-	I-coding_system
IV	I-coding_system
codes	O
were	O
given	O
as	O
reference	O
.	O

Blood	O
samples	O
were	O
drawn	O
for	O
all	O
patients	O
between	O
8	O
and	O
9	O
a	O
.	O
m	O
.	O
after	O
12	O
h	O
overnight	O
fast	O
.	O

Immediately	O
after	O
collecting	O
blood	O
samples	O
TSH	O
serum	O
level	O
was	O
determined	O
using	O
automatic	O
analyzer	O
Dirui	O
CS	O
-	O
400	O
(	O
Dirui	O
,	O
China	O
)	O
.	O

For	O
the	O
normal	O
range	O
three	O
different	O
criteria	O
were	O
used	O
:	O
(	O
1	O
)	O
the	O
currently	O
accepted	O
0	O
.	O
4–5	O
.	O

0	O
μIU	O
/	O
mL	O
range	O
;	O
(	O
2	O
)	O
the	O
0	O
.	O
3–3	O
.	O

0	O
μIU	O
/	O
mL	O
range	O
proposed	O
by	O
the	O
American	O
Association	O
of	O
Clinical	O
Endocrinology	O
[	O
18	O
]	O
;	O
and	O
(	O
3	O
)	O
the	O
0	O
.	O
4–2	O
.	O

5	O
μIU	O
/	O
mL	O
range	O
recommended	O
by	O
The	O
National	O
Academy	O
of	O
Clinical	O
Biochemistry	O
(	O
NACB	O
)	O
[	O
19	O
]	O
.	O

Statistical	O
procedures	O
were	O
performed	O
with	O
STATA	O
13	O
.	O
1	O
(	O
StataCorp	O
,	O
USA	O
)	O
.	O

Simple	O
descriptive	O
statistics	O
(	O
means	O
and	O
standard	O
deviations	O
)	O
were	O
generated	O
for	O
continuous	O
variables	O
.	O

For	O
discrete	O
variables	O
number	O
of	O
patients	O
and	O
percentages	O
are	O
given	O
.	O

Normality	O
of	O
distribution	O
was	O
tested	O
with	O
Shapiro–Wilk	O
test	O
.	O

TSH	O
level	O
did	O
not	O
follow	O
normal	O
distribution	O
,	O
even	O
after	O
transformation	O
of	O
this	O
variable	O
.	O

Inter	O
-	O
group	O
differences	O
were	O
analyzed	O
using	O
Kruskal–Wallis	O
test	O
(	O
for	O
TSH	O
level	O
)	O
or	O
one	O
-	O
way	O
ANOVA	O
(	O
for	O
age	O
)	O
,	O
intra	O
-	O
group	O
differences	O
were	O
analyzed	O
using	O
Wilcoxon	O
rank	O
-	O
sum	O
test	O
.	O

The	O
difference	O
between	O
proportions	O
was	O
analyzed	O
with	O
the	O
Chi	O
square	O
test	O
.	O

Associations	O
were	O
tested	O
by	O
Spearman’s	O
correlation	O
coefficient	O
.	O

The	O
significant	O
level	O
was	O
set	O
at	O
p	O
<	O
0	O
.	O
05	O
.	O

We	O
used	O
data	O
from	O
the	O
Veterans	O
Aging	O
Cohort	O
Study	O
(	O
VACS	O
)	O
,	O
which	O
has	O
been	O
described	O
in	O
detail	O
(	O
Fultz	O
et	O
al	O
.	O
,	O
2006	O
,	O
Justice	O
et	O
al	O
.	O
,	O
2006	O
)	O
.	O

Briefly	O
,	O
VACS	O
is	O
a	O
large	O
observational	O
cohort	O
based	O
on	O
data	O
from	O
the	O
national	O
Veterans	O
Health	O
Administration	O
(	O
VA	O
)	O
electronic	O
health	O
records	O
(	O
EHR	O
)	O
that	O
includes	O
all	O
HIV	O
-	O
infected	O
patients	O
in	O
VA	O
care	O
(	O
>	O
50	O
,	O
000	O
HIV	O
+	O
subjects	O
)	O
and	O
uninfected	O
patients	O
(	O
>	O
100	O
,	O
000	O
)	O
1	O
:	O
2	O
matched	O
on	O
region	O
,	O
age	O
,	O
race	O
/	O
ethnicity	O
,	O
and	O
sex	O
.	O

VACS	O
has	O
been	O
approved	O
by	O
the	O
institutional	O
review	O
boards	O
of	O
the	O
VA	O
Connecticut	O
Healthcare	O
System	O
and	O
Yale	O
School	O
of	O
Medicine	O
,	O
granted	O
a	O
waiver	O
of	O
informed	O
consent	O
,	O
and	O
deemed	O
Health	O
Insurance	O
Portability	O
and	O
Accountability	O
Act	O
compliant	O
.	O

For	O
this	O
analysis	O
,	O
we	O
included	O
HIV	O
+	O
and	O
HIV	O
-	O
uninfected	O
patients	O
who	O
did	O
(	O
gabapentin	O
exposed	O
)	O
and	O
did	O
not	O
(	O
gabapentin	O
unexposed	O
)	O
receive	O
gabapentin	O
dispensed	O
at	O
VA	O
pharmacies	O
.	O

For	O
the	O
gabapentin	O
exposed	O
group	O
,	O
we	O
included	O
all	O
patients	O
who	O
received	O
gabapentin	O
for	O
at	O
least	O
180	O
continuous	O
days	O
for	O
any	O
indication	O
between	O
1	O
January	O
2009	O
and	O
30	O
September	O
2015	O
from	O
the	O
following	O
VA	O
clinics	O
:	O
primary	O
care	O
,	O
infectious	O
disease	O
,	O
neurology	O
,	O
general	O
internal	O
medicine	O
,	O
physical	O
medicine	O
and	O
rehabilitation	O
services	O
,	O
pain	O
,	O
podiatry	O
,	O
orthopedics	O
,	O
women’s	O
clinic	O
,	O
and	O
rheumatology	O
.	O

These	O
clinics	O
were	O
chosen	O
because	O
they	O
were	O
the	O
source	O
of	O
most	O
gabapentin	O
prescriptions	O
.	O

To	O
ensure	O
that	O
unexposed	O
patients	O
came	O
from	O
the	O
same	O
source	O
population	O
and	O
had	O
an	O
equal	O
opportunity	O
to	O
receive	O
gabapentin	O
,	O
we	O
randomly	O
selected	O
one	O
outpatient	O
visit	O
date	O
per	O
calendar	O
year	O
to	O
identify	O
patients	O
who	O
attended	O
one	O
of	O
the	O
listed	O
clinics	O
but	O
never	O
received	O
gabapentin	O
.	O

Importantly	O
,	O
we	O
did	O
not	O
include	O
patients	O
with	O
gabapentin	O
prescriptions	O
from	O
substance	O
use	O
treatment	O
programs	O
;	O
however	O
,	O
we	O
did	O
not	O
exclude	O
patients	O
who	O
subsequently	O
visited	O
a	O
substance	O
use	O
treatment	O
program	O
during	O
follow	O
-	O
up	O
.	O

To	O
allow	O
us	O
to	O
follow	O
exposed	O
and	O
unexposed	O
patients	O
over	O
similar	O
calendar	O
time	O
,	O
we	O
created	O
an	O
“index	O
date”	O
(	O
also	O
referred	O
to	O
as	O
“baseline”	O
)	O
which	O
was	O
defined	O
as	O
the	O
first	O
fill	O
date	O
for	O
gabapentin	O
exposed	O
patients	O
and	O
the	O
random	O
outpatient	O
visit	O
date	O
for	O
unexposed	O
patients	O
.	O

We	O
utilized	O
a	O
12	O
-	O
month	O
washout	O
period	O
to	O
identify	O
new	O
episodes	O
of	O
gabapentin	O
exposure	O
.	O

Therefore	O
,	O
patients	O
who	O
received	O
gabapentin	O
in	O
2008	O
were	O
only	O
eligible	O
to	O
be	O
followed	O
after	O
a	O
one	O
-	O
year	O
period	O
of	O
no	O
gabapentin	O
exposure	O
.	O

We	O
excluded	O
patients	O
who	O
had	O
no	O
outpatient	O
care	O
in	O
the	O
VA	O
in	O
the	O
year	O
prior	O
to	O
their	O
index	O
date	O
and	O
those	O
who	O
had	O
no	O
measurement	O
of	O
alcohol	O
consumption	O
in	O
the	O
two	O
years	O
prior	O
to	O
their	O
index	O
date	O
.	O

We	O
also	O
excluded	O
patients	O
who	O
reported	O
no	O
alcohol	O
consumption	O
based	O
on	O
the	O
closest	O
measurement	O
to	O
baseline	O
.	O

To	O
address	O
concerns	O
of	O
confounding	O
by	O
indication	O
,	O
whereby	O
patients	O
with	O
specific	O
alcohol	O
consumption	O
patterns	O
might	O
be	O
more	O
likely	O
to	O
receive	O
gabapentin	O
,	O
we	O
generated	O
propensity	O
scores	O
.	O

Propensity	O
scores	O
are	O
used	O
to	O
adjust	O
for	O
the	O
conditional	O
probability	O
of	O
being	O
prescribed	O
gabapentin	O
given	O
a	O
set	O
of	O
covariates	O
that	O
are	O
associated	O
with	O
both	O
gabapentin	O
receipt	O
and	O
alcohol	O
consumption	O
or	O
associated	O
with	O
alcohol	O
consumption	O
only	O
(	O
Brookhart	O
et	O
al	O
.	O
,	O
2006	O
)	O
.	O

Matching	O
by	O
propensity	O
score	O
provides	O
a	O
means	O
to	O
balanced	O
exposure	O
groups	O
similar	O
to	O
random	O
treatment	O
allocation	O
in	O
a	O
randomized	O
controlled	O
trial	O
(	O
Austin	O
,	O
2011	O
)	O
.	O

We	O
hypothesized	O
that	O
the	O
effects	O
of	O
gabapentin	O
on	O
alcohol	O
consumption	O
may	O
differ	O
in	O
patients	O
with	O
and	O
without	O
diagnosed	O
AUD	O
prior	O
to	O
their	O
index	O
date	O
.	O

Therefore	O
,	O
propensity	O
scores	O
(	O
i	O
.	O
e	O
.	O
the	O
predicted	O
probability	O
of	O
gabapentin	O
exposure	O
)	O
were	O
estimated	O
using	O
separate	O
multivariable	O
logistic	O
regression	O
models	O
for	O
patients	O
with	O
and	O
without	O
AUD	O
at	O
baseline	O
,	O
as	O
defined	O
below	O
.	O

Estimating	O
propensity	O
scores	O
separately	O
has	O
been	O
shown	O
to	O
be	O
unbiased	O
,	O
particularly	O
in	O
subgroup	O
analyses	O
with	O
small	O
sample	O
sizes	O
(	O
Eeren	O
et	O
al	O
.	O
,	O
2015	O
,	O
Green	O
and	O
Stuart	O
,	O
2014	O
,	O
Rassen	O
et	O
al	O
.	O
,	O
2012	O
)	O
.	O

Variables	O
used	O
in	O
the	O
propensity	O
score	O
models	O
were	O
selected	O
a	O
priori	O
based	O
on	O
clinical	O
knowledge	O
(	O
Hernan	O
et	O
al	O
.	O
,	O
2002	O
)	O
and	O
included	O
:	O
year	O
of	O
index	O
date	O
,	O
age	O
at	O
baseline	O
,	O
race	O
,	O
smoking	O
status	O
,	O
body	O
mass	O
index	O
at	O
baseline	O
,	O
site	O
prescribing	O
pattern	O
(	O
the	O
proportion	O
of	O
patients	O
who	O
initiated	O
gabapentin	O
stratified	O
by	O
year	O
and	O
HIV	O
status	O
)	O
,	O
lab	O
values	O
closest	O
to	O
the	O
index	O
date	O
(	O
including	O
haemoglobin	O
,	O
international	O
normalized	O
ratio	O
,	O
triglycerides	O
,	O
CD4	O
cell	O
count	O
)	O
,	O
hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
status	O
,	O
HIV	O
status	O
,	O

history	O
of	O
seizure	O
prior	O
to	O
baseline	O
,	O
diabetes	O
complications	O
severity	O
index	O
(	O
Young	O
et	O
al	O
.	O
,	O
2008	O
)	O
at	O
baseline	O
,	O
history	O
of	O
pain	O
diagnoses	O
prior	O
to	O
baseline	O
(	O
including	O
neuropathy	O
,	O
osteoarthritis	O
,	O
or	O
pain	O
in	O
the	O
abdomen	O
,	O
back	O
,	O
chest	O
,	O
extremity	O
,	O
or	O
neck	O
,	O
headache	O
,	O
or	O
fracture	O
)	O
,	O
and	O
history	O
of	O
medical	O
and	O
psychiatric	O
conditions	O
prior	O
to	O
baseline	O
(	O
including	O
atrial	O
fibrillation	O
,	O
myocardial	O
infarction	O
/	O
coronary	O
artery	O
disease	O
,	O
peripheral	O
vascular	O
disease	O
,	O
diabetes	O
,	O
nephrolithiasis	O
,	O
glomerulonephritis	O
,	O
hyperlipidemia	O
,	O

pancreatitis	O
,	O
drug	O
use	O
disorders	O
,	O
post	O
-	O
traumatic	O
stress	O
disorder	O
(	O
PTSD	O
)	O
,	O
major	O
or	O
other	O
depression	O
,	O
anxiety	O
,	O
bipolar	O
disorder	O
,	O
schizophrenia	O
and	O
schizoaffective	O
disorder	O
)	O
.	O

We	O
also	O
included	O
variables	O
that	O
captured	O
attendance	O
to	O
clinics	O
(	O
including	O
primary	O
care	O
,	O
dialysis	O
,	O
diabetic	O
retinal	O
screening	O
,	O
rheumatology	O
,	O
infectious	O
disease	O
,	O
nephrology	O
,	O
neurology	O
,	O
pain	O
,	O
allergy	O
,	O
chiropractic	O
,	O
dental	O
,	O
diabetes	O
,	O
emergency	O
department	O
,	O
electrocardiogram	O
lab	O
,	O
ophthalmology	O
,	O
hematology	O
,	O
oncology	O
,	O
homeless	O
program	O
,	O
nutrition	O
,	O
orthopedics	O
,	O
substance	O
use	O
,	O
mental	O
health	O
,	O
PTSD	O
)	O
,	O
frequency	O
of	O
all	O
-	O
cause	O
hospitalizations	O
,	O
and	O
the	O
total	O
number	O
of	O
unique	O
clinics	O
visited	O
in	O
the	O
year	O
prior	O
to	O
baseline	O
.	O

Lastly	O
,	O
variables	O
denoting	O
receipt	O
of	O
other	O
prescriptions	O
(	O
starting	O
on	O
or	O
elapsing	O
baseline	O
)	O
to	O
treat	O
pain	O
(	O
including	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
,	O
opioids	O
,	O
muscle	O
relaxants	O
,	O
and	O
antidepressants	O
)	O
and	O
seizures	O
were	O
included	O
in	O
the	O
model	O
.	O

Interaction	O
terms	O
were	O
explored	O
for	O
significance	O
,	O
and	O
six	O
were	O
kept	O
in	O
the	O
final	O
model	O
(	O
all	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
model	O
c	O
-	O
statistic	O
was	O
0	O
.	O
83	O
for	O
patients	O
with	O
AUD	O
and	O
0	O
.	O
84	O
in	O
patients	O
without	O
AUD	O
,	O
indicating	O
adequate	O
discrimination	O
between	O
gabapentin	O
exposed	O
and	O
unexposed	O
patients	O
in	O
both	O
models	O
(	O
Hosmer	O
and	O
Lemeshow	O
,	O
2000	O
)	O
.	O

Since	O
the	O
distribution	O
of	O
propensity	O
scores	O
for	O
exposed	O
patients	O
was	O
different	O
than	O
that	O
of	O
unexposed	O
patients	O
,	O
we	O
used	O
propensity	O
score	O
matching	O
to	O
exclude	O
non	O
-	O
exchangeable	O
unexposed	O
patients	O
(	O
Figure	O
1	O
)	O
(	O
Spoendlin	O
et	O
al	O
.	O
,	O
2016	O
)	O
.	O

We	O
conducted	O
propensity	O
score	O
matching	O
within	O
pre	O
-	O
specified	O
subgroups	O
of	O
patients	O
based	O
on	O
baseline	O
Alcohol	O
Use	O
Disorders	O
Identification	O
Test	O
–	O
Consumption	O
(	O
AUDIT	O
-	O
C	O
)	O
scores	O
and	O
aggregated	O
these	O
subgroup	O
strata	O
to	O
create	O
the	O
full	O
matched	O
cohort	O
(	O
Wang	O
et	O
al	O
.	O
,	O
2018	O
)	O
.	O

Each	O
exposed	O
patient	O
was	O
matched	O
to	O
up	O
to	O
five	O
unexposed	O
patients	O
with	O
index	O
dates	O
in	O
the	O
same	O
calendar	O
year	O
,	O
using	O
a	O
greedy	O
matching	O
algorithm	O
(	O
Cormen	O
,	O
2009	O
)	O
.	O

Baseline	B-phenotype
AUD	I-phenotype
was	O
determined	O
by	O
one	O
inpatient	O
or	O
two	O
outpatient	O
ICD	B-coding_system
-	I-coding_system
9	I-coding_system
codes	O
(	O
303	B-code
.	I-code
X	I-code
or	O
305–305	B-code
.	I-code
03	I-code
)	O
at	O
any	O
time	O
prior	O
to	O
baseline	O
.	O

Alcohol	O
consumption	O
was	O
assessed	O
using	O
the	O
AUDIT	O
-	O
C	O
,	O
a	O
three	O
-	O
question	O
self	O
-	O
report	O
alcohol	O
screening	O
questionnaire	O
that	O
detects	O
heavy	O
drinking	O
and	O
/	O
or	O
active	O
AUD	O
(	O
Bush	O
et	O
al	O
.	O
,	O
1998	O
,	O
Fiellin	O
et	O
al	O
.	O
,	O
2000	O
)	O
.	O

AUDIT	O
-	O
C	O
scores	O
range	O
from	O
0–12	O
with	O
the	O
likelihood	O
of	O
physiologic	O
injury	O
and	O
mortality	O
increasing	O
as	O
AUDIT	O
-	O
C	O
scores	O
increase	O
(	O
Justice	O
et	O
al	O
.	O
,	O
2016	O
)	O
.	O

An	O
AUDIT	O
-	O
C	O
score	O
of	O
zero	O
is	O
defined	O
as	O
no	O
current	O
alcohol	O
use	O
,	O
1–3	O
suggests	O
lower	O
-	O
risk	O
drinking	O
,	O
4–7	O
suggests	O
at	O
-	O
risk	O
drinking	O
,	O
and	O
≥8	O
suggest	O
hazardous	O
or	O
heavy	O
episodic	O
alcohol	O
consumption	O
.	O

Since	O
2007	O
,	O
the	O
VA	O
has	O
required	O
annual	O
AUDIT	O
-	O
C	O
screening	O
on	O
all	O
patients	O
in	O
primary	O
care	O
(	O
Bradley	O
et	O
al	O
.	O
,	O
2006	O
)	O
.	O

All	O
patients	O
were	O
followed	O
from	O
their	O
index	O
date	O
for	O
a	O
maximum	O
of	O
two	O
years	O
or	O
until	O
their	O
last	O
VA	O
visit	O
or	O
death	O
.	O

Additionally	O
,	O
gabapentin	O
exposed	O
patients	O
were	O
censored	O
at	O
30	O
days	O
after	O
the	O
end	O
of	O
their	O
last	O
gabapentin	O
prescription	O
(	O
allowing	O
for	O
a	O
maximum	O
30	O
-	O
day	O
gap	O
between	O
fills	O
)	O
.	O

To	O
ensure	O
equal	O
follow	O
-	O
up	O
time	O
within	O
matched	O
sets	O
,	O
unexposed	O
patients	O
were	O
censored	O
at	O
the	O
total	O
follow	O
-	O
up	O
time	O
of	O
their	O
matched	O
exposed	O
patient	O
.	O

All	O
statistical	O
analyses	O
were	O
performed	O
separately	O
for	O
patients	O
with	O
and	O
without	O
AUD	O
at	O
baseline	O
.	O

While	O
evidence	O
of	O
alcohol	O
consumption	O
at	O
baseline	O
as	O
measured	O
by	O
the	O
AUDIT	O
-	O
C	O
was	O
a	O
criterion	O
for	O
study	O
inclusion	O
,	O
we	O
did	O
not	O
restrict	O
matching	O
eligibility	O
on	O
the	O
availability	O
of	O
a	O
follow	O
-	O
up	O
AUDIT	O
-	O
C	O
(	O
the	O
outcome	O
)	O
as	O
such	O
a	O
restriction	O
would	O
not	O
be	O
available	O
at	O
baseline	O
in	O
an	O
analogous	O
randomized	O
clinical	O
trial	O
.	O

Thus	O
,	O
1	O
,	O
119	O
(	O
44	O
%	O
)	O
exposed	O
patients	O
in	O
the	O
propensity	O
score	O
matched	O
sample	O
did	O
not	O
have	O
a	O
follow	O
-	O
up	O
AUDIT	O
-	O
C	O
and	O
were	O
unable	O
to	O
be	O
included	O
in	O
regression	O
models	O
.	O

If	O
an	O
exposed	O
patient	O
did	O
not	O
have	O
a	O
follow	O
-	O
up	O
AUDIT	O
-	O
C	O
,	O
we	O
removed	O
their	O
entire	O
matched	O
set	O
of	O
unexposed	O
patients	O
to	O
maintain	O
a	O
balanced	O
sample	O
.	O

If	O
an	O
unexposed	O
patient	O
did	O
not	O
have	O
a	O
follow	O
-	O
up	O
AUDIT	O
-	O
C	O
,	O
we	O
kept	O
the	O
remaining	O
patients	O
in	O
their	O
matched	O
set	O
in	O
the	O
analytic	O
sample	O
as	O
long	O
as	O
there	O
was	O
another	O
unexposed	O
patient	O
in	O
the	O
set	O
.	O

We	O
used	O
chi	O
-	O
square	O
tests	O
to	O
examine	O
balance	O
between	O
exposed	O
and	O
unexposed	O
patients	O
included	O
in	O
the	O
full	O
sample	O
,	O
propensity	O
-	O
score	O
matched	O
sample	O
,	O
and	O
final	O
analytic	O
sample	O
.	O

Among	O
those	O
in	O
the	O
final	O
analytic	O
sample	O
,	O
we	O
calculated	O
the	O
average	O
pre	O
-	O
and	O
post	O
-	O
index	O
AUDIT	O
-	O
C	O
scores	O
.	O

Pre	O
-	O
index	O
AUDIT	O
-	O
C	O
scores	O
were	O
defined	O
as	O
the	O
closest	O
on	O
or	O
before	O
the	O
index	O
date	O
,	O
within	O
a	O
maximum	O
of	O
two	O
years	O
.	O

Post	O
-	O
index	O
AUDIT	O
-	O
C	O
scores	O
were	O
defined	O
as	O
the	O
closest	O
measure	O
to	O
the	O
end	O
of	O
exposure	O
or	O
within	O
30	O
days	O
of	O
end	O
of	O
follow	O
-	O
up	O
.	O

We	O
then	O
used	O
multivariable	O
difference	O
-	O
in	O
-	O
difference	O
(	O
DiD	O
)	O
linear	O
regression	O
models	O
(	O
Donald	O
and	O
Lang	O
,	O
2007	O
,	O
Lechner	O
,	O
2011	O
)	O
to	O
estimate	O
the	O
differential	O
change	O
between	O
pre	O
-	O
and	O
post	O
-	O
index	O
AUDIT	O
-	O
C	O
scores	O
.	O

We	O
a	O
priori	O
considered	O
a	O
DiD	O
estimate	O
≥1	O
point	O
clinically	O
meaningful	O
(	O
Rubinsky	O
et	O
al	O
.	O
,	O
2013	O
)	O
.	O

To	O
account	O
for	O
residual	O
confounding	O
not	O
captured	O
by	O
propensity	O
score	O
matching	O
,	O
models	O
were	O
adjusted	O
for	O
any	O
characteristic	O
shown	O
to	O
be	O
unbalanced	O
between	O
exposed	O
and	O
unexposed	O
patients	O
in	O
addition	O
to	O
age	O
,	O
total	O
number	O
of	O
medications	O
prescribed	O
during	O
follow	O
-	O
up	O
,	O
and	O
VACS	O
Index	O
.	O

The	O
VACS	O
Index	O
–	O
a	O
measure	O
of	O
physiologic	O
injury	O
incorporating	O
age	O
,	O
CD4	O
count	O
,	O
HIV	O
-	O
1	O
RNA	O
,	O
hemoglobin	O
,	O
a	O
marker	O
of	O
liver	O
fibrosis	O
(	O
FIB	O
-	O
4	O
)	O
,	O
estimated	O
glomerular	O
filtration	O
rate	O
(	O
eGFR	O
)	O
,	O
and	O
HCV	O
status	O
–	O
has	O
been	O
shown	O
to	O
predict	O
acquired	O
immunodeficiency	O
syndrome	O
(	O
AIDS	O
)	O
and	O
non	O
-	O
AIDS	O
morbidity	O
and	O
mortality	O
in	O
multiple	O
settings	O
(	O
Akgun	O
et	O
al	O
.	O
,	O
2013	O
,	O
Akgun	O
et	O
al	O
.	O
,	O
2014	O
,	O
Escota	O
et	O
al	O
.	O
,	O
2015	O
,	O
Justice	O
et	O
al	O
.	O
,	O
2013	O
,	O
Marquine	O
et	O
al	O
.	O
,	O
2014	O
,	O
Tate	O
et	O
al	O
.	O
,	O
2013	O
,	O
Womack	O
et	O
al	O
.	O
,	O
2013	O
)	O
.	O

We	O
also	O
performed	O
subgroup	O
analyses	O
by	O
self	O
-	O
reported	O
level	O
of	O
alcohol	O
consumption	O
at	O
baseline	O
(	O
as	O
determined	O
by	O
AUDIT	O
-	O
C	O
)	O
and	O
average	O
daily	O
gabapentin	O
dose	O
during	O
follow	O
-	O
up	O
.	O

Daily	O
dose	O
was	O
categorized	O
to	O
include	O
roughly	O
equal	O
numbers	O
of	O
patients	O
in	O
each	O
group	O
:	O
low	O
(	O
<	O
600	O
milligrams	O
[	O
mg	O
]	O
)	O
,	O
medium	O
(	O
600	O
mg	O
-	O
1	O
,	O
499	O
mg	O
)	O
,	O
and	O
high	O
(	O
≥1	O
,	O
500	O
mg	O
)	O
.	O

Lastly	O
,	O
we	O
conducted	O
a	O
sensitivity	O
analysis	O
excluding	O
patients	O
with	O
a	O
visit	O
to	O
a	O
substance	O
use	O
treatment	O
program	O
during	O
follow	O
-	O
up	O
.	O

All	O
statistical	O
analyses	O
were	O
performed	O
using	O
SAS	O
version	O
9	O
.	O
4	O
(	O
SAS	O
Institute	O
Inc	O
.	O
,	O
Cary	O
,	O
NC	O
,	O
USA	O
)	O
.	O

Norway	O
has	O
a	O
total	O
population	O
of	O
five	O
million	O
people	O
.	O

Compared	O
to	O
the	O
UK	O
and	O
many	O
other	O
countries	O
,	O
Norway	O
has	O
more	O
rural	O
areas	O
and	O
a	O
lower	O
population	O
density	O
.	O

The	O
standard	O
of	O
living	O
is	O
generally	O
high	O
.	O

Mental	O
health	O
service	O
provisions	O
for	O
adults	O
consist	O
of	O
primary	O
care	O
and	O
specialized	O
mental	O
health	O
services	O
.	O

The	O
primary	O
health	O
-	O
care	O
services	O
run	O
by	O
the	O
429	O
municipalities	O
consist	O
of	O
general	O
practitioners	O
(	O
GPs	O
)	O
and	O
primary	O
care	O
mental	O
health	O
teams	O
,	O
usually	O
staffed	O
by	O
psychiatric	O
nurses	O
,	O
social	O
workers	O
,	O
and	O
occupational	O
therapists	O
.	O

Many	O
municipalities	O
have	O
residential	O
care	O
,	O
day	O
-	O
care	O
centres	O
for	O
people	O
with	O
mental	O
health	O
problems	O
,	O
and	O
ambulatory	O
care	O
.	O

The	O
specialized	O
mental	O
health	O
services	O
run	O
by	O
the	O
20	O
health	O
authorities	O
and	O
trusts	O
include	O
75	O
CMHCs	O
,	O
hospitals	O
with	O
acute	O
psychiatric	O
wards	O
and	O
specialized	O
wards	O
,	O
and	O
psychiatrists	O
/	O
psychologists	O
in	O
private	O
practice	O
.	O

The	O
CMHCs	O
usually	O
consist	O
of	O
outpatient	O
clinics	O
,	O
in	O
-	O
patient	O
wards	O
,	O
day	O
care	O
,	O
and	O
one	O
or	O
more	O
specialized	O
teams	O
(	O
case	O
management	O
teams	O
,	O
early	O
intervention	O
teams	O
for	O
first	O
-	O
episode	O
psychoses	O
,	O
CRTs	O
,	O
and	O
assertive	O
community	O
treatment	O
teams	O
)	O
.	O

Specialized	O
services	O
for	O
substance	O
abuse	O
are	O
usually	O
organized	O
as	O
part	O
of	O
the	O
specialized	O
mental	O
health	O
services	O
run	O
by	O
the	O
health	O
authorities	O
.	O

In	O
2005	O
,	O
the	O
Norwegian	O
national	O
health	O
authorities	O
decided	O
to	O
implement	O
CRTs	O
in	O
all	O
CMHCs	O
.	O

The	O
aim	O
was	O
to	O
increase	O
the	O
availability	O
and	O
mobility	O
of	O
specialized	O
mental	O
health	O
services	O
to	O
manage	O
episodes	O
of	O
acute	O
mental	O
health	O
crisis	O
outside	O
in	O
-	O
patient	O
wards	O
[	O
4	O
]	O
.	O

In	O
Norway	O
,	O
patients	O
may	O
be	O
admitted	O
either	O
to	O
in	O
-	O
patient	O
mental	O
health	O
care	O
in	O
acute	O
psychiatric	O
wards	O
in	O
hospitals	O
or	O
to	O
in	O
-	O
patient	O
wards	O
in	O
CMHCs	O
(	O
both	O
referred	O
to	O
below	O
as	O
in	O
-	O
patient	O
wards	O
)	O
.	O

CRTs	O
can	O
admit	O
patients	O
to	O
both	O
.	O

In	O
2008	O
,	O
there	O
were	O
61	O
CMHCs	O
beds	O
and	O
21	O
acute	O
psychiatric	O
ward	O
beds	O
in	O
hospitals	O
per	O
100	O
,	O
000	O
inhabitants	O
[	O
18	O
]	O
.	O

Only	O
acute	O
psychiatric	O
wards	O
in	O
hospitals	O
have	O
a	O
mandatory	O
duty	O
to	O
accept	O
emergency	O
admissions	O
.	O

Most	O
of	O
the	O
in	O
-	O
patient	O
CMHC	O
wards	O
are	O
not	O
certified	O
for	O
involuntary	O
treatment	O
.	O

Unlike	O
the	O
UK	O
system	O
,	O
where	O
CRTs	O
gate	O
-	O
keep	O
the	O
beds	O
,	O
the	O
Norwegian	O
CRTs	O
do	O
not	O
have	O
a	O
gate	O
-	O
keeping	O
role	O
.	O

In	O
-	O
patient	O
referrals	O
are	O
made	O
by	O
GPs	O
,	O
casualty	O
clinics	O
,	O
CRTs	O
,	O
or	O
other	O
CMHC	O
teams	O
or	O
clinical	O
units	O
.	O

The	O
sample	O
consisted	O
of	O
680	O
consecutive	O
patients	O
aged	O
18	O
years	O
or	O
older	O
who	O
presented	O
with	O
a	O
mental	O
health	O
crisis	O
in	O
a	O
face	O
-	O
to	O
-	O
face	O
consultation	O
in	O
one	O
of	O
eight	O
CRTs	O
during	O
a	O
3	O
-	O
month	O
inclusion	O
period	O
in	O
2005	O
/	O
2006	O
.	O

Detailed	O
descriptions	O
of	O
patients	O
,	O
CRT	O
teams	O
,	O
and	O
the	O
content	O
of	O
treatment	O
have	O
been	O
reported	O
previously	O
[	O
19	O
,	O
20	O
]	O
.	O

The	O
eight	O
participating	O
CRTs	O
comprised	O
all	O
of	O
the	O
CRTs	O
in	O
Norway	O
at	O
that	O
time	O
,	O
except	O
one	O
that	O
had	O
recently	O
carried	O
out	O
a	O
study	O
of	O
its	O
own	O
[	O
21	O
]	O
.	O

The	O
populations	O
of	O
the	O
eight	O
catchment	O
areas	O
ranged	O
from	O
65	O
,	O
000	O
to	O
115	O
,	O
000	O
.	O

There	O
were	O
CRTs	O
from	O
each	O
of	O
the	O
five	O
health	O
regions	O
of	O
the	O
country	O
,	O
from	O
both	O
urban	O
and	O
rural	O
areas	O
.	O

Norway	O
is	O
a	O
homogeneous	O
society	O
with	O
relatively	O
minor	O
differences	O
in	O
living	O
standards	O
between	O
urban	O
and	O
rural	O
areas	O
.	O

None	O
of	O
the	O
catchment	O
areas	O
can	O
be	O
characterized	O
as	O
highly	O
deprived	O
.	O

None	O
of	O
the	O
CRTs	O
operated	O
with	O
a	O
rapid	O
response	O
,	O
24	O
/	O
7	O
availability	O
,	O
nor	O
had	O
gate	O
-	O
keeping	O
functions	O
for	O
acute	O
wards	O
[	O
19	O
]	O
.	O

Compared	O
to	O
the	O
UK	O
,	O
the	O
Norwegian	O
CRTs	O
provide	O
less	O
intensive	O
and	O
less	O
out	O
-	O
of	O
-	O
office	O
care	O
(	O
7	O
.	O
4	O
%	O
of	O
the	O
patients	O
had	O
had	O
consultations	O
more	O
than	O
twice	O
weekly	O
)	O
[	O
20	O
]	O
.	O

Referral	O
practices	O
to	O
in	O
-	O
patient	O
wards	O
from	O
the	O
CRTs	O
varied	O
between	O
the	O
teams	O
.	O

Some	O
CRTs	O
wanted	O
GPs	O
and	O
casualty	O
clinics	O
to	O
admit	O
patients	O
directly	O
to	O
the	O
in	O
-	O
patient	O
wards	O
when	O
there	O
was	O
no	O
doubt	O
that	O
the	O
patient	O
should	O
be	O
admitted	O
.	O

Others	O
wanted	O
involuntary	O
admissions	O
to	O
go	O
directly	O
to	O
hospitals	O
during	O
the	O
CRT’s	O
opening	O
hours	O
.	O

By	O
2010	O
,	O
CRTs	O
had	O
been	O
established	O
at	O
51	O
of	O
the	O
75	O
CMHCs	O
in	O
Norway	O
.	O

Thirty	O
of	O
these	O
operated	O
only	O
during	O
office	O
hours	O
,	O
and	O
only	O
one	O
had	O
24	O
-	O
hour	O
availability	O
[	O
22	O
]	O
.	O

Half	O
of	O
the	O
teams	O
established	O
in	O
2008	O
had	O
no	O
full	O
-	O
time	O
psychiatrist	O
[	O
18	O
]	O
.	O

This	O
indicates	O
that	O
the	O
CRTs	O
may	O
not	O
have	O
changed	O
significantly	O
since	O
our	O
data	O
were	O
collected	O
,	O
and	O
that	O
our	O
data	O
are	O
still	O
representative	O
.	O

A	O
registration	O
form	O
was	O
used	O
to	O
record	O
information	O
about	O
the	O
patients	O
and	O
their	O
treatment	O
from	O
admission	O
to	O
discharge	O
.	O

The	O
form	O
was	O
developed	O
and	O
piloted	O
in	O
collaboration	O
with	O
the	O
clinical	O
staff	O
of	O
the	O
CRTs	O
from	O
2003	O
to	O
2005	O
.	O

The	O
clinicians	O
in	O
each	O
team	O
jointly	O
completed	O
the	O
form	O
for	O
every	O
patient	O
who	O
received	O
at	O
least	O
one	O
consultation	O
.	O

The	O
inclusion	O
period	O
started	O
at	O
different	O
time	O
points	O
for	O
different	O
CRTs	O
(	O
between	O
November	O
2005	O
and	O
April	O
2006	O
)	O
.	O

The	O
CRTs	O
included	O
all	O
patients	O
referred	O
during	O
the	O
3	O
-	O
month	O
inclusion	O
period	O
,	O
and	O
where	O
necessary	O
the	O
period	O
was	O
extended	O
to	O
obtain	O
a	O
minimum	O
of	O
60	O
patients	O
to	O
provide	O
a	O
reasonable	O
sample	O
of	O
patients	O
from	O
each	O
team	O
for	O
a	O
comparative	O
data	O
analysis	O
.	O

Each	O
team	O
leader	O
also	O
completed	O
a	O
questionnaire	O
about	O
the	O
organization	O
and	O
operation	O
of	O
the	O
team	O
.	O

Data	O
was	O
obtained	O
on	O
socio	O
-	O
demographic	O
and	O
clinical	O
characteristics	O
,	O
contact	O
during	O
the	O
48	O
hours	O
prior	O
to	O
referral	O
to	O
the	O
CRT	O
,	O
and	O
the	O
referral	O
process	O
.	O

Type	O
and	O
severity	O
of	O
psychiatric	B-phenotype
problems	I-phenotype
and	O
level	O
of	O
functioning	O
were	O
assessed	O
using	O
the	O
International	B-coding_system
Statistical	I-coding_system
Classification	I-coding_system
of	I-coding_system
Diseases	I-coding_system
and	I-coding_system
Related	I-coding_system
Health	I-coding_system
Problems	I-coding_system
,	I-coding_system
10th	I-coding_system
revision	I-coding_system
(	I-coding_system
ICD	I-coding_system
-	I-coding_system
10	I-coding_system
)	I-coding_system
for	O
diagnoses	O
[	O
23	O
]	O
,	O
the	O
Health	O
of	O
the	O
Nation	O
Outcome	O
Scale	O
(	O
HoNOS	O
)	O
[	O
24	O
]	O
,	O
and	O
Global	O
Assessment	O
of	O
Functioning	O
Scale	O
(	O
GAF	O
)	O
[	O
25	O
]	O
.	O

The	O
HoNOS	O
consists	O
of	O
12	O
problem	O
area	O
subscales	O
,	O
each	O
of	O
which	O
rates	O
problems	O
using	O
the	O
options	O
of	O
0	O
(	O
no	O
problem	O
)	O
,	O
1	O
(	O
minor	O
problem	O
requiring	O
no	O
action	O
)	O
,	O
2	O
(	O
mild	O
problem	O
,	O
but	O
definitely	O
present	O
)	O
,	O
3	O
(	O
moderately	O
severe	O
problem	O
)	O
,	O
to	O
4	O
(	O
severe	O
to	O
very	O
severe	O
problem	O
)	O
.	O

The	O
subscales	O
relevant	O
to	O
,	O
and	O
included	O
in	O
,	O
this	O
study	O
were	O
non	O
-	O
accidental	O
self	O
-	O
injury	O
(	O
HoNOS	O
2	O
)	O
,	O
problems	O
with	O
drinking	O
or	O
drug	O
-	O
taking	O
(	O
HoNOS	O
3	O
)	O
,	O
problems	O
with	O
hallucinations	O
and	O
delusions	O
(	O
HoNOS	O
6	O
)	O
,	O
and	O
problems	O
with	O
depressed	O
mood	O
(	O
HoNOS	O
7	O
)	O
.	O

Clinicians	O
received	O
4	O
hours’	O
training	O
in	O
the	O
use	O
of	O
the	O
HoNOS	O
,	O
based	O
on	O
the	O
training	O
model	O
developed	O
in	O
the	O
UK	O
.	O

An	O
earlier	O
study	O
,	O
which	O
used	O
the	O
same	O
training	O
for	O
clinicians	O
,	O
showed	O
acceptable	O
inter	O
-	O
rater	O
reliability	O
(	O
intra	O
-	O
class	O
correlation	O
coefficient	O
of	O
0	O
.	O
60–0	O
.	O

89	O
)	O
for	O
the	O
HoNOS	O
subscales	O
used	O
in	O
this	O
paper	O
[	O
26	O
]	O
.	O

Several	O
studies	O
have	O
indicated	O
moderately	O
high	O
internal	O
consistency	O
and	O
low	O
item	O
redundancy	O
for	O
the	O
HoNOS	O
sum	O
score	O
,	O
and	O
therefore	O
support	O
the	O
instrument	O
as	O
an	O
adequate	O
measure	O
of	O
symptom	O
severity	O
[	O
27	O
]	O
.	O

We	O
used	O
a	O
split	O
version	O
of	O
the	O
GAF	O
consisting	O
of	O
two	O
scales	O
ranging	O
from	O
1	O
to	O
100	O
for	O
symptom	O
severity	O
and	O
functional	O
impairment	O
[	O
25	O
]	O
.	O

Clinicians	O
were	O
familiar	O
with	O
the	O
use	O
of	O
the	O
GAF	O
because	O
it	O
is	O
a	O
routine	O
measure	O
in	O
Norwegian	O
mental	O
health	O
services	O
.	O

Jones	O
et	O
al	O
.	O
found	O
the	O
GAF	O
scales’	O
reliability	O
and	O
validity	O
to	O
be	O
satisfactory	O
[	O
28	O
]	O
.	O

Söderberg	O
et	O
al	O
.	O
suggested	O
that	O
when	O
staff	O
use	O
patients’	O
GAF	O
scores	O
to	O
measure	O
changes	O
and	O
outcomes	O
,	O
it	O
might	O
be	O
necessary	O
to	O
use	O
several	O
raters	O
for	O
each	O
individual	O
patient	O
[	O
29	O
]	O
.	O

In	O
our	O
study	O
,	O
two	O
or	O
more	O
raters	O
usually	O
collaborated	O
to	O
complete	O
the	O
registration	O
form	O
,	O
including	O
the	O
GAF	O
score	O
.	O

Suicide	O
risk	O
was	O
coded	O
as	O
:	O
(	O
i	O
)	O
no	O
suicidal	O
thoughts	O
or	O
plans	O
;	O
(	O
ii	O
)	O
passive	O
death	O
wishes	O
or	O
suicidal	O
thoughts	O
without	O
concrete	O
plans	O
;	O
(	O
iii	O
)	O
concrete	O
suicidal	O
plans	O
or	O
self	O
-	O
injury	O
,	O
but	O
no	O
death	O
intention	O
;	O
and	O
(	O
iv	O
)	O
self	O
-	O
injury	O
with	O
death	O
intention	O
.	O

This	O
scale	O
was	O
designed	O
in	O
collaboration	O
with	O
the	O
National	O
Centre	O
for	O
Suicide	O
Research	O
and	O
Prevention	O
[	O
30	O
]	O
.	O

Some	O
patients	O
were	O
brought	O
to	O
the	O
attention	O
of	O
the	O
CRTs	O
by	O
reports	O
from	O
seriously	O
concerned	O
family	O
,	O
friends	O
,	O
or	O
neighbours	O
,	O
from	O
the	O
staff	O
at	O
casualty	O
departments	O
,	O
CMHCs	O
or	O
primary	O
care	O
mental	O
health	O
teams	O
,	O
or	O
from	O
GPs	O
.	O

The	O
police	O
were	O
asked	O
for	O
assistance	O
in	O
a	O
crisis	O
if	O
there	O
was	O
a	O
risk	O
of	O
harm	O
to	O
the	O
patient	O
or	O
others	O
,	O
or	O
if	O
the	O
crisis	O
was	O
occurring	O
in	O
the	O
community	O
and	O
the	O
public	O
was	O
concerned	O
for	O
their	O
safety	O
.	O

Some	O
of	O
these	O
patients	O
were	O
uncooperative	O
during	O
the	O
initial	O
assessment	O
.	O

The	O
questionnaire	O
to	O
the	O
team	O
leaders	O
sought	O
information	O
on	O
opening	O
hours	O
,	O
whether	O
there	O
was	O
a	O
full	O
-	O
time	O
doctor	O
on	O
the	O
team	O
,	O
number	O
of	O
patients	O
treated	O
during	O
the	O
inclusion	O
period	O
,	O
number	O
of	O
team	O
members	O
,	O
focus	O
on	O
home	O
treatment	O
,	O
whether	O
there	O
was	O
a	O
psychosis	O
team	O
in	O
the	O
catchment	O
area	O
,	O
whether	O
the	O
CRT	O
had	O
the	O
authority	O
to	O
admit	O
patients	O
to	O
acute	O
in	O
-	O
patient	O
wards	O
,	O
and	O
whether	O
they	O
accepted	O
self	O
-	O
referrals	O
.	O

The	O
study	O
was	O
approved	O
by	O
the	O
Regional	O
Committee	O
on	O
Ethics	O
in	O
Medical	O
Research	O
,	O
the	O
Norwegian	O
Data	O
Inspectorate	O
and	O
the	O
Directorate	O
of	O
Health	O
.	O

Written	O
consent	O
was	O
not	O
requested	O
because	O
the	O
Regional	O
Committee	O
on	O
Ethics	O
in	O
Medical	O
Research	O
agreed	O
that	O
,	O
for	O
ethical	O
reasons	O
,	O
it	O
was	O
important	O
to	O
include	O
all	O
patients	O
in	O
need	O
of	O
acute	O
treatment	O
,	O
especially	O
those	O
with	O
severe	O
mental	O
illnesses	O
who	O
probably	O
would	O
not	O
have	O
had	O
the	O
capacity	O
to	O
give	O
written	O
consent	O
.	O

The	O
in	O
-	O
patient	O
wards	O
admit	O
patients	O
from	O
areas	O
with	O
and	O
without	O
CRTs	O
,	O
and	O
the	O
Norwegian	O
Data	O
Inspectorate	O
did	O
not	O
allow	O
us	O
to	O
record	O
in	O
which	O
municipalities	O
the	O
patients	O
lived	O
.	O

We	O
were	O
therefore	O
unable	O
to	O
analyse	O
differences	O
in	O
admission	O
rates	O
between	O
wards	O
with	O
and	O
without	O
CRTs	O
in	O
their	O
areas	O
.	O

Representatives	O
of	O
the	O
user	O
organizations	O
,	O
Mental	O
Health	O
Norway	O
and	O
The	O
National	O
Association	O
for	O
Relatives	O
in	O
Mental	O
Health	O
,	O
participated	O
in	O
a	O
reference	O
group	O
and	O
in	O
the	O
workshops	O
for	O
the	O
planning	O
and	O
preparation	O
of	O
the	O
study	O
.	O

HoNOS	O
scales	O
with	O
missing	O
values	O
were	O
set	O
to	O
0	O
.	O

This	O
was	O
considered	O
the	O
most	O
probable	O
rating	O
,	O
based	O
on	O
the	O
skewed	O
distribution	O
,	O
where	O
most	O
patients	O
rated	O
0	O
,	O
and	O
the	O
assumption	O
that	O
clinicians	O
most	O
easily	O
forgot	O
to	O
mark	O
the	O
rating	O
when	O
there	O
was	O
no	O
indication	O
of	O
problems	O
.	O

It	O
was	O
also	O
chosen	O
over	O
imputation	O
because	O
it	O
was	O
the	O
most	O
conservative	O
way	O
to	O
measure	O
the	O
severity	O
of	O
patients’	O
mental	O
health	O
problems	O
.	O

Diagnoses	O
were	O
missing	O
for	O
53	O
.	O
5	O
%	O
and	O
17	O
.	O
4	O
%	O
of	O
the	O
patients	O
in	O
two	O
of	O
the	O
teams	O
and	O
for	O
3	O
.	O
4–10	O
.	O

4	O
%	O
in	O
the	O
other	O
six	O
teams	O
.	O

In	O
Norway	O
,	O
only	O
physicians	O
,	O
psychiatrists	O
,	O
and	O
psychologists	O
are	O
authorized	O
to	O
make	O
ICD–10	B-coding_system
diagnoses	O
.	O

The	O
teams	O
with	O
the	O
highest	O
number	O
of	O
missing	O
values	O
on	O
the	O
diagnosis	O
variable	O
operated	O
without	O
a	O
physician	O
,	O
psychiatrist	O
,	O
or	O
psychologist	O
as	O
a	O
regular	O
member	O
of	O
the	O
team	O
.	O

In	O
these	O
teams	O
,	O
diagnoses	O
were	O
made	O
by	O
physicians	O
who	O
were	O
not	O
part	O
of	O
the	O
team	O
.	O

For	O
this	O
reason	O
,	O
the	O
HoNOS	O
scales	O
were	O
used	O
instead	O
of	O
diagnoses	O
in	O
the	O
analysis	O
of	O
the	O
type	O
and	O
severity	O
of	O
the	O
psychiatric	O
problems	O
.	O

Socio	O
-	O
demographic	O
and	O
clinical	O
characteristics	O
were	O
described	O
as	O
frequencies	O
and	O
percentages	O
or	O
means	O
and	O
standard	O
deviations	O
,	O
as	O
appropriate	O
.	O

Differences	O
between	O
those	O
who	O
were	O
and	O
were	O
not	O
admitted	O
to	O
in	O
-	O
patient	O
wards	O
were	O
analysed	O
by	O
chi	O
-	O
squared	O
tests	O
for	O
categorical	O
variables	O
,	O
and	O
independent	O
samples	O
t	O
-	O
tests	O
for	O
continuous	O
variables	O
,	O
including	O
skewed	O
variables	O
,	O
as	O
comparison	O
with	O
a	O
non	O
-	O
parametric	O
alternative	O
exhibited	O
only	O
marginal	O
differences	O
in	O
p	O
-	O
values	O
.	O

To	O
explore	O
the	O
potential	O
predictors	O
for	O
admission	O
vs	O
.	O
non	O
-	O
admission	O
,	O
data	O
on	O
both	O
patient	O
and	O
team	O
levels	O
were	O
used	O
.	O

The	O
selection	O
of	O
potential	O
predictors	O
on	O
both	O
levels	O
was	O
based	O
primarily	O
on	O
earlier	O
studies	O
referred	O
to	O
in	O
the	O
background	O
section	O
[	O
14	O
-	O
17	O
]	O
.	O

The	O
significant	O
covariates	O
in	O
the	O
bivariate	O
analyses	O
between	O
patients	O
admitted	O
and	O
not	O
admitted	O
were	O
used	O
as	O
potential	O
predictors	O
,	O
while	O
age	O
and	O
gender	O
were	O
used	O
regardless	O
of	O
their	O
significance	O
.	O

Attempted	O
suicide	O
,	O
deliberate	O
self	O
-	O
harm	O
and	O
GAF	O
were	O
not	O
included	O
in	O
the	O
regression	O
analysis	O
for	O
hierarchical	O
data	O
even	O
though	O
they	O
were	O
significant	O
.	O

This	O
was	O
because	O
of	O
the	O
risk	O
of	O
interaction	O
effects	O
between	O
these	O
and	O
other	O
similar	O
variables	O
,	O
such	O
as	O
the	O
HoNOS	O
subscales	O
.	O

To	O
assess	O
the	O
association	O
between	O
admission	O
status	O
and	O
potential	O
predictors	O
on	O
both	O
levels	O
,	O
a	O
hierarchical	O
logistic	O
regression	O
model	O
with	O
random	O
effects	O
for	O
intercepts	O
was	O
fitted	O
(	O
SAS	O
GLIMMIX	O
procedure	O
)	O
.	O

Such	O
a	O
model	O
takes	O
possible	O
correlations	O
between	O
members	O
of	O
the	O
same	O
cluster	O
(	O
i	O
.	O
e	O
.	O
,	O
team	O
)	O
into	O
account	O
,	O
and	O
might	O
protect	O
against	O
false	O
significant	O
findings	O
.	O

Crude	O
odds	O
ratios	O
were	O
calculated	O
by	O
bivariate	O
analyses	O
,	O
and	O
then	O
adjusted	O
by	O
estimating	O
a	O
multivariate	O
model	O
.	O

The	O
model	O
with	O
all	O
selected	O
predictors	O
included	O
was	O
reduced	O
by	O
a	O
stepwise	O
selection	O
procedure	O
with	O
entry	O
and	O
stay	O
probabilities	O
close	O
to	O
one	O
[	O
31	O
]	O
.	O

This	O
method	O
produces	O
a	O
sequence	O
of	O
models	O
starting	O
with	O
the	O
null	O
model	O
(	O
no	O
predictors	O
)	O
and	O
ending	O
with	O
the	O
full	O
model	O
(	O
all	O
potential	O
predictors	O
included	O
)	O
.	O

At	O
each	O
step	O
,	O
Akaike’s	O
information	O
criterion	O
(	O
AIC	O
)	O
was	O
calculated	O
and	O
the	O
model	O
with	O
the	O
lowest	O
AIC	O
value	O
chosen	O
as	O
the	O
final	O
one	O
.	O

Patient	O
-	O
level	O
interactions	O
between	O
the	O
following	O
variables	O
were	O
considered	O
:	O
delivered	O
to	O
CRT	O
by	O
the	O
police	O
and	O
physical	O
attacks	O
on	O
others	O
,	O
suicide	O
risk	O
and	O
depressive	O
symptoms	O
,	O
and	O
psychiatric	O
admission	O
in	O
the	O
past	O
12	O
months	O
,	O
and	O
psychotic	O
symptoms	O
.	O

One	O
team	O
-	O
level	O
interaction	O
was	O
considered	O
:	O
number	O
of	O
team	O
members	O
and	O
number	O
of	O
patients	O
treated	O
.	O

No	O
cross	O
-	O
level	O
interactions	O
were	O
included	O
.	O

The	O
statistical	O
analyses	O
were	O
conducted	O
using	O
software	O
SAS	O
version	O
9	O
.	O
2	O
for	O
Windows	O
(	O
SAS	O
Institute	O
Inc	O
.	O
,	O
Cary	O
,	O
NC	O
)	O
and	O
SPSS	O
software	O
version	O
18	O
.	O
0	O
for	O
Windows	O
(	O
SPSS	O
Inc	O
.	O
,	O
Chicago	O
,	O
IL	O
)	O
.	O

The	O
significance	O
level	O
was	O
set	O
at	O
5	O
%	O
.	O

Holm’s	O
method	O
[	O
32	O
]	O
was	O
used	O
in	O
the	O
regression	O
analysis	O
to	O
control	O
the	O
family	O
-	O
wise	O
error	O
rate	O
.	O

The	O
original	O
p	O
-	O
values	O
were	O
presented	O
in	O
a	O
table	O
,	O
but	O
the	O
predictors	O
that	O
remained	O
significant	O
after	O
the	O
adjustment	O
were	O
singled	O
out	O
.	O

This	O
is	O
a	O
multicentric	O
,	O
ongoing	O
,	O
prospective	O
longitudinal	O
cohort	O
study	O
.	O

This	O
study	O
is	O
taking	O
place	O
in	O
France	O
and	O
involves	O
50	O
%	O
of	O
all	O
French	O
autism	O
research	O
centres	O
(	O
n=13	O
)	O
.	O

According	O
to	O
national	O
guidelines	O
,	O
ASD	O
diagnosis	O
has	O
to	O
be	O
based	O
on	O
an	O
exhaustive	O
multidisciplinary	O
process	O
.	O

It	O
is	O
mainly	O
achieved	O
in	O
France	O
in	O
secondary	O
settings	O
,	O
but	O
with	O
inconsistencies	O
in	O
practices	O
across	O
areas	O
.	O

For	O
these	O
reasons	O
,	O
the	O
recruitment	O
was	O
planed	O
from	O
tertiary	O
centres	O
.	O

These	O
centres	O
,	O
spread	O
throughout	O
the	O
French	O
territories	O
,	O
are	O
specialised	O
in	O
the	O
assessment	O
and	O
diagnosis	O
of	O
ASD	O
and	O
other	O
neurodevelopmental	O
disorders	O
and	O
respectful	O
of	O
best	O
practices	O
guidelines	O
.	O

Children	O
were	O
ordinarily	O
referred	O
from	O
primary	O
or	O
secondary	O
care	O
by	O
their	O
family	O
doctor	O
,	O
child	O
psychiatrist	O
or	O
paediatrician	O
.	O

Recruitment	O
started	O
in	O
2012	O
and	O
will	O
continue	O
until	O
2020	O
to	O
include	O
1000	O
participants	O
.	O

The	O
inclusion	O
criteria	O
are	O
participants	O
between	O
2	O
and	O
16	O
years	O
of	O
age	O
,	O
referred	O
for	O
a	O
first	O
diagnostic	O
established	O
by	O
a	O
multidisciplinary	O
clinical	O
assessment	O
to	O
one	O
of	O
the	O
13	O
autism	O
research	O
centres	O
,	O
diagnosed	O
with	O
pervasive	B-phenotype
developmental	I-phenotype
disorders	I-phenotype
(	I-phenotype
PDDs	I-phenotype
)	I-phenotype
or	I-phenotype
ASD	I-phenotype
according	O
to	O
the	O
International	B-coding_system
Classification	I-coding_system
of	I-coding_system
Diseases	I-coding_system
(	I-coding_system
ICD	I-coding_system
)	I-coding_system
10	I-coding_system
(	I-coding_system
which	I-coding_system
was	I-coding_system
recommended	I-coding_system
in	I-coding_system
France	I-coding_system
at	I-coding_system
the	I-coding_system
onset	I-coding_system
of	I-coding_system
the	I-coding_system
study	I-coding_system
29	I-coding_system
30	I-coding_system
)	I-coding_system
,	O
and	O
whose	O
parents	O
read	O
and	O
speak	O
French	O
.	O

After	O
the	O
publication	O
in	O
France	O
in	O
2014	O
of	O
the	O
Diagnostic	B-coding_system
and	I-coding_system
Statistical	I-coding_system
Manual	I-coding_system
of	I-coding_system
Mental	I-coding_system
Disorders	I-coding_system
(	I-coding_system
DSM	I-coding_system
-	I-coding_system
5	I-coding_system
)	I-coding_system
,	O
all	O
the	O
children	O
were	O
diagnosed	O
with	O
this	O
classification	O
,	O
and	O
those	O
diagnosed	O
before	O
as	O
PDD	B-phenotype
were	O
recoded	O
using	O
DSM	B-coding_system
-	I-coding_system
5	I-coding_system
.	O

The	O
exclusion	O
criterion	O
is	O
parental	O
refusal	O
.	O

Participants	O
were	O
recruited	O
nationally	O
in	O
public	O
settings	O
from	O
tertiary	O
centres	O
in	O
the	O
course	O
of	O
a	O
multidisciplinary	O
assessment	O
.	O

After	O
ascertaining	O
patient	O
eligibility	O
,	O
information	O
concerning	O
the	O
study	O
protocol	O
was	O
given	O
to	O
parents	O
during	O
a	O
medical	O
consultation	O
by	O
the	O
autism	O
research	O
centre	O
investigator	O
and	O
their	O
written	O
consent	O
was	O
collected	O
.	O

Parents	O
/	O
caregivers	O
who	O
agreed	O
to	O
participate	O
received	O
online	O
questionnaires	O
about	O
their	O
child	O
.	O

As	O
of	O
1	O
November	O
2018	O
,	O
844	O
children	O
were	O
eligible	O
to	O
participate	O
in	O
the	O
study	O
and	O
written	O
parental	O
consent	O
was	O
obtained	O
for	O
766	O
(	O
acceptation	O
rate	O
:	O
91	O
%	O
)	O
.	O

A	O
flow	O
chart	O
describing	O
the	O
study	O
protocol	O
and	O
selection	O
of	O
the	O
children	O
participating	O
in	O
the	O
multicEntric	O
Longitudinal	O
study	O
of	O
childrEN	O
with	O
ASD	O
(	O
ELENA	O
)	O
study	O
is	O
shown	O
in	O
figure	O
1	O
.	O

The	O
geographical	O
breakdown	O
of	O
the	O
included	O
participants	O
is	O
uneven	O
(	O
illustrated	O
in	O
online	O
supplementary	O
figure	O
A	O
)	O
,	O
with	O
most	O
of	O
the	O
cases	O
recruited	O
from	O
the	O
south	O
of	O
France	O
.	O

Flow	O
chart	O
of	O
the	O
615	O
children	O
from	O
the	O
ongoing	O
open	O
ELENA	O
cohort	O
.	O

ELENA	O
,	O
multicEntric	O
Longitudinal	O
study	O
of	O
childrEN	O
with	O
ASD	O
;	O
W	O
,	O
wave	O
.	O

Following	O
the	O
baseline	O
clinical	O
examination	O
(	O
wave	O
0	O
)	O
,	O
subsequent	O
follow	O
-	O
ups	O
take	O
place	O
at	O
18	O
months	O
(	O
W1	O
)	O
and	O
at	O
3	O
(	O
W2	O
)	O
,	O
4	O
.	O
5	O
(	O
W3	O
)	O
and	O
6	O
(	O
W4	O
)	O
years	O
after	O
the	O
baseline	O
examination	O
,	O
consisting	O
of	O
alternate	O
postal	O
/	O
online	O
questionnaires	O
alone	O
(	O
W1	O
and	O
W3	O
)	O
and	O
postal	O
questionnaires	O
and	O
clinical	O
examinations	O
(	O
W2	O
and	O
W4	O
)	O
to	O
assess	O
the	O
evolution	O
of	O
pervasive	O
clinical	O
and	O
behavioural	O
symptoms	O
of	O
the	O
disorder	O
.	O

At	O
each	O
visit	O
(	O
W2	O
and	O
W4	O
)	O
,	O
a	O
clinical	O
report	O
summarising	O
the	O
results	O
of	O
the	O
assessments	O
and	O
the	O
clinician’s	O
analysis	O
concerning	O
the	O
child’s	O
outcome	O
since	O
the	O
previous	O
visit	O
is	O
provided	O
to	O
parents	O
and	O
local	O
healthcare	O
or	O
educational	O
services	O
designated	O
by	O
the	O
parents	O
.	O

The	O
primary	O
study	O
outcome	O
consists	O
of	O
the	O
scores	O
for	O
the	O
three	O
domains	O
of	O
the	O
Vineland	O
Scale	O
(	O
communication	O
,	O
socialisation	O
and	O
daily	O
living	O
skills	O
)	O
as	O
highly	O
correlated	O
with	O
intellectual	O
measures	O
and	O
adequately	O
translating	O
the	O
individual’s	O
cognitive	O
abilities	O
in	O
real	O
life	O
.	O

31–33	O
The	O
Vineland	O
Scale	O
can	O
be	O
used	O
in	O
all	O
children	O
for	O
each	O
monitoring	O
of	O
the	O
follow	O
-	O
up	O
,	O
even	O
in	O
those	O
where	O
cognitive	O
tests	O
cannot	O
be	O
performed	O
.	O

34	O

The	O
secondary	O
outcomes	O
include	O
autistic	O
symptoms	O
,	O
sensory	O
profile	O
,	O
language	O
level	O
,	O
intellectual	O
functioning	O
,	O
individual	O
and	O
familial	O
QoL	O
,	O
parental	O
stress	O
,	O
and	O
school	O
achievement	O
.	O

Autistic	O
status	O
was	O
also	O
reviewed	O
and	O
discussed	O
by	O
a	O
committee	O
of	O
trained	O
clinicians	O
(	O
child	O
psychiatrists	O
,	O
psychologists	O
and	O
speech	O
therapist	O
)	O
to	O
obtain	O
a	O
consensus	O
on	O
the	O
ASD	B-phenotype
diagnosis	O
according	O
to	O
the	O
DSM	B-coding_system
-	I-coding_system
5	I-coding_system
criteria	O
.	O

Data	O
are	O
collected	O
by	O
licensed	O
psychologists	O
from	O
the	O
multidisciplinary	O
clinical	O
assessments	O
using	O
standardised	O
tools	O
at	O
baseline	O
and	O
at	O
each	O
follow	O
-	O
up	O
visit	O
(	O
detailed	O
in	O
table	O
1	O
)	O
.	O

The	O
medical	O
data	O
are	O
completed	O
directly	O
online	O
at	O
every	O
site	O
on	O
a	O
data	O
entry	O
form	O
created	O
via	O
specific	O
software	O
(	O
Ennov	O
Clinical	O
)	O
.	O

This	O
software	O
respects	O
the	O
recommendations	O
of	O
the	O
Food	O
and	O
Drug	O
Administration	O
(	O
FDA	O
)	O
concerning	O
informatics	O
systems	O
for	O
the	O
management	O
of	O
clinical	O
trials	O
and	O
standards	O
(	O
clinical	O
data	O
interchange	O
standards	O
consortium	O
(	O
CDISC	O
)	O
,	O
International	O
Conference	O
on	O
Harmonization	O
(	O
ICH	O
)	O
,	O
good	O
clinical	O
practice	O
(	O
GCP	O
)	O
2001	O
/	O
20	O
/	O
CE	O
)	O
.	O

In	O
addition	O
,	O
parents	O
complete	O
online	O
self	O
-	O
reported	O
questionnaires	O
.	O

All	O
data	O
are	O
anonymous	O
and	O
personally	O
identifiable	O
information	O
is	O
stored	O
separately	O
from	O
the	O
other	O
data	O
.	O

Measurements	O
of	O
the	O
ELENA	O
study	O
at	O
the	O
four	O
timepoints	O
of	O
the	O
follow	O
-	O
up	O

ABC	O
,	O
Aberrant	O
Behavior	O
Checklist	O
;	O
ADI	O
-	O
R	O
,	O
revised	O
version	O
of	O
the	O
Autism	O
Diagnostic	O
Interview	O
;	O
ADOS	O
-	O
2	O
,	O
Autism	O
Diagnostic	O
Observation	O
Schedule	O
;	O
ASD	O
,	O
autism	O
spectrum	O
disorder	O
;	O
CBCL	O
,	O
Child	O
Behavior	O
Checklist	O
;	O
CGH=	O
Comparative	O
genomic	O
hybridization	O
;	O
ELENA	O
,	O
multicEntric	O
Longitudinal	O
study	O
of	O
childrEN	O
with	O
ASD	O
;	O
HADS	O
,	O
Hospital	O
Anxiety	O
and	O
Depression	O
Scale	O
;	O
NIMH	O
,	O
NationalInstitute	O
of	O
Mental	O
Health	O
;	O
Par	O
-	O
DD	O
-	O
QoL	O
,	O
Parental	O
-	O
Developmental	O
Disorder	O
-	O
Quality	O
of	O
Life	O
;	O
PPVT	O
-	O
R	O
,	O
Peabody	O
Picture	O
Vocabulary	O
Test	O
-	O
Revised	O
;	O

PSI	O
-	O
4	O
-	O
SF	O
,	O
Parenting	O
Stress	O
Index	O
,	O
Fourth	O
Edition	O
Short	O
Form	O
;	O
QoL	O
,	O
quality	O
of	O
life	O
;	O
VABS	O
-	O
II	O
,	O
Vineland	O
Adaptive	O
Behavior	O
Scales	O
,	O
Second	O
Edition	O
W	O
,	O
wave	O
;	O
WCC	O
-	O
R	O
,	O
French	O
Ways	O
of	O
Coping	O
Checklist	O
.	O

The	O
ASD	O
diagnostic	O
process	O
is	O
based	O
on	O
a	O
two	O
-	O
step	O
procedure	O
.	O

First	O
,	O
a	O
certified	O
child	O
psychiatrist	O
or	O
psychologist	O
administers	O
a	O
battery	O
of	O
four	O
clinical	O
tools	O
consisting	O
of	O
the	O
Autism	O
Diagnostic	O
Observation	O
Schedule	O
(	O
ADOS	O
-	O
2	O
)	O
,	O
35	O
the	O
revised	O
version	O
of	O
the	O
Autism	O
Diagnostic	O
Interview	O
(	O
ADI	O
-	O
R	O
)	O
,	O
36	O
a	O
best	O
estimate	O
of	O
the	O
intellectual	O
functioning	O
level	O
and	O
the	O
Vineland	O
Adaptive	O
Behavior	O
Scales	O
,	O
Second	O
Edition	O
(	O
VABS	O
-	O
II	O
)	O
37	O
(	O
all	O
items	O
are	O
detailed	O
below	O
)	O
.	O

Second	O
,	O
a	O
committee	O
of	O
trained	O
clinicians	O
and	O
child	O
psychiatrists	O
or	O
psychologists	O
discuss	O
and	O
review	O
all	O
cases	O
to	O
obtain	O
a	O
consensus	O
on	O
the	O
ASD	O
diagnosis	O
(	O
at	O
baseline	O
and	O
follow	O
-	O
up	O
)	O
according	O
to	O
the	O
ICD	O
or	O
DSM	O
-	O
5	O
criteria	O
,	O
which	O
were	O
the	O
recommended	O
classification	O
in	O
France	O
until	O
2018	O
.	O

38	O
The	O
ASD	O
diagnostic	O
tools	O
,	O
all	O
available	O
in	O
French	O
version	O
and	O
used	O
in	O
previous	O
French	O
prospective	O
cohorts	O
,	O
are	O
as	O
follows	O
:	O
The	O
ADOS	O
-	O
2	O
35	O
is	O
a	O
semistructured	O
,	O
standardised	O
questionnaire	O
that	O
assesses	O
four	O
domains	O
of	O
the	O
individual’s	O
behaviour	O
:	O
(	O
1	O
)	O
communication	O
,	O
(	O
2	O
)	O
reciprocal	O
social	O
interaction	O
,	O
(	O
3	O
)	O
imagination	O
/	O
creativity	O
,	O
and	O
(	O
4	O
)	O
stereotyped	O
behaviours	O
and	O
restricted	O
interests	O
.	O

Beyond	O
the	O
ASD	O
diagnosis	O
,	O
ADOS	O
provides	O
a	O
measure	O
of	O
the	O
severity	O
of	O
the	O
symptoms	O
encompassing	O
the	O
(	O
1	O
)	O
social	O
affect	O
(	O
involving	O
communication	O
and	O
social	O
interaction	O
items	O
)	O
and	O
(	O
2	O
)	O
restricted	O
and	O
repetitive	O
behaviour	O
(	O
involving	O
repetitive	O
and	O
stereotyped	O
behaviour	O
items	O
)	O
.	O

Based	O
on	O
this	O
assessment	O
,	O
a	O
10	O
-	O
point	O
ADOS	O
severity	O
score	O
is	O
determined	O
for	O
each	O
participant	O
.	O

35	O
39	O
The	O
ADI	O
-	O
R	O
36	O
is	O
a	O
standardised	O
semistructured	O
parent	O
/	O
caregiver	O
interview	O
.	O

It	O
consists	O
of	O
93	O
items	O
and	O
explores	O
the	O
child’s	O
early	O
development	O
,	O
acquisition	O
of	O
language	O
skills	O
,	O
language	O
and	O
communication	O
functioning	O
,	O
loss	O
of	O
both	O
speech	O
and	O
motor	O
skills	O
,	O
social	O
development	O
and	O
play	O
,	O
interests	O
,	O
and	O
behaviour	O
.	O

Three	O
scores	O
are	O
derived	O
to	O
assess	O
abilities	O
in	O
communication	O
,	O
social	O
reciprocity	O
,	O
and	O
restricted	O
and	O
repetitive	O
behaviour	O
.	O

A	O
fourth	O
score	O
that	O
assesses	O
expressive	O
language	O
and	O
speech	O
is	O
derived	O
but	O
does	O
not	O
enter	O
into	O
the	O
ASD	O
diagnosis	O
clinical	O
tools	O
.	O

The	O
ADOS	O
-	O
2	O
35	O
is	O
a	O
semistructured	O
,	O
standardised	O
questionnaire	O
that	O
assesses	O
four	O
domains	O
of	O
the	O
individual’s	O
behaviour	O
:	O
(	O
1	O
)	O
communication	O
,	O
(	O
2	O
)	O
reciprocal	O
social	O
interaction	O
,	O
(	O
3	O
)	O
imagination	O
/	O
creativity	O
,	O
and	O
(	O
4	O
)	O
stereotyped	O
behaviours	O
and	O
restricted	O
interests	O
.	O

Beyond	O
the	O
ASD	O
diagnosis	O
,	O
ADOS	O
provides	O
a	O
measure	O
of	O
the	O
severity	O
of	O
the	O
symptoms	O
encompassing	O
the	O
(	O
1	O
)	O
social	O
affect	O
(	O
involving	O
communication	O
and	O
social	O
interaction	O
items	O
)	O
and	O
(	O
2	O
)	O
restricted	O
and	O
repetitive	O
behaviour	O
(	O
involving	O
repetitive	O
and	O
stereotyped	O
behaviour	O
items	O
)	O
.	O

Based	O
on	O
this	O
assessment	O
,	O
a	O
10	O
-	O
point	O
ADOS	O
severity	O
score	O
is	O
determined	O
for	O
each	O
participant	O
.	O

35	O
39	O

The	O
ADI	O
-	O
R	O
36	O
is	O
a	O
standardised	O
semistructured	O
parent	O
/	O
caregiver	O
interview	O
.	O

It	O
consists	O
of	O
93	O
items	O
and	O
explores	O
the	O
child’s	O
early	O
development	O
,	O
acquisition	O
of	O
language	O
skills	O
,	O
language	O
and	O
communication	O
functioning	O
,	O
loss	O
of	O
both	O
speech	O
and	O
motor	O
skills	O
,	O
social	O
development	O
and	O
play	O
,	O
interests	O
,	O
and	O
behaviour	O
.	O

Three	O
scores	O
are	O
derived	O
to	O
assess	O
abilities	O
in	O
communication	O
,	O
social	O
reciprocity	O
,	O
and	O
restricted	O
and	O
repetitive	O
behaviour	O
.	O

A	O
fourth	O
score	O
that	O
assesses	O
expressive	O
language	O
and	O
speech	O
is	O
derived	O
but	O
does	O
not	O
enter	O
into	O
the	O
ASD	O
diagnosis	O
clinical	O
tools	O
.	O

In	O
addition	O
to	O
the	O
ASD	O
clinical	O
tools	O
,	O
the	O
clinical	O
examination	O
of	O
the	O
child	O
includes	O
the	O
following	O
:	O
The	O
best	O
estimate	O
of	O
intellectual	O
level	O
(	O
defined	O
as	O
the	O
ratio	O
of	O
the	O
developmental	O
age	O
scores	O
on	O
age	O
and	O
multiplied	O
by	O
100	O
)	O
is	O
based	O
on	O
an	O
age	O
-	O
appropriate	O
test	O
according	O
to	O
the	O
approach	O
of	O
Howlin	O
et	O
al	O
.	O
40	O
An	O
intellectual	O
quotient	O
is	O
derived	O
from	O
the	O
Wechsler	O
Intelligence	O
Scales	O
41–46	O
and	O
Kaufman	O
Assessment	O
Battery	O
for	O
Children	O
.	O

47	O
When	O
it	O
is	O
not	O
possible	O
to	O
derive	O
an	O
intellectual	O
quotient	O
(	O
when	O
the	O
participants	O
cannot	O
understand	O
the	O
test	O
instructions	O
or	O
requirements	O
)	O
,	O
a	O
developmental	O
quotient	O
is	O
determined	O
based	O
on	O
revised	O
psychoeducational	O
profile	O
48	O
and	O
developmental	O
scales	O
.	O

49	O
50	O
VABS	O
-	O
II	O
37	O
is	O
a	O
standardised	O
semistructured	O
interview	O
administered	O
to	O
parents	O
to	O
evaluate	O
children’s	O
adaptive	O
skills	O
.	O

From	O
this	O
questionnaire	O
,	O
three	O
subscores	O
are	O
commonly	O
derived	O
that	O
assess	O
the	O
child’s	O
abilities	O
in	O
communication	O
,	O
daily	O
living	O
skills	O
and	O
socialisation	O
.	O

The	O
VABS	O
-	O
II	O
evaluation	O
has	O
already	O
been	O
performed	O
in	O
a	O
subsample	O
of	O
the	O
study	O
at	O
18	O
,	O
36	O
and	O
72	O
months	O
of	O
follow	O
-	O
up	O
(	O
n=329	O
at	O
18	O
months	O
,	O
n=158	O
at	O
36	O
months	O
and	O
n=23	O
at	O
72	O
months	O
of	O
follow	O
-	O
up	O
as	O
of	O
1	O
November	O
2018	O
;	O
see	O
figure	O
1	O
)	O
.	O

Child	O
language	O
assessment	O
:	O
(	O
1	O
)	O
The	O
Peabody	O
Picture	O
Vocabulary	O
Test	O
-	O
Revised	O
51	O
52	O
comprised	O
170	O
items	O
designed	O
to	O
evaluate	O
the	O
general	O
receptive	O
vocabulary	O
of	O
children	O
and	O
adolescents	O
.	O

It	O
is	O
administered	O
by	O
speech	O
therapists	O
with	O
no	O
time	O
limit	O
.	O

For	O
each	O
item	O
of	O
the	O
test	O
,	O
the	O
examiner	O
says	O
a	O
word	O
and	O
the	O
participant	O
then	O
selects	O
the	O
corresponding	O
picture	O
from	O
among	O
four	O
pictures	O
presented	O
on	O
a	O
page	O
.	O

(	O
2	O
)	O
Expressive	O
language	O
and	O
speech	O
are	O
clinically	O
described	O
according	O
to	O
three	O
levels	O
:	O
(	O
a	O
)	O
spontaneous	O
and	O
functional	O
speech	O
with	O
sentences	O
,	O
(	O
b	O
)	O
utterances	O
or	O
phrase	O
speech	O
,	O
including	O
at	O
least	O
five	O
different	O
words	O
,	O
and	O
(	O
c	O
)	O
the	O
use	O
of	O
fewer	O
than	O
five	O
words	O
measured	O
using	O
item	O
‘number	O
19’	O
of	O
ADI	O
-	O
R	O
.	O

The	O
best	O
estimate	O
of	O
intellectual	O
level	O
(	O
defined	O
as	O
the	O
ratio	O
of	O
the	O
developmental	O
age	O
scores	O
on	O
age	O
and	O
multiplied	O
by	O
100	O
)	O
is	O
based	O
on	O
an	O
age	O
-	O
appropriate	O
test	O
according	O
to	O
the	O
approach	O
of	O
Howlin	O
et	O
al	O
.	O
40	O
An	O
intellectual	O
quotient	O
is	O
derived	O
from	O
the	O
Wechsler	O
Intelligence	O
Scales	O
41–46	O
and	O
Kaufman	O
Assessment	O
Battery	O
for	O
Children	O
.	O

47	O
When	O
it	O
is	O
not	O
possible	O
to	O
derive	O
an	O
intellectual	O
quotient	O
(	O
when	O
the	O
participants	O
cannot	O
understand	O
the	O
test	O
instructions	O
or	O
requirements	O
)	O
,	O
a	O
developmental	O
quotient	O
is	O
determined	O
based	O
on	O
revised	O
psychoeducational	O
profile	O
48	O
and	O
developmental	O
scales	O
.	O

49	O
50	O

VABS	O
-	O
II	O
37	O
is	O
a	O
standardised	O
semistructured	O
interview	O
administered	O
to	O
parents	O
to	O
evaluate	O
children’s	O
adaptive	O
skills	O
.	O

From	O
this	O
questionnaire	O
,	O
three	O
subscores	O
are	O
commonly	O
derived	O
that	O
assess	O
the	O
child’s	O
abilities	O
in	O
communication	O
,	O
daily	O
living	O
skills	O
and	O
socialisation	O
.	O

The	O
VABS	O
-	O
II	O
evaluation	O
has	O
already	O
been	O
performed	O
in	O
a	O
subsample	O
of	O
the	O
study	O
at	O
18	O
,	O
36	O
and	O
72	O
months	O
of	O
follow	O
-	O
up	O
(	O
n=329	O
at	O
18	O
months	O
,	O
n=158	O
at	O
36	O
months	O
and	O
n=23	O
at	O
72	O
months	O
of	O
follow	O
-	O
up	O
as	O
of	O
1	O
November	O
2018	O
;	O
see	O
figure	O
1	O
)	O
.	O

Child	O
language	O
assessment	O
:	O
(	O
1	O
)	O
The	O
Peabody	O
Picture	O
Vocabulary	O
Test	O
-	O
Revised	O
51	O
52	O
comprised	O
170	O
items	O
designed	O
to	O
evaluate	O
the	O
general	O
receptive	O
vocabulary	O
of	O
children	O
and	O
adolescents	O
.	O

It	O
is	O
administered	O
by	O
speech	O
therapists	O
with	O
no	O
time	O
limit	O
.	O

For	O
each	O
item	O
of	O
the	O
test	O
,	O
the	O
examiner	O
says	O
a	O
word	O
and	O
the	O
participant	O
then	O
selects	O
the	O
corresponding	O
picture	O
from	O
among	O
four	O
pictures	O
presented	O
on	O
a	O
page	O
.	O

(	O
2	O
)	O
Expressive	O
language	O
and	O
speech	O
are	O
clinically	O
described	O
according	O
to	O
three	O
levels	O
:	O
(	O
a	O
)	O
spontaneous	O
and	O
functional	O
speech	O
with	O
sentences	O
,	O
(	O
b	O
)	O
utterances	O
or	O
phrase	O
speech	O
,	O
including	O
at	O
least	O
five	O
different	O
words	O
,	O
and	O
(	O
c	O
)	O
the	O
use	O
of	O
fewer	O
than	O
five	O
words	O
measured	O
using	O
item	O
‘number	O
19’	O
of	O
ADI	O
-	O
R	O
.	O

In	O
addition	O
to	O
the	O
children’s	O
clinical	O
and	O
developmental	O
examinations	O
,	O
parents	O
are	O
invited	O
to	O
complete	O
web	O
-	O
based	O
self	O
-	O
reported	O
questionnaires	O
including	O
the	O
following	O
:	O
Sociodemographic	O
information	O
:	O
parent’s	O
age	O
,	O
marital	O
status	O
,	O
educational	O
level	O
,	O
socioeconomic	O
status	O
and	O
siblings	O
.	O

Medically	O
relevant	O
information	O
:	O
pregnancy	O
,	O
birth	O
and	O
neonatal	O
care	O
,	O
as	O
well	O
as	O
information	O
on	O
early	O
development	O
,	O
medical	O
diagnoses	O
assigned	O
to	O
the	O
child	O
and	O
medical	O
observations	O
(	O
related	O
to	O
prescribed	O
medication	O
,	O
diet	O
and	O
gastrointestinal	O
outcomes	O
)	O
.	O

Intervention	O
:	O
age	O
at	O
first	O
intervention	O
,	O
type	O
of	O
intervention	O
,	O
and	O
mainstream	O
or	O
specialised	O
school	O
.	O

Psychosocial	O
information	O
concerning	O
(	O
1	O
)	O
parents’	O
perception	O
of	O
their	O
child’s	O
QoL	O
using	O
the	O
Kidscreen	O
-	O
27	O
Parental	O
Form	O
53	O
;	O
(	O
2	O
)	O
parents’	O
perception	O
of	O
the	O
impact	O
of	O
ASD	O
on	O
their	O
QoL	O
using	O
the	O
Parental	O
-	O
Developmental	O
Disorder	O
-	O
Quality	O
of	O
Life	O
11	O
14	O
;	O
(	O
3	O
)	O
parents’	O
coping	O
strategies	O
using	O
the	O
French	O
Ways	O
of	O
Coping	O
Checklist	O
54	O
and	O
parents’	O
stress	O
level	O
directly	O
associated	O
with	O
their	O
parenting	O
role	O
using	O
the	O
Parenting	O
Stress	O
Index	O
,	O
Fourth	O
Edition	O
Short	O
Form	O
55	O
;	O
and	O
(	O
4	O
)	O
parents’	O
anxiety	O
and	O
depression	O
using	O

the	O
Hospital	O
Anxiety	O
and	O
Depression	O
Scale	O
.	O

56	O
Child’s	O
behaviour	O
collected	O
through	O
standardised	O
scales	O
consisting	O
of	O
the	O
following	O
:	O
The	O
Child	O
Behavior	O
Checklist	O
1–5	O
and	O
6–18	O
57–59	O
is	O
a	O
norm	O
-	O
referenced	O
measure	O
that	O
assesses	O
a	O
wide	O
range	O
of	O
emotional	O
and	O
behavioural	O
disorders	O
in	O
children	O
aged	O
1	O
.	O
5–5	O
years	O
and	O
6–18	O
years	O
,	O
respectively	O
,	O
consisting	O
of	O
two	O
broadband	O
scales	O
and	O
five	O
different	O
DSM	O
-	O
oriented	O
scales	O
.	O

Briefly	O
,	O
children	O
in	O
the	O
clinical	O
or	O
borderline	O
clinical	O
range	O
are	O
compared	O
with	O
children	O
in	O
the	O
normal	O
range	O
for	O
each	O
of	O
the	O
seven	O
scales	O
.	O

The	O
construction	O
and	O
cut	O
-	O
off	O
for	O
each	O
range	O
and	O
each	O
scale	O
are	O
detailed	O
in	O
online	O
supplementary	O
methods	O
.	O

The	O
Aberrant	O
Behavior	O
Checklist	O
60	O
is	O
a	O
58	O
-	O
item	O
behaviour	O
rating	O
scale	O
that	O
measures	O
behavioural	O
problems	O
across	O
four	O
domains	O
:	O
irritability	O
,	O
lethargy	O
/	O
withdrawal	O
,	O
stereotypy	O
and	O
hyperactivity	O
.	O

For	O
each	O
domain	O
,	O
scores	O
are	O
computed	O
and	O
reduced	O
to	O
a	O
scale	O
of	O
100	O
,	O
with	O
higher	O
scores	O
indicating	O
higher	O
levels	O
of	O
aberrant	O
behaviour	O
.	O

More	O
details	O
are	O
provided	O
in	O
online	O
supplementary	O
methods	O
.	O

The	O
Sensory	O
Profile	O
61	O
is	O
a	O
caregiver	O
questionnaire	O
of	O
125	O
items	O
measuring	O
sensory	O
processing	O
abilities	O
.	O

Results	O
are	O
presented	O
in	O
four	O
quadrants	O
:	O
low	O
registration	O
,	O
sensory	O
seeking	O
,	O
sensory	O
sensitivity	O
and	O
sensory	O
avoiding	O
.	O

Lower	O
scores	O
indicate	O
more	O
severe	O
sensory	O
processing	O
difficulties	O
.	O

Sociodemographic	O
information	O
:	O
parent’s	O
age	O
,	O
marital	O
status	O
,	O
educational	O
level	O
,	O
socioeconomic	O
status	O
and	O
siblings	O
.	O

Medically	O
relevant	O
information	O
:	O
pregnancy	O
,	O
birth	O
and	O
neonatal	O
care	O
,	O
as	O
well	O
as	O
information	O
on	O
early	O
development	O
,	O
medical	O
diagnoses	O
assigned	O
to	O
the	O
child	O
and	O
medical	O
observations	O
(	O
related	O
to	O
prescribed	O
medication	O
,	O
diet	O
and	O
gastrointestinal	O
outcomes	O
)	O
.	O

Intervention	O
:	O
age	O
at	O
first	O
intervention	O
,	O
type	O
of	O
intervention	O
,	O
and	O
mainstream	O
or	O
specialised	O
school	O
.	O

Psychosocial	O
information	O
concerning	O
(	O
1	O
)	O
parents’	O
perception	O
of	O
their	O
child’s	O
QoL	O
using	O
the	O
Kidscreen	O
-	O
27	O
Parental	O
Form	O
53	O
;	O
(	O
2	O
)	O
parents’	O
perception	O
of	O
the	O
impact	O
of	O
ASD	O
on	O
their	O
QoL	O
using	O
the	O
Parental	O
-	O
Developmental	O
Disorder	O
-	O
Quality	O
of	O
Life	O
11	O
14	O
;	O
(	O
3	O
)	O
parents’	O
coping	O
strategies	O
using	O
the	O
French	O
Ways	O
of	O
Coping	O
Checklist	O
54	O
and	O
parents’	O
stress	O
level	O
directly	O
associated	O
with	O
their	O
parenting	O
role	O
using	O
the	O
Parenting	O
Stress	O
Index	O
,	O
Fourth	O
Edition	O
Short	O
Form	O
55	O
;	O
and	O
(	O
4	O
)	O
parents’	O
anxiety	O
and	O
depression	O
using	O

the	O
Hospital	O
Anxiety	O
and	O
Depression	O
Scale	O
.	O

56	O

Child’s	O
behaviour	O
collected	O
through	O
standardised	O
scales	O
consisting	O
of	O
the	O
following	O
:	O

The	O
Child	O
Behavior	O
Checklist	O
1–5	O
and	O
6–18	O
57–59	O
is	O
a	O
norm	O
-	O
referenced	O
measure	O
that	O
assesses	O
a	O
wide	O
range	O
of	O
emotional	O
and	O
behavioural	O
disorders	O
in	O
children	O
aged	O
1	O
.	O
5–5	O
years	O
and	O
6–18	O
years	O
,	O
respectively	O
,	O
consisting	O
of	O
two	O
broadband	O
scales	O
and	O
five	O
different	O
DSM	O
-	O
oriented	O
scales	O
.	O

Briefly	O
,	O
children	O
in	O
the	O
clinical	O
or	O
borderline	O
clinical	O
range	O
are	O
compared	O
with	O
children	O
in	O
the	O
normal	O
range	O
for	O
each	O
of	O
the	O
seven	O
scales	O
.	O

The	O
construction	O
and	O
cut	O
-	O
off	O
for	O
each	O
range	O
and	O
each	O
scale	O
are	O
detailed	O
in	O
online	O
supplementary	O
methods	O
.	O

The	O
Aberrant	O
Behavior	O
Checklist	O
60	O
is	O
a	O
58	O
-	O
item	O
behaviour	O
rating	O
scale	O
that	O
measures	O
behavioural	O
problems	O
across	O
four	O
domains	O
:	O
irritability	O
,	O
lethargy	O
/	O
withdrawal	O
,	O
stereotypy	O
and	O
hyperactivity	O
.	O

For	O
each	O
domain	O
,	O
scores	O
are	O
computed	O
and	O
reduced	O
to	O
a	O
scale	O
of	O
100	O
,	O
with	O
higher	O
scores	O
indicating	O
higher	O
levels	O
of	O
aberrant	O
behaviour	O
.	O

More	O
details	O
are	O
provided	O
in	O
online	O
supplementary	O
methods	O
.	O

The	O
Sensory	O
Profile	O
61	O
is	O
a	O
caregiver	O
questionnaire	O
of	O
125	O
items	O
measuring	O
sensory	O
processing	O
abilities	O
.	O

Results	O
are	O
presented	O
in	O
four	O
quadrants	O
:	O
low	O
registration	O
,	O
sensory	O
seeking	O
,	O
sensory	O
sensitivity	O
and	O
sensory	O
avoiding	O
.	O

Lower	O
scores	O
indicate	O
more	O
severe	O
sensory	O
processing	O
difficulties	O
.	O

In	O
addition	O
,	O
linkage	O
of	O
the	O
ELENA	O
study	O
children	O
to	O
the	O
anonymised	O
French	O
National	O
Health	O
Data	O
Base	O
will	O
allow	O
the	O
group	O
to	O
collect	O
data	O
on	O
medication	O
,	O
hospitalisation	O
events	O
and	O
history	O
since	O
birth	O
.	O

Medical	O
events	O
and	O
drug	O
consumption	O
during	O
pregnancy	O
will	O
also	O
be	O
collected	O
.	O

The	O
study	O
is	O
coordinated	O
by	O
the	O
Autism	O
Resources	O
Center	O
of	O
Montpellier	O
University	O
(	O
AB	O
is	O
the	O
scientific	O
coordinator	O
)	O
.	O

We	O
have	O
implemented	O
quality	O
control	O
procedures	O
concerning	O
training	O
and	O
data	O
collection	O
in	O
all	O
centres	O
of	O
the	O
ELENA	O
study	O
.	O

Meetings	O
were	O
organised	O
in	O
each	O
centre	O
before	O
the	O
beginning	O
of	O
enrolment	O
to	O
set	O
up	O
protocol	O
procedures	O
.	O

We	O
ensured	O
that	O
ADOS	O
and	O
ADI	O
were	O
administered	O
and	O
scored	O
by	O
qualified	O
/	O
certified	O
personnel	O
.	O

We	O
performed	O
cross	O
-	O
site	O
training	O
for	O
the	O
administration	O
and	O
scoring	O
of	O
VABS	O
-	O
II	O
.	O

Regular	O
phone	O
meetings	O
with	O
investigators	O
or	O
staff	O
involved	O
in	O
data	O
collection	O
are	O
regularly	O
held	O
to	O
discuss	O
patient	O
enrolment	O
and	O
problems	O
encountered	O
in	O
conducting	O
the	O
study	O
,	O
and	O
representatives	O
from	O
all	O
centres	O
meet	O
in	O
Montpellier	O
once	O
a	O
year	O
.	O

Computerised	O
tests	O
have	O
been	O
implemented	O
to	O
ensure	O
the	O
completeness	O
,	O
consistency	O
and	O
reliability	O
of	O
data	O
during	O
data	O
entry	O
and	O
before	O
the	O
statistical	O
analysis	O
.	O

Each	O
site	O
investigator	O
is	O
responsible	O
for	O
their	O
contribution	O
to	O
the	O
ELENA	O
study	O
and	O
is	O
part	O
of	O
the	O
ELENA	O
group	O
.	O

The	O
centres	O
associated	O
with	O
the	O
project	O
are	O
organised	O
into	O
a	O
consortium	O
.	O

A	O
steering	O
committee	O
and	O
a	O
scientific	O
committee	O
meet	O
each	O
year	O
to	O
ensure	O
correct	O
follow	O
-	O
up	O
of	O
the	O
project	O
.	O

Based	O
on	O
our	O
extensive	O
experience	O
of	O
working	O
in	O
collaboration	O
with	O
patient	O
and	O
public	O
involvement	O
(	O
PPI	O
)	O
representatives	O
,	O
we	O
included	O
in	O
our	O
scientific	O
committee	O
two	O
PPI	O
representatives	O
.	O

They	O
assisted	O
the	O
project	O
research	O
team	O
to	O
build	O
the	O
research	O
proposal	O
by	O
paying	O
attention	O
to	O
the	O
importance	O
and	O
relevance	O
of	O
the	O
research	O
question	O
for	O
the	O
patient’s	O
family	O
as	O
well	O
as	O
the	O
acceptability	O
of	O
the	O
research	O
design	O
for	O
patients	O
.	O

Parents	O
of	O
ASD	O
children	O
included	O
in	O
the	O
ELENA	O
cohort	O
received	O
a	O
written	O
summary	O
of	O
their	O
child’s	O
visit	O
results	O
and	O
study	O
updates	O
through	O
an	O
annual	O
newsletter	O
and	O
information	O
on	O
the	O
ELENA	O
cohort	O
website	O
(	O
www	O
.	O
elena	O
-	O
cohorte	O
.	O
org	O
)	O
.	O

We	O
will	O
use	O
latent	O
class	O
growth	O
modelling	O
methods	O
62	O
63	O
to	O
perform	O
the	O
clinical	O
feature	O
trajectories	O
of	O
children	O
with	O
ASD	O
and	O
further	O
identify	O
patterns	O
of	O
ASD	O
clinical	O
outcome	O
trajectories	O
based	O
on	O
the	O
large	O
panel	O
of	O
clinical	O
and	O
behavioural	O
ASD	O
features	O
.	O

We	O
estimated	O
that	O
107	O
children	O
with	O
data	O
for	O
at	O
least	O
three	O
timepoints	O
of	O
the	O
follow	O
-	O
up	O
will	O
be	O
necessary	O
to	O
successfully	O
conduct	O
these	O
analyses	O
.	O

Inclusion	O
of	O
1000	O
children	O
at	O
baseline	O
,	O
even	O
considering	O
an	O
attrition	O
rate	O
of	O
10	O
%	O
commonly	O
observed	O
in	O
ASD	O
cohorts	O
,	O
20	O
exceeds	O
the	O
minimal	O
subject	O
number	O
required	O
to	O
achieve	O
the	O
first	O
objective	O
and	O
will	O
provide	O
sufficient	O
power	O
to	O
investigate	O
the	O
heterogeneity	O
of	O
factors	O
(	O
sociodemographic	O
,	O
family	O
,	O
comorbidities	O
and	O
diagnostic	O
factors	O
)	O
associated	O
with	O
the	O
preidentified	O
trajectories	O
within	O
the	O
entire	O
population	O
and	O
in	O
each	O
childhood	O
age	O
group	O
,	O
for	O
each	O
gender	O
and	O
according	O
to	O
each	O
ASD	O
primary	O
diagnosis	O
,	O

by	O
multivariate	O
analysis	O
.	O

Indeed	O
,	O
we	O
estimated	O
a	O
minimal	O
sample	O
size	O
of	O
250	O
participants	O
to	O
perform	O
relevant	O
multivariate	O
analyses	O
according	O
to	O
(	O
1	O
)	O
the	O
number	O
of	O
available	O
covariates	O
(	O
approximately	O
25	O
)	O
and	O
(	O
2	O
)	O
the	O
recommendation	O
of	O
at	O
least	O
10	O
participants	O
for	O
one	O
single	O
predictor	O
.	O

64	O
Finally	O
,	O
our	O
objective	O
is	O
to	O
obtain	O
the	O
largest	O
sample	O
possible	O
to	O
allow	O
us	O
to	O
study	O
the	O
outcome	O
according	O
to	O
criteria	O
such	O
as	O
age	O
and	O
clinical	O
subgroup	O
.	O

For	O
a	O
statistical	O
power	O
of	O
80	O
%	O
with	O
an	O
α	O
at	O
0	O
.	O
05	O
,	O
a	O
sample	O
size	O
of	O
1000	O
children	O
is	O
targeted	O
to	O
allow	O
assessment	O
of	O
the	O
determinants	O
of	O
the	O
natural	O
history	O
of	O
ASD	O
and	O
its	O
clinical	O
heterogeneity	O
and	O
the	O
examination	O
of	O
the	O
prognostic	O
factors	O
.	O

The	O
report	O
of	O
this	O
study	O
will	O
be	O
prepared	O
in	O
accordance	O
with	O
the	O
guidelines	O
set	O
by	O
the	O
Strengthening	O
the	O
Reporting	O
of	O
Observational	O
Studies	O
in	O
Epidemiology	O
statement	O
for	O
observational	O
studies	O
.	O

65	O
Data	O
will	O
be	O
collected	O
and	O
analysed	O
by	O
confirmed	O
statisticians	O
of	O
the	O
ELENA	O
study	O
.	O

Χ	O
2	O
tests	O
(	O
for	O
categorical	O
variables	O
)	O
,	O
Student’s	O
t	O
-	O
tests	O
and	O
Fisher’s	O
tests	O
(	O
for	O
normally	O
distributed	O
continuous	O
variables	O
)	O
and	O
Mann	O
-	O
Whitney	O
U	O
/	O
Kruskal	O
-	O
Wallis	O
tests	O
(	O
for	O
non	O
-	O
normally	O
distributed	O
continuous	O
variables	O
)	O
will	O
be	O
used	O
for	O
the	O
description	O
of	O
characteristics	O
and	O
their	O
comparison	O
based	O
on	O
the	O
primary	O
ASD	O
diagnosis	O
.	O

Missing	O
data	O
will	O
be	O
analysed	O
and	O
multiple	O
imputation	O
performed	O
if	O
required	O
.	O

Longitudinal	O
relationships	O
between	O
risk	O
factors	O
and	O
identified	O
trajectories	O
will	O
be	O
studied	O
using	O
multivariable	O
linear	O
and	O
logistic	O
regression	O
models	O
to	O
assess	O
factors	O
associated	O
with	O
severity	O
and	O
specific	O
long	O
-	O
term	O
adaptive	O
trajectories	O
of	O
ASD	O
in	O
childhood	O
,	O
based	O
on	O
the	O
primary	O
ASD	O
diagnosis	O
/	O
phenotype	O
.	O

The	O
primary	O
limitation	O
of	O
this	O
study	O
is	O
loss	O
to	O
follow	O
-	O
up	O
and	O
missing	O
data	O
points	O
that	O
would	O
challenge	O
the	O
internal	O
validity	O
of	O
the	O
reported	O
results	O
of	O
ELENA	O
.	O

However	O
,	O
our	O
research	O
team	O
has	O
extensive	O
experience	O
in	O
achieving	O
high	O
follow	O
-	O
up	O
rates	O
in	O
similar	O
studies	O
of	O
long	O
-	O
term	O
follow	O
-	O
up	O
of	O
patients	O
.	O

20	O
Efforts	O
to	O
minimise	O
loss	O
to	O
follow	O
-	O
up	O
will	O
include	O
respecting	O
the	O
time	O
commitment	O
of	O
families	O
and	O
the	O
use	O
of	O
formal	O
tracking	O
procedures	O
of	O
enrolled	O
families	O
,	O
including	O
obtaining	O
multiple	O
contacts	O
for	O
arranging	O
follow	O
-	O
up	O
and	O
the	O
strong	O
interpersonal	O
skills	O
of	O
the	O
study	O
staff	O
.	O

The	O
study	O
poses	O
no	O
risk	O
to	O
participants	O
and	O
their	O
families	O
.	O

Signed	O
informed	O
consent	O
is	O
obtained	O
from	O
all	O
participating	O
families	O
.	O

Participation	O
in	O
the	O
study	O
does	O
not	O
interfere	O
with	O
the	O
typical	O
care	O
patients	O
receive	O
in	O
the	O
autism	O
centre	O
.	O

Clinical	O
follow	O
-	O
up	O
is	O
provided	O
by	O
clinicians	O
in	O
the	O
centres	O
and	O
,	O
if	O
necessary	O
,	O
participants	O
are	O
referred	O
for	O
additional	O
clinical	O
management	O
(	O
eg	O
,	O
rehabilitation	O
,	O
clinical	O
psychology	O
)	O
.	O

Results	O
from	O
this	O
study	O
will	O
be	O
disseminated	O
at	O
national	O
and	O
international	O
conferences	O
and	O
in	O
peer	O
-	O
reviewed	O
journals	O
.	O

The	O
study	O
will	O
provide	O
indepth	O
insight	O
into	O
the	O
heterogeneity	O
of	O
the	O
clinical	O
presentation	O
of	O
ASD	O
and	O
associated	O
factors	O
.	O

The	O
prospectively	O
collected	O
clinical	O
data	O
will	O
allow	O
us	O
to	O
describe	O
the	O
outcome	O
trajectories	O
of	O
ELENA	O
participants	O
for	O
the	O
6	O
years	O
following	O
their	O
inclusion	O
and	O
their	O
determinants	O
.	O

The	O
study	O
results	O
will	O
inform	O
clinicians	O
,	O
patients	O
and	O
their	O
families	O
of	O
the	O
expected	O
course	O
of	O
ASD	O
severity	O
during	O
childhood	O
based	O
on	O
the	O
ASD	O
characteristics	O
obtained	O
at	O
the	O
time	O
of	O
diagnosis	O
.	O

A	O
detailed	O
understanding	O
of	O
the	O
importance	O
of	O
perinatal	O
factors	O
,	O
socioenvironmental	O
factors	O
,	O
comorbidities	O
,	O
early	O
medical	O
care	O
and	O
medical	O
care	O
of	O
the	O
mother	O
during	O
pregnancy	O
will	O
assist	O
in	O
targeting	O
patients	O
at	O
high	O
risk	O
of	O
unfavourable	O
behaviours	O
and	O
clinical	O
ASD	O
trajectories	O
,	O
who	O
are	O
the	O
most	O
likely	O
to	O
benefit	O
from	O
specific	O
interventions	O
.	O

This	O
strategy	O
is	O
essential	O
to	O
guide	O
optimal	O
clinical	O
care	O
and	O
follow	O
-	O
up	O
of	O
children	O
with	O
ASD	O
.	O

In	O
addition	O
,	O
we	O
will	O
investigate	O
the	O
prevalence	O
of	O
a	O
broad	O
autistic	O
phenotype	O
and	O
psychiatric	O
/	O
neurodevelopmental	O
disorders	O
among	O
siblings	O
of	O
ASD	O
,	O
as	O
we	O
are	O
regularly	O
collecting	O
information	O
about	O
siblings	O
in	O
our	O
database	O
.	O

Prenatal	O
and	O
perinatal	O
occupational	O
and	O
residential	O
histories	O
will	O
be	O
collected	O
through	O
a	O
web	O
-	O
based	O
questionnaire	O
tailored	O
from	O
early	O
life	O
exposure	O
assessment	O
tool	O
(	O
ELEAT	O
)	O
(	O
https	O
:	O
/	O
/	O
eleat	O
.	O
ucdavis	O
.	O
edu	O
/	O
)	O
.	O

Then	O
,	O
personal	O
exposure	O
to	O
particulate	O
matter	O
(	O
PM10	O
,	O
PM2	O
.	O
5	O
)	O
will	O
be	O
achieved	O
through	O
aerosol	O
optical	O
depth	O
daily	O
measurements	O
by	O
satellite	O
images	O
(	O
resolution	O
1	O
km	O
)	O
combined	O
with	O
other	O
geographical	O
data	O
and	O
calibrated	O
with	O
air	O
quality	O
monitoring	O
station	O
measurements	O
.	O

Personal	O
exposure	O
to	O
pesticides	O
will	O
be	O
done	O
using	O
geographical	O
information	O
systems	O
and	O
land	O
use	O
data	O
(	O
or	O
public	O
data	O
from	O
agricultural	O
statistics	O
)	O
to	O
determine	O
the	O
proximity	O
and	O
the	O
type	O
of	O
crops	O
within	O
a	O
1	O
km	O
radius	O
around	O
each	O
home’s	O
address	O
.	O

A	O
pesticides	O
matrix	O
will	O
convert	O
the	O
crops	O
exposure	O
levels	O
into	O
pesticide	O
exposure	O
levels	O
for	O
each	O
family	O
of	O
pesticides	O
.	O

The	O
challenge	O
is	O
to	O
determine	O
the	O
role	O
of	O
pesticides	O
and	O
air	O
pollution	O
in	O
the	O
aetiology	O
of	O
ASD	O
,	O
in	O
comparison	O
with	O
children	O
without	O
ASD	O
from	O
a	O
large	O
French	O
birth	O
cohort	O
french	O
longitudinal	O
study	O
of	O
children	O
(	O
ELFE	O
)	O
,	O
as	O
well	O
as	O
in	O
the	O
ASD	O
severity	O
and	O
trajectories	O
.	O

In	O
addition	O
,	O
a	O
biobank	O
is	O
intended	O
,	O
comprising	O
blood	O
samples	O
from	O
the	O
antecubital	O
vein	O
and	O
droplets	O
from	O
fingertips	O
on	O
dried	O
blood	O
spot	O
(	O
DBS	O
)	O
collected	O
by	O
experienced	O
nurses	O
during	O
a	O
centre	O
visit	O
.	O

Genetic	O
and	O
epigenetic	O
studies	O
are	O
scheduled	O
across	O
three	O
tasks	O
:	O
(	O
1	O
)	O
to	O
identify	O
simple	O
genetic	O
abnormalities	O
(	O
such	O
as	O
monogenic	O
Mendelian	O
or	O
simple	O
digenic	O
forms	O
)	O
,	O
(	O
2	O
)	O
to	O
understand	O
complex	O
genetic	O
forms	O
architecture	O
,	O
including	O
digenic	O
,	O
oligogenic	O
or	O
polygenic	O
multifactorial	O
models	O
,	O
and	O
(	O
3	O
)	O
to	O
highlight	O
epigenetic	O
profiles	O
on	O
patient	O
blood	O
DNA	O
.	O

Patient	O
exome	O
sequencing	O
and	O
methylation	O
profile	O
on	O
Illumina’s	O
EPIC	O
chip	O
will	O
be	O
analysed	O
by	O
the	O
National	O
Center	O
for	O
Research	O
in	O
Human	O
Genomics	O
.	O

Bioinformatics	O
analysis	O
will	O
be	O
performed	O
in	O
collaboration	O
with	O
a	O
molecular	O
genetics	O
laboratory	O
,	O
first	O
on	O
a	O
400	O
ASD	O
genes	O
panel	O
,	O
and	O
if	O
no	O
mutation	O
would	O
be	O
found	O
on	O
the	O
whole	O
online	O
mendelian	O
inheritance	O
in	O
man	O
(	O
OMIM	O
)	O
genes	O
then	O
complex	O
genetic	O
form	O
architecture	O
will	O
be	O
studied	O
in	O
collaboration	O
with	O
a	O
bioinformatics	O
company	O
.	O

SUCCEAT	O
is	O
a	O
two‐arm	O
multicentre	O
,	O
parallel	O
group	O
RCT	O
with	O
a	O
nonrandomised	O
control	O
group	O
(	O
see	O
Figure	O
1	O
)	O
.	O

Incoming	O
patients	O
are	O
screened	O
for	O
AN	O
or	O
atypical	O
AN	O
and	O
are	O
randomly	O
allocated	O
to	O
the	O
Intervention	O
group	O
1	O
(	O
workshop	O
support	O
groups	O
)	O
or	O
the	O
Intervention	O
group	O
2	O
(	O
web‐based	O
support	O
groups	O
)	O
,	O
respectively	O
,	O
in	O
addition	O
to	O
treatment	O
as	O
usual	O
(	O
TAU	O
)	O
,	O
and	O
compared	O
with	O
a	O
nonrandomised	O
control	O
group	O
(	O
TAU	O
)	O
.	O

The	O
study	O
is	O
conducted	O
in	O
Austria	O
and	O
Germany	O
.	O

Diagram	O
of	O
the	O
trial	O
design	O
of	O
the	O
intervention	O
:	O
Supporting	O
Carers	O
of	O
Children	O
and	O
Adolescents	O
with	O
Eating	O
Disorders	O
in	O
Austria	O

The	O
following	O
are	O
the	O
inclusion	O
criteria	O
for	O
children	O
and	O
adolescents	O
:	O
Age	O
between	O
10	O
and	O
19	O
years	O
Diagnosis	O
of	O
AN	B-phenotype
(	O
F50	B-code
.	I-code
0	I-code
)	O
or	O
atypical	B-phenotype
AN	I-phenotype
(	O
F50	B-code
.	I-code
1	I-code
)	O
according	O
to	O
the	O
International	B-coding_system
Classification	I-coding_system
of	I-coding_system
Diseases	I-coding_system
(	I-coding_system
World	I-coding_system
Health	I-coding_system
Organization	I-coding_system
,	I-coding_system
1990	I-coding_system
)	I-coding_system
Fluent	O
German	O
in	O
order	O
to	O
answer	O
outcome	O
questionnaires	O
Ability	O
to	O
provide	O
informed	O
consent	O
Children	O
and	O
adolescents	O
have	O
to	O
receive	O
TAU	O
according	O
to	O
the	O
NICE	O
guidelines	O
(	O
NICE	O
,	O
2017	O
)	O
.	O

TAU	O
is	O
multidisciplinary	O
,	O
coordinated	O
between	O
services	O
,	O
and	O
includes	O
psychological	O
treatment	O
,	O
psychoeducation	O
,	O
and	O
monitoring	O
of	O
weight	O
,	O
mental	O
,	O
and	O
physical	O
health	O
.	O

Psychological	O
treatment	O
for	O
children	O
and	O
young	O
people	O
includes	O
sessions	O
without	O
and	O
together	O
with	O
their	O
family	O
members	O
(	O
for	O
further	O
information	O
,	O
see	O
Section	O
2	O
.	O
3	O
.	O

2	O
)	O
.	O

The	O
frequency	O
and	O
duration	O
of	O
the	O
psychological	O
treatment	O
for	O
the	O
patients	O
depend	O
on	O
their	O
needs	O
.	O

Dietary	O
counselling	O
and	O
medication	O
for	O
the	O
patients	O
are	O
only	O
offered	O
as	O
part	O
of	O
a	O
multidisciplinary	O
approach	O
.	O

For	O
patients	O
with	O
an	O
acute	O
mental	O
health	O
risk	O
,	O
psychiatric	O
inpatient	O
care	O
is	O
considered	O
.	O

Patients	O
whose	O
physical	O
health	O
is	O
severely	O
compromised	O
are	O
admitted	O
to	O
inpatient	O
or	O
day‐patient	O
service	O
for	O
medical	O
stabilisation	O
and	O
to	O
initiate	O
refeeding	O
,	O
if	O
these	O
cannot	O
be	O
done	O
in	O
an	O
outpatient	O
setting	O
.	O

Age	O
between	O
10	O
and	O
19	O
years	O

Diagnosis	O
of	O
AN	B-phenotype
(	O
F50	B-code
.	I-code
0	I-code
)	O
or	O
atypical	B-phenotype
AN	I-phenotype
(	O
F50	B-code
.	I-code
1	I-code
)	O
according	O
to	O
the	O
International	B-coding_system
Classification	I-coding_system
of	I-coding_system
Diseases	I-coding_system
(	I-coding_system
World	I-coding_system
Health	I-coding_system
Organization	I-coding_system
,	I-coding_system
1990	I-coding_system
)	I-coding_system

Fluent	O
German	O
in	O
order	O
to	O
answer	O
outcome	O
questionnaires	O

Ability	O
to	O
provide	O
informed	O
consent	O

Children	O
and	O
adolescents	O
have	O
to	O
receive	O
TAU	O
according	O
to	O
the	O
NICE	O
guidelines	O
(	O
NICE	O
,	O
2017	O
)	O
.	O

TAU	O
is	O
multidisciplinary	O
,	O
coordinated	O
between	O
services	O
,	O
and	O
includes	O
psychological	O
treatment	O
,	O
psychoeducation	O
,	O
and	O
monitoring	O
of	O
weight	O
,	O
mental	O
,	O
and	O
physical	O
health	O
.	O

Psychological	O
treatment	O
for	O
children	O
and	O
young	O
people	O
includes	O
sessions	O
without	O
and	O
together	O
with	O
their	O
family	O
members	O
(	O
for	O
further	O
information	O
,	O
see	O
Section	O
2	O
.	O
3	O
.	O

2	O
)	O
.	O

The	O
frequency	O
and	O
duration	O
of	O
the	O
psychological	O
treatment	O
for	O
the	O
patients	O
depend	O
on	O
their	O
needs	O
.	O

Dietary	O
counselling	O
and	O
medication	O
for	O
the	O
patients	O
are	O
only	O
offered	O
as	O
part	O
of	O
a	O
multidisciplinary	O
approach	O
.	O

For	O
patients	O
with	O
an	O
acute	O
mental	O
health	O
risk	O
,	O
psychiatric	O
inpatient	O
care	O
is	O
considered	O
.	O

Patients	O
whose	O
physical	O
health	O
is	O
severely	O
compromised	O
are	O
admitted	O
to	O
inpatient	O
or	O
day‐patient	O
service	O
for	O
medical	O
stabilisation	O
and	O
to	O
initiate	O
refeeding	O
,	O
if	O
these	O
cannot	O
be	O
done	O
in	O
an	O
outpatient	O
setting	O
.	O

The	O
following	O
are	O
the	O
exclusion	O
criteria	O
for	O
children	O
and	O
adolescents	O
:	O
Severe	O
comorbidity	O
at	O
baseline	O
(	O
e	O
.	O
g	O
.	O
,	O
psychosis	O
)	O
No	O
main	O
carer	O
(	O
e	O
.	O
g	O
.	O
,	O
live	O
in	O
a	O
children	O
'	O
s	O
home	O
with	O
no	O
contact	O
to	O
own	O
family	O
)	O

Severe	O
comorbidity	O
at	O
baseline	O
(	O
e	O
.	O
g	O
.	O
,	O
psychosis	O
)	O

No	O
main	O
carer	O
(	O
e	O
.	O
g	O
.	O
,	O
live	O
in	O
a	O
children	O
'	O
s	O
home	O
with	O
no	O
contact	O
to	O
own	O
family	O
)	O

The	O
following	O
are	O
the	O
inclusion	O
criteria	O
for	O
main	O
carers	O
who	O
complete	O
outcome	O
assessment	O
:	O
Ability	O
to	O
provide	O
informed	O
consent	O
The	O
main	O
carer	O
has	O
to	O
speak	O
German	O
fluently	O
in	O
order	O
to	O
answer	O
the	O
outcome	O
questionnaires	O
.	O

The	O
main	O
carer	O
is	O
the	O
one	O
who	O
spends	O
the	O
most	O
time	O
with	O
the	O
patient	O
.	O

Only	O
the	O
main	O
carer	O
will	O
answer	O
the	O
questionnaires	O
about	O
the	O
outcome	O
measures	O
.	O

Besides	O
the	O
main	O
carer	O
,	O
other	O
family	O
members	O
and	O
carers	O
are	O
also	O
invited	O
to	O
take	O
part	O
in	O
the	O
intervention	O
.	O

Ability	O
to	O
provide	O
informed	O
consent	O

The	O
main	O
carer	O
has	O
to	O
speak	O
German	O
fluently	O
in	O
order	O
to	O
answer	O
the	O
outcome	O
questionnaires	O
.	O

The	O
main	O
carer	O
is	O
the	O
one	O
who	O
spends	O
the	O
most	O
time	O
with	O
the	O
patient	O
.	O

Only	O
the	O
main	O
carer	O
will	O
answer	O
the	O
questionnaires	O
about	O
the	O
outcome	O
measures	O
.	O

Besides	O
the	O
main	O
carer	O
,	O
other	O
family	O
members	O
and	O
carers	O
are	O
also	O
invited	O
to	O
take	O
part	O
in	O
the	O
intervention	O
.	O

The	O
following	O
are	O
the	O
exclusion	O
criteria	O
for	O
main	O
carers	O
:	O
Severe	O
morbidity	O
at	O
baseline	O
,	O
which	O
prevents	O
carers	O
from	O
participating	O
in	O
the	O
RCT	O
(	O
e	O
.	O
g	O
.	O
,	O
acute	O
inpatient	O
treatment	O
because	O
of	O
physical	O
illness	O
)	O
Carers	O
without	O
internet	O
access	O
(	O
85	O
%	O
of	O
Austrian	O
and	O
92	O
%	O
of	O
German	O
households	O
have	O
internet	O
access	O
;	O
European	O
Commission	O
,	O
2016	O
)	O

Severe	O
morbidity	O
at	O
baseline	O
,	O
which	O
prevents	O
carers	O
from	O
participating	O
in	O
the	O
RCT	O
(	O
e	O
.	O
g	O
.	O
,	O
acute	O
inpatient	O
treatment	O
because	O
of	O
physical	O
illness	O
)	O

Carers	O
without	O
internet	O
access	O
(	O
85	O
%	O
of	O
Austrian	O
and	O
92	O
%	O
of	O
German	O
households	O
have	O
internet	O
access	O
;	O
European	O
Commission	O
,	O
2016	O
)	O

Patients	O
and	O
carers	O
will	O
be	O
recruited	O
at	O
different	O
inpatient	O
and	O
outpatient	O
centres	O
with	O
ED	O
units	O
,	O
where	O
they	O
receive	O
TAU	O
.	O

Carers	O
and	O
patients	O
who	O
meet	O
the	O
eligibility	O
criteria	O
are	O
invited	O
to	O
participate	O
in	O
the	O
study	O
.	O

Patients	O
and	O
carers	O
both	O
give	O
their	O
informed	O
consent	O
,	O
and	O
parents	O
give	O
their	O
informed	O
consent	O
for	O
children	O
who	O
are	O
minors	O
.	O

Carers	O
and	O
patients	O
of	O
the	O
two	O
SUCCEAT	O
intervention	O
groups	O
will	O
be	O
recruited	O
at	O
the	O
Medical	O
University	O
of	O
Vienna	O
,	O
Department	O
of	O
Child	O
and	O
Adolescent	O
Psychiatry	O
,	O
and	O
by	O
consultant	O
child	O
and	O
adolescent	O
psychiatrists	O
and	O
at	O
different	O
centres	O
with	O
ED	O
units	O
in	O
adjacent	O
federal	O
states	O
to	O
Vienna	O
.	O

Patients	O
and	O
carers	O
in	O
the	O
two	O
intervention	O
groups	O
give	O
their	O
informed	O
consent	O
and	O
complete	O
the	O
questionnaires	O
at	O
the	O
Medical	O
University	O
of	O
Vienna	O
,	O
Department	O
of	O
Child	O
and	O
Adolescent	O
Psychiatry	O
.	O

For	O
the	O
control	O
group	O
,	O
patients	O
and	O
their	O
carers	O
will	O
be	O
recruited	O
and	O
receive	O
TAU	O
at	O
three	O
centres	O
:	O
at	O
the	O
Wilhelminenspital	O
in	O
Vienna	O
,	O
Department	O
of	O
Child	O
and	O
Adolescent	O
Medicine	O
,	O
Inpatient	O
and	O
Outpatient	O
Unit	O
for	O
Children	O
and	O
Adolescents	O
;	O
at	O
the	O
Clinical	O
Centre	O
Klagenfurt	O
,	O
Department	O
of	O
Neurology	O
and	O
Psychiatry	O
for	O
Children	O
and	O
Adolescents	O
;	O
and	O
at	O
the	O
Parkland‐Clinic	O
for	O
Psychosomatic	O
and	O
Psychotherapy	O
in	O
Bad	O
Wildungen	O
,	O
Germany	O
.	O

Patients	O
and	O
carers	O
in	O
the	O
control	O
group	O
give	O
their	O
informed	O
consent	O
and	O
complete	O
the	O
questionnaires	O
at	O
the	O
recruiting	O
site	O
.	O

The	O
interventions	O
started	O
in	O
November	O
2014	O
and	O
will	O
continue	O
approximately	O
until	O
April	O
2018	O
.	O

Follow‐up	O
assessments	O
for	O
the	O
remaining	O
patients	O
are	O
expected	O
to	O
be	O
completed	O
by	O
April	O
2019	O
.	O

The	O
main	O
ethics	O
approval	O
has	O
been	O
granted	O
by	O
the	O
Medical	O
University	O
of	O
Vienna	O
Ethics	O
Committee	O
(	O
1840	O
/	O
2013	O
)	O
.	O

Site‐specific	O
ethics	O
approvals	O
are	O
granted	O
for	O
all	O
participating	O
sites	O
.	O

The	O
SUCCEAT	O
intervention	O
consists	O
of	O
eight	O
weekly	O
workshop	O
sessions	O
and	O
web‐based	O
modules	O
respectively	O
(	O
see	O
Table	O
1	O
for	O
content	O
)	O
,	O
a	O
SUCCEAT	O
workbook	O
,	O
and	O
the	O
DVD	O
How	O
to	O
Care	O
for	O
Someone	O
with	O
an	O
Eating	O
Disorder	O
(	O
The	O
Succeed	O
Foundation	O
,	O
2011	O
;	O
German	O
translation	O
by	O
our	O
research	O
group	O
)	O
.	O

The	O
SUCCEAT	O
workshop	O
support	O
groups	O
and	O
SUCCEAT	O
web‐based	O
support	O
groups	O
consist	O
of	O
the	O
same	O
content	O
and	O
are	O
designed	O
to	O
encourage	O
the	O
carers	O
to	O
read	O
the	O
materials	O
,	O
watch	O
the	O
DVD	O
,	O
and	O
try	O
new	O
behaviours	O
as	O
“experiments”	O
at	O
home	O
.	O

The	O
contents	O
of	O
the	O
intervention	O
and	O
the	O
DVD	O
were	O
translated	O
into	O
the	O
German	O
language	O
and	O
adapted	O
to	O
a	O
German‐speaking	O
cultural	O
context	O
(	O
e	O
.	O
g	O
.	O

,	O
German	O
names	O
of	O
actors	O
and	O
meals	O
and	O
topics	O
of	O
the	O
conversations	O
:	O
lyrics	O
from	O
a	O
German	O
singer	O
)	O
prior	O
to	O
the	O
study	O
by	O
the	O
SUCCEAT	O
research	O
group	O
.	O

The	O
audio	O
track	O
of	O
the	O
DVD	O
How	O
to	O
Care	O
for	O
Someone	O
with	O
an	O
Eating	O
Disorder	O
(	O
The	O
Succeed	O
Foundation	O
,	O
2011	O
)	O
has	O
been	O
synchronised	O
to	O
the	O
German	O
language	O
,	O
and	O
the	O
texts	O
have	O
been	O
translated	O
.	O

Almost	O
all	O
of	O
the	O
scenes	O
in	O
the	O
DVD	O
show	O
young	O
patients	O
who	O
still	O
live	O
with	O
their	O
parents	O
.	O

Therefore	O
,	O
the	O
DVD	O
is	O
applicable	O
to	O
the	O
carers	O
of	O
adolescent	O
patients	O
in	O
our	O
RCT	O
.	O

One	O
scene	O
shows	O
a	O
young	O
adult	O
patient	O
(	O
who	O
already	O
lives	O
with	O
her	O
partner	O
)	O
,	O
but	O
the	O
content	O
of	O
the	O
scene	O
(	O
over‐exercising	O
)	O
is	O
also	O
applicable	O
to	O
patients	O
who	O
are	O
minors	O
.	O

Carers	O
of	O
patients	O
with	O
ED	O
(	O
who	O
were	O
not	O
included	O
in	O
the	O
study	O
)	O
tested	O
the	O
German	O
materials	O
prior	O
to	O
the	O
study	O
and	O
gave	O
us	O
feedback	O
.	O

The	O
DVD	O
shows	O
examples	O
for	O
communication	O
with	O
HEE	O
and	O
the	O
same	O
scenarios	O
with	O
good	O
communication	O
incorporating	O
change	O
(	O
e	O
.	O
g	O
.	O
,	O
a	O
family	O
with	O
a	O
child	O
with	O
AN	O
in	O
a	O
restaurant	O
and	O
shopping	O
for	O
food	O
with	O
a	O
daughter	O
suffering	O
from	O
AN	O
)	O
.	O

Both	O
intervention	O
groups	O
(	O
workshop	O
support	O
groups	O
and	O
web‐based	O
support	O
groups	O
)	O
will	O
involve	O
six	O
subgroups	O
.	O

Each	O
subgroup	O
will	O
include	O
the	O
carers	O
of	O
about	O
eight	O
patients	O
.	O

The	O
same	O
two	O
professional	O
SUCCEAT	O
coaches	O
guide	O
all	O
the	O
carers	O
in	O
each	O
of	O
the	O
SUCCEAT	O
workshop	O
support	O
groups	O
and	O
in	O
the	O
SUCCEAT	O
web‐based	O
support	O
groups	O
.	O

One	O
coach	O
is	O
a	O
consultant	O
psychiatrist	O
,	O
child	O
and	O
adolescent	O
psychiatrist	O
,	O
and	O
psychotherapist	O
;	O
and	O
the	O
other	O
coach	O
is	O
a	O
senior	O
registrar	O
in	O
child	O
and	O
adolescent	O
psychiatry	O
and	O
a	O
psychologist	O
.	O

The	O
two	O
coaches	O
were	O
trained	O
in	O
a	O
2‐day	O
workshop	O
by	O
Gill	O
Todd	O
(	O
e	O
.	O
g	O
.	O

,	O
Salerno	O
,	O
Rhind	O
,	O
Hibbs	O
,	O
Micali	O
,	O
Schmidt	O
,	O
Gowers	O
,	O
Macdonald	O
,	O
Goddard	O
,	O
Todd	O
,	O
Tchanturia	O
,	O
et	O
al	O
.	O
,	O
2016b	O
)	O
,	O
who	O
is	O
experienced	O
in	O
working	O
with	O
carers	O
of	O
patients	O
with	O
ED	O
applying	O
“The	O
New	O
Maudsley	O
Method”	O
(	O
Treasure	O
et	O
al	O
.	O
,	O
2010	O
;	O
Treasure	O
,	O
Smith	O
,	O
et	O
al	O
.	O
,	O
2007	O
)	O
.	O

All	O
SUCCEAT	O
workshop	O
support	O
groups	O
are	O
held	O
at	O
the	O
Medical	O
University	O
of	O
Vienna	O
,	O
Department	O
of	O
Child	O
and	O
Adolescent	O
Psychiatry	O
,	O
once	O
in	O
a	O
week	O
in	O
the	O
evening	O
(	O
from	O
6	O
p	O
.	O
m	O
.	O
to	O
8	O
p	O
.	O
m	O
.	O
)	O
and	O
consist	O
of	O
eight	O
weekly	O
workshop	O
sessions	O
(	O
see	O
Table	O
1	O
)	O
.	O

Carers	O
receive	O
the	O
SUCCEAT	O
workbook	O
as	O
a	O
hardcopy	O
and	O
the	O
DVD	O
(	O
The	O
Succeed	O
Foundation	O
,	O
2011	O
;	O
German	O
translation	O
of	O
our	O
research	O
group	O
)	O
at	O
the	O
first	O
workshop	O
session	O
.	O

The	O
two	O
SUCCEAT	O
coaches	O
present	O
the	O
contents	O
of	O
the	O
SUCCEAT	O
intervention	O
listed	O
in	O
Table	O
1	O
with	O
a	O
PowerPoint	O
presentation	O
and	O
support	O
the	O
carers	O
personally	O
during	O
the	O
sessions	O
.	O

In	O
each	O
session	O
,	O
the	O
carers	O
will	O
get	O
a	O
hardcopy	O
handout	O
with	O
a	O
summary	O
of	O
the	O
workshop	O
session	O
.	O

The	O
workshops	O
are	O
designed	O
to	O
be	O
interactive	O
with	O
role	O
plays	O
and	O
group	O
work	O
for	O
the	O
carers	O
.	O

The	O
carers	O
are	O
encouraged	O
to	O
talk	O
about	O
their	O
concerns	O
and	O
experiences	O
with	O
each	O
other	O
.	O

They	O
have	O
time	O
to	O
report	O
their	O
“experiments”	O
and	O
to	O
reflect	O
together	O
.	O

All	O
the	O
carers	O
get	O
to	O
know	O
the	O
two	O
SUCCEAT	O
coaches	O
and	O
the	O
other	O
participating	O
carers	O
of	O
their	O
web‐based	O
support	O
group	O
personally	O
in	O
a	O
welcome	O
meeting	O
at	O
the	O
beginning	O
of	O
the	O
intervention	O
at	O
the	O
Medical	O
University	O
of	O
Vienna	O
,	O
Department	O
of	O
Child	O
and	O
Adolescent	O
Psychiatry	O
,	O
and	O
subsequently	O
complete	O
the	O
programme	O
at	O
home	O
via	O
Internet	O
.	O

The	O
web‐based	O
support	O
groups	O
consist	O
of	O
eight	O
weekly	O
web‐based	O
modules	O
(	O
see	O
Table	O
1	O
)	O
.	O

The	O
SUCCEAT	O
web‐based	O
modules	O
and	O
the	O
SUCCEAT	O
workbook	O
are	O
available	O
on	O
a	O
website	O
within	O
a	O
structured	O
program	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
succeat	O
.	O
at	O
)	O
.	O

The	O
formal	O
conditions	O
are	O
introduced	O
at	O
the	O
welcome	O
meeting	O
,	O
and	O
the	O
carers	O
receive	O
the	O
DVD	O
(	O
The	O
Succeed	O
Foundation	O
,	O
2011	O
;	O
German	O
translation	O
of	O
our	O
research	O
group	O
)	O
.	O

Carers	O
get	O
access	O
to	O
one	O
new	O
web‐based	O
module	O
weekly	O
.	O

They	O
are	O
instructed	O
how	O
to	O
work	O
on	O
the	O
program	O
at	O
any	O
time	O
.	O

Within	O
the	O
modules	O
,	O
carers	O
fill	O
in	O
interactive	O
fields	O
of	O
the	O
exercises	O
and	O
report	O
on	O
their	O
experiences	O
and	O
the	O
“experiments”	O
they	O
carried	O
out	O
at	O
home	O
.	O

In	O
addition	O
,	O
carers	O
are	O
invited	O
to	O
use	O
the	O
opportunity	O
to	O
contact	O
the	O
coaches	O
via	O
a	O
personal	O
message	O
system	O
on	O
the	O
website	O
.	O

The	O
coaches	O
offer	O
their	O
support	O
and	O
give	O
weekly	O
feedback	O
to	O
the	O
exercises	O
and	O
the	O
“experiments”	O
of	O
the	O
carers	O
via	O
the	O
personal	O
message	O
system	O
.	O

The	O
carers	O
have	O
the	O
additional	O
possibility	O
to	O
communicate	O
with	O
the	O
other	O
carers	O
and	O
to	O
discuss	O
different	O
topics	O
in	O
an	O
unguided	O
online	O
forum	O
on	O
the	O
website	O
.	O

This	O
online	O
forum	O
is	O
controlled	O
regularly	O
by	O
the	O
coaches	O
and	O
the	O
coaches	O
delete	O
disturbing	O
comments	O
.	O

Carers	O
and	O
patients	O
receive	O
TAU	O
at	O
inpatient	O
and	O
outpatient	O
centres	O
with	O
ED	O
units	O
according	O
to	O
the	O
NICE	O
guidelines	O
(	O
NICE	O
,	O
2017	O
)	O
.	O

Therefore	O
,	O
carers	O
take	O
part	O
in	O
conventional	O
carers	O
'	O
support	O
groups	O
or	O
in	O
other	O
treatments	O
for	O
families	O
(	O
e	O
.	O
g	O
.	O
,	O
psychotherapy	O
,	O
medical	O
counselling	O
,	O
and	O
psychoeducation	O
)	O
.	O

When	O
patients	O
with	O
AN	O
are	O
weighed	O
at	O
specialist	O
services	O
,	O
the	O
results	O
are	O
shared	O
with	O
their	O
family	O
members	O
or	O
carers	O
(	O
if	O
appropriate	O
)	O
.	O

Family	O
members	O
or	O
carers	O
(	O
as	O
appropriate	O
)	O
are	O
included	O
in	O
any	O
dietary	O
education	O
or	O
meal	O
planning	O
for	O
the	O
patients	O
.	O

Psychological	O
treatment	O
of	O
the	O
patients	O
includes	O
some	O
family	O
sessions	O
together	O
with	O
their	O
family	O
members	O
and	O
psychoeducation	O
.	O

The	O
therapy	O
emphasises	O
the	O
role	O
of	O
the	O
family	O
in	O
helping	O
the	O
person	O
to	O
recover	O
.	O

Early	O
in	O
treatment	O
,	O
a	O
good	O
therapeutic	O
alliance	O
with	O
the	O
parents	O
or	O
carers	O
and	O
other	O
family	O
members	O
is	O
established	O
and	O
the	O
parents	O
or	O
carers	O
are	O
supported	O
to	O
take	O
a	O
central	O
role	O
in	O
helping	O
the	O
patients	O
manage	O
their	O
eating	O
.	O

In	O
the	O
second	O
phase	O
,	O
parents	O
and	O
carers	O
help	O
to	O
support	O
the	O
patients	O
to	O
establish	O
a	O
level	O
of	O
independence	O
appropriate	O
for	O
their	O
level	O
of	O
development	O
.	O

The	O
families	O
'	O
concerns	O
are	O
addressed	O
and	O
family	O
members	O
are	O
supported	O
in	O
order	O
to	O
cope	O
with	O
distress	O
.	O

To	O
describe	O
the	O
sample	O
,	O
clinical	O
data	O
and	O
demographic	O
information	O
about	O
the	O
patients	O
and	O
their	O
carers	O
are	O
collected	O
at	O
baseline	O
(	O
T0	O
;	O
age	O
,	O
sex	O
,	O
educational	O
level	O
,	O
family	O
situation	O
,	O
migration	O
status	O
,	O
and	O
socio‐economic	O
status	O
)	O
.	O

Further	O
assessments	O
for	O
the	O
primary	O
and	O
secondary	O
outcome	O
measures	O
(	O
see	O
Table	O
2	O
)	O
will	O
take	O
place	O
before	O
starting	O
the	O
intervention	O
(	O
T0	O
)	O
,	O
after	O
3	O
months	O
(	O
postintervention	O
,	O
T1	O
)	O
,	O
and	O
1	O
year	O
after	O
the	O
intervention	O
(	O
follow‐up	O
,	O
T2	O
)	O
.	O

The	O
semistructured	O
interview	O
of	O
the	O
Eating	O
Disorder	O
Examination	O
(	O
Fairburn	O
&	O
Cooper	O
,	O
1993	O
;	O
German	O
version	O
:	O
Hilbert	O
&	O
Tuschen‐Caffier	O
,	O
2006	O
)	O
is	O
conducted	O
face‐to‐face	O
or	O
via	O
telephone	O
by	O
professionals	O
(	O
clinical	O
and	O
health	O
psychologists	O
and	O
psychotherapists	O
)	O
.	O

These	O
professionals	O
also	O
administer	O
the	O
other	O
questionnaires	O
,	O
which	O
are	O
answered	O
in	O
a	O
paper–pencil	O
version	O
by	O
the	O
carers	O
and	O
patients	O
themselves	O
.	O

These	O
professionals	O
have	O
already	O
been	O
trained	O
to	O
use	O
these	O
measures	O
before	O
this	O
RCT	O
(	O
by	O
experienced	O
professionals	O
in	O
this	O
field	O
)	O
or	O
received	O
training	O
by	O
G	O
.	O

W	O
.	O
prior	O
to	O
the	O
study	O
.	O

The	O
questionnaires	O
for	O
the	O
process	O
evaluation	O
are	O
answered	O
by	O
the	O
carers	O
of	O
the	O
SUCCEAT	O
intervention	O
after	O
each	O
workshop	O
session	O
or	O
web‐based	O
module	O
and	O
at	O
T1	O
and	O
T2	O
.	O

Table	O
2	O
and	O
Supplement	O
S1	O
contain	O
further	O
information	O
about	O
the	O
questionnaires	O
.	O

Power	O
analysis	O
was	O
done	O
with	O
G	O
*	O
Power	O
version	O
3	O
.	O
1	O
.	O
5	O
.	O

In	O
order	O
to	O
detect	O
a	O
difference	O
for	O
the	O
primary	O
outcome	O
(	O
General	O
Health	O
Questionnaire	O
,	O
see	O
Sepulveda	O
,	O
Lopez	O
,	O
Todd	O
,	O
et	O
al	O
.	O
,	O
2008	O
)	O
by	O
calculating	O
repeated	O
measures	O
analysis	O
of	O
variance	O
(	O
ANOVA	O
;	O
if	O
the	O
s	O
phericity	O
assumption	O
is	O
not	O
met	O
)	O
at	O
a	O
5	O
%	O
significance	O
level	O
with	O
0	O
.	O
88	O
power	O
,	O
carers	O
of	O
40	O
patients	O
per	O
group	O
are	O
needed	O
to	O
detect	O
medium	O
effects	O
(	O
Faul	O
,	O
Erdfelder	O
,	O
Lang	O
,	O
&	O
Buchner	O
,	O
2007	O
)	O
.	O

We	O
expect	O
a	O
dropout	O
rate	O
of	O
about	O
17	O
%	O
(	O
see	O
Wagner	O
et	O
al	O
.	O
,	O
2015	O
)	O
.	O

Therefore	O
,	O
we	O
plan	O
to	O
include	O
the	O
carers	O
of	O
48	O
patients	O
per	O
treatment	O
arm	O
,	O
resulting	O
in	O
a	O
total	O
sample	O
size	O
of	O
144	O
.	O

After	O
recruitment	O
of	O
the	O
patients	O
and	O
their	O
carers	O
(	O
at	O
the	O
Medical	O
University	O
of	O
Vienna	O
,	O
Department	O
of	O
Child	O
and	O
Adolescent	O
Psychiatry	O
,	O
and	O
by	O
consultant	O
child	O
and	O
adolescent	O
psychiatrists	O
in	O
adjacent	O
federal	O
states	O
to	O
Vienna	O
)	O
,	O
patients	O
and	O
carers	O
who	O
meet	O
the	O
eligibility	O
criteria	O
give	O
their	O
informed	O
consent	O
,	O
perform	O
baseline	O
assessments	O
,	O
and	O
are	O
randomly	O
allocated	O
to	O
one	O
of	O
the	O
two	O
intervention	O
groups	O
(	O
SUCCEAT	O
workshop	O
support	O
group	O
or	O
SUCCEAT	O
web‐based	O
support	O
group	O
)	O
by	O
our	O
research	O
group	O
at	O
the	O

Medical	O
University	O
of	O
Vienna	O
.	O

Random	O
allocation	O
is	O
made	O
in	O
a	O
blockwise	O
manner	O
in	O
order	O
to	O
keep	O
the	O
sizes	O
of	O
treatment	O
groups	O
similar	O
.	O

Incoming	O
patients	O
are	O
numbered	O
consecutively	O
,	O
and	O
randomisation	O
is	O
done	O
blockwise	O
according	O
to	O
the	O
consecutive	O
numbering	O
,	O
in	O
blocks	O
of	O
eight	O
participants	O
in	O
the	O
workshop	O
support	O
group	O
and	O
web‐based	O
support	O
group	O
,	O
respectively	O
.	O

The	O
control	O
group	O
is	O
not	O
randomised	O
.	O

The	O
clinical	O
and	O
health	O
psychologists	O
and	O
psychotherapists	O
,	O
who	O
conduct	O
the	O
assessments	O
,	O
are	O
not	O
blinded	O
to	O
the	O
treatment	O
arms	O
.	O

The	O
treatment	O
effect	O
will	O
be	O
analysed	O
by	O
using	O
mixed‐design	O
ANOVAs	O
.	O

The	O
time	O
points	O
will	O
be	O
included	O
as	O
within	O
group	O
factor	O
,	O
and	O
the	O
group	O
(	O
workshop	O
support	O
group	O
vs	O
.	O
web‐based	O
support	O
group	O
vs	O
.	O

TAU	O
)	O
will	O
be	O
included	O
as	O
between	O
group	O
factor	O
.	O

t	O
tests	O
for	O
dependent	O
and	O
independent	O
samples	O
will	O
also	O
be	O
used	O
in	O
order	O
to	O
explore	O
differences	O
between	O
specific	O
groups	O
and	O
specific	O
time	O
points	O
.	O

Two	O
analysis	O
strategies	O
will	O
be	O
applied	O
to	O
account	O
for	O
missing	O
data	O
:	O
Intention‐to‐treat	O
analysis	O
will	O
be	O
used	O
as	O
the	O
primary	O
analysis	O
strategy	O
.	O

If	O
posttreatment	O
or	O
follow‐up	O
data	O
are	O
missing	O
,	O
the	O
last‐value‐put‐forward	O
method	O
will	O
be	O
used	O
.	O

Additionally	O
,	O
the	O
analyses	O
will	O
be	O
repeated	O
by	O
including	O
completers	O
only	O
.	O

Completers	O
will	O
be	O
defined	O
by	O
attending	O
more	O
than	O
50	O
%	O
of	O
the	O
workshop	O
sessions	O
or	O
web‐based	O
modules	O
.	O

To	O
analyse	O
the	O
potential	O
effect	O
of	O
treatment	O
moderators	O
,	O
additional	O
ANOVAs	O
will	O
be	O
calculated	O
including	O
patient	O
'	O
s	O
age	O
and	O
duration	O
of	O
illness	O
as	O
covariates	O
.	O

This	O
multicenter	O
,	O
prospective	O
,	O
non	O
-	O
interventional	O
study	O
was	O
designed	O
according	O
to	O
the	O
German	O
Medicinal	O
Products	O
Act	O
and	O
approved	O
by	O
the	O
Freiburg	O
ethics	O
commission	O
international	O
(	O
Approval	O
number	O
:	O
014	O
/	O
1336	O
)	O
.	O

Diagnosis	O
,	O
treatment	O
and	O
monitoring	O
of	O
patients	O
were	O
conducted	O
in	O
a	O
naturalistic	O
,	O
usual	O
care	O
treatment	O
setting	O
.	O

Prospective	O
collection	O
of	O
the	O
data	O
was	O
chosen	O
to	O
collect	O
high	O
quality	O
data	O
,	O
and	O
a	O
multicenter	O
approach	O
was	O
chosen	O
to	O
ensure	O
an	O
adequate	O
sample	O
size	O
.	O

Patients	O
were	O
only	O
recruited	O
for	O
the	O
study	O
after	O
the	O
treating	O
psychiatrist	O
had	O
chosen	O
AOM	O
treatment	O
for	O
these	O
patients	O
based	O
on	O
clinical	O
grounds	O
.	O

Since	O
this	O
was	O
a	O
naturalistic	O
sample	O
,	O
combinations	O
with	O
other	O
psychiatric	O
medications	O
,	O
including	O
oral	O
antipsychotics	O
were	O
based	O
on	O
clinician’s	O
choice	O
.	O

Participation	O
in	O
the	O
study	O
had	O
no	O
influence	O
on	O
treatment	O
choice	O
.	O

Seventy	O
-	O
five	O
centers	O
participating	O
in	O
this	O
study	O
were	O
located	O
throughout	O
Germany	O
.	O

The	O
observation	O
period	O
for	O
each	O
patient	O
was	O
about	O
6	O
months	O
.	O

Data	O
were	O
collected	O
from	O
July	O
2014	O
to	O
March	O
2016	O
,	O
when	O
the	O
last	O
patient	O
of	O
the	O
target	O
sample	O
had	O
reached	O
6	O
months	O
.	O

Data	O
were	O
collected	O
at	O
seven	O
time	O
points	O
(	O
T0	O
-	O
T6	O
)	O
,	O
each	O
about	O
4	O
weeks	O
apart	O
(	O
−	O
2	O
/	O
+	O
5	O
days	O
)	O
.	O

BPRS	O
data	O
were	O
collected	O
at	O
T0	O
,	O
T3	O
(	O
month	O
3	O
)	O
and	O
T6	O
(	O
month	O
6	O
)	O
,	O
and	O
data	O
for	O
all	O
other	O
endpoints	O
were	O
collected	O
at	O
each	O
monthly	O
time	O
point	O
(	O
except	O
CGI	O
-	O
I	O
,	O
no	O
baseline	O
assessment	O
possible	O
;	O
Fig	O
.	O

1	O
)	O
.	O

Fig	O
.	O

1	O
Study	O
design	O
.	O

Patients	O
were	O
treated	O
with	O
AOM	O
at	O
seven	O
time	O
points	O
(	O
T0	O
-	O
T6	O
)	O
that	O
were	O
each	O
4	O
weeks	O
apart	O
.	O

Data	O
for	O
the	O
different	O
endpoints	O
were	O
collected	O
at	O
the	O
indicated	O
time	O
points	O
.	O

AOM	O
,	O
Aripiprazole	O
once	O
-	O
monthly	O
;	O
BPRS	O
,	O
Brief	O
Psychiatric	O
Rating	O
Scale	O
;	O
CGI	O
-	O
S	O
,	O
Clinical	O
Global	O
Impression	O
–	O
Severity	O
;	O
CGI	O
-	O
I	O
,	O
Clinical	O
Global	O
Impression	O
–	O
Improvement	O
;	O
TRAE	O
,	O
treatment	O
related	O
adverse	O
events	O

Study	O
design	O
.	O

Patients	O
were	O
treated	O
with	O
AOM	O
at	O
seven	O
time	O
points	O
(	O
T0	O
-	O
T6	O
)	O
that	O
were	O
each	O
4	O
weeks	O
apart	O
.	O

Data	O
for	O
the	O
different	O
endpoints	O
were	O
collected	O
at	O
the	O
indicated	O
time	O
points	O
.	O

AOM	O
,	O
Aripiprazole	O
once	O
-	O
monthly	O
;	O
BPRS	O
,	O
Brief	O
Psychiatric	O
Rating	O
Scale	O
;	O
CGI	O
-	O
S	O
,	O
Clinical	O
Global	O
Impression	O
–	O
Severity	O
;	O
CGI	O
-	O
I	O
,	O
Clinical	O
Global	O
Impression	O
–	O
Improvement	O
;	O
TRAE	O
,	O
treatment	O
related	O
adverse	O
events	O

Patients	O
in	O
the	O
study	O
cohort	O
were	O
≥	O
18	O
years	O
old	O
and	O
diagnosed	O
with	O
schizophrenia	B-phenotype
(	O
F20	B-code
.	I-code
X	I-code
)	O
according	O
to	O
ICD	B-coding_system
-	I-coding_system
10	I-coding_system
.	O

Starting	O
from	O
the	O
time	O
of	O
inclusion	O
in	O
the	O
study	O
,	O
patients	O
were	O
treated	O
with	O
AOM	O
on	O
an	O
outpatient	O
basis	O
according	O
to	O
prescribing	O
information	O
and	O
clinical	O
need	O
.	O

The	O
treatment	O
choice	O
was	O
independent	O
from	O
the	O
study	O
.	O

All	O
patients	O
gave	O
written	O
informed	O
consent	O
.	O

Exclusion	O
criteria	O
for	O
the	O
study	O
were	O
contraindications	O
for	O
AOM	O
,	O
being	O
a	O
member	O
or	O
being	O
related	O
to	O
a	O
member	O
of	O
the	O
study	O
staff	O
,	O
pregnancy	O
,	O
planning	O
a	O
pregnancy	O
,	O
breastfeeding	O
,	O
or	O
expected	O
reluctance	O
to	O
follow	O
the	O
prespecified	O
monitoring	O
plan	O
(	O
as	O
assessed	O
by	O
the	O
treating	O
psychiatrist	O
)	O
.	O

The	O
BPRS	O
is	O
a	O
clinician	O
-	O
rated	O
scale	O
[	O
23	O
]	O
which	O
is	O
well	O
established	O
in	O
clinical	O
routine	O
,	O
and	O
therefore	O
it	O
was	O
used	O
as	O
the	O
primary	O
endpoint	O
in	O
this	O
study	O
.	O

Eighteen	O
items	O
were	O
assessed	O
that	O
are	O
grouped	O
into	O
5	O
domains	O
:	O
anxiety	O
/	O
depression	O
,	O
anergia	O
,	O
thought	O
disorders	O
,	O
activation	O
and	O
hostility	O
/	O
mistrust	O
.	O

Each	O
of	O
the	O
respective	O
items	O
was	O
rated	O
on	O
a	O
seven	O
-	O
point	O
scale	O
ranging	O
from	O
1	O
(	O
not	O
present	O
)	O
to	O
7	O
(	O
extremely	O
severe	O
)	O
.	O

The	O
Clinical	O
Global	O
Impression	O
-	O
Severity	O
scale	O
(	O
CGI	O
-	O
S	O
)	O
was	O
used	O
to	O
report	O
the	O
current	O
severity	O
of	O
the	O
patient’s	O
mental	O
illness	O
on	O
a	O
seven	O
-	O
point	O
scale	O
ranging	O
from	O
1	O
(	O
normal	O
,	O
not	O
at	O
all	O
ill	O
)	O
to	O
7	O
(	O
extremely	O
ill	O
)	O
[	O
24	O
]	O
.	O

This	O
rating	O
was	O
complemented	O
by	O
the	O
CGI	O
-	O
I	O
(	O
Improvement	O
)	O
scale	O
,	O
in	O
which	O
improvement	O
of	O
the	O
mental	O
illness	O
from	O
the	O
beginning	O
of	O
the	O
study	O
is	O
rated	O
on	O
a	O
seven	O
-	O
point	O
scale	O
(	O
1	O
,	O
very	O
much	O
improved	O
to	O
7	O
,	O
very	O
much	O
worse	O
)	O
.	O

Any	O
patient	O
reported	O
adverse	O
events	O
were	O
documented	O
during	O
the	O
study	O
and	O
rated	O
by	O
the	O
clinicians	O
as	O
treatment	O
related	O
adverse	O
events	O
(	O
TRAE	O
)	O
or	O
unrelated	O
to	O
treatment	O
.	O

Patients	O
were	O
asked	O
about	O
adverse	O
events	O
,	O
comorbidities	O
and	O
comedications	O
at	O
every	O
visit	O
.	O

Adverse	O
events	O
were	O
coded	O
according	O
to	O
MedDRA	O
19	O
.	O
0	O
.	O

Other	O
rating	O
scales	O
used	O
in	O
the	O
same	O
study	O
will	O
be	O
discussed	O
elsewhere	O
.	O

The	O
primary	O
outcome	O
,	O
change	O
in	O
BPRS	O
total	O
score	O
from	O
baseline	O
to	O
endpoint	O
was	O
analyzed	O
using	O
the	O
Wilcoxon	O
Signed	O
-	O
Rank	O
test	O
for	O
paired	O
samples	O
,	O
and	O
the	O
Wilcoxon’s	O
rank	O
-	O
sum	O
test	O
for	O
independent	O
samples	O
.	O

Changes	O
in	O
marginal	O
distributions	O
in	O
contingency	O
tables	O
of	O
categorical	O
outcomes	O
were	O
analyzed	O
using	O
Bhapkar’s	O
test	O
and	O
proportions	O
within	O
one	O
group	O
of	O
patients	O
with	O
the	O
binomial	O
test	O
.	O

Fisher’s	O
exact	O
test	O
was	O
used	O
to	O
compare	O
proportions	O
between	O
groups	O
of	O
patients	O
.	O

Missing	O
values	O
were	O
imputed	O
using	O
the	O
Last	O
Observation	O
Carried	O
Forward	O
(	O
LOCF	O
)	O
method	O
if	O
there	O
was	O
a	O
value	O
for	O
T0	O
and	O
at	O
least	O
one	O
post	O
-	O
baseline	O
time	O
point	O
.	O

There	O
was	O
one	O
prespecified	O
subgroup	O
analysis	O
for	O
the	O
primary	O
outcome	O
,	O
i	O
.	O
e	O
.	O
,	O
the	O
comparison	O
of	O
patients	O
aged	O
≤35	O
years	O
old	O
vs	O
patients	O
aged	O
>	O
35	O
years	O
old	O
,	O
as	O
the	O
younger	O
age	O
group	O
had	O
performed	O
significantly	O
better	O
than	O
the	O
older	O
age	O
group	O
in	O
a	O
prior	O
AOM	O
efficacy	O
study	O
[	O
25	O
]	O
.	O

Subgroup	O
comparisons	O
by	O
age	O
group	O
were	O
covaried	O
using	O
a	O
linear	O
regression	O
analysis	O
with	O
backward	O
selection	O
of	O
effects	O
for	O
variables	O
that	O
differed	O
significantly	O
between	O
the	O
two	O
age	O
groups	O
at	O
baseline	O
at	O
p	O
<	O
0	O
.	O
05	O
(	O
see	O
Table	O
1	O
)	O
.	O

All	O
data	O
were	O
processed	O
using	O
SAS™	O
software	O
(	O
SAS	O
Institute	O
,	O
Cary	O
,	O
NC	O
/	O
USA	O
)	O
,	O
with	O
all	O
tests	O
being	O
two	O
-	O
sided	O
and	O
alpha	O
=	O
0	O
.	O
05	O
,	O
without	O
correction	O
for	O
multiple	O
testing	O
for	O
secondary	O
outcomes	O
.	O

Table	O
1	O
Patient	O
baseline	O
demographics	O
Characteristic	O
Total	O
(	O
n	O
=	O
242	O
)	O
Patients	O
aged	O
≤35	O
years	O
(	O
n	O
=	O
89	O
)	O
Patients	O
aged	O
>	O
35	O
years	O
(	O
n	O
=	O
153	O
)	O
P	O
-	O
value	O
Age	O
,	O
mean	O
(	O
SD	O
)	O
,	O
years	O
43	O
.	O
1	O
(	O
15	O
.	O
1	O
)	O
28	O
.	O
8	O
(	O
4	O
.	O
3	O
)	O
51	O
.	O
3	O
(	O
12	O
.	O
7	O
)	O
<	O
0	O
.	O
0001	O
a	O
Sex	O
,	O
male	O
,	O
n	O
(	O
%	O
)	O
133	O
(	O
55	O
.	O
0	O
)	O
57	O
(	O
64	O
.	O
0	O
)	O
76	O
(	O
49	O
.	O
7	O
)	O
0	O
.	O
0328	O
b	O
Family	O
status	O
,	O
n	O
(	O
%	O
)	O
<	O
.	O

0001	O
b	O
Single	O
151	O
(	O
62	O
.	O
7	O
)	O
74	O
(	O
84	O
.	O
1	O
)	O
77	O
(	O
50	O
.	O
3	O
)	O
Married	O
/	O
in	O
a	O
relationship	O
53	O
(	O
22	O
.	O
0	O
)	O
13	O
(	O
14	O
.	O
8	O
)	O
40	O
(	O
26	O
.	O
1	O
)	O
Divorced	O
23	O
(	O
9	O
.	O
5	O
)	O
1	O
(	O
1	O
.	O
1	O
)	O
25	O
(	O
16	O
.	O
3	O
)	O
Widowed	O
11	O
(	O
4	O
.	O
6	O
)	O
0	O
(	O
0	O
.	O
0	O
)	O
11	O
(	O
7	O
.	O
2	O
)	O
Employment	O
status	O
,	O
n	O
(	O
%	O
)	O
<	O
.	O

0001	O
b	O
Employed	O
43	O
(	O
18	O
.	O
0	O
)	O
23	O
(	O
26	O
.	O
4	O
)	O
20	O
(	O
13	O
.	O
2	O
)	O
Unemployed	O
73	O
(	O
30	O
.	O
5	O
)	O
36	O
(	O
41	O
.	O
4	O
)	O
37	O
(	O
24	O
.	O
3	O
)	O
Annuitant	O
99	O
(	O
41	O
.	O
4	O
)	O
13	O
(	O
14	O
.	O
9	O
)	O
86	O
(	O
56	O
.	O
6	O
)	O
Housewife	O
/	O
househusband	O
11	O
(	O
4	O
.	O
6	O
)	O
2	O
(	O
2	O
.	O
3	O
)	O
9	O
(	O
5	O
.	O
9	O
)	O
In	O
school	O
/	O
education	O
/	O
re	O
-	O
education	O
13	O
(	O
5	O
.	O
4	O
)	O
13	O
(	O
15	O
.	O
0	O
)	O
0	O
(	O
0	O
.	O
0	O
)	O
Duration	O
of	O
untreated	O
psychosis	O
,	O
mean	O
(	O
SD	O
)	O
,	O
years	O
1	O
.	O
2	O
(	O
8	O
.	O
0	O
)	O
1	O
.	O
4	O
(	O
3	O
.	O
2	O
)	O
1	O
.	O
0	O
(	O
9	O
.	O
8	O
)	O
0	O
.	O
7719	O
a	O
Age	O
at	O
diagnosis	O
,	O
mean	O
(	O
SD	O
)	O
,	O
years	O
30	O
.	O
9	O
(	O
13	O
.	O
0	O
)	O
23	O
.	O
0	O
(	O
4	O
.	O
3	O
)	O
35	O
.	O
3	O
(	O
14	O
.	O
2	O
)	O
<	O
.	O

0001	O
a	O
Time	O
of	O
diagnosis	O
,	O
n	O
(	O
%	O
)	O
<	O
.	O

0001	O
b	O
Within	O
the	O
last	O
5	O
years	O
78	O
(	O
32	O
.	O
4	O
)	O
47	O
(	O
53	O
.	O
4	O
)	O
31	O
(	O
20	O
.	O
3	O
)	O
More	O
than	O
5	O
years	O
ago	O
163	O
(	O
67	O
.	O
6	O
)	O
41	O
(	O
46	O
.	O
6	O
)	O
122	O
(	O
79	O
.	O
7	O
)	O
No	O
.	O

of	O
illness	O
episodes	O
,	O
n	O
(	O
%	O
)	O
0	O
.	O
0002	O
b	O
First	O
episode	O
of	O
schizophrenia	O
19	O
(	O
7	O
.	O
9	O
)	O
≤	O
5	O
episodes	O
137	O
(	O
57	O
.	O
1	O
)	O
64	O
(	O
72	O
.	O
7	O
)	O
73	O
(	O
48	O
.	O
0	O
)	O
>	O
5	O
episodes	O
103	O
(	O
42	O
.	O
9	O
)	O
24	O
(	O
27	O
.	O
3	O
)	O
79	O
(	O
52	O
.	O
0	O
)	O
BMI	O
,	O
mean	O
(	O
SD	O
)	O
,	O
kg	O
/	O
m	O
2	O
29	O
.	O
3	O
(	O
6	O
.	O
9	O
)	O
28	O
.	O
6	O
(	O
7	O
.	O
3	O
)	O
29	O
.	O
7	O
(	O
6	O
.	O
6	O
)	O
0	O
.	O
2381	O
a	O
Underweight	O
(	O
<	O
18	O
,	O
5	O
)	O
,	O
n	O
(	O
%	O
)	O
3	O
(	O
1	O
.	O
3	O
)	O
3	O
(	O
3	O
.	O
5	O
)	O
0	O
(	O
0	O
.	O
0	O
)	O
Normal	O
weight	O
(	O
18	O
,	O
5	O
<	O
25	O
)	O
,	O
n	O
(	O
%	O
)	O
59	O
(	O
24	O
.	O
6	O
)	O
21	O
(	O
24	O
.	O
1	O
)	O
38	O
(	O
24	O
.	O
8	O
)	O
Overweight	O
(	O
25	O
<	O
30	O
)	O
,	O
n	O
(	O
%	O
)	O
95	O
(	O
39	O
.	O
6	O
)	O
36	O
(	O
41	O
.	O
4	O
)	O
59	O
(	O
38	O
.	O
6	O
)	O
Obese	O
(	O
≥	O
30	O
)	O
,	O
n	O
(	O
%	O
)	O
83	O
(	O
34	O
.	O
6	O
)	O
27	O
(	O
31	O
.	O
0	O
)	O
56	O
(	O
36	O
.	O
6	O
)	O
BPRS	O
at	O
baseline	O
,	O
mean	O
(	O
SD	O
)	O
54	O
.	O
1	O
(	O
15	O
.	O
6	O
)	O
c	O
53	O
.	O
0	O
(	O
16	O
.	O
1	O
)	O

d	O
53	O
.	O
7	O
(	O
15	O
.	O
9	O
)	O
d	O
0	O
.	O
7608	O
a	O
CGI	O
-	O
S	O
at	O
baseline	O
,	O
mean	O
(	O
SD	O
)	O
4	O
.	O
8	O
(	O
0	O
.	O
8	O
)	O
4	O
.	O
7	O
(	O
0	O
.	O
9	O
)	O
4	O
.	O
8	O
(	O
0	O
.	O
8	O
)	O
CGI	O
-	O
S	O
at	O
baseline	O
,	O
n	O
(	O
%	O
)	O
0	O
.	O
7081	O
b	O
Mildly	O
ill	O
12	O
(	O
5	O
.	O
0	O
)	O
6	O
(	O
6	O
.	O
8	O
)	O
6	O
(	O
4	O
.	O
0	O
)	O
Moderately	O
ill	O
79	O
(	O
32	O
.	O
9	O
)	O
30	O
(	O
34	O
.	O
1	O
)	O
49	O
(	O
32	O
.	O
2	O
)	O
Markedly	O
ill	O
100	O
(	O
41	O
.	O
7	O
)	O
33	O
(	O
37	O
.	O
5	O
)	O
67	O
(	O
44	O
.	O
1	O
)	O
Severely	O
ill	O
48	O
(	O
20	O
.	O
0	O
)	O
19	O
(	O
21	O
.	O
6	O
)	O
29	O
(	O
19	O
.	O
1	O
)	O
Extremely	O
ill	O
1	O
(	O
0	O
.	O
4	O
)	O
0	O
(	O
0	O
.	O
0	O
)	O
1	O
(	O
0	O
.	O
7	O
)	O
In	O
cases	O
where	O
percentages	O
do	O
not	O
add	O
up	O
to	O
100	O
,	O
data	O
were	O
missing	O
for	O
some	O
patients	O
BMI	O
body	O
mass	O
index	O
,	O
BPRS	O
Brief	O
Psychiatric	O
Rating	O
Scale	O
,	O
CGI	O
-	O
S	O
Clinical	O
Global	O
Impressions	O
-	O
Severity	O

Scale	O
,	O
SD	O
standard	O
deviation	O
a	O
t	O
-	O
Test	O
b	O
Fisher’s	O
exact	O
Test	O
c	O
full	O
analysis	O
set	O
(	O
last	O
observation	O
carried	O
forward	O
)	O
d	O
all	O
values	O

Patient	O
baseline	O
demographics	O

In	O
cases	O
where	O
percentages	O
do	O
not	O
add	O
up	O
to	O
100	O
,	O
data	O
were	O
missing	O
for	O
some	O
patients	O

BMI	O
body	O
mass	O
index	O
,	O
BPRS	O
Brief	O
Psychiatric	O
Rating	O
Scale	O
,	O
CGI	O
-	O
S	O
Clinical	O
Global	O
Impressions	O
-	O
Severity	O
Scale	O
,	O
SD	O
standard	O
deviation	O

a	O
t	O
-	O
Test	O

b	O
Fisher’s	O
exact	O
Test	O

c	O
full	O
analysis	O
set	O
(	O
last	O
observation	O
carried	O
forward	O
)	O

d	O
all	O
values	O

The	O
trial	O
was	O
approved	O
by	O
the	O
Danish	O
Data	O
Protection	O
Agency	O
and	O
The	O
Danish	O
National	O
Committee	O
on	O
Biomedical	O
Research	O
Ethics	O
under	O
number	O
VN	O
-	O
20070070	O
.	O

The	O
trial	O
was	O
also	O
registered	O
at	O
ClinicalTrials	O
.	O
gov	O
with	O
identifier	O
:	O
NCT01282307	O
.	O

The	O
study	O
design	O
was	O
descriptive	O
,	O
and	O
based	O
on	O
data	O
,	O
notes	O
,	O
and	O
observations	O
from	O
a	O
randomized	O
controlled	O
trial	O
testing	O
a	O
novel	O
intervention	O
in	O
six	O
outpatient	O
teams	O
.	O

During	O
the	O
recruitment	O
period	O
all	O
eligible	O
participants	O
were	O
registered	O
in	O
a	O
logbook	O
containing	O
information	O
about	O
:	O
participation	O
in	O
information	O
meetings	O
,	O
reasons	O
for	O
declining	O
or	O
participating	O
in	O
the	O
trial	O
,	O
and	O
comments	O
regarding	O
the	O
trial	O
from	O
either	O
the	O
eligible	O
participant	O
or	O
his	O
/	O
her	O
mental	O
health	O
care	O
professional	O
(	O
MHCP	O
)	O
.	O

The	O
observations	O
and	O
notes	O
from	O
the	O
recruitment	O
period	O
and	O
the	O
data	O
collection	O
were	O
used	O
to	O
describe	O
and	O
distinguish	O
the	O
recruitment	O
challenges	O
not	O
related	O
to	O
patients	O
from	O
those	O
connected	O
with	O
patients’	O
readiness	O
to	O
take	O
part	O
in	O
and	O
complete	O
the	O
trial	O
.	O

Further	O
,	O
the	O
strategies	O
chosen	O
to	O
overcome	O
them	O
were	O
described	O
.	O

In	O
addition	O
,	O
data	O
from	O
the	O
trial	O
were	O
registered	O
to	O
report	O
and	O
calculate	O
proportions	O
of	O
withdrawal	O
from	O
treatment	O
and	O
dropout	O
from	O
the	O
trial	O
.	O

Withdrawal	O
from	O
treatment	O
occurs	O
when	O
participants	O
withdraw	O
from	O
the	O
intervention	O
being	O
tested	O
in	O
the	O
trial	O
either	O
prior	O
to	O
or	O
during	O
the	O
treatment	O
period	O
but	O
continue	O
in	O
the	O
data	O
collection	O
in	O
the	O
trial	O
.	O

Dropout	O
is	O
defined	O
as	O
the	O
participants	O
who	O
left	O
the	O
trial	O
before	O
the	O
trial	O
end	O
[	O
8	O
,	O
9	O
]	O
.	O

A	O
total	O
of	O
101	O
outpatients	O
from	O
three	O
Assertive	O
Outreach	O
Teams	O
(	O
AOT	O
)	O
and	O
three	O
District	O
Teams	O
(	O
DT	O
)	O
in	O
the	O
northern	O
part	O
of	O
Denmark	O
participated	O
in	O
the	O
study	O
.	O

Fifty	O
-	O
one	O
were	O
randomly	O
assigned	O
to	O
the	O
intervention	O
group	O
which	O
received	O
an	O
immediate	O
individual	O
training	O
program	O
consisting	O
of	O
approximately	O
ten	O
sessions	O
with	O
the	O
Guided	O
Self	O
-	O
Determination	O
(	O
GSD	O
)	O
method	O
[	O
20	O
-	O
24	O
]	O
.	O

Fifty	O
patients	O
were	O
randomly	O
assigned	O
to	O
a	O
waiting	O
list	O
for	O
a	O
12	O
-	O
month	O
delayed	O
individual	O
training	O
program	O
with	O
GSD	O
(	O
control	O
group	O
)	O
.	O

Both	O
groups	O
also	O
continued	O
treatment	O
as	O
usual	O
during	O
the	O
entire	O
trial	O
.	O

Participants	O
completed	O
four	O
self	O
-	O
rating	O
questionnaires	O
,	O
a	O
demographic	O
data	O
sheet	O
(	O
containing	O
data	O
about	O
medication	O
,	O
alcohol	O
use	O
,	O
substance	O
use	O
and	O
course	O
of	O
illness	O
)	O
,	O
an	O
interview	O
concerning	O
psychopathology	O
and	O
an	O
assessment	O
of	O
social	O
functioning	O
at	O
baseline	O
and	O
after	O
3	O
,	O
6	O
,	O
and	O
12	O
months	O
conducted	O
in	O
their	O
own	O
home	O
or	O
in	O
a	O
team	O
office	O
according	O
to	O
the	O
participants’	O
preferences	O
.	O

Thirty	O
-	O
six	O
MHCPs	O
,	O
primarily	O
registered	O
nurses	O
specially	O
trained	O
within	O
psychiatry	O
,	O
provided	O
the	O
intervention	O
and	O
the	O
principal	O
investigator	O
(	O
PI	O
)	O
(	O
first	O
author	O
)	O
conducted	O
the	O
data	O
collection	O
.	O

The	O
study	O
took	O
place	O
in	O
Region	O
North	O
(	O
0	O
.	O
6	O
million	O
inhabitants	O
)	O
,	O
the	O
smallest	O
of	O
Denmark’s	O
five	O
Regions	O
.	O

Psychiatric	O
Health	O
Care	O
Services	O
covers	O
both	O
inpatient	O
(	O
269	O
beds	O
)	O
and	O
outpatient	O
care	O
(	O
approximately	O
4700	O
patients	O
yearly	O
)	O
and	O
is	O
publicly	O
funded	O
.	O

To	O
be	O
eligible	O
for	O
the	O
trial	O
,	O
participants	O
had	O
to	O
receive	O
treatment	O
in	O
an	O
AOT	O
or	O
meet	O
the	O
requirements	O
to	O
receive	O
treatment	O
in	O
an	O
AOT	O
.	O

Requirements	O
for	O
patients	O
in	O
AOTs	O
were	O
:	O
having	O
frequent	O
and	O
/	O
or	O
long	O
admissions	O
poor	O
or	O
no	O
improvement	O
in	O
psychopathology	O
and	O
illness	O
management	O
,	O
frequent	O
discontinuation	O
of	O
treatment	O
,	O
or	O
relapse	O
.	O

Further	O
inclusion	O
criteria	O
for	O
the	O
trial	O
were	O
:	O
meeting	O
the	O
criteria	O
for	O
schizophrenia	B-phenotype
ICD	B-coding_system
-	I-coding_system
10	I-coding_system
F	B-code
.	I-code
20	I-code
.	I-code
0	I-code
-	I-code
9	I-code
or	O
schizoaffective	B-phenotype
disorder	I-phenotype
F	B-code
.	I-code
25	I-code
.	I-code
0	I-code
-	I-code
9	I-code
according	O
to	O
participants’	O
hospital	O
records	O
,	O
age	O
18	O
–	O
70	O
years	O
,	O
ability	O
to	O
understand	O
,	O
speak	O
and	O
write	O
Danish	O
,	O
and	O
signed	O
informed	O
written	O
consent	O
.	O

The	O
AOT	O
and	O
DT	O
treatment	O
offered	O
the	O
following	O
treatment	O
modalities	O
:	O
psychopharmacology	O
,	O
cognitive	O
behavioral	O
therapy	O
,	O
cognitive	O
milieu	O
therapy	O
,	O
psycho	O
-	O
education	O
,	O
and	O
social	O
skills	O
training	O
,	O
which	O
was	O
considered	O
treatment	O
as	O
usual	O
(	O
TAU	O
)	O
during	O
the	O
trial	O
.	O

Exclusion	O
criteria	O
were	O
:	O
previous	O
participation	O
with	O
the	O
method	O
GSD	O
,	O
having	O
a	O
mental	O
handicap	O
or	O
diagnosis	O
of	O
dementia	O
or	O
an	O
organic	O
brain	O
disease	O
according	O
to	O
the	O
hospital	O
record	O
,	O
in	O
need	O
of	O
an	O
interpreter	O
to	O
understand	O
,	O
speak	O
and	O
write	O
Danish	O
,	O
and	O
withdrawal	O
of	O
informed	O
consent	O
.	O

Statistical	O
power	O
calculation	O
was	O
performed	O
which	O
demonstrated	O
that	O
50	O
participants	O
in	O
each	O
group	O
were	O
needed	O
.	O

Before	O
recruitment	O
of	O
participants	O
,	O
all	O
teams	O
were	O
visited	O
by	O
the	O
PI	O
and	O
informed	O
about	O
the	O
clinical	O
trial	O
and	O
provided	O
with	O
education	O
about	O
how	O
to	O
conduct	O
the	O
intervention	O
using	O
the	O
GSD	O
method	O
.	O

Written	O
information	O
about	O
the	O
recruitment	O
process	O
,	O
the	O
clinical	O
trial	O
and	O
the	O
GSD	O
method	O
was	O
given	O
to	O
each	O
MHCP	O
.	O

Approximately	O
16	O
hours	O
(	O
over	O
2	O
-	O
3	O
days	O
)	O
of	O
information	O
and	O
education	O
were	O
provided	O
.	O

During	O
the	O
recruitment	O
period	O
the	O
PI	O
visited	O
,	O
mailed	O
and	O
/	O
or	O
telephoned	O
the	O
teams	O
and	O
team	O
members	O
at	O
least	O
twice	O
a	O
month	O
to	O
discuss	O
eligible	O
participants	O
and	O
to	O
encourage	O
the	O
MHCPs	O
to	O
participate	O
in	O
the	O
trial	O
,	O
and	O
was	O
also	O
available	O
for	O
questions	O
and	O
supervision	O
during	O
the	O
entire	O
trial	O
,	O
both	O
in	O
relation	O
to	O
the	O
trial	O
procedures	O
and	O
the	O
intervention	O
.	O

Information	O
and	O
education	O
were	O
given	O
to	O
all	O
MHCPs	O
(	O
n	O
=	O
43	O
)	O
in	O
the	O
six	O
teams	O
,	O
as	O
it	O
was	O
determined	O
by	O
the	O
hospital	O
management	O
as	O
mandatory	O
to	O
participate	O
in	O
the	O
trial	O
.	O

The	O
MHCPs	O
completed	O
the	O
recruitment	O
strategy	O
as	O
part	O
of	O
their	O
clinical	O
work	O
.	O

First	O
,	O
the	O
MHCPs	O
distributed	O
a	O
patient	O
information	O
sheet	O
for	O
all	O
eligible	O
participants	O
and	O
invited	O
them	O
to	O
an	O
individual	O
appointment	O
with	O
the	O
PI	O
to	O
further	O
discuss	O
the	O
trial	O
.	O

When	O
the	O
eligible	O
participants	O
agreed	O
to	O
meet	O
with	O
the	O
PI	O
,	O
the	O
MHCP	O
contacted	O
the	O
PI	O
and	O
made	O
arrangements	O
for	O
a	O
meeting	O
.	O

According	O
to	O
the	O
person’s	O
preferences	O
the	O
meetings	O
took	O
place	O
either	O
in	O
the	O
person’s	O
own	O
home	O
or	O
in	O
a	O
team	O
office	O
.	O

At	O
the	O
information	O
meeting	O
the	O
eligible	O
participants	O
often	O
brought	O
community	O
support	O
workers	O
,	O
spouses	O
or	O
their	O
MHCP	O
.	O

During	O
the	O
meeting	O
,	O
detailed	O
written	O
information	O
about	O
the	O
trial	O
was	O
provided	O
,	O
oral	O
information	O
was	O
given	O
,	O
and	O
the	O
eligible	O
participants	O
were	O
encouraged	O
to	O
ask	O
questions	O
.	O

They	O
were	O
then	O
given	O
time	O
to	O
make	O
the	O
decision	O
about	O
participation	O
.	O

Some	O
made	O
their	O
decision	O
immediately	O
and	O
some	O
made	O
it	O
after	O
a	O
few	O
days	O
.	O

For	O
those	O
who	O
signed	O
the	O
informed	O
consent	O
,	O
an	O
appointment	O
for	O
a	O
baseline	O
interview	O
was	O
made	O
.	O

Recruitment	O
was	O
an	O
ongoing	O
process	O
,	O
which	O
started	O
with	O
the	O
implementation	O
of	O
the	O
first	O
AOT	O
in	O
February	O
2008	O
through	O
July	O
2011	O
.	O

GSD	O
is	O
a	O
shared	O
decision	O
making	O
and	O
problem	O
-	O
solving	O
method	O
focusing	O
on	O
facilitating	O
empowerment	O
[	O
25	O
]	O
developed	O
from	O
qualitative	O
research	O
using	O
Grounded	O
Theory	O
[	O
20	O
,	O
22	O
,	O
23	O
]	O
originally	O
developed	O
for	O
Type	O
1	O
Diabetes	O
.	O

The	O
method	O
has	O
been	O
modified	O
for	O
other	O
diagnoses	O
,	O
including	O
schizophrenia	O
[	O
26	O
]	O
.	O

The	O
purpose	O
of	O
the	O
method	O
is	O
to	O
guide	O
the	O
individual	O
through	O
a	O
process	O
of	O
exploring	O
difficulties	O
in	O
living	O
with	O
an	O
illness	O
systematically	O
and	O
creatively	O
by	O
means	O
of	O
words	O
and	O
drawings	O
and	O
then	O
to	O
focus	O
on	O
which	O
difficulties	O
to	O
change	O
in	O
order	O
to	O
develop	O
internally	O
motivated	O
self	O
-	O
management	O
of	O
the	O
illness	O
[	O
24	O
]	O
.	O

GSD	O
uses	O
21	O
reflection	O
sheets	O
designed	O
to	O
guide	O
the	O
participant	O
and	O
MHCP	O
through	O
a	O
process	O
of	O
autonomy	O
-	O
supportive	O
problem	O
solving	O
.	O

The	O
reflection	O
sheets	O
are	O
completed	O
by	O
the	O
participant	O
before	O
,	O
and	O
between	O
conversations	O
with	O
their	O
MHCP	O
,	O
with	O
each	O
entitled	O
to	O
have	O
their	O
own	O
opinions	O
and	O
perceptions	O
about	O
the	O
content	O
.	O

More	O
details	O
about	O
the	O
GSD	O
method	O
and	O
a	O
case	O
study	O
where	O
an	O
individual	O
diagnosed	O
with	O
schizophrenia	O
used	O
GSD	O
are	O
elaborated	O
on	O
elsewhere	O
[	O
26	O
]	O
.	O

The	O
GSD	O
training	O
in	O
the	O
trial	O
was	O
conducted	O
with	O
the	O
participants	O
individually	O
with	O
an	O
instructive	O
and	O
flexible	O
program	O
consisting	O
of	O
10	O
sessions	O
,	O
each	O
lasting	O
30	O
-	O
60	O
minutes	O
.	O

The	O
intervention	O
period	O
was	O
decided	O
to	O
be	O
six	O
months	O
with	O
a	O
follow	O
-	O
up	O
period	O
of	O
six	O
months	O
.	O

No	O
participants	O
were	O
excluded	O
from	O
the	O
trial	O
if	O
they	O
spent	O
more	O
than	O
six	O
months	O
with	O
the	O
intervention	O
.	O

Data	O
for	O
this	O
study	O
were	O
extracted	O
from	O
baseline	O
assessment	O
conducted	O
within	O
the	O
context	O
of	O
a	O
randomized	O
community	O
effectiveness	O
trial	O
of	O
“An	O
Individualized	O
Mental	O
Health	O
Intervention	O
for	O
ASD”	O
(	O
AIM	O
HI	O
;	O
Brookman	O
-	O
Frazee	O
and	O
Drahota	O
2010	O
)	O
that	O
was	O
conducted	O
in	O
publicly	O
-	O
funded	O
community	O
and	O
school	O
-	O
based	O
mental	O
health	O
settings	O
.	O

AIM	O
HI	O
was	O
designed	O
to	O
address	O
challenging	O
behaviors	O
,	O
the	O
most	O
common	O
presenting	O
problems	O
in	O
children	O
with	O
ASD	O
receiving	O
mental	O
health	O
services	O
(	O
Brookman	O
-	O
Frazee	O
et	O
al	O
.	O
2012b	O
)	O
.	O

Per	O
procedures	O
in	O
the	O
randomized	O
community	O
effectiveness	O
trial	O
of	O
AIM	O
HI	O
,	O
therapists	O
were	O
first	O
recruited	O
from	O
participating	O
mental	O
health	O
programs	O
and	O
then	O
child	O
-	O
caregiver	O
dyads	O
were	O
recruited	O
from	O
the	O
caseloads	O
of	O
participating	O
therapists	O
.	O

Children	O
were	O
eligible	O
if	O
they	O
:	O
(	O
1	O
)	O
were	O
aged	O
5–13	O
years	O
old	O
at	O
the	O
time	O
of	O
recruitment	O
(	O
2	O
)	O
reported	O
English	O
or	O
Spanish	O
as	O
their	O
primary	O
language	O
,	O
(	O
3	O
)	O
had	O
an	O
existing	O
ASD	O
diagnosis	O
on	O
record	O
,	O
and	O
(	O
4	O
)	O
exhibited	O
clinically	O
significant	O
ASD	O
symptoms	O
on	O
at	O
least	O
one	O
of	O
two	O
standardized	O
ASD	O
diagnostic	O
measures	O
:	O
the	O
Autism	O
Diagnostic	O
Observation	O
Schedule	O
-	O
2	O
(	O
ADOS	O
-	O
2	O
;	O
Lord	O
et	O
al	O
.	O
2012	O
)	O
or	O
the	O
Social	O
Responsiveness	O
Scale	O
-	O
2	O
(	O
Constantino	O
&	O
Gruber	O
2012	O
)	O
.	O

The	O
ADOS	O
-	O
2	O
was	O
administered	O
by	O
research	O
staff	O
who	O
were	O
clinical	O
psychologists	O
or	O
directly	O
supervised	O
by	O
clinical	O
psychologists	O
.	O

Caregivers	O
were	O
eligible	O
for	O
the	O
community	O
effectiveness	O
trial	O
of	O
AIM	O
HI	O
if	O
they	O
:	O
(	O
1	O
)	O
were	O
the	O
primary	O
caregiver	O
of	O
the	O
eligible	O
child	O
,	O
and	O
(	O
2	O
)	O
spoke	O
English	O
or	O
Spanish	O
as	O
their	O
primary	O
language	O
.	O

Teachers	O
were	O
eligible	O
if	O
they	O
were	O
identified	O
by	O
the	O
participating	O
child’s	O
caregiver	O
as	O
the	O
child’s	O
primary	O
teacher	O
for	O
the	O
child’s	O
current	O
academic	O
year	O
.	O

The	O
specific	O
data	O
used	O
for	O
the	O
current	O
study	O
were	O
drawn	O
from	O
the	O
baseline	O
assessments	O
of	O
the	O
AIM	O
HI	O
trial	O
.	O

These	O
assessments	O
were	O
conducted	O
in	O
person	O
with	O
separate	O
caregiver	O
and	O
child	O
interview	O
assessments	O
lasting	O
between	O
2	O
and	O
3	O
h	O
.	O

Families	O
received	O
a	O
$40	O
gift	O
card	O
for	O
completing	O
the	O
baseline	O
assessment	O
.	O

After	O
an	O
eligible	O
child	O
-	O
caregiver	O
dyad	O
agreed	O
to	O
be	O
part	O
of	O
the	O
study	O
,	O
the	O
caregiver	O
was	O
asked	O
to	O
provide	O
the	O
contact	O
information	O
for	O
the	O
child’s	O
primary	O
school	O
teacher	O
who	O
was	O
sent	O
a	O
web	O
-	O
based	O
survey	O
about	O
the	O
participating	O
child	O
.	O

Teachers	O
received	O
a	O
$20	O
gift	O
card	O
for	O
completing	O
the	O
online	O
survey	O
.	O

Study	O
procedures	O
were	O
approved	O
by	O
the	O
institution	O
through	O
which	O
this	O
study	O
was	O
conducted	O
.	O

Informed	O
consent	O
was	O
obtained	O
from	O
all	O
individual	O
participants	O
included	O
in	O
the	O
study	O
.	O

A	O
subset	O
that	O
included	O
141	O
of	O
the	O
202	O
children	O
enrolled	O
in	O
the	O
larger	O
effectiveness	O
trial	O
were	O
included	O
in	O
the	O
current	O
study	O
.	O

To	O
be	O
included	O
in	O
the	O
current	O
study	O
,	O
two	O
additional	O
inclusion	O
criteria	O
were	O
required	O
:	O
(	O
1	O
)	O
the	O
child	O
was	O
classified	O
as	O
“autism”	O
or	O
“ASD”	O
on	O
the	O
ADOS	O
-	O
2	O
;	O
and	O
(	O
2	O
)	O
the	O
child	O
had	O
both	O
caregiver	O
and	O
teacher	O
responses	O
on	O
the	O
outcome	O
measure	O
(	O
Eyberg	O
Child	O
Behavior	O
Inventory	O
for	O
caregivers	O
and	O
Sutter	O
-	O
Eyberg	O
Student	O
Behavior	O
Inventory	O
-	O
Revised	O
for	O
teachers	O
)	O
to	O
calculate	O
scores	O
per	O
scoring	O
guidelines	O
(	O
Eyberg	O
and	O
Pincus	O
1999	O
)	O
.	O

The	O
61	O
children	O
who	O
were	O
not	O
included	O
in	O
the	O
current	O
study	O
were	O
excluded	O
for	O
the	O
following	O
reasons	O
:	O
11	O
children	O
were	O
classified	O
as	O
“non	O
-	O
spectrum”	O
on	O
the	O
ADOS	O
-	O
2	O
,	O
two	O
children	O
had	O
missing	O
classification	O
data	O
on	O
the	O
ADOS	O
-	O
2	O
,	O
47	O
children	O
had	O
no	O
teacher	O
data	O
(	O
primarily	O
because	O
they	O
were	O
home	O
-	O
schooled	O
or	O
teachers	O
were	O
unable	O
to	O
be	O
contacted	O
)	O
,	O
and	O
one	O
child	O
had	O
insufficient	O
caregiver	O
data	O
on	O
the	O
outcome	O
measure	O
to	O
calculate	O
a	O
score	O
.	O

Differences	O
in	O
demographic	O
and	O
clinical	O
characteristics	O
between	O
children	O
included	O
in	O
the	O
current	O
study	O
(	O
n	O
=	O
141	O
)	O
and	O
those	O
excluded	O
(	O
n	O
=	O
61	O
)	O
were	O
examined	O
using	O
one	O
-	O
way	O
analyses	O
of	O
variance	O
(	O
for	O
continuous	O
measures	O
)	O
and	O
Chi	O
square	O
analyses	O
(	O
for	O
categorical	O
measures	O
)	O
.	O

Children	O
in	O
the	O
current	O
study	O
did	O
not	O
differ	O
significantly	O
(	O
p	O
-	O
vales	O
>	O
0	O
.	O
05	O
)	O
from	O
excluded	O
children	O
based	O
on	O
age	O
,	O
gender	O
,	O
ethnicity	O
,	O
maternal	O
education	O
,	O
family	O
income	O
,	O
psychiatric	O
comorbidity	O
,	O
or	O
cognitive	O
abilities	O
.	O

Due	O
to	O
caregiver	O
and	O
teacher	O
reporting	O
on	O
multiple	O
children	O
,	O
a	O
total	O
of	O
138	O
caregivers	O
and	O
134	O
teachers	O
completed	O
measures	O
about	O
these	O
141	O
children	O
.	O

Children	O
were	O
an	O
average	O
of	O
9	O
.	O
07	O
years	O
(	O
SD	O
=	O
2	O
.	O
36	O
;	O
Range	O
4–14	O
years	O
)	O
,	O
84	O
%	O
(	O
n	O
=	O
118	O
)	O
male	O
,	O
and	O
56	O
%	O
were	O
Hispanic	O
(	O
n	O
=	O
79	O
)	O
.	O

See	O
Table	O
1	O
for	O
more	O
details	O
about	O
child	O
demographic	O
and	O
clinical	O
information	O
.	O

Caregivers	O
were	O
an	O
average	O
of	O
40	O
.	O
28	O
years	O
old	O
(	O
SD	O
=	O
8	O
.	O
09	O
)	O
,	O
92	O
%	O
were	O
female	O
(	O
n	O
=	O
127	O
)	O
,	O
and	O
88	O
%	O
were	O
the	O
child’s	O
biological	O
or	O
adoptive	O
mother	O
(	O
n	O
=	O
121	O
)	O
,	O
7	O
%	O
were	O
the	O
child’s	O
biological	O
father	O
(	O
n	O
=	O
10	O
)	O
,	O
and	O
5	O
%	O
were	O
relatives	O
or	O
other	O
caregivers	O
(	O
n	O
=	O
7	O
)	O
.	O

Teachers	O
were	O
84	O
%	O
female	O
(	O
n	O
=	O
112	O
)	O
,	O
84	O
%	O
White	O
(	O
n	O
=	O
113	O
)	O
and	O
an	O
average	O
age	O
of	O
45	O
.	O
04	O
years	O
(	O
SD	O
=	O
10	O
.	O
83	O
;	O
Range	O
23–71	O
)	O
.	O

In	O
terms	O
of	O
education	O
,	O
64	O
%	O
had	O
a	O
Master’s	O
degree	O
(	O
n	O
=	O
85	O
)	O
,	O
31	O
%	O
had	O
a	O
teaching	O
credential	O
(	O
n	O
=	O
41	O
)	O
,	O
3	O
%	O
(	O
n	O
=	O
4	O
)	O
had	O
a	O
bachelor’s	O
degree	O
,	O
and	O
2	O
%	O
(	O
n	O
=	O
2	O
)	O
reported	O
their	O
education	O
as	O
“Other	O
.	O
”	O
Regarding	O
classroom	O
type	O
,	O
47	O
%	O
of	O
teachers	O
reported	O
teaching	O
in	O
a	O
general	O
education	O
setting	O
(	O
n	O
=	O
63	O
)	O
,	O
39	O
%	O
reported	O
teaching	O
in	O
a	O
special	O
day	O
classroom	O
(	O
n	O
=	O
51	O
)	O
,	O
and	O
14	O
%	O
reported	O
teaching	O
in	O
an	O
“Other”	O
classroom	O
type	O
(	O
n	O
=	O
18	O
)	O
.	O

On	O
average	O
,	O
teachers	O
reported	O
that	O
they	O
had	O
been	O
teaching	O
for	O
15	O
.	O
51	O
years	O
(	O
SD	O
=	O
8	O
.	O
98	O
;	O
Range	O
1–37	O
years	O
)	O
and	O
had	O
19	O
.	O
97	O
students	O
in	O
their	O
classroom	O
(	O
SD	O
=	O
8	O
.	O
93	O
;	O
Range	O
4–38	O
students	O
)	O
.	O

Teachers	O
reported	O
that	O
they	O
knew	O
the	O
child	O
about	O
whom	O
they	O
were	O
reporting	O
at	O
least	O
“somewhat”	O
(	O
48	O
%	O
;	O
n	O
=	O
63	O
)	O
to	O
“very	O
well”	O
(	O
39	O
%	O
;	O
n	O
=	O
52	O
)	O
.	O

For	O
67	O
%	O
of	O
children	O
(	O
n	O
=	O
89	O
)	O
,	O
teachers	O
reported	O
that	O
the	O
child	O
spent	O
greater	O
than	O
75	O
%	O
of	O
their	O
school	O
time	O
in	O
the	O
reporting	O
teacher’s	O
classroom	O
.	O

The	O
ECBI	O
is	O
a	O
36	O
-	O
item	O
caregiver	O
-	O
report	O
measure	O
that	O
assesses	O
the	O
frequency	O
and	O
intensity	O
of	O
child	O
disruptive	O
behaviors	O
.	O

The	O
ECBI	O
has	O
strong	O
test	O
-	O
rest	O
reliability	O
(	O
reliability	O
coefficient	O
of	O
0	O
.	O
86	O
for	O
the	O
Intensity	O
score	O
)	O
and	O
good	O
construct	O
and	O
concurrent	O
validity	O
(	O
Boggs	O
et	O
al	O
.	O
1990	O
;	O
Eyberg	O
and	O
Ross	O
1978	O
;	O
Robinson	O
et	O
al	O
.	O
1980	O
)	O
.	O

Two	O
scores	O
are	O
yielded	O
:	O
an	O
Intensity	O
score	O
that	O
represents	O
the	O
current	O
frequency	O
of	O
disruptive	O
behaviors	O
and	O
it	O
is	O
rated	O
on	O
a	O
7	O
-	O
point	O
Likert	O
scale	O
,	O
and	O
a	O
Problem	O
score	O
that	O
represents	O
the	O
total	O
number	O
of	O
child	O
behaviors	O
that	O
caregivers	O
endorsed	O
as	O
currently	O
being	O
a	O
problem	O
for	O
them	O
.	O

For	O
this	O
study	O
,	O
the	O
Intensity	O
t	O
-	O
score	O
(	O
M	O
=	O
50	O
;	O
SD	O
=	O
10	O
)	O
was	O
used	O
to	O
characterize	O
the	O
severity	O
of	O
the	O
child’s	O
behavior	O
problems	O
.	O

Internal	O
consistency	O
was	O
strong	O
in	O
this	O
study’s	O
sample	O
(	O
α=	O
93	O
)	O
.	O

The	O
SESBI	O
-	O
R	O
is	O
the	O
corresponding	O
teacher	O
-	O
report	O
version	O
of	O
the	O
ECBI	O
.	O

The	O
SESBI	O
-	O
R	O
has	O
strong	O
test–retest	O
reliability	O
(	O
test	O
-	O
rest	O
correlations	O
reported	O
between	O
0	O
.	O
89	O
and	O
0	O
.	O
98	O
)	O
(	O
Funderburk	O
and	O
Eyberg	O
1989	O
;	O
Ladish	O
et	O
al	O
.	O
1989	O
)	O
and	O
established	O
convergent	O
and	O
discriminant	O
validity	O
(	O
Dumas	O
1992	O
;	O
Funderburk	O
and	O
Eyberg	O
1989	O
;	O
Schaughency	O
et	O
al	O
.	O
1990	O
)	O
.	O

Consistent	O
with	O
the	O
ECBI	O
,	O
the	O
Intensity	O
t	O
-	O
score	O
(	O
M	O
=	O
50	O
;	O
SD	O
=	O
10	O
)	O
was	O
used	O
for	O
this	O
study	O
.	O

Internal	O
consistency	O
was	O
similarly	O
strong	O
in	O
this	O
study’s	O
sample	O
(	O
α	O
=	O
0	O
.	O
97	O
)	O
.	O

Caregiver	O
-	O
reported	O
child	O
gender	O
,	O
age	O
,	O
race	O
/	O
ethnicity	O
,	O
and	O
educational	O
placement	O
at	O
the	O
time	O
of	O
the	O
baseline	O
assessment	O
were	O
included	O
.	O

One	O
of	O
two	O
cognitive	O
assessments	O
was	O
administered	O
to	O
characterize	O
children’s	O
global	O
cognitive	O
abilities	O
based	O
primarily	O
on	O
their	O
chronological	O
age	O
.	O

Six	O
trained	O
research	O
staff	O
administered	O
the	O
cognitive	O
assessments	O
to	O
estimate	O
the	O
child’s	O
full	O
scale	O
IQ	O
.	O

The	O
WASI	O
-	O
II	O
is	O
a	O
brief	O
standardized	O
assessment	O
of	O
cognitive	O
ability	O
that	O
was	O
administered	O
by	O
a	O
trained	O
member	O
of	O
the	O
research	O
team	O
.	O

Four	O
subtests	O
are	O
administered	O
to	O
yield	O
a	O
FSIQ	O
that	O
is	O
represented	O
as	O
a	O
standard	O
score	O
(	O
M	O
=	O
100	O
;	O
SD	O
=	O
15	O
)	O
.	O

The	O
WASI	O
-	O
II	O
has	O
strong	O
internal	O
consistency	O
,	O
with	O
the	O
average	O
reliability	O
coefficients	O
ranging	O
from	O
0	O
.	O
87	O
to	O
0	O
.	O
91	O
for	O
children	O
,	O
and	O
good	O
convergent	O
and	O
discriminant	O
validity	O
(	O
Wechsler	O
2011	O
)	O
.	O

The	O
WASI	O
-	O
II	O
was	O
administered	O
to	O
children	O
age	O
6	O
years	O
and	O
over	O
at	O
the	O
time	O
of	O
the	O
baseline	O
assessment	O
.	O

The	O
DAS	O
-	O
II	O
is	O
a	O
comprehensive	O
assessment	O
of	O
cognitive	O
ability	O
that	O
was	O
administered	O
by	O
a	O
trained	O
member	O
of	O
the	O
research	O
team	O
.	O

A	O
General	O
Conceptual	O
Ability	O
(	O
GCA	O
)	O
score	O
and	O
three	O
core	O
composites	O
(	O
Nonverbal	O
Reasoning	O
Ability	O
,	O
Verbal	O
Ability	O
,	O
and	O
Spatial	O
Ability	O
)	O
are	O
produced	O
.	O

The	O
GCA	O
and	O
three	O
core	O
composites	O
are	O
represented	O
as	O
standard	O
scores	O
(	O
M	O
=	O
100	O
;	O
SD	O
=	O
15	O
)	O
.	O

The	O
DAS	O
-	O
II	O
has	O
established	O
psychometric	O
characteristics	O
with	O
strong	O
internal	O
consistency	O
for	O
both	O
the	O
standardization	O
sample	O
and	O
special	O
clinical	O
populations	O
and	O
strong	O
support	O
for	O
convergent	O
and	O
discriminant	O
validity	O
(	O
Elliott	O
2007	O
)	O
.	O

The	O
DAS	O
-	O
II	O
was	O
administered	O
to	O
children	O
younger	O
than	O
6	O
years	O
at	O
the	O
time	O
of	O
the	O
baseline	O
assessment	O
.	O

Teachers	O
reported	O
on	O
the	O
child’s	O
educational	O
placement	O
(	O
general	O
education	O
,	O
special	O
day	O
,	O
or	O
another	O
classroom	O
type	O
)	O
at	O
the	O
time	O
of	O
the	O
baseline	O
assessment	O
.	O

The	O
Mini	O
-	O
International	O
Neuropsychiatric	O
Interview	O
,	O
parent	O
version	O
(	O
MINI	O
-	O
KID	O
-	O
P	O
;	O
Sheehan	O
et	O
al	O
.	O
1998	O
)	O
was	O
used	O
to	O
determine	O
the	O
presence	O
of	O
co	O
-	O
occurring	O
psychiatric	O
disorders	O
.	O

The	O
MINI	O
-	O
KID	O
-	O
P	O
is	O
a	O
structured	O
diagnostic	O
interview	O
to	O
assess	O
symptoms	O
of	O
Axis	O
I	O
disorders	O
as	O
listed	O
in	O
the	O
DSM	B-coding_system
-	I-coding_system
IV	I-coding_system
and	O
ICD	B-coding_system
-	I-coding_system
10	I-coding_system
(	I-coding_system
World	I-coding_system
Health	I-coding_system
Organization	I-coding_system
1993	I-coding_system
)	O
.	O

It	O
has	O
strong	O
interrater	O
and	O
test–retest	O
reliability	O
and	O
established	O
construct	O
validity	O
.	O

Sensitivity	O
(	O
0	O
.	O
61–1	O
.	O

00	O
)	O
and	O
specificity	O
(	O
0	O
.	O
81–1	O
.	O

00	O
)	O
are	O
also	O
strong	O
(	O
Sheehan	O
et	O
al	O
.	O
2010	O
)	O
.	O

The	O
MINI	O
-	O
KID	O
-	O
P	O
was	O
administered	O
in	O
person	O
or	O
via	O
phone	O
to	O
the	O
caregiver	O
identified	O
as	O
knowing	O
the	O
child	O
well	O
by	O
a	O
trained	O
member	O
of	O
the	O
research	O
staff	O
.	O

The	O
following	O
twelve	O
MINI	O
-	O
KID	O
-	O
P	O
modules	O
were	O
used	O
based	O
on	O
the	O
most	O
common	O
psychiatric	O
comorbid	O
disorders	O
for	O
children	O
with	O
ASD	O
in	O
MH	O
settings	O
(	O
Brookman	O
-	O
Frazee	O
et	O
al	O
.	O
2010	O
,	O
2012b	O
;	O
Joshi	O
et	O
al	O
.	O
2010	O
)	O
:	O
ADHD	O
,	O
ODD	O
,	O
Panic	O
Disorder	O
,	O
Agoraphobia	O
,	O
Separation	O
Anxiety	O
Disorder	O
,	O
Social	O
Phobia	O
,	O
Specific	O
Phobia	O
,	O
OCD	O
,	O
GAD	O
,	O
Tic	O
Disorders	O
,	O
Major	O
Depressive	O
Episode	O
,	O
Manic	O
and	O
Hypomanic	O
Episodes	O
.	O

The	O
MINI	O
-	O
KID	O
-	O
P	O
was	O
adapted	O
for	O
an	O
ASD	O
sample	O
by	O
adding	O
follow	O
-	O
up	O
probes	O
to	O
aid	O
in	O
differentiation	O
between	O
ASD	O
symptoms	O
and	O
other	O
symptoms	O
of	O
other	O
psychiatric	O
disorders	O
.	O

For	O
example	O
,	O
prior	O
to	O
asking	O
about	O
anxiety	O
,	O
caregivers	O
were	O
provided	O
a	O
brief	O
explanation	O
of	O
the	O
physiological	O
symptoms	O
associated	O
with	O
anxiety	O
to	O
reduce	O
over	O
-	O
endorsement	O
based	O
on	O
similar	O
behaviors	O
that	O
may	O
be	O
observed	O
in	O
ASD	O
.	O

For	O
most	O
modules	O
,	O
caregivers	O
were	O
asked	O
to	O
provide	O
examples	O
following	O
endorsement	O
of	O
screening	O
items	O
,	O
skip	O
patterns	O
were	O
removed	O
,	O
and	O
additional	O
items	O
were	O
added	O
to	O
the	O
OCD	O
and	O
Tic	O
modules	O
to	O
assist	O
in	O
distinguishing	O
between	O
restrictive	O
,	O
repetitive	O
behaviors	O
(	O
characteristic	O
of	O
ASD	O
)	O
and	O
compulsions	O
or	O
tics	O
(	O
required	O
for	O
OCD	O
and	O
Tic	O
diagnoses	O
)	O
.	O

Last	O
,	O
questions	O
in	O
the	O
Dysthymia	O
module	O
were	O
embedded	O
within	O
the	O
Major	O
Depressive	O
Episode	O
module	O
to	O
reduce	O
caregiver	O
burden	O
.	O

All	O
interviewers	O
were	O
trained	O
to	O
criterion	O
prior	O
to	O
administering	O
the	O
MINI	O
-	O
KID	O
-	O
P	O
by	O
a	O
study	O
investigator	O
who	O
is	O
a	O
licensed	O
clinical	O
psychologist	O
with	O
clinical	O
expertise	O
in	O
child	O
mental	O
health	O
and	O
ASD	O
diagnostic	O
assessment	O
.	O

Six	O
trained	O
study	O
personnel	O
administered	O
the	O
MINI	O
-	O
KID	O
-	O
P	O
to	O
caregivers	O
as	O
part	O
of	O
the	O
baseline	O
assessments	O
conducted	O
as	O
part	O
of	O
the	O
larger	O
effectiveness	O
trial	O
.	O

Please	O
see	O
Stadnick	O
et	O
al	O
.	O
(	O
2016	O
)	O
for	O
specific	O
details	O
about	O
MINI	O
-	O
KID	O
-	O
P	O
training	O
and	O
quality	O
monitoring	O
procedures	O
.	O

For	O
the	O
current	O
study	O
,	O
the	O
number	O
of	O
non	O
-	O
ASD	O
psychiatric	O
disorders	O
for	O
which	O
the	O
child	O
met	O
criteria	O
on	O
the	O
MINI	O
-	O
KID	O
-	O
P	O
was	O
used	O
as	O
the	O
measure	O
of	O
psychiatric	O
comorbidity	O
.	O

The	O
ADOS	O
-	O
2	O
is	O
a	O
semi	O
-	O
structured	O
observational	O
assessment	O
administered	O
by	O
a	O
trained	O
provider	O
to	O
assist	O
in	O
the	O
diagnosis	O
of	O
ASD	O
.	O

The	O
quality	O
of	O
the	O
child’s	O
social	O
affect	O
,	O
communication	O
,	O
and	O
restricted	O
,	O
repetitive	O
behaviors	O
are	O
rated	O
.	O

An	O
algorithm	O
is	O
applied	O
to	O
the	O
scores	O
and	O
result	O
in	O
a	O
classification	O
of	O
“Autism	O
,	O
”	O
“Autism	O
Spectrum	O
Disorder	O
,	O
”	O
or	O
“Non	O
-	O
Spectrum”	O
based	O
on	O
standardized	O
cut	O
-	O
off	O
values	O
.	O

The	O
Overall	O
Total	O
score	O
and	O
the	O
child’s	O
chronological	O
age	O
are	O
used	O
to	O
identify	O
the	O
ADOS	O
-	O
2	O
Comparison	O
Score	O
that	O
ranges	O
from	O
1	O
(	O
Minimal	O
-	O
To	O
-	O
No	O
-	O
Evidence	O
of	O
ASD	O
-	O
related	O
symptoms	O
)	O
to	O
10	O
(	O
High	O
level	O
of	O
ASD	O
-	O
related	O
symptoms	O
)	O
.	O

The	O
ADOS	O
-	O
2	O
has	O
strong	O
reliability	O
and	O
validity	O
across	O
modules	O
(	O
Lord	O
et	O
al	O
.	O
2012	O
)	O
.	O

Children	O
were	O
administered	O
one	O
of	O
the	O
modules	O
based	O
on	O
their	O
language	O
and	O
developmental	O
level	O
.	O

All	O
ADOS	O
-	O
2	O
administrators	O
were	O
research	O
reliable	O
.	O

For	O
this	O
study	O
the	O
ADOS	O
-	O
2	O
Comparison	O
Score	O
was	O
used	O
to	O
characterize	O
ASD	O
severity	O
.	O

In	O
this	O
retrospective	O
observational	O
cohort	O
study	O
using	O
linked	O
primary	O
care	O
and	O
hospital	O
data	O
,	O
we	O
investigate	O
the	O
relationship	O
between	O
having	O
a	O
care	O
plan	O
and	O
/	O
or	O
an	O
annual	O
physical	O
health	O
review	O
,	O
and	O
time	O
from	O
diagnosis	O
of	O
SMI	O
to	O
unplanned	O
hospital	O
utilisation	O
.	O

The	O
main	O
data	O
source	O
is	O
the	O
Clinical	O
Practice	O
Research	O
Datalink	O
(	O
CPRD	O
)	O
GOLD	O
,	O
which	O
holds	O
linked	O
individual	O
-	O
level	O
anonymised	O
primary	O
care	O
records	O
from	O
participating	O
general	O
practices	O
in	O
the	O
UK	O
.	O

These	O
data	O
are	O
representative	O
of	O
the	O
English	O
population	O
with	O
respect	O
to	O
age	O
and	O
gender	O
,	O
but	O
not	O
region	O
.	O

For	O
example	O
,	O
the	O
north	O
-	O
east	O
of	O
England	O
is	O
under	O
-	O
sampled	O
relative	O
to	O
areas	O
in	O
the	O
west	O
and	O
south	O
.	O

25	O
The	O
CPRD	O
data	O
service	O
provided	O
information	O
on	O
all	O
patients	O
eligible	O
for	O
linkage	O
and	O
registered	O
with	O
a	O
participating	O
practice	O
in	O
England	O
,	O
and	O
with	O
a	O
diagnosis	O
of	O
SMI	O
documented	O
on	O
or	O
before	O
31	O
March	O
2014	O
recorded	O
in	O
clinical	O
notes	O
or	O
referral	O
records	O
,	O
using	O
the	O
event	O
date	O
entered	O
by	O
the	O
GP	O
.	O

The	O
sample	O
was	O
limited	O
to	O
patients	O
whose	O
records	O
met	O
an	O
acceptable	O
standard	O
based	O
on	O
recording	O
of	O
registration	O
,	O
clinical	O
events	O
and	O
demographic	O
details	O
,	O
at	O
practices	O
deemed	O
up	O
to	O
standard	O
according	O
to	O
a	O
CPRD	O
algorithm	O
.	O

25	O
Most	O
of	O
the	O
primary	O
care	O
information	O
is	O
recorded	O
using	O
a	O
hierarchical	O
coding	O
system	O
known	O
as	O
‘Read	O
codes’	O
,	O
26	O
which	O
we	O
use	O
to	O
identify	O
records	O
of	O
SMI	O
diagnosis	O
,	O
care	O
quality	O
indicators	O
and	O
morbidity	O
profiles	O
.	O

CPRD	O
records	O
were	O
linked	O
to	O
Hospital	O
Episode	O
Statistics	O
(	O
HES	O
)	O
,	O
which	O
comprise	O
detailed	O
records	O
for	O
all	O
National	O
Health	O
Service	O
(	O
NHS	O
)	O
patients	O
admitted	O
to	O
hospital	O
and	O
presentations	O
to	O
A	O
&	O
E	O
in	O
England	O
.	O

CPRD	O
provided	O
deterministically	O
linked	O
admission	O
and	O
A	O
&	O
E	O
data	O
for	O
all	O
patients	O
included	O
in	O
the	O
study	O
.	O

To	O
preserve	O
anonymity	O
,	O
all	O
linkages	O
were	O
carried	O
out	O
under	O
the	O
CPRD	O
routine	O
linkage	O
scheme	O
.	O

Our	O
sample	O
covers	O
eight	O
financial	O
years	O
,	O
from	O
1	O
April	O
2006	O
to	O
31	O
March	O
2014	O
.	O

The	O
care	O
plan	O
indicator	O
was	O
introduced	O
in	O
2006	O
/	O
07	O
and	O
the	O
last	O
year	O
of	O
HES	O
data	O
available	O
to	O
us	O
at	O
the	O
start	O
of	O
the	O
study	O
was	O
2013	O
/	O
14	O
.	O

The	O
sample	O
comprises	O
patients	O
aged	O
18	O
years	O
and	O
older	O
,	O
whose	O
earliest	O
recorded	O
diagnosis	O
of	O
SMI	O
in	O
primary	O
care	O
was	O
after	O
31	O
March	O
2006	O
,	O
and	O
who	O
were	O
registered	O
with	O
the	O
same	O
practice	O
for	O
at	O
least	O
365	O
days	O
before	O
that	O
diagnosis	O
.	O

A	O
&	O
E	O
data	O
are	O
only	O
available	O
from	O
2007	O
/	O
08	O
,	O
so	O
the	O
analysis	O
of	O
A	O
&	O
E	O
presentations	O
is	O
limited	O
to	O
patients	O
with	O
a	O
first	O
diagnosis	O
after	O
31	O
March	O
2007	O
.	O

The	O
restriction	O
to	O
newly	O
diagnosed	O
patients	O
excludes	O
those	O
whose	O
unobserved	O
past	O
care	O
or	O
events	O
could	O
influence	O
their	O
subsequent	O
care	O
.	O

We	O
analyse	O
three	O
outcomes	O
taken	O
from	O
HES	O
data	O
:	O
time	O
to	O
(	O
i	O
)	O
presentations	O
to	O
A	O
&	O
E	O
,	O
(	O
ii	O
)	O
unplanned	O
hospital	O
admission	O
for	O
SMI	O
and	O
(	O
iii	O
)	O
unplanned	O
admissions	O
for	O
ambulatory	O
care	O
sensitive	O
conditions	O
(	O
ACSCs	O
)	O
.	O

Unplanned	O
admissions	O
,	O
based	O
on	O
the	O
HES	O
admission	O
method	O
codes	O
for	O
emergency	O
admissions	O
,	O
were	O
classified	O
by	O
International	B-coding_system
Classification	I-coding_system
of	I-coding_system
Diseases	I-coding_system
(	I-coding_system
ICD	I-coding_system
-	I-coding_system
10	I-coding_system
)	I-coding_system
codes	O
.	O

For	O
SMI	B-phenotype
admissions	I-phenotype
,	O
this	O
included	O
admissions	O
with	O
primary	O
diagnosis	O
field	O
code	O
categories	O
F20	B-code
to	O
F31	B-code
.	I-code

27	I-code
For	O
ACSC	O
,	O
the	O
codes	O
were	O
those	O
defined	O
by	O
Bardsley	O
et	O
al	O
28	O
(	O
see	O
online	O
supplementary	O
table	O
1	O
for	O
the	O
list	O
of	O
conditions	O
included	O
)	O
.	O

A	O
&	O
E	O
presentations	O
of	O
any	O
cause	O
(	O
mental	O
or	O
physical	O
health	O
)	O
were	O
included	O
.	O

Primary	O
care	O
quality	O
indicators	O
were	O
taken	O
from	O
CPRD	O
data	O
,	O
and	O
capture	O
care	O
plans	O
and	O
annual	O
reviews	O
of	O
physical	O
health	O
based	O
on	O
Read	O
codes	O
specified	O
under	O
the	O
QOF	O
to	O
identify	O
those	O
two	O
indicators	O
.	O

A	O
good	O
quality	O
care	O
plan	O
documents	O
the	O
patient’s	O
current	O
health	O
and	O
social	O
care	O
needs	O
and	O
how	O
these	O
will	O
be	O
addressed	O
,	O
in	O
agreement	O
with	O
patients	O
and	O
caregivers	O
.	O

It	O
should	O
specify	O
arrangements	O
with	O
secondary	O
care	O
services	O
(	O
where	O
applicable	O
)	O
,	O
and	O
recommendations	O
in	O
case	O
of	O
relapse	O
,	O
including	O
the	O
patient’s	O
care	O
preferences	O
and	O
goals	O
.	O

19	O
20	O
The	O
QOF	O
incentivises	O
GPs	O
to	O
document	O
care	O
plans	O
annually	O
,	O
so	O
we	O
analyse	O
‘current’	O
care	O
plans	O
,	O
those	O
recorded	O
in	O
the	O
last	O
12	O
months	O
.	O

However	O
,	O
we	O
hypothesise	O
that	O
an	O
older	O
care	O
plan	O
may	O
still	O
influence	O
patients’	O
health	O
service	O
utilisation	O
,	O
and	O
therefore	O
also	O
analyse	O
‘expired’	O
care	O
plans	O
,	O
those	O
recorded	O
more	O
than	O
a	O
year	O
ago	O
.	O

Conversely	O
,	O
only	O
‘current’	O
annual	O
reviews	O
(	O
recorded	O
within	O
the	O
last	O
12	O
months	O
)	O
are	O
included	O
in	O
the	O
analysis	O
,	O
since	O
expired	O
monitoring	O
of	O
physical	O
health	O
is	O
unlikely	O
to	O
have	O
ongoing	O
benefits	O
.	O

The	O
choice	O
of	O
the	O
12	O
-	O
month	O
window	O
to	O
determine	O
expiration	O
status	O
is	O
based	O
on	O
the	O
QOF	O
guidance	O
that	O
a	O
care	O
plan	O
or	O
annual	O
review	O
should	O
be	O
reviewed	O
annually	O
.	O

3	O

From	O
2006	O
/	O
2007	O
to	O
2010	O
/	O
2011	O
the	O
QOF	O
annual	O
review	O
indicator	O
entailed	O
the	O
patient	O
being	O
given	O
appropriate	O
health	O
promotion	O
and	O
prevention	O
advice	O
.	O

In	O
2011	O
/	O
2012	O
,	O
this	O
broad	O
indicator	O
was	O
split	O
into	O
more	O
specific	O
indicators	O
:	O
a	O
record	O
of	O
alcohol	O
consumption	O
,	O
checks	O
of	O
blood	O
pressure	O
,	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
,	O
blood	O
glucose	O
or	O
glycated	O
haemoglobin	O
,	O
and	O
ratio	O
of	O
total	O
to	O
high	O
-	O
density	O
lipoprotein	O
cholesterol	O
,	O
and	O
,	O
where	O
appropriate	O
,	O
cervical	O
screening	O
.	O

In	O
order	O
to	O
explore	O
annual	O
reviews	O
for	O
the	O
full	O
period	O
of	O
our	O
analysis	O
,	O
we	O
formulate	O
an	O
aggregate	O
indicator	O
.	O

This	O
signifies	O
that	O
the	O
patient	O
had	O
at	O
least	O
three	O
of	O
four	O
‘health	O
risk’	O
checks	O
(	O
blood	O
pressure	O
,	O
BMI	O
,	O
cholesterol	O
and	O
glucose	O
)	O
documented	O
within	O
a	O
3	O
month	O
period	O
.	O

29	O
The	O
date	O
of	O
the	O
aggregate	O
indicator	O
is	O
the	O
date	O
of	O
the	O
final	O
check	O
.	O

In	O
our	O
analysis	O
,	O
patients	O
are	O
considered	O
to	O
have	O
a	O
‘current’	O
annual	O
review	O
for	O
twelve	O
months	O
after	O
either	O
an	O
annual	O
review	O
(	O
using	O
the	O
original	O
Read	O
coding	O
)	O
,	O
or	O
from	O
the	O
date	O
of	O
this	O
aggregate	O
indicator	O
.	O

The	O
analysis	O
includes	O
three	O
time	O
-	O
varying	O
care	O
quality	O
indicator	O
variables	O
.	O

For	O
annual	O
reviews	O
,	O
the	O
base	O
case	O
is	O
no	O
annual	O
review	O
of	O
physical	O
health	O
within	O
the	O
last	O
12	O
months	O
.	O

For	O
care	O
plans	O
the	O
base	O
case	O
is	O
never	O
having	O
had	O
a	O
care	O
plan	O
.	O

Two	O
binary	O
variables	O
indicate	O
whether	O
a	O
care	O
plan	O
or	O
annual	O
review	O
has	O
been	O
recorded	O
within	O
the	O
last	O
12	O
months	O
(	O
‘current	O
care	O
plan’	O
and	O
‘current	O
annual	O
review’	O
)	O
.	O

If	O
a	O
patient	O
receives	O
a	O
further	O
care	O
plan	O
or	O
annual	O
review	O
within	O
the	O
12	O
-	O
month	O
window	O
,	O
the	O
‘current’	O
period	O
is	O
extended	O
accordingly	O
.	O

A	O
third	O
variable	O
indicates	O
that	O
the	O
patient	O
received	O
a	O
care	O
plan	O
more	O
than	O
12	O
months	O
ago	O
(	O
‘expired	O
care	O
plan’	O
)	O
but	O
none	O
in	O
the	O
last	O
12	O
months	O
(	O
mutually	O
exclusive	O
with	O
‘current	O
care	O
plan’	O
)	O
.	O

Using	O
primary	O
care	O
data	O
,	O
we	O
control	O
for	O
patients’	O
age	O
,	O
gender	O
,	O
ethnicity	O
,	O
deprivation	O
profile	O
of	O
their	O
area	O
of	O
residence	O
,	O
30	O
year	O
of	O
SMI	O
diagnosis	O
,	O
Charlson	O
comorbidities	O
,	O
31	O
diagnosis	O
of	O
depression	O
,	O
history	O
of	O
smoking	O
and	O
number	O
of	O
primary	O
care	O
attendances	O
in	O
the	O
year	O
prior	O
to	O
diagnosis	O
.	O

Their	O
diagnosis	O
of	O
SMI	O
was	O
classified	O
as	O
‘schizophrenia	O
and	O
other	O
psychoses’	O
,	O
‘bipolar	O
disorder	O
and	O
affective	O
psychoses’	O
,	O
or	O
both	O
,	O
if	O
the	O
patient	O
had	O
both	O
recorded	O
.	O

(	O
See	O
online	O
supplementary	O
table	O
2	O
for	O
a	O
list	O
of	O
codes	O
.	O
)	O
From	O
HES	O
data	O
we	O
capture	O
number	O
of	O
hospital	O
admissions	O
in	O
the	O
year	O
prior	O
to	O
diagnosis	O
.	O

We	O
estimate	O
Cox	O
survival	O
models	O
,	O
32	O
examining	O
duration	O
from	O
SMI	O
diagnosis	O
to	O
each	O
of	O
the	O
three	O
outcomes	O
separately	O
:	O
first	O
A	O
&	O
E	O
presentation	O
,	O
first	O
SMI	O
admission	O
and	O
first	O
ACSC	O
admission	O
.	O

We	O
follow	O
each	O
individual	O
until	O
the	O
outcome	O
of	O
interest	O
or	O
until	O
censoring	O
.	O

Censoring	O
can	O
occur	O
because	O
(	O
i	O
)	O
a	O
patient	O
dies	O
,	O
(	O
ii	O
)	O
registration	O
with	O
the	O
practice	O
ends	O
or	O
(	O
iii	O
)	O
the	O
study	O
period	O
ends	O
(	O
ie	O
,	O
the	O
patient	O
is	O
still	O
registered	O
on	O
31	O
March	O
2014	O
)	O
.	O

In	O
the	O
Cox	O
model	O
the	O
hazard	O
of	O
the	O
outcome	O
occurring	O
is	O
a	O
function	O
of	O
the	O
baseline	O
hazard	O
,	O
the	O
care	O
indicators	O
and	O
patient	O
demographic	O
and	O
clinical	O
characteristics	O
.	O

In	O
the	O
main	O
model	O
,	O
we	O
assume	O
patient	O
characteristics	O
to	O
be	O
fixed	O
at	O
baseline	O
,	O
while	O
the	O
care	O
indicators	O
may	O
vary	O
over	O
time	O
.	O

(	O
Further	O
details	O
available	O
in	O
online	O
supplementary	O
material	O
.	O
)	O
We	O
stratify	O
on	O
practice	O
,	O
so	O
that	O
the	O
baseline	O
hazard	O
varies	O
across	O
practices	O
,	O
to	O
allow	O
for	O
unobserved	O
differences	O
in	O
patient	O
populations	O
and	O
practice	O
characteristics	O
,	O
and	O
standard	O
errors	O
are	O
adjusted	O
for	O
clustering	O
at	O
practice	O
level	O
to	O
account	O
for	O
within	O
-	O
practice	O
correlation	O
.	O

Coefficient	O
estimates	O
are	O
presented	O
as	O
HRs	O
with	O
associated	O
95	O
%	O
CIs	O
,	O
where	O
values	O
greater	O
than	O
1	O
indicate	O
an	O
increase	O
in	O
the	O
hazard	O
of	O
the	O
outcome	O
associated	O
with	O
a	O
unit	O
change	O
in	O
the	O
explanatory	O
variable	O
,	O
and	O
vice	O
versa	O
for	O
a	O
HR	O
below	O
1	O
.	O

All	O
analyses	O
were	O
performed	O
in	O
Stata	O
V	O
.	O
14	O
(	O
StataCorp	O
)	O
.	O

We	O
undertake	O
five	O
tests	O
of	O
the	O
sensitivity	O
of	O
our	O
findings	O
to	O
alternate	O
specifications	O
of	O
the	O
model	O
.	O

First	O
,	O
we	O
test	O
the	O
robustness	O
of	O
the	O
annual	O
review	O
variable	O
,	O
which	O
in	O
our	O
main	O
analysis	O
is	O
the	O
composite	O
indicator	O
constructed	O
from	O
both	O
the	O
QOF	O
-	O
specified	O
Read	O
codes	O
and	O
the	O
specific	O
health	O
checks	O
that	O
contribute	O
to	O
such	O
reviews	O
.	O

We	O
explore	O
the	O
impact	O
of	O
restricting	O
this	O
to	O
the	O
QOF	O
-	O
specified	O
Read	O
codes	O
,	O
which	O
necessitates	O
limiting	O
the	O
observation	O
period	O
to	O
2006	O
/	O
2007	O
to	O
2010	O
/	O
2011	O
(	O
or	O
2007	O
/	O
2008	O
to	O
2010	O
/	O
2011	O
for	O
the	O
A	O
&	O
E	O
outcome	O
)	O
.	O

Second	O
,	O
we	O
assume	O
the	O
indicators	O
expire	O
after	O
15	O
months	O
instead	O
of	O
12	O
months	O
.	O

Third	O
,	O
instead	O
of	O
fixing	O
the	O
number	O
of	O
Charlson	O
comorbidities	O
at	O
baseline	O
,	O
we	O
allow	O
this	O
to	O
increase	O
over	O
the	O
period	O
of	O
observation	O
if	O
patients	O
are	O
diagnosed	O
with	O
new	O
comorbidities	O
.	O

We	O
lastly	O
apply	O
two	O
alternate	O
specifications	O
of	O
practice	O
-	O
level	O
characteristics	O
,	O
instead	O
of	O
stratifying	O
on	O
practice	O
.	O

The	O
first	O
assumes	O
no	O
practice	O
-	O
level	O
differences	O
in	O
baseline	O
hazard	O
,	O
but	O
includes	O
practice	O
characteristics	O
(	O
rurality	O
and	O
distance	O
from	O
closest	O
acute	O
hospital	O
and	O
inpatient	O
psychiatric	O
unit	O
)	O
as	O
covariates	O
.	O

The	O
second	O
includes	O
practice	O
fixed	O
effects	O
as	O
explanatory	O
variables	O
.	O

Both	O
models	O
adjust	O
the	O
standard	O
errors	O
for	O
clustering	O
at	O
the	O
practice	O
level	O
as	O
before	O
.	O

Two	O
co	O
-	O
authors	O
on	O
the	O
multidisciplinary	O
team	O
responsible	O
for	O
this	O
study	O
have	O
lived	O
experience	O
of	O
SMI	O
.	O

They	O
contributed	O
to	O
the	O
design	O
of	O
the	O
research	O
questions	O
and	O
methodological	O
approach	O
,	O
interpretation	O
of	O
the	O
findings	O
and	O
writing	O
the	O
paper	O
.	O

We	O
conducted	O
an	O
observational	O
study	O
of	O
RE	O
probands	O
and	O
their	O
siblings	O
with	O
clinical	O
data	O
acquired	O
at	O
a	O
single	O
time	O
point	O
to	O
determine	O
distribution	O
of	O
reading	O
disability	O
.	O

We	O
combined	O
this	O
with	O
a	O
nested	O
case	O
-	O
control	O
design	O
to	O
assess	O
associations	O
of	O
RD	O
,	O
in	O
which	O
the	O
source	O
population	O
comprised	O
children	O
with	O
RE	O
,	O
and	O
where	O
probands	O
and	O
siblings	O
affected	O
by	O
RD	O
were	O
treated	O
as	O
cases	O
and	O
RD	O
unaffected	O
probands	O
and	O
siblings	O
as	O
controls	O
.	O

Typical	O
RE	O
probands	O
and	O
their	O
families	O
were	O
prospectively	O
recruited	O
for	O
genetic	O
studies	O
principally	O
from	O
US	O
pediatric	O
neurology	O
centers	O
in	O
New	O
York	O
,	O
New	O
Jersey	O
,	O
Pennsylvania	O
,	O
Connecticut	O
,	O
Rhode	O
Island	O
and	O
Massachusetts	O
between	O
2004–2009	O
;	O
and	O
from	O
south	O
-	O
eastern	O
UK	O
pediatric	O
centers	O
between	O
2009–2012	O
.	O

These	O
centers	O
were	O
the	O
principal	O
diagnostic	O
and	O
treatment	O
locations	O
for	O
children	O
with	O
RE	O
from	O
the	O
community	O
.	O

Referring	O
clinicians	O
specialized	O
either	O
in	O
pediatric	O
neurology	O
(	O
US	O
)	O
or	O
pediatrics	O
(	O
UK	O
)	O
,	O
reflecting	O
national	O
referral	O
pathways	O
[	O
33	O
]	O
.	O

Ascertainment	O
was	O
through	O
the	O
proband	O
,	O
with	O
no	O
other	O
family	O
member	O
required	O
to	O
be	O
affected	O
.	O

A	O
proportion	O
of	O
the	O
US	O
cases	O
have	O
been	O
included	O
in	O
previous	O
reports	O
[	O
4	O
]	O
.	O

RE	O
cases	O
were	O
enrolled	O
if	O
they	O
met	O
stringent	O
eligibility	O
criteria	O
including	O
:	O
at	O
least	O
one	O
witnessed	O
seizure	O
with	O
typical	O
features	O
:	O
nocturnal	O
,	O
simple	O
partial	O
seizures	O
affecting	O
one	O
side	O
of	O
the	O
body	O
,	O
or	O
on	O
alternate	O
sides	O
;	O
oro	O
-	O
facial	O
-	O
pharyngeal	O
sensorimotor	O
symptoms	O
,	O
with	O
speech	O
arrest	O
and	O
hypersalivation	O
;	O
age	O
of	O
onset	O
between	O
3	O
and	O
12	O
years	O
;	O
no	O
previous	O
epilepsy	O
type	O
;	O
normal	O
global	O
developmental	O
milestones	O
;	O
normal	O
neurological	O
examination	O
;	O
at	O
least	O
one	O
interictal	O
EEG	O
with	O
centrotemporal	O
sharp	O
waves	O

and	O
normal	O
background	O
;	O
and	O
neuroimaging	O
(	O
if	O
performed	O
)	O
that	O
excluded	O
an	O
alternative	O
structural	O
,	O
inflammatory	O
,	O
or	O
metabolic	O
cause	O
for	O
the	O
seizures	O
.	O

Both	O
prevalent	O
and	O
incident	O
cases	O
were	O
eligible	O
.	O

Thus	O
cases	O
with	O
unwitnessed	O
episodes	O
,	O
or	O
with	O
only	O
secondary	O
generalized	O
seizures	O
were	O
excluded	O
,	O
even	O
if	O
the	O
EEG	O
was	O
typical	O
.	O

Experts	O
in	O
epileptology	O
,	O
neurophysiology	O
,	O
and	O
neuroimaging	O
centrally	O
reviewed	O
all	O
of	O
the	O
probands’	O
charts	O
,	O
EEGs	O
,	O
and	O
neuroimaging	O
for	O
eligibility	O
prior	O
to	O
recruitment	O
.	O

Table	O
1	O
shows	O
the	O
basic	O
characteristics	O
of	O
probands	O
and	O
siblings	O
.	O

Nineteen	O
probands	O
had	O
no	O
corresponding	O
siblings	O
;	O
56	O
probands	O
had	O
one	O
sibling	O
;	O
22	O
had	O
two	O
;	O
10	O
had	O
three	O
;	O
and	O
one	O
had	O
four	O
.	O

A	O
pediatric	O
-	O
trained	O
physician	O
(	O
TC	O
,	O
ST	O
,	O
DKP	O
)	O
interviewed	O
all	O
families	O
either	O
at	O
home	O
,	O
in	O
clinic	O
,	O
or	O
by	O
phone	O
.	O

Both	O
parents	O
were	O
interviewed	O
when	O
possible	O
,	O
either	O
together	O
or	O
separately	O
,	O
and	O
the	O
proband	O
and	O
siblings	O
were	O
also	O
interviewed	O
when	O
age	O
appropriate	O
to	O
complement	O
information	O
about	O
seizure	O
semiology	O
and	O
education	O
.	O

Participants	O
completed	O
a	O
125	O
-	O
item	O
questionnaire	O
covering	O
perinatal	O
,	O
developmental	O
,	O
medical	O
,	O
educational	O
,	O
family	O
history	O
and	O
detailed	O
seizure	O
semiology	O
and	O
treatment	O
history	O
[	O
4	O
]	O
.	O

The	O
same	O
relevant	O
questionnaire	O
items	O
were	O
used	O
for	O
the	O
siblings	O
.	O

Questions	O
that	O
were	O
answered	O
positively	O
were	O
followed	O
up	O
in	O
detail	O
by	O
clinical	O
interview	O
to	O
establish	O
ICD	B-coding_system
-	I-coding_system
10	I-coding_system
diagnoses	O
and	O
to	O
distinguish	O
specific	O
from	O
global	O
learning	O
disability	O
.	O

The	O
questionnaire	O
included	O
nine	O
items	O
addressing	O
the	O
ICD	B-coding_system
-	I-coding_system
10	I-coding_system
definitions	O
of	O
reading	B-phenotype
disorder	I-phenotype
F81	B-code
.	I-code
0	I-code
,	O
and	O
13	O
items	O
addressing	O
speech	B-phenotype
sound	I-phenotype
disorder	I-phenotype
(	I-phenotype
SSD	I-phenotype
)	I-phenotype
F80	B-code
.	I-code
0	I-code
.	O

RD	O
was	O
identified	O
by	O
significant	O
impairment	O
in	O
the	O
development	O
of	O
reading	O
skills	O
not	O
solely	O
accounted	O
for	O
by	O
mental	O
age	O
,	O
sensory	O
problems	O
,	O
mother	O
tongue	O
,	O
or	O
inadequate	O
schooling	O
.	O

Operationally	O
,	O
we	O
asked	O
about	O
difficulties	O
and	O
teacher	O
concerns	O
about	O
learning	O
to	O
read	O
in	O
the	O
first	O
two	O
years	O
of	O
elementary	O
school	O
;	O
reading	O
remediation	O
;	O
educational	O
assessments	O
and	O
repeating	O
a	O
grade	O
.	O

We	O
also	O
excluded	O
,	O
by	O
clinical	O
interview	O
and	O
in	O
some	O
cases	O
by	O
audiological	O
examination	O
,	O
hearing	O
impairment	O
,	O
social	O
and	O
educational	O
deprivation	O
,	O
and	O
other	O
factors	O
that	O
were	O
inconsistent	O
with	O
the	O
diagnosis	O
of	O
RD	O
.	O

We	O
checked	O
available	O
school	O
and	O
psychologist’s	O
reports	O
for	O
confirmation	O
,	O
and	O
validated	O
our	O
phenotype	O
assessments	O
of	O
RD	O
in	O
a	O
subset	O
of	O
cases	O
and	O
siblings	O
in	O
New	O
York	O
and	O
Providence	O
,	O
RI	O
by	O
formal	O
neuropsychological	O
evaluation	O
[	O
9	O
]	O
,	O
showing	O
that	O
ICD	B-coding_system
-	I-coding_system
10	I-coding_system
classifications	O
in	O
this	O
dataset	O
had	O
a	O
100	O
%	O
positive	O
predictive	O
value	O
and	O
90	O
%	O
negative	O
predictive	O
value	O
for	O
reading	O
impairment	O
[	O
9	O
]	O
.	O

SSD	O
is	O
defined	O
by	O
developmentally	O
inappropriate	O
errors	O
(	O
e	O
.	O
g	O
.	O
,	O
deletions	O
and	O
substitutions	O
)	O
in	O
speech	O
production	O
that	O
reduce	O
intelligibility	O
[	O
34	O
]	O
,	O
and	O
which	O
are	O
distinct	O
from	O
stuttering	O
,	O
mutism	O
,	O
or	O
aphasia	O
.	O

Operationally	O
,	O
we	O
sought	O
a	O
history	O
of	O
delay	O
in	O
the	O
normal	O
acquisition	O
of	O
milestones	O
expected	O
for	O
age	O
,	O
e	O
.	O
g	O
.	O
no	O
single	O
words	O
at	O
16	O
months	O
,	O
no	O
two	O
-	O
word	O
sentences	O
at	O
2	O
years	O
of	O
age	O
,	O
age	O
-	O
inappropriate	O
difficulty	O
for	O
strangers	O
to	O
understand	O
speech	O
,	O
and	O
preschool	O
speech	O
therapy	O
intervention	O
.	O

We	O
included	O
only	O
families	O
where	O
English	O
was	O
a	O
first	O
language	O
and	O
excluded	O
individuals	O
with	O
chronic	O
hearing	O
impairment	O
or	O
recurrent	O
otitis	O
media	O
from	O
the	O
definition	O
.	O

SSD	O
has	O
its	O
highest	O
prevalence	O
in	O
the	O
preschool	O
period	O
,	O
and	O
declines	O
sharply	O
by	O
the	O
age	O
of	O
5–6	O
years	O
[	O
35	O
]	O
.	O

Hence	O
a	O
lifetime	O
history	O
of	O
SSD	O
probably	O
represents	O
a	O
more	O
accurate	O
estimate	O
of	O
SSD	O
than	O
a	O
speech	O
pathologist	O
/	O
therapist	O
evaluation	O
conducted	O
many	O
years	O
after	O
SSD	O
has	O
resolved	O
.	O

We	O
asked	O
US	O
parents	O
to	O
fill	O
out	O
Attention	O
Deficit	O
Disorders	O
Evaluation	O
Scale	O
(	O
ADDES	O
-	O
Third	O
Edition	O
Home	O
Version	O
)	O
[	O
36	O
]	O
,	O
and	O
UK	O
parents	O
to	O
fill	O
out	O
Conners	O
Rating	O
Scale	O
[	O
37	O
]	O
.	O

Both	O
measures	O
are	O
based	O
on	O
the	O
DSM	B-coding_system
-	I-coding_system
IV	I-coding_system
,	O
the	O
most	O
widely	O
recognised	O
definition	O
of	O
ADHD	B-phenotype
[	O
38	O
]	O
.	O

The	O
ADDES	O
is	O
a	O
46	O
item	O
questionnaire	O
,	O
based	O
on	O
symptoms	O
of	O
inattention	O
,	O
hyperactivity	O
and	O
impulsivity	O
to	O
be	O
used	O
for	O
children	O
between	O
3–18	O
years	O
.	O

Conners	O
CPRS	O
-	O
R	O
contains	O
80	O
items	O
and	O
gives	O
standardized	O
scores	O
for	O
hyperactivity	O
,	O
inattention	O
,	O
DSM	B-coding_system
-	I-coding_system
IV	I-coding_system
symptom	O
subscales	O
as	O
well	O
as	O
an	O
ADHD	O
index	O
.	O

Both	O
measures	O
perform	O
similarly	O
and	O
have	O
comparable	O
diagnostic	O
utility	O
[	O
39	O
]	O
and	O
are	O
well	O
validated	O
[	O
40	O
]	O
.	O

We	O
calculated	O
the	O
frequency	O
of	O
ADHD	O
among	O
probands	O
in	O
separate	O
US	O
and	O
UK	O
strata	O
;	O
no	O
ADHD	O
data	O
was	O
available	O
for	O
siblings	O
.	O

A	O
subset	O
of	O
siblings	O
,	O
between	O
the	O
ages	O
of	O
4	O
and	O
16	O
years	O
,	O
who	O
were	O
able	O
to	O
travel	O
to	O
a	O
study	O
center	O
(	O
Columbia	O
Medical	O
Center	O
,	O
NYC	O
or	O
Kings	O
College	O
Hospital	O
,	O
London	O
)	O
underwent	O
45–60	O
minute	O
sleep	O
electroencephalographs	O
(	O
EEGs	O
)	O
to	O
assess	O
focal	O
sharp	O
waves	O
[	O
20	O
]	O
.	O

EEGs	O
were	O
then	O
evaluated	O
blind	O
to	O
identity	O
by	O
two	O
sets	O
of	O
independent	O
neurophysiologists	O
(	O
ZAA	O
/	O
SG	O
in	O
UK	O
and	O
CA	O
/	O
LK	O
in	O
US	O
)	O
.	O

We	O
calculated	O
the	O
frequency	O
of	O
RD	O
,	O
SSD	O
,	O
ADHD	O
in	O
probands	O
;	O
and	O
RD	O
and	O
SSD	O
in	O
siblings	O
.	O

Data	O
were	O
excluded	O
on	O
participants	O
who	O
were	O
below	O
the	O
age	O
range	O
at	O
risk	O
for	O
diagnosis	O
of	O
RD	O
(	O
6	O
years	O
)	O
,	O
or	O
SSD	O
(	O
2	O
years	O
)	O
.	O

We	O
also	O
computed	O
kappa	O
scores	O
for	O
the	O
inter	O
-	O
rater	O
reliability	O
of	O
the	O
two	O
EEG	O
observers	O
.	O

We	O
then	O
assessed	O
the	O
univariate	O
associations	O
between	O
RD	O
and	O
demographic	O
and	O
clinical	O
variables	O
:	O
age	O
at	O
interview	O
;	O
sex	O
;	O
number	O
of	O
lifetime	O
seizures	O
;	O
age	O
at	O
seizure	O
onset	O
;	O
exposure	O
to	O
no	O
AEDs	O
,	O
one	O
AED	O
(	O
monotherapy	O
)	O
or	O
multiple	O
AEDs	O
(	O
polytherapy	O
)	O
in	O
probands	O
.	O

We	O
also	O
assessed	O
univariate	O
associations	O
between	O
RD	O
and	O
age	O
,	O
sex	O
,	O
SSD	O
and	O
EEG	O
focal	O
sharp	O
waves	O
among	O
siblings	O
,	O
using	O
generalized	O
estimating	O
equations	O
to	O
account	O
for	O
the	O
clustering	O
of	O
siblings	O
within	O
families	O
.	O

We	O
used	O
multiple	O
logistic	O
regression	O
to	O
investigate	O
the	O
associations	O
of	O
SSD	O
,	O
ADHD	O
,	O
sex	O
,	O
age	O
onset	O
,	O
seizure	O
and	O
treatment	O
variables	O
among	O
probands	O
and	O
to	O
test	O
the	O
principal	O
hypothesis	O
,	O
computing	O
the	O
odds	O
ratios	O
(	O
OR	O
)	O
,	O
after	O
adjusting	O
for	O
other	O
known	O
risk	O
factors	O
,	O
and	O
95	O
%	O
confidence	O
intervals	O
(	O
CI	O
)	O
.	O

We	O
used	O
generalised	O
estimating	O
equations	O
(	O
GEE	O
)	O
with	O
a	O
logit	O
link	O
and	O
an	O
exchangeable	O
correlation	O
matrix	O
accounting	O
for	O
the	O
clustering	O
of	O
siblings	O
within	O
families	O
,	O
to	O
test	O
the	O
independent	O
effects	O
of	O
the	O
significant	O
univariate	O
risk	O
factors	O
for	O
reading	O
on	O
the	O
siblings	O
alone	O
.	O

The	O
case	O
-	O
control	O
sample	O
had	O
high	O
power	O
to	O
answer	O
the	O
study	O
questions	O
,	O
eg	O
91	O
%	O
power	O
to	O
detect	O
a	O
0	O
.	O
4	O
difference	O
in	O
SSD	O
frequency	O
.	O

Analyses	O
were	O
performed	O
using	O
Stata	O
13	O
.	O
1	O
for	O
Macintosh	O
OS	O
X	O
[	O
41	O
]	O
blind	O
to	O
subject	O
identity	O
.	O

The	O
institutional	O
review	O
boards	O
or	O
ethical	O
committees	O
of	O
the	O
New	O
York	O
State	O
Psychiatric	O
Institute	O
,	O
Columbia	O
University	O
Medical	O
Center	O
;	O
King’s	O
Health	O
Partners	O
;	O
and	O
all	O
collaborating	O
centers	O
approved	O
the	O
study	O
.	O

All	O
participants	O
gave	O
written	O
informed	O
consent	O
,	O
and	O
assent	O
where	O
appropriate	O
,	O
in	O
accordance	O
with	O
the	O
Declaration	O
of	O
Helsinki	O
.	O

We	O
used	O
neuropsychological	O
data	O
from	O
the	O
fourth	O
wave	O
(	O
T4	O
)	O
and	O
genetic	O
data	O
of	O
the	O
TRacking	O
Adolescents’	O
Individual	O
Lives	O
Survey	O
(	O
TRAILS	O
)	O
,	O
a	O
large	O
representative	O
prospective	O
population	O
cohort	O
study	O
from	O
the	O
North	O
of	O
the	O
Netherlands	O
.	O

The	O
baseline	O
sample	O
comprised	O
a	O
diverse	O
sample	O
of	O
2230	O
10–12	O
year	O
-	O
olds	O
of	O
predominantly	O
Dutch	O
ethnicity	O
(	O
89	O
.	O
7	O
%	O
)	O
,	O
of	O
whom	O
1881	O
(	O
83	O
.	O
4	O
%	O
)	O
participated	O
at	O
T4	O
and	O
1515	O
(	O
77	O
.	O
4	O
%	O
of	O
the	O
total	O
T4	O
TRAILS	O
sample	O
)	O
successfully	O
completed	O
a	O
sustained	O
attention	O
task	O
(	O
criteria	O
are	O
described	O
in	O
[	O
1	O
]	O
)	O
.	O

Genotypic	O
data	O
were	O
available	O
for	O
1095	O
of	O
these	O
participants	O
,	O
of	O
whom	O
one	O
of	O
each	O
sibling	O
pair	O
and	O
participants	O
from	O
non	O
-	O
Dutch	O
ancestry	O
were	O
excluded	O
(	O
n	O
=	O
87	O
)	O
.	O

An	O
additional	O
44	O
participants	O
were	O
excluded	O
because	O
they	O
used	O
medication	O
targeting	O
catecholaminergic	O
systems	O
,	O
which	O
could	O
affect	O
our	O
behavioral	O
measures	O
(	O
see	O
below	O
)	O
.	O

The	O
final	O
sample	O
for	O
this	O
study	O
therefore	O
included	O
964	O
individuals	O
(	O
mean	O
age	O
:	O
19	O
.	O
0	O
±	O
0	O
.	O
6	O
years	O
,	O
53	O
.	O
3	O
%	O
females	O
)	O
.	O

The	O
selected	O
participants	O
were	O
slightly	O
younger	O
(	O
mean	O
age	O
=	O
19	O
.	O
0	O
±	O
0	O
.	O
6	O
years	O
)	O
than	O
the	O
unselected	O
T4	O
participants	O
(	O
n	O
=	O
790	O
,	O
mean	O
age	O
=	O
19	O
.	O
2	O
±	O
0	O
.	O
6	O
years	O
,	O
t	O
(	O
1752	O
)	O
=	O
7	O
.	O
4	O
,	O
p	O
<	O
.	O
001	O
)	O
,	O
but	O
similar	O
in	O
male	O
-	O
female	O
ratio	O
(	O
t	O
(	O
1752	O
)	O
=	O
1	O
.	O
0	O
,	O
p	O
=	O
.	O
31	O
)	O
.	O

The	O
TRAILS	O
study	O
was	O
approved	O
by	O
the	O
Dutch	O
Central	O
Committee	O
on	O
Research	O
Involving	O
Human	O
Subjects	O
(	O
CCMO	O
,	O
no	O
.	O

NL22114	O
.	O
042	O
.	O
08	O
)	O
.	O

Written	O
informed	O
consent	O
was	O
obtained	O
from	O
both	O
the	O
parents	O
and	O
the	O
participants	O
.	O

For	O
more	O
details	O
on	O
the	O
sampling	O
procedure	O
and	O
methods	O
see	O
[	O
27	O
–	O
29	O
]	O
.	O

Medication	O
use	O
was	O
coded	O
according	O
to	O
the	O
Anatomical	B-coding_system
Therapeutic	I-coding_system
Chemical	I-coding_system
(	I-coding_system
ATC	I-coding_system
)	I-coding_system
classification	O
system	O
of	O
the	O
WHO	O
Collaborating	O
Centre	O
for	O
Drug	O
Statistics	O
Methodology	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
whocc	O
.	O
no	O
)	O
.	O

Participants	O
were	O
excluded	O
if	O
they	O
used	O
medication	O
targeting	O
catecholaminergic	O
systems	O
,	O
that	O
is	O
,	O
cardiovascular	B-phenotype
medication	I-phenotype
based	I-phenotype
on	I-phenotype
beta	I-phenotype
blocking	I-phenotype
agents	I-phenotype
(	O
C07A	B-code
)	O
such	O
as	O
propranolol	O
(	O
adrenergic	O
receptor	O
blocker	O
)	O
,	O
drugs	B-phenotype
for	I-phenotype
functional	I-phenotype
gastrointestinal	I-phenotype
disorders	I-phenotype
(	O
A03	B-code
)	O
such	O
as	O
domperidone	O
(	O
dopamine	O
receptor	O
antagonist	O
)	O
,	O
adrenergic	B-phenotype
respiratory	I-phenotype
medication	I-phenotype
(	O
R03A	B-code
)	O
such	O
as	O
salbutamol	O
(	O
adrenergic	O
receptor	O
agonist	O
)	O
,	O
psychostimulants	B-phenotype
(	O
N06B	B-code
)	O
such	O
as	O
methylphenidate	O
(	O
dopamine	O
reuptake	O
inhibitor	O
)	O
,	O
antipsychotics	B-phenotype

(	O
N05A	B-code
)	O
such	O
as	O
haloperidol	O
(	O
mainly	O
dopamine	O
receptor	O
antagonists	O
)	O
,	O
and	O
the	O
sex	O
hormone	O
cabergoline	O
(	O
a	O
dopamine	O
receptor	O
agonist	O
)	O
.	O

The	O
Sustained	O
Attention	O
Dot	O
(	O
SAD	O
)	O
patterns	O
task	O
was	O
part	O
of	O
a	O
test	O
battery	O
of	O
five	O
tasks	O
assessing	O
neurocognitive	O
functioning	O
taken	O
from	O
the	O
Amsterdam	O
Neuropsychological	O
Tasks	O
(	O
ANT	O
)	O
battery	O
[	O
30	O
]	O
.	O

During	O
the	O
SAD	O
task	O
,	O
participants	O
had	O
to	O
respond	O
as	O
quickly	O
as	O
possible	O
to	O
patterns	O
with	O
3	O
,	O
4	O
or	O
5	O
dots	O
by	O
pressing	O
the	O
mouse	O
button	O
with	O
their	O
dominant	O
hand	O
(	O
‘yes’	O
response	O
)	O
when	O
there	O
were	O
4	O
dots	O
,	O
and	O
pressing	O
the	O
mouse	O
button	O
with	O
their	O
non	O
-	O
dominant	O
hand	O
(	O
‘no’	O
response	O
)	O
when	O
there	O
were	O
3	O
or	O
5	O
dots	O
.	O

The	O
three	O
types	O
of	O
dot	O
patterns	O
occurred	O
with	O
equal	O
frequency	O
and	O
were	O
randomly	O
presented	O
across	O
50	O
series	O
of	O
12	O
trials	O
without	O
breaks	O
.	O

A	O
dot	O
pattern	O
disappeared	O
immediately	O
after	O
a	O
response	O
had	O
been	O
given	O
(	O
valid	O
response	O
window	O
:	O
200–6000	O
ms	O
)	O
,	O
entailing	O
that	O
the	O
task	O
pace	O
was	O
largely	O
determined	O
by	O
the	O
participant’s	O
behavior	O
.	O

Each	O
stimulus	O
was	O
followed	O
by	O
a	O
fixed	O
post	O
response	O
interval	O
of	O
250	O
ms	O
.	O

Detailed	O
procedures	O
concerning	O
data	O
preparation	O
,	O
frequency	O
domain	O
definitions	O
,	O
and	O
frequency	O
domain	O
analysis	O
have	O
been	O
described	O
previously	O
[	O
1	O
]	O
.	O

In	O
brief	O
,	O
the	O
RT	O
data	O
were	O
:	O
1	O
)	O
normalized	O
by	O
a	O
natural	O
logarithmic	O
transformation	O
(	O
ln	O
)	O
with	O
a	O
displacement	O
parameter	O
of	O
150	O
ms	O
;	O
and	O
2	O
)	O
individually	O
adjusted	O
for	O
the	O
average	O
reaction	O
time	O
for	O
each	O
stimulus	O
type	O
(	O
i	O
.	O
e	O
.	O
,	O
3	O
,	O
4	O
,	O
or	O
5	O
dots	O
)	O
.	O

Power	O
spectral	O
analysis	O
was	O
applied	O
to	O
these	O
adjusted	O
logarithmic	O
RT	O
series	O
(	O
alnRT	O
)	O
based	O
on	O
fast	O
Fourier	O
Transform	O
using	O
CARSPAN	O
[	O
31	O
]	O
.	O

Power	O
was	O
calculated	O
for	O
neurophysiologically	O
defined	O
oscillation	O
bands	O
Slow	O
-	O
4	O
(	O
0	O
.	O
027–0	O
.	O

073	O
Hz	O
)	O
and	O
Slow	O
-	O
5	O
(	O
0	O
.	O
010–0	O
.	O

027	O
Hz	O
)	O
[	O
3	O
,	O
26	O
]	O
as	O
DMN	O
-	O
oscillations	O
have	O
generally	O
been	O
related	O
to	O
frequencies	O
below	O
0	O
.	O
1	O
Hz	O
(	O
e	O
.	O
g	O
.	O
[	O
32	O
,	O
33	O
]	O
)	O
.	O

Note	O
that	O
power	O
is	O
a	O
relative	O
measure	O
;	O
it	O
indicates	O
the	O
percentage	O
of	O
the	O
total	O
variance	O
the	O
Slow	O
-	O
4	O
and	O
Slow	O
-	O
5	O
bands	O
account	O
for	O
in	O
a	O
particular	O
subject	O
.	O

Higher	O
values	O
are	O
indicative	O
of	O
an	O
amplification	O
at	O
these	O
power	O
spectra	O
(	O
i	O
.	O
e	O
.	O
,	O
a	O
greater	O
magnitude	O
of	O
these	O
low	O
-	O
frequency	O
RT	O
fluctuations	O
)	O
.	O

Blood	O
samples	O
or	O
buccal	O
swabs	O
(	O
Cytobrush	O
)	O
were	O
collected	O
at	O
T3	O
.	O

DNA	O
extraction	O
,	O
using	O
the	O
manual	O
salting	O
out	O
procedure	O
[	O
34	O
]	O
,	O
and	O
genotyping	O
of	O
all	O
SNPs	O
were	O
performed	O
at	O
the	O
Department	O
of	O
Genetics	O
,	O
University	O
Medical	O
Center	O
Groningen	O
,	O
The	O
Netherlands	O
.	O

Genotyping	O
was	O
executed	O
on	O
the	O
Golden	O
Gate	O
Illumina	O
BeadStation	O
500	O
platform	O
(	O
Illumina	O
Inc	O
.	O
,	O
San	O
Diego	O
,	O
CA	O
,	O
USA	O
)	O
according	O
to	O
the	O
manufacturer’s	O
protocol	O
.	O

Genotype	O
data	O
clustering	O
was	O
performed	O
in	O
BeadStudio	O
3	O
.	O
0	O
(	O
Illumina	O
Inc	O
.	O
,	O
San	O
Diego	O
,	O
CA	O
,	O
USA	O
)	O
.	O

Concordance	O
between	O
DNA	O
replicates	O
showed	O
a	O
100	O
%	O
genotyping	O
accuracy	O
.	O

Data	O
cleaning	O
was	O
in	O
line	O
with	O
standard	O
procedures	O
[	O
35	O
]	O
.	O

In	O
addition	O
to	O
this	O
candidate	O
gene	O
genotyping	O
,	O
genome	O
-	O
wide	O
genotyping	O
was	O
performed	O
using	O
the	O
Illumina	O
HumanCytoSNP12	O
v2	O
beadchip	O
assay	O
(	O
Illumina	O
,	O
Inc	O
;	O
San	O
Diego	O
,	O
CA	O
,	O
USA	O
)	O
.	O

Genotypes	O
were	O
called	O
with	O
the	O
Illumina	O
GenomeStudio	O
software	O
package	O
(	O
Illumina	O
,	O
Inc	O
)	O
.	O

Details	O
on	O
genotyping	O
and	O
quality	O
control	O
have	O
been	O
given	O
elsewhere	O
[	O
36	O
]	O
.	O

Next	O
,	O
imputation	O
was	O
carried	O
out	O
with	O
Impute	O
v2	O
[	O
37	O
]	O
using	O
the	O
1000	O
Genomes	O
(	O
release	O
March	O
2012	O
)	O
as	O
reference	O
panel	O
.	O

For	O
the	O
DRD4	O
VNTR	O
polymorphism	O
,	O
the	O
48	O
base	O
pair	O
repeat	O
sequence	O
located	O
in	O
exon	O
3	O
was	O
determined	O
by	O
direct	O
analysis	O
on	O
an	O
automated	O
capillary	O
sequencer	O
(	O
ABI3730	O
,	O
Applied	O
Biosystems	O
,	O
Nieuwerkerk	O
a	O
/	O
d	O
IJssel	O
,	O
The	O
Netherlands	O
)	O
using	O
standard	O
conditions	O
at	O
the	O
CCKL	O
quality	O
-	O
certified	O
Research	O
lab	O
for	O
Multifactorial	O
Diseases	O
within	O
the	O
Human	O
Genetics	O
department	O
of	O
the	O
Radboud	O
University	O
Nijmegen	O
Medical	O
Centre	O
(	O
Nijmegen	O
,	O
The	O
Netherlands	O
)	O
.	O

Three	O
percent	O
blanks	O
as	O
well	O
as	O
duplicates	O
between	O
plates	O
were	O
included	O
for	O
quality	O
controls	O
.	O

Call	O
rate	O
and	O
DNA	O
replicate	O
consistency	O
were	O
98	O
%	O
and	O
100	O
%	O
,	O
respectively	O
.	O

Genotypic	O
data	O
for	O
the	O
DRD4	O
VNTR	O
were	O
coded	O
with	O
0	O
,	O
1	O
,	O
and	O
2	O
to	O
represent	O
the	O
number	O
of	O
copies	O
of	O
the	O
7	O
repeat	O
allele	O
.	O

Genetic	O
variants	O
were	O
selected	O
according	O
to	O
the	O
catecholamine	O
system	O
-	O
wide	O
association	O
approach	O
developed	O
by	O
Cummins	O
and	O
colleagues	O
[	O
25	O
,	O
38	O
]	O
.	O

In	O
brief	O
,	O
SNPs	O
were	O
selected	O
from	O
23	O
autosomal	O
catecholamine	O
genes	O
,	O
namely	O
those	O
that	O
are	O
known	O
to	O
be	O
involved	O
in	O
synthesis	O
,	O
degradation	O
,	O
transport	O
and	O
receptor	O
signaling	O
of	O
DA	O
and	O
/	O
or	O
NA	O
(	O
as	O
identified	O
in	O
the	O
KEGG	O
,	O
[	O
http	O
:	O
/	O
/	O
www	O
.	O
genome	O
.	O
jp	O
/	O
kegg	O
/	O
pathway	O
.	O
html	O
]	O
and	O
Gene	O
Ontology	O
[	O
http	O
:	O
/	O
/	O
www	O
.	O
geneontology	O
.	O
org	O
]	O
)	O
metabolic	O
pathway	O
databases	O
)	O
.	O

Note	O
that	O
the	O
ANKK1	O
gene	O
was	O
included	O
in	O
the	O
set	O
of	O
autosomal	O
catecholamine	O
genes	O
,	O
because	O
SNPs	O
within	O
this	O
gene	O
are	O
in	O
strong	O
linkage	O
disequilibrium	O
(	O
LD	O
)	O
with	O
SNPs	O
of	O
DRD2	O
[	O
39	O
]	O
.	O

Haplotype	O
tagging	O
SNPs	O
were	O
identified	O
to	O
provide	O
5′–3′	O
coverage	O
of	O
each	O
gene	O
using	O
the	O
HapMap	O
project	O
database	O
[	O
40	O
]	O
.	O

We	O
favored	O
the	O
inclusion	O
of	O
SNPs	O
as	O
tags	O
if	O
they	O
had	O
been	O
shown	O
to	O
modify	O
the	O
risk	O
for	O
ADHD	O
,	O
were	O
at	O
exon—intron	O
boundaries	O
(	O
300bp	O
)	O
or	O
mapped	O
to	O
within	O
5kb	O
of	O
the	O
genes	O
of	O
interest	O
including	O
the	O
5′	O
and	O
3′	O
untranslated	O
(	O
UTR	O
)	O
regions	O
,	O
which	O
may	O
have	O
regulatory	O
roles	O
.	O

Only	O
tagging	O
SNPs	O
(	O
r	O
2	O
≥	O
0	O
.	O
8	O
)	O
with	O
a	O
minor	O
allele	O
frequency	O
of	O
>	O
0	O
.	O
1	O
were	O
selected	O
(	O
see	O
[	O
25	O
]	O
for	O
SNP	O
selection	O
criteria	O
)	O
.	O

This	O
process	O
yielded	O
dense	O
coverage	O
of	O
the	O
23	O
autosomal	O
catecholamine	O
genes	O
with	O
152	O
tagging	O
SNPs	O
.	O

In	O
addition	O
,	O
the	O
48	O
base	O
pair	O
VNTR	O
mapped	O
to	O
exon	O
3	O
of	O
the	O
DRD4	O
gene	O
was	O
included	O
.	O

This	O
selection	O
of	O
SNPs	O
/	O
VNTRs	O
was	O
extracted	O
from	O
the	O
TRAILS	O
database	O
.	O

We	O
included	O
rs4680	O
of	O
the	O
COMT	O
gene	O
and	O
SNPs	O
for	O
the	O
ADRA2C	O
and	O
PNMT	O
genes	O
that	O
failed	O
during	O
genotyping	O
in	O
the	O
original	O
papers	O
[	O
25	O
,	O
38	O
]	O
.	O

However	O
,	O
two	O
previously	O
studied	O
VNTRs	O
in	O
the	O
SLC6A3	O
gene	O
[	O
25	O
,	O
38	O
]	O
were	O
not	O
genotyped	O
in	O
the	O
TRAILS	O
dataset	O
and	O
hence	O
could	O
not	O
be	O
included	O
in	O
this	O
study	O
.	O

Initial	O
correlation	O
analyses	O
indicated	O
that	O
while	O
age	O
was	O
not	O
significantly	O
associated	O
with	O
the	O
Slow	O
-	O
4	O
and	O
Slow	O
-	O
5	O
measures	O
,	O
gender	O
approached	O
significant	O
association	O
at	O
uncorrected	O
levels	O
with	O
Slow	O
-	O
4	O
(	O
r	O
=	O
.	O
06	O
,	O
p	O
=	O
.	O
056	O
)	O
and	O
was	O
significantly	O
associated	O
at	O
corrected	O
significance	O
levels	O
with	O
Slow	O
-	O
5	O
(	O
r	O
=	O
.	O
16	O
,	O
p	O
<	O
.	O
001	O
)	O
.	O

Thus	O
,	O
gender	O
was	O
included	O
as	O
a	O
covariate	O
in	O
a	O
single	O
step	O
Monte	O
-	O
Carlo	O
permutation	O
method	O
that	O
tested	O
for	O
genetic	O
associations	O
with	O
Slow	O
-	O
4	O
and	O
Slow	O
-	O
5	O
via	O
an	O
additive	O
regression	O
model	O
.	O

Permutation	O
methods	O
are	O
considered	O
the	O
gold	O
standard	O
when	O
conducting	O
association	O
analyses	O
,	O
because	O
they	O
provide	O
unbiased	O
control	O
for	O
type	O
1	O
error	O
and	O
maintain	O
statistical	O
power	O
while	O
correcting	O
for	O
multiple	O
comparisons	O
.	O

As	O
densely	O
typed	O
SNP	O
sets	O
show	O
complex	O
patterns	O
of	O
correlation	O
(	O
LD	O
)	O
arising	O
from	O
DNA	O
recombination	O
,	O
our	O
permutation	O
method	O
corrected	O
for	O
correlated	O
samples	O
(	O
SNP	O
data	O
)	O
to	O
give	O
a	O
critical	O
value	O
of	O
α	O
=	O
.	O
00042	O
for	O
examining	O
the	O
association	O
between	O
a	O
cognitive	O
measure	O
and	O
any	O
genetic	O
marker	O
(	O
see	O
[	O
25	O
]	O
for	O
a	O
full	O
description	O
of	O
this	O
method	O
)	O
.	O

We	O
then	O
corrected	O
for	O
the	O
number	O
of	O
cognitive	O
variables	O
examined	O
(	O
2	O
;	O
Slow	O
-	O
4	O
,	O
Slow	O
-	O
5	O
)	O
to	O
give	O
a	O
final	O
critical	O
value	O
,	O
of	O
α	O
=	O
.	O
00021	O
(	O
.	O
00042	O
/	O
2	O
)	O
,	O
α	O
FWE	O
=	O
.	O
05	O
.	O

With	O
this	O
permutation	O
method	O
that	O
stringently	O
corrects	O
for	O
both	O
genotypic	O
and	O
phenotypic	O
measures	O
,	O
our	O
sample	O
size	O
of	O
964	O
participants	O
yielded	O
greater	O
than	O
80	O
%	O
power	O
to	O
detect	O
a	O
small	O
effect	O
size	O
(	O
f	O
2	O
=	O
0	O
.	O
02	O
)	O
and	O
100	O
%	O
power	O
to	O
detect	O
a	O
small	O
/	O
medium	O
effect	O
size	O
(	O
f	O
2	O
=	O
0	O
.	O
15	O
)	O
.	O

We	O
also	O
present	O
results	O
that	O
are	O
significant	O
at	O
the	O
uncorrected	O
significance	O
level	O
for	O
our	O
a	O
priori	O
candidates	O
(	O
COMT	O
/	O
val158met	O
and	O
ADRA2A	O
gene	O
variants	O
)	O
,	O
and	O
note	O
that	O
we	O
have	O
100	O
%	O
power	O
to	O
detect	O
associations	O
of	O
small	O
effect	O
size	O
at	O
this	O
level	O
.	O

Power	O
calculations	O
were	O
performed	O
using	O
G	O
*	O
Power	O
3	O
.	O
1	O
[	O
41	O
]	O
.	O

This	O
is	O
a	O
multicentre	O
,	O
non	O
-	O
randomised	O
,	O
mixed	O
-	O
method	O
study	O
to	O
evaluate	O
feasibility	O
,	O
acceptability	O
,	O
effectiveness	O
and	O
analysis	O
of	O
direct	O
costs	O
(	O
eg	O
,	O
care	O
cost	O
,	O
hospital	O
bed	O
costs	O
etc	O
)	O
of	O
an	O
integrated	O
care	O
pathway	O
,	O
TRIumPH	O
.	O

Qualitative	O
and	O
quantitative	O
data	O
will	O
be	O
collected	O
and	O
analysed	O
.	O

The	O
study	O
has	O
two	O
adopter	O
organisations—early	O
intervention	O
in	O
psychosis	O
teams	O
in	O
Southern	O
Health	O
NHS	O
Foundation	O
Trust	O
and	O
Sheffield	O
Health	O
and	O
Social	O
Care	O
NHS	O
Foundation	O
Trust	O
and	O
two	O
comparator	O
organisations—EIP	O
teams	O
in	O
Solent	O
NHS	O
Trust	O
and	O
Dorset	O
Healthcare	O
University	O
NHS	O
Foundation	O
Trust	O
.	O

TRIumPH	O
is	O
an	O
integrated	O
care	O
pathway	O
for	O
psychosis	O
that	O
prescribes	O
time	O
frames	O
around	O
access	O
and	O
clinical	O
interventions	O
as	O
developed	O
in	O
the	O
UK	O
(	O
figures	O
1	O
and	O
2	O
)	O
.	O

23	O
The	O
work	O
has	O
used	O
a	O
similar	O
approach	O
to	O
that	O
taken	O
to	O
improve	O
care	O
in	O
other	O
health	O
areas	O
like	O
stroke	O
care	O
,	O
where	O
there	O
has	O
been	O
a	O
demonstrable	O
improvement	O
in	O
outcomes	O
for	O
patients	O
and	O
carers	O
.	O

This	O
new	O
psychosis	O
pathway	O
aims	O
to	O
reduce	O
the	O
impact	O
of	O
disease	O
and	O
promote	O
recovery	O
by	O
ensuring	O
that	O
every	O
individual	O
gets	O
the	O
best	O
evidence	O
-	O
based	O
care	O
at	O
the	O
right	O
time	O
and	O
in	O
the	O
right	O
place	O
.	O

TRIumPH	O
pathway—routine	O
referral	O
.	O

TRIumPH	O
pathway—crisis	O
pathway	O
.	O

In	O
developing	O
the	O
pathway	O
,	O
a	O
multipronged	O
approach	O
has	O
been	O
used	O
,	O
using	O
(	O
i	O
)	O
intelligence	O
from	O
information	O
,	O
(	O
ii	O
)	O
co	O
-	O
production	O
with	O
individuals	O
with	O
lived	O
experience	O
of	O
mental	O
illness	O
and	O
their	O
carers	O
and	O
(	O
iii	O
)	O
engagement	O
with	O
clinicians	O
and	O
other	O
stakeholders	O
,	O
including	O
commissioners	O
,	O
primary	O
care	O
and	O
third	O
-	O
sector	O
organisations	O
.	O

The	O
approach	O
has	O
used	O
a	O
robust	O
methodology	O
that	O
can	O
be	O
adapted	O
and	O
adopted	O
nationally	O
and	O
internationally	O
.	O

In	O
developing	O
the	O
psychosis	O
pathway	O
,	O
the	O
Wessex	O
Academic	O
Health	O
Sciences	O
Network	O
(	O
AHSN	O
)	O
commissioned	O
Janssen	O
Healthcare	O
Innovation	O
to	O
build	O
a	O
comprehensive	O
picture	O
of	O
service	O
use	O
in	O
Wessex	O
from	O
national	O
data	O
sets	O
by	O
pseudonymising	O
,	O
non	O
-	O
sensitive	O
patient	O
-	O
level	O
data	O
for	O
2012–2013	O
.	O

Licensed	O
from	O
the	O
Health	O
and	O
Social	O
Care	O
Information	O
Centre	O
,	O
the	O
Mental	O
Health	O
Minimum	O
Data	O
Set	O
(	O
MHMDS	O
)	O
,	O
and	O
Hospital	O
Episode	O
Statistics	O
(	O
HES	O
)	O
were	O
searched	O
for	O
individuals	O
identified	O
using	O
the	O
relevant	O
ICD	B-coding_system
-	I-coding_system
10	I-coding_system
clinical	O
codes	O
;	O
Mental	O
health	O
(	O
Payment	O
by	O
Results	O
)	O
PbR	O
clusters	O
and	O
Health	O
of	O
the	O
Nation	O
Outcome	O
Scale	O
(	O
HoNOS	O
)	O
.	O

The	O
data	O
confirmed	O
that	O
individuals	O
who	O
suffered	O
with	O
psychosis	O
:	O
23	O
Had	O
higher	O
psychiatric	O
hospital	O
admissions	O
with	O
longer	O
stays	O
(	O
on	O
average	O
over	O
50	O
%	O
longer	O
than	O
other	O
mental	O
health	O
conditions	O
)	O
;	O
Accounted	O
for	O
the	O
majority	O
of	O
community	O
health	O
professional	O
contacts	O
(	O
around	O
three	O
times	O
more	O
)	O
;	O
Had	O
more	O
attendances	O
and	O
admissions	O
to	O
local	O
accident	O
and	O
emergency	O
departments	O
Are	O
keen	O
to	O
work	O
but	O
could	O
not	O
find	O
employment	O
.	O

Had	O
higher	O
psychiatric	O
hospital	O
admissions	O
with	O
longer	O
stays	O
(	O
on	O
average	O
over	O
50	O
%	O
longer	O
than	O
other	O
mental	O
health	O
conditions	O
)	O
;	O

Accounted	O
for	O
the	O
majority	O
of	O
community	O
health	O
professional	O
contacts	O
(	O
around	O
three	O
times	O
more	O
)	O
;	O

Had	O
more	O
attendances	O
and	O
admissions	O
to	O
local	O
accident	O
and	O
emergency	O
departments	O

Are	O
keen	O
to	O
work	O
but	O
could	O
not	O
find	O
employment	O
.	O

Limitations	O
with	O
the	O
data	O
and	O
method	O
used	O
were	O
acknowledged	O
.	O

The	O
information	O
on	O
service	O
use	O
was	O
consistent	O
with	O
other	O
areas	O
in	O
the	O
country	O
.	O

23	O

The	O
Wessex	O
AHSN	O
supported	O
co	O
-	O
production	O
workshops	O
that	O
enabled	O
patient	O
,	O
carer	O
and	O
clinician	O
feedback	O
.	O

The	O
aim	O
of	O
the	O
coproduction	O
workshops	O
was	O
to	O
understand	O
opportunities	O
and	O
challenges	O
of	O
current	O
service	O
provision	O
and	O
understand	O
how	O
‘experts	O
by	O
lived	O
experience’	O
would	O
like	O
to	O
see	O
services	O
improve	O
.	O

Southampton	O
voluntary	O
services	O
(	O
UK	O
)	O
provided	O
rooms	O
for	O
the	O
workshops	O
that	O
were	O
attended	O
by	O
integrated	O
stakeholders—20	O
patients	O
from	O
across	O
Hampshire	O
,	O
3	O
carers	O
and	O
5	O
healthcare	O
professionals—and	O
lasted	O
4	O
hours	O
.	O

The	O
workshops	O
were	O
facilitated	O
by	O
Stripes	O
partners	O
(	O
a	O
global	O
strategy	O
and	O
innovation	O
studio	O
that	O
support	O
organisations	O
to	O
understand	O
their	O
customers	O
better	O
by	O
providing	O
a	O
fresh	O
perspective	O
and	O
a	O
deep	O
understanding	O
ie	O
,	O
then	O
shared	O
by	O
the	O
team	O
collectively	O
)	O
to	O
establish	O
a	O
‘bottom	O
-	O
up’	O
understanding	O
of	O
priorities	O
specific	O
to	O
Wessex	O
.	O

Following	O
an	O
ice	O
breaker	O
exercise	O
,	O
participants	O
were	O
asked	O
to	O
write	O
about	O
their	O
‘hopes	O
and	O
fears	O
.	O
’	O
In	O
the	O
second	O
stage	O
,	O
rather	O
than	O
start	O
with	O
any	O
assumptions	O
,	O
the	O
facilitators	O
let	O
participants	O
define	O
what	O
was	O
important	O
to	O
them	O
by	O
asking	O
them	O
to	O
write	O
postcards	O
about	O
a	O
chosen	O
experience	O
and	O
address	O
it	O
to	O
a	O
person	O
who	O
they	O
felt	O
should	O
hear	O
their	O
story	O
.	O

Hundreds	O
of	O
postcards	O
were	O
obtained	O
,	O
yielding	O
many	O
first	O
-	O
hand	O
experiences	O
of	O
current	O
care	O
.	O

The	O
feedback	O
was	O
then	O
collated	O
into	O
themes	O
by	O
the	O
facilitators	O
.	O

The	O
themes	O
were	O
then	O
rated	O
by	O
individual	O
participants	O
in	O
terms	O
of	O
importance	O
and	O
experiences	O
in	O
different	O
settings	O
.	O

23	O
Below	O
are	O
the	O
key	O
themes	O
rated	O
as	O
high	O
priority	O
with	O
examples	O
of	O
quotes	O
from	O
the	O
participants	O
:	O
Prevention	O
:	O
‘I	O
was	O
introduced	O
to	O
the	O
system	O
after	O
I	O
committed	O
a	O
crime	O
.	O

It	O
could	O
have	O
been	O
avoided	O
if	O
I	O
had	O
received	O
the	O
right	O
support	O
and	O
intervention’	O
.	O

Consistent	O
:	O
‘My	O
brother	O
always	O
complains	O
that	O
his	O
carers	O
and	O
Psychiatrists	O
change	O
all	O
the	O
time	O
,	O
he	O
tells	O
one	O
person	O
all	O
about	O
himself	O
and	O
then	O
,	O
some	O
months	O
or	O
weeks	O
later	O
,	O
he	O
has	O
to	O
tell	O
it	O
all	O
over	O
again	O
.	O

He	O
says	O
he	O
gets	O
fed	O
up	O
with	O
this’	O
.	O

Responsive	O
:	O
‘If	O
services	O
intervened	O
early	O
,	O
hospitalisation	O
could	O
have	O
been	O
avoided	O
.	O

If	O
I	O
had	O
been	O
able	O
to	O
get	O
rapid	O
response	O
might	O
also	O
have	O
avoided	O
crisis’	O
.	O

Empathetic	O
:	O
‘My	O
husband	O
called	O
the	O
hospital	O
at	O
home	O
team	O
and	O
he	O
did	O
not	O
feel	O
listened	O
to’	O
.	O

Seamless	O
:	O
‘The	O
most	O
difficult	O
aspect	O
of	O
my	O
care	O
is	O
that	O
since	O
I	O
moved	O
there	O
is	O
little	O
communication	O
between	O
agencies’	O
.	O

Prevention	O
:	O
‘I	O
was	O
introduced	O
to	O
the	O
system	O
after	O
I	O
committed	O
a	O
crime	O
.	O

It	O
could	O
have	O
been	O
avoided	O
if	O
I	O
had	O
received	O
the	O
right	O
support	O
and	O
intervention’	O
.	O

Consistent	O
:	O
‘My	O
brother	O
always	O
complains	O
that	O
his	O
carers	O
and	O
Psychiatrists	O
change	O
all	O
the	O
time	O
,	O
he	O
tells	O
one	O
person	O
all	O
about	O
himself	O
and	O
then	O
,	O
some	O
months	O
or	O
weeks	O
later	O
,	O
he	O
has	O
to	O
tell	O
it	O
all	O
over	O
again	O
.	O

He	O
says	O
he	O
gets	O
fed	O
up	O
with	O
this’	O
.	O

Responsive	O
:	O
‘If	O
services	O
intervened	O
early	O
,	O
hospitalisation	O
could	O
have	O
been	O
avoided	O
.	O

If	O
I	O
had	O
been	O
able	O
to	O
get	O
rapid	O
response	O
might	O
also	O
have	O
avoided	O
crisis’	O
.	O

Empathetic	O
:	O
‘My	O
husband	O
called	O
the	O
hospital	O
at	O
home	O
team	O
and	O
he	O
did	O
not	O
feel	O
listened	O
to’	O
.	O

Seamless	O
:	O
‘The	O
most	O
difficult	O
aspect	O
of	O
my	O
care	O
is	O
that	O
since	O
I	O
moved	O
there	O
is	O
little	O
communication	O
between	O
agencies’	O
.	O

This	O
approach	O
helped	O
us	O
to	O
understand	O
what	O
was	O
intrinsically	O
important	O
to	O
patients	O
and	O
carers	O
,	O
rather	O
than	O
relying	O
on	O
assumptions	O
.	O

The	O
pathway	O
attempts	O
to	O
address	O
the	O
key	O
areas	O
,	O
as	O
standardising	O
care	O
improves	O
quality	O
through	O
multidisciplinary	O
communication	O
using	O
care	O
planning	O
that	O
makes	O
care	O
consistent	O
,	O
seamless	O
and	O
responsive	O
.	O

The	O
pathway	O
emphasises	O
prevention	O
through	O
communication	O
with	O
primary	O
care	O
and	O
reduction	O
in	O
DUP	O
;	O
it	O
emphasises	O
consistency	O
and	O
seamless	O
care	O
through	O
a	O
prescribed	O
standardised	O
approach	O
in	O
every	O
phase	O
;	O
responsiveness	O
through	O
early	O
access	O
and	O
interventions	O
.	O

Through	O
a	O
standardised	O
approach	O
to	O
assessment	O
and	O
treatment	O
,	O
it	O
promotes	O
empathy	O
.	O

Wider	O
engagement	O
events	O
were	O
held	O
with	O
patients	O
,	O
carers	O
,	O
clinicians	O
,	O
managers	O
and	O
wider	O
stakeholders	O
like	O
commissioners	O
,	O
academics	O
and	O
these	O
also	O
gained	O
political	O
support	O
.	O

Feedback	O
can	O
be	O
viewed	O
on	O
:	O
http	O
:	O
/	O
/	O
wessexahsn	O
.	O
org	O
.	O
uk	O
/	O
programmes	O
/	O
show	O
/	O
5	O
/	O
mental	O
-	O
health	O

A	O
steering	O
group	O
was	O
then	O
set	O
up	O
,	O
involving	O
clinicians	O
,	O
commissioners	O
,	O
patient	O
and	O
carer	O
representatives	O
,	O
general	O
practitioners	O
and	O
other	O
stakeholders	O
who	O
were	O
essential	O
to	O
the	O
development	O
of	O
the	O
pathway	O
.	O

Information	O
from	O
the	O
acquired	O
data	O
and	O
coproduction	O
workshops	O
were	O
triangulated	O
with	O
clinical	O
expertise	O
and	O
national	O
evidence	O
to	O
chart	O
process	O
maps	O
.	O

24	O
The	O
process	O
map	O
identified	O
the	O
scope	O
of	O
the	O
pathway	O
and	O
key	O
outcomes	O
desired	O
,	O
including	O
the	O
specific	O
timeframes	O
for	O
access	O
and	O
intervention	O
and	O
highlight	O
the	O
potential	O
challenges	O
and	O
opportunities	O
.	O

23	O

The	O
pathway	O
has	O
been	O
implemented	O
in	O
the	O
EIP	O
teams	O
of	O
two	O
organisations	O
,	O
called	O
the	O
adopter	O
sites	O
.	O

In	O
implementing	O
the	O
pathway	O
,	O
a	O
multipronged	O
approach	O
has	O
been	O
used	O
,	O
including	O
training	O
of	O
EIP	O
team	O
clinicians	O
and	O
development	O
of	O
a	O
guide	O
supporting	O
the	O
pathway	O
;	O
establishment	O
of	O
a	O
pathway	O
facilitator	O
and	O
collection	O
and	O
discussion	O
of	O
live	O
data	O
in	O
clinical	O
teams	O
.	O

A	O
guide	O
on	O
how	O
to	O
use	O
the	O
pathway	O
has	O
been	O
produced	O
and	O
placed	O
on	O
the	O
trust	O
website	O
.	O

All	O
participant	O
EIP	O
teams	O
in	O
adopter	O
sites	O
have	O
received	O
information	O
and	O
training	O
on	O
different	O
aspects	O
of	O
implementing	O
the	O
pathway	O
.	O

Training	O
has	O
followed	O
the	O
philosophy	O
and	O
psychological	O
principles	O
that	O
underpin	O
quality	O
improvement	O
initiatives	O
.	O

Training	O
has	O
also	O
been	O
provided	O
on	O
key	O
aspects	O
of	O
care	O
like	O
how	O
to	O
conduct	O
physical	O
health	O
examination	O
;	O
how	O
to	O
deal	O
with	O
comorbidity	O
of	O
alcohol	O
and	O
substance	O
misuse	O
among	O
other	O
aspects	O
.	O

A	O
pathway	O
facilitator	O
role	O
has	O
been	O
established	O
within	O
the	O
EIP	O
teams	O
.	O

The	O
facilitator	O
supports	O
the	O
EIP	O
teams	O
in	O
adopter	O
sites	O
to	O
implement	O
the	O
pathway	O
and	O
maintain	O
consistency	O
and	O
fidelity	O
to	O
the	O
model	O
.	O

Regular	O
data	O
collection	O
and	O
feedback	O
to	O
clinicians	O
,	O
managers	O
and	O
the	O
pathway	O
steering	O
group	O
has	O
been	O
informing	O
effective	O
implementation	O
of	O
the	O
pathway	O
.	O

This	O
pathway	O
needs	O
to	O
be	O
evaluated	O
for	O
its	O
feasibility	O
,	O
acceptability	O
,	O
effectiveness	O
and	O
direct	O
costs	O
.	O

Therefore	O
,	O
this	O
study	O
will	O
:	O
Assess	O
the	O
feasibility	O
of	O
implementing	O
the	O
pathway	O
from	O
the	O
perspective	O
of	O
patients	O
,	O
carers	O
and	O
staff	O
Measure	O
patient	O
outcomes	O
to	O
assess	O
effectiveness	O
of	O
the	O
pathway	O
Assess	O
the	O
acceptability	O
of	O
the	O
pathway	O
to	O
patients	O
,	O
carers	O
and	O
clinicians	O
.	O

Evaluate	O
direct	O
costs	O
(	O
eg	O
,	O
care	O
cost	O
,	O
hospital	O
bed	O
costs	O
etc	O
)	O
of	O
the	O
pathway	O

Assess	O
the	O
feasibility	O
of	O
implementing	O
the	O
pathway	O
from	O
the	O
perspective	O
of	O
patients	O
,	O
carers	O
and	O
staff	O

Measure	O
patient	O
outcomes	O
to	O
assess	O
effectiveness	O
of	O
the	O
pathway	O

Assess	O
the	O
acceptability	O
of	O
the	O
pathway	O
to	O
patients	O
,	O
carers	O
and	O
clinicians	O
.	O

Evaluate	O
direct	O
costs	O
(	O
eg	O
,	O
care	O
cost	O
,	O
hospital	O
bed	O
costs	O
etc	O
)	O
of	O
the	O
pathway	O

Participants	O
in	O
the	O
control	O
arm	O
will	O
receive	O
care	O
as	O
usual	O
.	O

There	O
is	O
a	O
significant	O
variability	O
in	O
provision	O
of	O
care	O
,	O
despite	O
NICE	O
guidelines	O
on	O
treatment	O
and	O
management	O
of	O
first	O
episode	O
psychosis	O
.	O

14	O
The	O
study	O
team	O
will	O
record	O
any	O
uptake	O
of	O
NICE	O
recommended	O
programmes	O
during	O
the	O
study	O
,	O
and	O
collate	O
information	O
from	O
centres	O
about	O
uptake	O
of	O
NICE	O
recommendations	O
more	O
widely	O
.	O

These	O
organisations	O
are	O
similar	O
to	O
the	O
adopter	O
sites	O
in	O
that	O
they	O
aspire	O
to	O
follow	O
the	O
EIP	O
policy	O
implementation	O
guide	O
and	O
meet	O
the	O
access	O
and	O
waiting	O
time	O
(	O
AWT	O
)	O
standard	O
.	O

There	O
are	O
also	O
differences	O
as	O
there	O
is	O
a	O
variability	O
in	O
the	O
way	O
care	O
is	O
provided	O
in	O
each	O
team	O
and	O
organisation	O
depending	O
on	O
culture	O
of	O
the	O
team	O
,	O
resources	O
allocated	O
and	O
leadership	O
.	O

Feasibility	O
and	O
acceptability	O
of	O
the	O
pathway	O
will	O
be	O
assessed	O
through	O
quantitative	O
and	O
qualitative	O
data	O
collection	O
regarding	O
adherence	O
to	O
the	O
process	O
measures	O
of	O
the	O
pathway	O
,	O
including	O
timeliness	O
of	O
access	O
and	O
intervention	O
;	O
type	O
of	O
intervention	O
offered	O
,	O
including	O
medication	O
,	O
physical	O
health	O
assessment	O
,	O
psychological	O
intervention	O
etc	O
and	O
reasons	O
for	O
deviation	O
from	O
the	O
pathway	O
.	O

Additionally	O
,	O
satisfaction	O
and	O
acceptability	O
will	O
be	O
assessed	O
using	O
questionnaires	O
and	O
focus	O
groups	O
consisting	O
of	O
the	O
following	O
qualitative	O
methods	O
;	O
patient	O
experience	O
using	O
specifically	O
designed	O
patient	O
experience	O
questionnaires	O
and	O
focus	O
groups	O
,	O
staff	O
experience	O
using	O
staff	O
questionnaires	O
designed	O
to	O
measure	O
the	O
impact	O
of	O
the	O
pathway	O
on	O
staff	O
experience	O
and	O
carer	O
experience	O
using	O
carer	O
focus	O
groups	O
.	O

Effectiveness	O
will	O
be	O
assessed	O
through	O
data	O
collection	O
and	O
evaluation	O
in	O
patient	O
outcomes	O
,	O
including	O
clinical	O
(	O
eg	O
,	O
HoNOS	O
:	O
Health	O
of	O
Nation	O
Outcome	O
Score	O
)	O
,	O
functional	O
and	O
recovery	O
outcomes	O
(	O
eg	O
,	O
employment	O
,	O
vocation	O
,	O
physical	O
health	O
)	O
,	O
among	O
other	O
measures	O
.	O

Analysis	O
of	O
direct	O
costs	O
will	O
be	O
measured	O
through	O
a	O
change	O
in	O
service	O
use	O
(	O
eg	O
,	O
routinely	O
collected	O
data	O
on	O
crisis	O
,	O
admissions	O
,	O
detentions	O
,	O
Emergency	O
Department	O
(	O
ED	O
)	O
attendances	O
)	O
.	O

See	O
table	O
1	O
for	O
full	O
details	O
.	O

TRIumPH	O
study	O
quantitative	O
outcome	O
measures	O

All	O
outcome	O
measures	O
will	O
be	O
assessed	O
at	O
baseline	O
and	O
after	O
12	O
and	O
24	O
months	O
to	O
measure	O
if	O
there	O
is	O
an	O
effect	O
and	O
if	O
so	O
,	O
whether	O
this	O
is	O
sustained	O
over	O
the	O
longer	O
term	O
.	O

Outcomes	O
measures	O
at	O
the	O
adopter	O
sites	O
will	O
be	O
compared	O
to	O
their	O
own	O
baseline	O
and	O
against	O
comparator	O
sites	O
.	O

As	O
this	O
is	O
a	O
feasibility	O
prospective	O
study	O
,	O
no	O
a	O
priori	O
power	O
and	O
sample	O
size	O
calculations	O
have	O
been	O
performed	O
.	O

Instead	O
,	O
data	O
for	O
all	O
available	O
patients	O
and	O
staff	O
during	O
the	O
study	O
period	O
as	O
a	O
convenience	O
sample	O
of	O
consecutive	O
participants	O
will	O
be	O
used	O
.	O

Routinely	O
collected	O
data	O
on	O
every	O
patient	O
that	O
are	O
accepted	O
by	O
the	O
EIP	O
teams	O
in	O
participant	O
organisations	O
during	O
the	O
study	O
period	O
.	O

Patient	O
questionnaires	O
and	O
focus	O
groups	O
:	O

Routinely	O
collected	O
data	O
on	O
every	O
patient	O
that	O
are	O
accepted	O
by	O
the	O
EIP	O
teams	O
in	O
participant	O
organisations	O
during	O
the	O
study	O
period	O
.	O

Patient	O
questionnaires	O
and	O
focus	O
groups	O
:	O

Participants	O
will	O
be	O
eligible	O
for	O
inclusion	O
in	O
the	O
study	O
if	O
they	O
are	O
:	O
On	O
the	O
EIP	O
caseloads	O
,	O
Are	O
able	O
to	O
give	O
written	O
informed	O
consent	O
,	O
Are	O
able	O
and	O
willing	O
to	O
attend	O
and	O
participate	O
in	O
a	O
focus	O
group	O
,	O
Are	O
able	O
to	O
speak	O
and	O
read	O
English	O
.	O

On	O
the	O
EIP	O
caseloads	O
,	O

Are	O
able	O
to	O
give	O
written	O
informed	O
consent	O
,	O

Are	O
able	O
and	O
willing	O
to	O
attend	O
and	O
participate	O
in	O
a	O
focus	O
group	O
,	O

Are	O
able	O
to	O
speak	O
and	O
read	O
English	O
.	O

Participants	O
are	O
excluded	O
from	O
the	O
study	O
if	O
they	O
have	O
a	O
:	O
Acute	O
episode	O
of	O
mental	O
illness	O
that	O
could	O
seriously	O
reduce	O
their	O
ability	O
to	O
consent	O
and	O
understand	O
the	O
information	O
,	O
Significant	O
alcohol	O
or	O
substance	O
misuse	O
which	O
,	O
in	O
the	O
opinion	O
of	O
the	O
principal	O
investigator	O
,	O
would	O
limit	O
the	O
patient	O
'	O
s	O
ability	O
to	O
participate	O
in	O
the	O
study	O
due	O
to	O
lack	O
of	O
ability	O
to	O
understand	O
the	O
information	O
,	O
Diagnosis	O
of	O
learning	O
disability	O
that	O
impacts	O
on	O
capacity	O
to	O
consent	O
and	O
understand	O
the	O
information	O
,	O
3	O
.	O

Staff	O
questionnaires	O
:	O
anonymous	O
questionnaires	O
will	O
be	O
offered	O
to	O
all	O
staff	O
in	O
Adult	O
mental	O
health	O
services	O
in	O
all	O
the	O
participant	O
sites	O
at	O
baseline	O
and	O
at	O
follow	O
-	O
up	O
.	O

4	O
.	O

Carer	O
focus	O
groups	O
:	O
carers	O
of	O
patients	O
on	O
EIP	O
caseloads	O
who	O
are	O
willing	O
and	O
have	O
the	O
capacity	O
to	O
consent	O
will	O
be	O
invited	O
.	O

Acute	O
episode	O
of	O
mental	O
illness	O
that	O
could	O
seriously	O
reduce	O
their	O
ability	O
to	O
consent	O
and	O
understand	O
the	O
information	O
,	O

Significant	O
alcohol	O
or	O
substance	O
misuse	O
which	O
,	O
in	O
the	O
opinion	O
of	O
the	O
principal	O
investigator	O
,	O
would	O
limit	O
the	O
patient	O
'	O
s	O
ability	O
to	O
participate	O
in	O
the	O
study	O
due	O
to	O
lack	O
of	O
ability	O
to	O
understand	O
the	O
information	O
,	O

Diagnosis	O
of	O
learning	O
disability	O
that	O
impacts	O
on	O
capacity	O
to	O
consent	O
and	O
understand	O
the	O
information	O
,	O

3	O
.	O

Staff	O
questionnaires	O
:	O
anonymous	O
questionnaires	O
will	O
be	O
offered	O
to	O
all	O
staff	O
in	O
Adult	O
mental	O
health	O
services	O
in	O
all	O
the	O
participant	O
sites	O
at	O
baseline	O
and	O
at	O
follow	O
-	O
up	O
.	O

4	O
.	O

Carer	O
focus	O
groups	O
:	O
carers	O
of	O
patients	O
on	O
EIP	O
caseloads	O
who	O
are	O
willing	O
and	O
have	O
the	O
capacity	O
to	O
consent	O
will	O
be	O
invited	O
.	O

The	O
study	O
will	O
be	O
promoted	O
within	O
clinical	O
teams	O
and	O
in	O
areas	O
where	O
mental	O
health	O
services	O
are	O
delivered	O
.	O

Research	O
facilitators	O
will	O
work	O
with	O
EIP	O
clinical	O
teams	O
within	O
the	O
participant	O
mental	O
health	O
trusts	O
to	O
identify	O
potentially	O
eligible	O
participants	O
from	O
their	O
caseload	O
for	O
questionnaire	O
surveys	O
and	O
focus	O
groups	O
.	O

Every	O
patient	O
with	O
psychosis	O
that	O
is	O
accepted	O
by	O
the	O
EIP	O
teams	O
during	O
the	O
study	O
period	O
in	O
the	O
participant	O
teams	O
identified	O
through	O
their	O
care	O
workers	O
and	O
those	O
who	O
meet	O
the	O
inclusion	O
criteria	O
will	O
receive	O
the	O
questionnaire	O
.	O

During	O
the	O
study	O
,	O
no	O
personal	O
information	O
will	O
be	O
collected	O
other	O
than	O
a	O
person	O
'	O
s	O
name	O
for	O
consent	O
purposes	O
and	O
telephone	O
number	O
for	O
contact	O
purposes	O
.	O

Every	O
staff	O
member	O
from	O
adult	O
mental	O
health	O
in	O
the	O
participant	O
teams	O
will	O
be	O
invited	O
to	O
participate	O
in	O
the	O
anonymised	O
survey	O
.	O

Patient	O
,	O
carer	O
and	O
staff	O
focus	O
groups	O
will	O
be	O
conducted	O
.	O

A	O
purposive	O
sample	O
will	O
be	O
recruited	O
of	O
individuals	O
who	O
meet	O
the	O
inclusion	O
criteria	O
.	O

On	O
the	O
basis	O
of	O
previous	O
qualitative	O
research	O
involving	O
individuals	O
with	O
schizophrenia	O
,	O
25	O
it	O
is	O
expected	O
that	O
15–20	O
individuals	O
for	O
each	O
set	O
of	O
stakeholders	O
will	O
need	O
to	O
be	O
recruited	O
for	O
this	O
study	O
to	O
reach	O
a	O
point	O
of	O
data	O
saturation	O
(	O
ie	O
,	O
no	O
new	O
insights	O
can	O
be	O
gained	O
and	O
information	O
provided	O
begins	O
to	O
repeat	O
itself	O
)	O
.	O

Focus	O
groups	O
will	O
be	O
composed	O
of	O
6–8	O
individuals	O
.	O

26	O

Initial	O
contact	O
with	O
potential	O
participants	O
will	O
be	O
made	O
by	O
care	O
coordinators	O
or	O
care	O
professionals	O
.	O

Interested	O
individuals	O
will	O
then	O
be	O
contacted	O
by	O
the	O
research	O
team	O
via	O
phone	O
or	O
in	O
person	O
.	O

In	O
other	O
cases	O
,	O
interested	O
individuals	O
may	O
contact	O
the	O
research	O
team	O
directly	O
,	O
through	O
self	O
-	O
referral	O
via	O
a	O
study	O
advertisement	O
,	O
by	O
phone	O
or	O
in	O
person	O
.	O

Study	O
advertisements	O
will	O
be	O
posted	O
in	O
the	O
participant	O
sites	O
.	O

After	O
contact	O
has	O
been	O
established	O
,	O
individuals	O
will	O
meet	O
with	O
the	O
research	O
team	O
to	O
discuss	O
the	O
study	O
and	O
be	O
provided	O
with	O
an	O
informational	O
sheet	O
.	O

If	O
the	O
individual	O
is	O
interested	O
in	O
participating	O
in	O
the	O
study	O
,	O
informed	O
consent	O
will	O
then	O
be	O
obtained	O
.	O

Individuals	O
will	O
be	O
given	O
as	O
much	O
time	O
as	O
needed	O
to	O
determine	O
whether	O
they	O
would	O
like	O
to	O
participate	O
in	O
the	O
study	O
.	O

Interested	O
carers	O
of	O
people	O
who	O
are	O
part	O
of	O
the	O
pathway	O
will	O
be	O
contacted	O
via	O
care	O
coordinators	O
or	O
they	O
may	O
contact	O
the	O
research	O
team	O
directly	O
,	O
through	O
self	O
-	O
referral	O
via	O
a	O
study	O
advertisement	O
,	O
by	O
phone	O
or	O
in	O
person	O
.	O

Study	O
advertisements	O
will	O
be	O
posted	O
in	O
the	O
participant	O
sites	O
.	O

After	O
contact	O
has	O
been	O
established	O
,	O
individuals	O
will	O
meet	O
with	O
the	O
research	O
team	O
to	O
discuss	O
the	O
study	O
and	O
be	O
provided	O
with	O
an	O
informational	O
sheet	O
.	O

If	O
the	O
individual	O
is	O
interested	O
in	O
participating	O
in	O
the	O
study	O
,	O
informed	O
consent	O
will	O
then	O
be	O
obtained	O
.	O

Individuals	O
will	O
be	O
given	O
as	O
much	O
time	O
as	O
needed	O
to	O
determine	O
whether	O
they	O
would	O
like	O
to	O
participate	O
in	O
the	O
study	O
.	O

Informed	O
consent	O
will	O
be	O
obtained	O
prior	O
to	O
the	O
focus	O
group	O
taking	O
place	O
.	O

Interested	O
individuals	O
may	O
contact	O
the	O
research	O
team	O
directly	O
,	O
through	O
self	O
-	O
referral	O
via	O
a	O
study	O
advertisement	O
,	O
by	O
phone	O
or	O
in	O
person	O
.	O

Study	O
advertisements	O
will	O
be	O
posted	O
in	O
the	O
participant	O
sites	O
.	O

After	O
contact	O
has	O
been	O
established	O
,	O
individuals	O
will	O
meet	O
with	O
the	O
research	O
team	O
to	O
discuss	O
the	O
study	O
and	O
be	O
provided	O
with	O
an	O
informational	O
sheet	O
.	O

If	O
the	O
individual	O
is	O
interested	O
in	O
participating	O
in	O
the	O
study	O
,	O
informed	O
consent	O
will	O
then	O
be	O
obtained	O
.	O

Participants	O
will	O
be	O
invited	O
to	O
participate	O
in	O
a	O
focus	O
group	O
in	O
a	O
quiet	O
room	O
.	O

A	O
safe	O
environment	O
will	O
be	O
chosen	O
which	O
is	O
known	O
to	O
the	O
individuals	O
.	O

Focus	O
groups	O
will	O
be	O
led	O
by	O
staff	O
trained	O
in	O
conducting	O
qualitative	O
studies	O
involving	O
people	O
with	O
psychosis	O
.	O

Written	O
informed	O
consent	O
will	O
be	O
sought	O
from	O
participants	O
.	O

Once	O
consent	O
has	O
been	O
received	O
,	O
the	O
participants	O
will	O
participate	O
in	O
a	O
1–2	O
hour	O
(	O
max	O
)	O
focus	O
group	O
.	O

At	O
the	O
beginning	O
of	O
the	O
focus	O
group	O
,	O
participants	O
will	O
be	O
asked	O
to	O
fill	O
out	O
a	O
demographic	O
information	O
sheet	O
.	O

Participants	O
may	O
withdraw	O
themselves	O
from	O
the	O
focus	O
groups	O
,	O
if	O
they	O
so	O
choose	O
.	O

If	O
a	O
participant	O
chooses	O
to	O
withdraw	O
after	O
a	O
focus	O
group	O
starts	O
,	O
it	O
will	O
not	O
be	O
possible	O
to	O
remove	O
their	O
data	O
.	O

The	O
distribution	O
of	O
the	O
quantitative	O
variables	O
will	O
be	O
tested	O
by	O
Kolmogorov	O
-	O
Smirnov	O
or	O
Shapiro	O
-	O
Wilk	O
tests	O
,	O
as	O
appropriate	O
.	O

If	O
their	O
distribution	O
differs	O
from	O
the	O
Gaussian	O
(	O
normal	O
)	O
distribution	O
,	O
they	O
will	O
be	O
presented	O
by	O
median	O
and	O
IQR	O
.	O

Continuous	O
variables	O
(	O
eg	O
,	O
the	O
questionnaire	O
scores	O
at	O
baseline	O
)	O
will	O
be	O
compared	O
among	O
centres	O
using	O
t	O
-	O
tests	O
while	O
categorical	O
variables	O
(	O
eg	O
,	O
gender	O
)	O
will	O
be	O
compared	O
using	O
χ	O
2	O
or	O
Fisher’s	O
test	O
.	O

End	O
of	O
therapy	O
scores	O
on	O
various	O
outcome	O
measures	O
before	O
and	O
after	O
the	O
intervention	O
will	O
be	O
measured	O
using	O
paired	O
t	O
-	O
test	O
.	O

A	O
process	O
evaluation	O
will	O
be	O
undertaken	O
‘to	O
explain	O
discrepancies	O
between	O
expected	O
and	O
observed	O
outcomes	O
,	O
to	O
understand	O
how	O
context	O
influences	O
outcomes	O
,	O
and	O
to	O
provide	O
insights	O
to	O
aid	O
implementation’	O
.	O

27	O
Differences	O
between	O
the	O
Intervention	O
and	O
Control	O
groups	O
will	O
be	O
measured	O
using	O
a	O
linear	O
regression	O
.	O

The	O
statistical	O
software	O
package	O
SPSS	O
will	O
be	O
used	O
for	O
all	O
evaluations	O
as	O
licenced	O
to	O
the	O
Southern	O
Health	O
NHS	O
Foundation	O
Trust	O
.	O

Comparison	O
between	O
pre	O
-	O
intervention	O
and	O
post	O
intervention	O
scores	O
in	O
satisfaction	O
questionnaire	O
will	O
be	O
made	O
by	O
parametric	O
and	O
non	O
-	O
parametric	O
tests	O
.	O

Where	O
required	O
question	O
analysis	O
will	O
be	O
used	O
to	O
analyse	O
data	O
for	O
emerging	O
themes	O
.	O

Qualitative	O
analysis	O
will	O
be	O
used	O
to	O
explore	O
focus	O
group	O
discussions	O
on	O
the	O
acceptability	O
of	O
the	O
psychosis	O
pathway	O
to	O
patients	O
,	O
carers	O
and	O
staff	O
as	O
well	O
as	O
their	O
range	O
of	O
behaviours	O
and	O
perceptions	O
,	O
including	O
barriers	O
to	O
its	O
implementation	O
.	O

Thematic	O
content	O
analysis	O
will	O
be	O
used	O
to	O
identify	O
emerging	O
themes	O
from	O
focus	O
group	O
and	O
individual	O
interviews	O
with	O
staff	O
,	O
carers	O
and	O
patients	O
.	O

Data	O
will	O
be	O
audio	O
-	O
recorded	O
and	O
transcribed	O
verbatim	O
and	O
emergent	O
themes	O
generated	O
.	O

Data	O
analysis	O
will	O
involve	O
the	O
researchers	O
immersing	O
themselves	O
in	O
data	O
by	O
reading	O
and	O
re	O
-	O
reading	O
the	O
interview	O
transcripts	O
to	O
identify	O
emerging	O
themes	O
.	O

Field	O
notes	O
will	O
also	O
be	O
analysed	O
for	O
non	O
-	O
verbal	O
communication	O
and	O
behaviours	O
and	O
compared	O
to	O
interview	O
data	O
.	O

Each	O
group	O
will	O
consist	O
of	O
six	O
to	O
eight	O
participants	O
who	O
will	O
be	O
approached	O
by	O
researchers	O
,	O
experienced	O
in	O
qualitative	O
research	O
.	O

NViVO—a	O
qualitative	O
data	O
management	O
software	O
package—will	O
be	O
used	O
to	O
store	O
and	O
code	O
data	O
.	O

Content	O
data	O
will	O
be	O
recorded	O
and	O
transferred	O
for	O
analysis	O
using	O
NVivo	O
.	O

Triangulation	O
of	O
themes	O
will	O
be	O
conducted	O
to	O
assess	O
reliability	O
and	O
validity	O
of	O
the	O
analysis	O
.	O

Independent	O
researchers	O
will	O
review	O
a	O
selection	O
of	O
transcripts	O
to	O
check	O
for	O
accuracy	O
in	O
coding	O
of	O
themes	O
and	O
reliability	O
of	O
interpretation	O
.	O

Verbatim	O
extracts	O
will	O
be	O
included	O
to	O
support	O
interpretation	O
of	O
emergent	O
themes	O
.	O

The	O
evaluation	O
of	O
direct	O
costs	O
will	O
be	O
from	O
a	O
health	O
and	O
social	O
care	O
and	O
societal	O
perspective	O
.	O

It	O
will	O
consist	O
of	O
cost	O
analysis	O
for	O
estimation	O
of	O
direct	O
costs	O
of	O
care	O
(	O
eg	O
,	O
average	O
costs	O
such	O
as	O
inpatient	O
stay	O
costs	O
,	O
crisis	O
costs	O
,	O
ED	O
costs	O
etc	O
)	O
.	O

The	O
raw	O
data	O
(	O
digital	O
recordings	O
,	O
transcripts	O
)	O
will	O
be	O
stored	O
in	O
encrypted	O
form	O
on	O
a	O
password	O
-	O
protected	O
network	O
at	O
the	O
research	O
department	O
in	O
Southern	O
Health	O
NHS	O
Foundation	O
Trust	O
.	O

Consent	O
documents	O
,	O
demographic	O
forms	O
,	O
receipts	O
for	O
reimbursement	O
of	O
travel	O
will	O
be	O
stored	O
in	O
a	O
locked	O
filing	O
cabinet	O
in	O
the	O
department	O
.	O

Only	O
research	O
staff	O
will	O
have	O
access	O
to	O
the	O
above	O
facilities	O
.	O

Original	O
consent	O
forms	O
from	O
service	O
users	O
and	O
staff	O
who	O
wishes	O
to	O
take	O
part	O
in	O
the	O
interviews	O
will	O
be	O
sent	O
to	O
the	O
research	O
department	O
in	O
Southern	O
Health	O
NHS	O
Foundation	O
Trust	O
,	O
and	O
kept	O
in	O
the	O
Study	O
Master	O
File	O
.	O

Data	O
will	O
only	O
be	O
handled	O
by	O
senior	O
trust	O
staff	O
who	O
are	O
DBS	O
checked	O
and	O
will	O
comply	O
with	O
the	O
Data	O
protection	O
act	O
and	O
Information	O
Governance	O
policy	O
of	O
the	O
trust	O
.	O

All	O
data	O
will	O
be	O
completely	O
anonymised	O
for	O
subsequent	O
graphical	O
and	O
statistical	O
analyses	O
.	O

Southern	O
Health	O
NHS	O
Foundation	O
Trust	O
is	O
the	O
sponsor	O
for	O
the	O
study	O
and	O
,	O
therefore	O
,	O
has	O
overall	O
responsibility	O
for	O
the	O
study	O
along	O
with	O
the	O
Chief	O
Investigator	O
(	O
CI	O
)	O
.	O

Following	O
groups	O
govern	O
the	O
conduct	O
of	O
this	O
study	O
:	O
Psychosis	O
pathway	O
steering	O
group	O
:	O
This	O
group	O
is	O
chaired	O
by	O
the	O
first	O
author	O
who	O
is	O
also	O
CI	O
of	O
the	O
study	O
.	O

The	O
membership	O
includes	O
key	O
stakeholders	O
,	O
including	O
clinicians	O
,	O
managers	O
,	O
patient	O
representative	O
,	O
commissioners	O
,	O
Healthwatch	O
representative	O
,	O
pathway	O
facilitator	O
,	O
a	O
primary	O
care	O
representative	O
and	O
a	O
representative	O
from	O
the	O
AHSN	O
.	O

Key	O
strategies	O
for	O
successful	O
implementation	O
and	O
monitoring	O
are	O
planned	O
in	O
this	O
group	O
.	O

Data	O
Monitoring	O
and	O
Ethics	O
group	O
:	O
This	O
group	O
is	O
attended	O
by	O
the	O
CI	O
,	O
pathway	O
facilitator	O
,	O
a	O
representative	O
from	O
AHSN	O
,	O
research	O
department	O
manager	O
,	O
statistician	O
and	O
study	O
manager	O
.	O

Data	O
and	O
ethics	O
of	O
the	O
study	O
are	O
discussed	O
in	O
this	O
group	O
.	O

Study	O
management	O
group	O
:	O
This	O
group	O
is	O
attended	O
by	O
the	O
study	O
team	O
,	O
including	O
CI	O
,	O
study	O
manager	O
,	O
research	O
facilitators	O
,	O
pathway	O
facilitator	O
,	O
representatives	O
from	O
the	O
participant	O
sites	O
,	O
including	O
principal	O
investigators	O
and	O
trial	O
facilitators	O
.	O

The	O
Study	O
Management	O
Group	O
oversees	O
the	O
day	O
-	O
to	O
-	O
day	O
management	O
of	O
the	O
study	O
.	O

Psychosis	O
pathway	O
steering	O
group	O
:	O
This	O
group	O
is	O
chaired	O
by	O
the	O
first	O
author	O
who	O
is	O
also	O
CI	O
of	O
the	O
study	O
.	O

The	O
membership	O
includes	O
key	O
stakeholders	O
,	O
including	O
clinicians	O
,	O
managers	O
,	O
patient	O
representative	O
,	O
commissioners	O
,	O
Healthwatch	O
representative	O
,	O
pathway	O
facilitator	O
,	O
a	O
primary	O
care	O
representative	O
and	O
a	O
representative	O
from	O
the	O
AHSN	O
.	O

Key	O
strategies	O
for	O
successful	O
implementation	O
and	O
monitoring	O
are	O
planned	O
in	O
this	O
group	O
.	O

Data	O
Monitoring	O
and	O
Ethics	O
group	O
:	O
This	O
group	O
is	O
attended	O
by	O
the	O
CI	O
,	O
pathway	O
facilitator	O
,	O
a	O
representative	O
from	O
AHSN	O
,	O
research	O
department	O
manager	O
,	O
statistician	O
and	O
study	O
manager	O
.	O

Data	O
and	O
ethics	O
of	O
the	O
study	O
are	O
discussed	O
in	O
this	O
group	O
.	O

Study	O
management	O
group	O
:	O
This	O
group	O
is	O
attended	O
by	O
the	O
study	O
team	O
,	O
including	O
CI	O
,	O
study	O
manager	O
,	O
research	O
facilitators	O
,	O
pathway	O
facilitator	O
,	O
representatives	O
from	O
the	O
participant	O
sites	O
,	O
including	O
principal	O
investigators	O
and	O
trial	O
facilitators	O
.	O

The	O
Study	O
Management	O
Group	O
oversees	O
the	O
day	O
-	O
to	O
-	O
day	O
management	O
of	O
the	O
study	O
.	O

The	O
ethical	O
issues	O
in	O
this	O
study	O
will	O
be	O
related	O
to	O
the	O
identification	O
and	O
recruitment	O
of	O
patients	O
,	O
the	O
procedure	O
for	O
gaining	O
fully	O
informed	O
consent	O
and	O
data	O
protection	O
arrangements	O
.	O

Written	O
informed	O
consent	O
will	O
be	O
obtained	O
from	O
every	O
participant	O
.	O

Ethics	O
approval	O
for	O
this	O
study	O
was	O
obtained	O
from	O
East	O
of	O
Scotland	O
Research	O
Ethics	O
Service	O
(	O
EoSRES	O
)	O
(	O
REC	O
Ref	O
no	O
.	O

LR	O
/	O
15	O
/	O
ES	O
/	O
0091	O
)	O
.	O

This	O
study	O
complies	O
,	O
and	O
at	O
all	O
times	O
will	O
comply	O
,	O
with	O
The	O
Declaration	O
of	O
Helsinki	O
,	O
as	O
adopted	O
at	O
the	O
18th	O
World	O
Medical	O
Association	O
(	O
WMA	O
)	O
General	O
Assembly	O
,	O
Helsinki	O
,	O
Finland	O
,	O
1964	O
and	O
last	O
amended	O
at	O
the	O
64th	O
WMA	O
General	O
Assembly	O
,	O
Fortaleza	O
,	O
Brazil	O
,	O
October	O
2013	O
.	O

This	O
was	O
a	O
single	O
-	O
site	O
,	O
15	O
-	O
week	O
,	O
two	O
-	O
arm	O
,	O
external	O
pilot	O
RCT	O
.	O

Ethical	O
approval	O
for	O
the	O
protocol	O
was	O
granted	O
by	O
the	O
UK	O
National	O
Research	O
Ethics	O
Service	O
(	O
London	O
-	O
Fulham	O
Research	O
Ethics	O
Committee	O
:	O
153	O
/	O
LO	O
/	O
0656	O
)	O
.	O

The	O
study	O
is	O
registered	O
with	O
the	O
International	O
Standard	O
Randomised	O
Controlled	O
Trial	O
registry	O
(	O
ISRCTN164627831	O
)	O
.	O

The	O
research	O
questions	O
and	O
statistical	O
analysis	O
plan	O
were	O
pre	O
-	O
registered	O
with	O
the	O
Open	O
Science	O
Framework	O
(	O
Open	O
Science	O
Framework	O
,	O
2017	O
)	O
and	O
the	O
protocol	O
published	O
(	O
Marsden	O
et	O
al	O
.	O
,	O
2017b	O
)	O
.	O

Results	O
in	O
this	O
paper	O
are	O
reported	O
following	O
the	O
CONSORT	O
pilot	O
RCT	O
extension	O
(	O
Eldridge	O
et	O
al	O
.	O
,	O
2016	O
)	O
and	O
the	O
Template	O
for	O
Intervention	O
Description	O
and	O
Replication	O
(	O
Hoffmann	O
et	O
al	O
.	O
,	O
2014	O
)	O
.	O

All	O
participants	O
received	O
TAU	O
at	O
a	O
community	O
NHS	O
clinic	O
operated	O
by	O
South	O
London	O
and	O
Maudsley	O
NHS	O
Trust	O
(	O
the	O
clinic	O
,	O
herein	O
)	O
.	O

For	O
participants	O
with	O
primary	O
CUD	O
,	O
this	O
was	O
fortnightly	O
,	O
one	O
-	O
to	O
-	O
one	O
,	O
counselling	O
with	O
a	O
nurse	O
or	O
drug	O
worker	O
.	O

For	O
co	O
-	O
occurring	O
CUD	O
and	O
OUD	O
,	O
TAU	O
was	O
counselling	O
plus	O
opioid	O
agonist	O
maintenance	O
treatment	O
(	O
oral	O
methadone	O
,	O
buprenorphine	O
,	O
or	O
buprenorphine	O
-	O
naloxone	O
medication	O
)	O
.	O

All	O
assessments	O
and	O
follow	O
-	O
ups	O
were	O
done	O
face	O
-	O
to	O
-	O
face	O
in	O
a	O
private	O
interview	O
room	O
at	O
the	O
clinic	O
.	O

For	O
safety	O
reasons	O
(	O
and	O
to	O
facilitate	O
session	O
video	O
recording	O
)	O
the	O
cocaine	O
cue	O
-	O
induction	O
procedure	O
,	O
and	O
the	O
intensive	O
phase	O
of	O
MFCT	O
,	O
were	O
done	O
locally	O
at	O
the	O
outpatient	O
National	O
Institute	O
for	O
Health	O
Research	O
and	O
Wellcome	O
Trust	O
Clinical	O
Research	O
Facility	O
(	O
CRF	O
)	O
at	O
King	O
'	O
s	O
College	O
Hospital	O
,	O
London	O
.	O

Six	O
weeks	O
after	O
the	O
trial	O
started	O
,	O
we	O
secured	O
additional	O
funding	O
for	O
a	O
3	O
-	O
month	O
follow	O
-	O
up	O
and	O
relapse	O
prevention	O
session	O
.	O

Consent	O
materials	O
were	O
amended	O
after	O
securing	O
ethical	O
approval	O
.	O

This	O
was	O
implemented	O
in	O
time	O
for	O
all	O
participants	O
.	O

The	O
study	O
eligibility	O
criteria	O
were	O
:	O
(	O
1	O
)	O
age	O
≥	O
18	O
years	O
;	O
(	O
2	O
)	O
voluntarily	O
seeking	O
treatment	O
for	O
CUD	O
;	O
(	O
3	O
)	O
enrolled	O
in	O
TAU	O
for	O
≥14	O
days	O
;	O
(	O
4	O
)	O
current	O
(	O
any	O
)	O
use	O
of	O
cocaine	O
in	O
past	O
28	O
days	O
(	O
verified	O
by	O
clinical	O
record	O
)	O
;	O
and	O
(	O
5	O
)	O
sufficient	O
English	O
fluency	O
to	O
receive	O
psychosocial	O
therapy	O
.	O

The	O
exclusion	O
criteria	O
were	O
:	O
(	O
1	O
)	O
suicide	O
planning	O
in	O
the	O
past	O
month	O
,	O
or	O
suicide	O
attempt	O
in	O
the	O
past	O
six	O
months	O
;	O
(	O
2	O
)	O
uncontrolled	O
mental	O
or	O
physical	O
health	O
conditions	O
;	O
(	O
3	O
)	O
current	O
non	O
-	O
abstinent	O
alcohol	O
use	O
disorder	O
;	O
(	O
4	O
)	O
co	O
-	O
occurring	O
CUD	O
and	O
PTSD	O
;	O
(	O
5	O
)	O
legal	O
proceedings	O
risking	O
incarceration	O
;	O
(	O
6	O
)	O
participation	O
in	O
a	O
substance	O
use	O
disorder	O
treatment	O
study	O
in	O
the	O
past	O
three	O
months	O
.	O

All	O
participants	O
were	O
recruited	O
from	O
the	O
clinic	O
.	O

A	O
psychology	O
assistant	O
(	O
C	O
.	O
G	O
.	O
)	O
screened	O
participants	O
to	O
the	O
planned	O
rate	O
of	O
one	O
per	O
week	O
.	O

Patients	O
were	O
told	O
that	O
the	O
aim	O
was	O
to	O
evaluate	O
a	O
new	O
cognitive	O
therapy	O
for	O
CUD	O
;	O
that	O
all	O
participants	O
would	O
be	O
assessed	O
and	O
undergo	O
two	O
cocaine	O
cue	O
-	O
induction	O
procedures	O
,	O
with	O
a	O
randomly	O
-	O
selected	O
group	O
then	O
receiving	O
MFCT	O
.	O

All	O
participants	O
provided	O
their	O
written	O
informed	O
consent	O
.	O

A	O
senior	O
psychologist	O
(	O
J	O
.	O
M	O
.	O
)	O
diagnosed	O
CUD	B-phenotype
for	O
all	O
potential	O
participants	O
using	O
the	O
Structured	O
Clinical	O
Interview	O
for	O
DSM5	B-coding_system
(	O
SCID	O
(	O
First	O
et	O
al	O
.	O
,	O
2015	O
)	O
;	O
corresponding	O
to	O
categories	O
F14·10	B-code
and	O
F14·20	B-code
in	O
ICD	B-coding_system
-	I-coding_system
10	I-coding_system
)	O
.	O

Participants	O
then	O
completed	O
a	O
C	O
.	O
G	O
.	O
administered	O
,	O
1	O
-	O
h	O
,	O
baseline	O
interview	O
which	O
included	O
the	O
Treatment	O
Outcome	O
Profile	O
(	O
TOP	O
(	O
Sobell	O
&	O
Sobell	O
,	O
1996	O
)	O
;	O
a	O
‘timeline	O
follow	O
-	O
back’	O
structured	O
interview	O
to	O
record	O
each	O
day	O
of	O
cocaine	O
use	O
in	O
past	O
28	O
days	O
)	O
,	O
and	O
the	O
CEQ	O
-	O
F	O
(	O
recall	O
period	O
,	O
past	O
two	O
weeks	O
;	O
item	O
response	O
:	O
‘not	O
at	O
all’	O
to	O
‘constantly’	O
[	O
0−10	O
]	O
;	O
item	O
scores	O
summed	O
as	O
a	O
total	O
score	O
[	O
percentage	O
]	O
for	O
tabulation	O
.	O

After	O
completion	O
of	O
the	O
baseline	O
interview	O
,	O
all	O
participants	O
were	O
invited	O
to	O
attend	O
three	O
,	O
90	O
-	O
min	O
,	O
cognitive	O
conceptualisation	O
assessments	O
,	O
during	O
the	O
following	O
fortnight	O
.	O

The	O
aim	O
was	O
to	O
develop	O
a	O
functional	O
formulation	O
of	O
CUD	O
maintenance	O
,	O
focusing	O
on	O
recent	O
drug	O
use	O
situations	O
,	O
recalled	O
images	O
,	O
sensations	O
,	O
beliefs	O
/	O
appraisals	O
,	O
avoidance	O
/	O
coping	O
strategies	O
,	O
cocaine	O
use	O
and	O
post	O
-	O
drug	O
use	O
evaluations	O
.	O

These	O
sessions	O
were	O
facilitated	O
by	O
a	O
senior	O
psychologist	O
(	O
J	O
.	O
M	O
.	O

,	O
L	O
.	O
M	O
.	O
or	O
T	O
.	O
M	O
.	O
)	O
and	O
assisted	O
by	O
C	O
.	O
G	O
.	O

Session	O
audio	O
-	O
recording	O
was	O
by	O
consent	O
.	O

An	O
independent	O
clinician	O
rated	O
a	O
5	O
%	O
random	O
sample	O
of	O
recordings	O
from	O
different	O
participants	O
using	O
the	O
10	O
-	O
item	O
assessment	O
version	O
of	O
the	O
Cognitive	O
Therapy	O
Scale	O
-	O
Revised	O
(	O
CTS	O
-	O
R	O
)	O
(	O
Blackburn	O
et	O
al	O
.	O
,	O
2001	O
)	O
.	O

Between	O
the	O
first	O
and	O
second	O
assessment	O
,	O
each	O
participant	O
was	O
asked	O
to	O
:	O
(	O
1	O
)	O
take	O
point	O
-	O
of	O
-	O
view	O
digital	O
pictures	O
of	O
drug	O
-	O
associated	O
neutral	O
cues	O
(	O
e	O
.	O
g	O
.	O
street	O
corners	O
,	O
parks	O
,	O
pubs	O
/	O
bars	O
,	O
automated	O
teller	O
machines	O
[	O
ATM	O
]	O
,	O
bank	O
notes	O
,	O
lighters	O
,	O
hallways	O
,	O
chairs	O
and	O
tables	O
)	O
;	O
and	O
(	O
2	O
)	O
collect	O
a	O
selection	O
of	O
personal	O
cocaine	O
-	O
related	O
objects	O
(	O
e	O
.	O
g	O
.	O
used	O
drug	O
wraps	O
,	O
pipes	O
,	O
sealed	O
syringes	O
,	O
scrapers	O
[	O
for	O
collection	O
cocaine	O
residue	O
from	O
inside	O
pipes	O
]	O
,	O
cleaning	O
equipment	O
,	O
and	O
objects	O
used	O
to	O
sniff	O
cocaine	O
)	O
.	O

We	O
reviewed	O
pictures	O
taken	O
with	O
the	O
participant	O
and	O
agreed	O
which	O
ones	O
to	O
print	O
(	O
typically	O
four	O
-	O
eight	O
photographs	O
,	O
15	O
×	O
10	O
cm	O
)	O
,	O
and	O
which	O
objects	O
to	O
bring	O
in	O
(	O
typically	O
three	O
-	O
six	O
items	O
)	O
.	O

We	O
also	O
transcribed	O
the	O
participant	O
'	O
s	O
verbatim	O
description	O
of	O
a	O
recent	O
craving	O
experience	O
(	O
~	O
200	O
words	O
printed	O
on	O
A5	O
card	O
)	O
.	O

These	O
materials	O
were	O
placed	O
in	O
an	O
opaque	O
,	O
lidded	O
card	O
box	O
(	O
30	O
×	O
23	O
×	O
8cm	O
)	O
using	O
sheets	O
of	O
A4	O
card	O
to	O
separate	O
them	O
in	O
the	O
following	O
order	O
:	O
outdoor	O
photographs	O
at	O
the	O
top	O
,	O
then	O
craving	O
description	O
,	O
indoor	O
photographs	O
,	O
and	O
lastly	O
cocaine	O
-	O
related	O
objects	O
.	O

A	O
five	O
-	O
minute	O
audio	O
recording	O
of	O
the	O
participant	O
describing	O
craving	O
experiences	O
,	O
and	O
other	O
sounds	O
recalled	O
was	O
also	O
included	O
(	O
e	O
.	O
g	O
.	O

TV	O
show	O
often	O
watched	O
;	O
traffic	O
noise	O
;	O
music	O
playing	O
when	O
using	O
cocaine	O
)	O
.	O

At	O
the	O
end	O
of	O
the	O
third	O
cognitive	O
conceptualization	O
session	O
,	O
the	O
participant	O
was	O
assigned	O
(	O
1	O
:	O
1	O
)	O
to	O
the	O
control	O
or	O
the	O
intervention	O
group	O
,	O
using	O
a	O
web	O
-	O
accessed	O
,	O
computer	O
-	O
generated	O
random	O
sequence	O
(	O
with	O
random	O
varying	O
blocks	O
,	O
and	O
no	O
stratification	O
factors	O
)	O
independently	O
managed	O
by	O
the	O
King	O
'	O
s	O
College	O
London	O
Clinical	O
Trials	O
Unit	O
.	O

A	O
study	O
identification	O
number	O
and	O
the	O
participant	O
'	O
s	O
date	O
-	O
of	O
-	O
birth	O
was	O
entered	O
into	O
the	O
randomisation	O
system	O
by	O
C	O
.	O
G	O
.	O

It	O
was	O
not	O
feasible	O
to	O
mask	O
group	O
allocation	O
.	O

The	O
participant	O
was	O
immediately	O
informed	O
of	O
their	O
allocation	O
.	O

In	O
addition	O
to	O
continuing	O
TAU	O
,	O
we	O
invited	O
participants	O
in	O
the	O
control	O
group	O
to	O
attend	O
the	O
CRF	O
twice	O
(	O
on	O
Monday	O
and	O
Friday	O
)	O
to	O
complete	O
a	O
nine	O
-	O
minute	O
cocaine	O
cue	O
-	O
induction	O
procedure	O
and	O
research	O
measures	O
(	O
30	O
min	O
)	O
.	O

On	O
arrival	O
,	O
the	O
participant	O
was	O
asked	O
to	O
take	O
an	O
alcohol	O
breath	O
-	O
test	O
(	O
BACtrack	O
Mobile	O
Pro	O
;	O
www	O
.	O
bactrack	O
.	O
com	O
)	O
with	O
30	O
mg	O
/	O
ml	O
set	O
as	O
the	O
upper	O
limit	O
(	O
Peterson	O
et	O
al	O
.	O
,	O
1990	O
)	O
)	O
.	O

If	O
they	O
tested	O
above	O
this	O
limit	O
,	O
they	O
were	O
invited	O
to	O
wait	O
within	O
the	O
CRF	O
to	O
re	O
-	O
test	O
,	O
or	O
re	O
-	O
schedule	O
.	O

In	O
session	O
,	O
the	O
participant	O
was	O
asked	O
to	O
sit	O
at	O
a	O
table	O
in	O
a	O
private	O
room	O
.	O

The	O
closed	O
card	O
box	O
was	O
put	O
on	O
the	O
table	O
.	O

After	O
2	O
min	O
,	O
the	O
participant	O
was	O
asked	O
to	O
open	O
the	O
lid	O
and	O
,	O
for	O
the	O
next	O
5	O
min	O
,	O
to	O
retrieve	O
and	O
hold	O
each	O
item	O
in	O
turn	O
,	O
and	O
focus	O
on	O
any	O
images	O
,	O
sensations	O
and	O
emotions	O
elicited	O
(	O
see	O
protocol	O
for	O
full	O
description	O
(	O
Marsden	O
et	O
al	O
.	O
,	O
2017b	O
)	O
)	O
.	O

After	O
a	O
further	O
two	O
-	O
minutes	O
,	O
they	O
completed	O
the	O
strength	O
version	O
of	O
the	O
CEQ	O
for	O
cocaine	O
(	O
CEQ	O
-	O
S	O
;	O
recall	O
:	O
past	O
5	O
min	O
)	O
.	O

As	O
required	O
,	O
a	O
‘talk	O
down	O
/	O
attention	O
shift’	O
procedure	O
was	O
then	O
used	O
to	O
help	O
the	O
participant	O
return	O
any	O
elicited	O
craving	O
to	O
zero	O
,	O
or	O
to	O
a	O
level	O
no	O
higher	O
than	O
on	O
arrival	O
.	O

A	O
light	O
meal	O
was	O
provided	O
with	O
rest	O
for	O
30	O
min	O
.	O

After	O
completion	O
of	O
the	O
second	O
cue	O
-	O
induction	O
(	O
repeated	O
verbatim	O
)	O
,	O
each	O
participant	O
was	O
invited	O
to	O
attend	O
two	O
C	O
.	O
G	O
.	O
-	O
administered	O
,	O
30	O
-	O
minute	O
research	O
follow	O
-	O
ups	O
,	O
at	O
1	O
-	O
week	O
,	O
1	O
-	O
month	O
and	O
3	O
-	O
months	O
.	O

In	O
addition	O
to	O
continuing	O
TAU	O
,	O
we	O
invited	O
intervention	O
group	O
participants	O
to	O
complete	O
the	O
two	O
cue	O
-	O
inductions	O
(	O
as	O
described	O
in	O
Section	O
2	O
.	O
2	O
.	O

5	O
.	O
)	O
,	O
with	O
immediate	O
discussion	O
of	O
the	O
participant	O
'	O
s	O
interpretation	O
of	O
craving	O
-	O
related	O
images	O
and	O
emotions	O
to	O
guide	O
their	O
therapy	O
.	O

MFCT	O
was	O
five	O
,	O
120	O
-	O
minute	O
sessions	O
(	O
scheduled	O
on	O
consecutive	O
weekdays	O
)	O
and	O
two	O
60	O
-	O
minute	O
relapse	O
prevention	O
sessions	O
following	O
the	O
research	O
follow	O
-	O
ups	O
after	O
1	O
-	O
week	O
,	O
1	O
-	O
month	O
,	O
and	O
3	O
-	O
months	O
(	O
time	O
anchored	O
from	O
the	O
end	O
of	O
the	O
intensive	O
therapy	O
week	O
)	O
.	O

This	O
was	O
a	O
structured	O
one	O
-	O
to	O
-	O
one	O
intervention	O
(	O
therapist	O
'	O
s	O
manual	O
available	O
on	O
request	O
)	O
.	O

All	O
sessions	O
were	O
delivered	O
by	O
a	O
senior	O
psychologist	O
(	O
J	O
.	O
M	O
.	O

,	O
L	O
.	O
M	O
or	O
T	O
.	O
M	O
.	O
)	O
with	O
video	O
recording	O
by	O
consent	O
.	O

An	O
independent	O
clinician	O
rated	O
a	O
5	O
%	O
random	O
sample	O
of	O
recordings	O
from	O
different	O
participants	O
using	O
the	O
12	O
-	O
item	O
therapy	O
version	O
of	O
the	O
CTS	O
-	O
R	O
.	O

Ongoing	O
practice	O
reflection	O
was	O
by	O
clinical	O
supervision	O
as	O
well	O
as	O
clinical	O
practice	O
reviews	O
in	O
the	O
Trial	O
Management	O
Group	O
.	O

Treatment	O
included	O
education	O
about	O
cocaine	O
'	O
s	O
effects	O
on	O
thoughts	O
,	O
mood	O
and	O
behaviors	O
,	O
and	O
the	O
following	O
sequential	O
components	O
:	O
(	O
1	O
)	O
Hypothesis	O
of	O
SUD	O
maintenance	O
:	O
Drawing	O
on	O
detailed	O
descriptions	O
of	O
recent	O
cocaine	O
use	O
episodes	O
(	O
and	O
any	O
successful	O
episodes	O
in	O
which	O
craving	O
was	O
resisted	O
)	O
gathered	O
during	O
the	O
conceptualization	O
sessions	O
,	O
the	O
goal	O
of	O
this	O
component	O
was	O
to	O
identify	O
(	O
and	O
then	O
update	O
during	O
treatment	O
)	O
a	O
testable	O
,	O
idiosyncratic	O
theory	O
of	O
how	O
CUD	O
was	O
maintained	O
.	O

Unlike	O
the	O
memory	O
of	O
a	O
single	O
traumatic	O
event	O
,	O
CUD	O
patients	O
have	O
hundreds	O
of	O
different	O
cocaine	O
use	O
episodes	O
and	O
consolidated	O
memories	O
that	O
could	O
prevent	O
meaningful	O
synthesis	O
.	O

However	O
,	O
in	O
our	O
experience	O
most	O
patients	O
have	O
regular	O
and	O
repeating	O
patterns	O
of	O
drug	O
use	O
in	O
a	O
small	O
number	O
of	O
locations	O
.	O

In	O
most	O
cases	O
,	O
typical	O
recent	O
episodes	O
can	O
be	O
easily	O
identified	O
.	O

A	O
formulation	O
recorded	O
information	O
collected	O
by	O
Socratic	O
questioning	O
,	O
using	O
the	O
following	O
linked	O
model	O
:	O
A	O
.	O

Implicit	O
-	O
Autonomous	O
:	O
(	O
1	O
)	O
.	O

Associative	O
memory	O
representations	O
(	O
places	O
/	O
events	O
,	O
people	O
,	O
objects	O
,	O
sounds	O
,	O
sensations	O
,	O
smells	O
)	O
;	O
(	O
2	O
)	O
.	O

‘Fast’	O
thoughts	O
(	O
drug	O
-	O
related	O
low	O
-	O
level	O
cues	O
,	O
sensory	O
images	O
,	O
focus	O
of	O
attention	O
)	O
;	O
(	O
3	O
)	O
.	O

Autonomic	O
(	O
interoceptive	O
)	O
and	O
basic	O
emotion	O
(	O
breathing	O
,	O
heart	O
rate	O
,	O
sweating	O
,	O
surprise	O
,	O
gut	O
sensations	O
,	O
fear	O
,	O
anger	O
)	O
.	O

B	O
.	O

Explicit	O
-	O
Reflective	O
:	O
(	O
1	O
)	O
.	O

Episodic	O
/	O
autobiographical	O
/	O
declarative	O
memory	O
(	O
recall	O
of	O
events	O
,	O
knowledge	O
/	O
appraisal	O
of	O
self	O
and	O
facts	O
)	O
;	O
(	O
2	O
)	O
.	O

Controlled	O
attention	O
/	O
working	O
memory	O
(	O
elaboration	O
,	O
interpretation	O
,	O
conditional	O
/	O
instrumental	O
beliefs	O
[	O
rated	O
on	O
a	O
0–10	O
strength	O
scale	O
]	O
,	O
rules	O
)	O
;	O
(	O
3	O
)	O
.	O

Elaborated	O
cognition	O
and	O
autonomic	O
response	O
(	O
craving	O
[	O
desire	O
/	O
urge	O
using	O
the	O
language	O
and	O
concepts	O
used	O
by	O
the	O
patient	O
and	O
rated	O
on	O
a	O
0–10	O
strength	O
scale	O
]	O
,	O
ambivalence	O
,	O
physical	O
sensations	O
,	O
complex	O
emotion	O
)	O
.	O

C	O
.	O

Motivational	O
-	O
Behavioural	O
:	O
(	O
1	O
)	O
.	O

Plans	O
and	O
intentions	O
(	O
automatic	O
[	O
non	O
-	O
conflictual	O
]	O
,	O
deliberative	O
[	O
conflictual	O
]	O
,	O
drug	O
use	O
expectancies	O
)	O
;	O
(	O
2	O
)	O
.	O

Desistence	O
or	O
drug	O
-	O
approach	O
(	O
coping	O
strategies	O
,	O
drug	O
seeking	O
)	O
;	O
(	O
3	O
)	O
.	O

Cocaine	O
use	O
behaviors	O
(	O
preparation	O
ritual	O
,	O
consumption	O
,	O
actions	O
,	O
unwanted	O
behaviors	O
[	O
e	O
.	O
g	O
.	O
motor	O
stereotypy	O
]	O
,	O
complex	O
affect	O
[	O
e	O
.	O
g	O
.	O
suspiciousness	O
]	O
,	O
post	O
-	O
cocaine	O
use	O
evaluations	O
and	O
beliefs	O
)	O
.	O

The	O
aim	O
of	O
the	O
formulation	O
was	O
to	O
identify	O
episodes	O
with	O
the	O
strongest	O
craving	O
elaboration	O
linked	O
to	O
use	O
-	O
maintaining	O
beliefs	O
and	O
emotions	O
which	O
could	O
later	O
be	O
updated	O
with	O
an	O
alternative	O
appraisal	O
(	O
e	O
.	O
g	O
.	O
“cocaine	O
will	O
block	O
my	O
worries”	O
;	O
“cocaine	O
will	O
take	O
the	O
pain	O
away”	O
;	O
“using	O
will	O
stop	O
me	O
craving	O
and	O
I	O
won	O
'	O
t	O
want	O
more”	O
;	O
“the	O
quality	O
from	O
this	O
drug	O
seller	O
has	O
always	O
been	O
the	O
best”	O
;	O
“I	O
should	O
buy	O
more	O
crack	O
now	O
,	O
so	O
I	O
won	O
'	O
t	O
need	O
to	O
go	O
out	O
and	O
get	O
more”	O
)	O
.	O

(	O
2	O
)	O
Memory	O
reconsolidation	O
and	O
coping	O
strategies	O
:	O
The	O
treatment	O
goals	O
were	O
to	O
reconsolidate	O
memories	O
of	O
cocaine	O
use	O
,	O
tackle	O
maladaptive	O
beliefs	O
,	O
reduce	O
problematic	O
behaviors	O
and	O
support	O
coping	O
strategies	O
.	O

There	O
were	O
four	O
components	O
:	O
A	O
.	O

Socialising	O
:	O
(	O
1	O
)	O
.	O

Discussing	O
the	O
rationale	O
for	O
reliving	O
(	O
identifying	O
images	O
and	O
emotions	O
)	O
;	O
(	O
2	O
)	O
.	O

Reconstructing	O
the	O
structure	O
or	O
linear	O
sequence	O
of	O
a	O
target	O
memory	O
(	O
discussion	O
of	O
theory	O
that	O
cognitive	O
control	O
will	O
improve	O
if	O
the	O
memory	O
is	O
recalled	O
in	O
the	O
first	O
person	O
/	O
first	O
tense	O
and	O
then	O
updated	O
)	O
;	O
(	O
3	O
)	O
.	O

Stressing	O
the	O
safety	O
of	O
the	O
clinical	O
environment	O
for	O
reliving	O
(	O
importance	O
of	O
discriminating	O
then	O
from	O
now	O
thoughts	O
and	O
emotions	O
;	O
noticing	O
how	O
induced	O
desire	O
reduces	O
over	O
time	O
)	O
.	O

B	O
.	O

Eliciting	O
cocaine	O
memories	O
:	O
(	O
1	O
)	O
.	O

Therapist	O
-	O
guided	O
with	O
a	O
focus	O
on	O
sensory	O
detail	O
to	O
maximise	O
vividness	O
;	O
recording	O
craving	O
and	O
emotional	O
responses	O
[	O
rated	O
on	O
a	O
0–10	O
strength	O
scale	O
]	O
;	O
(	O
2	O
)	O
.	O

Reliving	O
of	O
elicited	O
memory	O
,	O
with	O
markers	O
for	O
the	O
start	O
and	O
end	O
of	O
the	O
memory	O
[	O
identifying	O
key	O
scenes	O
]	O
,	O
as	O
needed	O
and	O
focusing	O
on	O
emotional	O
‘hotspots’	O
,	O
sensory	O
images	O
and	O
meanings	O
[	O
e	O
.	O
g	O
.	O
“My	O
palms	O
are	O
sweaty	O
and	O
my	O
heart	O
is	O
pounding”	O
;	O
‘I	O
can	O
feel	O
the	O
wrap	O
of	O
cocaine	O
between	O
my	O
fingers”	O
;	O
“I	O
see	O
the	O
cloud	O
of	O
cocaine	O
in	O
front	O
of	O
me	O
as	O
I	O
exhale”	O
;	O
“I	O
am	O
pathetic	O
and	O
will	O
never	O
be	O
able	O
to	O
control	O
my	O
cravings”	O
]	O
.	O

This	O
is	O
comparable	O
to	O
the	O
identification	O
of	O
peri	O
-	O
traumatic	O
‘hotspot’	O
meanings	O
in	O
PTSD	O
fear	O
memory	O
(	O
Grey	O
et	O
al	O
.	O
,	O
2002	O
)	O
.	O

C	O
.	O

Cognitive	O
restructuring	O
and	O
imagery	O
re	O
-	O
scripting	O
:	O
(	O
1	O
)	O
.	O

In	O
vivo	O
exposure	O
to	O
personal	O
cocaine	O
-	O
related	O
objects	O
and	O
drug	O
-	O
related	O
photographs	O
(	O
patient	O
identification	O
of	O
alternative	O
appraisals	O
[	O
e	O
.	O
g	O
.	O
“that	O
'	O
s	O
just	O
a	O
street	O
corner	O
;	O
it	O
doesn	O
'	O
t	O
have	O
to	O
mean	O
drug	O
selling”	O
;	O
“that	O
'	O
s	O
just	O
a	O
plastic	O
bottle	O
;	O
it	O
doesn	O
'	O
t	O
have	O
to	O
mean	O
crack	O
smoking”	O
]	O
;	O
(	O
2	O
)	O
.	O

Cognitive	O
restructuring	O
outside	O
of	O
memory	O
reliving	O
(	O
e	O
.	O
g	O
.	O
discriminating	O
drug	O
-	O
neutral	O
and	O
drug	O
-	O
conditioned	O
triggers	O
:	O
“it	O
'	O
s	O
just	O
an	O
ATM	O
;	O
it	O
doesn	O
'	O
t	O
have	O
to	O
mean	O
a	O
source	O
of	O
money	O
for	O
cocaine”	O
]	O
;	O
evaluating	O
evidence	O
against	O
pro	O
-	O
drug	O
beliefs	O
and	O
alternative	O
perspectives	O
[	O
e	O
.	O
g	O
.	O
“using	O
cocaine	O
makes	O
my	O
worries	O
worse	O
not	O
better”	O
;	O
“actually	O
,	O
that	O
seller	O
often	O
has	O
rubbish	O
drugs”	O
]	O
;	O
(	O
3	O
)	O
.	O

Cognitive	O
restructuring	O
within	O
reliving	O
(	O
e	O
.	O
g	O
.	O
repeatedly	O
holding	O
an	O
image	O
in	O
mind	O
and	O
updating	O
with	O
new	O
information	O
or	O
an	O
alternative	O
appraisal	O
)	O
;	O
(	O
4	O
)	O
Repeated	O
imagery	O
re	O
-	O
scripting	O
by	O
manipulating	O
images	O
(	O
e	O
.	O
g	O
.	O
running	O
an	O
image	O
forward	O
from	O
desire	O
to	O
the	O
end	O
of	O
an	O
evening	O
when	O
the	O
cocaine	O
supply	O
is	O
exhausted	O
;	O
turning	O
away	O
from	O
approaching	O
a	O
seller	O
'	O
s	O
car	O
and	O
walking	O
home	O
;	O
bringing	O
to	O
mind	O
a	O
positive	O
sensory	O
image	O
)	O
.	O

D	O
.	O

Stopping	O
dysfunctional	O
behaviors	O
and	O
coping	O
strategies	O
:	O
(	O
1	O
)	O
.	O

Recovery	O
-	O
promoting	O
activities	O
(	O
cooking	O
a	O
meal	O
;	O
spending	O
time	O
with	O
family	O
members	O
;	O
listening	O
to	O
session	O
audio	O
recordings	O
;	O
keeping	O
a	O
diary	O
of	O
positive	O
experiences	O
)	O
;	O
(	O
2	O
)	O
.	O

Behavioural	O
experiments	O
(	O
engaging	O
in	O
new	O
or	O
dropped	O
social	O
activities	O
;	O
testing	O
reactions	O
when	O
in	O
cocaine	O
-	O
associated	O
places	O
;	O
holding	O
old	O
drug	O
paraphernalia	O
,	O
and	O
visiting	O
public	O
locations	O
related	O
to	O
drug	O
use	O
;	O
(	O
3	O
)	O
.	O

Applying	O
coping	O
strategies	O
(	O
responding	O
to	O
craving	O
by	O
noticing	O
images	O
,	O
sensations	O
and	O
emotions	O
,	O
and	O
acknowledging	O
these	O
as	O
normal	O
responses	O
to	O
a	O
memory	O
,	O
but	O
then	O
shifting	O
attention	O
[	O
e	O
.	O
g	O
.	O
changing	O
the	O
topic	O
of	O
conversation	O
;	O
brining	O
to	O
mind	O
an	O
alternative	O
sensory	O
image	O
]	O
)	O
.	O

Hypothesis	O
of	O
SUD	O
maintenance	O
:	O
Drawing	O
on	O
detailed	O
descriptions	O
of	O
recent	O
cocaine	O
use	O
episodes	O
(	O
and	O
any	O
successful	O
episodes	O
in	O
which	O
craving	O
was	O
resisted	O
)	O
gathered	O
during	O
the	O
conceptualization	O
sessions	O
,	O
the	O
goal	O
of	O
this	O
component	O
was	O
to	O
identify	O
(	O
and	O
then	O
update	O
during	O
treatment	O
)	O
a	O
testable	O
,	O
idiosyncratic	O
theory	O
of	O
how	O
CUD	O
was	O
maintained	O
.	O

Unlike	O
the	O
memory	O
of	O
a	O
single	O
traumatic	O
event	O
,	O
CUD	O
patients	O
have	O
hundreds	O
of	O
different	O
cocaine	O
use	O
episodes	O
and	O
consolidated	O
memories	O
that	O
could	O
prevent	O
meaningful	O
synthesis	O
.	O

However	O
,	O
in	O
our	O
experience	O
most	O
patients	O
have	O
regular	O
and	O
repeating	O
patterns	O
of	O
drug	O
use	O
in	O
a	O
small	O
number	O
of	O
locations	O
.	O

In	O
most	O
cases	O
,	O
typical	O
recent	O
episodes	O
can	O
be	O
easily	O
identified	O
.	O

A	O
formulation	O
recorded	O
information	O
collected	O
by	O
Socratic	O
questioning	O
,	O
using	O
the	O
following	O
linked	O
model	O
:	O
A	O
.	O

Implicit	O
-	O
Autonomous	O
:	O
(	O
1	O
)	O
.	O

Associative	O
memory	O
representations	O
(	O
places	O
/	O
events	O
,	O
people	O
,	O
objects	O
,	O
sounds	O
,	O
sensations	O
,	O
smells	O
)	O
;	O
(	O
2	O
)	O
.	O

‘Fast’	O
thoughts	O
(	O
drug	O
-	O
related	O
low	O
-	O
level	O
cues	O
,	O
sensory	O
images	O
,	O
focus	O
of	O
attention	O
)	O
;	O
(	O
3	O
)	O
.	O

Autonomic	O
(	O
interoceptive	O
)	O
and	O
basic	O
emotion	O
(	O
breathing	O
,	O
heart	O
rate	O
,	O
sweating	O
,	O
surprise	O
,	O
gut	O
sensations	O
,	O
fear	O
,	O
anger	O
)	O
.	O

B	O
.	O

Explicit	O
-	O
Reflective	O
:	O
(	O
1	O
)	O
.	O

Episodic	O
/	O
autobiographical	O
/	O
declarative	O
memory	O
(	O
recall	O
of	O
events	O
,	O
knowledge	O
/	O
appraisal	O
of	O
self	O
and	O
facts	O
)	O
;	O
(	O
2	O
)	O
.	O

Controlled	O
attention	O
/	O
working	O
memory	O
(	O
elaboration	O
,	O
interpretation	O
,	O
conditional	O
/	O
instrumental	O
beliefs	O
[	O
rated	O
on	O
a	O
0–10	O
strength	O
scale	O
]	O
,	O
rules	O
)	O
;	O
(	O
3	O
)	O
.	O

Elaborated	O
cognition	O
and	O
autonomic	O
response	O
(	O
craving	O
[	O
desire	O
/	O
urge	O
using	O
the	O
language	O
and	O
concepts	O
used	O
by	O
the	O
patient	O
and	O
rated	O
on	O
a	O
0–10	O
strength	O
scale	O
]	O
,	O
ambivalence	O
,	O
physical	O
sensations	O
,	O
complex	O
emotion	O
)	O
.	O

C	O
.	O

Motivational	O
-	O
Behavioural	O
:	O
(	O
1	O
)	O
.	O

Plans	O
and	O
intentions	O
(	O
automatic	O
[	O
non	O
-	O
conflictual	O
]	O
,	O
deliberative	O
[	O
conflictual	O
]	O
,	O
drug	O
use	O
expectancies	O
)	O
;	O
(	O
2	O
)	O
.	O

Desistence	O
or	O
drug	O
-	O
approach	O
(	O
coping	O
strategies	O
,	O
drug	O
seeking	O
)	O
;	O
(	O
3	O
)	O
.	O

Cocaine	O
use	O
behaviors	O
(	O
preparation	O
ritual	O
,	O
consumption	O
,	O
actions	O
,	O
unwanted	O
behaviors	O
[	O
e	O
.	O
g	O
.	O
motor	O
stereotypy	O
]	O
,	O
complex	O
affect	O
[	O
e	O
.	O
g	O
.	O
suspiciousness	O
]	O
,	O
post	O
-	O
cocaine	O
use	O
evaluations	O
and	O
beliefs	O
)	O
.	O

The	O
aim	O
of	O
the	O
formulation	O
was	O
to	O
identify	O
episodes	O
with	O
the	O
strongest	O
craving	O
elaboration	O
linked	O
to	O
use	O
-	O
maintaining	O
beliefs	O
and	O
emotions	O
which	O
could	O
later	O
be	O
updated	O
with	O
an	O
alternative	O
appraisal	O
(	O
e	O
.	O
g	O
.	O
“cocaine	O
will	O
block	O
my	O
worries”	O
;	O
“cocaine	O
will	O
take	O
the	O
pain	O
away”	O
;	O
“using	O
will	O
stop	O
me	O
craving	O
and	O
I	O
won	O
'	O
t	O
want	O
more”	O
;	O
“the	O
quality	O
from	O
this	O
drug	O
seller	O
has	O
always	O
been	O
the	O
best”	O
;	O
“I	O
should	O
buy	O
more	O
crack	O
now	O
,	O
so	O
I	O
won	O
'	O
t	O
need	O
to	O
go	O
out	O
and	O
get	O
more”	O
)	O
.	O

Implicit	O
-	O
Autonomous	O
:	O
(	O
1	O
)	O
.	O

Associative	O
memory	O
representations	O
(	O
places	O
/	O
events	O
,	O
people	O
,	O
objects	O
,	O
sounds	O
,	O
sensations	O
,	O
smells	O
)	O
;	O
(	O
2	O
)	O
.	O

‘Fast’	O
thoughts	O
(	O
drug	O
-	O
related	O
low	O
-	O
level	O
cues	O
,	O
sensory	O
images	O
,	O
focus	O
of	O
attention	O
)	O
;	O
(	O
3	O
)	O
.	O

Autonomic	O
(	O
interoceptive	O
)	O
and	O
basic	O
emotion	O
(	O
breathing	O
,	O
heart	O
rate	O
,	O
sweating	O
,	O
surprise	O
,	O
gut	O
sensations	O
,	O
fear	O
,	O
anger	O
)	O
.	O

Explicit	O
-	O
Reflective	O
:	O
(	O
1	O
)	O
.	O

Episodic	O
/	O
autobiographical	O
/	O
declarative	O
memory	O
(	O
recall	O
of	O
events	O
,	O
knowledge	O
/	O
appraisal	O
of	O
self	O
and	O
facts	O
)	O
;	O
(	O
2	O
)	O
.	O

Controlled	O
attention	O
/	O
working	O
memory	O
(	O
elaboration	O
,	O
interpretation	O
,	O
conditional	O
/	O
instrumental	O
beliefs	O
[	O
rated	O
on	O
a	O
0–10	O
strength	O
scale	O
]	O
,	O
rules	O
)	O
;	O
(	O
3	O
)	O
.	O

Elaborated	O
cognition	O
and	O
autonomic	O
response	O
(	O
craving	O
[	O
desire	O
/	O
urge	O
using	O
the	O
language	O
and	O
concepts	O
used	O
by	O
the	O
patient	O
and	O
rated	O
on	O
a	O
0–10	O
strength	O
scale	O
]	O
,	O
ambivalence	O
,	O
physical	O
sensations	O
,	O
complex	O
emotion	O
)	O
.	O

Motivational	O
-	O
Behavioural	O
:	O
(	O
1	O
)	O
.	O

Plans	O
and	O
intentions	O
(	O
automatic	O
[	O
non	O
-	O
conflictual	O
]	O
,	O
deliberative	O
[	O
conflictual	O
]	O
,	O
drug	O
use	O
expectancies	O
)	O
;	O
(	O
2	O
)	O
.	O

Desistence	O
or	O
drug	O
-	O
approach	O
(	O
coping	O
strategies	O
,	O
drug	O
seeking	O
)	O
;	O
(	O
3	O
)	O
.	O

Cocaine	O
use	O
behaviors	O
(	O
preparation	O
ritual	O
,	O
consumption	O
,	O
actions	O
,	O
unwanted	O
behaviors	O
[	O
e	O
.	O
g	O
.	O
motor	O
stereotypy	O
]	O
,	O
complex	O
affect	O
[	O
e	O
.	O
g	O
.	O
suspiciousness	O
]	O
,	O
post	O
-	O
cocaine	O
use	O
evaluations	O
and	O
beliefs	O
)	O
.	O

The	O
aim	O
of	O
the	O
formulation	O
was	O
to	O
identify	O
episodes	O
with	O
the	O
strongest	O
craving	O
elaboration	O
linked	O
to	O
use	O
-	O
maintaining	O
beliefs	O
and	O
emotions	O
which	O
could	O
later	O
be	O
updated	O
with	O
an	O
alternative	O
appraisal	O
(	O
e	O
.	O
g	O
.	O
“cocaine	O
will	O
block	O
my	O
worries”	O
;	O
“cocaine	O
will	O
take	O
the	O
pain	O
away”	O
;	O
“using	O
will	O
stop	O
me	O
craving	O
and	O
I	O
won	O
'	O
t	O
want	O
more”	O
;	O
“the	O
quality	O
from	O
this	O
drug	O
seller	O
has	O
always	O
been	O
the	O
best”	O
;	O
“I	O
should	O
buy	O
more	O
crack	O
now	O
,	O
so	O
I	O
won	O
'	O
t	O
need	O
to	O
go	O
out	O
and	O
get	O
more”	O
)	O
.	O

Memory	O
reconsolidation	O
and	O
coping	O
strategies	O
:	O
The	O
treatment	O
goals	O
were	O
to	O
reconsolidate	O
memories	O
of	O
cocaine	O
use	O
,	O
tackle	O
maladaptive	O
beliefs	O
,	O
reduce	O
problematic	O
behaviors	O
and	O
support	O
coping	O
strategies	O
.	O

There	O
were	O
four	O
components	O
:	O
A	O
.	O

Socialising	O
:	O
(	O
1	O
)	O
.	O

Discussing	O
the	O
rationale	O
for	O
reliving	O
(	O
identifying	O
images	O
and	O
emotions	O
)	O
;	O
(	O
2	O
)	O
.	O

Reconstructing	O
the	O
structure	O
or	O
linear	O
sequence	O
of	O
a	O
target	O
memory	O
(	O
discussion	O
of	O
theory	O
that	O
cognitive	O
control	O
will	O
improve	O
if	O
the	O
memory	O
is	O
recalled	O
in	O
the	O
first	O
person	O
/	O
first	O
tense	O
and	O
then	O
updated	O
)	O
;	O
(	O
3	O
)	O
.	O

Stressing	O
the	O
safety	O
of	O
the	O
clinical	O
environment	O
for	O
reliving	O
(	O
importance	O
of	O
discriminating	O
then	O
from	O
now	O
thoughts	O
and	O
emotions	O
;	O
noticing	O
how	O
induced	O
desire	O
reduces	O
over	O
time	O
)	O
.	O

B	O
.	O

Eliciting	O
cocaine	O
memories	O
:	O
(	O
1	O
)	O
.	O

Therapist	O
-	O
guided	O
with	O
a	O
focus	O
on	O
sensory	O
detail	O
to	O
maximise	O
vividness	O
;	O
recording	O
craving	O
and	O
emotional	O
responses	O
[	O
rated	O
on	O
a	O
0–10	O
strength	O
scale	O
]	O
;	O
(	O
2	O
)	O
.	O

Reliving	O
of	O
elicited	O
memory	O
,	O
with	O
markers	O
for	O
the	O
start	O
and	O
end	O
of	O
the	O
memory	O
[	O
identifying	O
key	O
scenes	O
]	O
,	O
as	O
needed	O
and	O
focusing	O
on	O
emotional	O
‘hotspots’	O
,	O
sensory	O
images	O
and	O
meanings	O
[	O
e	O
.	O
g	O
.	O
“My	O
palms	O
are	O
sweaty	O
and	O
my	O
heart	O
is	O
pounding”	O
;	O
‘I	O
can	O
feel	O
the	O
wrap	O
of	O
cocaine	O
between	O
my	O
fingers”	O
;	O
“I	O
see	O
the	O
cloud	O
of	O
cocaine	O
in	O
front	O
of	O
me	O
as	O
I	O
exhale”	O
;	O
“I	O
am	O
pathetic	O
and	O
will	O
never	O
be	O
able	O
to	O
control	O
my	O
cravings”	O
]	O
.	O

This	O
is	O
comparable	O
to	O
the	O
identification	O
of	O
peri	O
-	O
traumatic	O
‘hotspot’	O
meanings	O
in	O
PTSD	O
fear	O
memory	O
(	O
Grey	O
et	O
al	O
.	O
,	O
2002	O
)	O
.	O

C	O
.	O

Cognitive	O
restructuring	O
and	O
imagery	O
re	O
-	O
scripting	O
:	O
(	O
1	O
)	O
.	O

In	O
vivo	O
exposure	O
to	O
personal	O
cocaine	O
-	O
related	O
objects	O
and	O
drug	O
-	O
related	O
photographs	O
(	O
patient	O
identification	O
of	O
alternative	O
appraisals	O
[	O
e	O
.	O
g	O
.	O
“that	O
'	O
s	O
just	O
a	O
street	O
corner	O
;	O
it	O
doesn	O
'	O
t	O
have	O
to	O
mean	O
drug	O
selling”	O
;	O
“that	O
'	O
s	O
just	O
a	O
plastic	O
bottle	O
;	O
it	O
doesn	O
'	O
t	O
have	O
to	O
mean	O
crack	O
smoking”	O
]	O
;	O
(	O
2	O
)	O
.	O

Cognitive	O
restructuring	O
outside	O
of	O
memory	O
reliving	O
(	O
e	O
.	O
g	O
.	O
discriminating	O
drug	O
-	O
neutral	O
and	O
drug	O
-	O
conditioned	O
triggers	O
:	O
“it	O
'	O
s	O
just	O
an	O
ATM	O
;	O
it	O
doesn	O
'	O
t	O
have	O
to	O
mean	O
a	O
source	O
of	O
money	O
for	O
cocaine”	O
]	O
;	O
evaluating	O
evidence	O
against	O
pro	O
-	O
drug	O
beliefs	O
and	O
alternative	O
perspectives	O
[	O
e	O
.	O
g	O
.	O
“using	O
cocaine	O
makes	O
my	O
worries	O
worse	O
not	O
better”	O
;	O
“actually	O
,	O
that	O
seller	O
often	O
has	O
rubbish	O
drugs”	O
]	O
;	O
(	O
3	O
)	O
.	O

Cognitive	O
restructuring	O
within	O
reliving	O
(	O
e	O
.	O
g	O
.	O
repeatedly	O
holding	O
an	O
image	O
in	O
mind	O
and	O
updating	O
with	O
new	O
information	O
or	O
an	O
alternative	O
appraisal	O
)	O
;	O
(	O
4	O
)	O
Repeated	O
imagery	O
re	O
-	O
scripting	O
by	O
manipulating	O
images	O
(	O
e	O
.	O
g	O
.	O
running	O
an	O
image	O
forward	O
from	O
desire	O
to	O
the	O
end	O
of	O
an	O
evening	O
when	O
the	O
cocaine	O
supply	O
is	O
exhausted	O
;	O
turning	O
away	O
from	O
approaching	O
a	O
seller	O
'	O
s	O
car	O
and	O
walking	O
home	O
;	O
bringing	O
to	O
mind	O
a	O
positive	O
sensory	O
image	O
)	O
.	O

D	O
.	O

Stopping	O
dysfunctional	O
behaviors	O
and	O
coping	O
strategies	O
:	O
(	O
1	O
)	O
.	O

Recovery	O
-	O
promoting	O
activities	O
(	O
cooking	O
a	O
meal	O
;	O
spending	O
time	O
with	O
family	O
members	O
;	O
listening	O
to	O
session	O
audio	O
recordings	O
;	O
keeping	O
a	O
diary	O
of	O
positive	O
experiences	O
)	O
;	O
(	O
2	O
)	O
.	O

Behavioural	O
experiments	O
(	O
engaging	O
in	O
new	O
or	O
dropped	O
social	O
activities	O
;	O
testing	O
reactions	O
when	O
in	O
cocaine	O
-	O
associated	O
places	O
;	O
holding	O
old	O
drug	O
paraphernalia	O
,	O
and	O
visiting	O
public	O
locations	O
related	O
to	O
drug	O
use	O
;	O
(	O
3	O
)	O
.	O

Applying	O
coping	O
strategies	O
(	O
responding	O
to	O
craving	O
by	O
noticing	O
images	O
,	O
sensations	O
and	O
emotions	O
,	O
and	O
acknowledging	O
these	O
as	O
normal	O
responses	O
to	O
a	O
memory	O
,	O
but	O
then	O
shifting	O
attention	O
[	O
e	O
.	O
g	O
.	O
changing	O
the	O
topic	O
of	O
conversation	O
;	O
brining	O
to	O
mind	O
an	O
alternative	O
sensory	O
image	O
]	O
)	O
.	O

Socialising	O
:	O
(	O
1	O
)	O
.	O

Discussing	O
the	O
rationale	O
for	O
reliving	O
(	O
identifying	O
images	O
and	O
emotions	O
)	O
;	O
(	O
2	O
)	O
.	O

Reconstructing	O
the	O
structure	O
or	O
linear	O
sequence	O
of	O
a	O
target	O
memory	O
(	O
discussion	O
of	O
theory	O
that	O
cognitive	O
control	O
will	O
improve	O
if	O
the	O
memory	O
is	O
recalled	O
in	O
the	O
first	O
person	O
/	O
first	O
tense	O
and	O
then	O
updated	O
)	O
;	O
(	O
3	O
)	O
.	O

Stressing	O
the	O
safety	O
of	O
the	O
clinical	O
environment	O
for	O
reliving	O
(	O
importance	O
of	O
discriminating	O
then	O
from	O
now	O
thoughts	O
and	O
emotions	O
;	O
noticing	O
how	O
induced	O
desire	O
reduces	O
over	O
time	O
)	O
.	O

Eliciting	O
cocaine	O
memories	O
:	O
(	O
1	O
)	O
.	O

Therapist	O
-	O
guided	O
with	O
a	O
focus	O
on	O
sensory	O
detail	O
to	O
maximise	O
vividness	O
;	O
recording	O
craving	O
and	O
emotional	O
responses	O
[	O
rated	O
on	O
a	O
0–10	O
strength	O
scale	O
]	O
;	O
(	O
2	O
)	O
.	O

Reliving	O
of	O
elicited	O
memory	O
,	O
with	O
markers	O
for	O
the	O
start	O
and	O
end	O
of	O
the	O
memory	O
[	O
identifying	O
key	O
scenes	O
]	O
,	O
as	O
needed	O
and	O
focusing	O
on	O
emotional	O
‘hotspots’	O
,	O
sensory	O
images	O
and	O
meanings	O
[	O
e	O
.	O
g	O
.	O
“My	O
palms	O
are	O
sweaty	O
and	O
my	O
heart	O
is	O
pounding”	O
;	O
‘I	O
can	O
feel	O
the	O
wrap	O
of	O
cocaine	O
between	O
my	O
fingers”	O
;	O
“I	O
see	O
the	O
cloud	O
of	O
cocaine	O
in	O
front	O
of	O
me	O
as	O
I	O
exhale”	O
;	O
“I	O
am	O
pathetic	O
and	O
will	O
never	O
be	O
able	O
to	O
control	O
my	O
cravings”	O
]	O
.	O

This	O
is	O
comparable	O
to	O
the	O
identification	O
of	O
peri	O
-	O
traumatic	O
‘hotspot’	O
meanings	O
in	O
PTSD	O
fear	O
memory	O
(	O
Grey	O
et	O
al	O
.	O
,	O
2002	O
)	O
.	O

Cognitive	O
restructuring	O
and	O
imagery	O
re	O
-	O
scripting	O
:	O
(	O
1	O
)	O
.	O

In	O
vivo	O
exposure	O
to	O
personal	O
cocaine	O
-	O
related	O
objects	O
and	O
drug	O
-	O
related	O
photographs	O
(	O
patient	O
identification	O
of	O
alternative	O
appraisals	O
[	O
e	O
.	O
g	O
.	O
“that	O
'	O
s	O
just	O
a	O
street	O
corner	O
;	O
it	O
doesn	O
'	O
t	O
have	O
to	O
mean	O
drug	O
selling”	O
;	O
“that	O
'	O
s	O
just	O
a	O
plastic	O
bottle	O
;	O
it	O
doesn	O
'	O
t	O
have	O
to	O
mean	O
crack	O
smoking”	O
]	O
;	O
(	O
2	O
)	O
.	O

Cognitive	O
restructuring	O
outside	O
of	O
memory	O
reliving	O
(	O
e	O
.	O
g	O
.	O
discriminating	O
drug	O
-	O
neutral	O
and	O
drug	O
-	O
conditioned	O
triggers	O
:	O
“it	O
'	O
s	O
just	O
an	O
ATM	O
;	O
it	O
doesn	O
'	O
t	O
have	O
to	O
mean	O
a	O
source	O
of	O
money	O
for	O
cocaine”	O
]	O
;	O
evaluating	O
evidence	O
against	O
pro	O
-	O
drug	O
beliefs	O
and	O
alternative	O
perspectives	O
[	O
e	O
.	O
g	O
.	O
“using	O
cocaine	O
makes	O
my	O
worries	O
worse	O
not	O
better”	O
;	O
“actually	O
,	O
that	O
seller	O
often	O
has	O
rubbish	O
drugs”	O
]	O
;	O
(	O
3	O
)	O
.	O

Cognitive	O
restructuring	O
within	O
reliving	O
(	O
e	O
.	O
g	O
.	O
repeatedly	O
holding	O
an	O
image	O
in	O
mind	O
and	O
updating	O
with	O
new	O
information	O
or	O
an	O
alternative	O
appraisal	O
)	O
;	O
(	O
4	O
)	O
Repeated	O
imagery	O
re	O
-	O
scripting	O
by	O
manipulating	O
images	O
(	O
e	O
.	O
g	O
.	O
running	O
an	O
image	O
forward	O
from	O
desire	O
to	O
the	O
end	O
of	O
an	O
evening	O
when	O
the	O
cocaine	O
supply	O
is	O
exhausted	O
;	O
turning	O
away	O
from	O
approaching	O
a	O
seller	O
'	O
s	O
car	O
and	O
walking	O
home	O
;	O
bringing	O
to	O
mind	O
a	O
positive	O
sensory	O
image	O
)	O
.	O

Stopping	O
dysfunctional	O
behaviors	O
and	O
coping	O
strategies	O
:	O
(	O
1	O
)	O
.	O

Recovery	O
-	O
promoting	O
activities	O
(	O
cooking	O
a	O
meal	O
;	O
spending	O
time	O
with	O
family	O
members	O
;	O
listening	O
to	O
session	O
audio	O
recordings	O
;	O
keeping	O
a	O
diary	O
of	O
positive	O
experiences	O
)	O
;	O
(	O
2	O
)	O
.	O

Behavioural	O
experiments	O
(	O
engaging	O
in	O
new	O
or	O
dropped	O
social	O
activities	O
;	O
testing	O
reactions	O
when	O
in	O
cocaine	O
-	O
associated	O
places	O
;	O
holding	O
old	O
drug	O
paraphernalia	O
,	O
and	O
visiting	O
public	O
locations	O
related	O
to	O
drug	O
use	O
;	O
(	O
3	O
)	O
.	O

Applying	O
coping	O
strategies	O
(	O
responding	O
to	O
craving	O
by	O
noticing	O
images	O
,	O
sensations	O
and	O
emotions	O
,	O
and	O
acknowledging	O
these	O
as	O
normal	O
responses	O
to	O
a	O
memory	O
,	O
but	O
then	O
shifting	O
attention	O
[	O
e	O
.	O
g	O
.	O
changing	O
the	O
topic	O
of	O
conversation	O
;	O
brining	O
to	O
mind	O
an	O
alternative	O
sensory	O
image	O
]	O
)	O
.	O

The	O
primary	O
outcome	O
measure	O
was	O
the	O
percentage	O
total	O
score	O
on	O
the	O
CEQ	O
-	O
F	O
at	O
1	O
-	O
month	O
follow	O
-	O
up	O
.	O

There	O
were	O
two	O
secondary	O
cocaine	O
use	O
outcomes	O
.	O

Here	O
,	O
there	O
is	O
no	O
gold	O
-	O
standard	O
,	O
primary	O
drug	O
use	O
endpoint	O
for	O
CUD	O
treatment	O
trials	O
.	O

It	O
is	O
not	O
possible	O
to	O
reliably	O
infer	O
the	O
quantity	O
of	O
cocaine	O
consumed	O
,	O
and	O
while	O
total	O
abstinence	O
is	O
sometimes	O
used	O
,	O
this	O
is	O
insensitive	O
to	O
the	O
response	O
profile	O
of	O
a	O
patient	O
who	O
is	O
almost	O
completely	O
abstinent	O
bar	O
a	O
few	O
lapses	O
.	O

However	O
,	O
the	O
count	O
of	O
abstinent	O
days	O
and	O
the	O
duration	O
of	O
continuous	O
abstinence	O
has	O
been	O
recommended	O
by	O
experts	O
(	O
Carroll	O
et	O
al	O
.	O
,	O
2014	O
)	O
and	O
has	O
been	O
recently	O
accepted	O
by	O
the	O
US	O
Food	O
and	O
Drug	O
Administration	O
as	O
clinically	O
meaningful	O
(	O
U	O
.	O
S	O
.	O

Food	O
&	O
Drug	O
Administration	O
,	O
n	O
.	O
d	O
.	O
)	O
.	O

Accordingly	O
,	O
secondary	O
cocaine	O
use	O
outcomes	O
at	O
1	O
-	O
month	O
follow	O
-	O
up	O
were	O
:	O
(	O
1	O
)	O
.	O

percentage	O
days	O
abstinent	O
(	O
PDA	O
)	O
;	O
and	O
(	O
2	O
)	O
.	O

the	O
longest	O
period	O
(	O
days	O
)	O
of	O
abstinence	O
(	O
LPA	O
)	O
in	O
the	O
prior	O
28	O
days	O
.	O

These	O
measures	O
were	O
derived	O
from	O
the	O
TOP	O
interview	O
.	O

The	O
CEQ	O
-	O
F	O
,	O
PDA	O
and	O
LPA	O
outcomes	O
were	O
also	O
recorded	O
at	O
the	O
3	O
-	O
month	O
follow	O
-	O
up	O
.	O

There	O
were	O
two	O
exploratory	O
outcomes	O
:	O
(	O
1	O
)	O
.	O

the	O
point	O
prevalence	O
for	O
cocaine	O
abstinence	O
by	O
cocaine	O
-	O
negative	O
urine	O
drug	O
screen	O
(	O
UDS	O
;	O
primary	O
metabolite	O
:	O
benzoylecgonine	O
;	O
www	O
.	O
concateno	O
.	O
com	O
;	O
detection	O
sensitivity	O
:	O
300	O
ng	O
/	O
ml	O
)	O
at	O
1	O
-	O
week	O
,	O
1	O
-	O
month	O
and	O
3	O
-	O
month	O
follow	O
-	O
up	O
.	O

Typically	O
,	O
among	O
regular	O
cocaine	O
users	O
,	O
benzoylecgonine	O
can	O
be	O
detected	O
for	O
approximately	O
seven	O
days	O
after	O
drug	O
use	O
(	O
Antivenins	O
et	O
al	O
.	O
,	O
2000	O
)	O
;	O
(	O
2	O
)	O
.	O

DSM5	B-coding_system
CUD	B-phenotype
early	O
remission	O
status	O
at	O
3	O
-	O
month	O
follow	O
-	O
up	O
.	O

We	O
hypothesised	O
that	O
:	O
H1	O
Study	O
attrition	O
will	O
not	O
exceed	O
20	O
%	O
in	O
each	O
arm	O
.	O

This	O
is	O
a	O
common	O
standard	O
for	O
RCTs	O
and	O
bias	O
assurance	O
in	O
evidence	O
-	O
based	O
medicine	O
(	O
Dumville	O
et	O
al	O
.	O
,	O
2006	O
)	O
.	O

H2	O
Therapist	O
practice	O
will	O
meet	O
clinical	O
standards	O
,	O
as	O
evidenced	O
by	O
a	O
random	O
5	O
%	O
sample	O
of	O
audio	O
recordings	O
independent	O
rated	O
and	O
reaching	O
at	O
least	O
a	O
score	O
of	O
3	O
on	O
each	O
item	O
of	O
the	O
assessment	O
and	O
therapy	O
versions	O
of	O
the	O
CTS	O
-	O
R	O
.	O

H3	O
No	O
>	O
40	O
%	O
of	O
participants	O
in	O
each	O
arm	O
of	O
the	O
trial	O
will	O
report	O
an	O
increase	O
in	O
craving	O
between	O
the	O
first	O
and	O
second	O
cocaine	O
cue	O
-	O
induction	O
procedure	O
greater	O
that	O
the	O
Minimally	O
Detectable	O
Change	O
(	O
MDC	O
)	O
for	O
the	O
CEQ	O
-	O
S	O
(	O
recall	O
period	O
:	O
past	O
5	O
min	O
)	O
.	O

We	O
set	O
the	O
40	O
%	O
threshold	O
from	O
the	O
relapse	O
rate	O
among	O
participants	O
in	O
a	O
recent	O
study	O
who	O
received	O
an	O
in	O
-	O
vivo	O
drug	O
cue	O
-	O
reactivity	O
exposure	O
(	O
Marissen	O
et	O
al	O
.	O
,	O
2007	O
)	O
.	O

H4	O
The	O
standardised	O
ES	O
for	O
the	O
primary	O
outcome	O
associated	O
with	O
the	O
experimental	O
group	O
will	O
be	O
not	O
<	O
0·31	O
.	O

This	O
is	O
the	O
meta	O
-	O
analysis	O
ES	O
for	O
CBT	O
as	O
an	O
adjunct	O
to	O
psychosocial	O
TAU	O
(	O
Magill	O
&	O
Ray	O
,	O
2009	O
)	O
.	O

H5	O
The	O
standardised	O
ES	O
for	O
secondary	O
cocaine	O
use	O
outcomes	O
associated	O
with	O
the	O
experimental	O
arm	O
will	O
be	O
not	O
<	O
0·15	O
.	O

This	O
is	O
the	O
estimate	O
of	O
effectiveness	O
for	O
CBT	O
on	O
reduced	O
cocaine	O
use	O
from	O
meta	O
-	O
analysis	O
(	O
Magill	O
&	O
Ray	O
,	O
2009	O
)	O
.	O

Study	O
attrition	O
will	O
not	O
exceed	O
20	O
%	O
in	O
each	O
arm	O
.	O

This	O
is	O
a	O
common	O
standard	O
for	O
RCTs	O
and	O
bias	O
assurance	O
in	O
evidence	O
-	O
based	O
medicine	O
(	O
Dumville	O
et	O
al	O
.	O
,	O
2006	O
)	O
.	O

Therapist	O
practice	O
will	O
meet	O
clinical	O
standards	O
,	O
as	O
evidenced	O
by	O
a	O
random	O
5	O
%	O
sample	O
of	O
audio	O
recordings	O
independent	O
rated	O
and	O
reaching	O
at	O
least	O
a	O
score	O
of	O
3	O
on	O
each	O
item	O
of	O
the	O
assessment	O
and	O
therapy	O
versions	O
of	O
the	O
CTS	O
-	O
R	O
.	O

No	O
>	O
40	O
%	O
of	O
participants	O
in	O
each	O
arm	O
of	O
the	O
trial	O
will	O
report	O
an	O
increase	O
in	O
craving	O
between	O
the	O
first	O
and	O
second	O
cocaine	O
cue	O
-	O
induction	O
procedure	O
greater	O
that	O
the	O
Minimally	O
Detectable	O
Change	O
(	O
MDC	O
)	O
for	O
the	O
CEQ	O
-	O
S	O
(	O
recall	O
period	O
:	O
past	O
5	O
min	O
)	O
.	O

We	O
set	O
the	O
40	O
%	O
threshold	O
from	O
the	O
relapse	O
rate	O
among	O
participants	O
in	O
a	O
recent	O
study	O
who	O
received	O
an	O
in	O
-	O
vivo	O
drug	O
cue	O
-	O
reactivity	O
exposure	O
(	O
Marissen	O
et	O
al	O
.	O
,	O
2007	O
)	O
.	O

The	O
standardised	O
ES	O
for	O
the	O
primary	O
outcome	O
associated	O
with	O
the	O
experimental	O
group	O
will	O
be	O
not	O
<	O
0·31	O
.	O

This	O
is	O
the	O
meta	O
-	O
analysis	O
ES	O
for	O
CBT	O
as	O
an	O
adjunct	O
to	O
psychosocial	O
TAU	O
(	O
Magill	O
&	O
Ray	O
,	O
2009	O
)	O
.	O

The	O
standardised	O
ES	O
for	O
secondary	O
cocaine	O
use	O
outcomes	O
associated	O
with	O
the	O
experimental	O
arm	O
will	O
be	O
not	O
<	O
0·15	O
.	O

This	O
is	O
the	O
estimate	O
of	O
effectiveness	O
for	O
CBT	O
on	O
reduced	O
cocaine	O
use	O
from	O
meta	O
-	O
analysis	O
(	O
Magill	O
&	O
Ray	O
,	O
2009	O
)	O
.	O

There	O
is	O
no	O
consensus	O
on	O
the	O
minimum	O
sample	O
size	O
for	O
an	O
external	O
pilot	O
RCT	O
.	O

This	O
is	O
usually	O
determined	O
by	O
the	O
expected	O
ES	O
and	O
available	O
resources	O
and	O
desired	O
timeline	O
.	O

We	O
expected	O
at	O
least	O
a	O
small	O
-	O
to	O
-	O
medium	O
ES	O
,	O
and	O
followed	O
the	O
principle	O
of	O
neither	O
over	O
-	O
or	O
under	O
-	O
estimating	O
the	O
variance	O
of	O
the	O
outcome	O
(	O
Kieser	O
&	O
Wassmer	O
,	O
1996	O
)	O
.	O

Following	O
expert	O
recommendations	O
for	O
pilot	O
RCTs	O
,	O
we	O
set	O
a	O
planned	O
sample	O
size	O
of	O
30	O
participants	O
to	O
be	O
randomised	O
(	O
Lancaster	O
et	O
al	O
.	O
,	O
2002	O
)	O
.	O

We	O
emphasise	O
that	O
a	O
sample	O
of	O
this	O
size	O
is	O
insufficient	O
to	O
demonstrate	O
efficacy	O
of	O
MFCT	O
and	O
the	O
reported	O
between	O
-	O
group	O
effect	O
sizes	O
on	O
outcome	O
measures	O
and	O
the	O
exploratory	O
analyses	O
must	O
be	O
viewed	O
as	O
preliminary	O
evidence	O
and	O
interpreted	O
with	O
caution	O
.	O

The	O
analysis	O
was	O
done	O
in	O
Stata	O
15	O
,	O
by	O
intention	O
-	O
to	O
-	O
treat	O
.	O

Demographic	O
,	O
treatment	O
exposure	O
and	O
outcome	O
measures	O
were	O
summarised	O
by	O
reporting	O
the	O
number	O
of	O
participants	O
(	O
with	O
percentage	O
)	O
for	O
categorical	O
variables	O
,	O
or	O
the	O
mean	O
(	O
with	O
standard	O
deviation	O
[	O
SD	O
]	O
)	O
or	O
median	O
(	O
inter	O
-	O
quartile	O
range	O
[	O
IQR	O
]	O
)	O
for	O
scale	O
or	O
count	O
measures	O
.	O

For	O
the	O
cue	O
-	O
induction	O
safety	O
assessment	O
(	O
H3	O
)	O
,	O
we	O
used	O
the	O
coefficient	O
of	O
reliability	O
for	O
CEQ	O
-	O
S	O
to	O
calculate	O
the	O
mean	O
standard	O
error	O
for	O
the	O
MDC	O
(	O
Bland	O
&	O
Altman	O
,	O
1986	O
)	O
.	O

For	O
the	O
preliminary	O
efficacy	O
analysis	O
,	O
the	O
primary	O
outcome	O
was	O
assessed	O
with	O
a	O
95	O
%	O
CI	O
.	O

The	O
secondary	O
and	O
exploratory	O
outcomes	O
were	O
assessed	O
using	O
a	O
90	O
%	O
and	O
80	O
%	O
CI	O
,	O
respectively	O
.	O

Differences	O
between	O
the	O
intervention	O
and	O
control	O
groups	O
were	O
estimated	O
by	O
bias	O
corrected	O
Hedge	O
'	O
s	O
g	O
ES	O
(	O
Hedges	O
&	O
Olkin	O
,	O
1985	O
)	O
)	O
.	O

As	O
a	O
summary	O
measure	O
of	O
within	O
-	O
subjects	O
change	O
from	O
baseline	O
to	O
follow	O
up	O
,	O
we	O
calculated	O
the	O
median	O
ES	O
for	O
the	O
control	O
group	O
and	O
reported	O
the	O
proportion	O
of	O
the	O
experimental	O
group	O
exceeding	O
this	O
(	O
Cohen	O
'	O
s	O
U	O
3	O
(	O
Cohen	O
,	O
1988	O
)	O
)	O
.	O

A	O
Bayes	O
Factor	O
was	O
also	O
calculated	O
to	O
show	O
evidence	O
for	O
the	O
null	O
or	O
the	O
alternate	O
hypothesis	O
.	O

This	O
is	O
equivalent	O
to	O
a	O
likelihood	O
ratio	O
,	O
with	O
a	O
value	O
of	O
<	O
0·3	O
or	O
≥3·0	O
indicating	O
that	O
the	O
null	O
or	O
alternate	O
hypothesis	O
is	O
correct	O
,	O
respectively	O
(	O
Berger	O
,	O
2013	O
)	O
.	O

A	O
value	O
between	O
0·3	O
and	O
3·0	O
indicates	O
that	O
the	O
data	O
are	O
insensitive	O
(	O
Beard	O
et	O
al	O
.	O
,	O
2016	O
)	O
.	O

An	O
online	O
calculator	O
was	O
used	O
(	O
Dienes	O
,	O
n	O
.	O
d	O
.	O
)	O
specifying	O
a	O
prior	O
ES	O
(	O
0·31	O
ES	O
from	O
meta	O
-	O
analysis	O
(	O
Magill	O
&	O
Ray	O
,	O
2009	O
)	O
)	O
,	O
and	O
a	O
conservative	O
half	O
-	O
normal	O
distribution	O
.	O

In	O
the	O
event	O
of	O
missing	O
craving	O
,	O
cocaine	O
use	O
and	O
UDS	O
assessments	O
at	O
the	O
endpoint	O
or	O
exploratory	O
outcome	O
data	O
and	O
DSM	B-coding_system
data	O
at	O
the	O
3	O
-	O
month	O
follow	O
-	O
up	O
,	O
and	O
subject	O
to	O
a	O
check	O
on	O
missingness	O
assumptions	O
(	O
Little	O
'	O
s	O
mcartest	O
)	O
,	O
we	O
planned	O
a	O
multiple	O
imputation	O
procedure	O
using	O
the	O
Stata	O
commands	O
ice	O
and	O
uvis	O
to	O
generate	O
values	O
,	O
with	O
the	O
following	O
auxiliary	O
variables	O
:	O
sex	O
,	O
age	O
,	O
route	O
of	O
cocaine	O
administration	O
and	O
group	O
.	O

For	O
comparison	O
,	O
complete	O
case	O
results	O
are	O
shown	O
in	O
Table	O
S1	O
.	O

Subject	O
to	O
preliminary	O
efficacy	O
of	O
evidence	O
,	O
we	O
planned	O
a	O
multivariable	O
regression	O
analysis	O
with	O
sex	O
,	O
age	O
,	O
baseline	O
outcome	O
score	O
,	O
and	O
the	O
strongest	O
confounder	O
associated	O
with	O
the	O
primary	O
and	O
secondary	O
outcomes	O
(	O
by	O
ES	O
with	O
80	O
%	O
CI	O
)	O
.	O

In	O
addition	O
,	O
we	O
planned	O
to	O
screen	O
the	O
following	O
baseline	O
variables	O
:	O
months	O
of	O
regular	O
cocaine	O
use	O
;	O
oral	O
/	O
injecting	O
cocaine	O
administration	O
;	O
heroin	O
use	O
in	O
past	O
28	O
days	O
.	O

Multivariable	O
linear	O
regression	O
was	O
done	O
for	O
the	O
primary	O
outcome	O
and	O
Poisson	O
regression	O
for	O
the	O
secondary	O
outcomes	O
.	O

Standard	O
errors	O
were	O
estimated	O
by	O
bootstrapping	O
with	O
5000	O
replications	O
.	O

As	O
a	O
sensitivity	O
check	O
on	O
these	O
models	O
,	O
we	O
also	O
calculated	O
the	O
E	O
-	O
value	O
(	O
VanderWeele	O
&	O
Ding	O
,	O
2017	O
)	O
.	O

The	O
E	O
-	O
value	O
is	O
an	O
estimate	O
of	O
the	O
minimum	O
strength	O
of	O
association	O
that	O
an	O
unmeasured	O
confounder	O
would	O
need	O
to	O
account	O
for	O
a	O
treatment	O
-	O
outcome	O
association	O
,	O
conditional	O
on	O
the	O
included	O
covariates	O
.	O

When	O
computed	O
for	O
a	O
continuous	O
outcome	O
,	O
this	O
value	O
is	O
an	O
approximation	O
to	O
the	O
risk	O
ratio	O
scale	O
.	O

The	O
E	O
-	O
value	O
has	O
a	O
minimum	O
value	O
of	O
1	O
,	O
and	O
is	O
reported	O
alongside	O
a	O
risk	O
ratio	O
measure	O
of	O
its	O
uncertainty	O
,	O
which	O
quantifies	O
the	O
value	O
that	O
the	O
CI	O
for	O
the	O
association	O
would	O
need	O
to	O
shift	O
to	O
the	O
null	O
.	O

Finally	O
,	O
we	O
calculated	O
the	O
relative	O
risk	O
(	O
RR	O
)	O
for	O
negative	O
UDS	O
data	O
and	O
the	O
number	O
needed	O
to	O
treat	O
(	O
NNT	O
)	O
for	O
DSM5	B-coding_system
CUD	B-phenotype
remission	I-phenotype
in	I-phenotype
favour	I-phenotype
of	I-phenotype
MFCT	I-phenotype
.	O

All	O
adverse	O
events	O
were	O
recorded	O
and	O
classified	O
according	O
to	O
seriousness	O
and	O
the	O
likely	O
relationship	O
to	O
study	O
interventions	O
.	O

We	O
performed	O
secondary	O
analyses	O
using	O
data	O
from	O
a	O
pragmatic	O
RCT	O
comparing	O
TIMT	O
in	O
addition	O
to	O
TAU	O
following	O
inpatient	O
psychotherapy	O
to	O
TAU	O
only	O
(	O
N=400	O
)	O
[	O
15	O
]	O
.	O

The	O
RCT	O
was	O
conducted	O
in	O
a	O
German	O
clinic	O
providing	O
routine	O
mental	O
health	O
care	O
.	O

Study	O
outcomes	O
were	O
assessed	O
by	O
using	O
self	O
-	O
report	O
measures	O
that	O
were	O
completed	O
at	O
inpatient	O
admission	O
(	O
T1	O
)	O
,	O
end	O
of	O
inpatient	O
treatment	O
/	O
beginning	O
of	O
TIMT	O
(	O
T2	O
)	O
,	O
3	O
months	O
after	O
discharge	O
/	O
end	O
of	O
TIMT	O
(	O
T3	O
)	O
,	O
and	O
12	O
months	O
after	O
inpatient	O
treatment	O
completion	O
(	O
T4	O
)	O
.	O

The	O
study	O
was	O
powered	O
to	O
find	O
a	O
small	O
to	O
moderate	O
effect	O
size	O
in	O
the	O
main	O
effect	O
analyses	O
,	O
which	O
was	O
considered	O
to	O
be	O
the	O
smallest	O
relevant	O
difference	O
to	O
health	O
care	O
decision	O
makers	O
in	O
this	O
context	O
.	O

All	O
procedures	O
were	O
approved	O
by	O
the	O
university	O
and	O
the	O
hospital	O
institutional	O
review	O
boards	O
.	O

Design	O
and	O
results	O
of	O
the	O
effectiveness	O
trial	O
are	O
described	O
in	O
detail	O
in	O
a	O
previously	O
published	O
study	O
[	O
15	O
]	O
.	O

We	O
recruited	O
potential	O
participants	O
from	O
2189	O
patients	O
treated	O
for	O
a	O
variety	O
of	O
mental	O
disorders	O
between	O
July	O
2008	O
and	O
October	O
2009	O
in	O
the	O
study	O
hospital	O
.	O

Patients	O
were	O
eligible	O
for	O
the	O
study	O
if	O
they	O
(	O
1	O
)	O
were	O
age	O
18	O
years	O
or	O
older	O
,	O
(	O
2	O
)	O
met	O
criteria	O
for	O
a	O
mental	B-phenotype
disorder	I-phenotype
according	O
to	O
the	O
International	B-coding_system
Classification	I-coding_system
of	I-coding_system
Diseases	I-coding_system
,	I-coding_system
Tenth	I-coding_system
Revision	I-coding_system
(	I-coding_system
ICD	I-coding_system
-	I-coding_system
10	I-coding_system
)	I-coding_system
[	O
37	O
]	O
,	O
(	O
3	O
)	O
spoke	O
German	O
sufficiently	O
,	O
(	O
4	O
)	O
had	O
basic	O
reading	O
and	O
writing	O
skills	O
,	O
and	O
(	O
5	O
)	O
had	O
access	O
to	O
a	O
computer	O
with	O
an	O
Internet	O
connection	O
.	O

Exclusion	O
criteria	O
were	O
(	O
1	O
)	O
a	O
psychotic	O
diagnosis	O
,	O
(	O
2	O
)	O
acute	O
alcohol	O
or	O
substance	O
dependence	O
,	O
and	O
(	O
3	O
)	O
a	O
significant	O
risk	O
for	O
suicide	O
.	O

Participants	O
who	O
gave	O
full	O
written	O
informed	O
consent	O
were	O
randomly	O
assigned	O
to	O
receive	O
TAU	O
only	O
(	O
control	O
)	O
or	O
TAU	O
plus	O
TIMT	O
(	O
intervention	O
)	O
.	O

In	O
total	O
,	O
58	O
of	O
400	O
(	O
14	O
.	O
5	O
%	O
)	O
participants	O
did	O
not	O
complete	O
the	O
T3	O
assessment	O
and	O
113	O
(	O
28	O
.	O
5	O
%	O
)	O
did	O
not	O
complete	O
the	O
T4	O
assessment	O
.	O

Participants	O
who	O
did	O
not	O
provide	O
data	O
at	O
1	O
of	O
the	O
follow	O
-	O
ups	O
did	O
not	O
differ	O
from	O
participants	O
without	O
missing	O
data	O
on	O
baseline	O
psychopathological	O
symptom	O
severity	O
scores	O
or	O
any	O
other	O
clinical	O
characteristics	O
(	O
all	O
P	O
values	O
>	O
.	O
10	O
)	O
,	O
except	O
for	O
age	O
(	O
noncompleters	O
on	O
average	O
2	O
.	O
21	O
years	O
younger	O
than	O
completers	O
,	O
P	O
=	O
.	O
02	O
)	O
.	O

No	O
significant	O
interactions	O
were	O
found	O
between	O
missing	O
pattern	O
and	O
outcome	O
using	O
pattern	O
mixture	O
analyses	O
[	O
38	O
]	O
.	O

Thus	O
,	O
missing	O
data	O
appear	O
not	O
to	O
bias	O
the	O
results	O
.	O

Figure	O
1	O
summarizes	O
participant	O
enrollment	O
and	O
flow	O
throughout	O
the	O
study	O
[	O
15	O
]	O
.	O

Inpatient	O
treatment	O
was	O
based	O
on	O
CBT	O
[	O
39	O
]	O
.	O

Participants	O
received	O
1	O
session	O
of	O
individual	O
therapy	O
(	O
50	O
minutes	O
)	O
and	O
an	O
average	O
of	O
6	O
sessions	O
of	O
group	O
therapy	O
(	O
90	O
minutes	O
)	O
per	O
week	O
.	O

Interventions	O
were	O
supplemented	O
with	O
sports	O
therapy	O
and	O
physiotherapy	O
,	O
as	O
well	O
as	O
medical	O
treatment	O
(	O
including	O
pharmacotherapy	O
)	O
when	O
necessary	O
.	O

Treatment	O
was	O
delivered	O
by	O
6	O
experienced	O
therapists	O
and	O
14	O
therapists	O
in	O
training	O
.	O

Duration	O
of	O
treatment	O
ranged	O
between	O
22	O
and	O
98	O
days	O
(	O
mean	O
46	O
.	O
30	O
,	O
SD	O
8	O
.	O
17	O
)	O
.	O

Following	O
inpatient	O
treatment	O
,	O
all	O
participants	O
had	O
unstructured	O
access	O
to	O
outpatient	O
psychotherapy	O
and	O
standardized	O
outpatient	O
group	O
-	O
based	O
,	O
face	O
-	O
to	O
-	O
face	O
,	O
maintenance	O
treatment	O
[	O
40	O
]	O
as	O
typically	O
provided	O
by	O
the	O
referring	O
agencies	O
.	O

In	O
addition	O
,	O
there	O
was	O
no	O
restriction	O
on	O
the	O
use	O
of	O
medication	O
during	O
the	O
study	O
period	O
.	O

In	O
addition	O
to	O
TAU	O
,	O
the	O
intervention	O
group	O
had	O
TIMT	O
for	O
12	O
weeks	O
.	O

The	O
main	O
focus	O
of	O
TIMT	O
is	O
to	O
support	O
patients	O
in	O
the	O
sustained	O
utilization	O
of	O
skills	O
acquired	O
during	O
treatment	O
.	O

For	O
this	O
purpose	O
,	O
TIMT	O
works	O
to	O
help	O
participants	O
identify	O
activities	O
that	O
they	O
have	O
found	O
helpful	O
and	O
systematically	O
integrate	O
these	O
into	O
their	O
daily	O
life	O
routines	O
.	O

Because	O
TIMT	O
aims	O
to	O
enhance	O
whatever	O
strategy	O
patients	O
experienced	O
as	O
helpful	O
,	O
it	O
can	O
be	O
used	O
to	O
maintain	O
treatment	O
outcome	O
regardless	O
of	O
which	O
psychopathology	O
the	O
patient	O
is	O
suffering	O
from	O
and	O
regardless	O
of	O
the	O
kind	O
of	O
treatment	O
the	O
patient	O
received	O
before	O
.	O

TIMT	O
consists	O
of	O
5	O
core	O
components	O
.	O

The	O
first	O
component	O
is	O
the	O
generation	O
of	O
a	O
personal	O
development	O
plan	O
.	O

This	O
process	O
is	O
conducted	O
during	O
the	O
last	O
10	O
days	O
of	O
inpatient	O
treatment	O
in	O
which	O
TIMT	O
participants	O
complete	O
3	O
sessions	O
of	O
blended	O
(	O
face	O
-	O
to	O
-	O
face	O
and	O
online	O
)	O
standardized	O
goal	O
-	O
setting	O
and	O
action	O
planning	O
instead	O
of	O
inpatient	O
TAU	O
.	O

Participants	O
develop	O
a	O
detailed	O
plan	O
including	O
(	O
1	O
)	O
highly	O
relevant	O
personal	O
goals	O
they	O
want	O
to	O
achieve	O
during	O
the	O
intervention	O
phase	O
,	O
and	O
(	O
2	O
)	O
implementation	O
intentions	O
[	O
41	O
]	O
,	O
including	O
details	O
on	O
how	O
and	O
when	O
they	O
will	O
achieve	O
these	O
goals	O
.	O

The	O
second	O
and	O
central	O
component	O
of	O
TIMT	O
is	O
the	O
completion	O
of	O
a	O
structured	O
Web	O
diary	O
in	O
which	O
participants	O
evaluate	O
the	O
realization	O
of	O
their	O
personal	O
goals	O
weekly	O
and	O
set	O
specific	O
goals	O
for	O
the	O
next	O
week	O
.	O

The	O
third	O
component	O
of	O
TIMT	O
is	O
an	O
online	O
peer	O
support	O
group	O
.	O

Subgroups	O
consisting	O
of	O
3	O
to	O
6	O
participants	O
are	O
asked	O
to	O
give	O
asynchronous	O
online	O
feedback	O
to	O
one	O
another	O
on	O
their	O
Web	O
diaries	O
.	O

The	O
fourth	O
component	O
of	O
TIMT	O
is	O
coach	O
support	O
,	O
involving	O
weekly	O
asynchronous	O
written	O
online	O
feedback	O
from	O
a	O
therapist	O
regarding	O
a	O
participants’	O
Web	O
diary	O
.	O

Coaches	O
differed	O
in	O
their	O
level	O
of	O
formal	O
training	O
,	O
ranging	O
from	O
master’s	O
level	O
psychology	O
students	O
(	O
n=1	O
)	O
and	O
psychotherapists	O
-	O
in	O
-	O
training	O
(	O
n=1	O
)	O
to	O
experienced	O
CBT	O
-	O
trained	O
psychotherapists	O
with	O
more	O
than	O
10	O
years	O
of	O
professional	O
experience	O
(	O
n=3	O
)	O
.	O

Coaches	O
were	O
supervised	O
once	O
a	O
week	O
by	O
a	O
licensed	O
senior	O
therapist	O
,	O
as	O
is	O
usual	O
in	O
the	O
study	O
hospital	O
.	O

Coaches	O
were	O
advised	O
not	O
to	O
spend	O
more	O
than	O
30	O
minutes	O
per	O
week	O
on	O
support	O
per	O
patient	O
.	O

Total	O
duration	O
of	O
support	O
rendered	O
was	O
231	O
minutes	O
on	O
average	O
per	O
patient	O
(	O
range	O
:	O
10	O
-	O
490	O
,	O
SD	O
128	O
)	O
.	O

Finally	O
,	O
TIMT	O
included	O
weekly	O
online	O
monitoring	O
of	O
psychopathological	O
symptoms	O
.	O

The	O
intervention	O
and	O
control	O
group	O
did	O
not	O
differ	O
in	O
types	O
of	O
treatment	O
received	O
except	O
for	O
frequency	O
of	O
sedatives	O
taken	O
.	O

Participants	O
in	O
the	O
intervention	O
group	O
were	O
less	O
likely	O
to	O
take	O
sedatives	O
than	O
controls	O
(	O
P	O
<	O
.	O
001	O
)	O
[	O
15	O
]	O
.	O

In	O
total	O
,	O
we	O
included	O
11	O
pretreatment	O
participant	O
characteristics	O
:	O
age	O
,	O
sex	O
,	O
education	O
,	O
main	O
diagnosis	O
,	O
comorbid	O
personality	O
disorder	O
,	O
remission	O
status	O
at	O
the	O
end	O
of	O
inpatient	O
treatment	O
,	O
reliable	O
change	O
in	O
the	O
primary	O
outcome	O
during	O
inpatient	O
treatment	O
,	O
years	O
since	O
first	O
disorder	O
onset	O
,	O
Internet	O
/	O
computer	O
literacy	O
,	O
positive	O
outcome	O
expectations	O
,	O
and	O
health	O
-	O
related	O
self	O
-	O
efficacy	O
.	O

Information	O
on	O
sex	O
,	O
age	O
,	O
and	O
education	O
were	O
extracted	O
from	O
the	O
inpatient	O
clinic	O
patient	O
files	O
.	O

All	O
self	O
-	O
report	O
data	O
were	O
assessed	O
using	O
an	O
online	O
-	O
based	O
assessment	O
tool	O
.	O

Diagnoses	O
and	O
year	O
of	O
first	O
disorder	O
onsets	O
were	O
assessed	O
during	O
the	O
intake	O
interview	O
.	O

All	O
interviewers	O
were	O
experienced	O
psychotherapists	O
who	O
were	O
either	O
psychologists	O
or	O
physicians	O
with	O
a	O
master’s	O
degree	O
or	O
higher	O
,	O
trained	O
extensively	O
in	O
administering	O
the	O
structured	O
clinical	O
interviews	O
of	O
the	O
German	O
version	O
of	O
the	O
Diagnostic	B-coding_system
and	I-coding_system
Statistical	I-coding_system
Manual	I-coding_system
of	I-coding_system
Mental	I-coding_system
Disorders	I-coding_system
(	I-coding_system
Fourth	I-coding_system
Edition	I-coding_system
)	I-coding_system
(	I-coding_system
DSM	I-coding_system
-	I-coding_system
IV	I-coding_system
)	I-coding_system
[	O
42	O
]	O
.	O

Participants	O
were	O
classified	O
as	O
being	O
remitted	O
at	O
inpatient	O
discharge	O
(	O
yes	O
/	O
no	O
)	O
when	O
individual	O
scores	O
in	O
psychopathological	O
symptom	O
severity	O
(	O
primary	O
outcome	O
measure	O
as	O
described	O
subsequently	O
)	O
exceeded	O
a	O
raw	O
score	O
value	O
of	O
0	O
.	O
685	O
[	O
43	O
]	O
)	O
.	O

Reliable	O
change	O
in	O
symptom	O
severity	O
(	O
yes	O
/	O
no	O
)	O
was	O
determined	O
according	O
to	O
the	O
widely	O
used	O
reliable	O
change	O
index	O
of	O
Jacobson	O
and	O
Truax	O
[	O
44	O
]	O
.	O

Individual	O
reliable	O
change	O
scores	O
less	O
than	O
-	O
1	O
.	O
96	O
were	O
considered	O
to	O
reflect	O
reliable	O
(	O
positive	O
)	O
change	O
;	O
scores	O
equal	O
to	O
or	O
greater	O
than	O
-	O
1	O
.	O
96	O
reflected	O
no	O
reliable	O
change	O
.	O

Participants	O
were	O
classified	O
as	O
Internet	O
/	O
computer	O
illiterate	O
if	O
they	O
checked	O
the	O
not	O
at	O
all	O
response	O
category	O
for	O
the	O
item	O
“I	O
am	O
used	O
to	O
sending	O
and	O
receiving	O
emails”	O
(	O
1=not	O
at	O
all	O
;	O
4=completely	O
true	O
)	O
.	O

All	O
other	O
participants	O
were	O
classified	O
as	O
Internet	O
/	O
computer	O
literate	O
.	O

Participants	O
were	O
coded	O
as	O
having	O
a	O
low	O
education	O
level	O
if	O
they	O
reported	O
9	O
years	O
of	O
school	O
education	O
,	O
as	O
a	O
medium	O
education	O
level	O
if	O
they	O
reported	O
10	O
years	O
of	O
school	O
education	O
and	O
a	O
corresponding	O
degree	O
,	O
or	O
as	O
a	O
high	O
education	O
level	O
if	O
they	O
reported	O
a	O
minimum	O
of	O
13	O
years	O
of	O
school	O
/	O
college	O
education	O
and	O
a	O
corresponding	O
degree	O
.	O

Positive	O
outcome	O
expectations	O
were	O
assessed	O
by	O
using	O
the	O
respective	O
subscale	O
of	O
the	O
Patient	O
Questionnaire	O
on	O
Therapy	O
Expectation	O
and	O
Evaluation	O
(	O
PATHEV	O
)	O
[	O
45	O
]	O
.	O

This	O
scale	O
consists	O
of	O
4	O
items	O
measuring	O
participants’	O
expectations	O
regarding	O
the	O
effectiveness	O
of	O
their	O
inpatient	O
treatment	O
(	O
eg	O
,	O
“I	O
think	O
that	O
finally	O
my	O
problems	O
will	O
be	O
solved”	O
)	O
.	O

Response	O
scales	O
ranged	O
from	O
0	O
(	O
=do	O
not	O
agree	O
)	O
to	O
4	O
(	O
=agree	O
completely	O
)	O
.	O

Higher	O
scores	O
reflect	O
higher	O
positive	O
outcome	O
expectations	O
.	O

Construct	O
validity	O
of	O
the	O
scale	O
was	O
demonstrated	O
in	O
several	O
studies	O
[	O
45	O
]	O
.	O

In	O
the	O
present	O
study	O
,	O
internal	O
consistency	O
(	O
Cronbach	O
alpha	O
)	O
was	O
.	O
77	O
.	O

Health	O
-	O
related	O
self	O
-	O
efficacy	O
was	O
assessed	O
by	O
using	O
the	O
self	O
-	O
efficacy	O
subscale	O
of	O
the	O
49	O
-	O
item	O
short	O
form	O
of	O
the	O
Hamburg	O
Modules	O
for	O
the	O
Assessment	O
of	O
Psychosocial	O
Health	O
(	O
HEALTH	O
-	O
49	O
)	O
questionnaire	O
[	O
43	O
]	O
.	O
This	O
scale	O
includes	O
5	O
items	O
measuring	O
expected	O
persistence	O
and	O
success	O
in	O
several	O
domains	O
(	O
eg	O
,	O
“Despite	O
my	O
discomfort	O
,	O
I	O
achieve	O
the	O
personal	O
goals	O
that	O
I	O
set	O
for	O
myself”	O
score	O
inverted	O
for	O
scale	O
calculation	O
;	O
0=not	O
true	O
,	O
4=very	O
true	O
)	O
.	O

Higher	O
scores	O
denote	O
lower	O
self	O
-	O
efficacy	O
.	O

Internal	O
consistency	O
(	O
Cronbach	O
alpha	O
)	O
was	O
.	O
86	O
in	O
the	O
present	O
study	O
.	O

The	O
primary	O
outcome	O
from	O
the	O
effectiveness	O
trial	O
was	O
change	O
in	O
general	O
psychopathological	O
symptom	O
severity	O
(	O
symptom	O
severity	O
)	O
from	O
discharge	O
(	O
T2	O
)	O
to	O
3	O
-	O
and	O
12	O
-	O
month	O
follow	O
-	O
ups	O
(	O
T3	O
,	O
T4	O
)	O
.	O

Symptom	O
severity	O
was	O
assessed	O
by	O
using	O
the	O
HEALTH	O
-	O
49	O
,	O
a	O
widely	O
used	O
measure	O
of	O
symptom	O
severity	O
in	O
Germany	O
[	O
43	O
]	O
.	O

The	O
HEALTH	O
-	O
49	O
general	O
psychopathological	O
symptom	O
severity	O
scale	O
consists	O
of	O
18	O
items	O
related	O
to	O
somatoform	O
complaints	O
(	O
7	O
items	O
)	O
,	O
depressiveness	O
(	O
6	O
items	O
)	O
,	O
and	O
phobic	O
anxiety	O
(	O
5	O
items	O
)	O
.	O

Participants	O
were	O
asked	O
to	O
rate	O
the	O
severity	O
to	O
which	O
they	O
had	O
suffered	O
from	O
the	O
presented	O
symptoms	O
in	O
the	O
previous	O
2	O
weeks	O
(	O
0=not	O
at	O
all	O
;	O
4=very	O
much	O
)	O
.	O

Reliability	O
and	O
construct	O
validity	O
have	O
been	O
established	O
in	O
several	O
studies	O
based	O
on	O
large	O
clinical	O
and	O
nonclinical	O
samples	O
(	O
1548	O
psychotherapy	O
inpatients	O
,	O
5630	O
primary	O
care	O
patients	O
,	O
see	O
[	O
43	O
]	O
)	O
.	O

In	O
the	O
present	O
study	O
,	O
internal	O
consistency	O
(	O
Cronbach	O
alpha	O
coefficients	O
)	O
at	O
baseline	O
was	O
.	O
87	O
for	O
the	O
overall	O
general	O
psychopathological	O
symptom	O
severity	O
score	O
,	O
0	O
.	O
90	O
for	O
depressive	O
symptoms	O
,	O
0	O
.	O
86	O
for	O
somatoform	O
complaints	O
,	O
and	O
0	O
.	O
86	O
for	O
phobic	O
anxiety	O
.	O

Group	O
differences	O
regarding	O
baseline	O
characteristics	O
were	O
compared	O
via	O
chi	O
-	O
square	O
tests	O
for	O
categorical	O
variables	O
and	O
t	O
tests	O
for	O
continuous	O
variables	O
.	O

Interactions	O
between	O
pretreatment	O
participant	O
characteristics	O
(	O
moderators	O
)	O
and	O
interindividual	O
differences	O
in	O
intraindividual	O
changes	O
across	O
measurement	O
occasions	O
were	O
modeled	O
and	O
tested	O
via	O
multilevel	O
mixed	O
-	O
effect	O
models	O
.	O

Change	O
in	O
symptom	O
severity	O
over	O
time	O
was	O
dummy	O
coded	O
and	O
treated	O
as	O
a	O
fixed	O
level	O
-	O
1	O
(	O
ie	O
,	O
within	O
-	O
subjects	O
)	O
effect	O
(	O
dummy	O
1	O
:	O
T1	O
-	O
T2	O
,	O
dummy	O
2	O
:	O
T2	O
-	O
T3	O
,	O
dummy	O
3	O
:	O
T2	O
-	O
T4	O
)	O
.	O

Treatment	O
conditions	O
(	O
0=control	O
condition	O
,	O
1=intervention	O
condition	O
)	O
was	O
treated	O
as	O
a	O
fixed	O
level	O
-	O
2	O
(	O
ie	O
,	O
between	O
-	O
subjects	O
)	O
effect	O
.	O

More	O
important	O
for	O
the	O
present	O
purpose	O
,	O
interactions	O
between	O
moderator	O
and	O
treatment	O
condition	O
,	O
all	O
cross	O
-	O
level	O
interaction	O
effects	O
(	O
condition	O
×	O
T1	O
-	O
T2	O
,	O
T2	O
-	O
T3	O
,	O
T2	O
-	O
T4	O
;	O
moderator	O
×	O
T1	O
-	O
T2	O
,	O
T2	O
-	O
T3	O
,	O
T2	O
-	O
T4	O
)	O
,	O
and	O
3	O
-	O
way	O
interaction	O
effects	O
(	O
moderator	O
×	O
condition	O
×	O
T1	O
-	O
T2	O
,	O
T2	O
-	O
T3	O
,	O
T2	O
-	O
T4	O
)	O
were	O
also	O
included	O
in	O
the	O
models	O
.	O

A	O
3	O
-	O
way	O
interaction	O
effect	O
of	O
moderator	O
×	O
condition	O
×	O
T2	O
-	O
T3	O
or	O
moderator	O
×	O
condition	O
×	O
T2	O
-	O
T4	O
would	O
indicate	O
that	O
the	O
magnitude	O
of	O
the	O
intervention	O
effect	O
varies	O
as	O
a	O
function	O
of	O
the	O
moderator	O
.	O

The	O
model	O
imposed	O
no	O
restrictions	O
on	O
the	O
covariance	O
matrix	O
for	O
measurement	O
occasions	O
.	O

Thus	O
,	O
no	O
model	O
assumptions	O
were	O
tested	O
.	O

We	O
standardized	O
continuous	O
predictors	O
so	O
that	O
regression	O
coefficients	O
were	O
estimated	O
for	O
participants	O
with	O
average	O
scores	O
on	O
the	O
putative	O
moderator	O
.	O

To	O
increase	O
interpretability	O
and	O
allow	O
for	O
testing	O
nonlinear	O
effects	O
,	O
categorical	O
variables	O
with	O
more	O
than	O
2	O
categories	O
(	O
ie	O
,	O
diagnosis	O
,	O
years	O
since	O
first	O
disorder	O
onset	O
,	O
education	O
)	O
were	O
recoded	O
into	O
a	O
maximum	O
of	O
3	O
meaningful	O
categories	O
.	O

Because	O
of	O
low	O
prevalence	O
rates	O
,	O
we	O
excluded	O
diagnoses	O
other	O
than	O
depression	O
,	O
anxiety	O
disorders	O
,	O
and	O
adjustment	O
disorders	O
.	O

All	O
continuous	O
moderators	O
(	O
ie	O
,	O
age	O
,	O
self	O
-	O
efficacy	O
,	O
positive	O
outcome	O
expectations	O
)	O
were	O
standardized	O
so	O
that	O
regression	O
coefficients	O
refer	O
to	O
participants	O
with	O
average	O
scores	O
on	O
each	O
moderator	O
.	O

Aiming	O
at	O
an	O
intention	O
-	O
to	O
-	O
treat	O
(	O
ITT	O
)	O
design	O
,	O
we	O
included	O
all	O
participants	O
randomly	O
assigned	O
to	O
conditions	O
.	O

We	O
employed	O
a	O
full	O
information	O
maximum	O
likelihood	O
(	O
FIML	O
)	O
estimation	O
,	O
which	O
allows	O
for	O
all	O
available	O
data	O
to	O
be	O
included	O
without	O
replacement	O
or	O
imputation	O
of	O
missing	O
values	O
.	O

The	O
FIML	O
estimation	O
for	O
mixed	O
models	O
is	O
especially	O
robust	O
with	O
respect	O
to	O
missing	O
data	O
[	O
46	O
]	O
.	O

Additionally	O
,	O
we	O
conducted	O
follow	O
-	O
up	O
simple	O
slope	O
analyses	O
for	O
each	O
significant	O
3	O
-	O
way	O
interaction	O
effect	O
[	O
47	O
]	O
to	O
probe	O
the	O
relevant	O
lower	O
-	O
order	O
effects	O
.	O

In	O
this	O
method	O
,	O
the	O
slope	O
and	O
the	O
significance	O
of	O
the	O
intervention	O
main	O
effect	O
is	O
evaluated	O
for	O
conditional	O
values	O
of	O
the	O
moderator	O
.	O

For	O
significant	O
3	O
-	O
way	O
interactions	O
of	O
continuous	O
moderators	O
,	O
simple	O
slopes	O
were	O
calculated	O
for	O
the	O
mean	O
and	O
one	O
standard	O
deviation	O
above	O
and	O
below	O
the	O
mean	O
[	O
48	O
]	O
.	O

Effect	O
sizes	O
for	O
each	O
significant	O
moderator	O
were	O
calculated	O
based	O
on	O
comparing	O
the	O
effect	O
of	O
control	O
versus	O
intervention	O
groups	O
on	O
symptom	O
severity	O
scores	O
,	O
with	O
participants	O
grouped	O
by	O
the	O
significant	O
moderator	O
variable	O
.	O

Cohen’s	O
d	O
scores	O
[	O
49	O
]	O
were	O
calculated	O
by	O
standardizing	O
the	O
differences	O
between	O
baseline	O
and	O
follow	O
-	O
up	O
by	O
the	O
pooled	O
standard	O
deviation	O
of	O
baseline	O
scores	O
.	O

To	O
verify	O
whether	O
the	O
results	O
of	O
the	O
ITT	O
analyses	O
would	O
be	O
sustained	O
among	O
the	O
intervention	O
completers	O
sample	O
only	O
,	O
we	O
subsequently	O
repeated	O
all	O
mixed	O
-	O
effects	O
models	O
with	O
participants	O
who	O
stayed	O
within	O
key	O
treatment	O
parameters	O
(	O
completed	O
at	O
least	O
6	O
of	O
12	O
Web	O
diary	O
entries	O
or	O
more	O
than	O
25	O
posts	O
,	O
n=177	O
)	O
.	O

To	O
clarify	O
the	O
generalizability	O
of	O
our	O
findings	O
,	O
we	O
assessed	O
all	O
potential	O
moderators	O
also	O
from	O
patients	O
who	O
were	O
treated	O
during	O
the	O
recruitment	O
period	O
in	O
the	O
study	O
center	O
,	O
but	O
did	O
not	O
participate	O
in	O
the	O
trial	O
(	O
not	O
invited	O
,	O
declined	O
to	O
participate	O
,	O
not	O
fulfilling	O
inclusion	O
criteria	O
)	O
but	O
gave	O
informed	O
consent	O
to	O
use	O
their	O
data	O
for	O
research	O
purposes	O
(	O
n=1789	O
)	O
.	O

Study	O
participants	O
and	O
nonparticipants	O
were	O
compared	O
using	O
chi	O
-	O
square	O
tests	O
for	O
categorical	O
variables	O
and	O
t	O
tests	O
for	O
continuous	O
variables	O
.	O

Finally	O
,	O
if	O
a	O
significant	O
moderator	O
effect	O
contradicted	O
our	O
a	O
priori	O
expectations	O
,	O
we	O
conducted	O
post	O
hoc	O
simple	O
slope	O
analyses	O
for	O
the	O
control	O
and	O
intervention	O
groups	O
separately	O
to	O
identify	O
the	O
reasons	O
for	O
the	O
effect	O
.	O

All	O
analyses	O
were	O
performed	O
with	O
SPSS	O
19	O
(	O
IBM	O
Corp	O
,	O
Armonk	O
,	O
NY	O
,	O
USA	O
)	O
.	O

Table	O
1	O
shows	O
descriptive	O
statistics	O
for	O
the	O
dependent	O
variable	O
general	O
psychopathological	O
symptom	O
severity	O
.	O

Table	O
2	O
shows	O
descriptive	O
data	O
for	O
all	O
moderator	O
variables	O
.	O

Table	O
1	O
and	O
parts	O
of	O
Table	O
2	O
have	O
been	O
reported	O
in	O
previous	O
studies	O
[	O
15	O
]	O
.	O

Consistent	O
with	O
random	O
assignment	O
,	O
no	O
differences	O
were	O
found	O
between	O
intervention	O
and	O
control	O
group	O
on	O
any	O
of	O
the	O
pretreatment	O
variables	O
.	O

Participant	O
flow	O
and	O
study	O
dropouts	O
at	O
each	O
stage	O
of	O
the	O
study	O
.	O

Descriptives	O
for	O
primary	O
trial	O
main	O
outcome	O
,	O
psychopathological	O
symptom	O
severity	O
as	O
measured	O
by	O
the	O
general	O
psychopathological	O
symptom	O
severity	O
subscale	O
of	O
the	O
HEALTH	O
-	O
49	O
questionnaire	O
.	O

Descriptives	O
for	O
pretreatment	O
moderator	O
variables	O
.	O

a	O
All	O
differences	O
between	O
conditions	O
were	O
nonsignificant	O
.	O

If	O
percentages	O
do	O
not	O
reach	O
100	O
,	O
it	O
is	O
due	O
to	O
missing	O
data	O
.	O

b	O
n=1676	O
.	O

The	O
present	O
trial	O
protocol	O
is	O
reported	O
according	O
to	O
the	O
CONsolidated	O
Standards	O
Of	O
Reporting	O
Trials	O
(	O
CONSORT	O
)	O
Statement	O
and	O
Standard	O
Protocol	O
Items	O
:	O
Recommendations	O
for	O
Interventional	O
Trials	O
(	O
SPIRIT	O
)	O
[	O
35	O
–	O
37	O
]	O
(	O
Fig	O
.	O

1	O
,	O
Additional	O
file	O
1	O
)	O
.	O

Fig	O
.	O

1	O
Schedule	O
of	O
enrolment	O
,	O
interventions	O
,	O
and	O
outcome	O
assessments	O
in	O
the	O
RADMIS	O
trials	O

Schedule	O
of	O
enrolment	O
,	O
interventions	O
,	O
and	O
outcome	O
assessments	O
in	O
the	O
RADMIS	O
trials	O

The	O
trial	O
protocol	O
describes	O
two	O
individual	O
,	O
randomized	O
controlled	O
,	O
single	O
-	O
blind	O
,	O
parallel	O
-	O
group	O
trials	O
,	O
the	O
RADMIS	O
trials	O
,	O
investigating	O
the	O
effect	O
of	O
using	O
the	O
Monsenso	O
system	O
on	O
a	O
daily	O
basis	O
,	O
this	O
including	O
an	O
integrated	O
feedback	O
loop	O
and	O
context	O
-	O
aware	O
CBT	O
modules	O
,	O
compared	O
with	O
standard	O
treatment	O
in	O
adult	O
patients	O
with	O
unipolar	O
disorder	O
and	O
bipolar	O
disorder	O
,	O
respectively	O
.	O

The	O
RADMIS	O
trials	O
are	O
randomized	O
controlled	O
,	O
single	O
-	O
blind	O
,	O
parallel	O
-	O
group	O
trials	O
with	O
a	O
balanced	O
allocation	O
ratio	O
(	O
1	O
:	O
1	O
)	O
of	O
adult	O
patients	O
with	O
unipolar	O
disorder	O
or	O
bipolar	O
disorder	O
stratified	O
according	O
to	O
the	O
psychiatric	O
center	O
from	O
where	O
the	O
patients	O
are	O
discharged	O
and	O
the	O
number	O
of	O
former	O
hospitalizations	O
(	O
three	O
or	O
less	O
or	O
more	O
than	O
three	O
)	O
.	O

The	O
included	O
patients	O
are	O
randomized	O
separately	O
according	O
to	O
psychiatric	O
diagnosis	O
(	O
unipolar	O
disorder	O
or	O
bipolar	O
disorder	O
)	O
to	O
either	O
active	O
use	O
of	O
the	O
Monsenso	O
system	O
(	O
intervention	O
group	O
)	O
or	O
to	O
standard	O
treatment	O
(	O
control	O
group	O
)	O
.	O

Thus	O
,	O
the	O
RADMIS	O
trials	O
consists	O
of	O
two	O
separate	O
RCTs	O
with	O
two	O
patient	O
groups	O
investigating	O
the	O
effect	O
of	O
the	O
same	O
intervention	O
(	O
the	O
Monsenso	O
system	O
)	O
.	O

The	O
flow	O
diagram	O
of	O
the	O
RADMIS	O
trials	O
is	O
presented	O
in	O
Fig	O
.	O

2	O
.	O

The	O
trails	O
are	O
conducted	O
at	O
the	O
Psychiatric	O
Center	O
Copenhagen	O
,	O
Rigshospitalet	O
,	O
Copenhagen	O
,	O
Denmark	O
.	O

No	O
changes	O
in	O
study	O
design	O
or	O
methods	O
have	O
been	O
made	O
after	O
trial	O
commencement	O
.	O

Fig	O
.	O

2	O
Flow	O
diagram	O
of	O
the	O
RADMIS	O
trials	O

Flow	O
diagram	O
of	O
the	O
RADMIS	O
trials	O

Inclusion	O
criteria	O
:	O
all	O
patients	O
over	O
the	O
age	O
of	O
18	O
years	O
with	O
a	O
unipolar	B-phenotype
disorder	I-phenotype
or	I-phenotype
bipolar	I-phenotype
disorder	I-phenotype
diagnosis	I-phenotype
,	O
according	O
to	O
the	O
International	B-coding_system
Classification	I-coding_system
of	I-coding_system
Diseases	I-coding_system
,	I-coding_system
version	I-coding_system
10	I-coding_system
(	I-coding_system
ICD	I-coding_system
-	I-coding_system
10	I-coding_system
)	I-coding_system
using	O
Schedules	O
for	O
Clinical	O
Assessments	O
in	O
Neuropsychiatry	O
(	O
SCAN	O
)	O
[	O
38	O
]	O
,	O
who	O
are	O
discharged	O
from	O
a	O
psychiatric	O
hospital	O
in	O
The	O
Capital	O
Region	O
of	O
Denmark	O
during	O
the	O
period	O
March	O
2017	O
to	O
October	O
2018	O
following	O
an	O
affective	O
episode	O
(	O
depression	O
or	O
mania	O
)	O
are	O
invited	O
to	O
participate	O
in	O
the	O
RADMIS	O
trials	O
.	O

This	O
corresponds	O
to	O
approximately	O
1200	O
patients	O
with	O
unipolar	O
disorder	O
and	O
600	O
patients	O
with	O
bipolar	O
disorder	O
per	O
year	O
.	O

The	O
mental	O
health	O
services	O
in	O
The	O
Capital	O
Region	O
of	O
Denmark	O
covers	O
a	O
recruitment	O
area	O
of	O
the	O
Capital	O
Region	O
,	O
Denmark	O
,	O
corresponding	O
to	O
1	O
.	O
4	O
million	O
people	O
.	O

Exclusion	O
criteria	O
:	O
patients	O
who	O
are	O
pregnant	O
and	O
those	O
who	O
lack	O
Danish	O
language	O
skills	O
are	O
excluded	O
,	O
since	O
these	O
factors	O
may	O
influence	O
the	O
possible	O
effect	O
of	O
the	O
RADMIS	O
intervention	O
.	O

Potential	O
participants	O
are	O
invited	O
to	O
participate	O
in	O
the	O
RADMIS	O
trials	O
by	O
contact	O
with	O
the	O
staff	O
during	O
hospitalization	O
.	O

All	O
potential	O
participants	O
who	O
accept	O
to	O
meet	O
with	O
the	O
RADMIS	O
staff	O
for	O
further	O
trial	O
information	O
are	O
screened	O
by	O
trained	O
researcher	O
to	O
make	O
sure	O
that	O
they	O
fulfil	O
the	O
criteria	O
for	O
participation	O
,	O
and	O
are	O
then	O
included	O
in	O
the	O
RADMIS	O
trials	O
.	O

Following	O
inclusion	O
,	O
baseline	O
assessments	O
are	O
performed	O
on	O
all	O
patients	O
,	O
and	O
after	O
these	O
assessments	O
the	O
numbered	O
opaque	O
allocation	O
envelopes	O
are	O
distributed	O
by	O
a	O
research	O
secretary	O
(	O
HGN	O
)	O
to	O
the	O
RADMIS	O
study	O
nurses	O
.	O

The	O
included	O
patients	O
are	O
randomized	O
separately	O
according	O
to	O
psychiatric	O
diagnosis	O
(	O
unipolar	O
disorder	O
or	O
bipolar	O
disorder	O
)	O
to	O
either	O
the	O
intervention	O
group	O
or	O
the	O
control	O
group	O
for	O
a	O
6	O
-	O
month	O
trial	O
period	O
.	O

An	O
overview	O
of	O
the	O
outcome	O
assessments	O
conducted	O
by	O
researchers	O
blinded	O
to	O
intervention	O
group	O
is	O
presented	O
in	O
Table	O
1	O
.	O

Information	O
regarding	O
the	O
primary	O
outcome	O
,	O
re	O
-	O
admissions	O
and	O
duration	O
of	O
re	O
-	O
admissions	O
,	O
will	O
be	O
obtained	O
after	O
completion	O
of	O
the	O
two	O
RCTs	O
by	O
linkage	O
of	O
the	O
unique	O
personal	O
identification	O
number	O
(	O
CPR	O
)	O
which	O
is	O
assigned	O
to	O
all	O
5	O
.	O
4	O
million	O
persons	O
living	O
in	O
Denmark	O
[	O
39	O
]	O
with	O
the	O
Danish	O
Psychiatric	O
Central	O
Register	O
[	O
40	O
]	O
.	O

Table	O
1	O
Outcome	O
assessments	O
during	O
the	O
RADMIS	O
trial	O
SCAN	O
and	O
background	O
information	O
Rating	O
scales	O
Questionnaires	O
Clinical	O
information	O
Baseline	O
x	O
x	O
x	O
x	O
Randomization	O
to	O
(	O
1	O
)	O
smartphone	O
-	O
based	O
monitoring	O
and	O
treatment	O
(	O
the	O
intervention	O
group	O
)	O
or	O
(	O
2	O
)	O
treatment	O
-	O
as	O
-	O
usual	O
(	O
the	O
control	O
group	O
)	O
3	O
-	O
month	O
follow	O
-	O
up	O
x	O
x	O
x	O
6	O
-	O
month	O
follow	O
-	O
up	O
x	O
x	O
x	O
SCAN	O
Schedules	O
for	O
Clinical	O
Assessment	O
in	O
Neuropsychiatry	O
interview	O
Rating	O
scales	O
:	O
Hamilton	O
Depression	O
Rating	O
Scale	O
17	O
-	O
item	O
(	O
HDRS	O
-	O
17	O
)	O
;	O
Young	O
Mania	O
Rating	O
Scale	O
(	O
only	O
for	O

patients	O
with	O
a	O
bipolar	O
disorder	O
diagnosis	O
)	O
;	O
Psychosocial	O
functioning	O
test	O
(	O
Functional	O
Assessment	O
Short	O
Test	O
(	O
FAST	O
)	O
)	O
Questionnaires	O
:	O
perceived	O
stress	O
according	O
to	O
Cohen’s	O
Perceived	O
Stress	O
Scale	O
;	O
quality	O
of	O
life	O
according	O
to	O
the	O
WHO	O
Quality	O
of	O
Life	O
-	O
BREF	O
(	O
WHOQOL	O
-	O
BREF	O
)	O
;	O
self	O
-	O
rated	O
depressive	O
symptoms	O
according	O
to	O
Beck’s	O
Depressive	O
Inventory	O
(	O
BDI	O
)	O
;	O
self	O
-	O
rated	O
depressive	O
symptoms	O
according	O
to	O
the	O
Hamilton	O
Depression	O
Self	O
-	O
rating	O
Scale	O
6	O
-	O
item	O
(	O
HDRS	O
-	O
6	O
)	O
;	O
self	O
-	O
rated	O
manic	O
symptoms	O
according	O
to	O
the	O
Altman	O
Self	O
-	O
rating	O

Scale	O
for	O
Mania	O
(	O
ASRM	O
)	O
(	O
only	O
for	O
patients	O
with	O
a	O
bipolar	O
disorder	O
diagnosis	O
)	O
;	O
recovery	O
according	O
to	O
the	O
Recovery	O
Assessment	O
Scale	O
;	O
empowerment	O
according	O
to	O
Rogers’	O
Empowerment	O
Scale	O
;	O
adherence	O
to	O
medication	O
according	O
to	O
the	O
Medicine	O
Adherence	O
Rating	O
Scale	O
;	O
wellbeing	O
according	O
to	O
the	O
WHO	O
(	O
five	O
)	O
Wellbeing	O
Index	O
;	O
rumination	O
according	O
to	O
the	O
Rumination	O
Response	O
Scale	O
(	O
RRS	O
)	O
;	O
worrying	O
according	O
to	O
the	O
Penn	O
State	O
Worry	O
Questionnaire	O
(	O
PSWQ	O
)	O
;	O
satisfaction	O
according	O
to	O
the	O
Verona	O
Satisfaction	O
Scale	O
-	O
Affective	O

Disorder	O
(	O
VSS	O
-	O
A	O
)	O
.	O

The	O
HDRS	O
-	O
6	O
,	O
the	O
ASRM	O
and	O
the	O
WHO	O
(	O
five	O
)	O
are	O
filled	O
out	O
every	O
month	O
during	O
the	O
study	O
6	O
-	O
month	O
period	O
Clinical	O
information	O
:	O
re	O
-	O
admissions	O
and	O
duration	O
of	O
re	O
-	O
admissions	O
(	O
register	O
data	O
)	O
;	O
number	O
of	O
affective	O
episodes	O
;	O
number	O
of	O
contacts	O
with	O
clinicians	O
and	O
psychiatric	O
emergency	O
rooms	O
;	O
hospitalizations	O
;	O
medication	O
,	O
etc	O

Outcome	O
assessments	O
during	O
the	O
RADMIS	O
trial	O

SCAN	O
Schedules	O
for	O
Clinical	O
Assessment	O
in	O
Neuropsychiatry	O
interview	O

Rating	O
scales	O
:	O
Hamilton	O
Depression	O
Rating	O
Scale	O
17	O
-	O
item	O
(	O
HDRS	O
-	O
17	O
)	O
;	O
Young	O
Mania	O
Rating	O
Scale	O
(	O
only	O
for	O
patients	O
with	O
a	O
bipolar	O
disorder	O
diagnosis	O
)	O
;	O
Psychosocial	O
functioning	O
test	O
(	O
Functional	O
Assessment	O
Short	O
Test	O
(	O
FAST	O
)	O
)	O

Questionnaires	O
:	O
perceived	O
stress	O
according	O
to	O
Cohen’s	O
Perceived	O
Stress	O
Scale	O
;	O
quality	O
of	O
life	O
according	O
to	O
the	O
WHO	O
Quality	O
of	O
Life	O
-	O
BREF	O
(	O
WHOQOL	O
-	O
BREF	O
)	O
;	O
self	O
-	O
rated	O
depressive	O
symptoms	O
according	O
to	O
Beck’s	O
Depressive	O
Inventory	O
(	O
BDI	O
)	O
;	O
self	O
-	O
rated	O
depressive	O
symptoms	O
according	O
to	O
the	O
Hamilton	O
Depression	O
Self	O
-	O
rating	O
Scale	O
6	O
-	O
item	O
(	O
HDRS	O
-	O
6	O
)	O
;	O
self	O
-	O
rated	O
manic	O
symptoms	O
according	O
to	O
the	O
Altman	O
Self	O
-	O
rating	O
Scale	O
for	O
Mania	O
(	O
ASRM	O
)	O
(	O
only	O
for	O
patients	O
with	O
a	O
bipolar	O
disorder	O
diagnosis	O
)	O
;	O
recovery	O
according	O
to	O
the	O
Recovery	O

Assessment	O
Scale	O
;	O
empowerment	O
according	O
to	O
Rogers’	O
Empowerment	O
Scale	O
;	O
adherence	O
to	O
medication	O
according	O
to	O
the	O
Medicine	O
Adherence	O
Rating	O
Scale	O
;	O
wellbeing	O
according	O
to	O
the	O
WHO	O
(	O
five	O
)	O
Wellbeing	O
Index	O
;	O
rumination	O
according	O
to	O
the	O
Rumination	O
Response	O
Scale	O
(	O
RRS	O
)	O
;	O
worrying	O
according	O
to	O
the	O
Penn	O
State	O
Worry	O
Questionnaire	O
(	O
PSWQ	O
)	O
;	O
satisfaction	O
according	O
to	O
the	O
Verona	O
Satisfaction	O
Scale	O
-	O
Affective	O
Disorder	O
(	O
VSS	O
-	O
A	O
)	O
.	O

The	O
HDRS	O
-	O
6	O
,	O
the	O
ASRM	O
and	O
the	O
WHO	O
(	O
five	O
)	O
are	O
filled	O
out	O
every	O
month	O
during	O
the	O
study	O
6	O
-	O
month	O
period	O

Clinical	O
information	O
:	O
re	O
-	O
admissions	O
and	O
duration	O
of	O
re	O
-	O
admissions	O
(	O
register	O
data	O
)	O
;	O
number	O
of	O
affective	O
episodes	O
;	O
number	O
of	O
contacts	O
with	O
clinicians	O
and	O
psychiatric	O
emergency	O
rooms	O
;	O
hospitalizations	O
;	O
medication	O
,	O
etc	O

All	O
included	O
patients	O
have	O
been	O
discharged	O
from	O
a	O
psychiatric	O
hospital	O
at	O
The	O
Capital	O
Region	O
of	O
Denmark	O
during	O
the	O
period	O
from	O
May	O
2017	O
to	O
October	O
2018	O
following	O
an	O
affective	O
episode	O
(	O
depression	O
or	O
mania	O
)	O
.	O

All	O
included	O
patients	O
continue	O
standard	O
treatment	O
-	O
as	O
-	O
usual	O
at	O
a	O
community	O
psychiatric	O
centre	O
,	O
a	O
private	O
psychiatrist	O
,	O
a	O
general	O
practitioner	O
or	O
outpatient	O
treatment	O
at	O
a	O
hospital	O
during	O
the	O
trial	O
period	O
.	O

In	O
the	O
RADMIS	O
trials	O
,	O
the	O
Monsenso	O
system	O
is	O
available	O
for	O
smartphones	O
capable	O
of	O
collecting	O
subjective	O
and	O
automatically	O
generated	O
behavioral	O
data	O
on	O
measures	O
of	O
illness	O
activity	O
.	O

All	O
patients	O
randomized	O
to	O
the	O
intervention	O
group	O
are	O
offered	O
the	O
loan	O
of	O
an	O
Android	O
smartphone	O
free	O
of	O
charge	O
for	O
the	O
6	O
-	O
month	O
trial	O
period	O
.	O

The	O
patients	O
in	O
the	O
intervention	O
group	O
are	O
encouraged	O
to	O
use	O
the	O
Monsenso	O
system	O
for	O
daily	O
electronic	O
self	O
-	O
monitoring	O
.	O

Economic	O
costs	O
from	O
data	O
traffic	O
due	O
to	O
the	O
RADMIS	O
trials	O
are	O
refunded	O
to	O
all	O
participants	O
regardless	O
the	O
choice	O
of	O
smartphone	O
type	O
.	O

The	O
patients	O
randomized	O
to	O
the	O
intervention	O
group	O
,	O
regardless	O
the	O
choice	O
of	O
smartphone	O
are	O
,	O
on	O
a	O
daily	O
basis	O
,	O
prompted	O
by	O
an	O
alarm	O
in	O
the	O
Monsenso	O
system	O
at	O
a	O
self	O
-	O
chosen	O
time	O
during	O
the	O
day	O
to	O
evaluate	O
subjective	O
measures	O
of	O
illness	O
activity	O
.	O

The	O
following	O
subjective	O
(	O
self	O
-	O
monitored	O
)	O
measures	O
of	O
illness	O
activity	O
are	O
available	O
for	O
daily	O
evaluation	O
for	O
patients	O
with	O
unipolar	O
disorder	O
as	O
well	O
as	O
bipolar	O
disorder	O
:	O
sleep	O
duration	O
(	O
number	O
of	O
hours	O
slept	O
per	O
night	O
,	O
measured	O
in	O
half	O
-	O
hour	O
intervals	O
)	O
,	O
time	O
of	O
falling	O
asleep	O
the	O
previous	O
evening	O
(	O
hh	O
:	O
mm	O
)	O
,	O
time	O
woken	O
up	O
the	O
following	O
morning	O
(	O
hh	O
:	O
mm	O
)	O
,	O
medicine	O
intake	O
(	O
taken	O
as	O
prescribed	O
/	O
taken	O
with	O
changes	O
(	O
if	O
changes	O
,	O
the	O
patients	O
are	O
asked	O
to	O
specify	O
these	O
)	O
/	O
not	O
taken	O
)	O
,	O
anxiety	O
(	O
scored	O
from	O
“not	O
present	O
,	O
”	O

“present	O
to	O
some	O
degree”	O
or	O
“present”	O
on	O
a	O
scale	O
from	O
0	O
,	O
1	O
,	O
2	O
)	O
,	O
cognitive	O
problems	O
(	O
scored	O
from	O
“not	O
present	O
,	O
”	O
“present	O
to	O
some	O
degree”	O
or	O
“present”	O
on	O
a	O
scale	O
from	O
0	O
,	O
1	O
,	O
2	O
)	O
,	O
alcohol	O
consumption	O
(	O
number	O
of	O
units	O
consumed	O
per	O
day	O
,	O
0	O
to	O
+	O
10	O
scale	O
)	O
,	O
stress	O
(	O
scored	O
from	O
“not	O
present	O
,	O
”	O
“present	O
to	O
some	O
degree”	O
or	O
“present”	O
on	O
a	O
scale	O
from	O
0	O
,	O
1	O
,	O
2	O
)	O
,	O
menstruation	O
for	O
women	O
(	O
yes	O
/	O
no	O
)	O
,	O
individual	O
early	O
warning	O
signs	O
(	O
yes	O
/	O
no	O
)	O
,	O
a	O
number	O
(	O
unlimited	O
)	O
of	O
personal	O
parameters	O
(	O
created	O
by	O
the	O
patients	O
themselves	O
)	O
,	O

and	O
a	O
free	O
-	O
text	O
note	O
.	O

Suicidal	O
thoughts	O
will	O
not	O
be	O
evaluated	O
as	O
part	O
of	O
the	O
self	O
-	O
monitoring	O
due	O
to	O
ethical	O
concerns	O
and	O
since	O
deterioration	O
,	O
leading	O
to	O
suicidal	O
thoughts	O
,	O
will	O
be	O
reflected	O
on	O
other	O
of	O
the	O
self	O
-	O
monitored	O
parameters	O
in	O
the	O
system	O
.	O

Suicidal	O
patients	O
will	O
be	O
treated	O
using	O
standard	O
care	O
and	O
taken	O
care	O
of	O
by	O
the	O
usual	O
clinician	O
.	O

In	O
addition	O
to	O
these	O
items	O
,	O
the	O
following	O
self	O
-	O
monitored	O
measures	O
of	O
illness	O
activity	O
are	O
available	O
for	O
daily	O
evaluation	O
specifically	O
for	O
patients	O
with	O
unipolar	O
disorder	O
:	O
mood	O
(	O
scored	O
from	O
“euthymic”	O
to	O
“depressive”	O
on	O
a	O
scale	O
from	O
0	O
,	O
−0	O
.	O
5	O
,	O
−1	O
,	O
−2	O
,	O
−3	O
)	O
,	O
activity	O
level	O
(	O
scored	O
from	O
“normal”	O
to	O
“very	O
low”	O
on	O
a	O
scale	O
from	O
0	O
,	O
−1	O
,	O
−2	O
,	O
−3	O
)	O
,	O
irritability	O
(	O
scored	O
from	O
“not	O
present	O
,	O
”	O
“present	O
to	O
some	O
degree”	O
or	O
“present”	O
on	O
a	O
scale	O
from	O
0	O
,	O
1	O
,	O
2	O
)	O
.	O

Similarly	O
,	O
the	O
following	O
additional	O
self	O
-	O
monitored	O
measures	O
of	O
illness	O
activity	O
are	O
available	O
for	O
daily	O
evaluation	O
specifically	O
for	O
patients	O
with	O
bipolar	O
disorder	O
:	O
mood	O
(	O
scored	O
from	O
“depressive”	O
to	O
“manic”	O
on	O
a	O
scale	O
from	O
−3	O
,	O
−2	O
,	O
−1	O
,	O
−0	O
.	O
5	O
,	O
0	O
,	O
+	O
0	O
.	O
5	O
,	O
+	O
1	O
,	O
+	O
2	O
,	O
+	O
3	O
)	O
,	O
activity	O
level	O
(	O
scored	O
from	O
“very	O
low”	O
to	O
“very	O
high”	O
on	O
a	O
scale	O
from	O
−3	O
,	O
−2	O
,	O
−1	O
,	O
0	O
,	O
+	O
1	O
,	O
+	O
2	O
,	O
+	O
3	O
)	O
,	O
mixed	O
mood	O
(	O
yes	O
/	O
no	O
)	O
,	O
irritability	O
(	O
scored	O
from	O
“not	O
present	O
,	O
”	O
“present	O
to	O
some	O
degree”	O
or	O
“present”	O
on	O
a	O
scale	O
from	O
0	O
,	O
1	O
,	O
2	O
)	O
.	O

After	O
midnight	O
,	O
the	O
entered	O
subjective	O
(	O
self	O
-	O
monitored	O
)	O
measures	O
of	O
illness	O
activity	O
are	O
“locked”	O
and	O
further	O
changes	O
cannot	O
be	O
made	O
.	O

If	O
the	O
patients	O
wish	O
to	O
change	O
their	O
subjective	O
evaluation	O
they	O
can	O
enter	O
a	O
second	O
evaluation	O
in	O
addition	O
to	O
the	O
initial	O
one	O
,	O
and	O
both	O
of	O
the	O
subjective	O
evaluations	O
are	O
then	O
visible	O
for	O
the	O
patient	O
and	O
the	O
health	O
care	O
provider	O
when	O
logging	O
on	O
to	O
in	O
the	O
Monsenso	O
system	O
.	O

If	O
the	O
patients	O
forget	O
to	O
evaluate	O
the	O
subjective	O
measures	O
it	O
is	O
possible	O
to	O
enter	O
and	O
evaluate	O
retrospectively	O
for	O
up	O
to	O
2	O
days	O
.	O

It	O
is	O
then	O
noted	O
in	O
the	O
Monsenso	O
system	O
that	O
the	O
subjective	O
measures	O
are	O
collected	O
retrospectively	O
.	O

Screenshots	O
from	O
the	O
Monsenso	O
system	O
are	O
presented	O
in	O
Figs	O
.	O

3	O
and	O
4	O
.	O

A	O
user’s	O
guide	O
for	O
the	O
Monsenso	O
system	O
was	O
developed	O
and	O
handed	O
out	O
to	O
all	O
patients	O
in	O
the	O
intervention	O
group	O
(	O
can	O
be	O
obtained	O
by	O
contacting	O
the	O
corresponding	O
author	O
)	O
.	O

Fig	O
.	O

3	O
The	O
Monsenso	O
self	O
-	O
assessment	O
system	O
.	O

Screenshot	O
of	O
the	O
smartphone	O
-	O
based	O
self	O
-	O
assessment	O
Fig	O
.	O

4	O
The	O
Monsenso	O
self	O
-	O
assessment	O
system	O
.	O

Screenshot	O
of	O
the	O
smartphone	O
-	O
based	O
self	O
-	O
assessment	O
of	O
mood	O

The	O
Monsenso	O
self	O
-	O
assessment	O
system	O
.	O

Screenshot	O
of	O
the	O
smartphone	O
-	O
based	O
self	O
-	O
assessment	O

The	O
Monsenso	O
self	O
-	O
assessment	O
system	O
.	O

Screenshot	O
of	O
the	O
smartphone	O
-	O
based	O
self	O
-	O
assessment	O
of	O
mood	O

Smartphones	O
are	O
capable	O
of	O
collecting	O
automatically	O
generated	O
behavioral	O
data	O
on	O
measures	O
of	O
illness	O
activity	O
on	O
a	O
daily	O
basis	O
(	O
objective	O
data	O
)	O
during	O
the	O
6	O
-	O
month	O
trial	O
period	O
.	O

Examples	O
of	O
some	O
of	O
the	O
automatically	O
generated	O
behavioral	O
data	O
on	O
measures	O
of	O
illness	O
activity	O
collected	O
by	O
the	O
smartphones	O
:	O
(	O
1	O
)	O
phone	O
usage	O
measured	O
as	O
the	O
number	O
of	O
times	O
and	O
amount	O
of	O
time	O
the	O
smartphones	O
screen	O
are	O
turned	O
on	O
/	O
off	O
,	O
battery	O
usage	O
,	O
ambient	O
light	O
,	O
and	O
“proximity”	O
detection	O
,	O
(	O
2	O
)	O
social	O
activity	O
measured	O
as	O
the	O
number	O
of	O
in	O
-	O
and	O
outgoing	O
phone	O
calls	O
and	O
text	O
messages	O
,	O
the	O
duration	O
of	O
in	O
-	O
and	O
outgoing	O
phone	O
calls	O
,	O
the	O
length	O
of	O
the	O
text	O
messages	O
,	O
and	O
the	O
time	O
of	O
the	O
day	O
when	O
the	O
phone	O

calls	O
and	O
/	O
or	O
text	O
messages	O
are	O
made	O
/	O
sent	O
/	O
received	O
,	O
(	O
3	O
)	O
physical	O
activity	O
measured	O
by	O
the	O
step	O
counter	O
in	O
the	O
smartphones	O
,	O
and	O
(	O
4	O
)	O
mobility	O
based	O
on	O
the	O
location	O
estimation	O
available	O
in	O
the	O
smartphones	O
(	O
which	O
again	O
rely	O
on	O
,	O
e	O
.	O
g	O
.	O

,	O
GPD	O
or	O
GSM	O
cell	O
tower	O
information	O
depending	O
on	O
specific	O
circumstances	O
)	O
.	O

Furthermore	O
,	O
speech	O
activity	O
is	O
collected	O
by	O
extraction	O
of	O
different	O
voice	O
features	O
during	O
phone	O
calls	O
.	O

Voice	O
feature	O
extraction	O
will	O
take	O
place	O
directly	O
on	O
the	O
smartphones	O
and	O
no	O
recording	O
of	O
the	O
actual	O
speech	O
/	O
conversation	O
will	O
take	O
place	O
.	O

The	O
intention	O
is	O
to	O
synthesize	O
these	O
automatically	O
generated	O
behavioral	O
data	O
into	O
one	O
aggregated	O
objective	O
composite	O
measure	O
.	O

The	O
smartphone	O
-	O
based	O
CBT	O
modules	O
include	O
four	O
modules	O
:	O
psychoeducation	O
,	O
behavioral	O
activation	O
,	O
cognitive	O
restructuring	O
and	O
rumination	O
-	O
focused	O
CBT	O
.	O

The	O
psychoeducation	O
and	O
mood	O
-	O
monitoring	O
system	O
include	O
strategies	O
for	O
detecting	O
and	O
intervening	O
with	O
early	O
signs	O
of	O
relapse	O
.	O

Patients	O
are	O
encouraged	O
to	O
use	O
the	O
module	O
in	O
an	O
individualized	O
and	O
sequential	O
way	O
according	O
to	O
their	O
condition	O
,	O
affective	O
state	O
,	O
and	O
insight	O
and	O
following	O
guidance	O
from	O
the	O
study	O
nurse	O
if	O
wanted	O
.	O

The	O
behavioral	O
activation	O
module	O
was	O
inspired	O
by	O
Martell	O
et	O
al	O
.	O
(	O
2010	O
)	O
and	O
Lejuez	O
et	O
al	O
.	O
(	O
2001	O
)	O
[	O
41	O
,	O
42	O
]	O
.	O

It	O
includes	O
activity	O
monitoring	O
and	O
activity	O
scheduling	O
and	O
focus	O
on	O
regulation	O
of	O
sleep	O
and	O
daily	O
routines	O
.	O

Several	O
studies	O
have	O
established	O
the	O
efficacy	O
for	O
behavioral	O
activation	O
for	O
treating	O
depression	O
[	O
43	O
–	O
46	O
]	O
including	O
a	O
few	O
studies	O
of	O
behavioral	O
activation	O
using	O
smartphones	O
;	O
however	O
,	O
not	O
including	O
a	O
control	O
standard	O
treatment	O
arm	O
[	O
47	O
,	O
48	O
]	O
.	O

Further	O
,	O
regulating	O
patterns	O
of	O
activity	O
and	O
sleep	O
are	O
helpful	O
in	O
reducing	O
both	O
depressive	O
and	O
manic	O
symptoms	O
[	O
43	O
,	O
49	O
]	O
.	O

The	O
cognitive	O
restructuring	O
includes	O
simple	O
techniques	O
to	O
help	O
patients	O
to	O
identify	O
and	O
modify	O
dysfunctional	O
automatic	O
thoughts	O
.	O

Cognitive	O
restructuring	O
is	O
a	O
key	O
element	O
of	O
CBT	O
and	O
is	O
included	O
in	O
a	O
number	O
of	O
studies	O
that	O
show	O
the	O
efficiency	O
of	O
CBT	O
in	O
the	O
treatment	O
of	O
depression	O
including	O
some	O
studies	O
of	O
Internet	O
-	O
based	O
CBT	O
[	O
50	O
,	O
51	O
]	O
,	O
and	O
a	O
few	O
studies	O
including	O
patients	O
with	O
bipolar	O
disorder	O
[	O
20	O
,	O
22	O
]	O
.	O

A	O
main	O
purpose	O
of	O
the	O
smartphone	O
-	O
based	O
CBT	O
modules	O
was	O
to	O
help	O
patients	O
to	O
reduce	O
depressive	O
ruminations	O
.	O

Therefore	O
,	O
a	O
specific	O
rumination	O
-	O
focused	O
CBT	O
strategy	O
,	O
based	O
on	O
the	O
theory	O
and	O
practice	O
described	O
by	O
Watkins	O
et	O
al	O
.	O
[	O
25	O
]	O
,	O
was	O
included	O
.	O

Rumination	O
-	O
focused	O
CBT	O
has	O
shown	O
encouraging	O
results	O
in	O
the	O
treatment	O
of	O
residual	O
depression	O
[	O
25	O
]	O
and	O
the	O
Monsenso	O
system	O
includes	O
the	O
identification	O
and	O
reduction	O
of	O
unhelpful	O
ruminations	O
.	O

Study	O
nurses	O
with	O
experience	O
with	O
unipolar	O
disorder	O
and	O
bipolar	O
disorder	O
are	O
assigned	O
to	O
the	O
patients	O
allocated	O
to	O
the	O
intervention	O
group	O
of	O
the	O
RADMIS	O
trials	O
.	O

The	O
RADMIS	O
study	O
nurses	O
are	O
responsible	O
for	O
the	O
integrated	O
feedback	O
loop	O
.	O

Patients	O
allocated	O
to	O
the	O
intervention	O
group	O
of	O
the	O
RADMIS	O
trials	O
will	O
have	O
the	O
Monsenso	O
application	O
installed	O
on	O
a	O
smartphone	O
.	O

The	O
smartphone	O
automatically	O
transfers	O
the	O
self	O
-	O
monitored	O
subjective	O
measures	O
and	O
,	O
for	O
some	O
smartphones	O
,	O
also	O
the	O
automatically	O
generated	O
behavioral	O
data	O
on	O
measures	O
of	O
illness	O
activity	O
to	O
servers	O
at	O
the	O
hospital	O
through	O
secure	O
connections	O
(	O
I	O
-	O
suite	O
number	O
RHP	O
-	O
2011	O
-	O
03	O
)	O
.	O

By	O
giving	O
informed	O
consent	O
to	O
participate	O
in	O
the	O
RADMIS	O
,	O
the	O
patients	O
allow	O
for	O
the	O
RADMIS	O
study	O
nurses	O
and	O
their	O
health	O
care	O
provider	O
to	O
access	O
the	O
monitored	O
data	O
through	O
a	O
secure	O
web	O
interface	O
.	O

The	O
RADMIS	O
study	O
nurses	O
go	O
through	O
the	O
collected	O
data	O
approximately	O
two	O
to	O
three	O
times	O
a	O
week	O
,	O
or	O
more	O
often	O
on	O
patients	O
where	O
it	O
is	O
deemed	O
necessary	O
.	O

A	O
personal	O
homepage	O
is	O
set	O
up	O
on	O
a	O
server	O
allowing	O
the	O
patients	O
to	O
access	O
all	O
their	O
own	O
data	O
through	O
a	O
similar	O
secure	O
web	O
interface	O
.	O

The	O
feedback	O
loop	O
on	O
subjective	O
measures	O
:	O
regardless	O
the	O
type	O
of	O
smartphone	O
a	O
feedback	O
loop	O
on	O
the	O
subjective	O
measures	O
is	O
established	O
.	O

A	O
standard	O
of	O
scoring	O
thresholds	O
for	O
when	O
the	O
RADMIS	O
study	O
nurses	O
initially	O
should	O
react	O
was	O
made	O
.	O

For	O
example	O
,	O
the	O
RADMIS	O
study	O
nurses	O
react	O
if	O
the	O
patients	O
register	O
≥	O
−2	O
on	O
the	O
mood	O
item	O
for	O
2	O
days	O
or	O
more	O
,	O
or	O
if	O
the	O
patients	O
register	O
changes	O
in	O
their	O
sleep	O
patterns	O
of	O
1	O
h	O
or	O
more	O
for	O
more	O
than	O
3	O
days	O
.	O

Following	O
a	O
run	O
-	O
in	O
phase	O
of	O
approximately	O
2	O
to	O
4	O
weeks	O
of	O
self	O
-	O
monitoring	O
,	O
the	O
patients	O
and	O
the	O
RADMIS	O
study	O
nurses	O
individualize	O
the	O
thresholds	O
for	O
when	O
reaction	O
should	O
be	O
made	O
.	O

Also	O
the	O
RADMIS	O
study	O
nurses	O
and	O
the	O
patients	O
agree	O
on	O
a	O
concordance	O
status	O
in	O
(	O
a	O
)	O
the	O
patients’	O
most	O
important	O
items	O
for	O
identifying	O
prodromal	O
symptoms	O
of	O
depression	O
as	O
well	O
as	O
(	O
hypo	O
)	O
mania	O
(	O
only	O
for	O
patients	O
with	O
a	O
bipolar	O
disorder	O
diagnosis	O
)	O
,	O
(	O
b	O
)	O
the	O
threshold	O
for	O
future	O
early	O
warning	O
signs	O
,	O
and	O
(	O
c	O
)	O
actions	O
to	O
be	O
taken	O
in	O
case	O
of	O
depression	O
or	O
(	O
hypo	O
)	O
mania	O
(	O
only	O
for	O
patients	O
with	O
a	O
bipolar	O
disorder	O
diagnosis	O
)	O
The	O
integrated	O
feedback	O
loop	O
on	O
subjective	O
and	O
automatically	O
generated	O
behavioral	O
data	O
on	O

measures	O
of	O
illness	O
activity	O
:	O
a	O
feedback	O
loop	O
integrating	O
subjective	O
and	O
automatically	O
generated	O
behavioral	O
data	O
on	O
measures	O
of	O
illness	O
activity	O
is	O
established	O
.	O

The	O
feedback	O
loop	O
integrates	O
both	O
subjective	O
and	O
automatically	O
generated	O
behavioral	O
data	O
on	O
measures	O
of	O
illness	O
activity	O
in	O
a	O
flexible	O
and	O
adjustable	O
model	O
(	O
a	O
learning	O
system	O
)	O
resulting	O
in	O
prediction	O
analyses	O
of	O
the	O
collected	O
data	O
providing	O
messages	O
for	O
both	O
the	O
patients	O
and	O
the	O
RADMIS	O
study	O
nurses	O
such	O
as	O
:	O
“You	O
are	O
invited	O
to	O
contact	O
your	O
RADMIS	O
study	O
nurse	O
.	O
”	O

The	O
feedback	O
loop	O
on	O
subjective	O
measures	O
:	O
regardless	O
the	O
type	O
of	O
smartphone	O
a	O
feedback	O
loop	O
on	O
the	O
subjective	O
measures	O
is	O
established	O
.	O

A	O
standard	O
of	O
scoring	O
thresholds	O
for	O
when	O
the	O
RADMIS	O
study	O
nurses	O
initially	O
should	O
react	O
was	O
made	O
.	O

For	O
example	O
,	O
the	O
RADMIS	O
study	O
nurses	O
react	O
if	O
the	O
patients	O
register	O
≥	O
−2	O
on	O
the	O
mood	O
item	O
for	O
2	O
days	O
or	O
more	O
,	O
or	O
if	O
the	O
patients	O
register	O
changes	O
in	O
their	O
sleep	O
patterns	O
of	O
1	O
h	O
or	O
more	O
for	O
more	O
than	O
3	O
days	O
.	O

Following	O
a	O
run	O
-	O
in	O
phase	O
of	O
approximately	O
2	O
to	O
4	O
weeks	O
of	O
self	O
-	O
monitoring	O
,	O
the	O
patients	O
and	O
the	O
RADMIS	O
study	O
nurses	O
individualize	O
the	O
thresholds	O
for	O
when	O
reaction	O
should	O
be	O
made	O
.	O

Also	O
the	O
RADMIS	O
study	O
nurses	O
and	O
the	O
patients	O
agree	O
on	O
a	O
concordance	O
status	O
in	O
(	O
a	O
)	O
the	O
patients’	O
most	O
important	O
items	O
for	O
identifying	O
prodromal	O
symptoms	O
of	O
depression	O
as	O
well	O
as	O
(	O
hypo	O
)	O
mania	O
(	O
only	O
for	O
patients	O
with	O
a	O
bipolar	O
disorder	O
diagnosis	O
)	O
,	O
(	O
b	O
)	O
the	O
threshold	O
for	O
future	O
early	O
warning	O
signs	O
,	O
and	O
(	O
c	O
)	O
actions	O
to	O
be	O
taken	O
in	O
case	O
of	O
depression	O
or	O
(	O
hypo	O
)	O
mania	O
(	O
only	O
for	O
patients	O
with	O
a	O
bipolar	O
disorder	O
diagnosis	O
)	O

The	O
integrated	O
feedback	O
loop	O
on	O
subjective	O
and	O
automatically	O
generated	O
behavioral	O
data	O
on	O
measures	O
of	O
illness	O
activity	O
:	O
a	O
feedback	O
loop	O
integrating	O
subjective	O
and	O
automatically	O
generated	O
behavioral	O
data	O
on	O
measures	O
of	O
illness	O
activity	O
is	O
established	O
.	O

The	O
feedback	O
loop	O
integrates	O
both	O
subjective	O
and	O
automatically	O
generated	O
behavioral	O
data	O
on	O
measures	O
of	O
illness	O
activity	O
in	O
a	O
flexible	O
and	O
adjustable	O
model	O
(	O
a	O
learning	O
system	O
)	O
resulting	O
in	O
prediction	O
analyses	O
of	O
the	O
collected	O
data	O
providing	O
messages	O
for	O
both	O
the	O
patients	O
and	O
the	O
RADMIS	O
study	O
nurses	O
such	O
as	O
:	O
“You	O
are	O
invited	O
to	O
contact	O
your	O
RADMIS	O
study	O
nurse	O
.	O
”	O

Actions	O
taken	O
by	O
the	O
RADMIS	O
study	O
nurses	O
,	O
as	O
part	O
of	O
the	O
feedback	O
loop	O
in	O
the	O
intervention	O
group	O
,	O
in	O
case	O
of	O
signs	O
of	O
deterioration	O
of	O
a	O
patient	O
in	O
the	O
intervention	O
group	O
:	O
Contact	O
the	O
patient	O
and	O
give	O
advice	O
on	O
how	O
to	O
handle	O
the	O
situation	O
If	O
the	O
first	O
action	O
is	O
not	O
enough	O
,	O
the	O
study	O
nurses	O
ask	O
the	O
patient	O
to	O
contact	O
the	O
usual	O
physician	O
or	O
other	O
clinician	O
If	O
the	O
above	O
actions	O
are	O
not	O
enough	O
,	O
or	O
if	O
contact	O
with	O
the	O
patient	O
is	O
not	O
possible	O
,	O
the	O
study	O
nurses	O
contact	O
the	O
patient’s	O
usual	O
physician	O
or	O
other	O

clinician	O
themselves	O
In	O
case	O
of	O
acute	O
deterioration	O
and	O
/	O
or	O
severe	O
symptoms	O
,	O
the	O
study	O
nurses	O
recommend	O
the	O
patient	O
to	O
contact	O
the	O
psychiatric	O
emergency	O
service	O
in	O
Copenhagen	O
,	O
Denmark	O

Contact	O
the	O
patient	O
and	O
give	O
advice	O
on	O
how	O
to	O
handle	O
the	O
situation	O

If	O
the	O
first	O
action	O
is	O
not	O
enough	O
,	O
the	O
study	O
nurses	O
ask	O
the	O
patient	O
to	O
contact	O
the	O
usual	O
physician	O
or	O
other	O
clinician	O

If	O
the	O
above	O
actions	O
are	O
not	O
enough	O
,	O
or	O
if	O
contact	O
with	O
the	O
patient	O
is	O
not	O
possible	O
,	O
the	O
study	O
nurses	O
contact	O
the	O
patient’s	O
usual	O
physician	O
or	O
other	O
clinician	O
themselves	O

In	O
case	O
of	O
acute	O
deterioration	O
and	O
/	O
or	O
severe	O
symptoms	O
,	O
the	O
study	O
nurses	O
recommend	O
the	O
patient	O
to	O
contact	O
the	O
psychiatric	O
emergency	O
service	O
in	O
Copenhagen	O
,	O
Denmark	O

The	O
Monsenso	O
system	O
was	O
designed	O
in	O
an	O
interactive	O
process	O
between	O
patients	O
with	O
unipolar	O
disorder	O
,	O
bipolar	O
disorder	O
,	O
IT	O
researchers	O
,	O
clinicians	O
,	O
and	O
clinical	O
researchers	O
before	O
the	O
beginning	O
of	O
the	O
RADMIS	O
trial	O
.	O

Patients	O
allocated	O
to	O
the	O
control	O
group	O
continue	O
with	O
their	O
standard	O
treatment	O
-	O
as	O
-	O
usual	O
and	O
are	O
asked	O
to	O
continue	O
communicating	O
as	O
usual	O
using	O
their	O
mobile	O
phone	O
(	O
smartphone	O
)	O
.	O

Researchers	O
blinded	O
to	O
the	O
patients’	O
allocation	O
of	O
intervention	O
group	O
(	O
MFJ	O
and	O
one	O
other	O
physician	O
)	O
who	O
are	O
not	O
involved	O
in	O
the	O
treatment	O
of	O
the	O
patients	O
carry	O
out	O
all	O
outcome	O
assessments	O
.	O

The	O
unipolar	B-phenotype
disorder	I-phenotype
or	O
bipolar	B-phenotype
disorder	I-phenotype
diagnoses	I-phenotype
according	O
to	O
ICD	B-coding_system
-	I-coding_system
10	I-coding_system
are	O
confirmed	O
by	O
a	O
SCAN	O
interview	O
before	O
inclusion	O
of	O
the	O
patients	O
.	O

The	O
patients	O
are	O
,	O
regardless	O
of	O
randomization	O
group	O
,	O
enrolled	O
for	O
a	O
6	O
-	O
month	O
trial	O
period	O
and	O
invited	O
for	O
outcome	O
assessments	O
by	O
researchers	O
blinded	O
to	O
intervention	O
at	O
baseline	O
,	O
after	O
3	O
months	O
and	O
after	O
6	O
months	O
(	O
Table	O
1	O
)	O
.	O

At	O
each	O
visit	O
with	O
the	O
researchers	O
,	O
the	O
assessments	O
include	O
the	O
following	O
:	O

1	O
.	O

Clinician	O
-	O
administrated	O
rating	O
scales	O
:	O
the	O
severity	O
of	O
depressive	O
and	O
manic	O
symptoms	O
(	O
manic	O
symptoms	O
only	O
assessed	O
for	O
patients	O
with	O
a	O
bipolar	O
disorder	O
diagnosis	O
)	O
is	O
measured	O
using	O
the	O
Hamilton	O
Depression	O
Rating	O
Scale	O
17	O
-	O
item	O
(	O
HDRS	O
-	O
17	O
)	O
[	O
52	O
]	O
and	O
the	O
Young	O
Mania	O
Rating	O
Scale	O
(	O
YMRS	O
)	O
[	O
34	O
]	O
,	O
respectively	O
,	O
and	O
psychosocial	O
functioning	O
is	O
measured	O
using	O
the	O
Functioning	O
Assessment	O
Short	O
Test	O
(	O
FAST	O
)	O
[	O
53	O
]	O

2	O
.	O

Questionnaires	O
:	O
perceived	O
stress	O
according	O
to	O
Cohen’s	O
Perceived	O
Stress	O
Scale	O
[	O
54	O
]	O
,	O
quality	O
of	O
life	O
according	O
to	O
the	O
WHO	O
Quality	O
of	O
Life	O
-	O
BREF	O
(	O
WHOQOL	O
-	O
BREF	O
)	O
[	O
55	O
]	O
,	O
self	O
-	O
rated	O
depressive	O
symptoms	O
according	O
to	O
Beck’s	O
Depressive	O
Inventory	O
(	O
BDI	O
)	O
[	O
56	O
–	O
58	O
]	O
,	O
self	O
-	O
rated	O
depressive	O
symptoms	O
according	O
to	O
the	O
Hamilton	O
Depression	O
Self	O
-	O
rating	O
Scale	O
6	O
-	O
item	O
(	O
HDRS	O
-	O
6	O
)	O
[	O
59	O
]	O
,	O
self	O
-	O
rated	O
manic	O
symptoms	O
according	O
to	O
Altman	O
Self	O
-	O
rating	O
Scale	O
for	O
Mania	O
(	O
ASRM	O
)	O
(	O
only	O
for	O
patients	O
with	O
a	O
bipolar	O
disorder	O
diagnosis	O
)	O
[	O

34	O
]	O
,	O
recovery	O
according	O
to	O
the	O
Recovery	O
Assessment	O
Scale	O
[	O
60	O
]	O
,	O
empowerment	O
according	O
to	O
Rogers’	O
Empowerment	O
Scale	O
[	O
61	O
]	O
,	O
adherence	O
to	O
medication	O
according	O
to	O
the	O
Medicine	O
Adherence	O
Rating	O
Scale	O
[	O
62	O
]	O
,	O
wellbeing	O
according	O
to	O
the	O
WHO	O
(	O
five	O
)	O
Wellbeing	O
Index	O
[	O
63	O
]	O
,	O
rumination	O
according	O
to	O
the	O
Ruminative	O
Response	O
Scale	O
(	O
RRS	O
)	O
,	O
worrying	O
according	O
to	O
the	O
Penn	O
State	O
Worry	O
Questionnaire	O
(	O
PSWQ	O
)	O
[	O
64	O
]	O
,	O
and	O
satisfaction	O
according	O
to	O
the	O
Verona	O
Satisfaction	O
Scale	O
-	O
Affective	O
Disorder	O
(	O
VSS	O
-	O
A	O
)	O
[	O
65	O
]	O
.	O

The	O
patients	O
are	O
asked	O
to	O
fill	O
out	O
HDRS	O
-	O
6	O
,	O
ASRM	O
(	O
only	O
for	O
patients	O
with	O
a	O
bipolar	O
diagnosis	O
)	O
and	O
WHO	O
(	O
five	O
)	O
every	O
month	O
during	O
the	O
6	O
-	O
month	O
trial	O
period	O
in	O
both	O
groups	O
and	O
in	O
both	O
trials	O
.	O

Rate	O
and	O
duration	O
of	O
hospital	O
re	O
-	O
admissions	O
of	O
patients	O
with	O
unipolar	O
disorder	O
and	O
bipolar	O
disorder	O
,	O
respectively	O
,	O
as	O
according	O
to	O
data	O
retrieved	O
from	O
the	O
Danish	O
Psychiatric	O
Central	O
Register	O
[	O
40	O
]	O

Rate	O
and	O
duration	O
of	O
hospital	O
re	O
-	O
admissions	O
of	O
patients	O
with	O
unipolar	O
disorder	O
and	O
bipolar	O
disorder	O
,	O
respectively	O
,	O
as	O
according	O
to	O
data	O
retrieved	O
from	O
the	O
Danish	O
Psychiatric	O
Central	O
Register	O
[	O
40	O
]	O

Severity	O
of	O
depressive	O
symptoms	O
and	O
manic	O
symptoms	O
(	O
manic	O
symptoms	O
only	O
for	O
patients	O
with	O
a	O
bipolar	O
disorder	O
diagnosis	O
)	O
measured	O
using	O
the	O
HDRS	O
-	O
17	O
and	O
the	O
YMRS	O
,	O
respectively	O
Psychosocial	O
functioning	O
according	O
to	O
the	O
Functional	O
Assessment	O
Short	O
Test	O
(	O
FAST	O
)	O
Number	O
of	O
depressive	O
episodes	O
and	O
manic	O
episodes	O
(	O
manic	O
episodes	O
only	O
for	O
patients	O
with	O
a	O
bipolar	O
disorder	O
diagnosis	O
)	O
defined	O
as	O
HDRS	O
-	O
17	O
>	O
13	O
and	O
YMRS	O
>	O
13	O
,	O
respectively	O
Automatically	O
generated	O
behavioral	O
data	O
measured	O
as	O
an	O
aggregated	O
composite	O
measure	O

Severity	O
of	O
depressive	O
symptoms	O
and	O
manic	O
symptoms	O
(	O
manic	O
symptoms	O
only	O
for	O
patients	O
with	O
a	O
bipolar	O
disorder	O
diagnosis	O
)	O
measured	O
using	O
the	O
HDRS	O
-	O
17	O
and	O
the	O
YMRS	O
,	O
respectively	O

Psychosocial	O
functioning	O
according	O
to	O
the	O
Functional	O
Assessment	O
Short	O
Test	O
(	O
FAST	O
)	O

Number	O
of	O
depressive	O
episodes	O
and	O
manic	O
episodes	O
(	O
manic	O
episodes	O
only	O
for	O
patients	O
with	O
a	O
bipolar	O
disorder	O
diagnosis	O
)	O
defined	O
as	O
HDRS	O
-	O
17	O
>	O
13	O
and	O
YMRS	O
>	O
13	O
,	O
respectively	O

Automatically	O
generated	O
behavioral	O
data	O
measured	O
as	O
an	O
aggregated	O
composite	O
measure	O

Perceived	O
stress	O
according	O
to	O
Cohen’s	O
Perceived	O
Stress	O
Scale	O
[	O
54	O
]	O
,	O
quality	O
of	O
life	O
according	O
to	O
the	O
WHO	O
Quality	O
of	O
Life	O
-	O
BREF	O
(	O
WHOQOL	O
-	O
BREF	O
)	O
[	O
55	O
]	O
,	O
self	O
-	O
rated	O
depressive	O
symptoms	O
according	O
to	O
Beck’s	O
Depressive	O
Inventory	O
(	O
BDI	O
)	O
[	O
56	O
–	O
60	O
]	O
,	O
self	O
-	O
rated	O
depressive	O
symptoms	O
according	O
to	O
the	O
Hamilton	O
Depression	O
Self	O
-	O
rating	O
Scale	O
6	O
-	O
item	O
(	O
HDRS	O
-	O
6	O
)	O
[	O
59	O
]	O
,	O
self	O
-	O
rated	O
manic	O
symptoms	O
according	O
to	O
the	O
Altman	O
Self	O
-	O
rating	O
scale	O
for	O
Mania	O
(	O
ASRM	O
)	O
(	O
only	O
for	O
patients	O
with	O
a	O
bipolar	O
disorder	O
diagnosis	O
)	O
[	O
34	O
]	O
,	O
recovery	O

according	O
to	O
the	O
Recovery	O
Assessment	O
Scale	O
[	O
60	O
]	O
,	O
empowerment	O
according	O
to	O
Roger’s	O
Empowerment	O
Scale	O
[	O
61	O
]	O
,	O
adherence	O
to	O
medication	O
according	O
to	O
the	O
Medicine	O
Adherence	O
Rating	O
Scale	O
[	O
62	O
]	O
,	O
wellbeing	O
according	O
to	O
the	O
WHO	O
(	O
five	O
)	O
Wellbeing	O
Index	O
[	O
63	O
]	O
,	O
rumination	O
according	O
to	O
the	O
Ruminative	O
Response	O
Scale	O
(	O
RRS	O
)	O
,	O
worrying	O
according	O
to	O
the	O
Penn	O
State	O
Worry	O
Questionnaire	O
(	O
PSWQ	O
)	O
[	O
64	O
]	O
,	O
and	O
satisfaction	O
according	O
to	O
the	O
Verona	O
Satisfaction	O
Scale	O
-	O
Affective	O
Disorder	O
(	O
VSS	O
-	O
A	O
)	O
[	O
65	O
]	O

Perceived	O
stress	O
according	O
to	O
Cohen’s	O
Perceived	O
Stress	O
Scale	O
[	O
54	O
]	O
,	O
quality	O
of	O
life	O
according	O
to	O
the	O
WHO	O
Quality	O
of	O
Life	O
-	O
BREF	O
(	O
WHOQOL	O
-	O
BREF	O
)	O
[	O
55	O
]	O
,	O
self	O
-	O
rated	O
depressive	O
symptoms	O
according	O
to	O
Beck’s	O
Depressive	O
Inventory	O
(	O
BDI	O
)	O
[	O
56	O
–	O
60	O
]	O
,	O
self	O
-	O
rated	O
depressive	O
symptoms	O
according	O
to	O
the	O
Hamilton	O
Depression	O
Self	O
-	O
rating	O
Scale	O
6	O
-	O
item	O
(	O
HDRS	O
-	O
6	O
)	O
[	O
59	O
]	O
,	O
self	O
-	O
rated	O
manic	O
symptoms	O
according	O
to	O
the	O
Altman	O
Self	O
-	O
rating	O
scale	O
for	O
Mania	O
(	O
ASRM	O
)	O
(	O
only	O
for	O
patients	O
with	O
a	O
bipolar	O
disorder	O
diagnosis	O
)	O
[	O
34	O
]	O
,	O
recovery	O

according	O
to	O
the	O
Recovery	O
Assessment	O
Scale	O
[	O
60	O
]	O
,	O
empowerment	O
according	O
to	O
Roger’s	O
Empowerment	O
Scale	O
[	O
61	O
]	O
,	O
adherence	O
to	O
medication	O
according	O
to	O
the	O
Medicine	O
Adherence	O
Rating	O
Scale	O
[	O
62	O
]	O
,	O
wellbeing	O
according	O
to	O
the	O
WHO	O
(	O
five	O
)	O
Wellbeing	O
Index	O
[	O
63	O
]	O
,	O
rumination	O
according	O
to	O
the	O
Ruminative	O
Response	O
Scale	O
(	O
RRS	O
)	O
,	O
worrying	O
according	O
to	O
the	O
Penn	O
State	O
Worry	O
Questionnaire	O
(	O
PSWQ	O
)	O
[	O
64	O
]	O
,	O
and	O
satisfaction	O
according	O
to	O
the	O
Verona	O
Satisfaction	O
Scale	O
-	O
Affective	O
Disorder	O
(	O
VSS	O
-	O
A	O
)	O
[	O
65	O
]	O

No	O
changes	O
in	O
trial	O
outcomes	O
have	O
been	O
made	O
after	O
trial	O
commencement	O
.	O

The	O
statistical	O
power	O
and	O
sample	O
size	O
was	O
calculated	O
using	O
http	O
:	O
/	O
/	O
stat	O
.	O
ubc	O
.	O
ca	O
/	O
~	O
rollin	O
/	O
stats	O
/	O
ssize	O
/	O
n2	O
.	O
html	O
.	O

The	O
primary	O
outcomes	O
are	O
differences	O
in	O
the	O
number	O
and	O
duration	O
of	O
re	O
-	O
admissions	O
to	O
a	O
psychiatric	O
hospital	O
between	O
the	O
intervention	O
group	O
and	O
the	O
control	O
group	O
−	O
analyzed	O
separately	O
according	O
to	O
psychiatric	O
diagnosis	O
(	O
unipolar	O
disorder	O
or	O
bipolar	O
disorder	O
)	O
.	O

Power	O
calculations	O
are	O
similar	O
for	O
the	O
two	O
RCTs	O
/	O
patient	O
groups	O
(	O
unipolar	O
disorder	O
or	O
bipolar	O
disorder	O
)	O
.	O

Based	O
on	O
prior	O
findings	O
aiming	O
to	O
reduce	O
re	O
-	O
hospitalization	O
due	O
to	O
recurrent	O
depression	O
[	O
66	O
]	O
and	O
bipolar	O
disorder	O
[	O
9	O
]	O
,	O
combined	O
with	O
presumptions	O
of	O
positive	O
effects	O
of	O
the	O
immediate	O
early	O
contact	O
with	O
patients	O
during	O
the	O
vulnerable	O
period	O
following	O
discharge	O
from	O
a	O
psychiatric	O
hospital	O
,	O
regardless	O
of	O
diagnosis	O
,	O
we	O
expect	O
a	O
reduction	O
in	O
re	O
-	O
admissions	O
from	O
30	O
%	O
to	O
15	O
%	O
in	O
the	O
intervention	O
group	O
using	O
smartphone	O
-	O
based	O
treatment	O
.	O

Thus	O
,	O
anticipating	O
a	O
hazard	O
ratio	O
(	O
HR	O
)	O
of	O
0	O
.	O
50	O
in	O
the	O
comparison	O
of	O
the	O
intervention	O
group	O
with	O
the	O
control	O
group	O
on	O
the	O
primary	O
outcome	O
,	O
a	O
two	O
-	O
sided	O
risk	O
of	O
type	O
1	O
error	O
,	O
α	O
of	O
0	O
.	O
05	O
,	O
a	O
type	O
2	O
error	O
risk	O
,	O
β	O
,	O
a	O
statistical	O
power	O
of	O
80	O
%	O
,	O
the	O
sample	O
size	O
(	O
N	O
)	O
is	O
calculated	O
as	O
N	O
=	O
200	O
(	O
100	O
patients	O
in	O
each	O
arm	O
of	O
each	O
RCT	O
)	O
per	O
RCT	O
and	O
,	O
thus	O
,	O
a	O
total	O
of	O
400	O
patients	O
(	O
200	O
patients	O
with	O
unipolar	O
disorder	O
and	O
200	O
patients	O
with	O
bipolar	O
disorder	O
)	O
is	O
estimated	O
to	O
be	O
required	O
for	O
the	O
RADMIS	O
trial	O
.	O

Cumulated	O
durations	O
of	O
re	O
-	O
hospitalizations	O
comprise	O
similar	O
power	O
calculations	O
and	O
sample	O
sizes	O
.	O

Regarding	O
the	O
secondary	O
outcomes	O
,	O
the	O
clinically	O
relevant	O
difference	O
in	O
depressive	O
or	O
manic	O
symptoms	O
is	O
defined	O
as	O
a	O
minimum	O
of	O
three	O
scores	O
on	O
the	O
HDRS	O
-	O
17	O
or	O
on	O
the	O
YMRS	O
,	O
respectively	O
,	O
and	O
the	O
standard	O
deviation	O
(	O
SD	O
)	O
is	O
set	O
at	O
7	O
with	O
a	O
mean	O
score	O
of	O
12	O
versus	O
15	O
in	O
the	O
intervention	O
group	O
and	O
the	O
control	O
group	O
,	O
respectively	O
.	O

The	O
statistical	O
power	O
to	O
detect	O
a	O
three	O
-	O
score	O
difference	O
in	O
the	O
areas	O
under	O
the	O
curves	O
between	O
the	O
intervention	O
and	O
the	O
control	O
groups	O
on	O
the	O
HDRS	O
-	O
17	O
or	O
the	O
YMRS	O
,	O
respectively	O
,	O
is	O
80	O
%	O
with	O
α	O
=	O
0	O
.	O
05	O
for	O
a	O
two	O
-	O
sample	O
comparison	O
of	O
means	O
including	O
a	O
total	O
of	O
200	O
patients	O
(	O
100	O
patients	O
in	O
each	O
arm	O
)	O
in	O
each	O
of	O
the	O
two	O
RADMIS	O
RCTs	O
.	O

A	O
computer	O
-	O
generated	O
list	O
of	O
random	O
allocation	O
numbers	O
using	O
Pharma	O
Consulting	O
Group	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
pharmaconsultinggroup	O
.	O
com	O
)	O
will	O
be	O
generated	O
.	O

Patients	O
included	O
in	O
the	O
trial	O
are	O
randomized	O
with	O
a	O
balanced	O
allocation	O
ratio	O
of	O
1	O
:	O
1	O
to	O
(	O
1	O
)	O
using	O
the	O
Monsenso	O
system	O
,	O
including	O
the	O
integrated	O
feedback	O
loop	O
,	O
based	O
on	O
a	O
combination	O
of	O
subjective	O
self	O
-	O
monitored	O
measures	O
and	O
automatically	O
generated	O
behavioral	O
data	O
on	O
measures	O
of	O
illness	O
activity	O
)	O
including	O
context	O
-	O
aware	O
CBT	O
modules	O
(	O
the	O
intervention	O
group	O
)	O
or	O
to	O
(	O
2	O
)	O
standard	O
treatment	O
-	O
as	O
-	O
usual	O
(	O
the	O
control	O
group	O
)	O
(	O
Fig	O
.	O

1	O
)	O
.	O

Since	O
the	O
RADMIS	O
trial	O
is	O
single	O
-	O
blinded	O
,	O
random	O
block	O
sizes	O
are	O
used	O
to	O
help	O
preserve	O
unpredictability	O
[	O
67	O
,	O
68	O
]	O
.	O

The	O
RADMIS	O
study	O
nurses	O
are	O
unaware	O
of	O
the	O
range	O
of	O
numbers	O
in	O
the	O
block	O
sizes	O
.	O

The	O
study	O
will	O
use	O
a	O
stratified	O
design	O
,	O
where	O
patients	O
are	O
stratified	O
according	O
to	O
the	O
psychiatric	O
centres	O
where	O
patients	O
are	O
discharged	O
from	O
and	O
according	O
to	O
the	O
number	O
of	O
previous	O
hospitalizations	O
(	O
three	O
or	O
less	O
or	O
more	O
than	O
three	O
)	O
.	O

The	O
statistical	O
analyses	O
will	O
adjusted	O
for	O
the	O
two	O
stratification	O
variables	O
,	O
and	O
also	O
age	O
and	O
sex	O
as	O
possible	O
prognostic	O
variables	O
.	O

Further	O
,	O
in	O
analyses	O
on	O
continuous	O
variables	O
,	O
potential	O
differences	O
in	O
baseline	O
score	O
on	O
the	O
outcome	O
in	O
question	O
will	O
be	O
included	O
as	O
a	O
potential	O
confounder	O
.	O

If	O
there	O
are	O
no	O
statistically	O
significant	O
main	O
effects	O
of	O
age	O
and	O
sex	O
,	O
these	O
variables	O
will	O
be	O
excluded	O
from	O
the	O
final	O
statistical	O
analyses	O
.	O

The	O
allocation	O
sequence	O
is	O
concealed	O
from	O
the	O
researchers	O
(	O
e	O
.	O
g	O
.	O

,	O
MFJ	O
)	O
enrolling	O
and	O
assessing	O
the	O
patients	O
and	O
from	O
the	O
RADMIS	O
study	O
nurses	O
.	O

Allocation	O
is	O
concealed	O
in	O
numbered	O
,	O
opaque	O
and	O
sealed	O
envelopes	O
.	O

Owing	O
to	O
the	O
type	O
of	O
intervention	O
in	O
the	O
RADMIS	O
trials	O
,	O
the	O
patient	O
,	O
the	O
patients’	O
health	O
care	O
provider	O
and	O
the	O
RADMIS	O
study	O
nurses	O
are	O
aware	O
of	O
the	O
allocated	O
randomization	O
group	O
.	O

The	O
researchers	O
responsible	O
for	O
outcome	O
assessments	O
,	O
data	O
entry	O
,	O
data	O
analyses	O
,	O
interpretation	O
of	O
analyses	O
and	O
writing	O
of	O
papers	O
are	O
kept	O
blinded	O
to	O
allocation	O
at	O
all	O
times	O
during	O
the	O
trial	O
period	O
,	O
data	O
analyses	O
and	O
interpretation	O
of	O
analyses	O
.	O

The	O
trials	O
are	O
,	O
therefore	O
,	O
single	O
-	O
blinded	O
.	O

The	O
RADMIS	O
study	O
nurses	O
do	O
not	O
collect	O
any	O
outcome	O
measures	O
.	O

At	O
each	O
visit	O
with	O
the	O
researchers	O
,	O
all	O
patients	O
are	O
thoroughly	O
instructed	O
not	O
to	O
mention	O
anything	O
about	O
randomization	O
allocation	O
.	O

In	O
case	O
of	O
unblinding	O
of	O
the	O
included	O
patients’	O
allocation	O
status	O
,	O
one	O
of	O
the	O
other	O
researchers	O
blinded	O
to	O
intervention	O
in	O
the	O
RADMIS	O
trials	O
will	O
conduct	O
the	O
outcome	O
assessments	O
.	O

Data	O
from	O
all	O
randomized	O
patients	O
are	O
collected	O
until	O
dropout	O
or	O
the	O
end	O
of	O
the	O
trial	O
period	O
.	O

Analysis	O
will	O
be	O
carried	O
out	O
with	O
an	O
intention	O
-	O
to	O
-	O
treat	O
(	O
ITT	O
)	O
approach	O
.	O

The	O
primary	O
outcomes	O
are	O
differences	O
in	O
time	O
to	O
re	O
-	O
admission	O
and	O
duration	O
of	O
re	O
-	O
admissions	O
during	O
the	O
6	O
-	O
month	O
trial	O
period	O
between	O
the	O
intervention	O
group	O
and	O
the	O
control	O
group	O
.	O

Time	O
to	O
the	O
first	O
re	O
-	O
admission	O
will	O
be	O
estimated	O
using	O
a	O
Kaplan	O
-	O
Meier	O
plot	O
with	O
reasons	O
for	O
censoring	O
being	O
date	O
of	O
death	O
or	O
end	O
of	O
study	O
.	O

The	O
differences	O
in	O
cumulated	O
prevention	O
of	O
re	O
-	O
admission	O
in	O
the	O
intervention	O
group	O
and	O
the	O
control	O
group	O
will	O
tested	O
using	O
a	O
log	O
-	O
rank	O
test	O
.	O

Analysis	O
of	O
secondary	O
and	O
tertiary	O
outcomes	O
will	O
be	O
done	O
employing	O
a	O
linear	O
mixed	O
-	O
effects	O
model	O
with	O
random	O
intercept	O
for	O
each	O
participant	O
and	O
a	O
fixed	O
effect	O
of	O
visit	O
.	O

Differences	O
in	O
outcomes	O
between	O
the	O
intervention	O
group	O
and	O
the	O
control	O
group	O
will	O
be	O
analyzed	O
,	O
firstly	O
in	O
an	O
unadjusted	O
model	O
(	O
except	O
for	O
differences	O
in	O
baseline	O
values	O
of	O
the	O
outcome	O
variable	O
in	O
analyses	O
on	O
continuous	O
variables	O
)	O
and	O
then	O
in	O
models	O
adjusted	O
for	O
the	O
two	O
stratification	O
variables	O
(	O
1	O
)	O
psychiatric	O
center	O
and	O
(	O
2	O
)	O
the	O
number	O
of	O
prior	O
hospitalizations	O
,	O
and	O
also	O
for	O
age	O
and	O
sex	O
as	O
possible	O
prognostic	O
variables	O
.	O

If	O
there	O
are	O
no	O
statistically	O
significant	O
main	O
effects	O
of	O
age	O
and	O
sex	O
,	O
these	O
variables	O
will	O
be	O
excluded	O
from	O
the	O
final	O
analyses	O
.	O

Furthermore	O
,	O
subanalyses	O
will	O
be	O
done	O
employing	O
a	O
linear	O
mixed	O
-	O
effects	O
model	O
with	O
random	O
intercept	O
for	O
each	O
participant	O
and	O
a	O
fixed	O
effect	O
of	O
visit	O
on	O
differences	O
in	O
the	O
HDRS	O
-	O
17	O
and	O
the	O
YMRS	O
in	O
patients	O
with	O
the	O
presence	O
of	O
depressive	O
and	O
manic	O
symptoms	O
(	O
defined	O
as	O
HDRS	O
-	O
17	O
>	O
0	O
or	O
YMRS	O
>	O
0	O
,	O
respectively	O
)	O
at	O
a	O
given	O
time	O
point	O
during	O
the	O
trial	O
period	O
between	O
the	O
intervention	O
group	O
and	O
the	O
control	O
group	O
.	O

Additionally	O
,	O
in	O
addition	O
to	O
analyses	O
of	O
the	O
secondary	O
outcomes	O
,	O
we	O
will	O
analyze	O
differences	O
in	O
depressive	O
and	O
manic	O
episodes	O
defined	O
as	O
HDRS	O
≥14	O
and	O
YMRS	O
≥14	O
,	O
respectively	O
,	O
during	O
the	O
trial	O
period	O
.	O

Potential	O
interactions	O
between	O
randomization	O
group	O
and	O
visit	O
number	O
on	O
any	O
specific	O
outcome	O
variable	O
in	O
the	O
analyses	O
will	O
be	O
investigated	O
and	O
reported	O
accordingly	O
.	O

The	O
statistical	O
threshold	O
for	O
significance	O
is	O
p	O
≤	O
0	O
.	O
05	O
(	O
two	O
-	O
tailed	O
)	O
.	O

Data	O
will	O
be	O
managed	O
by	O
MFJ	O
and	O
entered	O
using	O
Epidata®	O
.	O

All	O
analyses	O
will	O
be	O
done	O
using	O
SPSS	O
,	O
version	O
22	O
.	O
0	O
(	O
IBM	O
,	O
New	O
York	O
,	O
NY	O
,	O
USA	O
)	O
and	O
STATA	O
version	O
12	O
(	O
StataCorp	O
LP	O
,	O
College	O
Station	O
,	O
TX	O
,	O
USA	O
)	O
.	O

Study	O
subjects	O
were	O
participants	O
of	O
the	O
Health	O
Retirement	O
Study	O
(	O
HRS	O
)	O
.	O

The	O
HRS	O
is	O
a	O
nationally	O
-	O
representative	O
,	O
longitudinal	O
study	O
of	O
37	O
,	O
000	O
US	O
residents	O
aged	O
51	O
years	O
or	O
older	O
.	O

19	O
The	O
HRS	O
uses	O
multi	O
-	O
stage	O
area	O
probability	O
sampling	O
from	O
all	O
US	O
states	O
and	O
the	O
District	O
of	O
Columbia	O
,	O
with	O
oversampling	O
of	O
Blacks	O
and	O
Hispanics	O
.	O

Every	O
2	O
years	O
since	O
1992	O
,	O
HRS	O
participants	O
have	O
been	O
interviewed	O
regarding	O
physical	O
health	O
and	O
functioning	O
,	O
cognitive	O
functioning	O
,	O
disability	O
,	O
health	O
insurance	O
,	O
and	O
other	O
factors	O
.	O

The	O
HRS	O
uses	O
standardized	O
instruments	O
to	O
collect	O
data	O
on	O
valid	O
,	O
generalizable	O
measures	O
that	O
are	O
applicable	O
to	O
stroke	O
,	O
MI	O
,	O
and	O
a	O
range	O
of	O
health	O
conditions	O
.	O

The	O
HRS	O
achieves	O
a	O
high	O
follow	O
-	O
up	O
rate	O
,	O
ranging	O
85	O
%	O
-	O
91	O
%	O
from	O
1998	O
to	O
2010	O
including	O
proxies	O
.	O

19	O

Data	O
regarding	O
inpatient	O
and	O
outpatient	O
medical	O
services	O
received	O
,	O
including	O
dates	O
of	O
hospitalizations	O
,	O
were	O
available	O
from	O
the	O
Centers	O
for	O
Medicare	O
and	O
Medicaid	O
Services	O
(	O
CMS	O
)	O
for	O
those	O
participants	O
who	O
were	O
enrolled	O
in	O
Medicare	O
fee	O
-	O
for	O
-	O
service	O
from	O
1991	O
through	O
2007	O
and	O
agreed	O
to	O
linkage	O
.	O

Approximately	O
80	O
%	O
of	O
Medicare	O
-	O
eligible	O
HRS	O
participants	O
consent	O
to	O
this	O
linkage	O
of	O
their	O
Medicare	O
data	O
.	O

The	O
HRS	O
protocol	O
was	O
approved	O
by	O
the	O
University	O
of	O
Michigan	O
Institutional	O
Review	O
Board	O
and	O
all	O
participants	O
provided	O
informed	O
consent	O
.	O

We	O
identified	O
all	O
subjects	O
hospitalized	O
with	O
a	O
principal	O
discharge	O
diagnosis	O
of	O
MI	B-phenotype
or	I-phenotype
stroke	I-phenotype
during	O
1998	O
to	O
2007	O
using	O
the	O
linked	O
Medicare	O
data	O
and	O
valid	O
ICD	B-coding_system
-	I-coding_system
9	I-coding_system
-	I-coding_system
CM	I-coding_system
codes	O
.	O

20	O
,	O
21	O
We	O
required	O
hospitalizations	O
to	O
be	O
≥1	O
day	O
and	O
subjects	O
to	O
have	O
≥1	O
functional	O
and	O
cognitive	O
measurement	O
before	O
and	O
after	O
the	O
index	O
MI	O
or	O
stroke	O
hospitalization	O
.	O

To	O
determine	O
the	O
unique	O
effects	O
of	O
the	O
exposures	O
,	O
MI	O
hospitalization	O
and	O
stroke	O
hospitalization	O
,	O
we	O
excluded	O
hospitalizations	O
in	O
which	O
another	O
vascular	O
event	O
or	O
pneumonia	O
was	O
diagnosed	O
and	O
listed	O
as	O
a	O
secondary	O
discharge	O
diagnosis	O
(	O
i	O
.	O
e	O
.	O
,	O
the	O
MI	O
group	O
included	O
individuals	O
hospitalized	O
with	O
a	O
principal	O
discharge	O
diagnosis	O
of	O
MI	O
and	O
no	O
secondary	O
diagnosis	O
of	O
stroke	O
or	O
pneumonia	O
and	O
the	O
stroke	O
group	O
included	O
individuals	O
hospitalized	O
with	O
hospitalized	O
for	O
stroke	O
)	O
.	O

Figure	O
1	O
shows	O
the	O
derivation	O
of	O
the	O
analytic	O
cohort	O
.	O

All	O
patients	O
were	O
followed	O
through	O
death	O
or	O
the	O
2010	O
HRS	O
interview	O
.	O

To	O
ascertain	O
functional	O
disability	O
,	O
respondents	O
(	O
or	O
their	O
proxies	O
)	O
were	O
asked	O
if	O
they	O
required	O
assistance	O
with	O
any	O
of	O
6	O
activities	O
of	O
daily	O
living	O
(	O
ADLs	O
)	O
:	O
walking	O
,	O
dressing	O
,	O
bathing	O
,	O
eating	O
,	O
getting	O
into	O
/	O
out	O
of	O
bed	O
,	O
and	O
toileting	O
,	O
and	O
5	O
instrumental	O
activities	O
of	O
daily	O
living	O
(	O
IADLs	O
)	O
:	O
preparing	O
a	O
hot	O
meal	O
,	O
grocery	O
shopping	O
,	O
making	O
telephone	O
calls	O
,	O
taking	O
medicines	O
,	O
and	O
managing	O
money	O
.	O

We	O
categorized	O
the	O
level	O
of	O
functional	O
disability	O
using	O
thresholds	O
utilized	O
in	O
prior	O
HRS	O
studies	O
,	O
defining	O
baseline	O
mild	O
-	O
to	O
-	O
moderate	O
disability	O
as	O
1	O
to	O
3	O
impairments	O
in	O
ADLs	O
and	O
IADLs	O
,	O
and	O
baseline	O
moderate	O
-	O
to	O
-	O
severe	O
disability	O
as	O
≥	O
4	O
impairments	O
.	O

9	O

Cognitive	O
impairment	O
was	O
assessed	O
using	O
versions	O
of	O
the	O
modified	O
Telephone	O
Interview	O
for	O
Cognitive	O
Status	O
(	O
TICS	O
-	O
m	O
)	O
.	O

22	O
,	O
23	O
Proxies	O
completed	O
cognitive	O
impairment	O
assessments	O
for	O
patients	O
unable	O
to	O
complete	O
the	O
interview	O
themselves	O
using	O
the	O
Informant	O
Questionnaire	O
on	O
Cognitive	O
Decline	O
in	O
the	O
Elderly	O
.	O

24	O
Thresholds	O
for	O
mild	O
-	O
moderate	O
and	O
moderate	O
-	O
severe	O
cognitive	O
impairment	O
were	O
based	O
on	O
HRS	O
research	O
and	O
the	O
methods	O
used	O
for	O
the	O
Aging	O
,	O
Demographics	O
,	O
and	O
Memory	O
Study	O
,	O
25	O
,	O
26	O
and	O
have	O
been	O
validated	O
against	O
neuropsychiatric	O
interviews	O
.	O

27	O

As	O
a	O
secondary	O
outcome	O
,	O
we	O
examined	O
trajectories	O
of	O
depression	O
before	O
and	O
after	O
stroke	O
and	O
MI	O
hospitalization	O
,	O
respectively	O
.	O

Depression	O
was	O
assessed	O
at	O
each	O
HRS	O
interview	O
using	O
an	O
8	O
-	O
item	O
version	O
of	O
the	O
Center	O
for	O
Epidemiologic	O
Studies	O
Depression	O
Scale	O
(	O
CES	O
-	O
D	O
)	O
28	O
from	O
patients	O
,	O
not	O
proxies	O
.	O

29	O
We	O
used	O
a	O
cutoff	O
score	O
of	O
≥	O
4	O
to	O
define	O
substantial	O
depressive	O
symptoms	O
because	O
this	O
threshold	O
is	O
comparable	O
to	O
the	O
cutoff	O
score	O
of	O
≥	O
16	O
on	O
the	O
full	O
CES	O
-	O
D	O
.	O
29	O

Information	O
on	O
demographics	O
(	O
e	O
.	O
g	O
.	O
,	O
age	O
,	O
race	O
/	O
ethnicity	O
,	O
sex	O
,	O
education	O
,	O
and	O
marital	O
/	O
partnered	O
status	O
)	O
and	O
health	O
-	O
risk	O
behaviors	O
(	O
e	O
.	O
g	O
.	O
,	O
alcohol	O
use	O
and	O
smoking	O
)	O
came	O
from	O
HRS	O
interviews	O
.	O

Baseline	O
Charlson	O
Comorbidity	O
score	O
30	O
and	O
hospitalization	O
-	O
related	O
characteristics	O
(	O
length	O
of	O
stay	O
,	O
intensive	O
care	O
unit	O
or	O
coronary	O
care	O
unit	O
admission	O
,	O
and	O
requirements	O
for	O
mechanical	O
ventilation	O
,	O
major	O
surgery	O
,	O
and	O
dialysis	O
)	O
were	O
obtained	O
from	O
Medicare	O
claims	O
.	O

Multivariable	O
regression	O
analyses	O
examined	O
the	O
adjusted	O
associations	O
between	O
MI	O
or	O
stroke	O
hospitalization	O
and	O
the	O
3	O
outcome	O
measures	O
.	O

For	O
analyses	O
of	O
functional	O
status	O
post	O
-	O
hospitalization	O
for	O
MI	O
or	O
stroke	O
,	O
our	O
dependent	O
variable	O
was	O
the	O
total	O
number	O
of	O
impairments	O
in	O
ADLs	O
and	O
IADLs	O
.	O

We	O
conducted	O
separate	O
analyses	O
for	O
MI	O
survivors	O
and	O
for	O
stroke	O
survivors	O
.	O

Initially	O
,	O
the	O
change	O
in	O
functional	O
status	O
over	O
time	O
was	O
graphed	O
using	O
piecewise	O
regression	O
models	O
with	O
one	O
knot	O
and	O
one	O
jump	O
to	O
account	O
for	O
the	O
change	O
in	O
status	O
at	O
the	O
time	O
of	O
the	O
acute	O
event	O
(	O
MI	O
or	O
stroke	O
)	O
.	O

31	O
We	O
used	O
fixed	O
-	O
effects	O
regression	O
to	O
model	O
trajectories	O
of	O
functional	O
impairments	O
over	O
time	O
with	O
control	O
for	O
all	O
stable	O
patient	O
characteristics	O
(	O
see	O
online	O
supplement	O
)	O
.	O

9	O
,	O
32	O
,	O
33	O
These	O
models	O
used	O
only	O
within	O
-	O
person	O
variation	O
over	O
time	O
to	O
estimate	O
the	O
effect	O
of	O
hospitalization	O
for	O
each	O
of	O
our	O
conditions	O
of	O
interest	O
(	O
i	O
.	O
e	O
.	O
,	O
patients	O
serve	O
as	O
their	O
own	O
controls	O
)	O
.	O

We	O
estimated	O
three	O
values	O
with	O
95	O
%	O
confidence	O
intervals	O
:	O
1	O
)	O
the	O
average	O
change	O
in	O
functional	O
impairments	O
over	O
time	O
before	O
the	O
MI	O
or	O
stroke	O
hospitalization	O
(	O
the	O
pre	O
-	O
event	O
slope	O
or	O
trajectory	O
)	O
,	O
2	O
)	O
the	O
acute	O
change	O
in	O
functional	O
impairments	O
at	O
the	O
time	O
of	O
the	O
MI	O
or	O
stroke	O
hospitalization	O
,	O
and	O
3	O
)	O
the	O
average	O
change	O
in	O
functional	O
impairments	O
over	O
time	O
after	O
the	O
MI	O
or	O
stroke	O
hospitalization	O
(	O
the	O
post	O
-	O
event	O
slope	O
)	O
.	O

We	O
used	O
all	O
available	O
information	O
on	O
the	O
outcome	O
measure	O
for	O
each	O
participant	O
to	O
calculate	O
these	O
estimates	O
.	O

We	O
also	O
adjusted	O
for	O
post	O
-	O
hospitalization	O
cognitive	O
impairment	O
to	O
examine	O
trajectories	O
beyond	O
that	O
associated	O
with	O
cognitive	O
impairment	O
.	O

Similarly	O
,	O
we	O
used	O
multivariable	O
conditional	O
logistic	O
regression	O
to	O
examine	O
the	O
impact	O
of	O
MI	O
or	O
stroke	O
hospitalization	O
on	O
each	O
outcome	O
,	O
development	O
of	O
moderate	O
-	O
to	O
-	O
severe	O
cognitive	O
impairment	O
or	O
the	O
presence	O
of	O
substantial	O
depressive	O
symptoms	O
.	O

Trajectories	O
reflect	O
the	O
change	O
in	O
the	O
odds	O
of	O
developing	O
each	O
outcome	O
over	O
time	O
before	O
or	O
after	O
the	O
event	O
(	O
e	O
.	O
g	O
.	O
,	O
the	O
odds	O
of	O
developing	O
cognitive	O
impairment	O
before	O
MI	O
per	O
year	O
)	O
.	O

Given	O
that	O
survivors	O
who	O
develop	O
cognitive	O
impairment	O
or	O
new	O
functional	O
impairments	O
after	O
MI	O
or	O
stroke	O
are	O
also	O
more	O
likely	O
to	O
develop	O
substantial	O
depressive	O
symptoms	O
,	O
we	O
added	O
time	O
-	O
dependent	O
variables	O
for	O
incident	O
mild	O
-	O
to	O
-	O
moderate	O
cognitive	O
impairment	O
,	O
moderate	O
-	O
to	O
-	O
severe	O
cognitive	O
impairment	O
,	O
and	O
functional	O
impairments	O
to	O
the	O
model	O
predicting	O
the	O
outcome	O
of	O
substantial	O
depressive	O
symptoms	O
.	O

Multivariable	O
results	O
are	O
reported	O
as	O
adjusted	O
odds	O
ratios	O
(	O
aORs	O
)	O
and	O
95	O
%	O
confidence	O
intervals	O

For	O
the	O
primary	O
analyses	O
,	O
patients	O
were	O
allowed	O
to	O
have	O
one	O
or	O
more	O
hospitalization	O
(	O
s	O
)	O
for	O
the	O
vascular	O
event	O
(	O
MI	O
or	O
stroke	O
)	O
.	O

We	O
repeated	O
analyses	O
using	O
only	O
the	O
first	O
MI	O
or	O
stroke	O
hospitalization	O
for	O
each	O
patient	O
.	O

Since	O
8	O
%	O
of	O
MI	O
survivors	O
and	O
11	O
%	O
of	O
stroke	O
survivors	O
were	O
missing	O
post	O
-	O
hospitalization	O
depression	O
measurements	O
because	O
they	O
required	O
a	O
proxy	O
,	O
we	O
used	O
non	O
-	O
response	O
propensity	O
score	O
adjustment	O
in	O
our	O
final	O
depression	O
model	O
to	O
quantify	O
potential	O
biases	O
in	O
our	O
results	O
.	O

34	O
Analyses	O
were	O
performed	O
with	O
the	O
IBM	O
SPSS	O
Statistics	O
18	O
(	O
SPSS	O
Inc	O
.	O
,	O
Chicago	O
,	O
IL	O
)	O
and	O
STATA	O
11	O
.	O
2	O
(	O
Stata	O
Corporation	O
,	O
College	O
Station	O
,	O
TX	O
)	O
statistical	O
software	O
programs	O
.	O

The	O
current	O
investigation	O
was	O
a	O
secondary	O
analysis	O
of	O
data	O
derived	O
from	O
a	O
randomized	O
controlled	O
trial	O
of	O
a	O
technology	O
-	O
enhanced	O
stepped	O
collaborative	O
care	O
intervention	O
targeting	O
PTSD	O
among	O
injured	O
inpatients	O
(	O
Zatzick	O
et	O
al	O
.	O
,	O
2015	O
)	O
.	O

The	O
study	O
was	O
approved	O
by	O
the	O
University’s	O
institutional	O
review	O
board	O
prior	O
to	O
study	O
initiation	O
.	O

Informed	O
consent	O
was	O
obtained	O
from	O
each	O
participant	O
at	O
bedside	O
.	O

The	O
study	O
utilized	O
an	O
established	O
electronic	O
medical	O
record	O
(	O
EMR	O
)	O
screening	O
method	O
to	O
identify	O
patients	O
with	O
a	O
likelihood	O
of	O
developing	O
high	O
levels	O
of	O
PTSD	O
symptoms	O
;	O
the	O
EMR	O
screen	O
demonstrated	O
adequate	O
sensitivity	O
(	O
0	O
.	O
71	O
)	O
,	O
specificity	O
(	O
0	O
.	O
66	O
)	O
,	O
and	O
area	O
under	O
the	O
ROC	O
curve	O
(	O
0	O
.	O
72	O
)	O
when	O
utilized	O
to	O
predict	O
scores	O
on	O
PTSD	O
Checklist	O
-	O
Civilian	O
Version	O
(	O
PCL	O
-	O
C	O
)	O
≥35	O
.	O

All	O
patients	O
were	O
given	O
a	O
study	O
laptop	O
while	O
at	O
baseline	O
in	O
the	O
trauma	O
ward	O
.	O

Patients	O
were	O
instructed	O
to	O
use	O
the	O
laptop	O
for	O
whatever	O
purposes	O
they	O
found	O
helpful	O
after	O
their	O
injury	O
including	O
email	O
,	O
social	O
network	O
or	O
obtaining	O
informational	O
material	O
on	O
post	O
-	O
injury	O
medical	O
and	O
psychiatric	O
problems	O
.	O

The	O
internet	O
browser	O
homepage	O
was	O
set	O
to	O
the	O
After	O
Deployment	O
website	O
,	O
a	O
United	O
States	O
Department	O
of	O
Defense	O
(	O
DoD	O
)	O
Defense	O
Centers	O
of	O
Excellent	O
(	O
DCOE	O
)	O
project	O
to	O
provide	O
resources	O
for	O
survivors	O
of	O
traumatic	O
life	O
experience	O
suffering	O
PTSD	O
and	O
it’s	O
comorbidities	O
(	O
Bush	O
,	O
Bosmajian	O
,	O
Fairall	O
,	O
McCann	O
,	O
&	O
Ciulla	O
,	O
2011	O
;	O
Ruzek	O
et	O
al	O
.	O
,	O
2011	O
)	O
.	O

As	O
a	O
part	O
of	O
the	O
informed	O
consent	O
process	O
,	O
patients	O
were	O
made	O
aware	O
that	O
their	O
laptop	O
usage	O
would	O
be	O
tracked	O
and	O
their	O
website	O
access	O
analyzed	O
.	O

The	O
K9	O
Web	O
Protection	O
software	O
(	O
Blue	O
Coat	O
Systems	O
,	O
Sunnyvale	O
,	O
CA	O
)	O
is	O
content	O
-	O
control	O
software	O
that	O
allows	O
an	O
administrator	O
to	O
view	O
metadata	O
related	O
to	O
web	O
-	O
browsing	O
,	O
including	O
the	O
website	O
address	O
and	O
the	O
time	O
spent	O
at	O
each	O
website	O
.	O

Each	O
patient’s	O
website	O
usage	O
data	O
were	O
first	O
filtered	O
to	O
remove	O
non	O
-	O
pertinent	O
websites	O
such	O
as	O
advertisements	O
and	O
commercials	O
.	O

The	O
websites	O
each	O
patient	O
visited	O
were	O
then	O
grouped	O
by	O
purpose	O
.	O

A	O
series	O
of	O
patient	O
self	O
-	O
report	O
items	O
were	O
adapted	O
from	O
prior	O
questionnaires	O
administered	O
to	O
civilian	O
emergency	O
department	O
patients	O
and	O
trauma	O
-	O
exposed	O
veteran	O
patients	O
(	O
Bush	O
,	O
et	O
al	O
.	O
,	O
2012	O
;	O
Ranney	O
,	O
et	O
al	O
.	O
,	O
2012	O
)	O
.	O

Patient	O
preferences	O
were	O
assessed	O
for	O
the	O
following	O
types	O
of	O
healthcare	O
-	O
related	O
communications	O
:	O
telephone	O
,	O
email	O
,	O
text	O
messaging	O
,	O
internet	O
website	O
,	O
and	O
social	O
networking	O
sites	O
,	O
as	O
well	O
as	O
more	O
traditional	O
methods	O
of	O
contact	O
including	O
US	O
mail	O
,	O
postcards	O
,	O
appointment	O
cards	O
,	O
and	O
in	O
-	O
person	O
discussions	O
with	O
doctors	O
.	O

The	O
investigation	O
also	O
assessed	O
patient	O
interest	O
and	O
capacity	O
in	O
DVD	O
or	O
video	O
-	O
related	O
communication	O
.	O

Patients	O
were	O
also	O
asked	O
at	O
baseline	O
about	O
their	O
possession	O
of	O
a	O
cell	O
phone	O
.	O

Patients	O
were	O
asked	O
to	O
characterize	O
their	O
cell	O
phone	O
as	O
either	O
a	O
basic	O
cell	O
phone	O
or	O
a	O
smart	O
phone	O
.	O

Patients	O
were	O
also	O
queried	O
about	O
whether	O
or	O
not	O
they	O
ever	O
used	O
applications	O
with	O
their	O
cell	O
phone	O
.	O

At	O
follow	O
-	O
up	O
interviews	O
in	O
order	O
to	O
assess	O
cell	O
phone	O
instability	O
,	O
patients	O
were	O
asked	O
about	O
physical	O
cell	O
phone	O
changes	O
and	O
cell	O
phone	O
number	O
changes	O
.	O

Additionally	O
,	O
in	O
order	O
to	O
triangulate	O
patient	O
self	O
-	O
reports	O
of	O
phone	O
instability	O
,	O
follow	O
-	O
up	O
interviewers	O
tracked	O
cell	O
phone	O
number	O
and	O
cell	O
phone	O
turnover	O
over	O
the	O
course	O
of	O
the	O
six	O
-	O
month	O
longitudinal	O
follow	O
-	O
up	O
.	O

Cell	O
phone	O
instability	O
was	O
defined	O
as	O
one	O
or	O
more	O
changes	O
in	O
physical	O
cell	O
phone	O
or	O
cell	O
phone	O
number	O
over	O
the	O
course	O
of	O
the	O
study	O
.	O

PTSD	O
symptoms	O
were	O
assessed	O
with	O
the	O
PCL	O
-	O
C	O
(	O
Weathers	O
,	O
Keane	O
,	O
&	O
Davidson	O
,	O
2001	O
)	O
,	O
which	O
has	O
established	O
reliability	O
and	O
validity	O
across	O
trauma	O
-	O
exposed	O
populations	O
(	O
Weathers	O
,	O
et	O
al	O
.	O
,	O
2001	O
)	O
.	O

The	O
investigation	O
determined	O
injury	B-phenotype
severity	I-phenotype
at	I-phenotype
baseline	I-phenotype
during	I-phenotype
the	I-phenotype
index	I-phenotype
admission	I-phenotype
from	O
the	O
medical	O
record	O
International	B-coding_system
Classification	I-coding_system
of	I-coding_system
Disease—9th	I-coding_system
Revision	I-coding_system
(	I-coding_system
ICD	I-coding_system
-	I-coding_system
9	I-coding_system
)	I-coding_system
using	O
the	O
Abbreviated	O
Injury	O
Scale	O
and	O
Injury	O
Severity	O
Score	O
.	O

Race	O
and	O
ethnicity	O
were	O
assessed	O
through	O
patient	O
self	O
-	O
report	O
.	O

Laboratory	O
toxicology	O
results	O
,	O
insurance	O
status	O
,	O
length	O
of	O
hospital	O
and	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
stays	O
,	O
and	O
other	O
clinical	O
characteristics	O
were	O
abstracted	O
from	O
the	O
EMR	O
.	O

The	O
investigation	O
first	O
described	O
the	O
demographic	O
and	O
clinical	O
characteristics	O
of	O
the	O
patients	O
.	O

Next	O
the	O
investigation	O
examined	O
patterns	O
of	O
patient	O
self	O
-	O
reported	O
technology	O
use	O
and	O
preferences	O
for	O
care	O
.	O

K	O
-	O
9	O
tracking	O
data	O
was	O
used	O
to	O
assess	O
composite	O
patient	O
laptop	O
activity	O
and	O
associated	O
time	O
patients	O
spent	O
with	O
each	O
category	O
of	O
activity	O
(	O
e	O
.	O
g	O
.	O
,	O
email	O
,	O
social	O
networking	O
sites	O
,	O
After	O
Deployment	O
)	O
(	O
Bush	O
,	O
et	O
al	O
.	O
,	O
2011	O
)	O
.	O

In	O
order	O
to	O
assess	O
cell	O
phone	O
instability	O
,	O
the	O
investigation	O
next	O
assessed	O
patterns	O
of	O
physical	O
phone	O
turnover	O
and	O
phone	O
number	O
changes	O
.	O

Exploratory	O
regression	O
analyses	O
assessed	O
the	O
association	O
between	O
cell	O
phone	O
instability	O
and	O
PTSD	O
symptom	O
levels	O
at	O
the	O
6	O
-	O
month	O
post	O
-	O
injury	O
time	O
point	O
.	O

An	O
initial	O
regression	O
analysis	O
controlled	O
only	O
for	O
baseline	O
PTSD	O
symptom	O
levels	O
in	O
the	O
assessment	O
of	O
the	O
association	O
between	O
instability	O
and	O
PTSD	O
symptoms	O
.	O

A	O
second	O
regression	O
model	O
adjusted	O
for	O
baseline	O
PTSD	O
symptoms	O
,	O
age	O
,	O
gender	O
,	O
ISS	O
,	O
treatment	O
group	O
,	O
education	O
and	O
insurance	O
status	O
.	O

We	O
conducted	O
a	O
case–control	O
study	O
within	O
Macabbi	O
Health	O
Services	O
electronic	O
medical	O
record	O
database	O
.	O

Macabbi	O
Health	O
Services	O
(	O
MHS	O
)	O
is	O
the	O
2nd	O
largest	O
HMO	O
in	O
Israel	O
with	O
approximately	O
two	O
million	O
enrollees	O
.	O

We	O
extracted	O
patient	O
information	O
including	O
demographic	O
data	O
(	O
sex	O
and	O
date	O
of	O
birth	O
)	O
,	O
medical	O
diagnosis	O
,	O
medications	O
,	O
and	O
the	O
results	O
of	O
all	O
blood	O
tests	O
conducted	O
from	O
January	O
1	O
,	O
2001	O
until	O
December	O
31	O
,	O
2017	O
.	O

Cases	O
were	O
MHS	O
enrollees	O
who	O
were	O
diagnosed	O
by	O
a	O
mental	O
health	O
professional	O
or	O
family	O
physician	O
as	O
suffering	O
from	O
generalized	B-phenotype
anxiety	I-phenotype
or	I-phenotype
a	I-phenotype
panic	I-phenotype
disorder	I-phenotype
as	O
defined	O
by	O
International	B-coding_system
Classification	I-coding_system
of	I-coding_system
Diseases	I-coding_system
,	I-coding_system
9th	I-coding_system
revision	I-coding_system
,	O
codes	O
300	B-code
.	I-code
02	I-code
and	O
300	B-code
.	I-code
01	I-code
,	O
and	O
who	O
received	O
at	O
least	O
1	O
prescription	O
of	O
SSRI	O
.	O

All	O
cases	O
were	O
older	O
than	O
age	O
18	O
years	O
at	O
diagnosis	O
.	O

To	O
be	O
included	O
in	O
this	O
study	O
,	O
cases	O
had	O
to	O
have	O
had	O
at	O
least	O
1	O
blood	O
serum	O
electrolytes	O
recorded	O
in	O
MHS	O
electronic	O
medical	O
records	O
before	O
the	O
date	O
of	O
the	O
SSRI	O
prescription	O
,	O
up	O
to	O
6	O
months	O
prior	O
to	O
the	O
diagnosis	O
of	O
anxiety	O
or	O
purchase	O
of	O
an	O
SSRI	O
,	O
the	O
latest	O
of	O
the	O
2	O
.	O

The	O
date	O
of	O
the	O
laboratory	O
test	O
was	O
defined	O
as	O
the	O
index	O
date	O
;	O
individuals	O
who	O
were	O
pregnant	O
at	O
the	O
time	O
of	O
laboratory	O
test	O
had	O
another	O
psychiatric	O
condition	O
,	O
received	O
medications	O
,	O
had	O
a	O
medical	O
condition	O
that	O
could	O
cause	O
hyponatremia	O
,	O
or	O
that	O
their	O
laboratory	O
tests	O
had	O
features	O
that	O
could	O
cause	O
pseudohyponatremia	O
,	O
as	O
described	O
in	O
Table	O
1	O
Supplementary	O
Data	O
,	O
were	O
excluded	O
from	O
this	O
group	O
.	O

Control	O
subjects	O
were	O
matched	O
from	O
all	O
MHS	O
database	O
to	O
cases	O
based	O
on	O
sex	O
and	O
year	O
of	O
birth	O
.	O

Patients	O
with	O
diagnosis	O
of	O
anxiety	O
or	O
panic	O
disorder	O
as	O
described	O
earlier	O
,	O
or	O
who	O
had	O
ever	O
received	O
a	O
prescription	O
for	O
an	O
SSRI	O
(	O
accounting	O
for	O
the	O
fact	O
that	O
patients	O
may	O
receive	O
anxiolytic	O
medications	O
without	O
proper	O
documentation	O
of	O
a	O
psychiatric	O
diagnosis	O
)	O
or	O
who	O
had	O
exclusion	O
criteria	O
as	O
described	O
for	O
cases	O
were	O
excluded	O
.	O

In	O
addition	O
,	O
controls	O
were	O
required	O
to	O
have	O
had	O
at	O
least	O
1	O
electrolyte	O
blood	O
test	O
at	O
the	O
same	O
age	O
as	O
matched	O
cases	O
and	O
due	O
to	O
seasonal	O
variations	O
in	O
sodium	O
concentration	O
the	O
lab	O
test	O
was	O
taken	O
within	O
1	O
calendar	O
month	O
prior	O
and	O
1	O
month	O
after	O
that	O
of	O
the	O
case	O
.	O

Matching	O
process	O
was	O
generated	O
twice	O
.	O

In	O
the	O
1st	O
step	O
,	O
controls	O
were	O
randomly	O
selected	O
in	O
1	O
:	O
30	O
ratio	O
based	O
on	O
sex	O
and	O
age	O
.	O

In	O
the	O
2nd	O
step	O
,	O
all	O
other	O
information	O
were	O
extracted	O
,	O
patients	O
were	O
excluded	O
accordingly	O
,	O
and	O
final	O
population	O
was	O
rematched	O
2	O
:	O
1	O
to	O
cases	O
.	O

For	O
subjects	O
in	O
the	O
case	O
group	O
,	O
a	O
2nd	O
lab	O
test	O
obtained	O
after	O
2	O
days	O
and	O
up	O
to	O
a	O
year	O
after	O
purchasing	O
their	O
1st	O
SSRI	O
was	O
also	O
taken	O
to	O
show	O
the	O
effect	O
of	O
SSRIs	O
on	O
serum	O
sodium	O
.	O

Variables	O
of	O
interest	O
among	O
lab	O
tests	O
included	O
serum	O
sodium	O
,	O
creatinine	O
,	O
and	O
urea	O
.	O

Urine	O
electrolytes	O
taken	O
within	O
a	O
2	O
-	O
week	O
interval	O
of	O
serum	O
electrolytes	O
were	O
also	O
obtained	O
.	O

Glomerular	O
filtration	O
rate	O
(	O
GFR	O
)	O
was	O
calculated	O
with	O
the	O
CKD	O
-	O
EPI	O
equation	O
.	O

[	O
19	O
]	O
Hyponatremia	O
was	O
defined	O
as	O
serum	O
sodium	O
<	O
135	O
mmol	O
/	O
L	O
and	O
borderline	O
hyponatremia	O
was	O
defined	O
as	O
serum	O
sodium	O
≥135	O
and	O
<	O
138	O
mmol	O
/	O
L	O
.	O

Dehydration	O
was	O
defined	O
as	O
urea	O
/	O
creatinine	O
(	O
U	O
/	O
Cr	O
)	O
ratio	O
above	O
100	O
and	O
an	O
“overhydration”	O
was	O
defined	O
as	O
U	O
/	O
Cr	O
ratio	O
below	O
40	O
.	O

All	O
blood	O
tests	O
were	O
analyzed	O
at	O
a	O
single	O
national	O
laboratory	O
.	O

eGFR	O
(	O
estimated	O
glomerular	O
filtration	O
rate	O
)	O
=	O
mL	O
/	O
min	O
/	O
1	O
.	O
73	O
m	O
2	O
;	O
S	O
Cr	O
(	O
standardized	O
serum	O
creatinine	O
)	O
=	O
mg	O
/	O
dL	O
;	O
κ	O
=	O
0	O
.	O
7	O
(	O
females	O
)	O
or	O
0	O
.	O
9	O
(	O
males	O
)	O
;	O
α	O
=	O
−0	O
.	O
329	O
(	O
females	O
)	O
or	O
−0	O
.	O
411	O
(	O
males	O
)	O
;	O
min	O
=	O
indicates	O
the	O
minimum	O
of	O
S	O
Cr	O
/	O
κ	O
or	O
1	O
;	O
max	O
=	O
indicates	O
the	O
maximum	O
of	O
S	O
Cr	O
/	O
κ	O
or	O
1	O
;	O
age	O
=	O
years	O
.	O

The	O
mean	O
serum	O
sodium	O
,	O
U	O
/	O
Cr	O
ratio	O
,	O
odds	O
ratio	O
(	O
OR	O
)	O
of	O
hyponatremia	O
,	O
borderline	O
hyponatremia	O
,	O
dehydration	O
,	O
and	O
overhydration	O
were	O
compared	O
between	O
the	O
case	O
and	O
control	O
groups	O
and	O
also	O
between	O
the	O
case	O
group	O
before	O
and	O
after	O
initiation	O
of	O
SSRIs	O
.	O

Data	O
management	O
and	O
statistical	O
analysis	O
were	O
performed	O
using	O
SPSS	O
statistics	O
software	O
,	O
version	O
24	O
(	O
IBM	O
,	O
Armonk	O
,	O
New	O
York	O
)	O
.	O

Baseline	O
characteristics	O
were	O
compared	O
between	O
the	O
case	O
and	O
control	O
groups	O
.	O

The	O
Chi	O
-	O
squared	O
test	O
was	O
used	O
to	O
compare	O
categorical	O
variables	O
.	O

For	O
continuous	O
variables	O
,	O
a	O
Shapiro–Wilk	O
test	O
of	O
normality	O
was	O
conducted	O
.	O

For	O
serum	O
sodium	O
,	O
a	O
normal	O
distribution	O
was	O
demonstrated	O
and	O
therefore	O
a	O
Student	O
t	O
test	O
was	O
used	O
to	O
compare	O
the	O
means	O
.	O

The	O
U	O
/	O
Cr	O
ratio	O
was	O
not	O
normally	O
distributed	O
and	O
therefore	O
the	O
nonparametric	O
Mann–Whitney	O
test	O
was	O
used	O
to	O
compare	O
the	O
means	O
of	O
the	O
2	O
groups	O
.	O

Multivariate	O
logistic	O
regression	O
models	O
were	O
constructed	O
to	O
assess	O
the	O
OR	O
of	O
hyponatremia	O
,	O
borderline	O
hyponatremia	O
,	O
and	O
dehydration	O
in	O
the	O
case	O
and	O
control	O
groups	O
.	O

The	O
multivariate	O
models	O
were	O
adjusted	O
for	O
the	O
baseline	O
characteristics	O
found	O
to	O
be	O
significantly	O
different	O
between	O
the	O
groups	O
,	O
as	O
shown	O
in	O
Table	O
1	O
,	O
including	O
GFR	O
group	O
,	O
cancer	O
,	O
chronic	O
kidney	O
disease	O
,	O
hypertension	O
,	O
and	O
atrial	O
fibrillation	O
.	O

The	O
populations	O
were	O
matched	O
for	O
age	O
and	O
gender	O
,	O
and	O
hence	O
age	O
and	O
gender	O
were	O
not	O
included	O
in	O
the	O
multivariate	O
analysis	O
.	O

Demographic	O
and	O
medical	O
characteristics	O
of	O
case	O
and	O
controls	O
groups	O
.	O

Subgroup	O
analysis	O
according	O
to	O
gender	O
,	O
age	O
groups	O
(	O
below	O
35	O
,	O
35–44	O
,	O
45–54	O
,	O
55–64	O
,	O
above	O
65	O
)	O
,	O
and	O
GFR	O
group	O
(	O
≥90	O
or	O
<	O
90	O
)	O
were	O
also	O
conducted	O
.	O

Then	O
effect	O
size	O
was	O
calculated	O
as	O
well	O
to	O
verify	O
if	O
the	O
statistical	O
differences	O
between	O
groups	O
is	O
significant	O
or	O
if	O
the	O
P	O
-	O
value	O
was	O
affected	O
by	O
sample	O
size	O
.	O

Due	O
to	O
the	O
small	O
differences	O
between	O
the	O
means	O
of	O
the	O
serum	O
sodium	O
and	O
U	O
/	O
Cr	O
ratios	O
,	O
although	O
significant	O
,	O
effect	O
size	O
was	O
calculated	O
as	O
followed	O
for	O
all	O
population	O
and	O
subgroup	O
analyses	O
:	O

The	O
magnitude	O
of	O
effect	O
size	O
is	O
as	O
followed	O
:	O
0	O
.	O
01	O
=	O
very	O
small	O
,	O
0	O
.	O
2	O
=	O
small	O
,	O
0	O
.	O
5	O
=	O
medium	O
,	O
0	O
.	O
8	O
=	O
large	O
,	O
1	O
.	O
2	O
=	O
very	O
large	O
,	O
and	O
2	O
=	O
huge	O
.	O

[	O
20	O
]	O

The	O
study	O
was	O
approved	O
by	O
the	O
Institutional	O
Ethics	O
Committee	O
of	O
Macabbi	O
Health	O
Services	O
at	O
Assuta	O
Hospital	O
in	O
Tel	O
Aviv	O
.	O

In	O
describing	O
the	O
design	O
of	O
this	O
study	O
the	O
CONSORT	O
2010	O
statement	O
was	O
followed	O
to	O
improve	O
the	O
reporting	O
quality	O
for	O
randomized	O
controlled	O
trials	O
(	O
RCT	O
)	O
[	O
14	O
]	O
.	O

The	O
study	O
is	O
designed	O
as	O
a	O
two	O
-	O
armed	O
cluster	O
RCT	O
with	O
randomisation	O
at	O
the	O
OP	O
level	O
(	O
Figure	O
1	O
)	O
.	O

All	O
participating	O
OPs	O
are	O
recruited	O
from	O
a	O
large	O
collaborating	O
OHS	O
in	O
the	O
Netherlands	O
.	O

The	O
OPs	O
are	O
randomised	O
to	O
an	O
intervention	O
group	O
or	O
a	O
control	O
group	O
.	O

Using	O
an	O
innovative	O
training	O
,	O
OPs	O
in	O
the	O
intervention	O
group	O
are	O
trained	O
to	O
counsel	O
sick	O
-	O
listed	O
workers	O
according	O
to	O
the	O
Dutch	O
national	O
guideline	O
‘Management	O
of	O
mental	O
health	O
problems	O
of	O
workers	O
by	O
occupational	O
physicians’	O
.	O

OPs	O
in	O
the	O
control	O
group	O
receive	O
no	O
training	O
and	O
counsel	O
sick	O
-	O
listed	O
workers	O
with	O
care	O
as	O
usual	O
.	O

Workers	O
are	O
invited	O
by	O
the	O
OHS	O
after	O
their	O
first	O
meeting	O
with	O
the	O
OP	O
.	O

Data	O
on	O
sick	O
leave	O
and	O
RTW	O
of	O
all	O
invited	O
workers	O
are	O
anonymously	O
extracted	O
from	O
the	O
registration	O
system	O
of	O
the	O
OHS	O
during	O
1	O
-	O
year	O
follow	O
-	O
up	O
.	O

In	O
addition	O
,	O
in	O
case	O
of	O
consent	O
the	O
worker	O
receives	O
a	O
questionnaire	O
at	O
baseline	O
(	O
T0	O
)	O
,	O
and	O
at	O
3	O
months	O
(	O
T1	O
)	O
,	O
6	O
months	O
(	O
T2	O
)	O
and	O
12	O
months	O
(	O
T3	O
)	O
post	O
baseline	O
.	O

In	O
addition	O
,	O
2	O
months	O
after	O
baseline	O
a	O
short	O
questionnaire	O
is	O
sent	O
to	O
their	O
supervisor	O
.	O

Flow	O
diagram	O
of	O
the	O
study	O
design	O
.	O

The	O
Medical	O
Research	O
Ethics	O
Committee	O
of	O
Elisabeth	O
Hospital	O
in	O
Tilburg	O
approved	O
the	O
study	O
design	O
,	O
protocol	O
,	O
information	O
letter	O
and	O
brochure	O
,	O
questionnaires	O
,	O
and	O
informed	O
consent	O
.	O

Participation	O
of	O
workers	O
is	O
voluntary	O
and	O
all	O
participants	O
signed	O
an	O
informed	O
consent	O
.	O

Each	O
participant	O
was	O
informed	O
about	O
their	O
right	O
to	O
withdraw	O
from	O
the	O
study	O
at	O
any	O
time	O
.	O

The	O
Dutch	O
guideline	O
‘The	O
management	O
of	O
mental	O
health	O
problems	O
of	O
workers	O
by	O
occupational	O
physicians’	O
promotes	O
an	O
activating	O
approach	O
of	O
the	O
OP	O
as	O
case	O
and	O
care	O
manager	O
to	O
enhance	O
the	O
problem	O
-	O
solving	O
capacity	O
of	O
the	O
workers	O
to	O
achieve	O
RTW	O
.	O

The	O
guideline	O
is	O
based	O
on	O
cognitive	O
behavioural	O
principles	O
to	O
enhance	O
the	O
problem	O
-	O
solving	O
capacity	O
of	O
workers	O
in	O
relation	O
to	O
their	O
work	O
environment	O
,	O
and	O
process	O
-	O
based	O
evaluation	O
.	O

The	O
guideline	O
consists	O
of	O
four	O
consecutive	O
steps	O
:	O

1	O
)	O
Problem	O
orientation	O
and	O
Diagnosis	O
:	O
an	O
early	O
involvement	O
of	O
the	O
OP	O
is	O
promoted	O
(	O
first	O
assessment	O
and	O
start	O
of	O
counselling	O
about	O
2	O
weeks	O
after	O
the	O
worker	O
reported	O
sick	O
)	O
.	O

A	O
simplified	O
classification	O
of	O
mental	O
health	O
problems	O
is	O
introduced	O
in	O
four	O
categories	O
:	O
i	O
)	O
Stress	O
-	O
related	O
complaints	O
,	O
ii	O
)	O
depression	O
,	O
iii	O
)	O
anxiety	O
disorder	O
,	O
and	O
iv	O
)	O
other	O
psychiatric	O
disorders	O
.	O

Furthermore	O
,	O
problem	O
inventory	O
should	O
focus	O
on	O
factors	O
related	O
to	O
the	O
worker	O
and	O
their	O
work	O
environment	O
and	O
the	O
interaction	O
between	O
these	O
two	O
.	O

2	O
)	O
Intervention	O
/	O
Treatment	O
:	O
the	O
OP	O
acts	O
as	O
case	O
manager	O
by	O
monitoring	O
and	O
evaluating	O
the	O
process	O
of	O
recovery	O
(	O
process	O
-	O
based	O
evaluation	O
)	O
.	O

When	O
recovery	O
stagnates	O
OPs	O
should	O
intervene	O
by	O
acting	O
as	O
care	O
manager	O
by	O
using	O
cognitive	O
behavioural	O
techniques	O
to	O
enhance	O
the	O
problem	O
-	O
solving	O
capacity	O
of	O
the	O
worker	O
,	O
providing	O
the	O
worker	O
and	O
work	O
environment	O
with	O
information	O
/	O
advice	O
on	O
the	O
recovery	O
and	O
the	O
RTW	O
process	O
,	O
contact	O
the	O
general	O
practitioner	O
when	O
problems	O
remain	O
the	O
same	O
or	O
increase	O
,	O
and	O
refer	O
the	O
worker	O
to	O
a	O
specialised	O
intervention	O
when	O
necessary	O
.	O

In	O
addition	O
,	O
the	O
OP	O
should	O
advise	O
the	O
work	O
environment	O
(	O
e	O
.	O
g	O
.	O
supervisors	O
,	O
managers	O
,	O
human	O
resource	O
managers	O
)	O
how	O
to	O
support	O
the	O
worker	O
and	O
enhance	O
the	O
recovery	O
and	O
RTW	O
process	O
.	O

3	O
)	O
Relapse	O
prevention	O
:	O
Integration	O
of	O
relapse	O
prevention	O
from	O
the	O
first	O
contact	O
with	O
the	O
worker	O
by	O
enhancing	O
the	O
problem	O
-	O
solving	O
capacity	O
of	O
the	O
worker	O
.	O

4	O
)	O
Evaluation	O
:	O
During	O
follow	O
-	O
up	O
meetings	O
evaluation	O
of	O
the	O
recovery	O
process	O
includes	O
the	O
perspectives	O
of	O
the	O
worker	O
,	O
supervisor	O
,	O
and	O
other	O
involved	O
professionals	O
.	O

Follow	O
-	O
up	O
meetings	O
with	O
the	O
worker	O
should	O
take	O
place	O
every	O
3	O
weeks	O
during	O
the	O
first	O
3	O
months	O
,	O
and	O
then	O
every	O
6	O
weeks	O
thereafter	O
.	O

The	O
supervisor	O
or	O
work	O
environment	O
should	O
be	O
contacted	O
once	O
a	O
month	O
.	O

Follow	O
-	O
up	O
contacts	O
with	O
the	O
general	O
practitioner	O
or	O
other	O
professionals	O
should	O
take	O
place	O
when	O
the	O
recovery	O
process	O
stagnates	O
or	O
when	O
there	O
is	O
doubt	O
about	O
the	O
diagnosis	O
or	O
treatment	O
.	O

OPs	O
participating	O
in	O
the	O
study	O
and	O
allocated	O
to	O
the	O
intervention	O
group	O
received	O
training	O
in	O
the	O
guideline	O
before	O
the	O
start	O
of	O
the	O
study	O
.	O

This	O
training	O
was	O
specifically	O
designed	O
for	O
the	O
purpose	O
of	O
this	O
study	O
and	O
consisted	O
of	O
8	O
meetings	O
within	O
12	O
months	O
.	O

Each	O
meeting	O
took	O
2	O
h	O
and	O
was	O
provided	O
in	O
groups	O
of	O
4	O
-	O
6	O
OPs	O
under	O
the	O
guidance	O
of	O
a	O
trainer	O
.	O

The	O
aim	O
of	O
the	O
training	O
was	O
to	O
enhance	O
guideline	O
adherence	O
of	O
the	O
participating	O
OPs	O
by	O
focussing	O
on	O
barriers	O
that	O
prevent	O
OPs	O
from	O
using	O
the	O
guideline	O
and	O
finding	O
solutions	O
to	O
overcome	O
these	O
barriers	O
.	O

This	O
is	O
considered	O
to	O
be	O
a	O
successful	O
strategy	O
for	O
the	O
implementation	O
of	O
guidelines	O
[	O
15	O
,	O
16	O
]	O
.	O

During	O
the	O
8	O
meetings	O
the	O
(	O
key	O
)	O
recommendations	O
within	O
each	O
consecutive	O
step	O
of	O
the	O
guideline	O
were	O
discussed	O
.	O

These	O
discussions	O
first	O
focussed	O
on	O
barriers	O
that	O
would	O
hinder	O
OPs	O
from	O
using	O
the	O
specific	O
recommendation	O
in	O
practice	O
.	O

The	O
analysis	O
of	O
barriers	O
was	O
structured	O
and	O
based	O
on	O
an	O
existing	O
framework	O
of	O
barriers	O
[	O
17	O
]	O
.	O

According	O
to	O
this	O
framework	O
guideline	O
adherence	O
can	O
be	O
affected	O
by	O
three	O
main	O
categories	O
:	O
1	O
)	O
knowledge	O
-	O
related	O
barriers	O
(	O
lack	O
of	O
awareness	O
and	O
lack	O
of	O
familiarity	O
)	O
,	O
2	O
)	O
attitude	O
-	O
related	O
barriers	O
(	O
lack	O
of	O
agreement	O
,	O
lack	O
of	O
self	O
-	O
efficacy	O
,	O
lack	O
of	O
outcome	O
expectancy	O
and	O
lack	O
of	O
motivation	O
/	O
inertia	O
of	O
previous	O
practice	O
)	O
and	O
3	O
)	O
external	O
barriers	O
that	O
hinder	O
physicians	O
to	O
apply	O
the	O
guideline	O
in	O
practice	O
(	O
guideline	O
factors	O
,	O
environmental	O
factors	O
and	O
patient	O
factors	O
)	O
.	O

Second	O
,	O
the	O
OPs	O
in	O
the	O
group	O
were	O
invited	O
to	O
suggest	O
solutions	O
to	O
address	O
the	O
perceived	O
barriers	O
taking	O
into	O
account	O
the	O
context	O
of	O
their	O
daily	O
practice	O
.	O

Third	O
,	O
the	O
OPs	O
drew	O
up	O
an	O
action	O
plan	O
of	O
how	O
to	O
implement	O
these	O
solutions	O
in	O
their	O
daily	O
practice	O
,	O
and	O
agreed	O
on	O
learning	O
objectives	O
and	O
‘homework’	O
assignments	O
.	O

Between	O
the	O
meetings	O
(	O
a	O
period	O
of	O
about	O
6	O
weeks	O
)	O
the	O
OPs	O
practiced	O
the	O
suggested	O
solutions	O
to	O
experience	O
if	O
and	O
how	O
these	O
would	O
help	O
to	O
apply	O
the	O
guideline	O
recommendations	O
.	O

During	O
the	O
next	O
meeting	O
the	O
experiences	O
of	O
the	O
OPs	O
were	O
evaluated	O
and	O
,	O
when	O
necessary	O
,	O
the	O
solutions	O
were	O
adjusted	O
to	O
what	O
the	O
OPs	O
had	O
experienced	O
in	O
practice	O
.	O

This	O
cycle	O
of	O
plan	O
-	O
do	O
-	O
check	O
-	O
act	O
was	O
repeated	O
in	O
each	O
meeting	O
for	O
all	O
the	O
recommendations	O
stated	O
in	O
the	O
guideline	O
.	O

The	O
OPs	O
in	O
the	O
control	O
group	O
do	O
not	O
receive	O
additional	O
training	O
.	O

They	O
provide	O
care	O
as	O
usual	O
to	O
workers	O
on	O
sick	O
leave	O
.	O

In	O
the	O
Netherlands	O
this	O
means	O
that	O
the	O
OP	O
guides	O
the	O
sick	O
-	O
listed	O
worker	O
during	O
sickness	O
absence	O
,	O
recovery	O
,	O
and	O
RTW	O
.	O

In	O
this	O
process	O
the	O
OP	O
makes	O
a	O
diagnosis	O
,	O
assesses	O
the	O
ability	O
to	O
work	O
,	O
gives	O
advice	O
on	O
work	O
adaptations	O
to	O
the	O
worker	O
and	O
the	O
work	O
environment	O
,	O
and	O
provides	O
relapse	O
prevention	O
.	O

Although	O
OPs	O
are	O
expected	O
to	O
work	O
in	O
accordance	O
with	O
the	O
Dutch	O
guideline	O
,	O
their	O
actual	O
adherence	O
is	O
low	O
[	O
12	O
,	O
13	O
]	O
.	O

The	O
extent	O
of	O
guideline	O
adherence	O
of	O
the	O
participating	O
OPs	O
will	O
be	O
measured	O
by	O
auditing	O
the	O
medical	O
records	O
of	O
workers	O
.	O

All	O
66	O
participating	O
OPs	O
were	O
recruited	O
between	O
October	O
2010	O
and	O
January	O
2011	O
from	O
the	O
collaborative	O
OHS	O
.	O

A	O
researcher	O
presented	O
the	O
study	O
during	O
OP	O
meetings	O
at	O
several	O
agencies	O
of	O
the	O
OHS	O
,	O
provided	O
written	O
information	O
about	O
the	O
study	O
,	O
and	O
provided	O
a	O
registration	O
form	O
and	O
informed	O
consent	O
.	O

OPs	O
participated	O
on	O
a	O
voluntary	O
basis	O
;	O
after	O
completing	O
the	O
training	O
the	O
OPs	O
in	O
the	O
intervention	O
group	O
received	O
educational	O
credits	O
.	O

The	O
study	O
is	O
conducted	O
in	O
the	O
southern	O
part	O
of	O
the	O
Netherlands	O
.	O

The	O
workers	O
eligible	O
for	O
this	O
study	O
are	O
on	O
sick	O
leave	O
due	O
to	O
CMD	O
diagnosed	O
by	O
the	O
OP	O
,	O
counselled	O
by	O
an	O
OP	O
participating	O
in	O
the	O
study	O
,	O
have	O
had	O
a	O
first	O
meeting	O
with	O
the	O
OP	O
,	O
and	O
are	O
aged	O
18–65	O
years	O
.	O

From	O
all	O
eligible	O
workers	O
data	O
on	O
sick	O
leave	O
and	O
RTW	O
will	O
be	O
extracted	O
from	O
the	O
registration	O
system	O
of	O
the	O
OHS	O
anonymously	O
.	O

Workers	O
eligible	O
for	O
the	O
data	O
collection	O
by	O
means	O
of	O
the	O
questionnaires	O
work	O
at	O
one	O
of	O
the	O
±	O
320	O
companies	O
served	O
by	O
this	O
collaborating	O
OHS	O
that	O
gave	O
permission	O
to	O
invite	O
their	O
workers	O
.	O

The	O
companies	O
vary	O
in	O
size	O
and	O
serve	O
different	O
sectors	O
.	O

These	O
workers	O
are	O
selected	O
from	O
the	O
registration	O
system	O
of	O
the	O
OHS	O
after	O
their	O
first	O
consultation	O
with	O
the	O
OP	O
.	O

They	O
are	O
sent	O
an	O
invitation	O
letter	O
from	O
the	O
OHS	O
,	O
as	O
well	O
as	O
written	O
information	O
about	O
the	O
study	O
.	O

Workers	O
who	O
do	O
not	O
want	O
to	O
be	O
contacted	O
further	O
can	O
indicate	O
this	O
on	O
a	O
reply	O
card	O
.	O

All	O
eligible	O
participants	O
are	O
contacted	O
for	O
additional	O
information	O
,	O
and	O
to	O
check	O
the	O
inclusion	O
and	O
exclusion	O
criteria	O
.	O

If	O
the	O
worker	O
is	O
willing	O
to	O
participate	O
in	O
the	O
study	O
and	O
meets	O
all	O
the	O
selection	O
criteria	O
,	O
an	O
informed	O
consent	O
and	O
the	O
baseline	O
questionnaire	O
will	O
be	O
sent	O
to	O
the	O
worker	O
.	O

Inclusion	O
criteria	O
for	O
this	O
study	O
are	O
:	O
1	O
)	O
CMD	B-phenotype
is	O
the	O
primary	O
reason	O
for	O
sick	O
leave	O
diagnosed	O
by	O
an	O
OP	O
according	O
to	O
the	O
Dutch	B-coding_system
Classification	I-coding_system
of	I-coding_system
Diseases	I-coding_system
(	I-coding_system
CAS	I-coding_system
)	I-coding_system
which	O
is	O
based	O
on	O
the	O
ICD	B-coding_system
-	I-coding_system
10	I-coding_system
,	O
2	O
)	O
on	O
current	O
sick	O
leave	O
when	O
selected	O
from	O
the	O
registration	O
system	O
of	O
the	O
OHS	O
after	O
the	O
first	O
meeting	O
with	O
the	O
OP	O
,	O
and	O
3	O
)	O
adequate	O
command	O
of	O
the	O
Dutch	O
language	O
.	O

Exclusion	O
criteria	O
are	O
:	O
being	O
suicidal	O
,	O
and	O
a	O
physical	O
problem	O
being	O
the	O
primary	O
reason	O
for	O
sick	O
leave	O
at	O
the	O
time	O
of	O
study	O
inclusion	O
.	O

Table	O
1	O
presents	O
an	O
overview	O
of	O
the	O
collected	O
data	O
and	O
the	O
study	O
time	O
path	O
.	O

Collection	O
of	O
data	O
and	O
time	O
path	O

The	O
primary	O
outcome	O
is	O
the	O
time	O
to	O
full	O
RTW	O
.	O

For	O
this	O
purpose	O
the	O
number	O
of	O
calendar	O
days	O
between	O
the	O
first	O
day	O
of	O
sickness	O
absence	O
due	O
to	O
CMD	O
and	O
the	O
first	O
day	O
of	O
full	O
RTW	O
is	O
calculated	O
.	O

Working	O
the	O
same	O
hours	O
as	O
prior	O
to	O
the	O
sickness	O
absence	O
in	O
own	O
or	O
equivalent	O
work	O
for	O
at	O
least	O
4	O
weeks	O
is	O
considered	O
full	O
RTW	O
.	O

This	O
means	O
that	O
reporting	O
sick	O
within	O
4	O
weeks	O
of	O
full	O
RTW	O
is	O
not	O
considered	O
as	O
a	O
new	O
period	O
of	O
sickness	O
absence	O
.	O

•Partial	O
RTW	O
is	O
defined	O
as	O
the	O
number	O
of	O
calendar	O
days	O
between	O
the	O
first	O
day	O
of	O
sickness	O
absence	O
due	O
to	O
CMD	O
and	O
the	O
first	O
day	O
of	O
RTW	O
,	O
irrespective	O
of	O
the	O
number	O
of	O
working	O
hours	O
per	O
week	O
.	O

•Total	O
number	O
of	O
calendar	O
days	O
of	O
sick	O
leave	O
is	O
calculated	O
for	O
the	O
1	O
-	O
year	O
follow	O
-	O
up	O
period	O
.	O

•CMD	O
symptoms	O
are	O
measured	O
by	O
the	O
Four	O
Dimensional	O
Symptoms	O
Questionnaire	O
(	O
4DSQ	O
)	O
,	O
a	O
self	O
-	O
report	O
questionnaire	O
measuring	O
the	O
four	O
dimensions	O
of	O
common	O
psychopathology	O
:	O
distress	O
,	O
depression	O
,	O
anxiety	O
and	O
somatisation	O
.	O

The	O
4DSQ	O
consists	O
of	O
50	O
items	O
(	O
each	O
scored	O
on	O
a	O
5	O
-	O
point	O
scale	O
)	O
and	O
refers	O
to	O
symptoms	O
during	O
the	O
past	O
week	O
.	O

The	O
4DSQ	O
has	O
good	O
psychometric	O
properties	O
[	O
18	O
]	O
.	O

•Burnout	O
symptoms	O
are	O
measured	O
by	O
the	O
Utrechtse	O
Burnout	O
Scale	O
-	O
General	O
Survey	O
(	O
UBOS	O
)	O
[	O
19	O
]	O
,	O
which	O
is	O
the	O
Dutch	O
version	O
of	O
the	O
Maslach	O
Burnout	O
Inventory	O
(	O
MBI	O
)	O
.	O

The	O
UBOS	O
is	O
a	O
self	O
-	O
report	O
questionnaire	O
which	O
measures	O
three	O
subscales	O
:	O
emotional	O
exhaustion	O
,	O
mental	O
distance	O
,	O
and	O
competence	O
.	O

Higher	O
scores	O
on	O
exhaustion	O
and	O
distance	O
and	O
lower	O
scores	O
on	O
competence	O
indicate	O
burnout	O
.	O

The	O
UBOS	O
is	O
a	O
reliable	O
and	O
valid	O
instrument	O
[	O
20	O
]	O
.	O

•Workability	O
is	O
measured	O
by	O
three	O
questions	O
(	O
items	O
1	O
,	O
2	O
,	O
3	O
)	O
of	O
the	O
shortened	O
version	O
of	O
the	O
Work	O
Ability	O
Index	O
(	O
WAI	O
)	O
[	O
21	O
,	O
22	O
]	O
.	O

The	O
WAI	O
is	O
a	O
self	O
-	O
report	O
questionnaire	O
and	O
is	O
a	O
reliable	O
and	O
valid	O
instrument	O
[	O
23	O
,	O
24	O
]	O
.	O

•Personal	O
characteristics	O
such	O
as	O
age	O
,	O
gender	O
,	O
level	O
of	O
education	O
,	O
sick	O
leave	O
in	O
the	O
previous	O
year	O
,	O
history	O
of	O
mental	O
disorders	O
,	O
and	O
expectations	O
about	O
full	O
RTW	O
are	O
measured	O
at	O
baseline	O
.	O

•Work	O
characteristics	O
such	O
as	O
number	O
of	O
working	O
hours	O
,	O
contract	O
type	O
,	O
type	O
of	O
work	O
,	O
profession	O
and	O
job	O
content	O
are	O
measured	O
at	O
baseline	O
.	O

Job	O
content	O
is	O
measured	O
with	O
the	O
Dutch	O
version	O
of	O
the	O
Job	O
Content	O
Questionnaire	O
(	O
JCQ	O
)	O
[	O
25	O
]	O
,	O
a	O
self	O
-	O
report	O
questionnaire	O
which	O
measures	O
the	O
social	O
and	O
psychological	O
characteristics	O
of	O
jobs	O
.	O

The	O
JCQ	O
assesses	O
the	O
following	O
scales	O
:	O
psychological	O
job	O
demands	O
,	O
decision	O
latitude	O
,	O
social	O
support	O
,	O
physical	O
demands	O
and	O
job	O
insecurity	O
.	O

Factors	O
which	O
can	O
be	O
influenced	O
by	O
the	O
intervention	O
and	O
thereby	O
can	O
influence	O
RTW	O
are	O
also	O
measured	O
.	O

The	O
results	O
of	O
these	O
additional	O
measures	O
will	O
be	O
reported	O
separately	O
from	O
the	O
results	O
of	O
this	O
RCT	O
.	O

•Coping	O
style	O
is	O
measured	O
with	O
the	O
shortened	O
19	O
-	O
item	O
version	O
of	O
the	O
Utrecht	O
Coping	O
List	O
(	O
UCL	O
)	O
[	O
26	O
]	O
,	O
a	O
self	O
-	O
report	O
questionnaire	O
which	O
measures	O
coping	O
behaviour	O
.	O

The	O
19	O
-	O
item	O
version	O
assesses	O
the	O
following	O
scales	O
:	O
1	O
)	O
active	O
problem	O
solving	O
,	O
2	O
)	O
seeking	O
social	O
support	O
,	O
3	O
)	O
palliative	O
reaction	O
pattern	O
,	O
4	O
)	O
avoidance	O
behaviour	O
,	O
and	O
5	O
)	O
expression	O
of	O
emotions	O
.	O

•Self	O
-	O
efficacy	O
with	O
regard	O
to	O
RTW	O
is	O
measured	O
by	O
the	O
RTW	O
-	O
SE	O
for	O
workers	O
with	O
mental	O
problems	O
.	O

The	O
RTW	O
-	O
SE	O
is	O
a	O
self	O
-	O
report	O
questionnaire	O
which	O
assesses	O
the	O
self	O
-	O
efficacy	O
in	O
the	O
RTW	O
process	O
.	O

The	O
RTW	O
-	O
SE	O
shows	O
promising	O
reliability	O
,	O
validity	O
and	O
prediction	O
of	O
actual	O
RTW	O
within	O
3	O
months	O
[	O
27	O
]	O
.	O

•Remoralization	O
(	O
perception	O
of	O
recovery	O
)	O
is	O
measured	O
with	O
the	O
12	O
-	O
item	O
Remoralization	O
Scale	O
(	O
RS	O
-	O
12	O
)	O
.	O

The	O
RS	O
-	O
12	O
is	O
a	O
self	O
-	O
report	O
questionnaire	O
which	O
indicates	O
the	O
level	O
of	O
morale	O
in	O
mental	O
health	O
care	O
and	O
has	O
shown	O
promising	O
reliability	O
and	O
validity	O
[	O
28	O
]	O
.	O

•Workers’	O
experiences	O
with	O
the	O
consultations	O
with	O
their	O
OP	O
,	O
and	O
the	O
contact	O
with	O
their	O
supervisor	O
,	O
are	O
measured	O
.	O

For	O
example	O
,	O
the	O
number	O
and	O
content	O
of	O
the	O
consultations	O
,	O
and	O
the	O
topics	O
of	O
the	O
conversations	O
.	O

Satisfaction	O
with	O
the	O
counselling	O
by	O
the	O
OP	O
is	O
measured	O
with	O
an	O
adapted	O
version	O
of	O
the	O
Patient	O
Satisfaction	O
with	O
Occupational	O
Health	O
Professionals	O
Questionnaire	O
(	O
PSOHPQ	O
)	O
[	O
29	O
]	O
.	O

•Experiences	O
of	O
the	O
supervisor	O
are	O
measured	O
using	O
self	O
-	O
formulated	O
questions	O
.	O

This	O
questionnaire	O
includes	O
topics	O
such	O
as	O
the	O
contact	O
with	O
worker	O
and	O
the	O
OP	O
,	O
previous	O
experience	O
with	O
CMD	O
and	O
sick	O
leave	O
in	O
general	O
,	O
and	O
policy	O
on	O
sick	O
leave	O
and	O
RTW	O
[	O
see	O
Additional	O
file	O
1	O
]	O
.	O

A	O
power	O
analysis	O
was	O
performed	O
to	O
determine	O
the	O
sample	O
size	O
needed	O
to	O
detect	O
a	O
difference	O
between	O
the	O
control	O
and	O
intervention	O
group	O
with	O
respect	O
to	O
the	O
time	O
workers	O
fully	O
return	O
to	O
their	O
work	O
(	O
primary	O
outcome	O
measure	O
)	O
.	O

Proportions	O
of	O
full	O
RTW	O
were	O
adopted	O
from	O
previous	O
studies	O
[	O
7	O
,	O
30	O
]	O
.	O

It	O
was	O
assumed	O
that	O
in	O
the	O
usual	O
care	O
(	O
control	O
)	O
group	O
55	O
%	O
of	O
the	O
workers	O
would	O
have	O
returned	O
to	O
work	O
after	O
3	O
months	O
and	O
75	O
%	O
after	O
6	O
months	O
,	O
whereas	O
in	O
the	O
intervention	O
group	O
these	O
figures	O
would	O
be	O
75	O
%	O
and	O
90	O
%	O
,	O
respectively	O
.	O

With	O
a	O
power	O
of	O
80	O
%	O
at	O
a	O
0	O
.	O
05	O
alpha	O
level	O
,	O
assuming	O
an	O
ICC	O
of	O
0	O
.	O
025	O
and	O
taking	O
into	O
account	O
a	O
correction	O
factor	O
for	O
the	O
clustered	O
design	O
,	O
it	O
was	O
calculated	O
that	O
2	O
×	O
97	O
workers	O
would	O
be	O
needed	O
to	O
detect	O
the	O
difference	O
after	O
3	O
months	O
and	O
2	O
×	O
110	O
workers	O
for	O
the	O
difference	O
after	O
6	O
months	O
.	O

Allowing	O
for	O
5	O
%	O
attrition	O
on	O
the	O
sick	O
leave	O
data	O
,	O
a	O
total	O
of	O
232	O
workers	O
need	O
to	O
be	O
included	O
.	O

Randomisation	O
takes	O
place	O
at	O
the	O
OP	O
level	O
,	O
because	O
workers	O
cannot	O
be	O
randomly	O
allocated	O
to	O
an	O
OP	O
in	O
the	O
intervention	O
group	O
or	O
an	O
OP	O
in	O
the	O
control	O
group	O
since	O
every	O
OP	O
is	O
allied	O
to	O
a	O
specific	O
company	O
.	O

All	O
participating	O
OPs	O
are	O
randomised	O
by	O
computerised	O
allocation	O
to	O
the	O
intervention	O
group	O
or	O
control	O
group	O
at	O
OHS	O
agency	O
level	O
.	O

Workers	O
and	O
companies	O
are	O
blinded	O
for	O
randomisation	O
since	O
they	O
are	O
not	O
aware	O
of	O
the	O
allocation	O
of	O
their	O
OP	O
.	O

The	O
researcher	O
who	O
performs	O
the	O
analyses	O
(	O
KvB	O
)	O
is	O
blinded	O
for	O
allocation	O
to	O
intervention	O
or	O
care	O
as	O
usual	O
.	O

Survival	O
analyses	O
will	O
be	O
used	O
to	O
analyse	O
the	O
primary	O
outcome	O
(	O
time	O
to	O
full	O
RTW	O
)	O
and	O
the	O
time	O
to	O
partial	O
RTW	O
comparing	O
the	O
intervention	O
and	O
the	O
control	O
group	O
,	O
while	O
taking	O
into	O
account	O
the	O
effect	O
of	O
clustering	O
of	O
workers	O
within	O
OPs	O
.	O

Longitudinal	O
multilevel	O
analysis	O
will	O
be	O
used	O
to	O
analyse	O
the	O
secondary	O
outcomes	O
.	O

To	O
detect	O
significant	O
differences	O
in	O
the	O
baseline	O
characteristics	O
between	O
the	O
intervention	O
group	O
and	O
control	O
group	O
descriptive	O
analyses	O
will	O
be	O
used	O
.	O

If	O
necessary	O
these	O
differences	O
will	O
be	O
taken	O
into	O
account	O
in	O
the	O
effect	O
evaluation	O
.	O

The	O
hypotheses	O
named	O
above	O
will	O
be	O
tested	O
in	O
a	O
prospective	O
and	O
controlled	O
cohort	O
study	O
that	O
is	O
quasi	O
-	O
experimental	O
due	O
to	O
the	O
patient´s	O
health	O
insurance	O
affiliation	O
.	O

The	O
intervention	O
of	O
AO	O
will	O
be	O
tested	O
against	O
TAU	O
.	O

Follow	O
-	O
up	O
occurs	O
after	O
six	O
and	O
12	O
months	O
.	O

The	O
main	O
outcome	O
parameters	O
are	O
the	O
number	O
of	O
admissions	O
to	O
inpatient	O
treatment	O
as	O
well	O
as	O
the	O
number	O
of	O
days	O
spent	O
there	O
.	O

Further	O
outcome	O
parameters	O
include	O
:	O
psychiatric	O
symptomatology	O
,	O
functional	O
status	O
,	O
life	O
satisfaction	O
,	O
adherence	O
to	O
medication	O
,	O
substance	O
misuse	O
,	O
use	O
of	O
services	O
,	O
and	O
satisfaction	O
with	O
chronic	O
care	O
.	O

For	O
details	O
of	O
the	O
scales	O
that	O
will	O
be	O
used	O
to	O
assess	O
these	O
outcome	O
parameters	O
,	O
please	O
see	O
Table	O
2	O
.	O

Instruments	O
to	O
assess	O
and	O
process	O

1	O
Scales	O
assess	O
outcome	O
as	O
well	O
as	O
process	O
:	O
receiving	O
care	O
in	O
concordance	O
with	O
the	O
chronic	O
care	O
model	O
(	O
PACIC	O
)	O
and	O
use	O
of	O
services	O
(	O
CSSRI	O
)	O
.	O

2	O
Is	O
assessed	O
at	O
t0	O
and	O
then	O
every	O
three	O
months	O
,	O
in	O
contrast	O
to	O
all	O
other	O
parameters	O
that	O
are	O
assessed	O
at	O
t0	O
and	O
six	O
and	O
12	O
months	O
later	O
.	O

When	O
selecting	O
scales	O
to	O
measure	O
outcome	O
parameters	O
,	O
we	O
did	O
not	O
only	O
consider	O
specificity	O
and	O
reliability	O
of	O
instruments	O
but	O
also	O
practicability	O
.	O

We	O
expect	O
that	O
the	O
patients	O
,	O
who	O
will	O
be	O
recruited	O
into	O
the	O
study	O
,	O
will	O
be	O
quite	O
impaired	O
by	O
the	O
illness	O
.	O

Therefore	O
,	O
questionnaires	O
need	O
to	O
be	O
simple	O
,	O
easy	O
to	O
handle	O
and	O
not	O
too	O
time	O
-	O
consuming	O
.	O

All	O
parameters	O
will	O
be	O
assessed	O
at	O
baseline	O
(	O
t0	O
)	O
,	O
after	O
six	O
months	O
(	O
t1	O
)	O
,	O
and	O
after	O
12	O
months	O
(	O
t2	O
)	O
from	O
all	O
patients	O
receiving	O
the	O
intervention	O
and	O
from	O
all	O
controls	O
.	O

The	O
use	O
of	O
services	O
however	O
will	O
be	O
assessed	O
every	O
three	O
months	O
(	O
5	O
times	O
)	O
from	O
both	O
groups	O
.	O

The	O
use	O
of	O
services	O
will	O
be	O
assessed	O
by	O
means	O
of	O
the	O
German	O
version	O
of	O
the	O
Client	O
Sociodemographic	O
and	O
Service	O
Receipt	O
Inventory	O
(	O
CSSRI	O
;	O

[	O
22	O
]	O
)	O
.	O

The	O
CSSRI	O
assesses	O
the	O
use	O
of	O
services	O
retrospectively	O
for	O
the	O
past	O
three	O
months	O
by	O
questioning	O
the	O
patient	O
.	O

The	O
CSSRI	O
reports	O
not	O
only	O
the	O
quantitative	O
use	O
of	O
inpatient	O
and	O
outpatient	O
medical	O
and	O
psychiatric	O
services	O
and	O
medication	O
,	O
but	O
also	O
the	O
use	O
of	O
other	O
forms	O
of	O
public	O
support	O
.	O

This	O
includes	O
the	O
use	O
of	O
social	O
services	O
,	O
such	O
as	O
housing	O
,	O
rehabilitation	O
services	O
,	O
the	O
patient’s	O
income	O
,	O
including	O
social	O
benefits	O
and	O
other	O
forms	O
of	O
state	O
payments	O
,	O
as	O
well	O
as	O
their	O
vocational	O
affiliation	O
and	O
number	O
of	O
days	O
of	O
sick	O
leave	O
.	O

Thus	O
,	O
the	O
CSSRI	O
assesses	O
not	O
only	O
the	O
main	O
outcome	O
,	O
i	O
.	O
e	O
.	O
,	O
days	O
spent	O
in	O
psychiatric	O
inpatient	O
care	O
,	O
but	O
also	O
serves	O
as	O
documentation	O
of	O
the	O
process	O
of	O
care	O
across	O
sectors	O
and	O
services	O
for	O
both	O
the	O
intervention	O
and	O
the	O
control	O
group	O
.	O

Finally	O
,	O
the	O
information	O
gathered	O
by	O
the	O
CSSRI	O
allows	O
for	O
calculating	O
direct	O
as	O
well	O
as	O
indirect	O
health	O
care	O
costs	O

[	O
22	O
,	O
23	O
]	O
.	O

Likewise	O
,	O
the	O
German	O
version	O
of	O
Patient	O
Assessment	O
of	O
Chronic	O
Care	O
(	O
PACIC	O
;	O

[	O
24	O
]	O
)	O
that	O
is	O
used	O
to	O
measure	O
patients´	O
satisfaction	O
with	O
chronic	O
care	O
,	O
serves	O
as	O
an	O
instrument	O
to	O
measure	O
outcome	O
as	O
well	O
as	O
process	O
.	O

The	O
PACIC	O
assesses	O
whether	O
patients	O
receive	O
specific	O
services	O
and	O
information	O
–	O
such	O
as	O
health	O
education	O
and	O
shared	O
decision	O
making	O
–	O
that	O
are	O
proven	O
to	O
be	O
significant	O
in	O
the	O
care	O
of	O
chronic	O
patients	O

[	O
25	O
]	O
.	O

Originally	O
,	O
the	O
PACIC	O
was	O
developed	O
for	O
somatic	O
medicine	O
.	O

However	O
,	O
it	O
has	O
been	O
shown	O
to	O
be	O
relevant	O
also	O
in	O
the	O
evaluation	O
of	O
care	O
provided	O
to	O
mentally	O
ill	O
patients	O

[	O
26	O
]	O
.	O

Patients	O
will	O
be	O
recruited	O
in	O
the	O
practices	O
of	O
office	O
-	O
based	O
psychiatrists	O
who	O
provide	O
AO	O
.	O

Recruitment	O
will	O
be	O
done	O
by	O
the	O
treating	O
psychiatrist	O
.	O

Unfortunately	O
,	O
we	O
were	O
not	O
successful	O
in	O
convincing	O
the	O
attending	O
psychiatrists	O
to	O
support	O
“real”	O
randomisation	O
of	O
patients	O
receiving	O
AO	O
or	O
those	O
receiving	O
TAU	O
.	O

“Real”	O
randomisation	O
would	O
have	O
meant	O
that	O
the	O
office	O
-	O
based	O
psychiatrists	O
would	O
lose	O
50	O
%	O
of	O
the	O
extra	O
money	O
they	O
receive	O
from	O
health	O
insurance	O
companies	O
when	O
providing	O
AO	O
.	O

Therefore	O
,	O
a	O
quasi	O
-	O
experimental	O
design	O
will	O
be	O
used	O
instead	O
.	O

As	O
patients	O
allocated	O
to	O
receive	O
the	O
intervention	O
all	O
those	O
patients	O
are	O
considered	O
,	O
who	O
are	O
insured	O
by	O
a	O
health	O
insurance	O
that	O
reimburses	O
AO	O
,	O
and	O
who	O
in	O
fact	O
receive	O
AO	O
.	O

All	O
patients	O
who	O
-	O
due	O
to	O
their	O
health	O
insurance	O
affiliation	O
-	O
are	O
not	O
eligible	O
for	O
AO	O
are	O
considered	O
to	O
be	O
controls	O
.	O

We	O
assume	O
that	O
the	O
affiliation	O
with	O
a	O
specific	O
statutory	O
health	O
insurance	O
company	O
is	O
more	O
or	O
less	O
random	O
.	O

Choice	O
of	O
health	O
insurance	O
company	O
is	O
free	O
,	O
all	O
statutory	O
health	O
insurance	O
companies	O
offer	O
approximately	O
the	O
same	O
services	O
,	O
cost	O
the	O
same	O
and	O
are	O
obliged	O
to	O
insure	O
people	O
regardless	O
of	O
their	O
health	O
and	O
financial	O
status	O
.	O

Even	O
if	O
there	O
might	O
be	O
some	O
differences	O
in	O
social	O
status	O
between	O
the	O
members	O
of	O
different	O
health	O
insurance	O
companies	O
,	O
these	O
differences	O
are	O
most	O
likely	O
obliterated	O
by	O
the	O
social	O
consequences	O
of	O
suffering	O
from	O
schizophrenia	O
.	O

In	O
this	O
quasi	O
-	O
experimental	O
design	O
,	O
all	O
attending	O
practices	O
recruit	O
the	O
same	O
number	O
of	O
patients	O
receiving	O
the	O
intervention	O
and	O
of	O
patients	O
being	O
controls	O
.	O

An	O
honorarium	O
of	O
150€	O
will	O
be	O
paid	O
to	O
the	O
practice	O
per	O
assessment	O
and	O
patient	O
.	O

Patients	O
will	O
receive	O
an	O
honorarium	O
of	O
20€	O
per	O
assessment	O
.	O

Eligibility	O
criteria	O
are	O
:	O
being	O
at	O
least	O
18	O
years	O
of	O
age	O
,	O
suffering	O
from	O
schizophrenia	B-phenotype
(	O
ICD	B-coding_system
-	I-coding_system
10	I-coding_system
F	B-code
20	I-code
)	O
as	O
diagnosed	O
clinically	O
by	O
the	O
treating	O
psychiatrist	O
,	O
having	O
a	O
maximum	O
score	O
of	O
60	O
on	O
the	O
Global	O
Assessment	O
of	O
Functioning	O
Scale	O
(	O
GAF	O
)	O

[	O
14	O
]	O
and	O
being	O
cognitively	O
and	O
linguistically	O
able	O
to	O
fill	O
out	O
the	O
patient	O
questionnaire	O
.	O

Recruitment	O
is	O
planned	O
to	O
take	O
a	O
year	O
.	O

The	O
methodology	O
of	O
the	O
study	O
was	O
developed	O
in	O
close	O
exchange	O
with	O
the	O
psychiatric	O
practices	O
of	O
the	O
management	O
association	O
providing	O
AO	O
.	O

To	O
make	O
this	O
pragmatic	O
trial	O

[	O
26	O
]	O
work	O
,	O
we	O
sought	O
to	O
adjust	O
our	O
study	O
design	O
as	O
closely	O
as	O
possible	O
to	O
the	O
conditions	O
and	O
requirements	O
of	O
daily	O
life	O
and	O
work	O
in	O
the	O
psychiatric	O
practices	O
.	O

Further	O
,	O
all	O
practices	O
are	O
visited	O
by	O
a	O
member	O
of	O
the	O
research	O
team	O
for	O
recruitment	O
and	O
for	O
explaining	O
the	O
study	O
.	O

This	O
team	O
member	O
then	O
becomes	O
the	O
personal	O
contact	O
for	O
this	O
practice	O
throughout	O
the	O
study	O
.	O

The	O
team	O
member	O
trains	O
the	O
practice	O
assistant	O
in	O
handing	O
out	O
and	O
collecting	O
the	O
study	O
materials	O
to	O
patients	O
receiving	O
the	O
intervention	O
and	O
to	O
controls	O
.	O

During	O
recruitment	O
and	O
assessment	O
times	O
the	O
study	O
-	O
team	O
member	O
holds	O
weekly	O
telephone	O
contact	O
to	O
its	O
assigned	O
practice	O
.	O

A	O
telephone	O
hotline	O
is	O
implemented	O
for	O
upcoming	O
urgent	O
questions	O
concerning	O
the	O
study	O
.	O

Previous	O
studies	O
performed	O
in	O
Leipzig	O
,	O
Germany	O
,	O
have	O
shown	O
a	O
mean	O
number	O
of	O
days	O
spent	O
in	O
psychiatric	O
inpatient	O
care	O
by	O
schizophrenic	O
patients	O
of	O
47	O
(	O
SD	O
83	O
)	O

[	O
27	O
]	O
.	O

Further	O
,	O
studies	O
estimated	O
the	O
mean	O
decrease	O
of	O
inpatient	O
days	O
that	O
can	O
be	O
expected	O
from	O
interventions	O
to	O
be	O
40	O
%	O

[	O
28	O
]	O
.	O

According	O
to	O
Hedeker	O
and	O
colleagues	O
(	O
1999	O
)	O
,	O
a	O
baseline	O
sample	O
size	O
of	O
242	O
participants	O
in	O
each	O
group	O
would	O
be	O
required	O
to	O
detect	O
a	O
small	O
effect	O
size	O
of	O
0	O
.	O
2	O
with	O
a	O
power	O
of	O
0	O
.	O
80	O
at	O
a	O
two	O
-	O
tailed	O
significance	O
level	O
of	O
0	O
.	O
05	O

[	O
29	O
]	O
.	O

Previous	O
studies	O
have	O
shown	O
that	O
20	O
%	O
of	O
patients	O
cannot	O
be	O
traced	O
for	O
follow	O
-	O
up	O
or	O
do	O
not	O
return	O
questionnaires	O
over	O
a	O
12	O
-	O
month	O
survey	O
period	O

[	O
27	O
]	O
.	O
We	O
aim	O
to	O
reduce	O
drop	O
-	O
out	O
numbers	O
by	O
keeping	O
records	O
of	O
patients	O
'	O
telephone	O
contact	O
details	O
as	O
well	O
as	O
secondary	O
contact	O
names	O
and	O
addresses	O
at	O
the	O
practices	O
of	O
the	O
attending	O
psychiatrists	O
.	O

If	O
patients	O
fail	O
to	O
return	O
for	O
assessment	O
to	O
the	O
attending	O
practice	O
,	O
they	O
are	O
contacted	O
by	O
phone	O
and	O
asked	O
whether	O
they	O
want	O
to	O
continue	O
with	O
the	O
study	O
.	O

This	O
way	O
,	O
we	O
hope	O
to	O
keep	O
the	O
number	O
of	O
drop	O
-	O
outs	O
at	O
a	O
rate	O
of	O
10	O
%	O
.	O

Thus	O
,	O
the	O
total	O
number	O
of	O
participants	O
to	O
be	O
initially	O
recruited	O
will	O
be	O
268	O
patients	O
per	O
group	O
or	O
536	O
in	O
total	O
.	O

Even	O
in	O
case	O
of	O
low	O
rates	O
of	O
non	O
-	O
response	O
,	O
patients	O
who	O
are	O
lost	O
to	O
follow	O
-	O
up	O
represent	O
a	O
potential	O
source	O
of	O
selection	O
bias	O
.	O

Therefore	O
we	O
will	O
present	O
a	O
flow	O
chart	O
containing	O
the	O
numbers	O
of	O
patients	O
in	O
different	O
stages	O
of	O
the	O
study	O
(	O
e	O
.	O
g	O
.	O
screened	O
for	O
eligibility	O
,	O
allocated	O
,	O
follow	O
-	O
up	O
)	O
and	O
report	O
reasons	O
for	O
non	O
-	O
response	O
.	O

Furthermore	O
,	O
we	O
will	O
compare	O
baseline	O
characteristics	O
of	O
non	O
-	O
responders	O
and	O
study	O
participants	O
(	O
age	O
,	O
gender	O
and	O
assessment	O
of	O
functioning	O
)	O
as	O
well	O
as	O
of	O
those	O
who	O
are	O
lost	O
to	O
follow	O
-	O
up	O
and	O
those	O
who	O
retain	O
.	O

We	O
will	O
analyse	O
data	O
using	O
per	O
-	O
protocol	O
analysis	O
,	O
considering	O
only	O
those	O
patients	O
who	O
successfully	O
completed	O
the	O
study	O
,	O
as	O
well	O
as	O
using	O
an	O
intention	O
-	O
to	O
-	O
treat	O
approach	O
.	O

Thereby	O
we	O
would	O
also	O
consider	O
those	O
patients	O
who	O
dropped	O
out	O
of	O
the	O
study	O
or	O
changed	O
their	O
originally	O
allocated	O
group	O
.	O

We	O
will	O
report	O
baseline	O
demographic	O
and	O
clinical	O
characteristics	O
for	O
each	O
study	O
condition	O
and	O
test	O
for	O
baseline	O
equivalence	O
using	O
parametric	O
and	O
non	O
-	O
parametric	O
test	O
as	O
appropriate	O
.	O

If	O
necessary	O
,	O
we	O
will	O
control	O
for	O
baseline	O
differences	O
.	O

Missing	O
data	O
will	O
be	O
analysed	O
.	O

Longitudinal	O
data	O
will	O
be	O
analysed	O
using	O
standard	O
models	O
for	O
repeated	O
measures	O
including	O
multivariate	O
mixed	O
effects	O
analysis	O
of	O
variance	O
,	O
random	O
effects	O
and	O
generalized	O
estimating	O
equation	O
(	O
GEE	O
)	O
models	O
,	O
as	O
appropriate	O
.	O

Whenever	O
possible	O
,	O
measures	O
of	O
"	O
practical	O
relevance	O
"	O
such	O
as	O
proportion	O
of	O
explained	O
variance	O
,	O
accuracy	O
of	O
prediction	O
,	O
or	O
effect	O
size	O
will	O
be	O
reported	O
.	O

Statistical	O
analyses	O
will	O
be	O
performed	O
using	O
standard	O
software	O
packages	O
(	O
SPSS	O
,	O
STATA	O
)	O
.	O

Written	O
consent	O
is	O
sought	O
from	O
all	O
participants	O
.	O

For	O
those	O
under	O
legal	O
guardianship	O
,	O
consent	O
is	O
also	O
sought	O
from	O
the	O
guardian	O
.	O

The	O
patients’	O
identity	O
on	O
the	O
questionnaires	O
will	O
be	O
pseudonymised	O
by	O
the	O
recruiting	O
practice	O
.	O

Only	O
the	O
pseudonymised	O
filled	O
-	O
out	O
questionnaires	O
will	O
be	O
sent	O
to	O
the	O
study	O
centre	O
.	O

Thus	O
,	O
there	O
is	O
no	O
direct	O
contact	O
between	O
patients	O
and	O
researchers	O
.	O

The	O
Research	O
Ethics	O
Committee	O
of	O
the	O
Lower	O
Saxony	O
Medical	O
Association	O
approved	O
the	O
study	O
(	O
Ärztekammer	O
Niedersachsen	O
BO	O
/	O
03	O
/	O
2011	O
)	O
.	O

It	O
is	O
compliant	O
with	O
the	O
Helsinki	O
Declaration	O
.	O

The	O
reporting	O
of	O
the	O
study	O
will	O
be	O
in	O
accordance	O
with	O
standards	O
of	O
the	O
CONSORT	O
extension	O
for	O
pragmatic	O
trials	O
and	O
the	O
TREND	O
statement	O

[	O
30	O
,	O
31	O
]	O
.	O

Using	O
data	O
from	O
Fiscal	O
Year	O
(	O
FY	O
)	O
2007	O
-	O
2010	O
,	O
we	O
studied	O
a	O
cohort	O
of	O
patients	O
in	O
the	O
Veterans	O
Affairs	O
healthcare	O
system	O
age	O
65	O
years	O
or	O
older	O
with	O
a	O
diagnosis	O
of	O
dementia	O
who	O
were	O
not	O
receiving	O
a	O
cholinesterase	O
inhibitor	O
during	O
a	O
one	O
-	O
year	O
baseline	O
period	O
.	O

Employing	O
a	O
new	O
-	O
user	O
design	O
,	O
we	O
identified	O
patients	O
who	O
subsequently	O
received	O
a	O
new	O
prescription	O
for	O
a	O
cholinesterase	O
inhibitor	O
over	O
the	O
following	O
year	O
,	O
and	O
a	O
control	O
group	O
of	O
patients	O
who	O
received	O
a	O
prescription	O
for	O
different	O
new	O
chronic	O
medication	O
over	O
the	O
same	O
time	O
period	O
.	O

To	O
maximize	O
completeness	O
of	O
medication	O
prescribing	O
data	O
,	O
we	O
excluded	O
patients	O
who	O
received	O
less	O
than	O
80	O
%	O
of	O
primary	O
care	O
or	O
specialty	O
visits	O
at	O
VA	O
medical	O
centers	O
or	O
were	O
enrolled	O
in	O
Medicare	O
managed	O
care	O
programs	O
during	O
the	O
study	O
period	O
,	O
as	O
those	O
patients	O
may	O
have	O
received	O
cholinesterase	O
inhibitors	O
from	O
other	O
sources	O
that	O
we	O
would	O
not	O
capture	O
.	O

We	O
applied	O
several	O
weight	O
-	O
based	O
exclusion	O
criteria	O
to	O
focus	O
on	O
patients	O
who	O
had	O
relatively	O
stable	O
weight	O
at	O
baseline	O
and	O
did	O
not	O
have	O
comorbid	O
conditions	O
associated	O
with	O
large	O
fluctuations	O
in	O
weight	O
.	O

We	O
excluded	O
patients	O
with	O
congestive	O
heart	O
failure	O
or	O
cancer	O
(	O
other	O
than	O
prostate	O
or	O
basal	O
-	O
cell	O
skin	O
cancer	O
)	O
,	O
patients	O
with	O
more	O
than	O
a	O
10	O
-	O
pound	O
weight	O
change	O
in	O
the	O
year	O
prior	O
,	O
and	O
patients	O
with	O
insufficient	O
weight	O
data	O
during	O
the	O
study	O
period	O
.	O

Among	O
eligible	O
patients	O
,	O
we	O
identified	O
patients	O
who	O
were	O
newly	O
prescribed	O
a	O
cholinesterase	O
inhibitor	O
(	O
donepezil	O
,	O
galantamine	O
,	O
rivastigmine	O
,	O
or	O
tacrine	O
)	O
through	O
a	O
VA	O
outpatient	O
pharmacy	O
during	O
FY	O
2008	O
–	O
2009	O
.	O

We	O
also	O
identified	O
a	O
separate	O
control	O
group	O
of	O
patients	O
not	O
prescribed	O
cholinesterase	O
inhibitors	O
,	O
but	O
who	O
were	O
started	O
on	O
other	O
new	O
chronic	O
medications	O
(	O
which	O
we	O
defined	O
as	O
medications	O
prescribed	O
with	O
a	O
>	O
=25	O
days	O
supply	O
)	O
during	O
that	O
time	O
period	O
.	O

If	O
a	O
patient	O
was	O
started	O
on	O
more	O
than	O
one	O
new	O
chronic	O
medication	O
,	O
we	O
randomly	O
selected	O
one	O
as	O
the	O
control	O
medication	O
for	O
this	O
study	O
.	O

An	O
index	O
date	O
for	O
each	O
patient	O
was	O
defined	O
as	O
the	O
day	O
the	O
new	O
medication	O
(	O
cholinesterase	O
inhibitor	O
or	O
other	O
chronic	O
medication	O
)	O
was	O
first	O
dispensed	O
.	O

We	O
used	O
ICD	B-coding_system
-	I-coding_system
9	I-coding_system
codes	O
to	O
define	O
patients	O
diagnosed	O
with	O
dementia	B-phenotype
or	I-phenotype
mild	I-phenotype
cognitive	I-phenotype
impairment	I-phenotype
using	O
established	O
methods	O
10	O
,	O
11	O
that	O
included	O
patients	O
who	O
had	O
at	O
least	O
one	O
inpatient	O
or	O
two	O
outpatient	O
encounter	O
ICD	B-coding_system
-	I-coding_system
9	I-coding_system
codes	O
for	O
dementia	B-phenotype
(	O
290	B-code
-	I-code
290	I-code
.	I-code
9	I-code
,	O
294	B-code
-	I-code
294	I-code
.	I-code
9	I-code
,	O
331	B-code
-	I-code
331	I-code
.	I-code
9	I-code
,	O
291	B-code
.	I-code
1	I-code
,	O
291	B-code
.	I-code
2	I-code
,	O
292	B-code
.	I-code
82	I-code
,	O
292	B-code
.	I-code
83	I-code
,	O
438	B-code
.	I-code
0	I-code
,	O
or	O
780	B-code
.	I-code
93	I-code
)	O
.	O

These	O
include	O
ICD	B-coding_system
-	I-coding_system
9	I-coding_system
codes	O
for	O
Alzheimer	B-phenotype
'	I-phenotype
s	I-phenotype
,	I-phenotype
vascular	I-phenotype
,	I-phenotype
and	I-phenotype
Lewy	I-phenotype
body	I-phenotype
dementia	I-phenotype
,	O
and	O
exclude	O
codes	O
for	O
dementia	B-phenotype
due	I-phenotype
to	I-phenotype
alcohol	I-phenotype
and	I-phenotype
drug	I-phenotype
-	I-phenotype
induced	I-phenotype
dementia	I-phenotype
,	I-phenotype
and	I-phenotype
general	I-phenotype
senility	I-phenotype
or	I-phenotype
frailty	I-phenotype
.	O

In	O
validation	O
studies	O
,	O
the	O
sensitivity	O
of	O
using	O
similar	O
ICD	B-coding_system
-	I-coding_system
9	I-coding_system
codes	O
to	O
identify	O
dementia	B-phenotype
ranges	I-phenotype
from	I-phenotype
30	I-phenotype
-	I-phenotype
87	I-phenotype
%	I-phenotype
,	I-phenotype
and	I-phenotype
specificity	I-phenotype
from	I-phenotype
84–100	I-phenotype
%	I-phenotype
.	I-phenotype

10	O

We	O
obtained	O
baseline	O
demographics	O
including	O
age	O
and	O
race	O
from	O
national	O
VA	O
and	O
Medicare	O
databases	O
.	O

We	O
defined	O
the	O
presence	O
of	O
each	O
of	O
22	O
comorbid	O
conditions	O
by	O
the	O
presence	O
of	O
2	O
or	O
more	O
outpatient	O
encounter	O
codes	O
or	O
1	O
or	O
more	O
inpatient	O
discharge	O
diagnosis	O
,	O
following	O
previously	O
described	O
methods	O
.	O

12	O
We	O
measured	O
health	O
services	O
utilization	O
by	O
examining	O
the	O
number	O
of	O
primary	O
and	O
specialty	O
clinic	O
visits	O
by	O
each	O
patient	O
to	O
the	O
VA	O
in	O
the	O
year	O
before	O
the	O
index	O
date	O
for	O
new	O
drug	O
.	O

We	O
used	O
both	O
VA	O
and	O
Medicare	O
date	O
to	O
determine	O
whether	O
patients	O
were	O
hospitalized	O
in	O
the	O
baseline	O
year	O
.	O

Weight	O
data	O
in	O
VA	O
are	O
collected	O
during	O
clinic	O
visits	O
and	O
entered	O
manually	O
into	O
the	O
electronic	O
medical	O
record	O
.	O

To	O
reduce	O
impact	O
of	O
erroneous	O
readings	O
or	O
data	O
entry	O
errors	O
,	O
we	O
eliminated	O
biologically	O
implausible	O
values	O
of	O
<	O
70	O
pounds	O
or	O
>	O
500	O
pounds	O
.	O

13	O
To	O
further	O
exclude	O
clearly	O
erroneous	O
weights	O
from	O
the	O
data	O
,	O
in	O
the	O
one	O
-	O
year	O
baseline	O
period	O
we	O
excluded	O
weight	O
measures	O
for	O
each	O
patient	O
that	O
were	O
more	O
than	O
20	O
%	O
different	O
from	O
their	O
median	O
weight	O
in	O
the	O
baseline	O
period	O
.	O

Similarly	O
,	O
in	O
the	O
follow	O
-	O
up	O
period	O
weight	O
measures	O
more	O
then	O
20	O
%	O
different	O
from	O
the	O
starting	O
weight	O
were	O
excluded	O
,	O
to	O
avoid	O
classifying	O
patients	O
to	O
as	O
having	O
weight	O
loss	O
based	O
on	O
a	O
single	O
aberrant	O
weight	O
measure	O
.	O

We	O
then	O
defined	O
weights	O
during	O
three	O
periods	O
.	O

First	O
,	O
we	O
established	O
the	O
weight	O
one	O
year	O
prior	O
to	O
drug	O
initiation	O
by	O
determining	O
the	O
mean	O
of	O
weights	O
recorded	O
between	O
245	O
-	O
485	O
days	O
before	O
the	O
index	O
date	O
.	O

Then	O
,	O
we	O
established	O
the	O
weight	O
at	O
the	O
index	O
date	O
(	O
the	O
“index	O
weight”	O
)	O
by	O
calculating	O
the	O
mean	O
of	O
recorded	O
weights	O
for	O
each	O
patient	O
between	O
30	O
days	O
before	O
to	O
5	O
days	O
after	O
the	O
index	O
date	O
.	O

We	O
used	O
this	O
date	O
range	O
because	O
patients	O
did	O
not	O
always	O
have	O
a	O
weight	O
on	O
their	O
exact	O
index	O
date	O
.	O

We	O
considered	O
the	O
difference	O
between	O
the	O
one	O
-	O
year	O
-	O
prior	O
weight	O
and	O
the	O
index	O
weight	O
to	O
be	O
the	O
weight	O
trajectory	O
for	O
each	O
patient	O
during	O
the	O
baseline	O
period	O
.	O

Finally	O
,	O
we	O
evaluated	O
weights	O
over	O
the	O
year	O
following	O
initiation	O
of	O
the	O
cholinesterase	O
inhibitor	O
or	O
control	O
drug	O
.	O

We	O
defined	O
10	O
-	O
pound	O
weight	O
loss	O
as	O
the	O
first	O
recorded	O
weight	O
in	O
the	O
follow	O
-	O
up	O
period	O
that	O
was	O
>	O
=10	O
pounds	O
lower	O
than	O
the	O
weight	O
at	O
the	O
time	O
the	O
drug	O
was	O
started	O
.	O

Our	O
primary	O
outcome	O
was	O
the	O
time	O
to	O
10	O
-	O
pound	O
weight	O
loss	O
during	O
the	O
first	O
year	O
after	O
initiating	O
a	O
cholinesterase	O
inhibitor	O
,	O
or	O
in	O
the	O
control	O
group	O
,	O
after	O
starting	O
a	O
different	O
chronic	O
medication	O
.	O

We	O
chose	O
10	O
pound	O
weight	O
loss	O
as	O
our	O
primary	O
outcome	O
,	O
as	O
this	O
represents	O
a	O
degree	O
of	O
weight	O
loss	O
that	O
would	O
be	O
noticed	O
by	O
a	O
clinician	O
and	O
may	O
prompt	O
further	O
action	O
in	O
in	O
considering	O
causes	O
and	O
work	O
-	O
up	O
of	O
weight	O
loss	O
.	O

Propensity	O
score	O
matching	O
was	O
used	O
to	O
match	O
new	O
users	O
of	O
cholinesterase	O
inhibitors	O
with	O
new	O
users	O
of	O
other	O
chronic	O
medications	O
who	O
had	O
similar	O
baseline	O
characteristics	O
,	O
using	O
a	O
propensity	O
score	O
model	O
with	O
3	O
:	O
1	O
nearest	O
neighbors	O
matching	O
.	O

The	O
propensity	O
score	O
model	O
included	O
demographic	O
factors	O
(	O
age	O
,	O
sex	O
,	O
race	O
)	O
;	O
baseline	O
degree	O
of	O
comorbid	O
burden	O
and	O
medication	O
use	O
(	O
presence	O
or	O
absence	O
of	O
22	O
common	O
conditions	O
in	O
older	O
adults	O
,	O
12	O
number	O
of	O
chronic	O
medications	O
,	O
use	O
of	O
memantine	O
)	O
;	O
weight	O
status	O
(	O
baseline	O
weight	O
,	O
weight	O
trajectory	O
over	O
prior	O
year	O
)	O
;	O
and	O
intensity	O
of	O
medical	O
care	O
(	O
frequency	O
of	O
weight	O
measurements	O
,	O
number	O
of	O
primary	O
care	O
and	O
specialty	O
visits	O
,	O
and	O
hospitalizations	O
over	O
the	O
baseline	O
year	O
)	O
.	O

We	O
used	O
Cox	O
-	O
proportional	O
hazards	O
models	O
to	O
compare	O
the	O
risk	O
of	O
weight	O
loss	O
between	O
cholinesterase	O
inhibitor	O
and	O
matched	O
controls	O
.	O

To	O
determine	O
if	O
there	O
were	O
clinically	O
important	O
subgroups	O
in	O
which	O
cholinesterase	O
inhibitors	O
were	O
associated	O
with	O
greater	O
risk	O
of	O
weight	O
loss	O
,	O
we	O
evaluated	O
treatment	O
-	O
by	O
-	O
subgroup	O
interaction	O
terms	O
for	O
a	O
priori	O
-	O
defined	O
subgroups	O
by	O
age	O
,	O
comorbid	O
burden	O
,	O
and	O
initial	O
weight	O
.	O

Number	O
needed	O
to	O
harm	O
was	O
calculated	O
using	O
survival	O
probabilities	O
,	O
which	O
does	O
not	O
assume	O
a	O
constant	O
hazard	O
ratio	O
over	O
time	O
.	O

A	O
secondary	O
outcome	O
was	O
the	O
mean	O
change	O
in	O
weight	O
over	O
one	O
year	O
.	O

We	O
used	O
mixed	O
-	O
effects	O
linear	O
regression	O
with	O
random	O
slopes	O
and	O
intercepts	O
to	O
estimate	O
a	O
one	O
-	O
year	O
weight	O
trajectory	O
for	O
each	O
patient	O
.	O

We	O
compared	O
the	O
predicted	O
weight	O
trajectory	O
in	O
the	O
two	O
groups	O
using	O
Student	O
'	O
s	O
t	O
-	O
test	O
.	O

We	O
did	O
several	O
sensitivity	O
analyses	O
.	O

First	O
,	O
we	O
examined	O
the	O
outcome	O
of	O
time	O
to	O
5	O
%	O
weight	O
loss	O
instead	O
of	O
10	O
-	O
pound	O
weight	O
loss	O
.	O

Second	O
,	O
we	O
used	O
regression	O
analysis	O
incorporating	O
the	O
propensity	O
score	O
to	O
evaluate	O
weight	O
loss	O
instead	O
of	O
matching	O
using	O
the	O
propensity	O
score	O
.	O

Third	O
,	O
we	O
evaluated	O
weight	O
loss	O
in	O
an	O
on	O
-	O
treatment	O
analysis	O
,	O
censoring	O
patients	O
from	O
further	O
weight	O
loss	O
assessments	O
30	O
days	O
after	O
they	O
stopped	O
taking	O
the	O
medication	O
.	O

In	O
the	O
on	O
-	O
treatment	O
analysis	O
,	O
in	O
addition	O
to	O
matching	O
on	O
propensity	O
score	O
we	O
also	O
matched	O
new	O
users	O
of	O
cholinesterase	O
inhibitors	O
to	O
control	O
patients	O
by	O
the	O
length	O
of	O
time	O
they	O
continued	O
filling	O
prescriptions	O
for	O
the	O
new	O
medication	O
.	O

Fourth	O
,	O
we	O
used	O
Cox	O
regression	O
to	O
compare	O
the	O
risk	O
of	O
weight	O
loss	O
among	O
donepezil	O
and	O
galantamine	O
,	O
the	O
two	O
most	O
commonly	O
used	O
cholinesterase	O
inhibitors	O
in	O
our	O
sample	O
,	O
controlling	O
for	O
the	O
same	O
types	O
of	O
variables	O
used	O
in	O
the	O
propensity	O
score	O
.	O

STATA	O
version	O
12	O
was	O
used	O
for	O
analysis	O
.	O

The	O
Committee	O
on	O
Human	O
Research	O
at	O
the	O
University	O
of	O
California	O
,	O
San	O
Francisco	O
,	O
and	O
the	O
Research	O
Committee	O
at	O
the	O
San	O
Francisco	O
VA	O
Medical	O
Center	O
approved	O
this	O
research	O
.	O

Patients	O
who	O
consented	O
to	O
participate	O
in	O
one	O
of	O
four	O
large	O
health	O
care	O
system–based	O
biobanks—the	O
MyCode	O
Community	O
Health	O
Initiative	O
at	O
the	O
Geisinger	O
Health	O
System	O
(	O
GHS	O
)	O
(	O
19	O
)	O
,	O
the	O
BioMe	O
Biobank	O
at	O
the	O
Mount	O
Sinai	O
School	O
of	O
Medicine	O
(	O
MSSM	O
)	O
(	O
20	O
)	O
,	O
the	O
Partners	O
HealthCare	O
System	O
(	O
PHS	O
)	O
biobank	O
(	O
21	O
)	O
,	O
and	O
the	O
Vanderbilt	O
University	O
Medical	O
Center	O
(	O
VUMC	O
)	O
biobank	O
(	O
BioVU	O
)	O
(	O
22	O
)	O
—and	O
had	O
available	O
EHR	O
and	O
genotype	O
data	O
were	O
included	O
in	O
these	O
analyses	O
.	O

At	O
each	O
site	O
,	O
patients	O
were	O
recruited	O
from	O
the	O
general	O
health	O
care	O
system	O
population	O
without	O
systematic	O
recruitment	O
for	O
any	O
particular	O
disease	O
or	O
diagnosis	O
.	O

It	O
is	O
well	O
known	O
that	O
PRSs	O
calculated	O
from	O
genome	O
-	O
wide	O
association	O
studies	O
(	O
GWASs	O
)	O
performed	O
primarily	O
in	O
one	O
ancestry	O
demonstrate	O
poorer	O
performance	O
in	O
other	O
ancestries	O
as	O
a	O
function	O
of	O
differing	O
linkage	O
disequilibrium	O
(	O
LD	O
)	O
structures	O
with	O
causal	O
variants	O
and	O
lack	O
of	O
diversity	O
on	O
genotyping	O
platforms	O
(	O
23	O
,	O
24	O
)	O
.	O

Thus	O
,	O
this	O
study	O
was	O
limited	O
to	O
patients	O
of	O
European	O
-	O
American	O
ancestry	O
for	O
whom	O
genetic	O
data	O
were	O
available	O
that	O
met	O
standard	O
quality	O
control	O
thresholds	O
(	O
see	O
below	O
)	O
.	O

Besides	O
these	O
data	O
availability	O
and	O
ancestry	O
filters	O
,	O
no	O
further	O
inclusion	O
or	O
exclusion	O
criteria	O
were	O
applied	O
.	O

Our	O
final	O
sample	O
included	O
44	O
,	O
436	O
patients	O
from	O
GHS	O
,	O
9	O
,	O
569	O
patients	O
from	O
MSSM	O
,	O
18	O
,	O
461	O
patients	O
from	O
PHS	O
,	O
and	O
33	O
,	O
694	O
patients	O
from	O
VUMC	O
(	O
a	O
total	O
of	O
106	O
,	O
160	O
patients	O
)	O
.	O

All	O
patients	O
gave	O
informed	O
consent	O
for	O
biobank	O
research	O
,	O
for	O
which	O
institutional	O
review	O
board	O
approval	O
was	O
obtained	O
at	O
each	O
site	O
.	O

Samples	O
were	O
genotyped	O
,	O
imputed	O
,	O
and	O
cleaned	O
at	O
each	O
site	O
individually	O
,	O
as	O
described	O
in	O
detail	O
in	O
the	O
Supplementary	O
Methods	O
section	O
of	O
the	O
online	O
supplement	O
.	O

Quality	O
control	O
procedures	O
at	O
each	O
site	O
followed	O
a	O
similar	O
standard	O
pipeline	O
.	O

DNA	O
from	O
blood	O
samples	O
obtained	O
from	O
biobank	O
participants	O
was	O
assayed	O
using	O
Illumina	O
bead	O
arrays	O
(	O
Omni	O
-	O
Express	O
Exome	O
,	O
Global	O
Screening	O
,	O
MEGA	O
,	O
MEGA	O
EX	O
,	O
or	O
MEG	O
BeadChips	O
)	O
containing	O
approximately	O
700	O
,	O
000	O
to	O
2	O
million	O
markers	O
.	O

Samples	O
at	O
each	O
site	O
were	O
genotyped	O
in	O
multiple	O
batches	O
;	O
indicators	O
for	O
genotyping	O
platform	O
and	O
batch	O
were	O
included	O
as	O
covariates	O
in	O
the	O
analyses	O
.	O

As	O
described	O
in	O
the	O
Supplementary	O
Methods	O
section	O
of	O
the	O
online	O
supplement	O
,	O
single	O
-	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
were	O
excluded	O
using	O
filters	O
for	O
call	O
rate	O
,	O
minor	O
allele	O
frequency	O
,	O
and	O
heterozygosity	O
at	O
a	O
minimum	O
.	O

Individuals	O
were	O
excluded	O
for	O
excessive	O
missing	O
data	O
or	O
sex	O
errors	O
;	O
a	O
random	O
individual	O
from	O
any	O
pair	O
of	O
related	O
individuals	O
was	O
also	O
excluded	O
(	O
kinship	O
coefficient	O
>	O
0	O
.	O
2	O
)	O
.	O

Principal	O
components	O
or	O
self	O
-	O
reported	O
ancestry	O
was	O
used	O
to	O
identify	O
individuals	O
of	O
European	O
ancestry	O
.	O

SNPs	O
that	O
passed	O
the	O
initial	O
phase	O
of	O
quality	O
control	O
were	O
imputed	O
and	O
then	O
converted	O
to	O
best	O
-	O
guess	O
genotypes	O
where	O
only	O
high	O
-	O
quality	O
markers	O
were	O
retained	O
.	O

Ten	O
principal	O
components	O
were	O
generated	O
within	O
the	O
European	O
sample	O
to	O
use	O
as	O
ancestry	O
covariates	O
in	O
all	O
subsequent	O
analyses	O
.	O

To	O
quantify	O
genetic	O
risk	O
for	O
schizophrenia	O
,	O
we	O
calculated	O
PRSs	O
using	O
summary	O
statistics	O
from	O
the	O
PGC	O
GWAS	O
of	O
schizophrenia	O
(	O
14	O
)	O
,	O
which	O
included	O
odds	O
ratios	O
for	O
9	O
,	O
444	O
,	O
230	O
variants	O
.	O

PRSs	O
were	O
calculated	O
by	O
two	O
methods	O
,	O
a	O
simple	O
and	O
widely	O
used	O
approach	O
in	O
which	O
SNPs	O
are	O
pruned	O
on	O
the	O
basis	O
of	O
LD	O
and	O
association	O
p	O
values	O
,	O
and	O
a	O
Bayesian	O
approach	O
that	O
can	O
increase	O
accuracy	O
by	O
directly	O
modeling	O
LD	O
structure	O
and	O
adjusting	O
SNP	O
weights	O
accordingly	O
.	O

We	O
excluded	O
rare	O
variants	O
(	O
minor	O
allele	O
frequency	O
<	O
1	O
%	O
)	O
and	O
variants	O
on	O
the	O
X	O
chromosome	O
,	O
and	O
then	O
,	O
at	O
each	O
site	O
,	O
we	O
clumped	O
SNPs	O
on	O
the	O
basis	O
of	O
association	O
p	O
value	O
(	O
the	O
variant	O
with	O
the	O
smallest	O
p	O
value	O
within	O
a	O
250	O
-	O
kb	O
range	O
was	O
retained	O
,	O
and	O
all	O
those	O
in	O
LD	O
[	O
r2	O
>	O
0	O
.	O
1	O
]	O
were	O
removed	O
)	O
.	O

The	O
resulting	O
SNP	O
lists	O
included	O
146	O
,	O
464	O
variants	O
at	O
GHS	O
,	O
79	O
,	O
837	O
variants	O
at	O
MSSM	O
,	O
166	O
,	O
477	O
variants	O
at	O
PHS	O
,	O
and	O
229	O
,	O
355	O
variants	O
at	O
VUMC	O
.	O

Using	O
all	O
available	O
variants	O
(	O
i	O
.	O
e	O
.	O
,	O
using	O
a	O
p	O
threshold	O
of	O
1	O
.	O
0	O
for	O
inclusion	O
)	O
,	O
we	O
generated	O
PRSs	O
for	O
each	O
individual	O
by	O
summing	O
all	O
risk	O
-	O
associated	O
variants	O
weighted	O
by	O
the	O
log	O
odds	O
ratio	O
for	O
that	O
allele	O
from	O
the	O
GWAS	O
.	O

PRSs	O
were	O
converted	O
to	O
z	O
-	O
scores	O
within	O
each	O
health	O
care	O
system	O
to	O
standardize	O
effects	O
across	O
all	O
sites	O
.	O

LD	O
pruning	O
and	O
PRS	O
generation	O
were	O
done	O
using	O
PRSice	O
(	O
25	O
)	O
.	O

We	O
used	O
PRS	O
-	O
CS	O
,	O
a	O
Bayesian	O
polygenic	O
prediction	O
method	O
,	O
as	O
an	O
alternative	O
approach	O
for	O
PRS	O
calculation	O
.	O

PRS	O
-	O
CS	O
places	O
a	O
continuous	O
shrinkage	O
(	O
CS	O
)	O
prior	O
on	O
SNP	O
effect	O
sizes	O
and	O
infers	O
posterior	O
SNP	O
weights	O
using	O
GWAS	O
summary	O
statistics	O
and	O
an	O
external	O
LD	O
reference	O
panel	O
(	O
1000	O
Genomes	O
Project	O
European	O
samples	O
;	O
N=503	O
)	O
.	O

PRS	O
-	O
CS	O
allows	O
multivariate	O
modeling	O
of	O
local	O
LD	O
patterns	O
and	O
is	O
robust	O
to	O
diverse	O
underlying	O
genetic	O
architectures	O
,	O
and	O
thus	O
can	O
increase	O
the	O
accuracy	O
of	O
PRS	O
over	O
conventional	O
approaches	O
(	O
26	O
)	O
.	O

At	O
each	O
site	O
,	O
weights	O
for	O
all	O
imputed	O
SNPs	O
present	O
on	O
the	O
1000	O
Genomes	O
reference	O
panel	O
and	O
the	O
HapMap3	O
panel	O
were	O
estimated	O
using	O
PRS	O
-	O
CS	O
,	O
resulting	O
in	O
833	O
,	O
502	O
available	O
SNPs	O
at	O
GHS	O
,	O
971	O
,	O
463	O
at	O
MSSM	O
,	O
833	O
,	O
502	O
at	O
PHS	O
,	O
and	O
604	O
,	O
645	O
at	O
VUMC	O
.	O

The	O
global	O
shrinkage	O
parameter	O
in	O
the	O
CS	O
prior	O
was	O
fixed	O
at	O
1	O
to	O
reflect	O
the	O
highly	O
polygenic	O
genetic	O
architecture	O
of	O
schizophrenia	O
.	O

We	O
generated	O
PRSs	O
for	O
each	O
individual	O
by	O
summing	O
all	O
risk	O
-	O
associated	O
variants	O
weighted	O
by	O
the	O
posterior	O
effect	O
size	O
inferred	O
by	O
PRS	O
-	O
CS	O
for	O
that	O
allele	O
and	O
then	O
converted	O
PRSs	O
to	O
z	O
-	O
scores	O
within	O
each	O
health	O
care	O
system	O
.	O

A	O
Python	O
package	O
for	O
PRS	O
-	O
CS	O
is	O
available	O
on	O
the	O
GitHub	O
repository	O
(	O
https	O
:	O
/	O
/	O
github	O
.	O
com	O
/	O
getian107	O
/	O
PRScs	O
)	O
.	O

PRSs	O
were	O
calculated	O
using	O
PLINK	O
,	O
version	O
1	O
.	O
9	O
(	O
27	O
)	O
.	O

EHRs	O
contain	O
thousands	O
of	O
diagnostic	O
billing	O
codes	O
from	O
ICD	B-coding_system
-	I-coding_system
9	I-coding_system
and	O
ICD	B-coding_system
-	I-coding_system
10	I-coding_system
,	O
arranged	O
hierarchically	O
.	O

For	O
example	O
,	O
ICD9	B-coding_system
:	O
295	B-code
is	O
“schizophrenic	O
disorders	B-phenotype
,	O
”	O
ICD9	B-coding_system
:	O
295	B-code
.	I-code
1	I-code
is	O
“disorganized	O
type	B-phenotype
schizophrenia	I-phenotype
,	O
”	O
and	O
ICD9	B-coding_system
:	O
295	B-code
.	I-code
12	I-code
is	O
“disorganized	O
type	B-phenotype
schizophrenia	I-phenotype
,	I-phenotype
chronic	I-phenotype
state”	O
;	O
in	O
total	O
,	O
the	O
ICD9	B-coding_system
:	O
295	B-code
category	O
contains	O
71	O
individual	O
ICD	B-coding_system
-	I-coding_system
9	I-coding_system
codes	O
.	O

To	O
define	O
case	O
status	O
for	O
a	O
variety	O
of	O
diseases	O
,	O
we	O
extracted	O
all	O
ICD	B-coding_system
-	I-coding_system
9	I-coding_system
and	O
ICD	B-coding_system
-	I-coding_system
10	I-coding_system
codes	O
available	O
for	O
participating	O
subjects	O
and	O
grouped	O
codes	O
into	O
1	O
,	O
860	O
disease	O
categories	O
(	O
called	O
“phecodes”	O
)	O
using	O
a	O
previously	O
developed	O
and	O
validated	O
hierarchical	O
structure	O
(	O
28	O
,	O
29	O
)	O
.	O

For	O
“schizophrenia	O
and	B-phenotype
other	I-phenotype
psychotic	I-phenotype
disorders	I-phenotype
,	O
”	O
for	O
example	O
,	O
89	O
individual	O
ICD	B-coding_system
-	I-coding_system
9	I-coding_system
codes—all	O
71	O
ICD	B-coding_system
-	I-coding_system
9	I-coding_system
295	B-code
codes	O
and	O
18	O
related	O
codes	O
(	O
e	O
.	O
g	O
.	O
,	O
298	B-code
.	I-code
9	I-code
,	O
unspecified	B-phenotype
psychosis	I-phenotype
)	O
—and	O
22	O
ICD	B-coding_system
-	I-coding_system
10	I-coding_system
codes	O
were	O
mapped	O
to	O
this	O
disease	O
category	O
.	O

Case	O
and	O
control	O
subjects	O
were	O
designated	O
for	O
each	O
phecode	O
.	O

Individuals	O
with	O
two	O
or	O
more	O
relevant	O
ICD	B-coding_system
-	I-coding_system
9	I-coding_system
/	I-coding_system
10	I-coding_system
codes	O
were	O
considered	O
case	O
subjects	O
,	O
those	O
with	O
zero	O
relevant	O
codes	O
were	O
considered	O
control	O
subjects	O
,	O
and	O
individuals	O
with	O
only	O
one	O
code	O
were	O
excluded	O
(	O
30	O
)	O
.	O

To	O
allow	O
analyses	O
of	O
phenome	O
-	O
wide	O
diagnoses	O
that	O
may	O
have	O
varying	O
onset	O
ages	O
,	O
we	O
did	O
not	O
restrict	O
the	O
age	O
range	O
of	O
participants	O
.	O

The	O
proportion	O
of	O
patients	O
(	O
case	O
and	O
control	O
subjects	O
)	O
included	O
in	O
a	O
given	O
PRS	O
-	O
phecode	O
association	O
varied	O
depending	O
on	O
the	O
prevalence	O
of	O
single	O
-	O
code	O
individuals	O
,	O
but	O
the	O
median	O
at	O
each	O
site	O
ranged	O
from	O
98	O
%	O
to	O
100	O
%	O
.	O

Phecodes	O
for	O
which	O
there	O
were	O
fewer	O
than	O
100	O
cases	O
were	O
excluded	O
from	O
the	O
PheWAS	O
.	O

To	O
assess	O
the	O
penetrance	O
of	O
schizophrenia	O
PRS	O
,	O
we	O
measured	O
absolute	O
risk	O
(	O
case	O
prevalence	O
as	O
a	O
function	O
of	O
PRS	O
)	O
and	O
relative	O
risk	O
(	O
odds	O
ratios	O
for	O
the	O
top	O
decile	O
of	O
schizophrenia	O
PRS	O
relative	O
to	O
the	O
remaining	O
population	O
,	O
as	O
well	O
as	O
to	O
the	O
bottom	O
decile	O
)	O
for	O
schizophrenia	B-phenotype
(	O
phecode	B-coding_system
295	B-code
.	I-code
1	I-code
)	O
and	O
psychotic	B-phenotype
disorders	I-phenotype
(	O
phecode	B-coding_system
295	B-code
)	O
.	O

Odds	O
ratios	O
were	O
calculated	O
at	O
each	O
site	O
for	O
both	O
PRS	O
methods	O
(	O
LD	O
-	O
pruned	O
and	O
Bayesian	O
)	O
,	O
regardless	O
of	O
the	O
number	O
of	O
available	O
cases	O
,	O
and	O
then	O
the	O
log	O
odds	O
ratios	O
were	O
combined	O
through	O
fixed	O
-	O
effect	O
inverse	O
variance	O
-	O
weighted	O
meta	O
-	O
analysis	O
using	O
the	O
metafor	O
R	O
package	O
(	O
https	O
:	O
/	O
/	O
cran	O
.	O
r	O
-	O
project	O
.	O
org	O
/	O
web	O
/	O
packages	O
/	O
metafor	O
/	O
)	O
.	O

We	O
conducted	O
PheWASs	O
for	O
both	O
PRS	O
methods	O
in	O
each	O
of	O
the	O
four	O
health	O
care	O
systems	O
,	O
using	O
all	O
phecodes	O
with	O
sufficient	O
sample	O
size	O
(	O
at	O
least	O
100	O
cases	O
)	O
.	O

Logistic	O
regressions	O
between	O
schizophrenia	O
PRSs	O
and	O
each	O
phecode	O
were	O
run	O
with	O
10	O
ancestry	O
principal	O
components	O
,	O
median	O
age	O
within	O
the	O
medical	O
record	O
calculated	O
for	O
each	O
individual	O
using	O
all	O
of	O
their	O
records	O
in	O
the	O
EHR	O
,	O
sex	O
,	O
genotyping	O
platform	O
,	O
and	O
genotyping	O
batch	O
(	O
when	O
available	O
)	O
included	O
as	O
covariates	O
,	O
using	O
the	O
PheWAS	O
R	O
package	O
(	O
29	O
)	O
.	O

We	O
used	O
a	O
Bonferroni	O
correction	O
for	O
establishing	O
statistical	O
significance	O
based	O
on	O
the	O
number	O
of	O
phecodes	O
tested	O
at	O
each	O
site	O
.	O

We	O
then	O
meta	O
-	O
analyzed	O
PheWAS	O
effects	O
across	O
health	O
care	O
systems	O
within	O
a	O
given	O
PRS	O
method	O
with	O
a	O
fixed	O
-	O
effect	O
inverse	O
variance	O
-	O
weighted	O
model	O
using	O
the	O
PheWAS	O
R	O
package	O
.	O

Phecodes	O
significantly	O
associated	O
with	O
schizophrenia	O
PRS	O
in	O
the	O
PheWAS	O
meta	O
-	O
analysis	O
were	O
carried	O
forward	O
for	O
a	O
follow	O
-	O
up	O
analysis	O
in	O
which	O
we	O
quantified	O
the	O
risk	O
of	O
the	O
phecode	O
at	O
the	O
extremes	O
of	O
the	O
PRS	O
distribution	O
at	O
each	O
site	O
.	O

Effects	O
were	O
combined	O
across	O
sites	O
through	O
meta	O
-	O
analysis	O
using	O
the	O
metafor	O
R	O
package	O
.	O

To	O
explore	O
whether	O
pleiotropic	O
effects	O
of	O
the	O
schizophrenia	O
PRS	O
were	O
mediated	O
by	O
the	O
diagnosis	O
of	O
schizophrenia	O
itself	O
or	O
by	O
the	O
prescription	O
of	O
antipsychotic	O
medication	O
(	O
the	O
most	O
common	O
treatment	O
for	O
schizophrenia	O
)	O
,	O
we	O
conducted	O
four	O
follow	O
-	O
up	O
PheWAS	O
analyses	O
.	O

Given	O
the	O
similarity	O
of	O
primary	O
PheWAS	O
results	O
from	O
the	O
two	O
PRS	O
methods	O
,	O
sensitivity	O
analyses	O
were	O
conducted	O
using	O
the	O
LD	O
-	O
pruned	O
PRS	O
method	O
only	O
.	O

For	O
each	O
follow	O
-	O
up	O
analysis	O
,	O
a	O
PheWAS	O
analysis	O
was	O
conducted	O
as	O
above	O
,	O
with	O
only	O
one	O
of	O
the	O
four	O
following	O
alterations	O
:	O
an	O
additional	O
covariate	O
for	O
diagnosis	O
of	O
psychotic	O
disorders	O
(	O
phecode	O
295	O
;	O
the	O
broadest	O
schizophrenia	O
-	O
related	O
phecode	O
)	O
,	O
an	O
additional	O
covariate	O
for	O
any	O
prescriptions	O
of	O
antipsychotic	O
medication	O
,	O
removing	O
psychosis	B-phenotype
cases	O
(	O
phecode	B-coding_system
295	B-code
)	O
,	O
and	O
removing	O
patients	O
with	O
any	O
antipsychotic	O
medication	O
prescription	O
history	O
.	O

A	O
multicentre	O
,	O
two	O
arm	O
,	O
parallel	O
cluster	O
randomized	O
controlled	O
trial	O
(	O
RCT	O
)	O
of	O
an	O
health	O
promotion	O
intervention	O
,	O
(	O
HPI	O
)	O
IMPACT	O
Therapy	O
.	O

The	O
study	O
was	O
planned	O
and	O
implemented	O
in	O
concordance	O
with	O
the	O
Consolidated	O
Standards	O
of	O
Reporting	O
Trials	O
(	O
CONSORT	O
)	O
cluster	O
trial	O
extension	O
standards	O
[	O
44	O
,	O
45	O
]	O
to	O
compare	O
the	O
cost	O
-	O
effectiveness	O
of	O
combining	O
treatment	O
as	O
usual	O
(	O
TAU	O
)	O
plus	O
IMPACT	O
Therapy	O
,	O
versus	O
TAU	O
alone	O
in	O
improving	O
health	O
at	O
one	O
-	O
year	O
follow	O
-	O
up	O
.	O

Figure	O
1	O
summarises	O
the	O
trial	O
design	O
.	O

Summary	O
of	O
Trial	O
design	O
for	O
Improving	O
Physical	O
health	O
and	O
reducing	O
substance	O
use	O
in	O
Psychosis	O
–	O
Randomised	O
Control	O
Trial	O
(	O
IMPACT	O
RCT	O
)	O
:	O
Study	O
protocol	O
.	O

The	O
study	O
will	O
take	O
place	O
within	O
community	O
mental	O
health	O
teams	O
(	O
CMHTs	O
)	O
,	O
including	O
continuing	O
care	O
/	O
recovery	O
teams	O
;	O
community	O
rehabilitation	O
;	O
assertive	O
outreach	O
and	O
community	O
forensic	O
teams	O
in	O
six	O
Mental	O
Health	O
NHS	O
Trusts	O
in	O
the	O
urban	O
and	O
rural	O
locations	O
of	O
South	O
London	O
,	O
Sussex	O
,	O
Somerset	O
,	O
Staffordshire	O
and	O
Shropshire	O
.	O

We	O
will	O
not	O
recruit	O
from	O
specialist	O
first	O
episode	O
psychosis	O
teams	O
.	O

Care	O
coordinators	O
permanently	O
employed	O
and	O
intending	O
to	O
remain	O
so	O
for	O
a	O
period	O
of	O
one	O
year	O
within	O
the	O
CMHT	O
settings	O
above	O
,	O
with	O
a	O
minimum	O
of	O
four	O
patients	O
on	O
their	O
caseload	O
with	O
a	O
primary	O
diagnosis	O
of	O
SMI	O
,	O
are	O
eligible	O
for	O
recruitment	O
to	O
the	O
trial	O
.	O

Patients	O
of	O
participating	O
care	O
co	O
-	O
ordinators	O
are	O
eligible	O
for	O
inclusion	O
in	O
the	O
study	O
if	O
:	O

a	O
)	O
Aged	O
between	O
18–65	O
years	O
old	O
.	O

b	O
)	O
A	O
diagnosis	O
of	O
a	O
psychotic	B-phenotype
disorder	I-phenotype
(	O
ICD	B-coding_system
10	I-coding_system
diagnosis	O
F20	B-code
-	I-code
29	I-code
,	O
F31	B-code
.	I-code
2	I-code
,	O
F31	B-code
.	I-code
5	I-code
,	O
)	O

Exclusion	O
criteria	O
:	O

a	O
)	O
A	O
primary	O
diagnosis	O
of	O
learning	O
disability	O
.	O

b	O
)	O
A	O
co	O
-	O
existing	O
physical	O
health	O
problem	O
that	O
would	O
,	O
in	O
the	O
opinion	O
of	O
the	O
medical	O
investigators	O
,	O
independently	O
impact	O
on	O
metabolic	O
measures	O
and	O
/	O
or	O
substance	O
use	O
habits	O
.	O

c	O
)	O
Current	O
pregnancy	O
,	O
plus	O
mothers	O
less	O
than	O
6	O
months	O
post	O
-	O
partum	O
.	O

d	O
)	O
Life	O
threatening	O
or	O
terminal	O
medical	O
conditions	O
where	O
intensive	O
care	O
is	O
already	O
provided	O
.	O

All	O
care	O
-	O
coordinators	O
in	O
participating	O
CMHTs	O
will	O
be	O
offered	O
best	O
practice	O
treatment	O
as	O
usual	O
training	O
on	O
physical	O
health	O
awareness	O
,	O
including	O
the	O
provision	O
of	O
health	O
promotion	O
leaflets	O
on	O
healthy	O
dietary	O
routines	O
and	O
physical	O
exercise	O
,	O
together	O
with	O
information	O
on	O
general	O
and	O
community	O
support	O
for	O
a	O
healthy	O
lifestyle	O
.	O

The	O
purpose	O
of	O
this	O
is	O
to	O
ensure	O
that	O
all	O
care	O
-	O
coordinators	O
,	O
irrespective	O
of	O
which	O
treatment	O
arm	O
they	O
are	O
allocated	O
to	O
,	O
have	O
the	O
same	O
baseline	O
level	O
of	O
understanding	O
of	O
physical	O
health	O
issues	O
,	O
thus	O
ensuring	O
more	O
standardised	O
treatment	O
as	O
usual	O
.	O

This	O
is	O
a	O
cluster	O
randomised	O
trial	O
and	O
the	O
randomisation	O
will	O
take	O
place	O
at	O
the	O
level	O
of	O
the	O
care	O
co	O
-	O
ordinator	O
.	O

To	O
select	O
the	O
order	O
in	O
which	O
first	O
care	O
co	O
-	O
ordinators	O
and	O
then	O
patients	O
are	O
approached	O
,	O
a	O
random	O
numbers	O
generator	O
will	O
be	O
used	O
.	O

Researchers	O
will	O
approach	O
each	O
eligible	O
care	O
coordinator	O
in	O
this	O
order	O
and	O
seek	O
consent	O
to	O
participate	O
in	O
the	O
trial	O
,	O
working	O
down	O
the	O
list	O
until	O
the	O
target	O
sample	O
size	O
is	O
achieved	O
.	O

Prior	O
to	O
randomisation	O
,	O
consenting	O
care	O
-	O
coordinators	O
will	O
provide	O
a	O
list	O
of	O
their	O
current	O
patient	O
caseload	O
.	O

Patients	O
on	O
that	O
caseload	O
meeting	O
the	O
inclusion	O
criteria	O
will	O
be	O
entered	O
into	O
the	O
random	O
numbers	O
generator	O
to	O
create	O
a	O
randomly	O
ordered	O
list	O
in	O
which	O
to	O
approach	O
potential	O
participants	O
.	O

Researchers	O
will	O
then	O
approach	O
these	O
patients	O
sequentially	O
and	O
seek	O
informed	O
consent	O
to	O
participate	O
in	O
the	O
RCT	O
.	O

In	O
situations	O
where	O
a	O
patient	O
does	O
not	O
wish	O
to	O
take	O
part	O
in	O
the	O
study	O
,	O
the	O
researcher	O
will	O
select	O
another	O
patient	O
from	O
the	O
list	O
in	O
that	O
random	O
order	O
.	O

After	O
completing	O
baseline	O
assessments	O
on	O
all	O
consenting	O
patients	O
in	O
a	O
care	O
co	O
-	O
ordinator’s	O
caseload	O
,	O
the	O
clinical	O
trials	O
unit	O
will	O
conduct	O
randomisation	O
of	O
the	O
care	O
coordinators	O
,	O
stratified	O
by	O
borough	O
,	O
using	O
randomisation	O
blocks	O
of	O
random	O
sizes	O
to	O
either	O
treatment	O
arm	O
(	O
IMPACT	O
Therapy	O
)	O
or	O
treatment	O
as	O
usual	O
(	O
TAU	O
)	O
.	O

Researchers	O
and	O
the	O
statistician	O
will	O
remain	O
blind	O
to	O
treatment	O
allocation	O
.	O

Outcome	O
assessments	O
will	O
only	O
be	O
conducted	O
by	O
researchers	O
blind	O
to	O
the	O
treatment	O
arm	O
.	O

Any	O
violations	O
of	O
the	O
study	O
protocol	O
will	O
be	O
recorded	O
and	O
reported	O
to	O
the	O
Trial	O
Steering	O
Committee	O
and	O
the	O
Data	O
Monitoring	O
and	O
Ethics	O
Committee	O
.	O

All	O
consenting	O
community	O
care	O
coordinators	O
randomised	O
to	O
the	O
IMPACT	O
Therapy	O
arm	O
will	O
receive	O
4	O
-	O
day	O
IMPACT	O
training	O
on	O
physical	O
health	O
and	O
substance	O
use	O
in	O
SMI	O
,	O
as	O
well	O
as	O
training	O
in	O
motivational	O
interviewing	O
(	O
MI	O
)	O
,	O
cognitive	O
behavioural	O
therapy	O
(	O
CBT	O
)	O
techniques	O
and	O
in	O
running	O
groups	O
to	O
deliver	O
health	O
promotion	O
.	O

The	O
patient	O
-	O
tailored	O
IMPACT	O
Therapy	O
aims	O
to	O
target	O
one	O
or	O
more	O
health	O
behaviours	O
from	O
a	O
pre	O
-	O
defined	O
list	O
that	O
includes	O
cannabis	O
use	O
;	O
alcohol	O
use	O
;	O
other	O
substance	O
use	O
;	O
cigarette	O
smoking	O
;	O
exercise	O
;	O
diet	O
and	O
diabetic	O
control	O
,	O
prioritising	O
those	O
identified	O
as	O
problematic	O
by	O
the	O
patient	O
,	O
taking	O
a	O
MI	O
and	O
CBT	O
approach	O
.	O

Participants	O
may	O
start	O
the	O
community	O
-	O
based	O
IMPACT	O
Therapy	O
as	O
soon	O
as	O
they	O
are	O
well	O
enough	O
to	O
attend	O
,	O
even	O
if	O
they	O
are	O
in	O
-	O
patients	O
,	O
to	O
mirror	O
clinical	O
practice	O
.	O

IMPACT	O
Therapy	O
is	O
supported	O
by	O
a	O
manual	O
,	O
a	O
reference	O
book	O
and	O
a	O
service	O
user	O
handbook	O
[	O
46	O
]	O
.	O

Each	O
care	O
coordinator	O
in	O
the	O
active	O
intervention	O
arm	O
of	O
the	O
study	O
will	O
receive	O
copies	O
of	O
these	O
books	O
.	O

Care	O
Coordinators	O
allocated	O
to	O
the	O
IMPACT	O
Therapy	O
arm	O
of	O
the	O
trial	O
will	O
also	O
receive	O
supervision	O
every	O
2	O
weeks	O
to	O
ensure	O
fidelity	O
of	O
the	O
intervention	O
and	O
to	O
provide	O
ongoing	O
support	O
and	O
training	O
.	O

The	O
supervision	O
will	O
be	O
provided	O
by	O
research	O
therapists	O
by	O
face	O
-	O
to	O
-	O
face	O
contact	O
,	O
via	O
video	O
link	O
or	O
via	O
Skype	O
,	O
supplemented	O
by	O
e	O
-	O
mail	O
and	O
/	O
or	O
telephone	O
support	O
.	O

Patients	O
participating	O
in	O
the	O
IMPACT	O
therapy	O
arm	O
will	O
have	O
the	O
option	O
to	O
receive	O
three	O
-	O
monthly	O
newsletters	O
throughout	O
the	O
trial	O
period	O
(	O
total	O
of	O
4	O
)	O
,	O
each	O
providing	O
tips	O
on	O
healthy	O
living	O
.	O

The	O
information	O
contained	O
in	O
the	O
newsletter	O
will	O
comprise	O
standard	O
information	O
that	O
is	O
readily	O
available	O
to	O
the	O
public	O
.	O

Outcomes	O
will	O
be	O
measured	O
by	O
self	O
-	O
report	O
,	O
objective	O
assessments	O
and	O
face	O
-	O
to	O
-	O
face	O
interviews	O
.	O

All	O
participants	O
will	O
be	O
assessed	O
at	O
the	O
following	O
time	O
points	O
:	O
baseline	O
(	O
T0	O
)	O
,	O
12	O
months	O
post	O
-	O
randomisation	O
(	O
T1	O
-	O
at	O
completion	O
of	O
intervention	O
)	O
and	O
at	O
3	O
months	O
after	O
the	O
end	O
of	O
treatment	O
(	O
15	O
months	O
post	O
-	O
randomisation	O
)	O
(	O
T2	O
-	O
)	O
(	O
Table	O
1	O
)	O
.	O

At	O
each	O
time	O
point	O
participants	O
will	O
be	O
asked	O
to	O
repeat	O
all	O
baseline	O
questionnaires	O
plus	O
provide	O
a	O
fasting	O
blood	O
sample	O
and	O
anthropometric	O
measurements	O
.	O

12	O
-	O
and	O
15	O
-	O
month	O
follow	O
-	O
up	O
windows	O
will	O
be	O
defined	O
as	O
minus	O
6	O
weeks	O
and	O
plus	O
4	O
weeks	O
for	O
12	O
month	O
,	O
and	O
plus	O
4	O
weeks	O
for	O
15	O
month	O
follow	O
-	O
up	O
.	O

Data	O
collected	O
outside	O
these	O
time	O
windows	O
will	O
be	O
recorded	O
but	O
not	O
used	O
for	O
the	O
main	O
analyses	O
.	O

IMPACT	O
outcome	O
measures	O
at	O
defined	O
timepoints	O

Variables	O
measured	O
at	O
baseline	O
,	O
12	O
months	O
and	O
15	O
months	O
follow	O
-	O
up	O
.	O

Baseline	O
measures	O
:	O

i	O
.	O

Sociodemographic	O
data	O
;	O
age	O
,	O
gender	O
,	O
self	O
-	O
reported	O
ethnicity	O
,	O
marital	O
status	O
.	O

ii	O
.	O

Quality	O
of	O
life	O
:	O
Short	O
Form	O
-	O
36	O
;	O
including	O
mental	O
health	O
and	O
physical	O
health	O
subscales	O
[	O
43	O
]	O
.	O

iii	O
.	O

Substance	O
use	O
measures	O
:	O
Time	O
Line	O
Follow	O
Back	O
;	O
[	O
47	O
]	O
Nicotine	O
Dependence	O
Questionnaire	O
;	O
[	O
48	O
,	O
49	O
]	O
Alcohol	O
Use	O
Disorders	O
Identification	O
Test	O
(	O
AUDIT	O
)	O
;	O
[	O
50	O
]	O
and	O
a	O
urine	O
drug	O
screen	O
.	O

iv	O
.	O

Biomedical	O
status	O
measures	O
:	O
waist	O
and	O
hip	O
circumference	O
;	O
height	O
and	O
weight	O
to	O
calculate	O
body	O
mass	O
index	O
;	O
blood	O
pressure	O
;	O
fasting	O
blood	O
glucose	O
;	O
insulin	O
(	O
to	O
calculate	O
the	O
homeostasis	O
model	O
assessment	O
-	O
estimated	O
insulin	O
resistance	O
(	O
HOMA	O
-	O
IR	O
)	O
index	O
)	O
;	O
long	O
term	O
blood	O
glucose	O
control	O
(	O
as	O
measured	O
by	O
glycated	O
haemoglobin	O
)	O
;	O
fasting	O
lipids	O
;	O
renal	O
and	O
liver	O
function	O
tests	O
and	O
other	O
markers	O
of	O
cardiovascular	O
risk	O
and	O
inflammation	O
.	O

v	O
.	O

Lifestyles	O
measures	O
:	O
adapted	O
Dietary	O
Instrument	O
for	O
Nutrition	O
Education	O
DINE	O
;	O
[	O
51	O
]	O
adapted	O
International	O
Physical	O
Activity	O
Questionnaire	O
(	O
IPAQ	O
)	O
[	O
52	O
]	O
.	O

vi	O
.	O

Mental	O
health	O
status	O
:	O
Positive	O
And	O
Negative	O
Syndrome	O
Scale	O
(	O
PANSS	O
)	O
[	O
53	O
]	O
,	O
Global	O
Assessment	O
of	O
Functioning	O
(	O
GAF	O
)	O
[	O
54	O
]	O
,	O
Montgomery	O
Asberg	O
Depression	O
Rating	O
Scale	O
(	O
MADRS	O
)	O
[	O
55	O
]	O
.	O

vii	O
.	O

Diagnosis	O
;	O
OPCRIT	O
(	O
Operational	O
Criteria	O
checklist	O
)	O
[	O
56	O
]	O
.	O

viii	O
.	O

Health	O
care	O
:	O
Medical	O
history	O
of	O
diabetes	O
,	O
cardiovascular	O
disease	O
and	O
cerebrovascular	O
disease	O
;	O
other	O
past	O
medical	O
history	O
.	O

Family	O
history	O
of	O
diabetes	O
and	O
related	O
disorders	O
.	O

ix	O
.	O

Current	O
medications	O
;	O
Composite	O
measure	O
of	O
compliance	O
scale	O
[	O
57	O
]	O
;	O
Liverpool	O
University	O
Neuroleptic	O
Side	O
Effect	O
Rating	O
Scale	O
(	O
LUNSERS	O
)	O
[	O
58	O
]	O
.	O

x	O
.	O

Costs	O
:	O
adapted	O
Client	O
Services	O
Receipt	O
Inventory	O
(	O
CSRI	O
)	O
[	O
59	O
]	O
.	O

xi	O
.	O

IMPACT	O
Therapy	O
dosage	O
measures	O
:	O
HPI	O
inputs	O
and	O
Supervision	O
log	O
form	O
.	O

The	O
power	O
analysis	O
is	O
performed	O
for	O
the	O
two	O
subscales	O
measures	O
,	O
Physical	O
and	O
Mental	O
health	O
components	O
of	O
SF	O
-	O
36	O
Quality	O
of	O
Life	O
scale	O
.	O
[	O
43	O
]	O
We	O
have	O
assumed	O
a	O
common	O
standard	O
deviation	O
of	O
the	O
change	O
scores	O
between	O
baseline	O
and	O
12	O
month	O
follow	O
-	O
up	O
of	O
10	O
for	O
the	O
Physical	O
component	O
score	O
and	O
12	O
for	O
the	O
Mental	O
health	O
component	O
score	O
(	O
based	O
on	O
the	O
QUATRO	O
study	O
[	O
60	O
]	O
)	O
,	O
supplemented	O
with	O
further	O
information	O
sought	O
directly	O
from	O
the	O
study	O
team	O
(	O
project	O
reference	O
:	O
QLG4	O
-	O
CT	O
-	O
2001	O
-	O
01734	O
,	O
European	O
Union	O
)	O
)	O
and	O
a	O

cluster	O
size	O
of	O
4	O
patients	O
per	O
care	O
coordinator	O
with	O
intraclass	O
correlation	O
of	O
0	O
.	O
05	O
.	O

Using	O
80	O
%	O
power	O
,	O
a	O
5	O
%	O
alpha	O
level	O
and	O
two	O
-	O
tailed	O
assumptions	O
,	O
a	O
sample	O
size	O
of	O
56	O
care	O
coordinators	O
and	O
216	O
patients	O
are	O
needed	O
to	O
detect	O
a	O
clinical	O
significant	O
difference	O
of	O
5	O
points	O
in	O
Mental	O
Health	O
Component	O
change	O
score	O
(	O
Cohen’s	O
d	O
=	O
0	O
.	O
42	O
)	O
,	O
between	O
two	O
groups	O
and	O
a	O
sample	O
size	O
of	O
38	O
care	O
coordinators	O
and	O
152	O
patients	O
are	O
needed	O
to	O
detect	O
a	O
clinical	O
significant	O
difference	O
of	O
5	O
points	O
in	O
Physical	O
Component	O
change	O
score	O
(	O
Cohen’s	O
d	O
=	O
0	O
.	O
5	O
)	O
between	O
two	O
groups	O
.	O

Assuming	O
a	O
drop	O
-	O
out	O
rate	O
of	O
20	O
%	O
of	O
the	O
care	O
-	O
coordinators	O
and	O
their	O
patients	O
and	O
an	O
additional	O
patient	O
drop	O
-	O
out	O
rate	O
of	O
30	O
%	O
,	O
a	O
total	O
sample	O
size	O
of	O
98	O
care	O
coordinators	O
and	O
392	O
participants	O
are	O
needed	O
for	O
the	O
Mental	O
health	O
score	O
and	O
70	O
care	O
coordinators	O
and	O
280	O
participants	O
for	O
the	O
Physical	O
health	O
score	O
.	O

The	O
analysis	O
will	O
follow	O
the	O
guidelines	O
of	O
the	O
Consort	O
statement	O
for	O
clustered	O
randomized	O
trials	O
[	O
45	O
]	O
and	O
recommendations	O
for	O
the	O
analysis	O
of	O
clustered	O
randomized	O
trials	O
when	O
presenting	O
and	O
analysing	O
the	O
data	O
.	O
[	O
61	O
,	O
62	O
]	O
The	O
trial	O
statistician	O
will	O
remain	O
blind	O
until	O
the	O
main	O
analyses	O
are	O
complete	O
.	O

Baseline	O
characteristics	O
of	O
the	O
study	O
population	O
will	O
be	O
summarised	O
separately	O
within	O
each	O
randomised	O
group	O
.	O

Baseline	O
characteristics	O
will	O
also	O
be	O
presented	O
for	O
drop	O
-	O
outs	O
and	O
completers	O
within	O
each	O
treatment	O
group	O
.	O

The	O
analysis	O
will	O
be	O
performed	O
on	O
the	O
basis	O
of	O
the	O
intention	O
-	O
to	O
-	O
treat	O
principle	O
and	O
will	O
utilise	O
all	O
available	O
follow	O
-	O
up	O
data	O
from	O
all	O
randomised	O
participants	O
.	O

Follow	O
-	O
up	O
data	O
will	O
be	O
collected	O
for	O
all	O
patients	O
whose	O
care	O
-	O
coordinator	O
was	O
randomized	O
independent	O
of	O
whether	O
a	O
care	O
coordinator	O
dropped	O
out	O
or	O
not	O
.	O

The	O
main	O
statistical	O
analyses	O
will	O
be	O
targeted	O
at	O
estimating	O
the	O
difference	O
in	O
the	O
mean	O
outcomes	O
of	O
Physical	O
and	O
Mental	O
health	O
components	O
of	O
SF36	O
[	O
43	O
]	O
at	O
12	O
and	O
15	O
months	O
follow	O
-	O
up	O
observation	O
time	O
point	O
between	O
treatment	O
and	O
control	O
group	O
using	O
a	O
mixed	O
effects	O
model	O
.	O

[	O
63	O
]	O
The	O
outcome	O
variables	O
are	O
assumed	O
to	O
arise	O
from	O
normal	O
distributions	O
.	O

This	O
will	O
be	O
checked	O
and	O
if	O
found	O
to	O
be	O
lacking	O
then	O
appropriate	O
transformations	O
will	O
be	O
applied	O
.	O

In	O
the	O
linear	O
mixed	O
effects	O
model	O
Physical	O
and	O
Mental	O
health	O
Component	O
scores	O
respectively	O
,	O
at	O
12	O
months	O
and	O
15	O
months	O
constitute	O
the	O
dependent	O
variables	O
.	O

“Treatment	O
randomisation	O
group	O
,	O
“time	O
(	O
with	O
two	O
levels	O
,	O
12	O
and	O
15	O
months	O
post	O
-	O
randomization	O
)	O
”	O
,	O
the	O
interaction	O
between	O
“treatment	O
group	O
and	O
time”	O
,	O
“Borough”	O
,	O
and	O
the	O
“baseline	O
values	O
of	O
Physical	O
and	O
Mental	O
Health	O
scores”	O
are	O
the	O
fixed	O
part	O
of	O
the	O
model	O
.	O

“Care	O
coordinator”	O
will	O
be	O
included	O
as	O
a	O
random	O
factor	O
in	O
the	O
model	O
to	O
account	O
for	O
the	O
dependency	O
of	O
the	O
observations	O
within	O
a	O
cluster	O
.	O

“Time”	O
will	O
be	O
entered	O
as	O
a	O
categorical	O
variable	O
.	O

It	O
is	O
possible	O
that	O
the	O
treatment	O
effects	O
will	O
vary	O
across	O
the	O
care	O
coordinators	O
delivering	O
the	O
interventions	O
.	O

We	O
will	O
therefore	O
also	O
assess	O
an	O
“intervention	O
group	O
x	O
care	O
coordinator”	O
interaction	O
term	O
.	O

A	O
likelihood	O
ratio	O
test	O
of	O
the	O
corresponding	O
variance	O
component	O
and	O
information	O
criteria	O
comparisons	O
will	O
be	O
used	O
to	O
assess	O
if	O
the	O
interactions	O
should	O
be	O
included	O
in	O
the	O
model	O
.	O

Similarly	O
,	O
the	O
interaction	O
between	O
treatment	O
and	O
time	O
will	O
be	O
assessed	O
.	O

Should	O
there	O
be	O
evidence	O
for	O
such	O
an	O
interaction	O
then	O
the	O
relevant	O
terms	O
will	O
be	O
kept	O
in	O
the	O
model	O
.	O

For	O
the	O
final	O
model	O
,	O
the	O
group	O
difference	O
estimates	O
and	O
associated	O
confidence	O
intervals	O
will	O
be	O
reported	O
for	O
12	O
and	O
15	O
months	O
after	O
randomization	O
.	O

No	O
a	O
priori	O
subgroups	O
were	O
defined	O
in	O
the	O
protocol	O
.	O

This	O
study	O
used	O
the	O
National	O
Sample	O
Cohort	O
data	O
from	O
the	O
National	O
Health	O
Insurance	O
Service	O
(	O
NHIS–NSC	O
)	O
of	O
Korea	O
.	O

The	O
NHIS	O
uses	O
a	O
systematic	O
sampling	O
approach	O
to	O
randomly	O
select	O
a	O
representative	O
population	O
of	O
approximately	O
1	O
million	O
people	O
between	O
2002	O
and	O
2013	O
,	O
which	O
is	O
2	O
.	O
2	O
%	O
of	O
the	O
total	O
population	O
.	O

The	O
sample	O
cohort	O
was	O
compared	O
with	O
the	O
entire	O
population	O
with	O
respect	O
to	O
the	O
average	O
total	O
annual	O
medical	O
expenses	O
,	O
residence	O
distribution	O
,	O
and	O
the	O
mean	O
and	O
standard	O
deviation	O
of	O
health	O
insurance	O
premiums	O
;	O
the	O
differences	O
were	O
negligible	O
during	O
the	O
cohort	O
years	O
[	O
21	O
]	O
.	O

The	O
data	O
gives	O
researchers	O
access	O
to	O
demographic	O
data	O
–	O
including	O
sex	O
,	O
age	O
recorded	O
at	O
5–year	O
intervals	O
,	O
income	O
level	O
,	O
and	O
date	O
of	O
death	O
–	O
as	O
well	O
as	O
the	O
health	O
care	O
data	O
–	O
including	O
clinical	O
diagnoses	O
,	O
medical	O
procedures	O
,	O
expenditures	O
,	O
and	O
drug	O
prescriptions	O
.	O

Information	O
on	O
prescribed	O
drugs	O
included	O
the	O
generic	O
drug	O
name	O
,	O
prescription	O
date	O
,	O
duration	O
,	O
and	O
route	O
of	O
administration	O
.	O

To	O
investigate	O
the	O
risk	O
of	O
depression	O
and	O
anxiety	O
in	O
patients	O
with	O
ACO	O
and	O
patients	O
with	O
COPD	O
alone	O
,	O
we	O
constructed	O
a	O
COPD	O
cohort	O
using	O
National	O
Sample	O
Cohort	O
data	O
for	O
the	O
period	O
between	O
January	O
2003	O
and	O
December	O
2011	O
.	O

The	O
COPD	O
cohort	O
included	O
patients	O
older	O
than	O
40	O
years	O
who	O
had	O
been	O
diagnosed	O
with	O
COPD	B-phenotype
at	O
least	O
twice	O
as	O
a	O
principal	O
or	O
secondary	O
diagnosis	O
coded	O
according	O
to	O
the	O
International	B-coding_system
Classification	I-coding_system
of	I-coding_system
Disease	I-coding_system
,	I-coding_system
tenth	I-coding_system
revision	I-coding_system
(	I-coding_system
ICD	I-coding_system
-	I-coding_system
10	I-coding_system
codes	O
J42	B-code
,	O
J43	B-code
,	O
and	O
J44	B-code
)	O
and	O
with	O
at	O
least	O
1	O
prescription	O
for	O
≥1	O
of	O
the	O
following	O
COPD	O
medications	O
:	O
inhaled	O
corticosteroids	O
(	O
ICSs	O
)	O
,	O
inhaled	O
long	O
-	O
acting	O
β2	O
-	O
agonists	O
(	O
LABAs	O
)	O
,	O
an	O
ICS	O
and	O
a	O
LABA	O
combined	O
in	O
a	O
single	O
inhaler	O
(	O
ICS	O
/	O
LABA	O
)	O
,	O
inhaled	O
short	O
-	O
acting	O
β2	O
-	O
agonists	O
(	O
SABAs	O
)	O
,	O
inhaled	O

long	O
-	O
acting	O
muscarinic	O
antagonists	O
(	O
LAMAs	O
)	O
,	O
short	O
-	O
acting	O
muscarinic	O
antagonists	O
(	O
SAMAs	O
)	O
,	O
a	O
SAMA	O
and	O
a	O
SABA	O
combined	O
in	O
a	O
single	O
inhaler	O
(	O
SAMA	O
/	O
SABA	O
)	O
,	O
oral	O
leukotriene	O
antagonists	O
,	O
xanthine	O
derivatives	O
,	O
mast	O
cell	O
stabilizers	O
,	O
and	O
systemic	O
corticosteroids	O
(	O
CSs	O
)	O
.	O

Within	O
the	O
COPD	O
cohort	O
,	O
patients	O
were	O
divided	O
into	O
ACO	O
and	O
COPD	O
alone	O
groups	O
,	O
based	O
on	O
the	O
following	O
asthma	O
criteria	O
:	O
(	O
1	O
)	O
diagnosis	O
with	O
asthma	B-phenotype
at	O
least	O
twice	O
,	O
as	O
a	O
principal	O
or	O
secondary	O
diagnosis	O
(	O
ICD	B-coding_system
-	I-coding_system
10	I-coding_system
codes	O
J45	B-code
and	O
J46	B-code
)	O
;	O
(	O
2	O
)	O
at	O
least	O
one	O
prescription	O
for	O
≥1	O
of	O
the	O
following	O
asthma	O
medications	O
:	O
ICSs	O
,	O
LABAs	O
,	O
ICS	O
/	O
LABA	O
,	O
SABAs	O
,	O
oral	O
leukotriene	O
antagonists	O
,	O
xanthine	O
derivatives	O
,	O
mast	O
cell	O
stabilizers	O
,	O
and	O
systemic	O
CSs	O
.	O

Patients	O
who	O
met	O
both	O
criteria	O
for	O
COPD	O
and	O
asthma	O
were	O
defined	O
as	O
ACO	O
.	O

Patients	O
were	O
excluded	O
from	O
the	O
analysis	O
of	O
the	O
incidence	O
of	O
depression	O
and	O
anxiety	O
if	O
they	O
were	O
diagnosed	O
with	O
depression	O
or	O
anxiety	O
within	O
1	O
year	O
of	O
the	O
index	O
date	O
.	O

A	O
study	O
flow	O
chart	O
is	O
presented	O
in	O
Fig	O
.	O

1	O
.	O

Fig	O
.	O

1	O
The	O
selection	O
of	O
study	O
subjects	O
.	O

COPD	O
,	O
chronic	O
obstructive	O
pulmonary	O
disease	O
;	O
ICD	B-coding_system
-	I-coding_system
10	I-coding_system
,	I-coding_system
International	I-coding_system
Classification	I-coding_system
of	I-coding_system
Diseases	I-coding_system
;	O
ACO	O
,	O
asthma	O
-	O
COPD	O
overlap	O

The	O
selection	O
of	O
study	O
subjects	O
.	O

COPD	O
,	O
chronic	O
obstructive	O
pulmonary	O
disease	O
;	O
ICD	B-coding_system
-	I-coding_system
10	I-coding_system
,	I-coding_system
International	I-coding_system
Classification	I-coding_system
of	I-coding_system
Diseases	I-coding_system
;	O
ACO	O
,	O
asthma	O
-	O
COPD	O
overlap	O

We	O
defined	O
the	O
outcome	O
as	O
time	O
to	O
first	O
diagnosis	O
with	O
depression	B-phenotype
(	O
ICD	B-coding_system
-	I-coding_system
10	I-coding_system
:	O
F32	B-code
and	O
F33	B-code
)	O
or	O
anxiety	B-phenotype
(	O
ICD	B-coding_system
-	I-coding_system
10	I-coding_system
:	O
F40	B-code
-	I-code
F42	I-code
)	O
as	O
the	O
primary	O
or	O
secondary	O
diagnosis	O
after	O
the	O
index	O
date	O
.	O

The	O
index	O
date	O
was	O
defined	O
as	O
the	O
first	O
date	O
that	O
both	O
definitions	O
of	O
COPD	O
and	O
asthma	O
were	O
met	O
.	O

For	O
example	O
,	O
if	O
a	O
patient	O
with	O
asthma	O
met	O
the	O
definition	O
of	O
COPD	O
later	O
,	O
the	O
patient	O
was	O
considered	O
eligible	O
for	O
inclusion	O
in	O
the	O
ACO	O
cohort	O
from	O
the	O
day	O
the	O
patient	O
met	O
the	O
definition	O
of	O
COPD	O
.	O

Patients	O
with	O
COPD	O
alone	O
were	O
defined	O
as	O
those	O
who	O
met	O
the	O
definition	O
of	O
COPD	O
but	O
did	O
not	O
meet	O
the	O
definition	O
of	O
asthma	O
,	O
and	O
the	O
index	O
date	O
was	O
defined	O
as	O
the	O
first	O
date	O
when	O
the	O
patient	O
met	O
the	O
definition	O
of	O
COPD	O
.	O

Follow	O
-	O
up	O
was	O
considered	O
to	O
have	O
started	O
on	O
the	O
index	O
date	O
and	O
to	O
have	O
ended	O
on	O
the	O
date	O
of	O
first	O
diagnosis	O
with	O
depression	O
or	O
anxiety	O
,	O
the	O
date	O
the	O
patient	O
died	O
,	O
or	O
31	O
December	O
,	O
2013	O
(	O
Fig	O
.	O

2	O
)	O
.	O

Fig	O
.	O

2	O
Design	O
of	O
the	O
retrospective	O
cohort	O
study	O

Design	O
of	O
the	O
retrospective	O
cohort	O
study	O

Age	O
,	O
sex	O
,	O
comorbidities	O
,	O
and	O
concurrent	O
medications	O
are	O
all	O
possible	O
confounders	O
of	O
the	O
association	O
between	O
ACO	O
or	O
COPD	O
and	O
depression	O
or	O
anxiety	O
.	O

We	O
calculated	O
the	O
Charlson	O
comorbidity	O
index	O
to	O
estimate	O
the	O
severity	O
of	O
disease	O
according	O
to	O
previous	O
diagnoses	O
within	O
one	O
year	O
before	O
the	O
index	O
date	O
.	O

We	O
selected	O
as	O
confounders	O
any	O
comorbidities	O
that	O
may	O
influence	O
the	O
risk	O
of	O
depression	O
or	O
anxiety	O
,	O
which	O
included	O
hypertension	O
,	O
diabetes	O
,	O
hyperlipidaemia	O
,	O
ischaemic	O
heart	O
disease	O
,	O
sleep	O
disorders	O
,	O
alcohol	O
-	O
related	O
illnesses	O
,	O
epilepsy	O
,	O
cancer	O
,	O
arthritis	O
,	O
Parkinson’s	O
disease	O
,	O
dementia	O
,	O
obesity	O
,	O
cerebrovascular	O
disease	O
,	O
and	O
atherosclerosis	O
[	O
22	O
]	O
.	O

Concurrent	O
medications	O
were	O
identified	O
based	O
on	O
the	O
prescriptions	O
within	O
6	O
months	O
before	O
the	O
date	O
of	O
each	O
outcome	O
to	O
adjust	O
the	O
effect	O
of	O
using	O
the	O
medications	O
just	O
before	O
the	O
occurrence	O
of	O
the	O
outcomes	O
;	O
in	O
analysing	O
the	O
incidence	O
of	O
depression	O
,	O
we	O
used	O
the	O
prescription	O
information	O
within	O
6	O
months	O
before	O
the	O
date	O
of	O
depression	O
,	O
and	O
in	O
the	O
same	O
way	O
,	O
we	O
used	O
the	O
prescription	O
information	O
within	O
6	O
months	O
before	O
the	O
date	O
of	O
anxiety	O
in	O
analysing	O
the	O
incidence	O
of	O
anxiety	O
.	O

Benzodiazepines	O
,	O
digitalis	O
,	O
and	O
calcium	O
antagonists	O
–	O
including	O
diltiazem	O
,	O
nifedipine	O
,	O
and	O
verapamil	O
–	O
were	O
selected	O
as	O
confounders	O
because	O
they	O
were	O
the	O
frequently	O
reported	O
medications	O
that	O
might	O
increase	O
the	O
risk	O
of	O
depression	O
or	O
anxiety	O
[	O
23	O
]	O
.	O

In	O
addition	O
,	O
patients’	O
history	O
of	O
exacerbation	O
and	O
healthcare	O
utilization	O
were	O
also	O
included	O
as	O
potential	O
confounders	O
.	O

Within	O
the	O
ACO	O
and	O
COPD	O
cohort	O
,	O
patients	O
were	O
classified	O
by	O
the	O
frequency	O
of	O
exacerbations	O
they	O
experienced	O
within	O
one	O
year	O
before	O
the	O
index	O
date	O
:	O
frequent	O
(	O
≥2	O
)	O
,	O
infrequent	O
(	O
1	O
)	O
,	O
and	O
not	O
exacerbated	O
(	O
0	O
)	O
.	O

Indicators	O
for	O
exacerbation	O
were	O
identified	O
based	O
on	O
ICD	B-coding_system
codes	O
(	O
primary	O
diagnosis	O
)	O
related	O
to	O
COPD	B-phenotype
(	I-phenotype
or	I-phenotype
asthma	I-phenotype
in	I-phenotype
ACO	I-phenotype
)	I-phenotype
present	O
in	O
combination	O
with	O
one	O
of	O
the	O
following	O
:	O
(	O
1	O
)	O
hospitalization	O
,	O
(	O
2	O
)	O
emergency	O
department	O
visit	O
,	O
or	O
(	O
3	O
)	O
outpatient	O
visit	O
with	O
either	O
an	O
oral	O
corticosteroid	O
or	O
antibiotic	O
prescription	O
within	O
5	O
days	O
of	O
the	O
visit	O
[	O
24	O
,	O
25	O
]	O
.	O

To	O
take	O
into	O
account	O
for	O
healthcare	O
use	O
other	O
than	O
for	O
exacerbation	O
,	O
we	O
included	O
non	O
-	O
exacerbation	O
related	O
healthcare	O
use	O
in	O
the	O
preceding	O
year	O
of	O
the	O
index	O
date	O
as	O
a	O
potential	O
confounder	O
,	O
which	O
was	O
further	O
classified	O
by	O
the	O
type	O
of	O
healthcare	O
use	O
:	O
(	O
1	O
)	O
hospitalizations	O
,	O
(	O
2	O
)	O
emergency	O
department	O
visit	O
,	O
or	O
(	O
3	O
)	O
outpatient	O
visit	O
.	O

We	O
estimated	O
the	O
propensity	O
scores	O
for	O
being	O
defined	O
as	O
having	O
ACO	O
regardless	O
of	O
the	O
outcomes	O
by	O
using	O
multiple	O
logistic	O
regression	O
analysis	O
with	O
the	O
following	O
variables	O
:	O
age	O
category	O
,	O
sex	O
,	O
Charlson	O
comorbidity	O
index	O
,	O
history	O
of	O
comorbidities	O
,	O
exacerbations	O
,	O
and	O
healthcare	O
use	O
in	O
previous	O
year	O
,	O
insurance	O
type	O
and	O
index	O
year	O
.	O

We	O
assessed	O
the	O
model	O
discrimination	O
using	O
the	O
C	O
statistic	O
.	O

Matching	O
was	O
performed	O
using	O
a	O
Greedy	O
5	O
→	O
1	O
digit	O
matching	O
macro	O
with	O
the	O
estimated	O
propensity	O
score	O
[	O
26	O
]	O
.	O

We	O
used	O
a	O
standardized	O
difference	O
to	O
compare	O
baseline	O
characteristics	O
between	O
patients	O
with	O
ACO	O
and	O
patients	O
with	O
COPD	O
alone	O
.	O

We	O
defined	O
significant	O
difference	O
as	O
an	O
absolute	O
value	O
greater	O
than	O
0	O
.	O
1	O
[	O
27	O
]	O
.	O

We	O
calculated	O
the	O
incidence	O
rate	O
per	O
1000	O
person	O
-	O
years	O
by	O
dividing	O
the	O
number	O
of	O
diagnoses	O
of	O
depression	O
or	O
anxiety	O
by	O
the	O
total	O
number	O
of	O
person	O
-	O
years	O
at	O
risk	O
and	O
multiplying	O
the	O
results	O
by	O
1000	O
.	O

We	O
also	O
calculated	O
the	O
associated	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
.	O

For	O
construction	O
of	O
the	O
multivariable	O
model	O
,	O
we	O
included	O
the	O
use	O
of	O
concurrent	O
medications	O
prescribed	O
within	O
6	O
months	O
before	O
the	O
date	O
of	O
the	O
outcome	O
as	O
the	O
adjusting	O
variable	O
.	O

We	O
used	O
the	O
Cox	O
regression	O
models	O
to	O
estimate	O
the	O
adjusted	O
hazard	O
ratios	O
(	O
aHRs	O
)	O
and	O
their	O
95	O
%	O
CIs	O
for	O
depression	O
and	O
anxiety	O
after	O
adjusting	O
for	O
the	O
concurrent	O
medications	O
in	O
the	O
propensity	O
-	O
based	O
matched	O
cohort	O
.	O

We	O
also	O
conducted	O
a	O
subgroup	O
analysis	O
for	O
the	O
incidence	O
of	O
depression	O
and	O
anxiety	O
according	O
to	O
age	O
group	O
,	O
sex	O
,	O
comorbidities	O
,	O
and	O
concurrent	O
medications	O
.	O

We	O
did	O
subgroup	O
analysis	O
with	O
interaction	O
terms	O
to	O
see	O
whether	O
the	O
association	O
between	O
ACO	O
and	O
incident	O
depression	O
or	O
anxiety	O
differed	O
significantly	O
by	O
comorbidities	O
and	O
concurrent	O
medications	O
.	O

All	O
tests	O
were	O
2	O
-	O
sided	O
,	O
with	O
a	O
significance	O
level	O
of	O
0	O
.	O
05	O
.	O

All	O
data	O
transformations	O
and	O
statistical	O
analyses	O
were	O
conducted	O
using	O
SAS	O
version	O
9	O
.	O
4	O
for	O
Windows	O
(	O
SAS	O
Institute	O
,	O
Cary	O
,	O
NC	O
,	O
USA	O
)	O
.	O

The	O
current	O
trial	O
is	O
an	O
investigator	O
-	O
initiated	O
,	O
randomized	O
clinical	O
superiority	O
trial	O
.	O

The	O
experimental	O
intervention	O
is	O
the	O
addition	O
of	O
feedback	O
to	O
standard	O
treatment	O
,	O
and	O
the	O
design	O
strategy	O
can	O
thus	O
be	O
categorized	O
as	O
additive	O
or	O
constructive	O
[	O
27	O
]	O
.	O

After	O
the	O
patients	O
have	O
been	O
offered	O
treatment	O
,	O
received	O
information	O
about	O
the	O
trial	O
,	O
and	O
signed	O
the	O
consent	O
form	O
,	O
the	O
patients	O
are	O
allocated	O
to	O
one	O
of	O
two	O
groups	O
(	O
at	O
a	O
ratio	O
of	O
1	O
:	O
1	O
)	O
.	O

The	O
first	O
(	O
experimental	O
)	O
group	O
consists	O
of	O
standard	O
treatment	O
with	O
feedback	O
intervention	O
(	O
feedback	O
:	O
ORS	O
and	O
GSRS	O
are	O
filled	O
out	O
and	O
included	O
in	O
the	O
treatment	O
according	O
to	O
the	O
FIT	O
intervention	O
manual	O
)	O
.	O

The	O
second	O
(	O
control	O
)	O
group	O
consists	O
of	O
standard	O
treatment	O
without	O
feedback	O
intervention	O
(	O
no	O
feedback	O
:	O
ORS	O
is	O
filled	O
out	O
but	O
not	O
included	O
in	O
the	O
treatment	O
)	O
.	O

The	O
inclusion	O
and	O
exclusion	O
criteria	O
are	O
divided	O
into	O
criteria	O
that	O
are	O
part	O
of	O
the	O
clinical	O
routine	O
at	O
the	O
trial	O
site	O
,	O
and	O
criteria	O
that	O
are	O
exclusive	O
to	O
the	O
trial	O
(	O
Table	O
1	O
)	O
.	O

Patients	O
excluded	O
as	O
part	O
of	O
the	O
clinical	O
routine	O
will	O
be	O
referred	O
to	O
treatment	O
elsewhere	O
or	O
back	O
to	O
the	O
referring	O
professional	O
.	O

Patients	O
that	O
are	O
offered	O
treatment	O
but	O
are	O
not	O
eligible	O
for	O
inclusion	O
in	O
the	O
trial	O
will	O
receive	O
standard	O
treatment	O
.	O

Excluded	O
patients	O
can	O
be	O
reassessed	O
and	O
included	O
in	O
the	O
trial	O
at	O
a	O
later	O
point	O
in	O
time	O
,	O
if	O
,	O
for	O
example	O
,	O
they	O
have	O
been	O
successfully	O
treated	O
for	O
severe	O
depression	O
and	O
subsequently	O
fulfil	O
the	O
inclusion	O
criteria	O
.	O

Inclusion	O
and	O
exclusion	O
criteria	O

BED	O
,	O
binge	O
eating	O
disorder	O
;	O
BMI	O
,	O
Body	O
Mass	O
Index	O
;	O
BN	O
,	O
bulimia	O
nervosa	O
;	O
EDNOS	O
,	O
eating	O
disorder	O
not	O
otherwise	O
specified	O
.	O

Participation	O
in	O
the	O
trial	O
is	O
voluntary	O
and	O
patients	O
can	O
withdraw	O
from	O
the	O
trial	O
at	O
any	O
time	O
,	O
without	O
any	O
implications	O
for	O
current	O
or	O
future	O
treatment	O
at	O
Stolpegaard	O
Psychotherapy	O
Centre	O
.	O

The	O
participants	O
are	O
kindly	O
asked	O
to	O
specify	O
which	O
aspects	O
of	O
the	O
trial	O
they	O
wish	O
to	O
withdraw	O
from	O
:	O
the	O
intervention	O
,	O
participation	O
in	O
follow	O
-	O
up	O
assessments	O
,	O
or	O
complete	O
withdrawal	O
from	O
the	O
trial	O
.	O

The	O
options	O
are	O
described	O
in	O
the	O
written	O
patient	O
information	O
.	O

Information	O
about	O
participation	O
in	O
the	O
trial	O
will	O
be	O
given	O
at	O
three	O
different	O
points	O
before	O
the	O
patients	O
start	O
therapy	O
:	O
1	O
)	O
written	O
information	O
before	O
the	O
first	O
routine	O
assessment	O
interview	O
;	O
2	O
)	O
verbal	O
information	O
at	O
a	O
routine	O
assessment	O
with	O
a	O
psychiatrist	O
or	O
an	O
attending	O
physician	O
;	O
and	O
3	O
)	O
verbal	O
information	O
at	O
an	O
assessment	O
session	O
with	O
the	O
principal	O
investigator	O
or	O
a	O
qualified	O
assistant	O
.	O

The	O
participants	O
can	O
give	O
their	O
written	O
consent	O
at	O
any	O
point	O
before	O
randomization	O
.	O

Fifteen	O
therapists	O
are	O
participating	O
in	O
the	O
trial	O
,	O
three	O
male	O
and	O
twelve	O
female	O
(	O
mean	O
age	O
=	O
44	O
.	O
3	O
years	O
,	O
SD	O
9	O
.	O
1	O
)	O
.	O

Their	O
general	O
average	O
experience	O
with	O
psychotherapy	O
is	O
7	O
.	O
2	O
years	O
(	O
SD	O
6	O
.	O
6	O
)	O
,	O
and	O
their	O
average	O
experience	O
with	O
the	O
treatment	O
of	O
eating	O
disorders	O
is	O
3	O
.	O
8	O
years	O
(	O
SD	O
5	O
.	O
2	O
)	O
.	O

As	O
part	O
of	O
the	O
clinical	O
routine	O
,	O
the	O
therapists	O
have	O
case	O
supervision	O
in	O
groups	O
with	O
team	O
colleagues	O
every	O
other	O
week	O
,	O
lasting	O
one	O
and	O
a	O
half	O
hours	O
.	O

The	O
supervision	O
format	O
is	O
systemic	O
and	O
narrative	O
,	O
structured	O
around	O
the	O
idea	O
of	O
‘reflecting	O
teams’	O
[	O
28	O
]	O
.	O

Before	O
data	O
collection	O
began	O
,	O
the	O
therapists	O
had	O
two	O
training	O
sessions	O
(	O
three	O
hours	O
each	O
)	O
in	O
feedback	O
-	O
informed	O
clinical	O
work	O
,	O
led	O
by	O
an	O
external	O
certified	O
FIT	O
trainer	O
and	O
associate	O
at	O
the	O
International	O
Center	O
for	O
Clinical	O
Excellence	O
[	O
20	O
]	O
.	O

The	O
therapists	O
were	O
introduced	O
to	O
the	O
method	O
and	O
instructed	O
in	O
the	O
use	O
of	O
the	O
measures	O
in	O
clinical	O
practice	O
[	O
17	O
]	O
.	O

Only	O
two	O
had	O
worked	O
with	O
FIT	O
in	O
previous	O
jobs	O
.	O

Each	O
therapist	O
was	O
placed	O
in	O
both	O
a	O
control	O
group	O
and	O
an	O
experimental	O
group	O
and	O
thus	O
provided	O
both	O
treatments	O
.	O

To	O
ensure	O
that	O
the	O
therapists	O
followed	O
the	O
feedback	O
method	O
and	O
to	O
reinforce	O
the	O
implementation	O
process	O
,	O
the	O
training	O
was	O
supplemented	O
with	O
one	O
and	O
a	O
half	O
hour	O
hour	O
monthly	O
FIT	O
supervision	O
during	O
the	O
data	O
collection	O
period	O
.	O

The	O
therapists	O
were	O
assumed	O
to	O
be	O
following	O
the	O
feedback	O
method	O
adequately	O
after	O
this	O
,	O
with	O
no	O
further	O
control	O
for	O
adherence	O
to	O
the	O
method	O
.	O

Because	O
of	O
the	O
lack	O
of	O
published	O
guidelines	O
for	O
the	O
use	O
of	O
feedback	O
in	O
group	O
therapy	O
,	O
the	O
therapists	O
were	O
encouraged	O
to	O
use	O
the	O
feedback	O
according	O
to	O
the	O
guidelines	O
for	O
individual	O
therapy	O
[	O
17	O
]	O
.	O

In	O
cases	O
where	O
these	O
guidelines	O
were	O
insufficient	O
,	O
the	O
supervisor	O
was	O
involved	O
.	O

Immediately	O
after	O
the	O
second	O
training	O
session	O
with	O
the	O
FIT	O
trainer	O
,	O
the	O
therapists	O
answered	O
an	O
attitude	O
survey	O
(	O
Davidsen	O
,	O
AH	O
;	O
allegiance	O
measure	O
;	O
unpublished	O
data	O
)	O
asking	O
if	O
they	O
believed	O
working	O
with	O
GSRS	O
and	O
ORS	O
would	O
make	O
a	O
positive	O
difference	O
in	O
their	O
therapeutic	O
work	O
.	O

All	O
therapists	O
agreed	O
that	O
it	O
would	O
improve	O
their	O
clinical	O
work	O
.	O

This	O
therapist	O
allegiance	O
can	O
potentially	O
positively	O
influence	O
the	O
results	O
and	O
exaggerate	O
an	O
effect	O
of	O
feedback	O
on	O
outcome	O
.	O

In	O
order	O
to	O
investigate	O
if	O
the	O
first	O
attitude	O
survey	O
was	O
influenced	O
by	O
the	O
‘rush’	O
after	O
the	O
training	O
session	O
,	O
we	O
asked	O
the	O
therapists	O
again	O
before	O
they	O
started	O
using	O
the	O
method	O
.	O

The	O
answers	O
were	O
the	O
same	O
in	O
the	O
second	O
survey	O
(	O
Davidsen	O
,	O
AH	O
;	O
allegiance	O
measure	O
;	O
unpublished	O
data	O
)	O
.	O

Standard	O
treatment	O
is	O
offered	O
in	O
both	O
groups	O
,	O
based	O
on	O
recommendations	O
from	O
the	O
Danish	O
National	O
Board	O
of	O
Health	O
[	O
2	O
]	O
and	O
on	O
guidelines	O
for	O
treating	O
eating	O
disorders	O
in	O
the	O
Capital	O
Region	O
of	O
Denmark	O
[	O
29	O
]	O
.	O

After	O
the	O
initial	O
assessment	O
interview	O
a	O
psychiatrist	O
or	O
attending	O
physician	O
decides	O
to	O
offer	O
the	O
patient	O
one	O
of	O
two	O
standard	O
treatments	O
:	O
basic	O
or	O
elaborate	O
.	O

This	O
decision	O
is	O
based	O
upon	O
an	O
assessment	O
of	O
eating	O
disorder	O
severity	O
,	O
co	O
-	O
morbidity	O
,	O
and	O
medical	O
and	O
/	O
or	O
social	O
factors	O
that	O
are	O
believed	O
to	O
complicate	O
the	O
treatment	O
of	O
the	O
eating	O
disorder	O
.	O

Treatment	O
length	O
(	O
from	O
the	O
first	O
assessment	O
session	O
to	O
the	O
last	O
follow	O
-	O
up	O
session	O
)	O
is	O
approximately	O
10	O
months	O
for	O
basic	O
treatment	O
and	O
12	O
to	O
14	O
months	O
for	O
elaborate	O
treatment	O
[	O
29	O
]	O
.	O

After	O
referral	O
and	O
before	O
starting	O
group	O
therapy	O
,	O
the	O
patient	O
undergoes	O
a	O
psychiatric	O
,	O
medical	O
,	O
and	O
somatic	O
assessment	O
,	O
followed	O
by	O
psycho	O
-	O
education	O
.	O

The	O
treatment	O
program	O
consists	O
of	O
20	O
sessions	O
for	O
patients	O
with	O
BN	O
or	O
EDNOS	O
,	O
and	O
25	O
sessions	O
for	O
patients	O
with	O
BED	O
.	O

Alongside	O
group	O
therapy	O
,	O
the	O
patients	O
are	O
offered	O
sessions	O
with	O
a	O
dietician	O
and	O
relatives	O
as	O
well	O
as	O
sessions	O
with	O
a	O
social	O
worker	O
(	O
as	O
needed	O
)	O
.	O

The	O
patients	O
in	O
the	O
elaborate	O
treatment	O
are	O
offered	O
an	O
extended	O
medical	O
assessment	O
and	O
more	O
sessions	O
with	O
relatives	O
and	O
a	O
dietician	O
.	O

In	O
some	O
cases	O
,	O
patients	O
start	O
psychotropic	O
drugs	O
before	O
or	O
during	O
treatment	O
;	O
this	O
is	O
a	O
possibility	O
in	O
both	O
groups	O
.	O

Patient	O
treatment	O
status	O
is	O
assessed	O
at	O
weekly	O
team	O
conferences	O
.	O

The	O
eating	O
disorders	O
treatment	O
provided	O
at	O
Stolpegaard	O
Psychotherapy	O
Centre	O
is	O
founded	O
on	O
systemic	O
and	O
narrative	O
theory	O
and	O
a	O
post	O
-	O
modern	O
view	O
on	O
patients	O
and	O
therapy	O
[	O
30	O
-	O
33	O
]	O
.	O

The	O
therapists	O
work	O
with	O
individual	O
therapy	O
in	O
the	O
group	O
,	O
which	O
is	O
structured	O
around	O
the	O
principles	O
of	O
the	O
reflecting	O
team	O
[	O
28	O
]	O
.	O

One	O
of	O
the	O
methods	O
used	O
in	O
the	O
therapy	O
is	O
externalization	O
of	O
the	O
eating	O
disorder	O
[	O
30	O
]	O
.	O

With	O
a	O
focus	O
on	O
the	O
patients’	O
resources	O
,	O
relations	O
,	O
future	O
and	O
unique	O
outcomes	O
[	O
34	O
]	O
,	O
patients	O
and	O
therapists	O
address	O
psychological	O
,	O
physiological	O
and	O
social	O
difficulties	O
associated	O
with	O
the	O
eating	O
disorder	O
.	O

The	O
effectiveness	O
of	O
this	O
specific	O
treatment	O
has	O
not	O
been	O
evaluated	O
but	O
a	O
recent	O
meta	O
-	O
analysis	O
of	O
38	O
randomized	O
controlled	O
trials	O
showed	O
that	O
systemic	O
therapy	O
,	O
on	O
which	O
the	O
treatment	O
at	O
the	O
Stolpegaard	O
Psychotherapy	O
Centre	O
outpatient	O
clinic	O
is	O
based	O
,	O
is	O
an	O
effective	O
psychotherapeutic	O
treatment	O
for	O
adults	O
with	O
eating	O
disorders	O
and	O
other	O
psychiatric	O
disorders	O
[	O
35	O
]	O
.	O

There	O
are	O
seven	O
patients	O
and	O
two	O
therapists	O
in	O
each	O
group	O
.	O

The	O
groups	O
are	O
slow	O
-	O
open	O
,	O
that	O
is	O
,	O
open	O
to	O
new	O
patients	O
as	O
others	O
end	O
treatment	O
.	O

Central	O
to	O
the	O
treatment	O
is	O
a	O
food	O
diary	O
that	O
patients	O
are	O
asked	O
to	O
keep	O
and	O
discuss	O
in	O
the	O
group	O
therapy	O
sessions	O
.	O

Patients	O
are	O
weighed	O
before	O
each	O
session	O
and	O
weight	O
fluctuation	O
is	O
monitored	O
and	O
addressed	O
in	O
the	O
case	O
of	O
rapid	O
weight	O
gain	O
or	O
weight	O
loss	O
.	O

The	O
patients	O
are	O
encouraged	O
to	O
set	O
individual	O
goals	O
for	O
the	O
treatment	O
,	O
typically	O
concerning	O
food	O
,	O
body	O
and	O
appearance	O
,	O
relations	O
,	O
and	O
future	O
[	O
36	O
]	O
.	O

The	O
duration	O
of	O
a	O
group	O
session	O
is	O
150	O
minutes	O
.	O

In	O
the	O
experimental	O
group	O
two	O
sets	O
of	O
measures	O
are	O
added	O
to	O
the	O
standard	O
treatment	O
:	O
ORS	O
and	O
GSRS	O
.	O

The	O
patients	O
mark	O
their	O
scores	O
on	O
the	O
ORS	O
and	O
GSRS	O
using	O
a	O
tablet	O
computer	O
with	O
a	O
computer	O
-	O
based	O
application	O
(	O
FIT	O
-	O
Outcomes	O
)	O
.	O

FIT	O
-	O
Outcomes	O
(	O
FIT	O
-	O
Outcomes	O
,	O
Hoersholm	O
,	O
Denmark	O
)	O
is	O
an	O
application	O
used	O
to	O
administer	O
,	O
score	O
and	O
aggregate	O
data	O
from	O
the	O
ORS	O
and	O
SRS	O
/	O
GSRS	O
[	O
37	O
]	O
.	O

When	O
the	O
patient	O
has	O
marked	O
his	O
or	O
her	O
scores	O
on	O
the	O
tablet	O
computer	O
,	O
the	O
management	O
system	O
produces	O
a	O
graph	O
illustrating	O
the	O
therapeutic	O
progress	O
on	O
the	O
ORS	O
and	O
GSRS	O
,	O
the	O
cutoff	O
scores	O
and	O
the	O
expected	O
treatment	O
response	O
(	O
ETR	O
)	O
.	O

Based	O
on	O
the	O
latest	O
score	O
on	O
the	O
ORS	O
and	O
GSRS	O
,	O
FIT	O
-	O
Outcomes	O
provides	O
immediate	O
feedback	O
to	O
the	O
therapists	O
.	O

The	O
therapists	O
discuss	O
the	O
ORS	O
and	O
GSRS	O
score	O
with	O
the	O
patient	O
in	O
the	O
present	O
or	O
the	O
following	O
group	O
session	O
[	O
17	O
]	O
.	O

Before	O
they	O
are	O
weighed	O
and	O
immediately	O
before	O
each	O
group	O
session	O
,	O
the	O
patients	O
complete	O
the	O
ORS	O
and	O
assess	O
their	O
individual	O
,	O
interpersonal	O
,	O
social	O
,	O
and	O
overall	O
wellbeing	O
during	O
the	O
preceding	O
week	O
.	O

The	O
clinical	O
cutoff	O
score	O
is	O
25	O
and	O
the	O
reliable	O
change	O
index	O
(	O
RCI	O
)	O
is	O
5	O
points	O
[	O
17	O
]	O
.	O

A	O
green	O
alert	O
in	O
the	O
FIT	O
-	O
Outcomes	O
system	O
means	O
that	O
the	O
patient	O
is	O
on	O
track	O
,	O
that	O
is	O
,	O
that	O
the	O
latest	O
score	O
indicates	O
progress	O
similar	O
to	O
successful	O
treatment	O
courses	O
.	O

A	O
red	O
alert	O
means	O
that	O
the	O
patient	O
is	O
off	O
track	O
,	O
that	O
is	O
,	O
that	O
the	O
latest	O
score	O
indicates	O
progress	O
similar	O
to	O
unsuccessful	O
treatment	O
courses	O
.	O

A	O
yellow	O
alert	O
means	O
an	O
uncertain	O
tendency	O
(	O
that	O
the	O
change	O
is	O
smaller	O
than	O
expected	O
)	O
.	O

The	O
therapists	O
are	O
encouraged	O
to	O
discuss	O
yellow	O
and	O
red	O
feedback	O
with	O
the	O
patients	O
as	O
soon	O
as	O
possible	O
[	O
17	O
]	O
.	O

The	O
patients	O
mark	O
a	O
score	O
on	O
the	O
GSRS	O
5	O
to	O
10	O
minutes	O
before	O
the	O
group	O
session	O
ends	O
,	O
and	O
the	O
therapists	O
respond	O
briefly	O
to	O
the	O
score	O
.	O

On	O
the	O
GSRS	O
,	O
the	O
patients	O
rate	O
the	O
present	O
group	O
session	O
concerning	O
relationship	O
,	O
goals	O
and	O
topics	O
,	O
approach	O
or	O
method	O
and	O
overall	O
.	O

The	O
clinical	O
cutoff	O
score	O
is	O
36	O
.	O

As	O
described	O
for	O
the	O
ORS	O
,	O
a	O
green	O
alert	O
from	O
FIT	O
-	O
Outcomes	O
means	O
that	O
there	O
is	O
no	O
reason	O
for	O
an	O
intervention	O
.	O

A	O
red	O
alert	O
encourages	O
the	O
therapists	O
to	O
consider	O
alliance	O
feedback	O
,	O
either	O
due	O
to	O
a	O
below	O
cutoff	O
score	O
or	O
a	O
drop	O
on	O
the	O
GSRS	O
of	O
more	O
than	O
one	O
point	O
.	O

The	O
therapists	O
are	O
encouraged	O
to	O
discuss	O
red	O
feedback	O
in	O
the	O
present	O
or	O
following	O
group	O
session	O
.	O

In	O
the	O
control	O
group	O
,	O
the	O
patients	O
fill	O
out	O
a	O
paper	O
version	O
of	O
the	O
ORS	O
before	O
each	O
group	O
session	O
.	O

However	O
,	O
they	O
will	O
not	O
receive	O
any	O
feedback	O
during	O
therapy	O
.	O

The	O
ORS	O
forms	O
are	O
gathered	O
in	O
sealed	O
envelopes	O
and	O
put	O
away	O
until	O
data	O
analyses	O
.	O

The	O
primary	O
outcome	O
is	O
treatment	O
attendance	O
in	O
the	O
intervention	O
period	O
,	O
defined	O
as	O
a	O
rate	O
(	O
number	O
of	O
attended	O
therapy	O
sessions	O
divided	O
by	O
the	O
number	O
of	O
planned	O
therapy	O
sessions	O
)	O
.	O

If	O
a	O
patient	O
ends	O
therapy	O
prematurely	O
,	O
and	O
this	O
is	O
in	O
accordance	O
with	O
the	O
therapists	O
,	O
the	O
number	O
of	O
attended	O
sessions	O
will	O
be	O
set	O
equal	O
to	O
the	O
planned	O
number	O
of	O
sessions	O
.	O

The	O
secondary	O
outcome	O
is	O
the	O
global	O
score	O
of	O
eating	O
disorder	O
examination	O
(	O
EDE	O
)	O
interview	O
,	O
assessed	O
at	O
the	O
end	O
of	O
intervention	O
.	O

The	O
mean	O
score	O
in	O
the	O
two	O
intervention	O
groups	O
are	O
compared	O
.	O

The	O
exploratory	O
outcomes	O
are	O
:	O
ORS	O
,	O
the	O
Symptom	O
Check	O
List	O
(	O
SCL	O
-	O
90R	O
)	O
,	O
the	O
Sheehan	O
Disability	O
Scale	O
(	O
SDS	O
)	O
,	O
the	O
WHO	O
-	O
Five	O
Wellbeing	O
Index	O
(	O
WHO	O
-	O
5	O
)	O
,	O
and	O
suicide	O
and	O
self	O
-	O
harm	O
.	O

For	O
all	O
outcomes	O
except	O
the	O
ORS	O
,	O
the	O
scores	O
obtained	O
in	O
the	O
two	O
intervention	O
groups	O
after	O
the	O
end	O
of	O
the	O
treatment	O
are	O
compared	O
.	O

With	O
regard	O
to	O
the	O
ORS	O
,	O
the	O
last	O
available	O
score	O
for	O
each	O
patient	O
in	O
the	O
two	O
groups	O
is	O
compared	O
(	O
see	O
further	O
description	O
of	O
these	O
outcomes	O
below	O
)	O
.	O

Demographic	O
variables	O
(	O
age	O
,	O
sex	O
,	O
social	O
conditions	O
,	O
education	O
,	O
connection	O
to	O
the	O
labor	O
market	O
)	O
,	O
previous	O
treatment	O
,	O
medication	O
,	O
use	O
of	O
alcohol	O
and	O
/	O
or	O
narcotics	O
,	O
BMI	O
,	O
pregnancy	O
,	O
ability	O
to	O
attend	O
treatment	O
,	O
and	O
language	O
skills	O
are	O
assessed	O
at	O
the	O
first	O
assessment	O
interview	O
with	O
a	O
therapist	O
and	O
by	O
a	O
psychiatrist	O
or	O
attending	O
physician	O
at	O
their	O
assessment	O
interview	O
(	O
part	O
of	O
the	O
clinical	O
routine	O
)	O
.	O

Eating	O
disorder	O
diagnosis	O
is	O
assessed	O
at	O
the	O
trial	O
assessment	O
interview	O
.	O

Diagnosis	O
is	O
set	O
using	O
the	O
EDE	O
[	O
38	O
]	O
.	O

Present	O
psychosis	O
and	O
depression	O
,	O
suicidal	O
risk	O
and	O
abuse	O
of	O
alcohol	O
,	O
medicine	O
and	O
/	O
or	O
narcotics	O
is	O
assessed	O
by	O
a	O
psychiatrist	O
or	O
attending	O
physician	O
at	O
the	O
patient’s	O
initial	O
assessment	O
interview	O
using	O
the	O
Mini	O
International	O
Neuropsychiatric	O
Interview	O
(	O
MINI	O
)	O
[	O
39	O
]	O
.	O

MINI	O
is	O
a	O
short	O
structured	O
diagnostic	O
interview	O
compatible	O
with	O
international	O
diagnostic	O
criteria	O
,	O
including	O
the	O
International	B-coding_system
Classification	I-coding_system
of	I-coding_system
Diseases	I-coding_system
(	I-coding_system
ICD	I-coding_system
-	I-coding_system
10	I-coding_system
)	I-coding_system
and	O
the	O
Diagnostic	B-coding_system
and	I-coding_system
Statistical	I-coding_system
Manual	I-coding_system
of	I-coding_system
Mental	I-coding_system
Disorders	I-coding_system
(	I-coding_system
DSM	I-coding_system
-	I-coding_system
IV	I-coding_system
)	I-coding_system
[	O
39	O
]	O
.	O

We	O
are	O
using	O
a	O
modified	O
version	O
of	O
the	O
authorized	O
Danish	O
version	O
of	O
the	O
MINI	O
5	O
.	O
0	O
.	O

We	O
have	O
included	O
the	O
suicidality	O
module	O
from	O
version	O
6	O
.	O
0	O
.	O

0	O
and	O
have	O
modified	O
the	O
alcohol	O
dependence	O
and	O
/	O
or	O
alcohol	O
abuse	O
module	O
to	O
Danish	O
norms	O
.	O

Previous	O
studies	O
of	O
the	O
psychometric	O
properties	O
of	O
MINI	O
have	O
shown	O
a	O
good	O
sensitivity	O
,	O
specificity	O
,	O
reliability	O
,	O
and	O
validity	O
[	O
39	O
]	O
.	O

The	O
possible	O
presence	O
of	O
a	O
DSM	O
-	O
IV	O
recognized	O
personality	O
disorder	O
is	O
assessed	O
with	O
SAPAS	O
[	O
40	O
]	O
at	O
the	O
trial	O
assessment	O
interview	O
.	O

We	O
are	O
using	O
a	O
researcher	O
-	O
rated	O
version	O
of	O
the	O
questionnaire	O
,	O
which	O
consists	O
of	O
eight	O
dichotomously	O
rated	O
questions	O
about	O
the	O
patient’s	O
personality	O
.	O

A	O
previous	O
study	O
indicated	O
that	O
a	O
score	O
of	O
3	O
or	O
4	O
on	O
the	O
SAPAS	O
correctly	O
identified	O
the	O
presence	O
of	O
a	O
personality	O
disorder	O
in	O
over	O
80	O
%	O
of	O
60	O
psychiatric	O
in	O
-	O
and	O
outpatients	O
[	O
40	O
]	O
.	O

The	O
same	O
study	O
reported	O
that	O
the	O
internal	O
consistency	O
,	O
test	O
-	O
retest	O
reliability	O
,	O
sensitivity	O
,	O
and	O
specificity	O
were	O
acceptable	O
.	O

Eating	O
disorder	O
symptoms	O
are	O
measured	O
with	O
the	O
EDE	O
interview	O
[	O
38	O
,	O
41	O
]	O
.	O

The	O
eating	O
disorder	O
examination	O
is	O
a	O
widely	O
used	O
interview	O
in	O
eating	O
disorders	O
research	O
and	O
is	O
considered	O
‘the	O
gold	O
standard’	O
in	O
diagnosing	O
eating	O
disorders	O
.	O

We	O
use	O
the	O
authorized	O
Danish	O
version	O
of	O
the	O
eating	O
disorder	O
examination	O
(	O
EDE	O
)	O
interview	O
(	O
version	O
12	O
)	O
,	O
including	O
the	O
binge	O
eating	O
disorder	O
module	O
from	O
version	O
16	O
,	O
as	O
the	O
secondary	O
outcome	O
measure	O
and	O
as	O
a	O
diagnostic	O
tool	O
[	O
38	O
,	O
42	O
]	O
.	O
We	O
use	O
the	O
global	O
score	O
to	O
compare	O
the	O
groups	O
post	O
treatment	O
.	O

A	O
high	O
degree	O
of	O
inter	O
-	O
rater	O
reliability	O
,	O
internal	O
consistency	O
and	O
discriminant	O
validity	O
has	O
been	O
reported	O
[	O
43	O
]	O
.	O

The	O
interviews	O
are	O
performed	O
by	O
five	O
interviewers	O
trained	O
by	O
an	O
experienced	O
clinician	O
and	O
researcher	O
.	O

The	O
training	O
consisted	O
of	O
two	O
days	O
at	O
six	O
hours	O
per	O
day	O
.	O

On	O
the	O
ORS	O
[	O
17	O
]	O
,	O
patients	O
assess	O
their	O
wellbeing	O
during	O
the	O
last	O
week	O
.	O

The	O
use	O
of	O
the	O
ORS	O
is	O
described	O
in	O
the	O
section	O
about	O
the	O
feedback	O
intervention	O
.	O

Psychological	O
problems	O
and	O
symptoms	O
of	O
psychopathology	O
are	O
measured	O
with	O
the	O
authorized	O
Danish	O
version	O
of	O
the	O
SCL	O
-	O
90R	O
[	O
44	O
,	O
45	O
]	O
.	O

The	O
SCL	O
-	O
90R	O
is	O
a	O
multidimensional	O
patient	O
-	O
reported	O
questionnaire	O
for	O
measuring	O
psychological	O
distress	O
or	O
the	O
degree	O
of	O
affective	O
distress	O
[	O
44	O
-	O
46	O
]	O
.	O

The	O
Global	O
Severity	O
Index	O
(	O
GSI	O
)	O
,	O
which	O
is	O
the	O
global	O
score	O
covering	O
all	O
90	O
items	O
,	O
will	O
be	O
used	O
in	O
the	O
trial	O
.	O

Internal	O
validity	O
has	O
been	O
tested	O
and	O
found	O
acceptable	O
for	O
all	O
subscales	O
,	O
besides	O
psychoticism	O
[	O
46	O
]	O
.	O

Functional	O
impairment	O
is	O
measured	O
with	O
the	O
SDS	O
[	O
47	O
]	O
.	O

The	O
SDS	O
is	O
a	O
patient	O
-	O
rated	O
measure	O
of	O
functional	O
disability	O
in	O
work	O
,	O
social	O
life	O
,	O
and	O
family	O
life	O
.	O

The	O
SDS	O
is	O
a	O
composite	O
of	O
three	O
self	O
-	O
rated	O
items	O
of	O
family	O
,	O
work	O
and	O
social	O
impairment	O
in	O
the	O
previous	O
two	O
weeks	O
[	O
48	O
]	O
.	O

Studies	O
of	O
the	O
psychometric	O
properties	O
of	O
the	O
SDS	O
have	O
demonstrated	O
an	O
acceptable	O
reliability	O
,	O
sensitivity	O
to	O
change	O
and	O
construct	O
validity	O
[	O
48	O
]	O
.	O

Psychological	O
wellbeing	O
is	O
measured	O
with	O
WHO	O
-	O
5	O
[	O
49	O
]	O
.	O

The	O
WHO	O
-	O
5	O
consists	O
of	O
five	O
items	O
that	O
cover	O
positive	O
mood	O
(	O
feeling	O
in	O
good	O
spirits	O
,	O
feeling	O
relaxed	O
)	O
,	O
vitality	O
(	O
being	O
active	O
and	O
waking	O
up	O
fresh	O
and	O
rested	O
)	O
,	O
and	O
being	O
interested	O
in	O
things	O
.	O

The	O
time	O
frame	O
is	O
the	O
past	O
two	O
weeks	O
and	O
a	O
high	O
score	O
indicates	O
good	O
wellbeing	O
,	O
with	O
a	O
low	O
score	O
indicating	O
the	O
opposite	O
[	O
49	O
]	O
.	O

Studies	O
have	O
found	O
the	O
scale	O
to	O
have	O
a	O
good	O
reliability	O
and	O
excellent	O
validity	O
[	O
50	O
]	O
.	O

To	O
assess	O
the	O
occurrence	O
of	O
self	O
-	O
harm	O
behaviour	O
,	O
we	O
have	O
selected	O
seven	O
questions	O
from	O
the	O
Self	O
-	O
Harm	O
Inventory	O
(	O
SHI	O
)	O
[	O
51	O
]	O
.	O

The	O
SHI	O
is	O
in	O
its	O
full	O
length	O
a	O
one	O
-	O
page	O
,	O
22	O
-	O
item	O
,	O
yes	O
/	O
no	O
questionnaire	O
that	O
explores	O
respondents’	O
history	O
of	O
self	O
-	O
harm	O
.	O

Each	O
item	O
is	O
preceded	O
by	O
the	O
phrase	O
,	O
‘Have	O
you	O
ever	O
intentionally	O
,	O
or	O
on	O
purpose…’	O
followed	O
by	O
(	O
in	O
our	O
modified	O
version	O
)	O
:	O
1	O
:	O
‘Cut	O
yourself’	O
;	O
2	O
:	O
‘Burned	O
yourself’	O
;	O
3	O
:	O
‘Hit	O
yourself’	O
;	O
4	O
:	O
‘Banged	O
your	O
head’	O
;	O
5	O
:	O
‘Scratched	O
yourself’	O
;	O
6	O
:	O
‘Prevented	O
wounds	O
from	O
healing’	O
;	O
7	O
:	O
‘Attempted	O
suicide’	O
.	O

The	O
time	O
frame	O
is	O
during	O
the	O
treatment	O
period	O
and	O
the	O
questions	O
are	O
presented	O
orally	O
by	O
the	O
assessor	O
at	O
the	O
end	O
of	O
intervention	O
.	O

A	O
recent	O
study	O
comparing	O
six	O
commonly	O
used	O
scales	O
on	O
deliberate	O
self	O
-	O
harm	O
demonstrated	O
that	O
the	O
SHI	O
was	O
psychometrically	O
sound	O
[	O
52	O
]	O
.	O

A	O
follow	O
-	O
up	O
assessment	O
will	O
be	O
performed	O
within	O
three	O
years	O
after	O
the	O
end	O
of	O
the	O
intervention	O
.	O

The	O
scores	O
of	O
all	O
secondary	O
and	O
explorative	O
outcome	O
measures	O
in	O
the	O
two	O
groups	O
at	O
the	O
longest	O
follow	O
-	O
up	O
(	O
up	O
to	O
36	O
months	O
)	O
are	O
compared	O
.	O

See	O
Table	O
2	O
for	O
the	O
method	O
and	O
timing	O
of	O
the	O
assessment	O
.	O

Method	O
and	O
timing	O
of	O
assessment	O

This	O
trial	O
will	O
be	O
conducted	O
in	O
compliance	O
with	O
the	O
protocol	O
approved	O
by	O
the	O
regulatory	O
authorities	O
:	O
The	O
Regional	O
Ethics	O
Committee	O
of	O
the	O
Capital	O
Region	O
(	O
journal	O
number	O
H	O
-	O
3-2011-151	O
)	O
and	O
the	O
Danish	O
Data	O
Protection	O
Agency	O
(	O
journal	O
number	O
2007-58-0015	O
)	O
,	O
and	O
according	O
to	O
good	O
clinical	O
practice	O
and	O
the	O
Declaration	O
of	O
Helsinki	O
in	O
its	O
latest	O
form	O
.	O

No	O
substantial	O
deviation	O
from	O
the	O
protocol	O
will	O
be	O
implemented	O
without	O
the	O
prior	O
review	O
and	O
approval	O
of	O
the	O
regulatory	O
authorities	O
except	O
where	O
it	O
may	O
be	O
necessary	O
to	O
eliminate	O
an	O
immediate	O
hazard	O
to	O
trial	O
participants	O
.	O

The	O
Copenhagen	O
Trial	O
Unit	O
(	O
CTU	O
)	O
will	O
be	O
responsible	O
for	O
the	O
central	O
randomization	O
.	O

They	O
have	O
no	O
clinical	O
involvement	O
in	O
the	O
trial	O
.	O

Randomization	O
is	O
carried	O
out	O
according	O
to	O
a	O
computer	O
-	O
generated	O
allocation	O
sequence	O
with	O
a	O
varying	O
block	O
size	O
kept	O
unknown	O
to	O
the	O
investigators	O
.	O

After	O
each	O
patient	O
is	O
assessed	O
to	O
be	O
eligible	O
for	O
the	O
trial	O
,	O
the	O
trial	O
secretary	O
will	O
call	O
CTU	O
,	O
provide	O
a	O
personal	O
pin	O
code	O
and	O
receive	O
the	O
randomization	O
result	O
.	O

The	O
randomization	O
is	O
stratified	O
for	O
eating	O
disorder	O
diagnosis	O
(	O
BN	O
,	O
EDNOS	O
or	O
BED	O
)	O
and	O
treatment	O
type	O
(	O
basic	O
or	O
elaborate	O
)	O
.	O

Patients	O
and	O
therapists	O
are	O
naturally	O
aware	O
of	O
the	O
patient	O
allocation	O
but	O
secondary	O
outcome	O
assessment	O
(	O
EDE	O
)	O
,	O
statistical	O
analyses	O
,	O
and	O
drawing	O
of	O
conclusions	O
will	O
be	O
done	O
with	O
the	O
blind	O
intact	O
.	O

Blinding	O
is	O
maintained	O
by	O
instructing	O
the	O
intervention	O
team	O
to	O
withhold	O
patient	O
information	O
from	O
the	O
research	O
team	O
.	O

The	O
research	O
team	O
has	O
no	O
clinical	O
contact	O
with	O
the	O
patients	O
from	O
assessment	O
to	O
end	O
of	O
intervention	O
,	O
and	O
the	O
assessors	O
have	O
no	O
knowledge	O
about	O
the	O
patient’s	O
randomization	O
status	O
at	O
the	O
end	O
of	O
intervention	O
.	O

In	O
order	O
to	O
prevent	O
the	O
risk	O
of	O
bias	O
,	O
such	O
as	O
when	O
therapists	O
are	O
assessing	O
patient	O
withdrawal	O
,	O
we	O
have	O
a	O
blinded	O
assessor	O
counting	O
the	O
attendance	O
rate	O
and	O
checking	O
each	O
patient’s	O
medical	O
file	O
.	O

In	O
order	O
to	O
prevent	O
actual	O
bias	O
,	O
the	O
research	O
team	O
is	O
not	O
present	O
in	O
supervision	O
or	O
when	O
the	O
therapists	O
are	O
discussing	O
patients	O
at	O
conferences	O
.	O

This	O
trial	O
is	O
carried	O
out	O
in	O
order	O
to	O
improve	O
treatment	O
for	O
patients	O
with	O
eating	O
disorders	O
.	O

If	O
the	O
results	O
support	O
our	O
hypothesis	O
,	O
the	O
addition	O
of	O
feedback	O
can	O
have	O
the	O
potential	O
of	O
improving	O
treatment	O
outcome	O
in	O
diagnoses	O
other	O
than	O
eating	O
disorders	O
.	O

The	O
control	O
group	O
receives	O
a	O
standardized	O
treatment	O
based	O
on	O
recommendations	O
from	O
the	O
Danish	O
National	O
Board	O
of	O
Health	O
[	O
2	O
]	O
and	O
on	O
guidelines	O
for	O
treating	O
eating	O
disorders	O
in	O
the	O
Capital	O
Region	O
of	O
Denmark	O
[	O
29	O
]	O
.	O

There	O
are	O
no	O
known	O
or	O
obvious	O
risks	O
concerning	O
participation	O
in	O
this	O
trial	O
.	O

The	O
only	O
inconvenience	O
is	O
that	O
participants	O
are	O
required	O
to	O
spend	O
more	O
time	O
on	O
assessment	O
than	O
in	O
clinical	O
routine	O
assessment	O
(	O
filling	O
out	O
questionnaires	O
as	O
well	O
as	O
attending	O
an	O
extra	O
assessment	O
interview	O
pre	O
and	O
post	O
treatment	O
)	O
.	O

The	O
assessment	O
provides	O
additional	O
information	O
about	O
the	O
patient’s	O
condition	O
for	O
the	O
intervention	O
team	O
to	O
use	O
in	O
the	O
treatment	O
process	O
.	O

Rating	O
the	O
feedback	O
scales	O
before	O
and	O
after	O
each	O
session	O
can	O
put	O
an	O
extra	O
strain	O
on	O
patients	O
and	O
they	O
are	O
offered	O
assistance	O
in	O
this	O
process	O
.	O

The	O
benefits	O
are	O
estimated	O
to	O
outweigh	O
the	O
risks	O
.	O

We	O
are	O
planning	O
a	O
trial	O
of	O
independent	O
experimental	O
participants	O
and	O
control	O
participants	O
randomized	O
at	O
a	O
1	O
:	O
1	O
ratio	O
.	O

Unpublished	O
data	O
(	O
Stolpegaard	O
Psychotherapy	O
Centre	O
,	O
routinely	O
collected	O
data	O
)	O
from	O
138	O
patients	O
with	O
eating	O
disorders	O
at	O
Stolpegaard	O
Psychotherapy	O
Centre	O
indicate	O
that	O
the	O
mean	O
number	O
of	O
attended	O
treatment	O
sessions	O
is	O
13	O
.	O
58	O
and	O
the	O
SD	O
is	O
5	O
.	O
82	O
sessions	O
.	O

We	O
expect	O
to	O
find	O
that	O
the	O
participants	O
in	O
the	O
experimental	O
group	O
attend	O
at	O
least	O
three	O
more	O
sessions	O
than	O
the	O
participants	O
in	O
the	O
control	O
group	O
.	O

Using	O
a	O
SD	O
of	O
six	O
sessions	O
,	O
we	O
need	O
to	O
include	O
64	O
participants	O
in	O
each	O
group	O
(	O
total	O
128	O
)	O
to	O
be	O
able	O
to	O
reject	O
the	O
null	O
hypothesis	O
that	O
number	O
of	O
attended	O
treatment	O
sessions	O
in	O
the	O
experimental	O
and	O
control	O
group	O
is	O
equal	O
with	O
probability	O
(	O
power	O
)	O
80	O
%	O
.	O

The	O
type	O
I	O
error	O
probability	O
associated	O
with	O
the	O
test	O
of	O
this	O
null	O
hypothesis	O
is	O
5	O
%	O
.	O

We	O
also	O
estimated	O
the	O
sample	O
size	O
using	O
a	O
power	O
of	O
90	O
%	O
.	O

This	O
resulted	O
in	O
a	O
total	O
of	O
170	O
participants	O
(	O
2	O
×	O
85	O
participants	O
)	O
.	O

We	O
therefore	O
plan	O
to	O
recruit	O
a	O
minimum	O
of	O
128	O
participants	O
,	O
and	O
in	O
order	O
to	O
reduce	O
the	O
risk	O
of	O
type	O
II	O
error	O
,	O
we	O
will	O
aim	O
to	O
recruit	O
up	O
to	O
170	O
participants	O
,	O
if	O
possible	O
in	O
the	O
14	O
months	O
recruitment	O
period	O
.	O

Power	O
and	O
sample	O
size	O
calculations	O
have	O
been	O
made	O
using	O
the	O
PS	O
Power	O
and	O
Sample	O
Size	O
Calculations	O
program	O
version	O
3	O
.	O
0	O
.	O

14	O
[	O
53	O
,	O
54	O
]	O
(	O
Dupont	O
&	O
Plummer	O
,	O
Nashville	O
,	O
USA	O
)	O
.	O

We	O
have	O
conducted	O
power	O
calculations	O
for	O
the	O
majority	O
of	O
the	O
secondary	O
and	O
exploratory	O
outcomes	O
(	O
Table	O
3	O
)	O
.	O

Based	O
on	O
unpublished	O
calculations	O
of	O
176	O
to	O
263	O
previous	O
patients	O
with	O
eating	O
disorders	O
in	O
routine	O
care	O
at	O
Stolpegaard	O
Psychotherapy	O
Centre	O
,	O
the	O
SDs	O
of	O
their	O
post	O
-	O
treatment	O
responses	O
to	O
SCL	O
-	O
90	O
-	O
R	O
and	O
WHO	O
-	O
5	O
were	O
used	O
.	O

Since	O
the	O
EDE	O
,	O
ORS	O
and	O
SDS	O
are	O
not	O
previously	O
used	O
at	O
Stolpegaard	O
Psychotherapy	O
Centre	O
,	O
power	O
calculation	O
is	O
based	O
on	O
norms	O
from	O
previous	O
studies	O
[	O
55	O
-	O
57	O
]	O
.	O

Power	O
calculations	O

The	O
analyses	O
are	O
intention–to	O
-	O
treat	O
analyses	O
using	O
a	O
two	O
-	O
sided	O
significance	O
test	O
at	O
5	O
%	O
.	O

All	O
analyses	O
will	O
be	O
conducted	O
blinded	O
with	O
the	O
two	O
intervention	O
groups	O
coded	O
as	O
A	O
and	O
B	O
.	O

The	O
primary	O
outcome	O
is	O
the	O
rate	O
of	O
attendance	O
.	O

It	O
is	O
defined	O
as	O
the	O
number	O
of	O
group	O
sessions	O
the	O
patient	O
has	O
attended	O
over	O
the	O
number	O
of	O
planned	O
sessions	O
(	O
20	O
or	O
25	O
sessions	O
)	O
.	O

If	O
at	O
group	O
session	O
#	O
n	O
(	O
n	O
<	O
20	O
)	O
the	O
therapist	O
decides	O
that	O
the	O
patient	O
needs	O
not	O
attend	O
further	O
sessions	O
,	O
the	O
number	O
of	O
planned	O
sessions	O
is	O
set	O
equal	O
to	O
n	O
.	O

When	O
a	O
patient	O
discontinues	O
treatment	O
early	O
,	O
the	O
therapists	O
decide	O
whether	O
this	O
is	O
in	O
accordance	O
with	O
the	O
treatment	O
plan	O
(	O
categorized	O
as	O
‘planned	O
withdrawal’	O
or	O
‘unplanned	O
withdrawal’	O
)	O
.	O

In	O
the	O
analysis	O
of	O
the	O
rate	O
data	O
,	O
the	O
model	O
fit	O
of	O
a	O
Poisson	O
model	O
and	O
a	O
negative	O
binomial	O
model	O
both	O
with	O
offset	O
equal	O
to	O
log	O
(	O
number	O
of	O
planned	O
sessions	O
)	O
are	O
compared	O
and	O
the	O
best	O
fitting	O
model	O
is	O
chosen	O
provided	O
it	O
fits	O
the	O
data	O
reasonably	O
well	O
.	O

In	O
the	O
analysis	O
of	O
continuous	O
outcomes	O
the	O
univariate	O
general	O
linear	O
model	O
is	O
used	O
.	O

If	O
the	O
assumptions	O
of	O
a	O
regression	O
are	O
not	O
fulfilled	O
,	O
a	O
non	O
-	O
parametric	O
test	O
is	O
used	O
(	O
Mann	O
-	O
Whitney	O
)	O
.	O

All	O
outcomes	O
are	O
analyzed	O
using	O
regression	O
analyses	O
,	O
including	O
the	O
binary	O
intervention	O
indicator	O
.	O

The	O
primary	O
results	O
are	O
those	O
adjusted	O
by	O
the	O
protocol	O
-	O
specified	O
stratification	O
variables	O
and	O
(	O
where	O
measured	O
)	O
the	O
baseline	O
value	O
as	O
covariates	O
.	O

In	O
an	O
exploratory	O
analysis	O
the	O
analyses	O
will	O
be	O
repeated	O
with	O
the	O
categorical	O
variable	O
ID	O
-	O
group	O
(	O
identity	O
code	O
of	O
the	O
group	O
)	O
as	O
an	O
additional	O
covariate	O
,	O
and	O
it	O
will	O
be	O
tested	O
if	O
the	O
outcome	O
depends	O
on	O
the	O
treatment	O
group	O
.	O

Then	O
it	O
will	O
be	O
tested	O
if	O
ID	O
-	O
group	O
and	O
the	O
intervention	O
indicator	O
interact	O
.	O

If	O
so	O
,	O
subgroup	O
analyses	O
of	O
the	O
various	O
treatment	O
groups	O
will	O
be	O
conducted	O
.	O

The	O
primary	O
and	O
the	O
secondary	O
outcome	O
are	O
tested	O
in	O
that	O
order	O
each	O
at	O
the	O
5	O
%	O
level	O
of	O
significance	O
.	O

If	O
the	O
first	O
test	O
is	O
not	O
significant	O
at	O
the	O
5	O
%	O
level	O
the	O
null	O
hypothesis	O
of	O
the	O
secondary	O
outcome	O
is	O
accepted	O
without	O
test	O
.	O

Missing	O
values	O
of	O
the	O
secondary	O
outcome	O
and	O
/	O
or	O
covariates	O
included	O
in	O
its	O
analysis	O
are	O
imputed	O
using	O
multiple	O
imputation	O
(	O
SPSS	O
)	O
,	O
if	O
the	O
percent	O
of	O
missing	O
patients	O
is	O
>	O
5	O
%	O
and	O
P	O
of	O
Little’s	O
test	O
is	O
<	O
5	O
%	O
.	O

The	O
result	O
of	O
the	O
analysis	O
of	O
the	O
imputed	O
datasets	O
is	O
then	O
the	O
primary	O
result	O
.	O

The	O
assumption	O
of	O
multiple	O
imputation	O
is	O
that	O
the	O
data	O
are	O
missing	O
at	O
random	O
,	O
i	O
.	O
e	O
.	O
,	O
that	O
for	O
a	O
given	O
quantity	O
with	O
missing	O
values	O
,	O
the	O
distribution	O
of	O
observed	O
values	O
of	O
this	O
quantity	O
conditional	O
on	O
values	O
observed	O
of	O
other	O
quantities	O
is	O
the	O
same	O
as	O
the	O
conditional	O
distribution	O
of	O
the	O
values	O
planned	O
to	O
be	O
observed	O
of	O
the	O
quantity	O
,	O
but	O
missing	O
.	O

If	O
this	O
condition	O
is	O
not	O
fulfilled	O
,	O
the	O
results	O
of	O
the	O
multiple	O
imputation	O
will	O
be	O
biased	O
.	O

To	O
obtain	O
the	O
range	O
of	O
plausible	O
bias	O
that	O
may	O
result	O
if	O
the	O
MAR	O
(	O
missing	O
at	O
random	O
)	O
condition	O
is	O
not	O
fulfilled	O
,	O
we	O
will	O
do	O
the	O
following	O
two	O
analyses	O
using	O
single	O
imputations	O
of	O
the	O
outcome	O
performed	O
as	O
a	O
sensitivity	O
analysis	O
:	O
1	O
)	O
missing	O
values	O
in	O
group	O
A	O
are	O
imputed	O
by	O
the	O
minimum	O
value	O
observed	O
in	O
the	O
material	O
,	O
while	O
missing	O
values	O
in	O
group	O
B	O
are	O
imputed	O
by	O
the	O
maximum	O
value	O
observed	O
,	O
and	O
the	O
two	O
groups	O
are	O
compared	O
;	O
and	O
2	O
)	O
vice	O
versa	O
.	O

This	O
observational	O
cohort	O
study	O
used	O
individual‐level	O
family	O
practice	O
administrative	O
data	O
linked	O
to	O
hospital	O
administrative	O
data	O
to	O
investigate	O
the	O
relationship	O
between	O
family	O
practice	O
continuity	O
of	O
care	O
for	O
people	O
with	O
SMI	O
and	O
time	O
to	O
unplanned	O
hospital	O
use	O
.	O

We	O
used	O
data	O
from	O
the	O
Clinical	O
Practice	O
Research	O
Datalink	O
(	O
CPRD	O
)	O
,	O
a	O
database	O
of	O
anonymized	O
patient	O
records	O
derived	O
from	O
over	O
600	O
family	O
practices	O
in	O
England	O
and	O
broadly	O
representative	O
of	O
the	O
national	O
population	O
with	O
respect	O
to	O
age	O
and	O
gender	O
.	O

36	O
The	O
records	O
were	O
linked	O
to	O
Hospital	O
Episode	O
Statistics	O
(	O
HES	O
)	O
,	O
which	O
capture	O
all	O
hospital	O
admissions	O
(	O
for	O
both	O
physical	O
and	O
mental	O
health	O
)	O
and	O
ED	O
presentations	O
funded	O
by	O
the	O
NHS	O
.	O

This	O
covers	O
the	O
majority	O
of	O
these	O
types	O
of	O
health	O
care	O
in	O
England	O
,	O
since	O
the	O
NHS	O
funds	O
88	O
percent	O
of	O
all	O
health	O
care	O
expenditure	O
37	O
and	O
92	O
percent	O
of	O
hospital	O
care	O
,	O
38	O
and	O
there	O
are	O
no	O
privately	O
funded	O
emergency	O
departments	O
.	O

The	O
sample	O
was	O
all	O
people	O
with	O
a	O
diagnosis	O
of	O
SMI	O
documented	O
in	O
primary	O
care	O
on	O
or	O
before	O
March	O
31	O
,	O
2014	O
(	O
the	O
end	O
of	O
the	O
study	O
period	O
)	O
,	O
whose	O
records	O
met	O
CPRD	O
quality	O
standards	O
,	O
and	O
who	O
were	O
registered	O
during	O
this	O
period	O
at	O
a	O
participating	O
practice	O
that	O
met	O
CPRD	O
standards	O
.	O

36	O
Diagnoses	O
of	O
SMI	O
were	O
based	O
on	O
clinical	O
information	O
in	O
routine	O
practice	O
data	O
recorded	O
in	O
Read	O
codes	O
,	O
an	O
hierarchical	O
coding	O
system	O
for	O
clinical	O
data	O
that	O
classifies	O
diseases	O
,	O
patient	O
characteristics	O
,	O
tests	O
,	O
and	O
procedures	O
39	O
,	O
40	O
(	O
see	O
Table	O
S1	O
for	O
a	O
list	O
of	O
the	O
Read	O
codes	O
used	O
in	O
this	O
study	O
)	O
.	O

The	O
start	O
date	O
of	O
observation	O
for	O
each	O
individual	O
was	O
the	O
latest	O
of	O
:	O
date	O
of	O
SMI	O
diagnosis	O
,	O
date	O
of	O
registration	O
at	O
the	O
practice	O
plus	O
1	O
year	O
of	O
observation	O
in	O
primary	O
care	O
records	O
,	O
January	O
1	O
of	O
the	O
calendar	O
year	O
after	O
the	O
person	O
turned	O
18	O
,	O
and	O
April	O
1	O
,	O
2007	O
(	O
because	O
data	O
on	O
ED	O
presentations	O
were	O
only	O
available	O
from	O
this	O
date	O
)	O
.	O

The	O
year	O
of	O
observation	O
in	O
primary	O
care	O
records	O
allowed	O
for	O
observation	O
of	O
baseline	O
characteristics	O
as	O
control	O
variables	O
.	O

Additionally	O
,	O
the	O
start	O
date	O
of	O
observation	O
for	O
each	O
individual	O
was	O
moved	O
later	O
if	O
necessary	O
so	O
that	O
no	O
patients	O
had	O
an	O
ED	O
presentation	O
or	O
a	O
hospital	O
admission	O
for	O
at	O
least	O
1	O
year	O
prior	O
to	O
the	O
start	O
date	O
,	O
since	O
hospital	O
care	O
could	O
influence	O
the	O
level	O
of	O
continuity	O
in	O
primary	O
care	O
.	O

The	O
observation	O
period	O
for	O
each	O
individual	O
was	O
divided	O
into	O
periods	O
of	O
3	O
months	O
dating	O
from	O
their	O
first	O
date	O
of	O
observation	O
,	O
with	O
continuity	O
measured	O
in	O
the	O
prior	O
12	O
months	O
.	O

Individuals	O
were	O
followed	O
until	O
outcome	O
or	O
censoring	O
,	O
where	O
censoring	O
is	O
due	O
to	O
the	O
person	O
changing	O
family	O
practice	O
,	O
death	O
,	O
or	O
the	O
end	O
of	O
the	O
study	O
period	O
(	O
March	O
31	O
,	O
2014	O
)	O
.	O

We	O
constructed	O
three	O
measures	O
of	O
unplanned	O
hospital	O
use	O
from	O
HES	O
:	O
(	O
a	O
)	O
ED	O
presentations	O
,	O
(	O
b	O
)	O
unplanned	O
admissions	O
for	O
SMI	O
,	O
and	O
(	O
c	O
)	O
unplanned	O
admissions	O
for	O
ambulatory	O
care‐sensitive	O
conditions	O
(	O
ACSC	O
)	O
,	O
41	O
which	O
are	O
conditions	O
thought	O
to	O
be	O
particularly	O
amenable	O
to	O
ambulatory	O
care	O
(	O
such	O
as	O
diabetes	O
,	O
angina	O
,	O
cellulitis	O
,	O
and	O
vaccine‐preventable	O
diseases	O
,	O
but	O
not	O
SMI	O
)	O
.	O

Hospital	O
admissions	O
were	O
classified	O
using	O
International	B-coding_system
Classification	I-coding_system
of	I-coding_system
Disease	I-coding_system
(	I-coding_system
ICD‐10	I-coding_system
)	I-coding_system
codes	O
to	O
identify	O
SMI	B-phenotype
and	I-phenotype
ACSC	I-phenotype
admissions	I-phenotype
.	O

(	O
The	O
codes	O
used	O
to	O
classify	O
ACSC	O
admissions	O
are	O
listed	O
in	O
Table	O
S2	O
.	O
)	O
All	O
ED	O
presentations	O
were	O
included	O
.	O

For	O
each	O
type	O
of	O
outcome	O
,	O
we	O
considered	O
only	O
the	O
first	O
observed	O
instance	O
(	O
presentation	O
or	O
admission	O
)	O
,	O
since	O
this	O
could	O
have	O
influenced	O
subsequent	O
continuity	O
.	O

The	O
occurrence	O
of	O
the	O
outcome	O
is	O
measured	O
in	O
the	O
3‐month	O
period	O
t	O
and	O
continuity	O
is	O
measured	O
over	O
a	O
lookback	O
period	O
of	O
the	O
prior	O
12	O
months	O
(	O
4	O
×	O
3	O
month	O
periods	O
t	O
−4	O
to	O
t	O
−1	O
)	O
.	O

That	O
is	O
,	O
there	O
is	O
no	O
overlap	O
between	O
the	O
12‐month	O
period	O
in	O
which	O
continuity	O
is	O
measured	O
and	O
the	O
subsequent	O
3‐month	O
period	O
in	O
which	O
outcomes	O
are	O
observed	O
.	O

The	O
outcome	O
variable	O
is	O
a	O
binary	O
variable	O
for	O
each	O
3‐month	O
period	O
indicating	O
whether	O
or	O
not	O
the	O
event	O
occurred	O
in	O
that	O
period	O
.	O

For	O
any	O
individual	O
who	O
did	O
not	O
experience	O
the	O
outcome	O
of	O
interest	O
(	O
eg	O
someone	O
who	O
did	O
not	O
present	O
to	O
ED	O
during	O
the	O
period	O
of	O
observation	O
)	O
,	O
this	O
variable	O
is	O
equal	O
to	O
zero	O
for	O
all	O
periods	O
.	O

As	O
we	O
only	O
analyzed	O
time	O
to	O
first	O
event	O
,	O
for	O
any	O
individual	O
who	O
did	O
experience	O
the	O
outcome	O
,	O
the	O
variable	O
is	O
equal	O
to	O
zero	O
for	O
all	O
periods	O
except	O
the	O
final	O
period	O
and	O
equal	O
to	O
one	O
for	O
the	O
final	O
period	O
,	O
with	O
all	O
periods	O
after	O
the	O
first	O
event	O
excluded	O
from	O
the	O
analysis	O
for	O
that	O
outcome	O
.	O

We	O
used	O
three	O
indices	O
measuring	O
different	O
dimensions	O
of	O
family	O
physician	O
relational	O
continuity	O
.	O

42	O
The	O
Continuity	O
of	O
Care	O
(	O
COC	O
)	O
index	O
measures	O
dispersion	O
of	O
visits	O
across	O
family	O
physicians	O
within	O
the	O
patient	O
'	O
s	O
registered	O
family	O
practice	O
,	O
by	O
capturing	O
how	O
many	O
different	O
practitioners	O
are	O
involved	O
and	O
how	O
many	O
visits	O
occur	O
to	O
each	O
.	O

The	O
Usual	O
Provider	O
of	O
Care	O
(	O
UPC	O
)	O
index	O
measures	O
density	O
of	O
visits	O
,	O
being	O
the	O
proportion	O
of	O
a	O
patient	O
'	O
s	O
visits	O
that	O
are	O
with	O
the	O
family	O
physician	O
most	O
frequently	O
seen	O
by	O
the	O
individual	O
in	O
that	O
year	O
out	O
of	O
the	O
total	O
number	O
of	O
visits	O
at	O
the	O
practice	O
.	O

The	O
Sequential	O
Continuity	O
(	O
SECON	O
)	O
index	O
measures	O
the	O
pattern	O
of	O
visits	O
across	O
different	O
practitioners	O
,	O
using	O
the	O
proportion	O
of	O
consecutive	O
pairs	O
of	O
visits	O
which	O
are	O
to	O
the	O
same	O
family	O
physician	O
out	O
of	O
the	O
total	O
number	O
of	O
consecutive	O
pairs	O
of	O
visits	O
at	O
the	O
practice	O
.	O

Each	O
index	O
ranges	O
from	O
zero	O
(	O
lowest	O
continuity	O
)	O
to	O
1	O
(	O
perfect	O
continuity	O
)	O
.	O

Additional	O
detail	O
on	O
each	O
index	O
is	O
in	O
the	O
Tables	O
S1‐S6	O
,	O
and	O
illustrative	O
examples	O
are	O
shown	O
in	O
Table	O
1	O
.	O

Examples	O
of	O
visit	O
patterns	O
and	O
associated	O
continuity	O
of	O
care	O
indices	O

We	O
measured	O
continuity	O
over	O
12	O
months	O
(	O
4	O
×	O
3	O
month	O
periods	O
)	O
,	O
considering	O
only	O
face‐to‐face	O
visits	O
with	O
family	O
physicians	O
.	O

There	O
is	O
no	O
standard	O
level	O
for	O
“high”	O
and	O
“low”	O
continuity	O
,	O
so	O
we	O
applied	O
one	O
recognized	O
method	O
that	O
classified	O
relational	O
continuity	O
as	O
“high”	O
if	O
the	O
level	O
of	O
continuity	O
was	O
above	O
the	O
median	O
for	O
the	O
index	O
,	O
and	O
“low”	O
if	O
at	O
or	O
below	O
the	O
median	O
level	O
.	O

43	O
,	O
44	O

A	O
minimum	O
of	O
two	O
visits	O
is	O
required	O
to	O
calculate	O
COC	O
and	O
SECON	O
,	O
but	O
to	O
improve	O
index	O
stability	O
we	O
set	O
the	O
minimum	O
to	O
three	O
visits	O
.	O

Periods	O
with	O
fewer	O
than	O
two	O
visits	O
in	O
the	O
prior	O
12‐month	O
lookback	O
period	O
were	O
included	O
in	O
the	O
analysis	O
with	O
continuity	O
categorized	O
as	O
“undefined	O
.	O
”	O
We	O
constructed	O
a	O
set	O
of	O
categorical	O
variables	O
based	O
on	O
visit	O
frequency	O
and	O
whether	O
continuity	O
was	O
low	O
or	O
high	O
.	O

This	O
allowed	O
for	O
different	O
effects	O
of	O
continuity	O
for	O
frequent	O
and	O
less	O
frequent	O
users	O
of	O
family	O
practice	O
,	O
as	O
suggested	O
by	O
previous	O
research	O
.	O

45	O
Visit	O
frequency	O
was	O
classified	O
into	O
low	O
,	O
moderate	O
,	O
and	O
high	O
:	O
low	O
(	O
0‐2	O
visits	O
)	O
,	O
moderate	O
(	O
3‐5	O
visits	O
)	O
,	O
and	O
high	O
(	O
6	O
or	O
more	O
visits	O
)	O
.	O

These	O
categories	O
correspond	O
to	O
tertiles	O
of	O
the	O
full‐visit	O
distribution	O
:	O
two	O
visits	O
is	O
the	O
33rd	O
percentile	O
and	O
five	O
visits	O
is	O
the	O
66th	O
percentile	O
.	O

Continuity	O
indices	O
were	O
defined	O
as	O
low	O
or	O
high	O
based	O
on	O
the	O
median	O
value	O
of	O
each	O
index	O
:	O
COC	O
low	O
(	O
0‐0	O
.	O
35	O
)	O
,	O
high	O
(	O
>	O
0	O
.	O
35	O
)	O
;	O
UPC	O
low	O
(	O
0‐0	O
.	O
67	O
)	O
,	O
high	O
(	O
>	O
0	O
.	O
67	O
)	O
;	O
SECON	O
low	O
(	O
0‐0	O
.	O
17	O
)	O
,	O
high	O
(	O
>	O
0	O
.	O
17	O
)	O
.	O

Periods	O
were	O
then	O
classified	O
into	O
five	O
categories	O
according	O
to	O
continuity	O
level	O
and	O
visit	O
frequency	O
in	O
the	O
prior	O
12	O
months	O
:	O
low	O
visit	O
frequency	O
(	O
with	O
continuity	O
undefined—the	O
base	O
category	O
)	O
,	O
moderate	O
visit	O
frequency	O
with	O
low	O
continuity	O
,	O
moderate	O
visit	O
frequency	O
with	O
high	O
continuity	O
,	O
high	O
visit	O
frequency	O
with	O
low	O
continuity	O
,	O
and	O
high	O
visit	O
frequency	O
with	O
high	O
continuity	O
.	O

This	O
analysis	O
captures	O
management	O
/	O
informational	O
continuity	O
separately	O
from	O
relational	O
continuity	O
according	O
to	O
whether	O
the	O
individual	O
had	O
a	O
care	O
plan	O
documented	O
by	O
a	O
family	O
physician	O
in	O
the	O
prior	O
12	O
months	O
.	O

Because	O
we	O
focus	O
on	O
within‐practice	O
family	O
physician	O
continuity	O
,	O
we	O
distinguish	O
relational	O
continuity	O
from	O
management	O
and	O
informational	O
continuity	O
represented	O
by	O
care	O
plans	O
.	O

Doctors	O
within	O
a	O
practice	O
have	O
access	O
to	O
the	O
same	O
medical	O
records	O
and	O
may	O
have	O
similar	O
approaches	O
to	O
management	O
.	O

46	O

Individual	O
characteristics	O
measured	O
at	O
baseline	O
were	O
as	O
follows	O
:	O
age	O
,	O
gender	O
,	O
ethnicity	O
,	O
deprivation	O
of	O
the	O
person	O
'	O
s	O
neighborhood	O
of	O
residence	O
,	O
47	O
history	O
of	O
smoking	O
,	O
number	O
of	O
Charlson	O
Index	O
comorbidities	O
,	O
48	O
comorbid	O
depression	O
,	O
diagnostic	O
subgroup	O
(	O
schizophrenia	O
and	O
other	O
psychoses	O
,	O
or	O
bipolar	O
disorder	O
and	O
affective	O
psychoses	O
)	O
and	O
number	O
of	O
years	O
since	O
diagnosis	O
.	O

Treatment	O
for	O
SMI	O
was	O
included	O
as	O
a	O
time‐varying	O
variable	O
indicating	O
that	O
the	O
individual	O
had	O
been	O
prescribed	O
an	O
antipsychotic	O
drug	O
at	O
least	O
once	O
in	O
the	O
12‐month	O
lookback	O
period	O
prior	O
to	O
the	O
current	O
period	O
.	O

The	O
necessity	O
of	O
creating	O
periods	O
for	O
continuity	O
measurement	O
led	O
us	O
to	O
employ	O
discrete‐time	O
survival	O
analysis	O
.	O

Although	O
the	O
outcomes	O
of	O
interest	O
are	O
(	O
effectively	O
)	O
continuous	O
measures	O
(	O
since	O
we	O
have	O
day‐level	O
data	O
on	O
when	O
these	O
occur	O
)	O
,	O
these	O
are	O
converted	O
into	O
discrete	O
outcomes	O
for	O
each	O
period	O
in	O
order	O
to	O
match	O
the	O
measurement	O
of	O
continuity	O
.	O

The	O
model	O
evaluates	O
the	O
association	O
between	O
continuity	O
in	O
the	O
prior	O
12	O
months	O
and	O
risk	O
of	O
the	O
outcome	O
in	O
a	O
particular	O
3‐month	O
period	O
.	O

A	O
complementary	O
log‐log	O
(	O
cloglog	O
)	O
proportional	O
hazards	O
model	O
was	O
fitted	O
for	O
each	O
outcome	O
.	O

This	O
model	O
produces	O
hazard	O
ratios	O
that	O
are	O
the	O
discrete‐time	O
equivalent	O
of	O
the	O
Cox	O
proportional	O
hazards	O
model	O
used	O
in	O
a	O
continuous‐time	O
context	O
.	O

49	O
A	O
flexible	O
piece‐wise	O
constant	O
baseline	O
hazard	O
function	O
was	O
applied	O
by	O
specifying	O
dummy	O
variables	O
for	O
each	O
3‐month	O
period	O
.	O

This	O
assumes	O
that	O
the	O
hazard	O
function	O
is	O
constant	O
within	O
each	O
period	O
,	O
but	O
can	O
vary	O
across	O
periods	O
.	O

The	O
resulting	O
exponentiated	O
coefficients	O
can	O
be	O
interpreted	O
as	O
hazard	O
ratios	O
,	O
the	O
discrete‐time	O
counterpart	O
of	O
the	O
hazard	O
from	O
a	O
continuous‐time	O
proportional	O
hazards	O
model	O
.	O

49	O
The	O
hazard	O
ratio	O
is	O
the	O
proportional	O
change	O
in	O
the	O
underlying	O
hazard	O
of	O
the	O
outcome	O
for	O
a	O
unit	O
change	O
in	O
the	O
variable	O
.	O

The	O
hazard	O
rate	O
(	O
HR	O
)	O
at	O
period	O
t	O
is	O
the	O
probability	O
of	O
observing	O
the	O
outcome	O
for	O
an	O
individual	O
in	O
period	O
t	O
,	O
conditional	O
on	O
the	O
individual	O
“surviving”	O
in	O
the	O
sample	O
to	O
period	O
t	O
(	O
ie	O
,	O
no	O
censoring	O
and	O
the	O
outcome	O
was	O
not	O
observed	O
in	O
prior	O
periods	O
for	O
that	O
individual	O
)	O
.	O

The	O
HR	O
is	O
a	O
nonlinear	O
function	O
of	O
time‐varying	O
factors	O
,	O
time‐invariant	O
factors	O
,	O
time‐period	O
dummy	O
variables	O
representative	O
of	O
the	O
baseline	O
hazard	O
,	O
and	O
normally	O
distributed	O
individual	O
unobserved	O
heterogeneity	O
.	O

Our	O
main	O
modeling	O
approach	O
accounts	O
for	O
individual	O
unobserved	O
heterogeneity	O
.	O

Due	O
to	O
the	O
incidental	O
parameter	O
problem	O
50	O
of	O
specifying	O
individual	O
fixed	O
effects	O
to	O
represent	O
such	O
heterogeneity	O
in	O
nonlinear	O
models	O
,	O
we	O
instead	O
assume	O
unobserved	O
heterogeneity	O
is	O
normally	O
distributed	O
and	O
specify	O
this	O
as	O
a	O
linear	O
function	O
of	O
the	O
means	O
of	O
time‐varying	O
variables	O
.	O

This	O
is	O
often	O
termed	O
a	O
correlated	O
random‐effects	O
model	O
,	O
following	O
Mundlak	O
.	O

51	O
The	O
time‐varying	O
variables	O
were	O
the	O
care	O
quality	O
indicators	O
plus	O
the	O
time‐varying	O
covariate	O
for	O
antipsychotic	O
treatment	O
,	O
while	O
the	O
remaining	O
individual	O
characteristics	O
included	O
as	O
covariates	O
were	O
time‐invariant	O
,	O
captured	O
at	O
baseline	O
.	O

The	O
variables	O
representing	O
the	O
means	O
of	O
the	O
time‐varying	O
variables	O
effectively	O
capture	O
confounding	O
by	O
unobserved	O
time‐invariant	O
individual	O
factors	O
(	O
eg	O
long‐standing	O
illness	O
,	O
health‐seeking	O
behavior	O
)	O
that	O
drive	O
both	O
continuity	O
and	O
use	O
of	O
hospital	O
services	O
.	O

The	O
period‐specific	O
levels	O
of	O
the	O
time‐varying	O
variables	O
capture	O
deviation	O
from	O
this	O
long‐term	O
average	O
and	O
can	O
be	O
interpreted	O
as	O
the	O
effect	O
of	O
continuity	O
specific	O
to	O
that	O
3‐month	O
period	O
,	O
given	O
the	O
person	O
'	O
s	O
overall	O
propensity	O
to	O
receive	O
continuity	O
of	O
care	O
.	O

(	O
See	O
Tables	O
S1‐S6	O
for	O
more	O
detail	O
of	O
the	O
model	O
.	O
)	O

To	O
allow	O
comparison	O
of	O
our	O
results	O
to	O
previous	O
studies	O
examining	O
the	O
effect	O
of	O
continuity	O
of	O
care	O
,	O
we	O
also	O
estimated	O
models	O
that	O
did	O
not	O
specify	O
individual	O
heterogeneity	O
as	O
a	O
function	O
of	O
the	O
means	O
of	O
the	O
time‐varying	O
variables	O
,	O
the	O
random‐effects	O
model	O
.	O

These	O
models	O
allow	O
for	O
normally	O
distributed	O
individual	O
heterogeneity	O
but	O
it	O
is	O
assumed	O
to	O
be	O
uncorrelated	O
with	O
the	O
explanatory	O
variables	O
contained	O
in	O
the	O
model	O
.	O

All	O
models	O
included	O
observed	O
individual	O
characteristics	O
as	O
explanatory	O
variables	O
and	O
adjusted	O
standard	O
errors	O
for	O
clustering	O
at	O
the	O
practice	O
level	O
.	O

We	O
estimated	O
separate	O
models	O
for	O
each	O
of	O
the	O
three	O
continuity	O
indices	O
because	O
of	O
multicollinearity	O
of	O
the	O
indices	O
.	O

All	O
analyses	O
were	O
conducted	O
using	O
Stata	O
v14	O
.	O

We	O
tested	O
the	O
sensitivity	O
of	O
the	O
results	O
to	O
the	O
level	O
of	O
visit	O
frequency	O
at	O
which	O
continuity	O
was	O
classified	O
as	O
“undefined”	O
.	O

The	O
minimum	O
level	O
for	O
measuring	O
continuity	O
(	O
and	O
corresponding	O
categories	O
for	O
low	O
vs	O
moderate	O
visit	O
frequency	O
)	O
was	O
set	O
to	O
two	O
or	O
four	O
visits	O
rather	O
than	O
three	O
visits	O
as	O
in	O
our	O
main	O
analysis	O
.	O

Given	O
the	O
significant	O
physical	O
health	O
comorbidities	O
of	O
people	O
with	O
SMI	O
,	O
we	O
examined	O
an	O
alternative	O
to	O
the	O
two	O
separate	O
hospital	O
admission	O
outcomes	O
:	O
all‐cause	O
hospital	O
admissions	O
,	O
capturing	O
all	O
unplanned	O
admissions	O
for	O
both	O
physical	O
and	O
mental	O
health	O
conditions	O
.	O

To	O
investigate	O
whether	O
receiving	O
specialist	O
mental	O
health	O
care	O
confounded	O
the	O
relationship	O
between	O
primary	O
care	O
quality	O
and	O
outcomes	O
,	O
we	O
ran	O
additional	O
analyses	O
capturing	O
care	O
in	O
specialist	O
mental	O
health	O
services	O
.	O

Data	O
on	O
specialist	O
care	O
from	O
the	O
Mental	O
Health	O
Services	O
Minimum	O
Dataset	O
(	O
MHMDS	O
)	O
were	O
only	O
available	O
to	O
link	O
to	O
the	O
main	O
dataset	O
from	O
April	O
1	O
,	O
2011	O
.	O

We	O
added	O
a	O
time‐varying	O
variable	O
to	O
indicate	O
whether	O
the	O
individual	O
received	O
any	O
care	O
in	O
specialist	O
mental	O
health	O
services	O
in	O
the	O
prior	O
12	O
months	O
and	O
ran	O
the	O
analysis	O
over	O
the	O
3‐year	O
period	O
of	O
observation	O
to	O
March	O
31	O
,	O
2014	O
.	O

We	O
tested	O
the	O
sensitivity	O
of	O
the	O
results	O
to	O
the	O
level	O
of	O
visit	O
frequency	O
at	O
which	O
continuity	O
was	O
classified	O
as	O
“undefined”	O
.	O

The	O
minimum	O
level	O
for	O
measuring	O
continuity	O
(	O
and	O
corresponding	O
categories	O
for	O
low	O
vs	O
moderate	O
visit	O
frequency	O
)	O
was	O
set	O
to	O
two	O
or	O
four	O
visits	O
rather	O
than	O
three	O
visits	O
as	O
in	O
our	O
main	O
analysis	O
.	O

Given	O
the	O
significant	O
physical	O
health	O
comorbidities	O
of	O
people	O
with	O
SMI	O
,	O
we	O
examined	O
an	O
alternative	O
to	O
the	O
two	O
separate	O
hospital	O
admission	O
outcomes	O
:	O
all‐cause	O
hospital	O
admissions	O
,	O
capturing	O
all	O
unplanned	O
admissions	O
for	O
both	O
physical	O
and	O
mental	O
health	O
conditions	O
.	O

To	O
investigate	O
whether	O
receiving	O
specialist	O
mental	O
health	O
care	O
confounded	O
the	O
relationship	O
between	O
primary	O
care	O
quality	O
and	O
outcomes	O
,	O
we	O
ran	O
additional	O
analyses	O
capturing	O
care	O
in	O
specialist	O
mental	O
health	O
services	O
.	O

Data	O
on	O
specialist	O
care	O
from	O
the	O
Mental	O
Health	O
Services	O
Minimum	O
Dataset	O
(	O
MHMDS	O
)	O
were	O
only	O
available	O
to	O
link	O
to	O
the	O
main	O
dataset	O
from	O
April	O
1	O
,	O
2011	O
.	O

We	O
added	O
a	O
time‐varying	O
variable	O
to	O
indicate	O
whether	O
the	O
individual	O
received	O
any	O
care	O
in	O
specialist	O
mental	O
health	O
services	O
in	O
the	O
prior	O
12	O
months	O
and	O
ran	O
the	O
analysis	O
over	O
the	O
3‐year	O
period	O
of	O
observation	O
to	O
March	O
31	O
,	O
2014	O
.	O

We	O
used	O
de	O
-	O
identified	O
medical	O
and	O
pharmacy	O
claims	O
data	O
from	O
the	O
Truven	O
MarketScan	O
database	O
(	O
2003–2014	O
)	O
.	O

This	O
database	O
contains	O
longitudinal	O
,	O
comprehensive	O
healthcare	O
data	O
from	O
several	O
different	O
commercial	O
managed	O
care	O
plans	O
,	O
representing	O
mostly	O
working	O
individuals	O
and	O
their	O
family	O
members	O
in	O
the	O
USA	O
from	O
all	O
50	O
states	O
.	O

22	O

We	O
identified	O
each	B-phenotype
rheumatic	I-phenotype
disease	I-phenotype
cohort	I-phenotype
(	I-phenotype
RA	I-phenotype
,	I-phenotype
SLE	I-phenotype
,	I-phenotype
PsA	I-phenotype
or	I-phenotype
AS	I-phenotype
)	I-phenotype
by	O
using	O
>	O
2	O
disease	O
-	O
specific	O
International	B-coding_system
Classification	I-coding_system
of	I-coding_system
Diseases	I-coding_system
(	I-coding_system
ICD	I-coding_system
-	I-coding_system
9	I-coding_system
)	I-coding_system
codes	O
,	O
which	O
were	O
7–365	O
days	O
apart	O
,	O
and	O
at	O
least	O
one	O
dispensing	O
for	O
disease	O
-	O
specific	O
medications	O
on	O
or	O
after	O
the	O
second	O
diagnosis	O
code	O
after	O
a	O
12	O
-	O
month	O
eligibility	O
period	O
(	O
figure	O
1	O
)	O
.	O

ICD	B-coding_system
-	I-coding_system
9	I-coding_system
codes	O
and	O
disease	O
-	O
specific	O
medications	O
for	O
each	O
of	O
the	O
cohorts	O
are	O
listed	O
in	O
online	O
supplementary	O
table	O
S1	O
.	O

The	O
index	O
date	O
was	O
defined	O
as	O
the	O
date	O
of	O
disease	O
-	O
specific	O
medication	O
prescription	O
fill	O
when	O
the	O
cohort	O
definition	O
was	O
met	O
.	O

The	O
four	O
rheumatic	O
disease	O
cohorts	O
were	O
mutually	O
exclusive	O
,	O
and	O
patients	O
were	O
enrolled	O
into	O
the	O
cohort	O
of	O
the	O
disease	O
for	O
which	O
they	O
first	O
met	O
the	O
cohort	O
definition	O
.	O

Cohort	O
and	O
study	O
design	O
diagram	O
AS	O
,	O
ankylosing	O
spondylitis	O
;	O
Dx	O
,	O
diagnosis	O
;	O
HTN	O
,	O
hypertension	O
;	O
PsA	O
,	O
psoriatic	O
arthritis	O
;	O
RA	O
,	O
rheumatoid	O
arthritis	O
;	O
Rx	O
,	O
prescription	O
;	O
SLE	O
,	O
systemic	O
lupus	O
erythematosus	O
.	O

We	O
matched	O
each	O
rheumatic	O
disease	O
cohort	O
patient	O
by	O
age	O
at	O
index	O
date	O
and	O
sex	O
to	O
a	O
patient	O
with	O
HTN	O
,	O
as	O
it	O
is	O
a	O
common	O
non	O
-	O
painful	O
,	O
non	O
-	O
inflammatory	O
,	O
chronic	O
condition	O
.	O

Patients	O
with	O
HTN	O
have	O
routine	O
outpatient	O
visits	O
during	O
which	O
medications	O
including	O
opioids	O
could	O
be	O
potentially	O
prescribed	O
and	O
baseline	O
covariates	O
can	O
be	O
measured	O
to	O
minimise	O
the	O
risk	O
of	O
ascertainment	O
bias	O
,	O
and	O
has	O
been	O
used	O
as	O
a	O
control	O
group	O
similarly	O
in	O
previous	O
claims	O
-	O
based	O
research	O
.	O

23	O
We	O
defined	O
HTN	B-phenotype
cohort	I-phenotype
status	I-phenotype
by	O
at	O
least	O
2	O
ICD	B-coding_system
-	I-coding_system
9	I-coding_system
codes	O
which	O
were	O
7–365	O
days	O
apart	O
for	O
HTN	O
,	O
and	O
at	O
least	O
one	O
anti	O
-	O
HTN	O
medication	O
prescription	O
on	O
or	O
after	O
the	O
second	O
diagnosis	O
code	O
after	O
a	O
12	O
-	O
month	O
eligibility	O
period	O
.	O

The	O
index	O
date	O
was	O
defined	O
as	O
the	O
date	O
of	O
anti	O
-	O
HTN	O
medication	O
prescription	O
when	O
the	O
HTN	O
cohort	O
definition	O
was	O
met	O
.	O

HTN	O
cohort	O
patients	O
required	O
never	O
having	O
had	O
a	O
diagnosis	O
of	O
RA	O
,	O
SLE	O
,	O
PsA	O
or	O
AS	O
during	O
the	O
study	O
period	O
.	O

We	O
required	O
all	O
patients	O
with	O
rheumatic	O
disease	O
and	O
HTN	O
to	O
be	O
>	O
18	O
years	O
of	O
age	O
at	O
index	O
date	O
and	O
to	O
have	O
a	O
follow	O
-	O
up	O
period	O
for	O
at	O
least	O
12	O
months	O
from	O
and	O
including	O
the	O
index	O
date	O
.	O

We	O
excluded	O
patients	O
with	O
history	O
of	O
malignancy	O
.	O

This	O
is	O
a	O
retrospective	O
database	O
study	O
;	O
patients	O
were	O
not	O
directly	O
involved	O
in	O
the	O
research	O
.	O

During	O
the	O
12	O
-	O
month	O
eligibility	O
period	O
prior	O
to	O
the	O
index	O
date	O
,	O
we	O
assessed	O
baseline	O
covariates	O
including	O
demographics	O
(	O
ie	O
,	O
age	O
,	O
sex	O
,	O
calendar	O
year	O
of	O
index	O
date	O
and	O
region	O
of	O
residence	O
)	O
and	O
healthcare	O
utilisation	O
patterns	O
(	O
ie	O
,	O
number	O
of	O
outpatient	O
visits	O
,	O
primary	O
care	O
visits	O
,	O
emergency	O
department	O
visits	O
,	O
hospitalisations	O
and	O
physical	O
therapy	O
use	O
)	O
.	O

We	O
also	O
assessed	O
comorbid	O
conditions	O
including	O
back	O
pain	O
,	O
fibromyalgia	O
,	O
substance	O
use	O
,	O
depression	O
,	O
migraine	O
headache	O
,	O
osteoarthritis	O
,	O
fracture	O
and	O
surgery	O
which	O
are	O
known	O
risk	O
factors	O
for	O
pain	O
or	O
opioid	O
use	O
,	O
and	O
other	O
comorbidities	O
including	O
heart	B-phenotype
disease	I-phenotype
,	I-phenotype
kidney	I-phenotype
disease	I-phenotype
,	I-phenotype
chronic	I-phenotype
obstructive	I-phenotype
pulmonary	I-phenotype
disease	I-phenotype
,	I-phenotype
liver	I-phenotype
disease	I-phenotype
by	O
ICD	B-coding_system
-	I-coding_system
9	I-coding_system
codes	O
and	O
calculated	O
combined	O
comorbidity	O
index	O
24	O
at	O
baseline	O
.	O

We	O
assessed	O
medication	O
use	O
of	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
,	O
COX	O
-	O
2	O
enzyme	O
inhibitors	O
(	O
COXIBs	O
)	O
,	O
benzodiazepines	O
,	O
antidepressant	O
use	O
and	O
gamma	O
-	O
aminobutyric	O
acid	O
(	O
GABA	O
)	O
analogues	O
.	O

We	O
measured	O
baseline	O
use	O
of	O
disease	O
related	O
medications	O
including	O
conventional	O
synthetic	O
and	O
biologic	O
disease	O
-	O
modifying	O
antirheumatic	O
drugs	O
(	O
DMARDs	O
)	O
,	O
and	O
assessed	O
baseline	O
glucocorticoid	O
use	O
and	O
cumulative	O
glucocorticoid	O
dose	O
in	O
mg	O
.	O

We	O
measured	O
baseline	O
use	O
of	O
opioids	O
,	O
naloxone	O
and	O
methadone	O
.	O

We	O
measured	O
long	O
-	O
term	O
opioid	O
prescriptions	O
dispensed	O
during	O
the	O
1	O
-	O
year	O
follow	O
-	O
up	O
period	O
from	O
the	O
index	O
date	O
as	O
our	O
primary	O
outcome	O
.	O

Opioid	O
medications	O
are	O
listed	O
in	O
online	O
supplementary	O
table	O
S2	O
.	O

We	O
defined	O
long	O
-	O
term	O
opioid	O
prescriptions	O
as	O
cumulative	O
opioid	O
prescriptions	O
dispensed	O
adding	O
up	O
to	O
>	O
90	O
days	O
of	O
opioid	O
prescription	O
during	O
the	O
1	O
-	O
year	O
follow	O
-	O
up	O
period	O
.	O

As	O
our	O
secondary	O
outcome	O
measures	O
,	O
we	O
assessed	O
any	O
opioid	O
prescriptions	O
dispensed	O
,	O
receipt	O
of	O
>	O
3	O
types	O
of	O
opioid	O
prescription	O
,	O
immediate	O
-	O
acting	O
and	O
extended	O
-	O
acting	O
opioid	O
in	O
all	O
rheumatic	O
disease	O
and	O
matched	O
HTN	O
cohorts	O
.	O

We	O
also	O
calculated	O
median	O
cumulative	O
morphine	O
equivalent	O
dose	O
per	O
day	O
of	O
opioid	O
prescription	O
(	O
calculated	O
as	O
cumulative	O
amount	O
of	O
opioids	O
in	O
milligrams	O
(	O
mg	O
)	O
in	O
morphine	O
equivalent	O
dose	O
divided	O
by	O
the	O
number	O
of	O
days	O
of	O
prescription	O
dispensing	O
)	O
during	O
1	O
-	O
year	O
follow	O
-	O
up	O
for	O
patients	O
receiving	O
any	O
opioid	O
use	O
in	O
rheumatic	O
disease	O
and	O
matched	O
HTN	O
cohorts	O
using	O
opioid	O
morphine	O
equivalent	O
conversion	O
factors	O
per	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
.	O

25	O
We	O
additionally	O
assessed	O
long	O
-	O
term	O
opioid	O
prescriptions	O
after	O
stratifying	O
patients	O
by	O
baseline	O
medication	O
use	O
of	O
biologic	O
DMARDs	O
for	O
RA	O
,	O
PsA	O
and	O
AS	O
cohorts	O
,	O
and	O
by	O
the	O
use	O
of	O
immunosuppressant	O
medications	O
other	O
than	O
hydroxychloroquine	O
for	O
SLE	O
.	O

We	O
compared	O
baseline	O
characteristics	O
of	O
the	O
four	O
rheumatic	O
disease	O
cohorts	O
and	O
their	O
matched	O
HTN	O
cohorts	O
.	O

We	O
compared	O
the	O
proportion	O
of	O
patients	O
receiving	O
long	O
-	O
term	O
,	O
any	O
use	O
,	O
>	O
3	O
types	O
,	O
immediate	O
-	O
acting	O
,	O
extended	O
-	O
acting	O
opioid	O
and	O
morphine	O
equivalent	O
dose	O
per	O
day	O
opioid	O
prescriptions	O
in	O
each	O
rheumatic	O
disease	O
cohort	O
to	O
their	O
matched	O
HTN	O
cohorts	O
.	O

We	O
calculated	O
the	O
proportion	O
of	O
patients	O
in	O
each	O
cohort	O
receiving	O
long	O
-	O
term	O
opioid	O
prescriptions	O
for	O
each	O
calendar	O
year	O
of	O
their	O
index	O
date	O
and	O
used	O
linear	O
regression	O
to	O
assess	O
for	O
significant	O
trends	O
in	O
opioid	O
use	O
over	O
the	O
calendar	O
years	O
within	O
each	O
cohort	O
.	O

We	O
estimated	O
relative	O
risk	O
of	O
receiving	O
long	O
-	O
term	O
opioid	O
prescriptions	O
by	O
using	O
a	O
Poisson	O
regression	O
model	O
(	O
PROC	O
GENMOD	O
)	O
,	O
adjusting	O
for	O
cohort	O
type	O
(	O
ie	O
,	O
RA	O
,	O
SLE	O
,	O
PsA	O
,	O
AS	O
or	O
HTN	O
)	O
,	O
age	O
,	O
sex	O
,	O
baseline	O
comorbidities	O
,	O
medication	O
use	O
and	O
healthcare	O
utilisation	O
patterns	O
.	O

The	O
variables	O
in	O
our	O
model	O
were	O
chosen	O
a	O
priori	O
as	O
potential	O
factors	O
associated	O
with	O
rheumatic	O
diseases	O
and	O
receiving	O
prescription	O
opioids	O
.	O

To	O
test	O
for	O
possible	O
collinearity	O
in	O
our	O
model	O
,	O
we	O
ran	O
a	O
multicollinearity	O
analysis	O
to	O
test	O
for	O
high	O
correlation	O
between	O
the	O
variables	O
.	O

Using	O
a	O
threshold	O
of	O
variation	O
inflation	O
factor	O
<	O
10	O
and	O
tolerance	O
>	O
0	O
.	O
1	O
,	O
we	O
found	O
no	O
evidence	O
of	O
multicollinearity	O
in	O
our	O
model	O
.	O

26	O
In	O
sensitivity	O
analysis	O
,	O
we	O
stratified	O
patients	O
with	O
AS	O
by	O
baseline	O
use	O
of	O
biologic	O
DMARDs	O
and	O
estimated	O
relative	O
risk	O
of	O
receiving	O
long	O
-	O
term	O
opioid	O
prescriptions	O
compared	O
with	O
their	O
matched	O
HTN	O
counterparts	O
,	O
adjusting	O
for	O
the	O
same	O
variables	O
as	O
in	O
our	O
main	O
model	O
.	O

All	O
analyses	O
were	O
conducted	O
using	O
SAS	O
V	O
.	O
9	O
.	O
4	O
(	O
SAS	O
Institute	O
)	O
.	O

Due	O
to	O
the	O
legal	O
and	O
organisational	O
framework	O
of	O
NWpG	O
-	O
IC	O
contracts	O
in	O
Germany	O
,	O
randomisation	O
and	O
blinding	O
of	O
study	O
participants	O
was	O
not	O
feasible	O
[	O
24	O
]	O
.	O

Therefore	O
,	O
a	O
multicentre	O
quasi	O
-	O
experimental	O
prospective	O
trial	O
comparing	O
outcomes	O
of	O
patients	O
enrolled	O
in	O
the	O
NWpG	O
-	O
IC	O
programme	O
with	O
a	O
control	O
group	O
of	O
patients	O
who	O
received	O
standard	O
care	O
was	O
conducted	O
.	O

Preference	O
-	O
based	O
group	O
allocation	O
was	O
performed	O
on	O
the	O
basis	O
of	O
type	O
of	O
care	O
provision	O
intended	O
for	O
the	O
coming	O
18	O
months	O
.	O

The	O
study	O
took	O
place	O
in	O
five	O
German	O
federal	O
states	O
(	O
Schleswig	O
-	O
Holstein	O
,	O
North	O
Rhine	O
-	O
Westphalia	O
,	O
Berlin	O
,	O
Saxony	O
and	O
Bavaria	O
)	O
covering	O
a	O
broad	O
range	O
of	O
catchment	O
areas	O
with	O
different	O
levels	O
of	O
urbanization	O
,	O
with	O
different	O
local	O
mental	O
health	O
service	O
systems	O
and	O
with	O
different	O
providers	O
of	O
NWpG	O
-	O
IC	O
services	O
.	O

Trial	O
duration	O
was	O
18	O
months	O
.	O

Data	O
were	O
collected	O
at	O
baseline	O
and	O
at	O
three	O
follow	O
-	O
ups	O
after	O
6	O
,	O
12	O
and	O
18	O
months	O
.	O

The	O
study	O
was	O
conducted	O
in	O
compliance	O
with	O
the	O
Declaration	O
of	O
Helsinki	O
2013	O
.	O

It	O
has	O
been	O
approved	O
by	O
the	O
Ethics	O
Committees	O
of	O
the	O
University	O
of	O
Ulm	O
(	O
application	O
number	O
:	O
129	O
/	O
13	O
)	O
and	O
of	O
the	O
TU	O
Dresden	O
(	O
application	O
number	O
:	O
EK	O
259072013	O
)	O
.	O

This	O
trial	O
is	O
registered	O
with	O
DRKS	O
(	O
German	O
Clinical	O
Trials	O
Register	O
)	O
and	O
ICTRP	O
(	O
International	O
Clinical	O
Trials	O
Registry	O
Platform	O
)	O
with	O
the	O
identifier	O
DRKS00005111	O
.	O

The	O
protocol	O
was	O
published	O
in	O
2014	O
[	O
24	O
]	O
.	O

Patients	O
were	O
eligible	O
for	O
enrolment	O
in	O
NWpG	O
-	O
IC	O
contracts	O
if	O
they	O
were	O
members	O
of	O
one	O
of	O
the	O
participating	O
health	O
insurances	O
and	O
if	O
they	O
fulfilled	O
the	O
following	O
criteria	O
:	O
being	O
diagnosed	O
with	O
a	O
mental	O
illness	O
of	O
the	O
categories	O
F20	O
-	O
F29	O
(	O
schizophrenia	O
,	O
schizotypal	O
and	O
delusional	O
disorders	O
)	O
,	O
F30	O
-	O
F39	O
(	O
affective	O
disorders	O
)	O
,	O
F40	O
-	O
F48	O
(	O
neurotic	O
,	O
stress	O
-	O
related	O
and	O
somatoform	O
disorders	O
)	O
,	O
F50	O
-	O
F59	O
(	O
behavioural	O
syndromes	O
associated	O
with	O
physiological	O
disturbances	O
and	O
physical	O
factors	O
)	O
,	O
F60	O
-	O
F69	O
(	O
disorders	O
of	O
adult	O

personality	O
and	O
behaviour	O
)	O
and	O
F91	O
-	O
F94	O
(	O
conduct	O
and	O
emotional	O
disorders	O
,	O
disorders	O
of	O
social	O
functioning	O
with	O
onset	O
usually	O
occurring	O
in	O
childhood	O
and	O
adolescence	O
)	O
of	O
the	O
ICD	O
-	O
10	O
during	O
the	O
last	O
12	O
months	O
.	O

having	O
either	O
had	O
a	O
psychiatric	O
inpatient	O
admission	O
or	O
an	O
ambulatory	O
prescription	O
of	O
antipsychotic	O
,	O
anxiolytic	O
or	O
antidepressant	O
drugs	O
during	O
the	O
last	O
12	O
months	O
.	O

being	O
between	O
18	O
and	O
80	O
years	O
old	O
not	O
being	O
eligible	O
for	O
receiving	O
benefits	O
from	O
statutory	O
long	O
-	O
term	O
care	O
insurance	O
[	O
25	O
]	O

being	O
diagnosed	O
with	O
a	O
mental	O
illness	O
of	O
the	O
categories	O
F20	O
-	O
F29	O
(	O
schizophrenia	O
,	O
schizotypal	O
and	O
delusional	O
disorders	O
)	O
,	O
F30	O
-	O
F39	O
(	O
affective	O
disorders	O
)	O
,	O
F40	O
-	O
F48	O
(	O
neurotic	O
,	O
stress	O
-	O
related	O
and	O
somatoform	O
disorders	O
)	O
,	O
F50	O
-	O
F59	O
(	O
behavioural	O
syndromes	O
associated	O
with	O
physiological	O
disturbances	O
and	O
physical	O
factors	O
)	O
,	O
F60	O
-	O
F69	O
(	O
disorders	O
of	O
adult	O
personality	O
and	O
behaviour	O
)	O
and	O
F91	O
-	O
F94	O
(	O
conduct	O
and	O
emotional	O
disorders	O
,	O
disorders	O
of	O
social	O
functioning	O
with	O
onset	O
usually	O
occurring	O
in	O
childhood	O
and	O
adolescence	O
)	O
of	O

the	O
ICD	O
-	O
10	O
during	O
the	O
last	O
12	O
months	O
.	O

having	O
either	O
had	O
a	O
psychiatric	O
inpatient	O
admission	O
or	O
an	O
ambulatory	O
prescription	O
of	O
antipsychotic	O
,	O
anxiolytic	O
or	O
antidepressant	O
drugs	O
during	O
the	O
last	O
12	O
months	O
.	O

being	O
between	O
18	O
and	O
80	O
years	O
old	O

not	O
being	O
eligible	O
for	O
receiving	O
benefits	O
from	O
statutory	O
long	O
-	O
term	O
care	O
insurance	O
[	O
25	O
]	O

All	O
criteria	O
were	O
assessed	O
on	O
the	O
basis	O
of	O
information	O
from	O
patients	O
.	O

In	O
case	O
of	O
implausible	O
information	O
the	O
patient	O
statements	O
were	O
verified	O
by	O
information	O
from	O
mental	O
health	O
care	O
staff	O
or	O
patient	O
records	O
.	O

Patients	O
who	O
fulfilled	O
eligibility	O
criteria	O
were	O
offered	O
the	O
opportunity	O
to	O
participate	O
in	O
the	O
NWpG	O
-	O
IC	O
program	O
by	O
phone	O
from	O
their	O
health	O
insurances	O
.	O

Thereafter	O
the	O
patient	O
was	O
invited	O
to	O
an	O
information	O
meeting	O
by	O
the	O
local	O
NWpG	O
-	O
IC	O
service	O
provider	O
.	O

After	O
the	O
information	O
meeting	O
the	O
patient	O
had	O
the	O
opportunity	O
to	O
decide	O
to	O
enrol	O
to	O
NwPG	O
-	O
IC	O
or	O
not	O
.	O

Patients	O
were	O
informed	O
that	O
the	O
decision	O
for	O
or	O
against	O
enrolment	O
had	O
no	O
consequences	O
for	O
their	O
health	O
insurance	O
membership	O
status	O
or	O
for	O
their	O
reimbursement	O
of	O
health	O
care	O
expenditures	O
.	O

In	O
order	O
to	O
replicate	O
the	O
heterogeneity	O
of	O
the	O
NWpG	O
-	O
IC	O
target	O
group	O
in	O
the	O
study	O
sample	O
,	O
a	O
consecutive	O
sampling	O
procedure	O
for	O
two	O
equal	O
-	O
sized	O
study	O
groups	O
was	O
chosen	O
.	O

Therefore	O
,	O
if	O
a	O
patient	O
decided	O
to	O
enrol	O
in	O
the	O
NWpG	O
-	O
IC	O
program	O
,	O
he	O
or	O
she	O
was	O
asked	O
to	O
participate	O
in	O
the	O
present	O
study	O
as	O
a	O
member	O
of	O
the	O
intervention	O
group	O
.	O

About	O
one	O
third	O
of	O
patients	O
refuses	O
to	O
enrol	O
in	O
the	O
NWpG	O
-	O
IC	O
program	O
.	O

Those	O
patients	O
were	O
asked	O
to	O
participate	O
as	O
members	O
of	O
the	O
control	O
group	O
.	O

In	O
addition	O
,	O
control	O
group	O
participants	O
were	O
recruited	O
in	O
a	O
broad	O
spectrum	O
of	O
outpatient	O
mental	O
health	O
care	O
facilities	O
(	O
office	O
-	O
based	O
psychiatrists	O
or	O
psychologists	O
,	O
outpatient	O
clinics	O
,	O
day	O
centres	O
,	O
residential	O
services	O
,	O
community	O
mental	O
health	O
care	O
centres	O
)	O
.	O

Inclusion	O
criteria	O
were	O
the	O
same	O
as	O
for	O
NWpG	O
-	O
IC	O
eligibility	O
(	O
see	O
above	O
)	O
,	O
with	O
the	O
exception	O
of	O
membership	O
in	O
one	O
of	O
the	O
health	O
insurance	O
providers	O
offering	O
NWpG	O
-	O
IC	O
.	O

In	O
order	O
to	O
acquire	O
comparable	O
study	O
groups	O
fulfilling	O
the	O
common	O
support	O
condition	O
necessary	O
for	O
propensity	O
score	O
adjustment	O
,	O
we	O
kept	O
track	O
of	O
patients’	O
age	O
,	O
gender	O
,	O
employment	O
status	O
and	O
ICD	B-coding_system
-	I-coding_system
10	I-coding_system
diagnosis	O
during	O
recruitment	O
.	O

If	O
needed	O
the	O
recruitment	O
focus	O
for	O
the	O
control	O
group	O
was	O
adapted	O
accordingly	O
e	O
.	O
g	O
.	O
by	O
trying	O
to	O
increase	O
the	O
proportion	O
of	O
control	O
group	O
participants	O
who	O
were	O
employed	O
at	O
the	O
time	O
of	O
inclusion	O
.	O

In	O
contrast	O
to	O
fee	O
for	O
service	O
reimbursement	O
of	O
usual	O
mental	O
health	O
care	O
in	O
Germany	O
,	O
the	O
NWpG	O
-	O
IC	O
program	O
was	O
financed	O
by	O
an	O
annual	O
per	O
-	O
capita	O
lump	O
sum	O
staggered	O
by	O
illness	O
severity	O
.	O

The	O
lump	O
sum	O
was	O
intended	O
to	O
cover	O
the	O
total	O
costs	O
of	O
psychiatric	O
hospital	O
admissions	O
and	O
psychiatric	O
outpatient	O
treatment	O
including	O
additional	O
NWpG	O
services	O
,	O
but	O
excluded	O
costs	O
of	O
ambulatory	O
medication	O
and	O
involuntary	O
psychiatric	O
admissions	O
.	O

Also	O
excluded	O
were	O
costs	O
of	O
residential	O
care	O
which	O
are	O
in	O
Germany	O
mainly	O
financed	O
by	O
taxes	O
and	O
costs	O
of	O
vocational	O
rehabilitation	O
which	O
are	O
in	O
most	O
part	O
financed	O
by	O
unemployment	O
or	O
pension	O
funds	O
.	O

In	O
contrast	O
to	O
TAU	O
,	O
the	O
NWpG	O
-	O
IC	O
service	O
package	O
included	O
provision	O
of	O
community	O
-	O
based	O
multi	O
-	O
professional	O
teams	O
,	O
psychiatric	O
case	O
management	O
,	O
crisis	O
intervention	O
by	O
means	O
of	O
home	O
treatment	O
or	O
crisis	O
beds	O
in	O
non	O
-	O
hospital	O
settings	O
,	O
and	O
family	O
-	O
oriented	O
psychoeducation	O
.	O

In	O
addition	O
,	O
all	O
patients	O
were	O
allowed	O
to	O
use	O
the	O
available	O
routine	O
mental	O
health	O
care	O
services	O
such	O
as	O
office	O
-	O
based	O
psychiatrists	O
and	O
psychiatric	O
inpatient	O
treatment	O
.	O

The	O
implementation	O
of	O
the	O
programme	O
and	O
the	O
budget	O
responsibility	O
rested	O
with	O
the	O
local	O
service	O
providers	O
and	O
was	O
independent	O
from	O
the	O
research	O
team	O
.	O

Beyond	O
the	O
alleviation	O
of	O
psychiatric	O
symptoms	O
,	O
integrated	O
types	O
of	O
community	O
treatment	O
commonly	O
aim	O
at	O
increasing	O
the	O
patients’	O
capacities	O
for	O
independent	O
living	O
and	O
comprehensive	O
social	O
and	O
vocational	O
inclusion	O
[	O
5	O
,	O
6	O
]	O
.	O

In	O
order	O
to	O
capture	O
this	O
broad	O
spectrum	O
of	O
outcomes	O
comprehensively	O
,	O
generalized	O
measures	O
of	O
quality	O
of	O
life	O
,	O
recovery	O
and	O
empowerment	O
are	O
widely	O
used	O
in	O
studies	O
related	O
to	O
the	O
effectiveness	O
of	O
integrated	O
care	O
approaches	O
[	O
26	O
,	O
27	O
]	O
.	O

The	O
primary	O
outcome	O
of	O
this	O
study	O
was	O
measured	O
by	O
means	O
of	O
the	O
questionnaire	O
for	O
the	O
assessment	O
of	O
empowerment	O
in	O
patients	O
with	O
affective	O
and	O
schizophrenic	O
disorders	O
(	O
EPAS	O
)	O
.	O

The	O
EPAS	O
measures	O
empowerment	O
as	O
the	O
patient’s	O
perceived	O
opportunity	O
to	O
control	O
his	O
/	O
her	O
own	O
living	O
circumstances	O
on	O
five	O
dimensions	O
:	O
“daily	O
living”	O
,	O
“social	O
relationships	O
and	O
sexuality”	O
,	O
“psychiatric	O
treatment”	O
,	O
“hope	O
and	O
self	O
-	O
efficacy”	O
and	O
“self	O
-	O
esteem”	O
.	O

The	O
EPAS	O
core	O
module	O
has	O
33	O
items	O
and	O
has	O
shown	O
high	O
reliability	O
(	O
Cronbach’s	O
Alpha	O
of	O
0	O
.	O
928	O
)	O
[	O
28	O
]	O
.	O

Secondary	O
outcome	O
measures	O
were	O
1	O
)	O
psychosocial	O
and	O
clinical	O
impairment	O
as	O
assessed	O
using	O
the	O
Health	O
of	O
the	O
Nation	O
Outcome	O
Scale	O
(	O
HoNOS	O
)	O
[	O
29	O
–	O
32	O
]	O
,	O
2	O
)	O
subjective	O
Quality	O
of	O
Life	O
measured	O
by	O
the	O
short	O
version	O
of	O
the	O
World	O
Health	O
Organisation	O
Quality	O
of	O
Life	O
questionnaire	O
(	O
WHOQOL	O
-	O
BREF	O
)	O
,	O
3	O
)	O
satisfaction	O
with	O
psychiatric	O
treatment	O
measured	O
by	O
using	O
the	O
German	O
Version	O
of	O
the	O
Client	O
Satisfaction	O
Questionnaire	O
(	O
CSQ	O
-	O
8	O
)	O
[	O
33	O
,	O
34	O
]	O
,	O
4	O
)	O
mental	O
health	O
service	O
needs	O
as	O
measured	O
by	O
the	O
Camberwell	O
Assessment	O

of	O
Needs	O
(	O
CAN	O
-	O
EU	O
)	O
and	O
5	O
)	O
prevalence	O
of	O
and	O
number	O
of	O
psychiatric	O
inpatient	O
admissions	O
during	O
follow	O
-	O
up	O
period	O
estimated	O
by	O
the	O
CSSRI	O
[	O
Client	O
Socio	O
-	O
Demographic	O
and	O
Service	O
Receipt	O
Inventory	O
]	O
[	O
35	O
]	O
.	O

Outcome	O
assessment	O
was	O
performed	O
by	O
trained	O
research	O
associates	O
.	O

Data	O
and	O
site	O
monitoring	O
by	O
the	O
study	O
coordinator	O
ensured	O
quality	O
assurance	O
[	O
24	O
]	O
.	O

The	O
sample	O
size	O
calculation	O
was	O
performed	O
for	O
the	O
change	O
in	O
the	O
empowerment	O
total	O
score	O
over	O
18	O
months	O
.	O

An	O
effect	O
size	O
of	O
f	O
=	O
0	O
.	O
2	O
was	O
assumed	O
to	O
be	O
clinically	O
relevant	O
for	O
the	O
within	O
-	O
between	O
interaction	O
of	O
group	O
*	O
time	O
in	O
repeated	O
-	O
measurements	O
ANOVA	O
with	O
two	O
groups	O
and	O
four	O
time	O
-	O
points	O
of	O
measurement	O
.	O

Based	O
on	O
this	O
effect	O
size	O
,	O
a	O
power	O
of	O
0	O
.	O
90	O
,	O
and	O
an	O
alpha	O
level	O
of	O
0	O
.	O
05	O
,	O
a	O
total	O
sample	O
size	O
of	O
n	O
=	O
350	O
was	O
needed	O
.	O

Sample	O
size	O
was	O
further	O
estimated	O
based	O
on	O
a	O
drop	O
-	O
out	O
rate	O
of	O
30	O
%	O
,	O
according	O
to	O
experience	O
from	O
the	O
ELAN	O
-	O
study	O
[	O
36	O
,	O
37	O
]	O
.	O

Based	O
on	O
this	O
assumption	O
,	O
a	O
total	O
of	O
500	O
patients	O
were	O
recruited	O
for	O
visit	O
1	O
.	O

The	O
sample	O
size	O
was	O
calculated	O
using	O
G	O
-	O
Power	O
3	O
.	O
1	O
.	O

Balance	O
between	O
study	O
groups	O
was	O
estimated	O
by	O
means	O
of	O
the	O
absolute	O
standardised	O
difference	O
.	O

Limited	O
balance	O
or	O
imbalance	O
was	O
indicated	O
by	O
absolute	O
standardised	O
differences	O
greater	O
than	O
0	O
.	O
1	O
or	O
0	O
.	O
2	O
,	O
respectively	O
.	O

Propensity	O
score	O
adjustment	O
was	O
used	O
to	O
control	O
selection	O
bias	O
[	O
38	O
]	O
.	O

Propensity	O
scores	O
were	O
estimated	O
on	O
the	O
basis	O
of	O
a	O
logistic	O
regression	O
model	O
including	O
variables	O
that	O
showed	O
limited	O
balance	O
between	O
study	O
groups	O
or	O
that	O
were	O
slightly	O
associated	O
(	O
p	O
<	O
0	O
.	O
10	O
)	O
with	O
the	O
outcome	O
(	O
change	O
in	O
EPAS	O
total	O
between	O
visit	O
1	O
and	O
visit	O
4	O
)	O
.	O

Linear	O
mixed	O
-	O
effect	O
regression	O
models	O
with	O
a	O
random	O
time	O
effect	O
,	O
a	O
fixed	O
group	O
effect	O
and	O
an	O
interaction	O
effect	O
between	O
time	O
and	O
study	O
group	O
adjusted	O
for	O
propensity	O
scores	O
were	O
computed	O
for	O
continuous	O
primary	O
and	O
secondary	O
outcome	O
variables	O
.	O

Parametrisation	O
of	O
regression	O
models	O
occurred	O
without	O
group	O
mean	O
centering	O
.	O

Therefore	O
,	O
all	O
effects	O
are	O
given	O
with	O
regard	O
to	O
the	O
reference	O
categories	O
of	O
the	O
other	O
model	O
variables	O
.	O

The	O
group	O
by	O
time	O
interaction	O
reflects	O
the	O
intervention	O
effect	O
.	O

The	O
analysis	O
was	O
conducted	O
on	O
the	O
intention	O
-	O
to	O
-	O
treat	O
population	O
.	O

Missing	O
values	O
were	O
taken	O
into	O
account	O
by	O
weighting	O
of	O
the	O
parameter	O
estimation	O
.	O

Logistic	O
mixed	O
-	O
effect	O
models	O
with	O
equivalent	O
features	O
were	O
computed	O
for	O
the	O
six	O
month	O
prevalence	O
of	O
psychiatric	O
inpatient	O
admission	O
.	O

The	O
interpretation	O
of	O
the	O
regression	O
coefficients	O
is	O
the	O
same	O
as	O
described	O
above	O
,	O
with	O
the	O
difference	O
that	O
the	O
presented	O
odds	O
ratios	O
(	O
OR	O
)	O
represent	O
the	O
proportional	O
effects	O
of	O
the	O
independent	O
variables	O
on	O
the	O
probability	O
of	O
the	O
outcome	O
event	O
.	O

For	O
investigating	O
the	O
effects	O
of	O
NWpG	O
-	O
IC	O
on	O
the	O
number	O
of	O
inpatient	O
treatment	O
days	O
a	O
random	O
-	O
effects	O
tobit	O
regression	O
model	O
taking	O
into	O
account	O
the	O
zero	O
inflation	O
of	O
the	O
distribution	O
was	O
applied	O
.	O

To	O
investigate	O
if	O
the	O
effect	O
of	O
NWpG	O
-	O
IC	O
is	O
related	O
to	O
the	O
psychiatric	B-phenotype
diagnosis	I-phenotype
,	O
we	O
included	O
the	O
primary	O
ICD	B-coding_system
-	I-coding_system
10	I-coding_system
diagnosis	O
group	O
into	O
the	O
mixed	O
effects	O
model	O
as	O
dummy	O
variables	O
.	O

The	O
reference	O
category	O
was	O
F20	B-code
-	I-code
F29	I-code
;	O
the	O
three	O
other	O
categories	O
were	O
F30	B-code
-	I-code
F39	I-code
,	O
F40	B-code
-	I-code
F48	I-code
and	O
‘other	O
psychiatric	O
diagnoses’	O
.	O

In	O
addition	O
we	O
extended	O
the	O
models	O
by	O
two	O
-	O
way	O
and	O
three	O
-	O
way	O
interaction	O
effects	O
between	O
treatment	O
group	O
,	O
time	O
and	O
ICD	B-coding_system
-	I-coding_system
10	I-coding_system
diagnosis	O
.	O

Due	O
to	O
the	O
parameterisation	O
of	O
the	O
three	O
-	O
way	O
interaction	O
models	O
the	O
regression	O
coefficient	O
for	O
the	O
main	O
effect	O
of	O
the	O
time	O
variable	O
indicates	O
the	O
change	O
of	O
the	O
outcome	O
variable	O
in	O
patients	O
with	O
an	O
F20	B-code
-	I-code
F29	I-code
diagnosis	O
in	O
the	O
control	O
group	O
.	O

The	O
main	O
effect	O
of	O
the	O
coefficient	O
for	O
the	O
study	O
group	O
indicates	O
the	O
mean	O
difference	O
of	O
the	O
outcome	O
variable	O
between	O
study	O
groups	O
in	O
patients	O
with	O
an	O
F20	B-code
-	I-code
F29	I-code
diagnosis	O
at	O
baseline	O
and	O
the	O
coefficients	O
for	O
the	O
main	O
effects	O
of	O
the	O
three	O
diagnosis	O
groups	O
(	O
F30	B-code
-	I-code
F39	I-code
;	O
F40	B-code
-	I-code
F48	I-code
and	O
others	O
)	O
indicate	O
the	O
mean	O
difference	O
of	O
the	O
outcome	O
variable	O
between	O
patients	O
with	O
F30	B-code
-	I-code
F39	I-code
,	O
F40	B-code
-	I-code
F48	I-code
or	O
other	O
diagnosis	O
and	O
patients	O
with	O
F20	B-code
-	I-code
F29	I-code
diagnosis	O
in	O
the	O
control	O
group	O
at	O
baseline	O
.	O

The	O
coefficients	O
for	O
the	O
two	O
-	O
way	O
interaction	O
effects	O
between	O
study	O
group	O
and	O
diagnosis	O
indicate	O
the	O
effect	O
of	O
the	O
respective	O
diagnosis	O
in	O
comparison	O
to	O
an	O
F20	B-code
-	I-code
F29	I-code
diagnosis	O
on	O
the	O
mean	O
difference	O
of	O
the	O
outcome	O
variable	O
between	O
study	O
groups	O
at	O
baseline	O
.	O

The	O
coefficients	O
for	O
the	O
two	O
-	O
way	O
interaction	O
effects	O
between	O
diagnosis	O
and	O
time	O
indicate	O
the	O
effect	O
of	O
the	O
respective	O
diagnosis	O
in	O
comparison	O
to	O
an	O
F20	B-code
-	I-code
F29	I-code
diagnosis	O
on	O
the	O
change	O
of	O
the	O
outcome	O
variable	O
in	O
the	O
control	O
group	O
.	O

The	O
coefficient	O
for	O
the	O
two	O
-	O
way	O
interaction	O
effect	O
between	O
study	O
group	O
and	O
time	O
indicate	O
the	O
intervention	O
effect	O
of	O
NWpG	O
-	O
IC	O
in	O
comparison	O
to	O
standard	O
care	O
in	O
the	O
F20	B-code
-	I-code
F29	I-code
diagnosis	O
group	O
.	O

The	O
coefficients	O
for	O
the	O
three	O
-	O
way	O
interaction	O
between	O
study	O
group	O
,	O
diagnosis	O
and	O
time	O
indicate	O
the	O
additional	O
diagnosis	O
specific	O
intervention	O
effect	O
.	O

The	O
repeated	O
measurements	O
for	O
patients	O
clustered	O
according	O
study	O
centres	O
were	O
taken	O
into	O
account	O
.	O

Data	O
capturing	O
was	O
performed	O
using	O
IBM	O
SPSS	O
21	O
.	O

Data	O
analysis	O
was	O
carried	O
out	O
using	O
SAS	O
9	O
.	O
4	O
and	O
STATA	O
14	O
.	O

The	O
flow	O
of	O
participants	O
in	O
the	O
study	O
is	O
presented	O
in	O
Figure	O
1	O
.	O

The	O
protocol	O
for	O
this	O
trial	O
and	O
supporting	O
Consort	O
checklist	O
are	O
available	O
as	O
supporting	O
information	O
,	O
see	O
Checklist	O
S1	O
and	O
Protocol	O
S1	O
and	O
S2	O
.	O

In	O
short	O
,	O
72	O
of	O
77	O
recruited	O
children	O
aged	O
10	O
to	O
12	O
years	O
completed	O
the	O
study	O
.	O

Five	O
children	O
were	O
omitted	O
from	O
the	O
present	O
analyses	O
due	O
to	O
changes	O
in	O
medication	O
during	O
the	O
project	O
period	O
.	O

The	O
presented	O
analyses	O
are	O
based	O
on	O
the	O
remaining	O
67	O
subjects	O
.	O

All	O
had	O
a	O
confirmed	O
diagnosis	O
of	O
F	B-code
-	I-code
90	I-code
ICD	B-coding_system
-	I-coding_system
10	I-coding_system
Hyperkinetic	B-phenotype
Disorder	I-phenotype
[	O
26	O
]	O
,	O
equivalent	O
to	O
the	O
DSM	B-coding_system
-	I-coding_system
IV	I-coding_system
diagnosis	O
of	O
ADHD	B-phenotype
combined	I-phenotype
type	I-phenotype
.	O

All	O
were	O
in	O
treatment	O
for	O
ADHD	O
within	O
the	O
Departments	O
for	O
Child	O
and	O
Adolescent	O
Psychiatry	O
in	O
Vestfold	O
or	O
Telemark	O
Hospitals	O
,	O
Norway	O
.	O

Exclusion	O
criteria	O
were	O
IQ	O
below	O
70	O
,	O
or	O
a	O
comorbid	O
diagnosis	O
of	O
Pervasive	O
Developmental	O
Disorders	O
,	O
Tourette’s	O
Disorder	O
,	O
evidence	O
of	O
psychosis	O
or	O
Bipolar	O
Disorder	O
and	O
Conduct	O
Disorder	O
.	O

Forty	O
-	O
one	O
of	O
the	O
final	O
participants	O
were	O
medicated	O
with	O
MPH	O
in	O
the	O
same	O
dosage	O
throughout	O
the	O
study	O
,	O
whereas	O
five	O
used	O
atomoxetine	O
.	O

One	O
patient	O
used	O
risperidone	O
as	O
well	O
.	O

Due	O
to	O
a	O
negative	O
attitude	O
against	O
medication	O
among	O
parents	O
or	O
as	O
a	O
result	O
of	O
medication	O
being	O
discontinued	O
,	O
21	O
participants	O
did	O
not	O
use	O
medication	O
at	O
the	O
time	O
of	O
inclusion	O
.	O

Forty	O
-	O
nine	O
boys	O
and	O
18	O
girls	O
participated	O
.	O

Mean	O
age	O
was	O
10	O
.	O
4	O
(	O
s	O
.	O
d	O
.	O

0	O
.	O
7	O
)	O
and	O
mean	O
IQ	O
was	O
94	O
(	O
s	O
.	O
d	O
.	O

12	O
)	O
.	O

There	O
were	O
no	O
differences	O
between	O
the	O
groups	O
with	O
regard	O
to	O
these	O
characteristics	O
,	O
nor	O
with	O
regard	O
to	O
the	O
education	O
level	O
of	O
their	O
parents	O
.	O

The	O
study	O
was	O
a	O
randomized	O
controlled	O
trial	O
.	O

The	O
half	O
of	O
the	O
participants	O
drawn	O
to	O
compose	O
the	O
control	O
group	O
was	O
offered	O
the	O
possibility	O
to	O
train	O
after	O
the	O
completion	O
of	O
the	O
study	O
.	O

The	O
experimental	O
intervention	O
is	O
described	O
below	O
.	O

Except	O
for	O
this	O
intervention	O
both	O
groups	O
received	O
treatment	O
as	O
usual	O
.	O

The	O
experimental	O
design	O
included	O
a	O
pretest	O
immediately	O
before	O
the	O
start	O
of	O
the	O
training	O
period	O
,	O
a	O
post	O
-	O
test	O
at	O
the	O
conclusion	O
of	O
the	O
training	O
period	O
and	O
follow	O
-	O
up	O
testing	O
.	O

The	O
original	O
plans	O
called	O
for	O
follow	O
-	O
up	O
testing	O
to	O
take	O
place	O
six	O
months	O
after	O
conclusion	O
of	O
the	O
training	O
period	O
,	O
but	O
due	O
to	O
unforeseen	O
delays	O
in	O
completing	O
the	O
training	O
program	O
due	O
to	O
a	O
flu	O
epidemic	O
,	O
the	O
actual	O
follow	O
-	O
up	O
testing	O
took	O
place	O
eight	O
months	O
after	O
conclusion	O
of	O
the	O
training	O
period	O
.	O

Participants	O
meeting	O
the	O
inclusion	O
criteria	O
were	O
matched	O
on	O
gender	O
and	O
medication	O
status	O
,	O
and	O
randomized	O
by	O
drawing	O
numbers	O
corresponding	O
to	O
ID	O
numbers	O
to	O
either	O
training	O
or	O
control	O
group	O
by	O
a	O
staff	O
member	O
not	O
involved	O
in	O
training	O
or	O
testing	O
.	O

Staff	O
members	O
responsible	O
for	O
testing	O
were	O
not	O
involved	O
in	O
conducting	O
the	O
training	O
sessions	O
for	O
the	O
intervention	O
group	O
,	O
which	O
took	O
place	O
at	O
participants’	O
schools	O
administered	O
by	O
a	O
teacher	O
or	O
other	O
person	O
designated	O
by	O
a	O
school	O
official	O
.	O

Training	O
sessions	O
took	O
place	O
at	O
the	O
participant’s	O
school	O
during	O
regular	O
school	O
hours	O
and	O
all	O
testing	O
took	O
place	O
at	O
the	O
Departments	O
for	O
Child	O
and	O
Adolescent	O
Psychiatry	O
in	O
Vestfold	O
or	O
Telemark	O
Hospital	O
Trusts	O
,	O
Norway	O
.	O

The	O
study	O
was	O
approved	O
18	O
.	O
06	O
.	O

2009	O
by	O
the	O
Regional	O
Committees	O
for	O
Medical	O
and	O
Health	O
Research	O
Ethics	O
(	O
REC	O
South	O
East	O
)	O
.	O

Recruitment	O
and	O
enrollment	O
began	O
in	O
01	O
.	O
08	O
.	O

2009	O
and	O
follow	O
-	O
up	O
testing	O
was	O
completed	O
31	O
.	O
12	O
.	O
2010	O
.	O

All	O
parents	O
,	O
as	O
well	O
as	O
children	O
over	O
12	O
years	O
of	O
age	O
,	O
had	O
signed	O
written	O
consent	O
forms	O
prior	O
to	O
participation	O
.	O

This	O
trial	O
was	O
prospectively	O
registered	O
with	O
,	O
and	O
publicly	O
available	O
on	O
,	O
the	O
website	O
of	O
the	O
Norwegian	O
Ethics	O
Committee	O
in	O
2009	O
:	O
https	O
:	O
/	O
/	O
helseforskning	O
.	O
etikkom	O
.	O
no	O
/	O
ikbViewer	O
/	O
page	O
/	O
prosjekterirek	O
/	O
prosjektregister	O
?	O
_	O
ikbLanguageCode=us	O
&	O
p	O
_	O
dim=34977	O
&	O
9F508B87E7D8620DE040F28156A418DC	O
.	O
p	O
_	O
search	O
_	O
id=26503	O
.	O

This	O
study	O
is	O
also	O
registered	O
as	O
ISRCTN19133620	O
(	O
www	O
.	O
controlled	O
-	O
trials	O
.	O
com	O
)	O
.	O

The	O
WM	O
training	O
consisted	O
of	O
Cogmed’s	O
RoboMemo	O
program	O
performed	O
on	O
a	O
daily	O
basis	O
at	O
school	O
for	O
5–7	O
weeks	O
.	O

The	O
program	O
lasts	O
for	O
30–45	O
minutes	O
and	O
consists	O
of	O
13	O
adaptive	O
exercises	O
selected	O
from	O
an	O
algorithm	O
that	O
continually	O
increased	O
or	O
decreased	O
the	O
difficulty	O
level	O
of	O
each	O
exercise	O
according	O
to	O
the	O
child’s	O
performance	O
.	O

Thus	O
,	O
the	O
participants	O
were	O
systematically	O
working	O
on	O
tasks	O
taxing	O
their	O
WM	O
capacity	O
.	O

The	O
training	O
regime	O
includes	O
three	O
letter	O
span	O
tasks	O
(	O
all	O
forward	O
condition	O
)	O
,	O
three	O
digit	O
span	O
tasks	O
(	O
one	O
forward	O
condition	O
,	O
two	O
backward	O
conditions	O
)	O
,	O
and	O
seven	O
visuospatial	O
tasks	O
(	O
all	O
forward	O
sequenced	O
)	O
,	O
including	O
static	O
visuospatial	O
tasks	O
(	O
one	O
2D	O
visuospatial	O
task	O
,	O
one	O
3D	O
visuospatial	O
task	O
)	O
,	O
and	O
two	O
dynamic	O
visuospatial	O
tasks	O
,	O
in	O
which	O
students	O
recall	O
the	O
positions	O
of	O
rotated	O
or	O
moving	O
objects	O
.	O

Nine	O
of	O
the	O
tasks	O
are	O
presented	O
purely	O
in	O
visual	O
format	O
,	O
and	O
four	O
are	O
delivered	O
with	O
an	O
auditive	O
input	O
.	O

Eleven	O
of	O
the	O
tasks	O
are	O
forward	O
sequenced	O
,	O
while	O
only	O
two	O
are	O
reverse	O
order	O
tasks	O
.	O
Every	O
five	O
days	O
,	O
new	O
training	O
tasks	O
were	O
introduced	O
to	O
replace	O
the	O
earlier	O
tasks	O
.	O

In	O
every	O
session	O
,	O
the	O
participant	O
trains	O
both	O
storage	O
and	O
manipulation	O
visually	O
and	O
verbally	O
.	O

Nine	O
tasks	O
were	O
visual	O
,	O
while	O
four	O
were	O
auditory	O
as	O
well	O
.	O

The	O
participant	O
received	O
daily	O
verbal	O
and	O
visual	O
feedback	O
about	O
increases	O
in	O
performance	O
and	O
personal	O
records	O
and	O
was	O
rewarded	O
after	O
training	O
by	O
being	O
allowed	O
to	O
play	O
the	O
RoboRacing	O
-	O
computer	O
game	O
.	O

Every	O
fifth	O
day	O
the	O
participant	O
received	O
an	O
additional	O
individualized	O
reward	O
.	O

A	O
teacher	O
or	O
assistant	O
was	O
present	O
during	O
training	O
.	O

Regarding	O
training	O
compliance	O
,	O
four	O
subjects	O
completed	O
less	O
than	O
the	O
planned	O
number	O
of	O
25	O
training	O
sessions	O
(	O
3	O
had	O
24	O
sessions	O
and	O
one	O
had	O
21	O
)	O
.	O

Average	O
improvement	O
index	O
in	O
the	O
training	O
program	O
for	O
the	O
whole	O
group	O
was	O
24	O
(	O
s	O
.	O
d	O
.	O
8	O
)	O
,	O
slightly	O
less	O
(	O
23	O
)	O
for	O
those	O
completing	O
less	O
than	O
25	O
training	O
days	O
.	O

Four	O
subjects	O
discontinued	O
training	O
for	O
about	O
one	O
week	O
or	O
more	O
during	O
the	O
planned	O
training	O
period	O
due	O
to	O
a	O
flu	O
epidemic	O
.	O

These	O
days	O
were	O
compensated	O
for	O
by	O
training	O
additional	O
days	O
when	O
they	O
returned	O
to	O
school	O
.	O

Due	O
to	O
varying	O
lengths	O
of	O
sick	O
leave	O
,	O
one	O
participant	O
trained	O
for	O
26	O
days	O
and	O
three	O
trained	O
for	O
30	O
days	O
.	O

The	O
participants	O
were	O
examined	O
with	O
a	O
wide	O
range	O
of	O
tests	O
and	O
measures	O
.	O

As	O
the	O
project	O
attempted	O
to	O
be	O
more	O
comprehensive	O
than	O
previous	O
studies	O
in	O
assessing	O
transfer	O
effects	O
,	O
it	O
was	O
important	O
not	O
to	O
single	O
out	O
selected	O
measures	O
for	O
analysis	O
.	O

However	O
,	O
reporting	O
on	O
potentially	O
more	O
than	O
one	O
hundred	O
between	O
-	O
group	O
analyses	O
would	O
increase	O
the	O
risk	O
of	O
type	O
I	O
errors	O
,	O
as	O
some	O
effects	O
could	O
be	O
accidentally	O
significant	O
.	O

On	O
the	O
other	O
hand	O
,	O
controlling	O
statistically	O
for	O
multiple	O
comparisons	O
would	O
require	O
such	O
a	O
low	O
p	O
-	O
level	O
that	O
nearly	O
no	O
effect	O
could	O
be	O
statistically	O
significant	O
,	O
increasing	O
the	O
risk	O
of	O
Type	O
II	O
errors	O
.	O

Thus	O
,	O
in	O
adherence	O
to	O
the	O
methodological	O
critique	O
of	O
previous	O
research	O
by	O
Shipstead	O
et	O
al	O
.	O
[	O
21	O
]	O
we	O
chose	O
to	O
reduce	O
the	O
number	O
of	O
comparisons	O
by	O
computing	O
composite	O
measures	O
where	O
relevant	O
and	O
possible	O
.	O

Below	O
is	O
a	O
presentation	O
of	O
the	O
measures	O
applied	O
and	O
the	O
computation	O
of	O
composite	O
measures	O
.	O

The	O
CW	O
-	O
test	O
is	O
an	O
extended	O
version	O
of	O
the	O
Stroop	O
test	O
[	O
28	O
]	O
based	O
on	O
four	O
tasks	O
:	O
Color	O
Naming	O
,	O
Word	O
Reading	O
,	O
Inhibition	O
and	O
Inhibition	O
-	O
Switching	O
.	O

The	O
first	O
two	O
tasks	O
are	O
considered	O
to	O
tap	O
semi	O
-	O
automatic	O
and	O
automatic	O
processes	O
,	O
while	O
the	O
two	O
Inhibition	O
tasks	O
demand	O
controlled	O
attention	O
.	O

TMT	O
is	O
an	O
extended	O
version	O
of	O
the	O
Halstead	O
-	O
Reitan	O
Trail	O
Making	O
Test	O
[	O
29	O
]	O
.	O

Tasks	O
2	O
through	O
4	O
were	O
administered	O
.	O

Tasks	O
2	O
and	O
3	O
tax	O
simple	O
visual	O
search	O
and	O
are	O
considered	O
to	O
measure	O
simple	O
processing	O
speed	O
,	O
while	O
Task	O
4	O
,	O
equivalent	O
to	O
TMT	O
B	O
in	O
the	O
original	O
Halstead	O
-	O
Reitan	O
version	O
,	O
is	O
considered	O
to	O
measure	O
divided	O
attention	O
.	O

The	O
scaled	O
scores	O
of	O
CW	O
1	O
and	O
2	O
and	O
TMT	O
2	O
and	O
3	O
were	O
averaged	O
into	O
a	O
composite	O
measure	O
of	O
Processing	O
speed	O
.	O

The	O
average	O
scaled	O
scores	O
for	O
speed	O
and	O
errors	O
on	O
CW	O
3	O
and	O
4	O
made	O
up	O
a	O
measure	O
of	O
Controlled	O
Attention	O
,	O
primarily	O
taxing	O
inhibition	O
.	O

TMT	O
4	O
measures	O
a	O
different	O
aspect	O
of	O
controlled	O
attention	O
and	O
is	O
reported	O
separately	O
.	O

This	O
is	O
a	O
high	O
signal	O
-	O
to	O
-	O
noise	O
continuous	O
performance	O
test	O
(	O
CPT	O
)	O
lasting	O
14	O
minutes	O
and	O
yielding	O
12	O
measures	O
.	O

Factor	O
-	O
analysis	O
has	O
shown	O
that	O
these	O
can	O
be	O
reduced	O
to	O
four	O
dimensions	O
[	O
31	O
]	O
,	O
[	O
32	O
]	O
.	O

Composite	O
measures	O
for	O
each	O
dimension	O
were	O
computed	O
.	O

Focused	O
attention	O
is	O
the	O
mean	O
T	O
-	O
score	O
of	O
Omissions	O
,	O
Perseverations	O
,	O
Variability	O
and	O
Hit	O
Reaction	O
time	O
Standard	O
Error	O
.	O

Hyperactivity	O
-	O
Impulsivity	O
is	O
computed	O
from	O
the	O
T	O
-	O
scores	O
of	O
Hit	O
Reaction	O
Time	O
,	O
Commission	O
Errors	O
and	O
Response	O
Style	O
.	O

Sustained	O
attention	O
is	O
computed	O
from	O
Block	O
Change	O
and	O
Block	O
Change	O
Standard	O
Error	O
,	O
measuring	O
the	O
change	O
in	O
reaction	O
time	O
or	O
increase	O
in	O
variability	O
of	O
reaction	O
time	O
as	O
a	O
function	O
of	O
time	O
on	O
task	O
.	O

Vigilance	O
is	O
computed	O
from	O
the	O
Interstimulus	O
-	O
interval	O
-	O
change	O
score	O
as	O
well	O
as	O
the	O
Standard	O
Error	O
of	O
ISI	O
-	O
change	O
,	O
measuring	O
a	O
possible	O
fall	O
in	O
reaction	O
time	O
following	O
longer	O
interstimulus	O
-	O
intervals	O
.	O

Two	O
tests	O
of	O
memory	O
were	O
applied	O
:	O
Children’s	O
Auditory	O
Verbal	O
Learning	O
Test	O
-	O
2	O
(	O
CAVLT	O
-	O
2	O
:	O
[	O
33	O
]	O
)	O
and	O
Benton	O
Visual	O
Retention	O
Test	O
,	O
fifth	O
edition	O
.	O

(	O
BVRT	O
)	O
[	O
34	O
]	O
.	O

Three	O
measures	O
derived	O
from	O
the	O
standard	O
administration	O
of	O
CAVLT	O
-	O
2	O
are	O
reported	O
:	O
Level	O
of	O
Learning	O
,	O
which	O
is	O
the	O
number	O
of	O
correct	O
responses	O
to	O
acquisition	O
trial	O
3–5	O
;	O
Free	O
Delayed	O
Recall	O
which	O
is	O
the	O
number	O
of	O
correctly	O
retrieved	O
items	O
after	O
30	O
minutes	O
and	O
Recognition	O
which	O
is	O
the	O
number	O
of	O
correctly	O
identified	O
items	O
from	O
a	O
32	O
-	O
item	O
long	O
recognition	O
list	O
.	O

In	O
BVRT	O
,	O
the	O
child	O
is	O
shown	O
10	O
designs	O
,	O
one	O
at	O
a	O
time	O
,	O
and	O
asked	O
to	O
reproduce	O
each	O
one	O
as	O
accurately	O
as	O
possible	O
on	O
a	O
plain	O
piece	O
of	O
paper	O
from	O
memory	O
.	O

The	O
measure	O
reported	O
is	O
the	O
number	O
of	O
correctly	O
reproduced	O
designs	O
.	O

In	O
listing	O
this	O
test	O
as	O
a	O
memory	O
test	O
,	O
we	O
adhere	O
to	O
the	O
manual	O
and	O
to	O
a	O
convention	O
within	O
in	O
neuropsychology	O
.	O

As	O
,	O
there	O
is	O
no	O
delay	O
necessitating	O
long	O
term	O
storage	O
,	O
it	O
could	O
in	O
fact	O
be	O
considered	O
a	O
measure	O
of	O
WM	O
.	O

Two	O
subtests	O
were	O
applied	O
:	O
The	O
Mental	O
computation	O
subtest	O
consists	O
of	O
18	O
verbally	O
presented	O
tasks	O
with	O
or	O
without	O
simultaneous	O
visual	O
information	O
to	O
be	O
answered	O
within	O
15	O
seconds	O
(	O
except	O
for	O
three	O
tasks	O
)	O
.	O

The	O
un	O
-	O
timed	O
Problem	O
-	O
solving	O
subtest	O
involves	O
18	O
daily	O
life	O
math	O
problems	O
,	O
where	O
the	O
subject	O
has	O
to	O
decide	O
on	O
what	O
part	O
of	O
the	O
text	O
presented	O
is	O
relevant	O
and	O
what	O
procedures	O
to	O
apply	O
.	O

The	O
scaled	O
scores	O
from	O
both	O
tests	O
were	O
averaged	O
into	O
a	O
composite	O
Mathematics	O
score	O
.	O

Reading	O
ability	O
was	O
assessed	O
with	O
the	O
computerized	O
test	O
battery	O
LOGOS	O
[	O
36	O
]	O
,	O
based	O
on	O
the	O
dual	O
route	O
-	O
model	O
of	O
reading	O
comprehension	O
and	O
word	O
decoding	O
.	O

Decoding	O
is	O
analyzed	O
phonologically	O
and	O
orthographically	O
.	O

The	O
test	O
yields	O
10	O
scores	O
measuring	O
different	O
aspects	O
of	O
reading	O
and	O
text	O
comprehension	O
.	O

Because	O
they	O
represent	O
the	O
end	O
-	O
point	O
of	O
reading	O
training	O
,	O
Text	O
Reading	O
speed	O
and	O
Percent	O
correct	O
read	O
are	O
reported	O
as	O
single	O
scores	O
.	O

These	O
measures	O
were	O
not	O
normally	O
distributed	O
,	O
and	O
could	O
not	O
be	O
included	O
in	O
a	O
composite	O
score	O
.	O

Two	O
composite	O
scores	O
representing	O
Word	O
Decoding	O
Speed	O
and	O
Quality	O
of	O
Decoding	O
,	O
were	O
also	O
computed	O
.	O

These	O
composites	O
consisted	O
of	O
the	O
average	O
processing	O
time	O
and	O
the	O
average	O
correctly	O
processed	O
single	O
words	O
under	O
three	O
conditions	O
:	O
phonologically	O
based	O
reading	O
of	O
meaningful	O
and	O
nonsense	O
words	O
as	O
well	O
as	O
orthographic	O
reading	O
of	O
single	O
words	O
.	O

ADHD	O
-	O
Rating	O
Scale	O
IV	O
[	O
37	O
]	O
was	O
distributed	O
to	O
both	O
parents	O
and	O
teachers	O
.	O

The	O
scale	O
yields	O
separate	O
measures	O
for	O
symptoms	O
of	O
inattention	O
and	O
hyperactivity	O
/	O
impulsivity	O
as	O
well	O
as	O
a	O
total	O
score	O
.	O

The	O
Attention	O
score	O
is	O
considered	O
the	O
most	O
relevant	O
measure	O
of	O
possible	O
transfer	O
effect	O
of	O
WM	O
training	O
and	O
is	O
reported	O
together	O
with	O
the	O
total	O
score	O
measuring	O
possible	O
overall	O
symptom	O
reduction	O
.	O

Strengths	O
&	O
Difficulties	O
Questionnaire	O
[	O
38	O
]	O
,	O
[	O
39	O
]	O
is	O
a	O
measure	O
of	O
pro	O
-	O
social	O
behavior	O
and	O
psychopathology	O
of	O
3–16	O
year	O
olds	O
and	O
was	O
also	O
completed	O
by	O
both	O
parents	O
and	O
teachers	O
.	O

It	O
yields	O
separate	O
measures	O
for	O
emotional	O
symptoms	O
,	O
conduct	O
problems	O
,	O
hyperactivity	O
-	O
inattention	O
,	O
peer	O
problems	O
and	O
a	O
prosocial	O
scale	O
.	O

We	O
report	O
the	O
Overall	O
score	O
computed	O
from	O
the	O
four	O
problem	O
/	O
symptom	O
-	O
scales	O
,	O
as	O
well	O
as	O
the	O
Impact	O
score	O
measuring	O
the	O
degree	O
to	O
which	O
the	O
problem	O
behavior	O
interferes	O
with	O
everyday	O
functioning	O
across	O
different	O
functional	O
domains	O
.	O

Behavior	O
Rating	O
Inventory	O
of	O
Executive	O
Function	O
(	O
BRIEF	O
:	O
[	O
40	O
]	O
)	O
parent	O
and	O
teacher	O
versions	O
:	O
The	O
BRIEF	O
is	O
designed	O
to	O
assess	O
executive	O
functioning	O
in	O
home	O
and	O
school	O
environments	O
in	O
children	O
aged	O
5–18	O
.	O

The	O
inventory	O
yields	O
eight	O
subscales	O
grouped	O
into	O
two	O
indexes	O
and	O
one	O
sum	O
-	O
score	O
.	O

We	O
report	O
the	O
Metacognition	O
index	O
based	O
on	O
the	O
Initiate	O
,	O
Working	O
Memory	O
,	O
Plan	O
/	O
Organize	O
,	O
Organization	O
of	O
Material	O
and	O
Monitor	O
-	O
subscales	O
.	O

The	O
Global	O
Executive	O
composite	O
(	O
GEC	O
)	O
is	O
also	O
reported	O
.	O

It	O
is	O
an	O
overall	O
measure	O
based	O
on	O
all	O
8	O
scales	O
,	O
i	O
.	O
e	O
.	O
including	O
the	O
three	O
scales	O
constituting	O
the	O
Behavior	O
Regulation	O
index	O
(	O
BRI	O
)	O
.	O

The	O
BRIEF	O
has	O
been	O
proven	O
useful	O
in	O
describing	O
the	O
details	O
of	O
EF	O
function	O
in	O
ADHD	O
and	O
previously	O
been	O
used	O
in	O
assessing	O
the	O
effects	O
of	O
WM	O
-	O
training	O
[	O
25	O
]	O
.	O

The	O
Norwegian	O
version	O
is	O
comparable	O
to	O
the	O
original	O
US	O
version	O
[	O
41	O
]	O
.	O

Demographic	O
and	O
clinical	O
background	O
information	O
at	O
baseline	O
was	O
analyzed	O
with	O
Analysis	O
of	O
Variance	O
for	O
continuous	O
variables	O
and	O
Chi	O
-	O
square	O
for	O
categorical	O
variables	O
.	O

Baseline	O
levels	O
for	O
all	O
dependent	O
measures	O
were	O
compared	O
between	O
the	O
un	O
-	O
medicated	O
and	O
the	O
medicated	O
group	O
.	O

Treatment	O
effects	O
are	O
analyzed	O
applying	O
Multivariate	O
Analysis	O
of	O
Covariance	O
(	O
MANCOVA	O
)	O
with	O
treatment	O
condition	O
as	O
between	O
group	O
factor	O
and	O
PT1	O
and	O
PT2	O
scores	O
as	O
within	O
group	O
factor	O
.	O

Pretest	O
scores	O
were	O
entered	O
as	O
covariates	O
.	O

Speed	O
and	O
quality	O
of	O
text	O
reading	O
did	O
not	O
satisfy	O
criteria	O
for	O
parametric	O
analyses	O
.	O

Differences	O
between	O
baseline	O
and	O
PT1	O
and	O
PT2	O
were	O
therefore	O
analyzed	O
with	O
the	O
Mann	O
-	O
Whitney	O
U	O
-	O
test	O
.	O

This	O
was	O
a	O
6½	O
-	O
month	O
prospective	O
cohort	O
study	O
of	O
oral	O
opioid	O
therapy	O
,	O
conducted	O
from	O
2009	O
-	O
2012	O
,	O
with	O
an	O
active	O
drug	O
/	O
placebo	O
run	O
-	O
in	O
period	O
,	O
in	O
CLBP	O
patients	O
with	O
low	O
,	O
moderate	O
,	O
and	O
high	O
levels	O
of	O
NA	O
(	O
ClinicalTrials	O
.	O
gov	O
Identifier	O
:	O
NCT01502644	O
)	O
.	O

Inclusion	O
criteria	O
were	O
:	O
1	O
)	O
Ages	O
21	O
-	O
75	O
;	O
2	O
)	O
CLBP	O
of	O
at	O
least	O
six	O
months	O
duration	O
with	O
an	O
average	O
pain	O
score	O
of	O
>	O
3	O
/	O
10	O
(	O
established	O
with	O
a	O
one	O
-	O
week	O
baseline	O
pain	O
observation	O
period	O
,	O
using	O
daily	O
,	O
electronic	O
pain	O
ratings	O
)	O
;	O
3	O
)	O
LBP	O
meeting	O
Quebec	O
Task	O
Force	O
Criteria	O
for	O
Grades	O
I	O
-	O
III	O
(	O
low	O
back	O
pain	O
[	O
LBP	O
]	O
only	O
to	O
LBP	O
with	O
intermittent	O
radicular	O
pain	O
[	O
not	O
constant	O
or	O
daily	O
]	O
and	O
no	O
neurological	O
signs	O
)	O
;	O
36	O
4	O
)	O
No	O
back	O
surgery	O
within	O
the	O
past	O
year	O
;	O
5	O
)	O
Having	O
degenerative	O
disc	O
disease	O
as	O
a	O
component	O
of	O
a	O
pain	O
syndrome	O

of	O
mixed	O
etiology	O
,	O
confirmed	O
by	O
history	O
,	O
examination	O
,	O
and	O
a	O
previous	O
lumbar	O
MRI	O
;	O
6	O
)	O
No	O
opioid	O
use	O
or	O
use	O
of	O
short	O
-	O
acting	O
opioids	O
only	O
,	O
and	O
<	O
90	O
mg	O
/	O
day	O
in	O
morphine	O
equivalents	O
.	O

Those	O
subjects	O
taking	O
opioids	O
must	O
also	O
have	O
agreed	O
to	O
a	O
2	O
-	O
week	O
opioid	O
washout	O
period	O
prior	O
to	O
beginning	O
medication	O
;	O
7	O
)	O
No	O
pregnancy	O
or	O
intent	O
to	O
become	O
pregnant	O
during	O
the	O
study	O
period	O
;	O
8	O
)	O
No	O
intent	O
to	O
begin	O
new	O
pain	O
or	O
psychiatric	O
treatments	O
during	O
the	O
study	O
(	O
such	O
as	O
pain	O
medication	O
,	O
nerve	O
blocks	O
,	O
physical	O
therapy	O
,	O
or	O
psychiatric	O
medication	O
)	O
,	O
or	O
increase	O
any	O
current	O
medications	O
;	O
9	O
)	O
No	O
current	O
,	O
active	O
substance	O
use	O
disorder	O
and	O
no	O
history	O
of	O
an	O
opioid	O
substance	O
use	O
disorder	O
(	O
assessed	O
with	O
the	O
Mini	O

International	O
Neuropsychiatric	O
Interview	O
)	O
;	O
37	O
and	O
10	O
)	O
No	O
active	O
suicidality	O
or	O
psychosis	O
(	O
assessed	O
by	O
the	O
Mini	O
International	O
Neuropsychiatric	O
Interview	O
as	O
well	O
)	O
.	O

Eligibility	O
was	O
determined	O
by	O
investigator	O
ADW	O
at	O
the	O
first	O
visit	O
through	O
a	O
review	O
of	O
a	O
history	O
and	O
physical	O
examination	O
,	O
and	O
MRI	O
findings	O
confirming	O
the	O
presence	O
of	O
degenerative	O
disc	O
disease	O
.	O

Patients	O
were	O
included	O
if	O
this	O
evaluation	O
found	O
that	O
there	O
was	O
at	O
least	O
one	O
degenerated	O
,	O
herniated	O
,	O
or	O
torn	O
lumbar	O
disc	O
with	O
either	O
a	O
minimum	O
Grade	O
III	O
disc	O
degeneration	O
,	O
38	O
abnormal	O
morphology	O
,	O
39	O
or	O
a	O
hyperintense	O
zone	O
.	O

40	O
These	O
inclusion	O
criteria	O
,	O
used	O
by	O
the	O
authors	O
in	O
previous	O
studies	O
,	O
5	O
,	O
41	O
,	O
42	O
narrow	O
the	O
heterogeneity	O
of	O
CLBP	O
phenotypes	O
by	O
including	O
those	O
with	O
the	O
commonly	O
presenting	O
mixed	O
syndrome	O
of	O
low	O
back	O
pain	O
with	O
underlying	O
degenerated	O
discs	O
,	O
and	O
possibly	O
spinal	O
stenosis	O
or	O
facet	O
disease	O
,	O
and	O
excluding	O
those	O
with	O
pain	O
due	O
to	O
purely	O
nonspecific	O
or	O
myofascial	O
causes	O
.	O

Institutional	O
Review	O
Board	O
approved	O
procedures	O
were	O
used	O
(	O
Brigham	O
and	O
Women	O
'	O
s	O
Hospital	O
,	O
Boston	O
,	O
MA	O
,	O
USA	O
)	O
.	O

Volunteers	O
were	O
recruited	O
from	O
the	O
Pain	O
Medicine	O
and	O
Physiatry	O
Spine	O
clinics	O
of	O
Brigham	O
and	O
Women	O
'	O
s	O
Hospital	O
.	O

In	O
addition	O
,	O
the	O
hospital	O
'	O
s	O
research	O
database	O
of	O
patients	O
with	O
CLBP	B-phenotype
ICD	B-coding_system
-	I-coding_system
9	I-coding_system
diagnosis	O
codes	O
was	O
queried	O
to	O
generate	O
lists	O
of	O
potential	O
subjects	O
,	O
and	O
their	O
corresponding	O
treating	O
providers	O
.	O

Letters	O
were	O
sent	O
to	O
those	O
providers	O
requesting	O
permission	O
to	O
contact	O
their	O
specific	O
patients	O
.	O

Upon	O
provider	O
approval	O
,	O
informational	O
letters	O
about	O
the	O
study	O
were	O
sent	O
to	O
these	O
potential	O
subjects	O
.	O

After	O
telephone	O
and	O
medical	O
record	O
prescreening	O
,	O
subjects	O
were	O
enrolled	O
at	O
Visit	O
1	O
and	O
signed	O
written	O
informed	O
consent	O
.	O

The	O
consent	O
document	O
included	O
opioid	O
therapy	O
instructions	O
regarding	O
the	O
appropriate	O
use	O
of	O
prescription	O
opioids	O
.	O

The	O
lead	O
investigator	O
(	O
ADW	O
)	O
confirmed	O
subject	O
eligibility	O
and	O
subjects	O
completed	O
baseline	O
self	O
-	O
report	O
questionnaires	O
,	O
along	O
with	O
a	O
history	O
and	O
physical	O
exam	O
.	O

The	O
primary	O
predictor	O
was	O
the	O
likely	O
presence	O
or	O
absence	O
of	O
psychiatric	O
comorbidity	O
.	O

This	O
was	O
determined	O
by	O
the	O
levels	O
of	O
NA	O
symptoms	O
within	O
the	O
past	O
week	O
,	O
which	O
were	O
assigned	O
as	O
low	O
,	O
moderate	O
,	O
or	O
a	O
high	O
level	O
to	O
each	O
subject	O
by	O
the	O
combined	O
depression	O
and	O
anxiety	O
subscale	O
scores	O
of	O
the	O
Hospital	O
Anxiety	O
Depression	O
Scale	O
(	O
HADS	O
total	O
score	O
)	O
.	O

43	O
We	O
have	O
used	O
the	O
HADS	O
total	O
score	O
as	O
an	O
operational	O
measure	O
of	O
NA	O
and	O
a	O
grouping	O
variable	O
in	O
previous	O
CLBP	O
treatment	O
outcome	O
studies	O
.	O

23	O
The	O
HADS	O
does	O
not	O
include	O
somatic	O
items	O
which	O
may	O
be	O
attributable	O
to	O
medical	O
illness	O
,	O
and	O
thus	O
it	O
is	O
more	O
appropriate	O
for	O
screening	O
in	O
chronic	O
pain	O
.	O

43	O
High	O
NA	O
was	O
defined	O
as	O
>	O
8	O
on	O
both	O
the	O
depression	O
and	O
anxiety	O
subscales	O
,	O
Low	O
NA	O
was	O
<	O
6	O
on	O
each	O
subscale	O
,	O
and	O
Moderate	O
NA	O
was	O
all	O
other	O
scores	O
in	O
between	O
these	O
cutoffs	O
.	O

44	O
In	O
CLBP	O
specifically	O
,	O
scores	O
meeting	O
high	O
NA	O
criteria	O
are	O
highly	O
correlated	O
with	O
a	O
patient	O
having	O
a	O
comorbid	O
major	O
depression	O
or	O
generalized	O
anxiety	O
disorder	O
,	O
and	O
those	O
meeting	O
low	O
NA	O
criterion	O
are	O
highly	O
unlikely	O
to	O
have	O
psychiatric	O
comorbidity	O
.	O

43	O
,	O
44	O
Recent	O
reviews	O
have	O
concluded	O
that	O
the	O
HADS	O
functions	O
best	O
as	O
a	O
unidimensional	O
measure	O
of	O
NA	O
,	O
while	O
retaining	O
excellent	O
psychiatric	O
case	O
-	O
finding	O
ability	O
.	O

45	O
,	O
46	O

Other	O
baseline	O
measures	O
included	O
:	O
the	O
Brief	O
Pain	O
Inventory	O
(	O
BPI	O
-	O
-	O
for	O
24	O
hour	O
pain	O
and	O
pain	O
interference	O
levels	O
)	O
,	O
47	O
the	O
Oswestry	O
Disability	O
Index	O
(	O
for	O
self	O
-	O
reported	O
function	O
)	O
,	O
48	O
the	O
Neuropathic	O
Pain	O
Questionnaire	O
Short	O
Form	O
(	O
for	O
symptoms	O
of	O
burning	O
,	O
shooting	O
,	O
and	O
sensitivity	O
to	O
touch	O
)	O
,	O
49	O
the	O
Neuroticism	O
Subscale	O
of	O
the	O
NEO	O
personality	O
inventory	O
,	O
50	O
the	O
Pain	O
Catastrophizing	O
Scale	O
,	O
51	O
and	O
the	O
Screener	O
and	O
Opioid	O
Assessment	O
for	O
Patients	O
with	O
Pain	O
,	O
Revised	O
(	O
SOAPP	O
-	O
R	O
,	O
for	O
estimating	O
the	O
risk	O
of	O
opioid	O

misuse	O
)	O
.	O

33	O
These	O
measures	O
were	O
chosen	O
to	O
conform	O
to	O
the	O
IMMPACT	O
Group	O
(	O
Initiative	O
on	O
Methods	O
,	O
Measurements	O
,	O
and	O
Pain	O
Assessment	O
in	O
Clinical	O
Trials	O
)	O
recommendations	O
for	O
analgesic	O
clinical	O
studies	O
.	O

52	O

During	O
Visit	O
1	O
a	O
urine	O
drug	O
test	O
(	O
UDT	O
)	O
was	O
collected	O
to	O
confirm	O
that	O
subjects	O
were	O
not	O
taking	O
opioids	O
and	O
not	O
using	O
illegal	O
drugs	O
.	O

For	O
those	O
subjects	O
prescribed	O
opioids	O
prior	O
to	O
enrollment	O
,	O
they	O
underwent	O
a	O
2	O
-	O
week	O
weaning	O
period	O
and	O
remained	O
off	O
of	O
opioids	O
for	O
at	O
least	O
7	O
days	O
prior	O
to	O
beginning	O
medication	O
at	O
Visit	O
2	O
(	O
a	O
period	O
similar	O
to	O
other	O
studies	O
)	O
.	O

53	O
Compliance	O
with	O
the	O
wean	O
was	O
confirmed	O
with	O
a	O
UDT	O
at	O
Visit	O
2	O
.	O

In	O
between	O
Visits	O
1	O
and	O
2	O
subjects	O
rated	O
their	O
average	O
pain	O
level	O
(	O
0	O
-	O
10	O
)	O
over	O
the	O
past	O
24	O
hours	O
(	O
Question	O
5	O
of	O
the	O
BPI	O
)	O
each	O
day	O
for	O
seven	O
days	O
using	O
an	O
electronic	O
diary	O
,	O
triggered	O
by	O
an	O
alarm	O
.	O

These	O
data	O
were	O
inspected	O
and	O
downloaded	O
at	O
Visit	O
2	O
and	O
were	O
averaged	O
to	O
determine	O
the	O
mean	O
level	O
of	O
baseline	O
pain	O
for	O
each	O
subject	O
.	O

Subjects	O
had	O
to	O
provide	O
data	O
for	O
at	O
least	O
4	O
/	O
7	O
days	O
to	O
continue	O
in	O
the	O
study	O
.	O

Subjects	O
completed	O
the	O
HADS	O
again	O
to	O
establish	O
the	O
stability	O
of	O
the	O
self	O
-	O
reported	O
NA	O
symptoms	O
,	O
and	O
to	O
continue	O
they	O
could	O
not	O
have	O
fallen	O
out	O
of	O
the	O
group	O
(	O
low	O
,	O
moderate	O
,	O
or	O
high	O
NA	O
)	O
to	O
which	O
they	O
were	O
assigned	O
(	O
no	O
subjects	O
changed	O
group	O
)	O
.	O

UDT	O
results	O
were	O
reviewed	O
,	O
and	O
a	O
psychiatrist	O
administered	O
a	O
structured	O
psychiatric	O
interview	O
to	O
determine	O
any	O
Diagnostic	O
and	O
Statistical	O
Manual	O
-	O
IV	O
Axis	O
1	O
diagnosis	O
,	O
including	O
a	O
current	O
substance	O
use	O
disorder	O
.	O

37	O

At	O
Visit	O
2	O
subjects	O
could	O
choose	O
to	O
be	O
prescribed	O
morphine	O
or	O
oxycodone	O
based	O
on	O
any	O
prior	O
experience	O
with	O
these	O
drugs	O
.	O

In	O
a	O
double	O
-	O
blinded	O
randomized	O
order	O
,	O
subjects	O
then	O
received	O
either	O
placebo	O
or	O
morphine	O
/	O
oxycodone	O
1	O
-	O
2	O
tabs	O
up	O
to	O
three	O
times	O
a	O
day	O
as	O
needed	O
for	O
1	O
week	O
each	O
(	O
crossover	O
)	O
,	O
dispensed	O
by	O
the	O
hospital	O
research	O
pharmacy	O
(	O
all	O
pills	O
looked	O
identical	O
)	O
.	O

The	O
hospital	O
research	O
pharmacy	O
followed	O
block	O
randomization	O
in	O
groups	O
of	O
8	O
and	O
maintained	O
the	O
double	O
blind	O
until	O
the	O
conclusion	O
of	O
the	O
study	O
.	O

The	O
doses	O
for	O
morphine	O
were	O
immediate	O
release	O
morphine	O
15	O
-	O
30	O
mgs	O
and	O
for	O
oxycodone	O
5	O
-	O
10	O
mgs	O
three	O
times	O
a	O
day	O
as	O
needed	O
for	O
pain	O
.	O

Subjects	O
completed	O
the	O
electronic	O
diary	O
daily	O
for	O
the	O
average	O
pain	O
rating	O
as	O
well	O
as	O
noting	O
the	O
number	O
of	O
medication	O
doses	O
they	O
took	O
each	O
day	O
.	O

The	O
run	O
-	O
in	O
period	O
allowed	O
subjects	O
to	O
acclimate	O
to	O
opioid	O
medication	O
and	O
to	O
become	O
familiar	O
with	O
the	O
daily	O
pain	O
rating	O
procedures	O
.	O

It	O
also	O
could	O
clarify	O
the	O
role	O
of	O
placebo	O
responses	O
in	O
predicting	O
opioid	O
analgesia	O
.	O

Subjects	O
continued	O
completing	O
the	O
electronic	O
diaries	O
daily	O
in	O
all	O
remaining	O
phases	O
of	O
the	O
study	O
,	O
which	O
were	O
inspected	O
at	O
each	O
study	O
visit	O
.	O

This	O
open	O
-	O
label	O
portion	O
of	O
the	O
trial	O
was	O
conducted	O
by	O
a	O
pain	O
medicine	O
physician	O
-	O
investigator	O
(	O
EM	O
)	O
blinded	O
to	O
group	O
assignment	O
who	O
used	O
a	O
standardized	O
titration	O
schedule	O
for	O
morphine	O
or	O
oxycodone	O
over	O
a	O
three	O
week	O
period	O
.	O

If	O
a	O
subject	O
could	O
not	O
tolerate	O
morphine	O
or	O
oxycodone	O
during	O
the	O
run	O
-	O
in	O
period	O
(	O
assessed	O
at	O
the	O
weekly	O
study	O
visits	O
)	O
,	O
the	O
blind	O
was	O
broken	O
and	O
they	O
were	O
allowed	O
to	O
switch	O
to	O
the	O
other	O
opioid	O
for	O
the	O
rest	O
of	O
the	O
study	O
.	O

The	O
average	O
pain	O
intensity	O
target	O
was	O
<	O
4	O
/	O
10	O
and	O
dosing	O
was	O
individually	O
adjusted	O
each	O
week	O
to	O
maximize	O
pain	O
relief	O
with	O
acceptable	O
side	O
effects	O
according	O
to	O
subject	O
tolerability	O
.	O

At	O
each	O
weekly	O
visit	O
the	O
subject	O
completed	O
the	O
Brief	O
Pain	O
Inventory	O
and	O
a	O
medication	O
log	O
(	O
inspected	O
by	O
the	O
study	O
physician	O
)	O
.	O

In	O
discussion	O
with	O
the	O
subject	O
,	O
the	O
dosing	O
was	O
adjusted	O
using	O
standardized	O
parameters	O
for	O
long	O
-	O
acting	O
and	O
breakthrough	O
medication	O
for	O
morphine	O
or	O
oxycodone	O
.	O

At	O
the	O
end	O
of	O
the	O
titration	O
period	O
the	O
maximum	O
allowable	O
daily	O
dose	O
in	O
morphine	O
equivalents	O
was	O
30	O
mgs	O
of	O
short	O
-	O
acting	O
plus	O
60	O
mgs	O
of	O
long	O
-	O
acting	O
medication	O
three	O
times	O
a	O
day	O
(	O
270	O
mgs	O
,	O
no	O
subjects	O
reached	O
the	O
maximum	O
possible	O
dose	O
)	O
.	O

Subjects	O
remained	O
at	O
their	O
individualized	O
dose	O
throughout	O
this	O
period	O
,	O
except	O
that	O
doses	O
could	O
be	O
reduced	O
(	O
due	O
to	O
side	O
effects	O
,	O
for	O
example	O
)	O
.	O

They	O
received	O
monthly	O
prescriptions	O
for	O
the	O
short	O
and	O
long	O
-	O
acting	O
opioids	O
at	O
monthly	O
visits	O
.	O

They	O
met	O
with	O
a	O
study	O
physician	O
and	O
completed	O
questionnaires	O
at	O
each	O
visit	O
(	O
including	O
global	O
impression	O
of	O
change	O
ratings	O
and	O
an	O
opioid	O
side	O
effects	O
checklist	O
used	O
in	O
our	O
previous	O
studies	O
)	O
.	O

54	O
In	O
addition	O
,	O
at	O
two	O
and	O
at	O
four	O
months	O
into	O
the	O
continuation	O
period	O
opioid	O
adherence	O
measures	O
were	O
collected	O
:	O
the	O
Current	O
Opioid	O
Misuse	O
Measure	O
(	O
COMM—for	O
self	O
-	O
reported	O
misuse	O
,	O
score	O
>	O
13	O
highly	O
predicts	O
misuse	O
using	O
revised	O
criteria	O
)	O
,	O
55	O
the	O
Addiction	O
Behaviors	O
Checklist	O
(	O
for	O
physician	O
-	O
rated	O
misuse	O
assessment	O
,	O
positive	O
score	O
>	O
2	O
)	O
,	O
56	O
and	O
a	O
UDT	O
.	O

Subjects	O
found	O
misusing	O
were	O
continued	O
in	O
the	O
study	O
.	O

We	O
asked	O
that	O
subjects	O
not	O
begin	O
any	O
new	O
pain	O
or	O
psychiatric	O
treatments	O
during	O
the	O
study	O
and	O
we	O
tracked	O
this	O
issue	O
at	O
monthly	O
visits	O
.	O

Subjects	O
returned	O
for	O
weekly	O
visits	O
during	O
this	O
period	O
and	O
the	O
individualized	O
opioid	O
dose	O
was	O
lowered	O
by	O
approximately	O
25	O
%	O
each	O
week	O
.	O

Subjects	O
were	O
off	O
of	O
opioids	O
by	O
the	O
end	O
of	O
the	O
study	O
.	O

Sample	O
size	O
calculations	O
were	O
based	O
on	O
a	O
power	O
of	O
.	O
80	O
and	O
a	O
5	O
%	O
significance	O
level	O
using	O
a	O
two	O
-	O
tailed	O
t	O
test	O
to	O
test	O
the	O
hypothesis	O
that	O
opioids	O
confer	O
diminished	O
analgesia	O
in	O
the	O
high	O
NA	O
vs	O
.	O
in	O
the	O
low	O
NA	O
group	O
.	O

The	O
primary	O
outcome	O
measure	O
was	O
the	O
percent	O
improvement	O
in	O
average	O
daily	O
pain	O
during	O
the	O
opioid	O
continuation	O
period	O
(	O
measured	O
with	O
daily	O
pain	O
ratings	O
on	O
the	O
electronic	O
diary	O
and	O
calculated	O
on	O
a	O
weekly	O
basis	O
)	O
,	O
in	O
comparison	O
to	O
the	O
average	O
baseline	O
pain	O
level	O
.	O

Based	O
on	O
our	O
previous	O
data	O
from	O
intravenous	O
morphine	O
administration	O
in	O
CLBP	O
patients	O
with	O
low	O
vs	O
.	O
high	O
NA	O
,	O
5	O
20	O
subjects	O
each	O
were	O
needed	O
in	O
the	O
low	O
and	O
high	O
groups	O
to	O
find	O
a	O
33	O
%	O
difference	O
in	O
average	O
percent	O
improvement	O
in	O
pain	O
between	O
groups	O
.	O

The	O
primary	O
comparisons	O
of	O
interest	O
were	O
the	O
outcomes	O
differences	O
between	O
the	O
low	O
and	O
high	O
groups	O
.	O

Target	O
study	O
completer	O
rates	O
in	O
these	O
groups	O
were	O
24	O
subjects	O
/	O
group	O
so	O
that	O
we	O
would	O
be	O
adequately	O
powered	O
using	O
multiple	O
comparison	O
corrections	O
to	O
examine	O
our	O
main	O
secondary	O
outcome	O
of	O
interest	O
,	O
the	O
rates	O
of	O
drug	O
misuse	O
between	O
groups	O
.	O

Those	O
in	O
the	O
moderate	O
group	O
continued	O
in	O
all	O
phases	O
of	O
the	O
study	O
,	O
since	O
little	O
is	O
known	O
about	O
their	O
opioid	O
analgesic	O
outcomes	O
as	O
well	O
,	O
and	O
their	O
data	O
is	O
presented	O
for	O
descriptive	O
purposes	O
only	O
.	O

Data	O
from	O
the	O
moderate	O
group	O
was	O
also	O
included	O
in	O
multiple	O
secondary	O
“sensitivity	O
analyses”	O
to	O
further	O
interrogate	O
our	O
findings	O
.	O

Statistical	O
analyses	O
were	O
based	O
on	O
a	O
“modified	O
intent	O
to	O
treat	O
principle	O
,	O
”	O
such	O
that	O
subjects	O
had	O
to	O
complete	O
at	O
least	O
50	O
%	O
of	O
the	O
opioid	O
treatment	O
period	O
to	O
have	O
their	O
data	O
included	O
for	O
analysis	O
.	O

Otherwise	O
,	O
they	O
were	O
termed	O
a	O
“drop	O
out”	O
and	O
these	O
data	O
were	O
not	O
included	O
.	O

Sources	O
of	O
missing	O
data	O
that	O
were	O
tracked	O
include	O
subject	O
dropout	O
,	O
subjects	O
missing	O
study	O
visits	O
,	O
or	O
subjects	O
not	O
completing	O
the	O
electronic	O
diaries	O
at	O
home	O
.	O

We	O
also	O
inspected	O
the	O
case	O
report	O
forms	O
to	O
understand	O
if	O
there	O
was	O
any	O
pattern	O
to	O
the	O
missing	O
data	O
.	O

For	O
the	O
primary	O
outcome	O
measure	O
we	O
used	O
linear	O
mixed	O
modeling	O
(	O
LMM	O
)	O
in	O
SPSS	O
version	O
22	O
(	O
Chicago	O
,	O
IL	O
,	O
USA	O
)	O
to	O
compare	O
the	O
low	O
vs	O
.	O
high	O
NA	O
groups	O
over	O
time	O
.	O

LMM	O
“borrows”	O
information	O
pertaining	O
to	O
the	O
relationship	O
between	O
the	O
weekly	O
outcomes	O
,	O
such	O
that	O
subjects	O
missing	O
some	O
weekly	O
data	O
(	O
but	O
not	O
all	O
)	O
can	O
still	O
be	O
used	O
for	O
analyses	O
.	O

Generally	O
,	O
in	O
longitudinal	O
trials	O
this	O
approach	O
allows	O
for	O
inclusion	O
in	O
the	O
analysis	O
of	O
the	O
majority	O
of	O
subjects	O
with	O
any	O
missing	O
data	O
.	O

57	O
For	O
the	O
LMM	O
model	O
,	O
Group	O
,	O
Group	O
X	O
week	O
,	O
average	O
baseline	O
pain	O
,	O
and	O
opioid	O
use	O
at	O
baseline	O
(	O
yes	O
/	O
no	O
)	O
were	O
entered	O
as	O
fixed	O
effects	O
using	O
an	O
autoregressive	O
covariance	O
structure	O
.	O

Subject	O
,	O
intercept	O
,	O
and	O
week	O
were	O
entered	O
as	O
random	O
effects	O
,	O
using	O
a	O
compound	O
symmetry	O
covariance	O
structure	O
.	O

This	O
approach	O
controls	O
for	O
possible	O
differences	O
in	O
baseline	O
pain	O
level	O
and	O
opioid	O
use	O
between	O
subjects	O
.	O

To	O
further	O
address	O
the	O
possible	O
impacts	O
of	O
missing	O
data	O
(	O
those	O
who	O
completed	O
at	O
least	O
50	O
%	O
but	O
not	O
100	O
%	O
of	O
the	O
opioid	O
treatment	O
period	O
)	O
we	O
imputed	O
data	O
using	O
Last	O
Observation	O
Carried	O
Forward	O
(	O
LOCF	O
)	O
and	O
Baseline	O
Observation	O
Carried	O
Forward	O
(	O
BOCF	O
)	O
methods	O
as	O
part	O
of	O
a	O
secondary	O
,	O
sensitivity	O
analysis	O
.	O

For	O
LOCF	O
we	O
used	O
the	O
percent	O
improvement	O
in	O
pain	O
for	O
the	O
last	O
week	O
the	O
subject	O
was	O
in	O
the	O
trial	O
during	O
the	O
opioid	O
continuation	O
period	O
,	O
and	O
the	O
first	O
week	O
of	O
this	O
period	O
for	O
the	O
BOCF	O
value	O
.	O

For	O
the	O
secondary	O
outcome	O
of	O
rates	O
of	O
opioid	O
misuse	O
between	O
groups	O
,	O
similar	O
to	O
our	O
previous	O
studies	O
,	O
58	O
,	O
59	O
we	O
determined	O
the	O
Drug	O
Misuse	O
Index	O
(	O
DMI	O
)	O
at	O
2	O
and	O
4	O
months	O
into	O
the	O
opioid	O
continuation	O
period	O
.	O

The	O
DMI	O
triangulates	O
three	O
domains	O
(	O
patient	O
self	O
-	O
report	O
[	O
COMM	O
]	O
,	O
provider	O
assessment	O
of	O
misuse	O
[	O
ABC	O
]	O
,	O
and	O
UDT	O
results	O
)	O
to	O
determine	O
adherence	O
to	O
opioids	O
(	O
adherence	O
vs	O
.	O
misuse	O
,	O
a	O
categorical	O
outcome	O
)	O
.	O

A	O
positive	O
DMI	O
is	O
a	O
positive	O
finding	O
of	O
misuse	O
on	O
any	O
of	O
these	O
3	O
measures	O
.	O

Of	O
note	O
,	O
positive	O
misuse	O
at	O
two	O
and	O
four	O
months	O
was	O
counted	O
as	O
one	O
episode	O
of	O
misuse	O
.	O

Chi	O
square	O
was	O
used	O
to	O
analyze	O
the	O
relationship	O
between	O
group	O
and	O
opioid	O
misuse	O
.	O

Comparisons	O
of	O
demographics	O
,	O
pain	O
history	O
data	O
,	O
baseline	O
questionnaires	O
,	O
and	O
additional	O
secondary	O
outcome	O
measures	O
in	O
relation	O
to	O
group	O
were	O
analyzed	O
using	O
Pearson	O
correlations	O
,	O
Chi	O
-	O
square	O
,	O
and	O
analysis	O
of	O
variance	O
(	O
ANOVA	O
)	O
,	O
depending	O
on	O
whether	O
the	O
variables	O
were	O
ordinal	O
or	O
numerical	O
.	O

Furthermore	O
,	O
sensitivity	O
analyses	O
using	O
analysis	O
of	O
covariance	O
(	O
ANCOVA	O
)	O
were	O
conducted	O
to	O
test	O
if	O
any	O
baseline	O
variables	O
were	O
significant	O
univariate	O
or	O
covariate	O
predictors	O
when	O
added	O
to	O
Group	O
of	O
total	O
average	O
percent	O
improvement	O
in	O
pain	O
during	O
the	O
opioid	O
continuation	O
period	O
.	O

We	O
also	O
analyzed	O
HADS	O
scores	O
as	O
a	O
continuous	O
predictor	O
of	O
pain	O
treatment	O
outcomes	O
.	O

This	O
was	O
a	O
population	O
-	O
based	O
epidemiological	O
cross	O
-	O
sectional	O
study	O
based	O
on	O
death	O
certificates	O
for	O
the	O
study	O
region	O
in	O
2011	O
.	O

The	O
study	O
region	O
included	O
selected	O
urban	O
areas	O
(	O
the	O
cities	O
of	O
Bochum	O
and	O
Münster	O
)	O
and	O
rural	O
areas	O
(	O
the	O
districts	O
of	O
Borken	O
and	O
Coesfeld	O
)	O
in	O
Westphalia–Lippe	O
in	O
the	O
federal	O
state	O
of	O
North	O
Rhine–Westphalia	O
(	O
Germany	O
)	O
.	O

On	O
December	O
31st	O
2010	O
,	O
the	O
study	O
region’s	O
population	O
was	O
1	O
,	O
243	O
,	O
957	O
,	O
representing	O
1	O
.	O
5	O
%	O
of	O
the	O
total	O
population	O
of	O
Germany	O
at	O
that	O
time	O
.	O

The	O
study	O
used	O
a	O
complete	O
dataset	O
of	O
death	O
certificates	O
for	O
the	O
study	O
region	O
.	O

In	O
all	O
,	O
12	O
,	O
914	O
death	O
certificates	O
were	O
available	O
for	O
2011	O
,	O
which	O
were	O
archived	O
in	O
each	O
local	O
public	O
health	O
department	O
and	O
had	O
to	O
be	O
analyzed	O
on	O
site	O
due	O
to	O
data	O
protection	O
regulations	O
.	O

Information	O
was	O
collected	O
about	O
age	O
,	O
sex	O
,	O
time	O
of	O
death	O
,	O
place	O
of	O
death	O
,	O
manner	O
of	O
death	O
,	O
and	O
cause	O
of	O
death	O
.	O

The	O
main	O
focus	O
of	O
the	O
analysis	O
was	O
on	O
the	O
cause	O
of	O
death	O
in	O
patients	O
with	O
dementia	O
.	O

Ten	O
other	O
selected	O
diseases	O
documented	O
by	O
the	O
physicians	O
on	O
the	O
death	O
certificate	O
were	O
also	O
examined	O
:	O
pneumonia	O
,	O
aspiration	O
,	O
sepsis	O
,	O
cardiac	O
failure	O
,	O
myocardial	O
infarction	O
,	O
intracerebral	O
bleeding	O
(	O
ICB	O
)	O
and	O
/	O
or	O
cerebral	O
stroke	O
,	O
malignant	O
neoplasia	O
,	O
chronic	O
obstructive	O
pulmonary	O
disease	O
(	O
COPD	O
)	O
,	O
renal	O
failure	O
,	O
and	O
Parkinson’s	O
disease	O
.	O

As	O
cases	O
of	O
dementia	O
mainly	O
become	O
clinically	O
manifest	O
in	O
the	O
elderly	O
,	O
the	O
analyses	O
was	O
restricted	O
to	O
deceased	O
persons	O
whose	O
age	O
at	O
death	O
was	O
65	O
or	O
over	O
and	O
who	O
had	O
a	O
natural	O
cause	O
of	O
death	O
(	O
n	O
=	O
10	O
,	O
364	O
)	O
.	O

In	O
accordance	O
with	O
German	O
law	O
,	O
all	O
deaths	O
have	O
to	O
be	O
certified	O
by	O
a	O
physician	O
.	O

The	O
form	O
and	O
structure	O
of	O
the	O
death	O
certificate	O
are	O
the	O
responsibility	O
of	O
each	O
federal	O
state	O
in	O
Germany	O
and	O
are	O
not	O
standardized	O
.	O

In	O
all	O
16	O
federal	O
states	O
,	O
however	O
,	O
the	O
question	O
of	O
the	O
cause	O
of	O
death	O
largely	O
follows	O
the	O
scheme	O
set	O
out	O
by	O
the	O
World	O
Health	O
Organization	O
.	O

Efforts	O
have	O
been	O
made	O
to	O
develop	O
a	O
standard	O
federal	O
death	O
certificate	O
,	O
but	O
the	O
project	O
has	O
so	O
far	O
been	O
blocked	O
by	O
several	O
states	O
.	O

It	O
is	O
also	O
intended	O
to	O
introduce	O
an	O
electronic	O
death	O
certificate	O
in	O
Germany	O
,	O
as	O
has	O
been	O
demanded	O
at	O
the	O
European	O
Union	O
level	O
,	O
but	O
this	O
project	O
has	O
not	O
yet	O
been	O
implemented	O
[	O
33	O
]	O
.	O

The	O
present	O
study	O
used	O
death	O
certificates	O
from	O
the	O
state	O
of	O
North	O
Rhine–Westphalia	O
.	O

Documentation	O
of	O
the	O
cause	O
of	O
death	O
is	O
specified	O
as	O
follows	O
here	O
:	O
“Section	O
I	O
,	O
”	O
I	O
.	O
a	O
)	O
“immediate	O
cause	O
of	O
death”	O
—	O
i	O
.	O
e	O
.	O
,	O
the	O
disease	O
that	O
led	O
directly	O
to	O
death	O
;	O
I	O
.	O
b	O
)	O
“this	O
is	O
a	O
result	O
of”	O
—	O
i	O
.	O
e	O
.	O
,	O
a	O
disease	O
that	O
is	O
derived	O
from	O
the	O
underlying	O
condition	O
and	O
causally	O
contributed	O
to	O
the	O
death	O
;	O
I	O
.	O
c	O
)	O
“the	O
underlying	O
cause”	O
—	O
i	O
.	O
e	O
.	O
,	O
the	O
disease	O
causally	O
leading	O
to	O
death	O
and	O
giving	O
rise	O
to	O
the	O
diseases	O
described	O
in	O
I	O
.	O
a	O
and	O
I	O
.	O
b	O
.	O

In	O
addition	O
,	O
the	O
physician	O
is	O
able	O
to	O
record	O
other	O
diseases	O
that	O
were	O
not	O
immediately	O
part	O
of	O
the	O
causal	O
chain	O
leading	O
to	O
the	O
death	O
in	O
“Section	O
II	O
.	O
”	O
The	O
heading	O
“Epicrisis”	O
also	O
provides	O
an	O
opportunity	O
to	O
document	O
additional	O
medical	O
details	O
on	O
the	O
sequence	O
of	O
the	O
disease	O
,	O
accident	O
occurrence	O
,	O
etc	O
.	O

The	O
analysis	O
of	O
death	O
certificates	O
is	O
carried	O
out	O
in	O
a	O
standardized	O
fashion	O
in	O
all	O
federal	O
states	O
.	O

The	O
non	O
-	O
confidential	O
section	O
(	O
time	O
of	O
death	O
,	O
manner	O
of	O
death	O
,	O
place	O
of	O
death	O
)	O
and	O
the	O
confidential	O
section	O
(	O
cause	O
of	O
death	O
)	O
in	O
the	O
medical	O
certificate	O
are	O
first	O
sent	O
to	O
the	O
local	O
civil	O
registry	O
office	O
where	O
the	O
patient	O
was	O
registered	O
with	O
his	O
or	O
her	O
place	O
of	O
residence	O
,	O
and	O
an	O
official	O
death	O
statistic	O
bulletin	O
is	O
drawn	O
up	O
.	O

During	O
this	O
official	O
procedure	O
,	O
the	O
medical	O
information	O
about	O
place	O
of	O
death	O
is	O
unfortunately	O
not	O
included	O
.	O

The	O
death	O
certificate	O
is	O
then	O
sent	O
on	O
to	O
the	O
responsible	O
public	O
health	O
office	O
.	O

There	O
,	O
the	O
medical	O
officer	O
of	O
health	O
checks	O
among	O
other	O
matters	O
whether	O
the	O
stated	O
diagnoses	O
are	O
compatible	O
with	O
the	O
sex	O
and	O
age	O
of	O
the	O
deceased	O
and	O
in	O
general	O
whether	O
sufficient	O
information	O
about	O
the	O
cause	O
of	O
death	O
is	O
given	O
.	O

In	O
a	O
third	O
step	O
,	O
the	O
information	O
is	O
then	O
transferred	O
to	O
the	O
state	O
statistical	O
offices	O
,	O
where	O
it	O
is	O
combined	O
with	O
the	O
death	O
statistic	O
bulletin	O
.	O

Trained	O
signatories	O
once	O
again	O
check	O
the	O
medical	O
details	O
on	O
the	O
cause	O
of	O
death	O
and	O
finally	O
determine	O
the	O
underlying	O
disease	O
in	O
accordance	O
with	O
the	O
regulations	O
in	O
the	O
International	B-coding_system
Statistical	I-coding_system
Classification	I-coding_system
of	I-coding_system
Diseases	I-coding_system
and	I-coding_system
Related	I-coding_system
Health	I-coding_system
Problems	I-coding_system
(	I-coding_system
ICD	I-coding_system
)	I-coding_system
,	O
volume	O
2	O
[	O
34	O
]	O
.	O

This	O
involves	O
monocausal	O
statistics	O
on	O
the	O
cause	O
of	O
death	O
—	O
i	O
.	O
e	O
.	O
,	O
only	O
one	O
underlying	O
disease	O
is	O
recorded	O
and	O
represented	O
(	O
“one	O
cause	O
per	O
death”	O
)	O
.	O

The	O
other	O
diagnoses	O
noted	O
on	O
the	O
death	O
certificate	O
are	O
ignored	O
.	O

Finally	O
,	O
this	O
information	O
is	O
sent	O
to	O
the	O
Federal	O
Office	O
of	O
Statistics	O
,	O
which	O
publishes	O
annually	O
cause	O
-	O
of	O
-	O
death	O
statistics	O
for	O
the	O
whole	O
of	O
Germany	O
.	O

In	O
contrast	O
to	O
the	O
official	O
cause	O
-	O
of	O
-	O
death	O
statistics	O
in	O
Germany	O
,	O
the	O
present	O
study	O
made	O
use	O
of	O
all	O
medical	O
information	O
available	O
on	O
the	O
cause	O
of	O
death	O
(	O
Sections	O
I	O
.	O
a	O
,	O
I	O
.	O
b	O
,	O
I	O
.	O
c	O
,	O
Section	O
II	O
,	O
and	O
epicrisis	O
)	O
in	O
order	O
to	O
identify	O
patients	O
with	O
dementia	O
and	O
other	O
selected	O
diseases	O
.	O

However	O
,	O
the	O
medically	O
documented	O
diagnosis	O
was	O
not	O
further	O
differentiated	O
according	O
to	O
Section	O
I	O
,	O
Section	O
II	O
,	O
or	O
epicrisis	O
.	O

The	O
reason	O
for	O
this	O
was	O
the	O
highly	O
time	O
-	O
consuming	O
logistic	O
effort	O
involved	O
in	O
obtaining	O
the	O
documentation	O
in	O
each	O
local	O
public	O
health	O
office	O
in	O
the	O
study	O
region	O
.	O

In	O
accordance	O
with	O
ICD	B-coding_system
-	I-coding_system
10	I-coding_system
,	O
patients	O
with	O
a	O
dementia	O
-	O
related	O
disease	O
constituted	O
the	O
study	O
population	O
if	O
the	O
medical	O
details	O
on	O
the	O
cause	O
of	O
death	O
were	O
described	O
as	O
follows	O
:	O
Alzheimer’s	B-phenotype
disease	I-phenotype
(	O
F00	B-code
,	O
G30	B-code
)	O
,	O
vascular	B-phenotype
dementia	I-phenotype
(	O
F01	B-code
)	O
,	O
dementia	B-phenotype
in	I-phenotype
other	I-phenotype
diseases	I-phenotype
classified	I-phenotype
elsewhere	I-phenotype
(	O
F02	B-code
)	O
,	O
and	O
unspecified	B-phenotype
dementia	I-phenotype
(	O
F03	B-code
)	O
.	O

All	O
death	O
certificates	O
were	O
analyzed	O
for	O
ten	O
additional	O
comorbid	O
conditions	O
and	O
classified	O
in	O
accordance	O
with	O
ICD	B-coding_system
-	I-coding_system
10	I-coding_system
:	O
pneumonia	B-phenotype
(	O
J12	B-code
.	I-code
0–J18	I-code
.	I-code
9	I-code
)	O
,	O
aspiration	B-phenotype
(	O
J69	B-code
.	I-code
0	I-code
,	O
J60	B-code
.	I-code
1	I-code
,	O
J69	B-code
.	I-code
8	I-code
;	O
J95	B-code
.	I-code
4	I-code
;	O
T17	B-code
.	I-code
2–T17	I-code
.	I-code
9	I-code
)	O
,	O
sepsis	B-phenotype
(	O
A39	B-code
.	I-code
2–39	I-code
.	I-code

4	I-code
,	O
A40	B-code
,	O
A41	B-code
,	O
B37	B-code
.	I-code
7	I-code
,	O
R52	B-code
.	I-code
7	I-code
)	O
,	O
cardiac	B-phenotype
failure	I-phenotype
(	O
I09	B-code
,	O
I25	B-code
.	I-code
1	I-code
,	O
I25	B-code
.	I-code
3–I25	I-code
.	I-code

9	I-code
,	O
I50	B-code
)	O
,	O
myocardial	B-phenotype
infarction	I-phenotype
(	O
I21	B-code
,	O
I22	B-code
,	O
I24	B-code
,	O
I25	B-code
.	I-code
2	I-code
)	O
,	O
intracerebral	B-phenotype
bleeding	I-phenotype
(	I-phenotype
ICB	I-phenotype
)	I-phenotype
or	I-phenotype
cerebral	I-phenotype
stroke	I-phenotype
(	O
I60	B-code
,	O
I61	B-code
,	O
I62	B-code
,	O
I63	B-code
,	O
I64	B-code
,	O
I69	B-code
)	O
,	O
malignant	B-phenotype
neoplasia	I-phenotype
(	O
C00–C97	B-code
)	O
,	O
chronic	B-phenotype
obstructive	I-phenotype
pulmonary	I-phenotype
disease	I-phenotype
(	I-phenotype
COPD	I-phenotype
)	I-phenotype
(	O
J41	B-code
,	O
J42	B-code
,	O
J44	B-code
)	O
,	O
renal	B-phenotype
failure	I-phenotype
(	O
N17	B-code
,	O
N18	B-code
,	O
N19	B-code
)	O
,	O
and	O
Parkinson’s	B-phenotype
disease	I-phenotype
(	O
G20	B-code
)	O
.	O

The	O
place	O
of	O
death	O
was	O
classified	O
in	O
the	O
study	O
as	O
home	O
environment	O
,	O
hospital	O
,	O
palliative	O
care	O
unit	O
,	O
retirement	O
home	O
or	O
nursing	O
home	O
,	O
hospice	O
,	O
and	O
other	O
locations	O
.	O

The	O
category	O
“home	O
environment”	O
combined	O
the	O
deceased	O
person’s	O
private	O
residence	O
as	O
well	O
as	O
other	O
private	O
homes	O
that	O
were	O
not	O
the	O
home	O
of	O
the	O
deceased	O
individual	O
.	O

Hospitals	O
,	O
psychiatric	O
clinics	O
,	O
and	O
sanatoriums	O
were	O
included	O
under	O
“hospital”	O
as	O
place	O
of	O
death	O
.	O

Palliative	O
care	O
units	O
were	O
counted	O
as	O
a	O
separate	O
place	O
of	O
death	O
.	O

The	O
category	O
“retirement	O
or	O
nursing	O
home”	O
included	O
all	O
institutions	O
involving	O
old	O
age	O
homes	O
,	O
retirement	O
homes	O
,	O
geriatric	O
care	O
homes	O
,	O
sheltered	O
housing	O
,	O
and	O
short	O
-	O
term	O
care	O
.	O

“Other	O
locations”	O
represented	O
other	O
public	O
areas	O
,	O
family	O
physicians’	O
practices	O
,	O
and	O
leisure	O
centers	O
.	O

To	O
assess	O
the	O
prevalence	O
,	O
the	O
absolute	O
number	O
of	O
individuals	O
aged	O
65	O
or	O
over	O
with	O
a	O
dementia	O
-	O
related	O
disease	O
was	O
counted	O
and	O
related	O
to	O
the	O
overall	O
number	O
of	O
deaths	O
in	O
that	O
age	O
group	O
(	O
relative	O
frequency	O
)	O
.	O

An	O
analysis	O
stratified	O
by	O
sex	O
and	O
specific	O
age	O
groups	O
(	O
65–69	O
,	O
70–74	O
,	O
75–79	O
,	O
80–84	O
,	O
85–89	O
,	O
90–94	O
,	O
≥	O
95	O
years	O
)	O
was	O
also	O
carried	O
out	O
.	O

In	O
addition	O
,	O
the	O
data	O
were	O
subjected	O
to	O
direct	O
age	O
standardization	O
.	O

For	O
this	O
purpose	O
,	O
the	O
age	O
-	O
specific	O
mortality	O
rate	O
in	O
the	O
study	O
population	O
was	O
calculated	O
,	O
weighted	O
with	O
the	O
age	O
-	O
specific	O
rate	O
in	O
a	O
standard	O
population	O
,	O
and	O
added	O
up	O
.	O

The	O
“Old	O
European	O
Standard	O
Population”	O
was	O
used	O
as	O
the	O
standard	O
population	O
.	O

The	O
characteristics	O
of	O
the	O
study	O
population	O
were	O
listed	O
by	O
sex	O
,	O
age	O
,	O
selected	O
comorbidities	O
and	O
number	O
of	O
comorbidities	O
(	O
no	O
.	O
:	O
1	O
,	O
2	O
,	O
3	O
,	O
4	O
,	O
≥	O
5	O
)	O
,	O
and	O
a	O
subdivision	O
relative	O
to	O
place	O
of	O
death	O
was	O
also	O
carried	O
out	O
.	O

It	O
was	O
investigated	O
whether	O
individuals	O
who	O
died	O
at	O
home	O
with	O
dementia	O
differed	O
significantly	O
from	O
those	O
with	O
a	O
different	O
place	O
of	O
death	O
(	O
hospital	O
,	O
palliative	O
care	O
unit	O
,	O
retirement	O
or	O
nursing	O
home	O
,	O
hospice	O
,	O
other	O
location	O
,	O
no	O
details	O
)	O
.	O

For	O
this	O
purpose	O
,	O
unpaired	O
t	O
-	O
tests	O
were	O
used	O
for	O
continuous	O
data	O
and	O
the	O
chi	O
-	O
squared	O
test	O
for	O
categorical	O
data	O
,	O
or	O
in	O
the	O
case	O
of	O
cell	O
numbers	O
fewer	O
than	O
five	O
,	O
Fisher’s	O
exact	O
test	O
was	O
used	O
.	O

Places	O
of	O
death	O
were	O
represented	O
using	O
absolute	O
and	O
relative	O
frequencies	O
,	O
and	O
sex	O
-	O
specific	O
differences	O
were	O
tested	O
using	O
the	O
chi	O
-	O
squared	O
test	O
.	O

As	O
no	O
deaths	O
at	O
“other	O
places”	O
were	O
observed	O
,	O
that	O
category	O
was	O
not	O
listed	O
further	O
in	O
the	O
results	O
.	O

An	O
association	O
between	O
“explanatory	O
factors”	O
and	O
the	O
dependent	O
variable	O
“place	O
of	O
death”	O
was	O
tested	O
using	O
a	O
multivariate	O
logic	O
regression	O
model	O
.	O

The	O
target	O
variable	O
“home”	O
(	O
0	O
)	O
was	O
investigated	O
relative	O
to	O
the	O
place	O
of	O
death	O
“hospital”	O
(	O
1	O
)	O
and	O
the	O
place	O
of	O
death	O
“retirement	O
or	O
nursing	O
home”	O
(	O
1	O
)	O
;	O
in	O
a	O
second	O
step	O
,	O
the	O
place	O
of	O
death	O
“retirement	O
or	O
nursing	O
home”	O
(	O
0	O
)	O
was	O
investigated	O
relative	O
to	O
the	O
places	O
of	O
death	O
“hospital”	O
(	O
1	O
)	O
.	O

Due	O
to	O
very	O
low	O
results	O
,	O
the	O
places	O
of	O
death	O
“palliative	O
care	O
unit”	O
(	O
n	O
=	O
6	O
)	O
and	O
“hospice”	O
(	O
n	O
=	O
14	O
)	O
were	O
not	O
subjected	O
to	O
multivariate	O
regression	O
analysis	O
.	O

“Independent	O
factors”	O
were	O
sex	O
(	O
women	O
(	O
1	O
)	O
vs	O
.	O
men	O
(	O
0	O
)	O
)	O
and	O
the	O
median	O
age	O
of	O
the	O
deceased	O
persons	O
(	O
≥	O
86	O
.	O
7	O
y	O
(	O
1	O
)	O
vs	O
.	O
<	O
86	O
.	O
7	O
y	O
(	O
0	O
)	O
)	O
.	O

In	O
addition	O
,	O
the	O
multivariate	O
regression	O
model	O
considered	O
all	O
ten	O
comorbidities	O
—	O
pneumonia	O
,	O
aspiration	O
,	O
sepsis	O
,	O
cardiac	O
failure	O
,	O
myocardial	O
infarction	O
,	O
intracerebral	O
bleeding	O
(	O
ICB	O
)	O
or	O
cerebral	O
stroke	O
,	O
malignant	O
tumour	O
,	O
chronic	O
obstructive	O
pulmonary	O
disease	O
(	O
COPD	O
)	O
,	O
renal	O
failure	O
,	O
and	O
Parkinson’s	O
disease	O
.	O

The	O
process	O
of	O
modeling	O
followed	O
primarily	O
clinical	O
aspects	O
.	O

The	O
aim	O
was	O
to	O
analyze	O
the	O
statistical	O
impact	O
of	O
each	O
explanatory	O
variable	O
(	O
sex	O
,	O
age	O
,	O
diseases	O
)	O
on	O
the	O
dependent	O
variable	O
“place	O
of	O
death”	O
.	O

Accordingly	O
,	O
we	O
used	O
a	O
block	O
method	O
and	O
not	O
a	O
stepwise	O
regression	O
procedure	O
(	O
forward	O
selection	O
or	O
backward	O
elimination	O
)	O
.	O

Under	O
these	O
conditions	O
,	O
we	O
accepted	O
a	O
possibly	O
poorer	O
adjustment	O
of	O
the	O
statistical	O
model	O
.	O

Odds	O
ratios	O
with	O
95	O
%	O
confidence	O
intervals	O
were	O
generated	O
from	O
this	O
model	O
.	O

The	O
Wald	O
test	O
was	O
used	O
to	O
examine	O
whether	O
the	O
independent	O
variable	O
had	O
any	O
significant	O
influence	O
on	O
the	O
target	O
variable	O
.	O

The	O
quality	O
of	O
the	O
statistical	O
model	O
was	O
expressed	O
using	O
Nagelkerke	O
pseudo	O
-	O
R	O
2	O
coefficients	O
.	O

To	O
minimize	O
the	O
global	O
increase	O
in	O
the	O
probability	O
of	O
alpha	O
error	O
due	O
to	O
multiple	O
testing	O
of	O
the	O
same	O
sample	O
,	O
the	O
significance	O
level	O
was	O
set	O
at	O
p	O
<	O
0	O
.	O
01	O
(	O
two	O
-	O
sided	O
)	O
.	O

All	O
analyses	O
were	O
carried	O
out	O
using	O
the	O
statistics	O
program	O
IBM	O
SPSS	O
Statistics	O
,	O
version	O
23	O
.	O

The	O
study	O
was	O
submitted	O
to	O
the	O
Ethics	O
Committee	O
of	O
the	O
Ruhr	O
University	O
of	O
Bochum	O
and	O
approved	O
after	O
examination	O
(	O
registry	O
no	O
.	O

4522	O
-	O
12	O
)	O
.	O

Letters	O
were	O
sent	O
to	O
the	O
public	O
health	O
offices	O
requesting	O
access	O
to	O
the	O
death	O
certificates	O
archived	O
there	O
.	O

Permission	O
to	O
collect	O
data	O
and	O
carry	O
out	O
the	O
scientific	O
analysis	O
,	O
while	O
observing	O
legal	O
data	O
protection	O
regulations	O
,	O
was	O
officially	O
granted	O
.	O

The	O
data	O
had	O
to	O
be	O
recorded	O
locally	O
in	O
the	O
public	O
health	O
offices	O
.	O

This	O
research	O
utilizes	O
data	O
from	O
the	O
Veterans	O
Aging	O
Cohort	O
Study	O
(	O
VACS	O
)	O
;	O
detailed	O
data	O
collection	O
and	O
survey	O
methodology	O
for	O
VACS	O
are	O
described	O
elsewhere	O
(	O
25	O
–	O
31	O
)	O
.	O

The	O
VACS	O
is	O
an	O
ongoing	O
,	O
prospective	O
cohort	O
study	O
of	O
HIV	O
-	O
infected	O
and	O
uninfected	O
veterans	O
receiving	O
medical	O
care	O
at	O
8	O
Veterans	O
Health	O
Administration	O
(	O
VHA	O
)	O
sites	O
located	O
throughout	O
the	O
United	O
States	O
.	O

Since	O
June	O
2002	O
,	O
VACS	O
has	O
enrolled	O
over	O
7	O
,	O
000	O
patients	O
from	O
the	O
infectious	O
disease	O
or	O
general	O
medical	O
clinics	O
in	O
Atlanta	O
,	O
Baltimore	O
,	O
Houston	O
,	O
Los	O
Angeles	O
,	O
Pittsburgh	O
,	O
Washington	O
D	O
.	O
C	O
.	O
,	O
and	O
multiple	O
sites	O
in	O
New	O
York	O
City	O
.	O

Participants	O
in	O
VACS	O
are	O
similar	O
to	O
other	O
veterans	O
receiving	O
care	O
within	O
the	O
VA	O
,	O
with	O
the	O
exception	O
of	O
participants	O
being	O
older	O
and	O
more	O
predominantly	O
black	O
(	O
30	O
)	O
.	O

This	O
comprehensive	O
,	O
longitudinal	O
database	O
contains	O
variables	O
from	O
surveys	O
completed	O
approximately	O
every	O
18	O
months	O
,	O
available	O
from	O
2002	O
-	O
2012	O
.	O

The	O
survey	O
data	O
is	O
also	O
linked	O
to	O
robust	O
VA	O
electronic	O
medical	O
records	O
(	O
EMR	O
)	O
containing	O
data	O
on	O
prescribed	O
medications	O
,	O
medical	O
and	O
substance	O
use	O
diagnoses	O
,	O
and	O
laboratory	O
results	O
for	O
each	O
patient	O
.	O

The	O
VACS	O
was	O
approved	O
by	O
the	O
institutional	O
review	O
boards	O
at	O
each	O
participating	O
VHA	O
Medical	O
Center	O
and	O
affiliated	O
academic	O
institutions	O
.	O

The	O
flow	O
chart	O
illustrating	O
the	O
selection	O
of	O
eligible	O
participants	O
is	O
illustrated	O
in	O
Figure	O
1	O
.	O

Of	O
7	O
,	O
324	O
potentially	O
eligible	O
VACS	O
participants	O
,	O
2	O
,	O
792	O
(	O
38	O
.	O
1	O
%	O
)	O
were	O
excluded	O
since	O
they	O
reported	O
“yes”	O
to	O
ever	O
using	O
a	O
prescription	O
opioid	O
non	O
-	O
medically	O
or	O
heroin	O
use	O
at	O
baseline	O
.	O

Of	O
these	O
participants	O
,	O
we	O
excluded	O
those	O
who	O
reported	O
any	O
injection	O
drug	O
use	O
at	O
baseline	O
,	O
or	O
who	O
were	O
previously	O
diagnosed	O
with	O
opioid	B-Phenotype
dependence	I-Phenotype
based	O
on	O
linked	O
EMR	O
records	O
(	O
ICD	B-Coding_system
-	I-Coding_system
9	I-Coding_system
code	O
304	B-Code
.	I-Code
0	I-Code
)	O
(	O
n=	O
399	O
)	O
.	O

Finally	O
,	O
we	O
excluded	O
participants	O
who	O
were	O
missing	O
or	O
had	O
invalid	O
NMUPO	O
and	O
heroin	O
use	O
responses	O
in	O
all	O
five	O
follow	O
-	O
up	O
surveys	O
(	O
n	O
=	O
186	O
)	O
or	O
only	O
completed	O
the	O
baseline	O
survey	O
(	O
n=551	O
)	O
.	O

Using	O
data	O
from	O
the	O
VHA	O
Patient	O
Treatment	O
File	O
,	O
the	O
Beneficiary	O
Identification	O
Records	O
Locating	O
System	O
(	O
which	O
tracks	O
VHA	O
death	O
benefits	O
,	O
the	O
Medicare	O
Vital	O
Status	O
file	O
,	O
and	O
the	O
Social	O
Security	O
National	O
Death	O
index	O
,	O
we	O
identified	O
203	O
(	O
36	O
.	O
9	O
%	O
)	O
deaths	O
among	O
those	O
participants	O
who	O
only	O
completed	O
the	O
baseline	O
survey	O
.	O

We	O
compared	O
the	O
characteristics	O
of	O
those	O
who	O
did	O
not	O
complete	O
at	O
least	O
one	O
follow	O
-	O
up	O
visit	O
due	O
to	O
death	O
or	O
other	O
reasons	O
with	O
those	O
who	O
were	O
eligible	O
(	O
see	O
Supplemental	O
File	O
)	O
.	O

We	O
accounted	O
for	O
biases	O
arising	O
from	O
potential	O
differential	O
loss	O
to	O
follow	O
-	O
up	O
in	O
weighted	O
statistical	O
analyses	O
(	O
see	O
below	O
)	O
.	O

The	O
final	O
analytic	O
sample	O
consisted	O
of	O
3	O
,	O
396	O
veterans	O
.	O

We	O
operationalized	O
the	O
main	O
exposure	O
of	O
NMUPO	O
using	O
responses	O
to	O
two	O
different	O
survey	O
questions	O
.	O

In	O
the	O
first	O
two	O
of	O
five	O
survey	O
waves	O
,	O
participants	O
were	O
shown	O
a	O
list	O
of	O
the	O
following	O
substances	O
:	O
“marijuana	O
,	O
cocaine	O
/	O
crack	O
,	O
stimulants	O
,	O
heroin	O
,	O
and	O
prescription	O
opioids	O
(	O
morphine	O
,	O
codeine	O
,	O
Vicodin	O
,	O
Percocet	O
,	O
OxyContin	O
)	O
”	O
and	O
asked	O
“For	O
each	O
of	O
the	O
following	O
drugs	O
,	O
please	O
fill	O
in	O
the	O
oval	O
that	O
best	O
indicates	O
how	O
often	O
in	O
the	O
past	O
12	O
months	O
you	O
have	O
used	O
each	O
drug	O
.	O
”	O
Those	O
participants	O
who	O
reported	O
any	O
use	O
of	O
prescription	O
opioids	O
were	O
categorized	O
as	O
reporting	O
NMUPO	O
.	O

In	O
the	O
final	O
three	O
follow	O
-	O
up	O
survey	O
waves	O
participants	O
were	O
asked	O
,	O
“Now	O
think	O
only	O
about	O
the	O
past	O
12	O
months	O
.	O

On	O
average	O
,	O
how	O
many	O
days	O
each	O
week	O
in	O
the	O
past	O
12	O
months	O
did	O
you	O
use	O
any	O
prescription	O
pain	O
reliever	O
that	O
was	O
not	O
prescribed	O
for	O
you	O
or	O
that	O
you	O
took	O
only	O
for	O
the	O
experience	O
or	O
feeling	O
that	O
it	O
caused	O
(	O
32	O
)	O
?	O
”	O
Again	O
,	O
participants	O
reporting	O
any	O
frequency	O
of	O
use	O
were	O
categorized	O
as	O
reporting	O
NMUPO	O
.	O

Participants	O
who	O
experienced	O
the	O
outcome	O
of	O
interest	O
(	O
i	O
.	O
e	O
.	O
,	O
heroin	O
initiation	O
)	O
in	O
the	O
same	O
year	O
that	O
they	O
initiated	O
NMUPO	O
were	O
included	O
in	O
the	O
analysis	O
;	O
thus	O
,	O
new	O
onset	O
NMUPO	O
was	O
considered	O
to	O
occur	O
prior	O
to	O
or	O
concurrently	O
with	O
heroin	O
initiation	O
.	O

Self	O
-	O
reported	O
heroin	O
initiation	O
was	O
ascertained	O
based	O
on	O
respondent	O
endorsement	O
of	O
following	O
time	O
-	O
updated	O
survey	O
item	O
:	O
“How	O
often	O
in	O
the	O
past	O
year	O
have	O
you	O
used	O
each	O
drug	O
–	O
Heroin	O
?	O
”	O
A	O
heroin	O
initiation	O
event	O
was	O
defined	O
as	O
change	O
in	O
respondent	O
'	O
s	O
answer	O
to	O
the	O
previous	O
survey	O
question	O
from	O
“Never”	O
,	O
to	O
a	O
response	O
indicating	O
some	O
frequency	O
of	O
heroin	O
use	O
in	O
the	O
previous	O
year	O
.	O

Selection	O
of	O
other	O
independent	O
variables	O
and	O
potential	O
confounders	O
of	O
the	O
relationship	O
between	O
NMUPO	O
and	O
heroin	O
initiation	O
were	O
chosen	O
for	O
analysis	O
based	O
on	O
the	O
extant	O
literature	O
(	O
22	O
,	O
28	O
,	O
33	O
–	O
36	O
)	O
.	O

Demographic	O
and	O
clinical	O
characteristics	O
were	O
ascertained	O
from	O
the	O
baseline	O
survey	O
data	O
and	O
included	O
age	O
,	O
sex	O
,	O
race	O
,	O
marital	O
status	O
,	O
and	O
gross	O
annual	O
income	O
.	O

HIV	O
status	O
was	O
identified	O
using	O
VA	O
Immunology	O
Case	O
Registry	O
and	O
hepatitis	B-Phenotype
C	I-Phenotype
virus	I-Phenotype
status	I-Phenotype
was	O
determined	O
using	O
ICD	B-Coding_system
-	I-Coding_system
9	I-Coding_system
codes	O
and	O
laboratory	O
data	O
.	O

Previous	O
posttraumatic	O
stress	O
disorder	O
(	O
PTSD	O
)	O
and	O
depression	O
diagnoses	O
were	O
ascertained	O
from	O
the	O
following	O
questions	O
:	O
“has	O
the	O
doctor	O
ever	O
told	O
you	O
that	O
you	O
have	O
PTSD	O
?	O
”	O
and	O
“has	O
the	O
doctor	O
ever	O
told	O
you	O
that	O
you	O
have	O
depression	O
?	O
”	O
Pain	O
interference	O
in	O
daily	O
life	O
was	O
ascertained	O
from	O
responses	O
to	O
the	O
following	O
time	O
-	O
updated	O
survey	O
item	O
:	O
“During	O
the	O
past	O
4	O
weeks	O
,	O
how	O
much	O
did	O
pain	O
interfere	O
with	O
your	O
normal	O
work	O
(	O
including	O
both	O
work	O
outside	O
the	O
home	O
and	O
housework	O
)	O
(	O
37	O
)	O
?	O
”	O
The	O
response	O
options	O
for	O
this	O

question	O
included	O
a	O
scale	O
from	O
“not	O
at	O
all”	O
to	O
“extremely”	O
,	O
which	O
we	O
dichotomized	O
into	O
“no	O
interference”	O
(	O
“not	O
at	O
all”	O
)	O
and	O
“any	O
interference”	O
(	O
any	O
other	O
response	O
)	O
.	O

Past	O
-	O
year	O
use	O
of	O
marijuana	O
,	O
cocaine	O
and	O
methamphetamines	O
was	O
dichotomized	O
as	O
yes	O
/	O
no	O
.	O

Alcohol	O
use	O
was	O
characterized	O
using	O
the	O
Alcohol	O
Use	O
Disorders	O
Identification	O
Test	O
(	O
AUDIT	O
)	O
;	O
a	O
score	O
of	O
4	O
and	O
above	O
indicated	O
unhealthy	O
alcohol	O
use	O
for	O
men	O
,	O
and	O
a	O
threshold	O
of	O
3	O
for	O
women	O
(	O
38	O
)	O
.	O

Responses	O
to	O
questions	O
regarding	O
substance	O
use	O
(	O
including	O
marijuana	O
,	O
cocaine	O
,	O
and	O
methamphetamines	O
)	O
,	O
unhealthy	O
alcohol	O
use	O
,	O
prior	O
PTSD	O
and	O
depression	O
diagnoses	O
,	O
and	O
pain	O
interference	O
in	O
daily	O
life	O
were	O
updated	O
at	O
each	O
survey	O
and	O
were	O
considered	O
time	O
-	O
dependent	O
covariates	O
.	O

Consistent	O
with	O
prior	O
methods	O
,	O
receipt	O
of	O
outpatient	O
prescribed	O
opioids	O
from	O
the	O
VHA	O
was	O
ascertained	O
from	O
linked	O
pharmacy	O
records	O
,	O
and	O
long	O
-	O
term	O
prescription	O
opioid	O
use	O
was	O
defined	O
as	O
≥90	O
days	O
of	O
continuous	O
use	O
allowing	O
for	O
a	O
30	O
day	O
gap	O
between	O
fill	O
and	O
refill	O
(	O
27	O
,	O
29	O
,	O
39	O
)	O
.	O

We	O
created	O
a	O
time	O
-	O
updated	O
variable	O
for	O
past	O
year	O
receipt	O
of	O
prescription	O
opioids	O
for	O
each	O
wave	O
of	O
data	O
,	O
and	O
categorized	O
it	O
into	O
“none”	O
,	O
“short	O
-	O
term”	O
,	O
and	O
“long	O
-	O
term”	O
.	O

First	O
,	O
we	O
used	O
chi	O
-	O
square	O
tests	O
to	O
examine	O
the	O
baseline	O
correlates	O
of	O
heroin	O
initiation	O
.	O

Additionally	O
,	O
in	O
a	O
post	O
hoc	O
analysis	O
,	O
we	O
examined	O
interaction	O
terms	O
between	O
NMUPO	O
and	O
race	O
.	O

Next	O
,	O
unadjusted	O
Kaplan–Meier	O
analysis	O
and	O
the	O
log	O
-	O
rank	O
test	O
were	O
used	O
to	O
calculate	O
the	O
incidence	O
of	O
heroin	O
initiation	O
and	O
compare	O
time	O
to	O
heroin	O
use	O
,	O
stratifying	O
by	O
prior	O
or	O
concurrent	O
NMUPO	O
.	O

To	O
analyze	O
the	O
factors	O
associated	O
with	O
heroin	O
initiation	O
,	O
we	O
used	O
Cox	O
proportional	O
hazards	O
regression	O
to	O
estimate	O
crude	O
hazard	O
ratios	O
(	O
CHRs	O
)	O
and	O
95	O
%	O
confidence	O
intervals	O
(	O
CI	O
)	O
for	O
each	O
variable	O
.	O

To	O
determine	O
the	O
independent	O
relationship	O
between	O
new	O
onset	O
NMUPO	O
and	O
heroin	O
initiation	O
,	O
we	O
then	O
constructed	O
a	O
multivariable	O
Cox	O
model	O
,	O
including	O
all	O
variables	O
assessed	O
in	O
bivariable	O
analyses	O
.	O

All	O
variables	O
were	O
found	O
to	O
meet	O
the	O
proportional	O
hazards	O
assumption	O
for	O
the	O
Cox	O
regression	O
models	O
(	O
i	O
.	O
e	O
.	O
,	O
none	O
exhibited	O
significant	O
deviance	O
from	O
this	O
assumption	O
at	O
p	O
<	O
0	O
.	O
05	O
)	O
(	O
40	O
)	O
.	O

We	O
created	O
inverse	O
probability	O
of	O
censoring	O
weights	O
(	O
IPCWs	O
)	O
to	O
account	O
for	O
potential	O
biases	O
arising	O
from	O
differential	O
dropout	O
(	O
41	O
)	O
.	O

The	O
use	O
of	O
IPCW	O
re	O
-	O
weights	O
the	O
sample	O
such	O
that	O
the	O
contribution	O
of	O
participants	O
who	O
remain	O
in	O
the	O
study	O
,	O
but	O
who	O
share	O
characteristics	O
of	O
those	O
who	O
dropout	O
,	O
are	O
inflated	O
(	O
42	O
)	O
.	O

Weights	O
were	O
obtained	O
through	O
fitting	O
a	O
weighted	O
pooled	O
logistic	O
regression	O
model	O
for	O
dropout	O
,	O
including	O
baseline	O
and	O
time	O
varying	O
predictors	O
of	O
dropping	O
out	O
.	O

We	O
included	O
a	O
robust	O
sandwich	O
estimator	O
in	O
all	O
Cox	O
regression	O
models	O
to	O
account	O
for	O
potential	O
clustering	O
heterogeneity	O
by	O
study	O
site	O
(	O
43	O
)	O
.	O

Analyses	O
were	O
conducted	O
using	O
SAS	O
version	O
9	O
.	O
4	O
.	O

In	O
order	O
to	O
assess	O
the	O
validity	O
of	O
our	O
exclusion	O
criteria	O
and	O
ensure	O
to	O
our	O
sample	O
was	O
restricted	O
to	O
heroin	O
naïve	O
participants	O
,	O
we	O
re	O
-	O
ran	O
the	O
adjusted	O
Cox	O
regression	O
model	O
excluding	O
those	O
participants	O
who	O
were	O
HCV	O
positive	O
at	O
baseline	O
(	O
n	O
=	O
701	O
)	O
,	O
under	O
the	O
assumption	O
that	O
the	O
majority	O
could	O
have	O
contracted	O
HCV	O
via	O
injecting	O
.	O

This	O
is	O
a	O
secondary	O
analysis	O
of	O
data	O
from	O
the	O
“Proactive	O
Smoking	O
Cessation	O
Treatment	O
for	O
Minnesota	O
Priority	O
Populations”	O
(	O
OPTIN	O
)	O
study	O
(	O
N=2406	O
)	O
(	O
Fu	O
et	O
al	O
.	O
,	O
2014	O
)	O
.	O

This	O
study	O
was	O
a	O
two	O
-	O
arm	O
randomized	O
controlled	O
trial	O
conducted	O
among	O
a	O
sample	O
of	O
smokers	O
enrolled	O
in	O
Minnesota	O
Health	O
Care	O
Programs	O
(	O
MHCP	O
)	O
,	O
which	O
is	O
a	O
state	O
-	O
funded	O
health	O
insurance	O
plan	O
for	O
low	O
-	O
income	O
persons	O
.	O

As	O
described	O
previously	O
,	O
this	O
study	O
demonstrated	O
the	O
effectiveness	O
of	O
proactive	O
outreach	O
relative	O
to	O
usual	O
care	O
for	O
boosting	O
rates	O
of	O
6	O
-	O
month	O
prolonged	O
smoking	O
abstinence	O
(	O
Fu	O
et	O
al	O
.	O
,	O
2016	O
)	O
.	O

The	O
study	O
population	O
sample	O
was	O
stratified	O
by	O
insurance	O
program	O
(	O
Medicaid	O
or	O
MinnesotaCare	O
)	O
,	O
age	O
group	O
(	O
18–24	O
,	O
25–34	O
,	O
35–64	O
)	O
,	O
and	O
sex	O
(	O
male	O
or	O
female	O
)	O
.	O

MHCP	O
insurance	O
claims	O
drawn	O
from	O
a	O
2	O
-	O
year	O
period	O
prior	O
to	O
study	O
initiation	O
were	O
used	O
to	O
obtain	O
ICD	B-coding_system
-	I-coding_system
9	I-coding_system
codes	O
for	O
participants	O
in	O
both	O
the	O
usual	O
care	O
condition	O
and	O
proactive	O
outreach	O
condition	O
.	O

Participants	O
with	O
ICD	B-coding_system
-	I-coding_system
9	I-coding_system
codes	O
indicative	O
of	O
schizophrenia	B-phenotype
spectrum	I-phenotype
disorders	I-phenotype
,	I-phenotype
psychotic	I-phenotype
disorders	I-phenotype
,	I-phenotype
bipolar	I-phenotype
I	I-phenotype
and	I-phenotype
II	I-phenotype
disorders	I-phenotype
,	I-phenotype
or	I-phenotype
severe	I-phenotype
/	I-phenotype
recurrent	I-phenotype
major	I-phenotype
depressive	I-phenotype
disorder	I-phenotype
were	O
categorized	O
as	O
having	O
SMI	O
(	O
n=939	O
)	O
.	O

Participants	O
without	O
one	O
of	O
these	O
codes	O
were	O
categorized	O
as	O
not	O
having	O
SMI	O
(	O
n=1382	O
)	O
,	O
and	O
those	O
who	O
did	O
not	O
have	O
insurance	O
claims	O
data	O
for	O
the	O
2	O
-	O
period	O
period	O
prior	O
to	O
study	O
initiation	O
were	O
not	O
included	O
in	O
these	O
analyses	O
(	O
n=85	O
)	O
.	O

The	O
OPTIN	O
study	O
was	O
approved	O
by	O
the	O
Institutional	O
Review	O
Boards	O
at	O
the	O
University	O
of	O
Minnesota	O
and	O
the	O
Minnesota	O
Department	O
of	O
Human	O
Services	O
(	O
DHS	O
)	O
,	O
and	O
all	O
participants	O
provided	O
informed	O
consent	O
prior	O
to	O
enrollment	O
.	O

The	O
demographic	O
measures	O
of	O
insurance	O
program	O
,	O
age	O
,	O
and	O
sex	O
were	O
drawn	O
from	O
MHCP	O
administrative	O
and	O
claims	O
data	O
,	O
as	O
were	O
the	O
ICD	B-coding_system
-	I-coding_system
9	I-coding_system
codes	O
used	O
to	O
assess	O
participants’	B-phenotype
mental	I-phenotype
health	I-phenotype
diagnoses	I-phenotype
.	O

All	O
remaining	O
measures	O
were	O
obtained	O
from	O
the	O
OPTIN	O
baseline	O
and	O
12	O
-	O
month	O
follow	O
-	O
up	O
surveys	O
.	O

A	O
self	O
-	O
report	O
measure	O
was	O
used	O
to	O
assess	O
6	O
-	O
month	O
prolonged	O
smoking	O
abstinence	O
at	O
12	O
-	O
month	O
follow	O
-	O
up	O
(	O
Hughes	O
et	O
al	O
.	O
,	O
2003	O
)	O
.	O

Participants	O
were	O
asked	O
whether	O
they	O
had	O
smoked	O
1	O
)	O
at	O
least	O
once	O
on	O
7	O
-	O
consecutive	O
days	O
,	O
or	O
2	O
)	O
at	O
least	O
once	O
on	O
2	O
-	O
consecutive	O
weekends	O
in	O
the	O
6	O
-	O
month	O
period	O
prior	O
to	O
the	O
follow	O
-	O
up	O
survey	O
.	O

Those	O
who	O
responded	O
yes	O
to	O
either	O
question	O
was	O
considered	O
continuing	O
smokers	O
.	O

Insurance	O
program	O
,	O
age	O
,	O
sex	O
,	O
race	O
/	O
ethnicity	O
,	O
education	O
,	O
employment	O
status	O
,	O
and	O
yearly	O
income	O
were	O
assessed	O
.	O

Participants	O
with	O
an	O
ICD	B-coding_system
-	I-coding_system
9	I-coding_system
code	O
in	O
the	O
range	O
of	O
303	B-code
.	I-code
90–303	I-code
.	I-code

99	I-code
were	O
considered	O
to	O
have	O
alcohol	B-phenotype
dependence	I-phenotype
.	O

An	O
item	O
from	O
the	O
Behavioral	O
Risk	O
Factor	O
Surveillance	O
System	O
(	O
BRFSS	O
)	O
was	O
used	O
to	O
assess	O
binge	O
drinking	O
asking	O
on	O
how	O
many	O
days	O
in	O
the	O
past	O
30	O
the	O
participant	O
had	O
consumed	O
5	O
or	O
more	O
drinks	O
(	O
4	O
or	O
more	O
drinks	O
for	O
women	O
)	O
(	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
(	O
CDC	O
)	O
,	O
2010	O
)	O
.	O

Participants	O
were	O
placed	O
into	O
“0	O
days”	O
,	O
“1	O
day”	O
,	O
“2–3	O
days”	O
,	O
or	O
“more	O
than	O
3	O
days”	O
categories	O
.	O

Items	O
from	O
the	O
BRFSS	O
were	O
also	O
used	O
to	O
assess	O
the	O
number	O
of	O
drinking	O
days	O
in	O
the	O
past	O
30	O
days	O
,	O
and	O
the	O
number	O
of	O
drinks	O
consumed	O
on	O
a	O
typical	O
occasion	O
in	O
the	O
past	O
30	O
days	O
.	O

Participants	O
with	O
at	O
least	O
one	O
ICD	B-coding_system
-	I-coding_system
9	I-coding_system
code	O
in	O
the	O
range	O
of	O
1	O
)	O
295	B-code
.	I-code
00–295	I-code
.	I-code

94	I-code
were	O
considered	O
to	O
have	O
a	O
schizophrenia	B-phenotype
spectrum	I-phenotype
disorder	I-phenotype
,	O
2	O
)	O
297	B-code
.	I-code
00–298	I-code
.	I-code

90	I-code
were	O
considered	O
to	O
have	O
a	O
psychotic	B-phenotype
disorder	I-phenotype
,	O
3	O
)	O
296	B-code
.	I-code
23–296	I-code
.	I-code

25	I-code
and	O
/	O
or	O
296	B-code
.	I-code
3–296	I-code
.	I-code

36	I-code
were	O
considered	O
to	O
have	O
severe	B-phenotype
or	I-phenotype
recurrent	I-phenotype
major	I-phenotype
depressive	I-phenotype
disorder	I-phenotype
,	O
4	O
)	O
296	B-code
.	I-code
00–296	I-code
.	I-code

13	I-code
and	O
/	O
or	O
296	B-code
.	I-code
4–296	I-code
.	I-code

9	I-code
were	O
considered	O
to	O
have	O
a	O
bipolar	B-phenotype
disorder	I-phenotype
.	O

A	O
Patient	O
-	O
Reported	O
Outcomes	O
Measurement	O
Information	O
System	O
(	O
PROMIS	O
)	O
instrument	O
was	O
used	O
to	O
assess	O
anxiety	O
symptoms	O
(	O
PROMIS	O
Cooperative	O
Group	O
,	O
2009	O
)	O
.	O

This	O
measure	O
took	O
the	O
sum	O
of	O
7	O
items	O
assessed	O
on	O
a	O
scale	O
from	O
1–5	O
,	O
with	O
higher	O
scores	O
indicating	O
greater	O
anxiety	O
.	O

A	O
T	O
-	O
score	O
was	O
then	O
calculated	O
by	O
multiplying	O
the	O
summed	O
score	O
by	O
7	O
and	O
dividing	O
by	O
the	O
number	O
of	O
items	O
that	O
the	O
participant	O
answered	O
.	O

The	O
Patient	O
Health	O
Questionnaire	O
2	O
-	O
item	O
(	O
PHQ	O
-	O
2	O
)	O
measure	O
was	O
used	O
to	O
assess	O
depressive	O
symptoms	O
(	O
Kroenke	O
et	O
al	O
.	O
,	O
2003	O
)	O
.	O

This	O
measure	O
took	O
the	O
sum	O
of	O
2	O
items	O
assessed	O
on	O
a	O
scale	O
from	O
0–3	O
,	O
with	O
higher	O
scores	O
indicating	O
greater	O
depressive	O
thoughts	O
.	O

A	O
composite	O
variable	O
measured	O
participants’	O
perceived	O
social	O
support	O
for	O
cessation	O
by	O
taking	O
the	O
mean	O
of	O
two	O
variables	O
that	O
assessed	O
perceived	O
social	O
support	O
for	O
quitting	O
and	O
others’	O
desire	O
for	O
the	O
participant	O
to	O
quit	O
smoking	O
,	O
respectively	O
(	O
University	O
of	O
San	O
Diego	O
,	O
2010	O
)	O
.	O

Both	O
items	O
were	O
assessed	O
on	O
a	O
5	O
-	O
point	O
scale	O
,	O
with	O
higher	O
scores	O
indicating	O
greater	O
levels	O
of	O
social	O
support	O
.	O

Participants	O
reported	O
the	O
proportion	O
of	O
their	O
close	O
friends	O
and	O
family	O
who	O
were	O
smokers	O
.	O

Participants	O
also	O
reported	O
whether	O
they	O
lived	O
with	O
a	O
child	O
under	O
the	O
age	O
of	O
18	O
,	O
whether	O
they	O
lived	O
with	O
another	O
smoker	O
,	O
and	O
the	O
smoking	O
rules	O
within	O
their	O
home	O
.	O

Healthcare	O
Effectiveness	O
Data	O
and	O
Information	O
Set	O
(	O
HEDIS	O
)	O
tobacco	O
performance	O
measures	O
were	O
used	O
to	O
assess	O
participants’	O
self	O
-	O
reported	O
past	O
year	O
healthcare	O
experiences	O
(	O
Davis	O
,	O
1997	O
)	O
.	O

Items	O
assessed	O
whether	O
participants	O
had	O
someone	O
they	O
thought	O
of	O
as	O
their	O
regular	O
doctor	O
,	O
whether	O
they	O
received	O
doctor	O
-	O
delivered	O
advice	O
to	O
quit	O
,	O
advice	O
to	O
use	O
cessation	O
medications	O
,	O
and	O
advice	O
to	O
use	O
ways	O
(	O
besides	O
products	O
)	O
to	O
help	O
with	O
quitting	O
.	O

A	O
composite	O
variable	O
of	O
perceptions	O
of	O
healthcare	O
provider	O
bias	O
was	O
created	O
by	O
summing	O
3	O
-	O
items	O
from	O
the	O
Physician	O
Bias	O
and	O
Interpersonal	O
Cultural	O
Competence	O
Measures	O
Scale	O
(	O
Johnson	O
et	O
al	O
.	O
,	O
2004	O
)	O
.	O

These	O
items	O
assessed	O
whether	O
the	O
participant	O
felt	O
they	O
were	O
treated	O
with	O
respect	O
,	O
the	O
healthcare	O
provider’s	O
understanding	O
of	O
the	O
participant’s	O
background	O
and	O
values	O
,	O
and	O
the	O
participant’s	O
perception	O
of	O
whether	O
the	O
healthcare	O
provider	O
looks	O
down	O
on	O
their	O
way	O
of	O
life	O
.	O

Each	O
item	O
was	O
assessed	O
on	O
a	O
5	O
-	O
point	O
scale	O
,	O
with	O
higher	O
values	O
indicating	O
greater	O
perceptions	O
of	O
healthcare	O
provider	O
bias	O
.	O

Analyses	O
conducted	O
on	O
the	O
summary	O
measure	O
created	O
for	O
these	O
items	O
yielded	O
an	O
unadjusted	O
Cronbach’s	O
alpha	O
reliability	O
score	O
of	O
0	O
.	O
74	O
.	O

Standard	O
questions	O
from	O
the	O
California	O
Tobacco	O
Survey	O
(	O
University	O
of	O
San	O
Diego	O
,	O
2010	O
)	O
and	O
the	O
BRFSS	O
(	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
(	O
CDC	O
)	O
,	O
2010	O
)	O
assessed	O
smoking	O
history	O
including	O
cigarettes	O
smoked	O
per	O
day	O
,	O
age	O
of	O
smoking	O
initiation	O
,	O
and	O
time	O
until	O
first	O
cigarette	O
after	O
waking	O
.	O

Self	O
-	O
efficacy	O
for	O
quitting	O
was	O
measured	O
on	O
a	O
scale	O
from	O
1	O
to	O
10	O
,	O
with	O
higher	O
values	O
indicating	O
greater	O
confidence	O
in	O
quitting	O
(	O
Baldwin	O
et	O
al	O
.	O
,	O
2006	O
)	O
.	O

The	O
Contemplation	O
Ladder	O
assessed	O
readiness	O
to	O
quit	O
on	O
a	O
scale	O
from	O
1	O
to	O
10	O
,	O
with	O
higher	O
values	O
indicating	O
a	O
greater	O
readiness	O
to	O
quit	O
(	O
Biener	O
and	O
Abrams	O
,	O
1991	O
)	O
.	O

Bivariate	O
analyses	O
,	O
using	O
t	O
-	O
tests	O
and	O
Pearson’s	O
chi	O
-	O
square	O
tests	O
,	O
compared	O
participants	O
with	O
and	O
without	O
SMI	O
across	O
demographic	O
,	O
alcohol	O
use	O
,	O
mental	O
health	O
,	O
social	O
environment	O
,	O
healthcare	O
provider	O
,	O
smoking	O
history	O
,	O
cessation	O
beliefs	O
,	O
and	O
smoking	O
abstinence	O
measures	O
.	O

In	O
order	O
to	O
provide	O
additional	O
information	O
on	O
the	O
mental	O
health	O
characteristics	O
of	O
these	O
groups	O
,	O
we	O
compared	O
smokers	O
with	O
SMI	O
to	O
those	O
without	O
SMI	O
across	O
a	O
series	O
of	O
mental	O
health	O
diagnoses	O
that	O
were	O
not	O
included	O
in	O
the	O
SMI	O
definition	O
(	O
see	O
Supplementary	O
Table	O
1	O
)	O
1	O
.	O

Multivariable	O
multinomial	O
regression	O
modeled	O
the	O
association	O
between	O
6	O
-	O
month	O
prolonged	O
smoking	O
abstinence	O
(	O
yes	O
vs	O
.	O
no	O
)	O
and	O
the	O
4	O
-	O
level	O
binge	O
drinking	O
outcome	O
variable	O
at	O
12	O
-	O
month	O
follow	O
-	O
up	O
,	O
stratified	O
by	O
SMI	O
category	O
(	O
SMI	O
vs	O
.	O
non	O
-	O
SMI	O
)	O
.	O

A	O
baseline	O
measure	O
of	O
binge	O
drinking	O
was	O
included	O
in	O
these	O
models	O
.	O

Multivariable	O
linear	O
regressions	O
modeled	O
the	O
association	O
between	O
6	O
-	O
month	O
prolonged	O
smoking	O
abstinence	O
and	O
PHQ	O
-	O
2	O
depression	O
score	O
and	O
PROMIS	O
anxiety	O
score	O
at	O
follow	O
-	O
up	O
,	O
stratified	O
by	O
SMI	O
category	O
.	O

Baseline	O
measures	O
of	O
each	O
outcome	O
variable	O
were	O
included	O
in	O
the	O
respective	O
models	O
.	O

A	O
series	O
of	O
bivariate	O
analyses	O
were	O
conducted	O
in	O
order	O
to	O
identify	O
differences	O
between	O
those	O
who	O
achieved	O
6	O
-	O
month	O
prolonged	O
smoking	O
abstinence	O
and	O
those	O
who	O
did	O
not	O
achieve	O
6	O
-	O
month	O
prolonged	O
smoking	O
abstinence	O
.	O

In	O
addition	O
to	O
checking	O
for	O
differences	O
in	O
the	O
rates	O
of	O
membership	O
in	O
the	O
proactive	O
outreach	O
intervention	O
,	O
the	O
groups	O
were	O
compared	O
across	O
select	O
demographic	O
,	O
social	O
environment	O
,	O
smoking	O
history	O
,	O
and	O
cessation	O
beliefs	O
variables	O
(	O
see	O
Supplementary	O
Table	O
2	O
)	O
2	O
.	O

In	O
addition	O
to	O
the	O
models	O
adjusting	O
only	O
for	O
baseline	O
levels	O
of	O
the	O
outcome	O
variable	O
(	O
model	O
1	O
)	O
,	O
hierarchical	O
models	O
were	O
used	O
to	O
incrementally	O
adjust	O
for	O
the	O
effects	O
of	O
the	O
intervention	O
(	O
model	O
2	O
)	O
,	O
the	O
demographic	O
variables	O
of	O
insurance	O
program	O
,	O
age	O
,	O
sex	O
,	O
race	O
/	O
ethnicity	O
,	O
and	O
income	O
(	O
model	O
3	O
)	O
,	O
the	O
proportion	O
of	O
close	O
friends	O
and	O
family	O
who	O
smoke	O
(	O
model	O
4	O
)	O
,	O
and	O
the	O
smoking	O
history	O
/	O
cessation	O
beliefs	O
variables	O
of	O
cigarettes	O
smoked	O
per	O
day	O
and	O
readiness	O
to	O
quit	O
(	O
model	O
5	O
)	O
.	O

When	O
describing	O
the	O
results	O
of	O
regression	O
analyses	O
,	O
we	O
focus	O
on	O
the	O
most	O
fully	O
adjusted	O
model	O
(	O
model	O
5	O
)	O
.	O

For	O
the	O
purposes	O
of	O
these	O
regression	O
analyses	O
,	O
the	O
“American	O
Indian	O
or	O
Alaska	O
Native”	O
,	O
“Hispanic	O
or	O
Latino”	O
,	O
and	O
“Asian	O
or	O
Pacific	O
Islander”	O
categories	O
were	O
collapsed	O
into	O
one	O
category	O
due	O
to	O
the	O
small	O
sizes	O
of	O
these	O
groups	O
.	O

The	O
study	O
will	O
be	O
conducted	O
as	O
an	O
investigator	O
-	O
initiated	O
prospective	O
,	O
randomised	O
,	O
placebo	O
-	O
controlled	O
,	O
double	O
-	O
blinded	O
,	O
parallel	O
,	O
3	O
-	O
month	O
intervention	O
trial	O
.	O

Referred	O
patients	O
who	O
meet	O
the	O
inclusion	O
criteria	O
will	O
receive	O
detailed	O
oral	O
and	O
written	O
information	O
about	O
the	O
study	O
according	O
to	O
the	O
national	O
ethical	O
guidelines	O
.	O

A	O
minimum	O
reflection	O
time	O
of	O
24	O
h	O
will	O
be	O
given	O
before	O
the	O
written	O
informed	O
consent	O
is	O
obtained	O
.	O

After	O
screening	O
,	O
enrolment	O
and	O
baseline	O
examinations	O
will	O
be	O
performed	O
.	O

Baseline	O
examinations	O
will	O
be	O
followed	O
by	O
an	O
intervention	O
period	O
of	O
12	O
to	O
maximum	O
16	O
weeks	O
.	O

Participants	O
will	O
be	O
randomised	O
to	O
subcutaneous	O
injections	O
(	O
once	O
weekly	O
)	O
with	O
either	O
exenatide	O
(	O
2	O
mg	O
)	O
or	O
placebo	O
.	O

A	O
trained	O
,	O
impartial	O
and	O
unblinded	O
researcher	O
will	O
be	O
responsible	O
for	O
the	O
computer	O
-	O
generated	O
randomisation	O
list	O
and	O
for	O
subsequent	O
allocation	O
to	O
treatment	O
with	O
either	O
exenatide	O
or	O
placebo	O
.	O

The	O
enrolment	O
will	O
continue	O
until	O
20	O
participants	O
in	O
each	O
arm	O
have	O
completed	O
follow	O
-	O
up	O
examinations	O
.	O

Owing	O
to	O
an	O
expected	O
attrition	O
of	O
10–20	O
%	O
the	O
enrolment	O
will	O
likely	O
include	O
up	O
to	O
50	O
patients	O
.	O

Trial	O
medication	O
will	O
be	O
administered	O
by	O
unblinded	O
research	O
staff	O
throughout	O
the	O
trial	O
.	O

The	O
randomisation	O
list	O
,	O
trial	O
medication	O
and	O
medication	O
documents	O
will	O
be	O
safely	O
concealed	O
from	O
the	O
blinded	O
principal	O
investigator	O
throughout	O
the	O
trial	O
.	O

Participants	O
will	O
be	O
blinded	O
throughout	O
the	O
entire	O
trial	O
.	O

Data	O
analysis	O
will	O
be	O
performed	O
after	O
unblinding	O
.	O

One	O
week	O
after	O
the	O
final	O
dose	O
of	O
trial	O
medication	O
and	O
on	O
successfully	O
completing	O
the	O
follow	O
-	O
up	O
examinations	O
,	O
trial	O
participation	O
will	O
be	O
terminated	O
.	O

A	O
flow	O
chart	O
of	O
the	O
study	O
is	O
provided	O
in	O
figure	O
1	O
.	O

Flow	O
chart	O
of	O
the	O
TAO	O
study	O
.	O

In	O
each	O
treatment	O
arm	O
20	O
participants	O
must	O
complete	O
follow	O
-	O
up	O
examinations	O
after	O
3	O
months	O
of	O
intervention	O
.	O

Adapted	O
after	O
the	O
CONSORT	O
statement	O
.	O

37	O

Patients	O
are	O
recruited	O
from	O
psychiatric	O
outpatient	O
and	O
inpatient	O
clinics	O
in	O
the	O
Capital	O
Region	O
of	O
Copenhagen	O
,	O
Denmark	O
.	O

The	O
principal	O
investigator	O
reviews	O
the	O
patient	O
referrals	O
to	O
secure	O
that	O
the	O
inclusion	O
and	O
exclusion	O
criteria	O
are	O
met	O
(	O
box	O
1	O
)	O
.	O

In	O
case	O
of	O
doubt	O
,	O
the	O
principal	O
investigator	O
involves	O
the	O
trial	O
sponsor	O
prior	O
to	O
final	O
inclusion	O
or	O
exclusion	O
.	O

After	O
screening	O
,	O
patients	O
who	O
meet	O
the	O
criteria	O
for	O
participation	O
will	O
be	O
enrolled	O
,	O
examined	O
(	O
baseline	O
examinations	O
)	O
and	O
finally	O
randomised	O
.	O

The	O
individual	O
patient	O
data	O
will	O
be	O
filed	O
according	O
to	O
the	O
progress	O
made	O
through	O
the	O
study	O
of	O
each	O
participant	O
and	O
grouped	O
into	O
corresponding	O
categories	O
as	O
shown	O
in	O
figure	O
1	O
.	O

Inclusion	O
criteria	O
Age	O
:	O
18–65	O
years	O
Diagnosis	O
in	O
the	O
schizophrenia	B-phenotype
spectrum	I-phenotype
(	B-coding_system
International	I-coding_system
Classification	I-coding_system
of	I-coding_system
Diseases	I-coding_system
(	I-coding_system
ICD	I-coding_system
)	I-coding_system
-	I-coding_system
10	I-coding_system
:	O
F20	B-code
.	I-code
x	I-code
,	O
F25	B-code
.	I-code
x	I-code
)	O
Current	O
and	O
unchanged	O
antipsychotic	O
treatment	O
for	O
a	O
minimum	O
of	O
3	O
months	O
Body	O
mass	O
index	O
≥30	O
kg	O
/	O
m	O
2	O
Glycated	O
haemoglobin	O
(	O
HbA1c	O
)	O
<	O
6	O
.	O
5	O
%	O
(	O
48	O
mmol	O
/	O
mol	O
)	O

Age	O
:	O
18–65	O
years	O

Diagnosis	O
in	O
the	O
schizophrenia	B-phenotype
spectrum	I-phenotype
(	O
International	B-coding_system
Classification	I-coding_system
of	I-coding_system
Diseases	I-coding_system
(	I-coding_system
ICD	I-coding_system
)	I-coding_system
-	I-coding_system
10	I-coding_system
:	O
F20	B-code
.	I-code
x	I-code
,	O
F25	B-code
.	I-code
x	I-code
)	O

Current	O
and	O
unchanged	O
antipsychotic	O
treatment	O
for	O
a	O
minimum	O
of	O
3	O
months	O

Body	O
mass	O
index	O
≥30	O
kg	O
/	O
m	O
2	O

Glycated	O
haemoglobin	O
(	O
HbA1c	O
)	O
<	O
6	O
.	O
5	O
%	O
(	O
48	O
mmol	O
/	O
mol	O
)	O

Exclusion	O
criteria	O
Substance	B-phenotype
dependence	I-phenotype
(	O
ICD	B-coding_system
-	I-coding_system
10	I-coding_system
:	O
F1x	B-code
.	I-code
2	I-code
(	O
apart	O
from	O
nicotine	O
addiction	O
F17	O
.	O
2	O
)	O
)	O
Diabetes	O
or	O
HbA1c	O
≥6	O
.	O
5	O
%	O
(	O
48	O
mmol	O
/	O
mol	O
)	O
Contraindications	O
to	O
MRI	O
(	O
eg	O
,	O
metal	O
implants	O
,	O
pacemakers	O
and	O
severe	O
claustrophobia	O
)	O
Previous	O
head	O
trauma	O
with	O
a	O
loss	O
of	O
consciousness	O
for	O
more	O
than	O
5	O
min	O
Pregnancy	O
(	O
screened	O
by	O
urine	O
human	O
chorionic	O
gonadotropin	O
)	O
,	O
lactation	O
or	O
no	O
acceptance	O
to	O
use	O
effective	O
contraception	O
during	O
the	O
intervention	O
period	O
Severe	O
somatic	O
disease	O
,	O
including	O
inflammatory	O
bowel	O
disease	O
and	O
nephropathy	O

Allergy	O
to	O
exenatide	O
Coercive	O
measures	O
according	O
to	O
the	O
Danish	O
Mental	O
Health	O
Act	O
Conditions	O
that	O
according	O
to	O
sponsor	O
and	O
/	O
or	O
investigators	O
are	O
not	O
congruous	O
with	O
participation	O
in	O
the	O
study	O
Suicidal	O
ideations	O

Substance	B-phenotype
dependence	I-phenotype
(	O
ICD	B-coding_system
-	I-coding_system
10	I-coding_system
:	O
F1x	B-code
.	I-code
2	I-code
(	O
apart	O
from	O
nicotine	B-phenotype
addiction	I-phenotype
F17	B-code
.	I-code
2	I-code
)	O
)	O

Diabetes	O
or	O
HbA1c	O
≥6	O
.	O
5	O
%	O
(	O
48	O
mmol	O
/	O
mol	O
)	O

Contraindications	O
to	O
MRI	O
(	O
eg	O
,	O
metal	O
implants	O
,	O
pacemakers	O
and	O
severe	O
claustrophobia	O
)	O

Previous	O
head	O
trauma	O
with	O
a	O
loss	O
of	O
consciousness	O
for	O
more	O
than	O
5	O
min	O

Pregnancy	O
(	O
screened	O
by	O
urine	O
human	O
chorionic	O
gonadotropin	O
)	O
,	O
lactation	O
or	O
no	O
acceptance	O
to	O
use	O
effective	O
contraception	O
during	O
the	O
intervention	O
period	O

Severe	O
somatic	O
disease	O
,	O
including	O
inflammatory	O
bowel	O
disease	O
and	O
nephropathy	O

Allergy	O
to	O
exenatide	O

Coercive	O
measures	O
according	O
to	O
the	O
Danish	O
Mental	O
Health	O
Act	O

Conditions	O
that	O
according	O
to	O
sponsor	O
and	O
/	O
or	O
investigators	O
are	O
not	O
congruous	O
with	O
participation	O
in	O
the	O
study	O

Suicidal	O
ideations	O

At	O
baseline	O
a	O
complete	O
medical	O
history	O
and	O
a	O
full	O
physical	O
examination	O
will	O
be	O
performed	O
.	O

Questionnaires	O
and	O
various	O
psychometric	O
assessments	O
will	O
be	O
collected	O
.	O

The	O
participants’	O
body	O
weight	O
(	O
in	O
fasting	O
state	O
)	O
will	O
be	O
recorded	O
.	O

Blood	O
sampling	O
and	O
whole	O
-	O
body	O
dual	O
-	O
energy	O
X	O
-	O
ray	O
absorptiometry	O
(	O
DEXA	O
)	O
scan	O
to	O
measure	O
the	O
body	O
composition	O
(	O
fat	O
mass	O
and	O
fat	O
distribution	O
)	O
will	O
be	O
performed	O
(	O
both	O
in	O
the	O
fasting	O
state	O
)	O
.	O

To	O
investigate	O
the	O
potential	O
blood	O
pressure	O
-	O
lowering	O
effect	O
of	O
exenatide	O
in	O
patients	O
with	O
schizophrenia	O
24	O
h	O
blood	O
pressure	O
monitoring	O
including	O
measurement	O
of	O
central	O
blood	O
pressure	O
and	O
augmentation	O
index	O
(	O
Mobil	O
-	O
O	O
-	O
Graph	O
24	O
-	O
h	O
PWA	O
monitor	O
,	O
Stolberg	O
,	O
Germany	O
)	O
will	O
be	O
performed	O
(	O
approximately	O
80	O
measures	O
in	O
a	O
24	O
h	O
period	O
)	O
.	O

All	O
baseline	O
examinations	O
including	O
MRI	O
will	O
be	O
performed	O
prior	O
to	O
randomisation	O
and	O
the	O
first	O
administration	O
of	O
trial	O
medication	O
.	O

All	O
the	O
participants	O
will	O
attend	O
four	O
planned	O
trial	O
visits	O
:	O
‘Baseline’	O
(	O
week	O
0	O
)	O
,	O
‘1	O
week’	O
(	O
7	O
days±2	O
days	O
)	O
,	O
‘4	O
weeks’	O
(	O
up	O
to	O
6	O
weeks	O
)	O
and	O
‘follow	O
-	O
up’	O
(	O
12–16	O
weeks	O
)	O
.	O

At	O
each	O
visit	O
(	O
except	O
visit	O
‘1	O
week’	O
)	O
blood	O
sampling	O
and	O
ECG	O
will	O
be	O
performed	O
(	O
table	O
1	O
)	O
.	O

Changes	O
of	O
any	O
prescribed	O
medication	O
during	O
the	O
intervention	O
period	O
will	O
be	O
recorded	O
.	O

Summarises	O
the	O
examinations	O
planned	O
on	O
the	O
four	O
trial	O
visits	O
:	O
baseline	O
,	O
1	O
week	O
,	O
4	O
weeks	O
and	O
follow	O
-	O
up	O

DEXA	O
,	O
dual	O
-	O
energy	O
X	O
-	O
ray	O
absorptiometry	O
;	O
ESRS	O
,	O
Extrapyramidal	O
Symptom	O
Rating	O
Scale	O
;	O
FFQ	O
,	O
Food	O
Frequency	O
Questionnaire	O
;	O
GAF	O
,	O
global	O
assessment	O
of	O
functioning	O
;	O
IPAQ	O
-	O
S	O
,	O
International	O
Physical	O
Activity	O
Questionnaire	O
;	O
PANSS	O
,	O
Positive	O
and	O
Negative	O
Syndrome	O
Scale	O
;	O
PSP	O
,	O
Personal	O
and	O
Social	O
Performance	O
Scale	O
;	O
UKU	O
-	O
S	O
Udvalg	O
af	O
kliniske	O
undersøgelser	O
.	O

Patients	O
will	O
be	O
randomised	O
after	O
completion	O
of	O
the	O
baseline	O
examinations	O
.	O

All	O
the	O
participants	O
will	O
receive	O
information	O
about	O
potential	O
adverse	O
effects	O
prior	O
to	O
medicine	O
administration	O
.	O

Trial	O
medication	O
,	O
exenatide	O
2	O
mg	O
once	O
weekly	O
(	O
fixed	O
dose	O
)	O
or	O
placebo	O
will	O
be	O
administered	O
as	O
subcutaneous	O
injections	O
by	O
unblinded	O
trial	O
personnel	O
throughout	O
the	O
trial	O
.	O

The	O
first	O
two	O
doses	O
will	O
be	O
given	O
at	O
the	O
hospital	O
(	O
Psychiatric	O
Center	O
Glostrup	O
)	O
.	O

In	O
order	O
to	O
maximise	O
the	O
trial	O
adherence	O
subsequent	O
trial	O
medication	O
will	O
be	O
administered	O
in	O
the	O
patient’s	O
home	O
by	O
trial	O
personnel	O
.	O

On	O
all	O
trial	O
visits	O
a	O
clinical	O
examination	O
and	O
recording	O
of	O
any	O
adverse	O
events	O
including	O
hypoglycaemia	O
will	O
be	O
performed	O
.	O

If	O
a	O
participant	O
develops	O
diabetes	O
during	O
the	O
intervention	O
,	O
the	O
participant	O
will	O
be	O
excluded	O
from	O
the	O
trial	O
and	O
referred	O
to	O
a	O
diabetes	O
outpatient	O
clinic	O
.	O

The	O
risk	O
associated	O
with	O
participating	O
in	O
the	O
experimental	O
procedures	O
in	O
the	O
present	O
trial	O
is	O
minimal	O
.	O

Blood	O
samples	O
will	O
be	O
taken	O
under	O
aseptic	O
conditions	O
.	O

During	O
the	O
entire	O
study	O
approximately	O
250	O
mL	O
of	O
blood	O
will	O
be	O
drawn	O
and	O
analysed	O
(	O
table	O
2	O
)	O
.	O

MRI	O
is	O
not	O
associated	O
with	O
any	O
known	O
health	O
risk	O
.	O

Mild	O
-	O
to	O
-	O
moderate	O
gastrointestinal	O
(	O
nausea	O
,	O
vomiting	O
and	O
diarrhoea	O
in	O
10–15	O
%	O
)	O
side	O
effects	O
are	O
common	O
but	O
transient	O
during	O
treatment	O
with	O
exenatide	O
once	O
weekly	O
.	O

Less	O
often	O
exenatide	O
causes	O
headaches	O
.	O

Patients	O
may	O
experience	O
abdominal	O
pain	O
,	O
decreased	O
appetite	O
,	O
fatigue	O
,	O
fever	O
,	O
dizziness	O
and	O
upper	O
respiratory	O
tract	O
infection	O
,	O
however	O
,	O
less	O
frequently	O
.	O

Uncommon	O
side	O
effects	O
include	O
gout	O
,	O
thyroid	O
adenoma	O
and	O
angioedema	O
.	O

The	O
injection	O
of	O
exenatide	O
may	O
result	O
in	O
a	O
small	O
haematoma	O
at	O
the	O
injection	O
site	O
and	O
transient	O
,	O
regional	O
redness	O
or	O
a	O
nodule	O
(	O
a	O
harmless	O
infiltration	O
of	O
the	O
skin	O
which	O
usually	O
disappears	O
within	O
4	O
weeks	O
)	O
.	O

Biochemistry	O
(	O
fasting	O
blood	O
samples	O
)	O
collected	O
on	O
the	O
trial	O
visits	O
:	O
baseline	O
,	O
4	O
weeks	O
and	O
follow	O
-	O
up	O
.	O

HbA1c	O
,	O
glycated	O
haemoglobin	O
;	O
HDL	O
,	O
high	O
-	O
density	O
lipoprotein	O
;	O
LDL	O
,	O
low	O
-	O
density	O
lipoprotein	O
;	O
TNFα	O
,	O
tumour	O
necrosis	O
factor	O
α	O
;	O
VLDL	O
,	O
very	O
low	O
-	O
density	O
lipoprotein	O
.	O

The	O
primary	O
endpoint	O
is	O
weight	O
loss	O
after	O
3	O
months’	O
treatment	O
with	O
exenatide	O
once	O
weekly	O
.	O

At	O
the	O
baseline	O
1	O
-	O
week	O
,	O
1	O
-	O
month	O
and	O
3	O
-	O
month	O
trial	O
visits	O
,	O
all	O
adverse	O
events	O
will	O
be	O
registered	O
and	O
body	O
weight	O
will	O
be	O
recorded	O
on	O
authorised	O
and	O
calibrated	O
weight	O
scales	O
(	O
Cardinal	O
Detecto	O
750	O
,	O
203	O
East	O
Daugherty	O
,	O
Webb	O
City	O
,	O
Missouri	O
,	O
USA	O
)	O
.	O

Participants	O
will	O
be	O
weighed	O
without	O
shoes	O
and	O
outerwear	O
and	O
in	O
a	O
fasting	O
state	O
.	O

Body	O
weight	O
will	O
be	O
reported	O
per	O
protocol	O
analysis	O
,	O
thus	O
only	O
including	O
participants	O
who	O
complete	O
a	O
minimum	O
of	O
12	O
weeks	O
of	O
intervention	O
.	O

All	O
adverse	O
events	O
will	O
be	O
reported	O
to	O
the	O
relevant	O
authorities	O
.	O

Secondary	O
endpoints	O
will	O
explore	O
the	O
effects	O
of	O
exenatide	O
on	O
various	O
parameters	O
including	O
psychopathological	O
,	O
cognitive	O
,	O
behavioural	O
,	O
cardiovascular	O
,	O
biochemistry	O
and	O
imaging	O
(	O
DEXA	O
and	O
MRI	O
;	O
table	O
1	O
)	O
.	O

The	O
Positive	O
and	O
Negative	O
Syndrome	O
Scale	O
(	O
PANSS	O
)	O
will	O
be	O
used	O
to	O
assess	O
the	O
severity	O
of	O
schizophrenia	O
symptoms	O
.	O

21	O
The	O
brief	O
assessment	O
of	O
cognition	O
in	O
schizophrenia	O
will	O
be	O
employed	O
to	O
assess	O
five	O
domains	O
of	O
cognitive	O
function	O
:	O
verbal	O
memory	O
,	O
working	O
memory	O
,	O
motor	O
speed	O
,	O
verbal	O
fluency	O
and	O
reasoning	O
and	O
problem	O
-	O
solving	O
.	O

22	O
The	O
REY	O
complex	O
figure	O
test	O
will	O
be	O
used	O
to	O
assess	O
visuospatial	O
memory	O
.	O

23	O
The	O
Danish	O
adult	O
reading	O
test	O
(	O
DART	O
,	O
Danish	O
version	O
of	O
NART	O
)	O
will	O
be	O
performed	O
to	O
estimate	O
premorbid	O
IQ	O
.	O
24	O
25	O
The	O
Extrapyramidal	O
Symptom	O
Rating	O
Scale	O
(	O
ESRS	O
)	O
will	O
be	O
used	O
to	O
assess	O
changes	O
in	O
antipsychotic	O
-	O
induced	O
parkinsonism	O
and	O
dyskinesia	O
and	O
further	O
information	O
concerning	O
side	O
effects	O
of	O
antipsychotic	O
treatment	O
will	O
be	O
obtained	O
using	O
the	O
questionnaire	O
UKU	O
-	O
S	O
(	O
Udvalg	O
af	O
kliniske	O
undersøgelser	O
)	O
.	O

26	O
27	O
The	O
IQOLA	O
SF	O
-	O
36	O
(	O
Danish	O
V	O
.	O
1	O
.	O
1	O
)	O
will	O
be	O
used	O
to	O
evaluate	O
patients’	O
subjective	O
perception	O
of	O
quality	O
of	O
life	O
.	O

28	O
Global	O
assessment	O
of	O
functioning	O
and	O
the	O
Personal	O
and	O
Social	O
Performance	O
Scale	O
(	O
PSP	O
)	O
will	O
be	O
used	O
to	O
assess	O
the	O
patient’s	O
overall	O
level	O
of	O
functioning	O
.	O

29	O
The	O
International	O
Physical	O
Activity	O
Questionnaire	O
will	O
be	O
employed	O
to	O
evaluate	O
physical	O
activity	O
.	O

30	O
The	O
Food	O
Frequency	O
Questionnaire	O
will	O
be	O
used	O
to	O
assess	O
food	O
intake	O
and	O
habits	O
.	O

31	O

We	O
will	O
use	O
a	O
Lunar	O
Prodigy	O
whole	O
-	O
body	O
scanner	O
(	O
GE	O
Medical	O
Systems	O
,	O
Madison	O
,	O
Wisconsin	O
,	O
USA	O
)	O
in	O
conjunction	O
with	O
the	O
Encore	O
V	O
.	O
14	O
.	O
1	O
software	O
to	O
assess	O
body	O
composition	O
(	O
total	O
fat	O
mass	O
and	O
fat	O
-	O
free	O
mass	O
and	O
their	O
distribution	O
in	O
the	O
trunk	O
and	O
upper	O
and	O
lower	O
limbs	O
)	O
.	O

We	O
will	O
use	O
a	O
Philips	O
Achieva	O
3	O
.	O
0	O
T	O
whole	O
-	O
body	O
MRI	O
scanner	O
(	O
Philips	O
Healthcare	O
,	O
Best	O
,	O
The	O
Netherlands	O
)	O
with	O
a	O
32	O
channel	O
SENSE	O
Head	O
Coil	O
(	O
Invivo	O
,	O
Orlando	O
,	O
Florida	O
,	O
USA	O
)	O
.	O

During	O
MRI	O
-	O
specific	O
structural	O
sequences	O
(	O
T1	O
and	O
T2	O
weighted	O
)	O
and	O
fluid	O
attenuated	O
inversion	O
recovery	O
will	O
be	O
performed	O
and	O
assessed	O
by	O
a	O
radiologist	O
regarding	O
potential	O
pathology	O
.	O

In	O
addition	O
,	O
diffusion	O
tensor	O
imaging	O
,	O
Quantitative	O
STAR	O
labelling	O
of	O
Arterial	O
Regions	O
(	O
QUASAR	O
)	O
and	O
pseudo	O
-	O
continuous	O
arterial	O
spin	O
labelling	O
measurements	O
will	O
be	O
performed	O
in	O
order	O
to	O
measure	O
the	O
integrity	O
of	O
white	O
matter	O
tracts	O
and	O
CBF	O
,	O
respectively	O
.	O

By	O
means	O
of	O
these	O
physiological	O
data	O
,	O
potential	O
neuroprotective	O
effects	O
and	O
changes	O
in	O
CBF	O
will	O
be	O
explored	O
.	O

These	O
changes	O
will	O
be	O
correlated	O
to	O
potential	O
improvements	O
in	O
the	O
global	O
cognitive	O
performance	O
,	O
with	O
mainly	O
the	O
hippocampus	O
,	O
prefrontal	O
cortex	O
and	O
hypothalamus	O
as	O
regions	O
of	O
interests	O
.	O

The	O
relation	O
between	O
potential	O
volumetric	O
changes	O
in	O
striatum	O
and	O
a	O
reduction	O
of	O
extrapyramidal	O
symptoms	O
will	O
be	O
explored	O
.	O

Duration	O
of	O
MRI	O
will	O
be	O
approximately	O
50	O
min	O
.	O

Finally	O
,	O
associations	O
between	O
potential	O
weight	O
loss	O
and	O
any	O
improvements	O
in	O
secondary	O
metabolic	O
parameters	O
(	O
induced	O
by	O
exenatide	O
)	O
will	O
be	O
related	O
to	O
possible	O
improvements	O
in	O
,	O
for	O
example	O
,	O
the	O
patients’	O
subjective	O
quality	O
of	O
life	O
and	O
/	O
or	O
psychopathology	O
.	O

Demographic	O
variables	O
and	O
clinical	O
characteristics	O
will	O
be	O
measured	O
by	O
frequency	O
(	O
percentage	O
)	O
for	O
categorical	O
data	O
,	O
mean	O
values	O
(	O
with	O
SDs	O
)	O
for	O
normally	O
distributed	O
,	O
continuous	O
variables	O
and	O
medians	O
(	O
range	O
)	O
for	O
other	O
continuous	O
variables	O
.	O

Changes	O
from	O
baseline	O
to	O
follow	O
-	O
up	O
will	O
be	O
analysed	O
for	O
all	O
participants	O
and	O
for	O
the	O
exenatide	O
and	O
placebo	O
arms	O
separately	O
.	O

The	O
primary	O
outcome	O
is	O
bodyweight	O
change	O
in	O
the	O
exenatide	O
group	O
compared	O
to	O
the	O
placebo	O
group	O
after	O
3	O
months	O
of	O
treatment	O
.	O

Weight	O
changes	O
will	O
be	O
correlated	O
to	O
various	O
variables	O
,	O
for	O
example	O
,	O
age	O
,	O
gender	O
,	O
baseline	O
body	O
weight	O
,	O
duration	O
of	O
obesity	O
,	O
type	O
of	O
antipsychotic	O
drug	O
and	O
changes	O
in	O
the	O
brain	O
structure	O
.	O

Changes	O
in	O
CBF	O
will	O
be	O
correlated	O
to	O
changes	O
in	O
,	O
for	O
example	O
,	O
cognition	O
,	O
subjective	O
quality	O
of	O
life	O
and	O
to	O
extrapyramidal	O
side	O
effects	O
of	O
antipsychotic	O
medication	O
.	O

We	O
hypothesise	O
a	O
weight	O
loss	O
of	O
2	O
.	O
5	O
kg	O
(	O
±2	O
.	O
5	O
kg	O
)	O
in	O
the	O
exenatide	O
arm	O
versus	O
0	O
kg	O
(	O
±2	O
.	O
5	O
kg	O
)	O
in	O
the	O
placebo	O
arm	O
,	O
which	O
results	O
in	O
an	O
observed	O
effect	O
size	O
(	O
Cohen’s	O
d	O
)	O
of	O
1	O
.	O
2	O
SDs	O
based	O
on	O
Drucker	O
et	O
al	O
.	O

32	O
In	O
a	O
priori	O
Student	O
t	O
test	O
(	O
two	O
-	O
sided	O
)	O
with	O
significance	O
level	O
α	O
of	O
0	O
.	O
05	O
and	O
a	O
desired	O
power	O
(	O
1−α	O
)	O
of	O
80	O
%	O
shows	O
that	O
16	O
patients	O
in	O
each	O
arm	O
is	O
adequate	O
to	O
test	O
this	O
hypothesis	O
.	O

We	O
will	O
include	O
a	O
minimum	O
of	O
20	O
patients	O
in	O
each	O
arm	O
to	O
ensure	O
the	O
power	O
of	O
the	O
primary	O
endpoint	O
(	O
>	O
80	O
%	O
)	O
and	O
to	O
increase	O
the	O
power	O
of	O
the	O
secondary	O
analyses	O
.	O

Homogeneity	O
of	O
variance	O
between	O
the	O
two	O
groups	O
will	O
be	O
assessed	O
using	O
the	O
Levene	O
'	O
s	O
test	O
.	O

Parametric	O
data	O
will	O
be	O
evaluated	O
using	O
parametric	O
testing	O
.	O

Non	O
-	O
normally	O
distributed	O
data	O
or	O
data	O
that	O
exhibit	O
unequal	O
variances	O
will	O
be	O
preferred	O
.	O

Fisher	O
'	O
s	O
or	O
χ	O
2	O
exact	O
tests	O
will	O
be	O
used	O
for	O
group	O
comparisons	O
between	O
categorical	O
data	O
.	O

The	O
Benjamini	O
-	O
Hochberg	O
procedure	O
will	O
be	O
used	O
to	O
control	O
the	O
type	O
I	O
error	O
rate	O
.	O

This	O
investigator	O
-	O
initiated	O
randomised	O
placebo	O
-	O
controlled	O
trial	O
will	O
explore	O
the	O
effect	O
of	O
exenatide	O
once	O
weekly	O
on	O
various	O
metabolic	O
parameters	O
of	O
importance	O
in	O
the	O
schizophrenia	O
population	O
.	O

All	O
patients	O
will	O
receive	O
oral	O
and	O
written	O
information	O
about	O
the	O
study	O
prior	O
to	O
participation	O
and	O
oral	O
and	O
written	O
informed	O
consent	O
of	O
participation	O
will	O
be	O
required	O
.	O

All	O
female	O
participants	O
of	O
childbearing	O
potential	O
will	O
be	O
tested	O
for	O
pregnancy	O
(	O
measurement	O
of	O
human	O
chorionic	O
gonadotropin	O
in	O
urine	O
)	O
and	O
assurance	O
of	O
anticonceptive	O
treatment	O
will	O
be	O
obligatory	O
throughout	O
the	O
study	O
period	O
.	O

Personal	O
integrity	O
and	O
privacy	O
concerning	O
participants	O
will	O
be	O
protected	O
by	O
the	O
Danish	O
Law	O
of	O
Health	O
.	O

The	O
study	O
will	O
be	O
conducted	O
in	O
accordance	O
with	O
the	O
Helsinki	O
Declaration	O
II	O
and	O
according	O
to	O
the	O
current	O
GCP	O
principles	O
(	O
ICH	O
-	O
GCP	O
)	O
.	O

Antipsychotic	O
-	O
associated	O
obesity	O
is	O
a	O
major	O
and	O
unresolved	O
clinical	O
problem	O
due	O
to	O
its	O
strong	O
association	O
to	O
increased	O
cardiovascular	O
morbidity	O
and	O
premature	O
death	O
among	O
patients	O
with	O
schizophrenia	O
and	O
other	O
mental	O
illnesses	O
.	O

2	O
4	O
33	O
34	O
Moreover	O
,	O
obesity	O
is	O
associated	O
with	O
accelerated	O
brain	O
deterioration	O
,	O
cognitive	O
decline	O
and	O
poor	O
quality	O
of	O
life	O
.	O

1	O
35	O
Today	O
'	O
s	O
interventions	O
against	O
antipsychotic	O
-	O
associated	O
obesity	O
do	O
not	O
facilitate	O
a	O
satisfying	O
and	O
lasting	O
weight	O
loss	O
.	O

7	O
36	O

The	O
TAO	O
study	O
may	O
provide	O
evidence	O
of	O
the	O
potential	O
weight	O
reducing	O
properties	O
of	O
the	O
GLP	O
-	O
1	O
receptor	O
agonist	O
treatment	O
in	O
patients	O
with	O
antipsychotic	O
-	O
associated	O
obesity	O
.	O

In	O
addition	O
,	O
we	O
may	O
also	O
unravel	O
neuroprotective	O
and	O
procognitive	O
effects	O
,	O
which	O
may	O
benefit	O
and	O
improve	O
the	O
global	O
level	O
of	O
functioning	O
in	O
patients	O
with	O
schizophrenia	O
.	O

Thus	O
,	O
the	O
outcome	O
of	O
our	O
study	O
may	O
well	O
have	O
direct	O
clinical	O
implications	O
for	O
the	O
future	O
management	O
of	O
antipsychotic	O
-	O
associated	O
obesity	O
.	O

The	O
positive	O
,	O
negative	O
and	O
inconclusive	O
results	O
of	O
the	O
trial	O
will	O
be	O
presented	O
at	O
national	O
and	O
international	O
scientific	O
meetings	O
.	O

Scientific	O
manuscripts	O
will	O
be	O
written	O
in	O
accordance	O
with	O
the	O
CONSORT	O
2010	O
Statement	O
and	O
submitted	O
to	O
peer	O
-	O
reviewed	O
journals	O
.	O

37	O

Recruitment	O
of	O
participants	O
occurred	O
from	O
September	O
2015	O
to	O
January	O
2016	O
from	O
online	O
ads	O
posted	O
in	O
major	O
American	O
cities	O
on	O
Craigslist	O
.	O

Craigslist	O
was	O
used	O
as	O
the	O
only	O
online	O
recruitment	O
platform	O
,	O
as	O
it	O
is	O
:	O
1	O
)	O
free	O
,	O
2	O
)	O
reaches	O
major	O
American	O
cities	O
,	O
and	O
3	O
)	O
ensured	O
that	O
recruitment	O
reflected	O
the	O
growing	O
number	O
of	O
people	O
who	O
seek	O
help	O
through	O
the	O
Internet	O
.	O

Participants	O
were	O
eligible	O
if	O
they	O
:	O
1	O
)	O
had	O
a	O
minimum	O
score	O
of	O
10	O
on	O
the	O
Patient	O
Health	O
Questionnaire	O
-	O
9	O
(	O
PHQ	O
-	O
9	O
;	O
Kroenke	O
&	O
Spitzer	O
,	O
2002	O
)	O
,	O
a	O
widely	O
held	O
cut	O
-	O
off	O
utilized	O
in	O
primary	O
care	O
settings	O
;	O
2	O
)	O
had	O
a	O
minimum	O
score	O
of	O
11	O
on	O
the	O
Quick	O
Inventory	O
of	O
Depressive	O
Symptoms	O
(	O
QIDS	O
;	O
Rush	O
et	O
al	O
.	O
,	O
2003	O
)	O
,	O
the	O
cutoff	O
for	O
moderate	O
depression	O
;	O
3	O
)	O
were	O
able	O
to	O
speak	O
and	O
read	O
English	O
;	O
4	O
)	O
were	O
at	O
least	O
18	O
years	O
old	O
;	O
5	O
)	O
owned	O
an	O
Android	O
phone	O
(	O
as	O
Android	O
comprises	O
the	O
largest	O
percent	O
of	O
the	O
market	O
)	O
;	O
6	O
)	O
had	O
no	O
visual	O
,	O

hearing	O
,	O
voice	O
,	O
or	O
motor	O
impairment	O
;	O
7	O
)	O
were	O
not	O
diagnosed	O
with	O
a	O
comorbid	O
diagnosis	O
for	O
which	O
participation	O
in	O
this	O
trial	O
was	O
either	O
inappropriate	O
or	O
dangerous	O
(	O
e	O
.	O
g	O
.	O
,	O
psychotic	O
,	O
bipolar	O
,	O
or	O
dissociative	O
disorders	O
,	O
substance	O
dependence	O
)	O
;	O
8	O
)	O
were	O
not	O
severely	O
suicidal	O
(	O
i	O
.	O
e	O
.	O
,	O
ideation	O
,	O
plan	O
,	O
and	O
intent	O
)	O
;	O
9	O
)	O
were	O
not	O
receiving	O
psychotherapy	O
;	O
and	O
10	O
)	O
were	O
on	O
a	O
stable	O
dose	O
of	O
an	O
antidepressant	O
medication	O
(	O
i	O
.	O
e	O
.	O
,	O
no	O
dose	O
changes	O
for	O
four	O
weeks	O
and	O
did	O
not	O
intend	O
to	O
change	O
the	O
dose	O
)	O
or	O
were	O
not	O
currently	O

on	O
an	O
antidepressant	O
medication	O
.	O

In	O
compliance	O
with	O
Institutional	O
Review	O
Board	O
(	O
IRB	O
)	O
approval	O
,	O
those	O
found	O
eligible	O
following	O
screening	O
(	O
i	O
.	O
e	O
.	O
,	O
an	O
online	O
survey	O
assessing	O
if	O
potential	O
participants	O
were	O
>	O
17	O
years	O
old	O
,	O
owned	O
an	O
Android	O
phone	O
,	O
and	O
were	O
not	O
diagnosed	O
with	O
a	O
diagnosis	O
of	O
exclusion	O
,	O
such	O
as	O
Bipolar	O
Disorder	O
)	O
were	O
invited	O
to	O
participate	O
in	O
a	O
baseline	O
eligibility	O
phone	O
assessment	O
.	O

Prior	O
to	O
the	O
phone	O
interview	O
,	O
participants	O
were	O
emailed	O
a	O
link	O
to	O
the	O
detailed	O
digital	O
version	O
of	O
the	O
study	O
consent	O
form	O
.	O

Subjects	O
agreed	O
to	O
participate	O
in	O
the	O
study	O
by	O
checking	O
a	O
“yes”	O
box	O
and	O
typing	O
in	O
their	O
name	O
.	O

After	O
the	O
study	O
consent	O
form	O
was	O
signed	O
online	O
,	O
and	O
before	O
completing	O
the	O
phone	O
assessment	O
,	O
detailed	O
information	O
regarding	O
the	O
consent	O
was	O
reviewed	O
with	O
the	O
participant	O
by	O
study	O
staff	O
.	O

Randomization	O
was	O
created	O
using	O
PROC	O
PLAN	O
in	O
SASv9	O
.	O
2	O
,	O
with	O
participants	O
randomly	O
assigned	O
in	O
randomization	O
blocks	O
of	O
six	O
to	O
either	O
Boost	O
Me	O
(	O
n	O
=	O
10	O
)	O
,	O
Thought	O
Challenger	O
(	O
n	O
=	O
10	O
)	O
,	O
or	O
waitlist	O
control	O
(	O
n	O
=	O
10	O
)	O
.	O

The	O
randomized	O
block	O
design	O
was	O
used	O
to	O
ensure	O
equal	O
numbers	O
were	O
randomized	O
to	O
each	O
group	O
at	O
a	O
given	O
time	O
,	O
should	O
the	O
study	O
end	O
early	O
,	O
or	O
if	O
there	O
were	O
seasonal	O
effects	O
.	O

Once	O
generated	O
,	O
this	O
list	O
was	O
uploaded	O
to	O
Research	O
Electronic	O
Data	O
Capture	O
(	O
REDCap	O
)	O
,	O
where	O
study	O
personnel	O
were	O
blinded	O
to	O
allocation	O
prior	O
to	O
randomization	O
,	O
and	O
participants	O
would	O
be	O
randomized	O
once	O
eligibility	O
was	O
determined	O
.	O

The	O
apps	O
were	O
developed	O
by	O
the	O
Center	O
for	O
Behavioral	O
Intervention	O
Technologies	O
(	O
CBITs	O
;	O
Lattie	O
et	O
al	O
.	O
,	O
2016	O
)	O
,	O
and	O
unlike	O
other	O
apps	O
on	O
the	O
market	O
,	O
were	O
selected	O
for	O
being	O
free	O
of	O
cost	O
,	O
and	O
complying	O
with	O
empirically	O
-	O
supported	O
behavioral	O
and	O
cognitive	O
intervention	O
strategies	O
.	O

Boost	O
Me	O
and	O
Thought	O
Challenger	O
participants	O
received	O
six	O
weeks	O
of	O
weekly	O
coaching	O
sessions	O
,	O
didactic	O
content	O
delivery	O
(	O
one	O
lesson	O
per	O
week	O
)	O
,	O
and	O
use	O
of	O
the	O
app	O
(	O
emailed	O
to	O
participants	O
via	O
an	O
attachment	O
they	O
downloaded	O
directly	O
to	O
their	O
phones	O
)	O
.	O

The	O
waitlist	O
control	O
group	O
did	O
not	O
receive	O
any	O
intervention	O
until	O
the	O
passage	O
of	O
10	O
weeks	O
occurred	O
,	O
to	O
account	O
for	O
both	O
the	O
intervention	O
period	O
(	O
six	O
weeks	O
)	O
and	O
follow	O
-	O
up	O
period	O
(	O
four	O
weeks	O
)	O
.	O

Following	O
their	O
completion	O
of	O
the	O
final	O
assessment	O
,	O
waitlist	O
control	O
participants	O
were	O
given	O
access	O
to	O
both	O
apps	O
.	O

Boost	O
Me	O
is	O
an	O
Android	O
app	O
based	O
upon	O
activity	O
scheduling	O
,	O
a	O
core	O
strategy	O
of	O
BA	O
,	O
which	O
aims	O
to	O
increase	O
rewarding	O
activities	O
and	O
monitoring	O
of	O
mood	O
in	O
relation	O
to	O
behavior	O
(	O
J	O
.	O

S	O
.	O

Beck	O
,	O
2011	O
)	O
.	O

Boost	O
Me	O
included	O
a	O
persistent	O
notification	O
(	O
i	O
.	O
e	O
.	O
,	O
a	O
small	O
box	O
in	O
the	O
Android	O
notification	O
tray	O
that	O
would	O
remain	O
visible	O
throughout	O
the	O
day	O
)	O
to	O
prompt	O
users	O
to	O
reflect	O
if	O
they	O
“Need	O
a	O
Boost	O
?	O
”	O
.	O

Boost	O
Me	O
is	O
currently	O
publicly	O
available	O
without	O
cost	O
.	O

Thought	O
Challenger	O
is	O
an	O
Android	O
app	O
based	O
upon	O
thought	O
restructuring	O
,	O
the	O
core	O
strategy	O
in	O
Cognitive	O
Therapy	O
(	O
CT	O
)	O
that	O
involves	O
identifying	O
and	O
appraising	O
maladaptive	O
thoughts	O
and	O
creating	O
adaptive	O
counter	O
thoughts	O
(	O
J	O
.	O

S	O
.	O

Beck	O
,	O
2011	O
)	O
.	O

Thought	O
Challenger	O
has	O
demonstrated	O
efficacy	O
in	O
improving	O
CT	O
knowledge	O
and	O
skills	O
following	O
initial	O
use	O
,	O
as	O
established	O
through	O
previous	O
usability	O
testing	O
(	O
Stiles	O
-	O
Shields	O
et	O
al	O
.	O
,	O
2017	O
)	O
.	O

Unlike	O
Boost	O
Me	O
,	O
Thought	O
Challenger	O
was	O
not	O
designed	O
to	O
have	O
a	O
persistent	O
notification	O
in	O
the	O
Android	O
notification	O
tray	O
.	O

Thought	O
Challenger	O
is	O
currently	O
publicly	O
available	O
without	O
cost	O
.	O

Participants	O
randomized	O
to	O
Boost	O
Me	O
or	O
Thought	O
Challenger	O
received	O
weekly	O
coaching	O
via	O
phone	O
or	O
email	O
.	O

Email	O
was	O
utilized	O
as	O
a	O
means	O
of	O
contact	O
if	O
:	O
1	O
)	O
the	O
participant	O
was	O
unable	O
to	O
be	O
reached	O
via	O
phone	O
,	O
or	O
2	O
)	O
the	O
participant	O
requested	O
email	O
contact	O
for	O
a	O
given	O
week	O
.	O

Coaching	O
was	O
based	O
on	O
the	O
supportive	O
accountability	O
model	O
,	O
which	O
proposes	O
that	O
coaches	O
increase	O
adherence	O
to	O
apps	O
by	O
providing	O
accountability	O
in	O
the	O
context	O
of	O
a	O
supportive	O
relationship	O
(	O
Mohr	O
,	O
Cuijpers	O
,	O
&	O
Lehman	O
,	O
2011	O
)	O
.	O

The	O
first	O
coaching	O
call	O
involved	O
asking	O
the	O
participant	O
to	O
open	O
the	O
app	O
during	O
the	O
call	O
to	O
discuss	O
the	O
app	O
features	O
.	O

All	O
coaching	O
calls	O
were	O
brief	O
(	O
i	O
.	O
e	O
.	O
,	O
typically	O
five	O
minutes	O
or	O
less	O
)	O
and	O
were	O
aimed	O
at	O
maintaining	O
engagement	O
with	O
the	O
app	O
,	O
and	O
not	O
in	O
providing	O
therapeutic	O
intervention	O
(	O
e	O
.	O
g	O
.	O
,	O
“How	O
could	O
you	O
use	O
the	O
app	O
this	O
week	O
to	O
help	O
your	O
mood	O
?	O
”	O
“What	O
would	O
be	O
a	O
good	O
goal	O
for	O
using	O
the	O
app	O
this	O
week	O
?	O
”	O
)	O
.	O

The	O
same	O
master’s	O
level	O
licensed	O
clinician	O
provided	O
coaching	O
to	O
all	O
participants	O
in	O
the	O
trial	O
.	O

The	O
baseline	O
assessment	O
interview	O
was	O
conducted	O
via	O
telephone	O
.	O

To	O
maximize	O
blinding	O
,	O
only	O
self	O
-	O
report	O
measures	O
were	O
administered	O
beyond	O
the	O
baseline	O
assessment	O
.	O

Self	O
-	O
report	O
assessments	O
occurred	O
at	O
baseline	O
,	O
weeks	O
3	O
and	O
6	O
(	O
mid	O
-	O
and	O
end	O
-	O
of	O
-	O
treatment	O
)	O
,	O
and	O
at	O
week	O
10	O
(	O
one	O
-	O
month	O
post	O
-	O
treatment	O
follow	O
-	O
up	O
)	O
via	O
REDCap	O
,	O
electronic	O
data	O
capture	O
tools	O
hosted	O
at	O
the	O
University	O
(	O
Harris	O
et	O
al	O
.	O
,	O
2009	O
)	O
.	O

Assessments	O
were	O
spaced	O
in	O
this	O
way	O
to	O
minimize	O
possible	O
assessment	O
burden	O
for	O
participants	O
.	O

Participants	O
were	O
compensated	O
$15	O
and	O
$10	O
for	O
the	O
baseline	O
and	O
follow	O
-	O
up	O
assessments	O
,	O
respectively	O
.	O

The	O
PHQ	O
-	O
9	O
is	O
a	O
self	O
-	O
report	O
instrument	O
measuring	O
depressive	O
symptomology	O
(	O
Kroenke	O
&	O
Spitzer	O
,	O
2002	O
)	O
,	O
administered	O
at	O
all	O
time	O
points	O
.	O

The	O
PHQ	O
-	O
9	O
was	O
selected	O
as	O
the	O
primary	O
outcome	O
measure	O
due	O
to	O
its	O
frequent	O
use	O
in	O
primary	O
care	O
to	O
screen	O
for	O
and	O
monitor	O
depression	O
,	O
enhancing	O
generalizability	O
to	O
primary	O
care	O
settings	O
.	O

The	O
QIDS	O
is	O
a	O
16	O
-	O
item	O
interview	O
intended	O
to	O
evaluate	O
objective	O
,	O
evaluator	O
-	O
rated	O
symptom	O
severity	O
(	O
Rush	O
et	O
al	O
.	O
,	O
2003	O
)	O
.	O

The	O
Mini	O
International	O
Neuropsychiatric	O
Interview	O
(	O
MINI	O
)	O
is	O
a	O
structured	O
diagnostic	O
interview	O
to	O
diagnose	O
Diagnostic	B-coding_system
and	I-coding_system
Statistical	I-coding_system
Manual	I-coding_system
-	I-coding_system
IV	I-coding_system
(	I-coding_system
DSM	I-coding_system
-	I-coding_system
IV	I-coding_system
)	I-coding_system
and	O
International	B-coding_system
Statistical	I-coding_system
Classification	I-coding_system
of	I-coding_system
Diseases	I-coding_system
and	I-coding_system
Related	I-coding_system
Health	I-coding_system
Problems	I-coding_system
(	I-coding_system
ICD	I-coding_system
-	I-coding_system
10	I-coding_system
)	I-coding_system
psychiatric	B-phenotype
disorders	I-phenotype
(	O
Sheehan	O
et	O
al	O
.	O
,	O
1997	O
)	O
.	O

The	O
QIDS	O
and	O
MINI	O
were	O
administered	O
at	O
baseline	O
to	O
assess	O
whether	O
the	O
depressive	O
symptoms	O
had	O
been	O
present	O
for	O
at	O
least	O
two	O
weeks	O
and	O
determine	O
eligibility	O
based	O
upon	O
possible	O
comorbid	O
conditions	O
that	O
would	O
make	O
participation	O
in	O
the	O
trial	O
inappropriate	O
,	O
respectively	O
.	O

The	O
System	O
Usability	O
Scale	O
(	O
SUS	O
)	O
is	O
a	O
self	O
-	O
report	O
instrument	O
measuring	O
a	O
user’s	O
rating	O
of	O
a	O
product’s	O
usability	O
(	O
Brooke	O
,	O
1996	O
)	O
and	O
was	O
administered	O
at	O
weeks	O
3	O
and	O
6	O
for	O
the	O
Boost	O
Me	O
and	O
Thought	O
Challenger	O
participants	O
.	O

To	O
ensure	O
participant	O
safety	O
,	O
any	O
participant	O
rating	O
higher	O
than	O
“1	O
:	O
Several	O
Days	O
,	O
”	O
on	O
item	O
9	O
of	O
the	O
PHQ	O
-	O
9	O
(	O
i	O
.	O
e	O
.	O
,	O
“Thoughts	O
that	O
you	O
would	O
be	O
better	O
off	O
dead	O
,	O
or	O
of	O
hurting	O
yourself”	O
)	O
was	O
prompted	O
to	O
also	O
answer	O
the	O
Beck	O
Depression	O
Inventory	O
(	O
BDI	O
)	O
,	O
item	O
9	O
(	O
i	O
.	O
e	O
.	O
,	O
“Suicidal	O
Thoughts	O
or	O
Wishes”	O
;	O
A	O
.	O

T	O
.	O

Beck	O
,	O
Ward	O
,	O
Mendelson	O
,	O
Mock	O
,	O
&	O
Erbaugh	O
,	O
1961	O
)	O
.	O

Participants	O
then	O
received	O
a	O
notification	O
that	O
the	O
response	O
would	O
be	O
reviewed	O
within	O
one	O
business	O
day	O
and	O
that	O
s	O
/	O
he	O
should	O
go	O
to	O
the	O
nearest	O
emergency	O
department	O
or	O
call	O
911	O
in	O
the	O
case	O
of	O
an	O
emergency	O
.	O

If	O
a	O
participant	O
rated	O
a	O
“2”	O
or	O
higher	O
on	O
the	O
BDI	O
item	O
,	O
study	O
staff	O
were	O
notified	O
by	O
REDCap	O
to	O
trigger	O
an	O
administration	O
of	O
the	O
Columbia	O
-	O
Suicide	O
Risk	O
Assessment	O
via	O
telephone	O
(	O
Posner	O
et	O
al	O
.	O
,	O
2011	O
)	O
.	O

Any	O
participants	O
with	O
severe	O
suicidality	O
(	O
i	O
.	O
e	O
.	O
,	O
ideation	O
,	O
plan	O
,	O
and	O
intent	O
)	O
were	O
excluded	O
.	O

Baseline	O
demographic	O
variables	O
were	O
compared	O
across	O
treatment	O
arms	O
using	O
one	O
-	O
way	O
Analysis	O
of	O
Variance	O
(	O
ANOVA	O
)	O
and	O
chi	O
-	O
square	O
tests	O
of	O
association	O
.	O

A	O
repeated	O
measures	O
ANOVA	O
was	O
conducted	O
to	O
examine	O
depressive	O
symptoms	O
over	O
time	O
and	O
across	O
treatment	O
groups	O
.	O

Participants	O
with	O
missing	O
data	O
were	O
eliminated	O
casewise	O
.	O

t	O
-	O
Tests	O
were	O
conducted	O
to	O
compare	O
usage	O
and	O
perceptions	O
of	O
usability	O
across	O
apps	O
.	O

Any	O
participants	O
without	O
usage	O
(	O
e	O
.	O
g	O
.	O
,	O
launch	O
of	O
the	O
app	O
)	O
or	O
engagement	O
with	O
the	O
coach	O
were	O
included	O
in	O
the	O
analyses	O
,	O
as	O
that	O
is	O
a	O
representation	O
of	O
their	O
total	O
usage	O
of	O
these	O
services	O
.	O

To	O
examine	O
the	O
relationship	O
between	O
usage	O
and	O
change	O
in	O
depressive	O
symptoms	O
,	O
bivariate	O
correlations	O
were	O
run	O
between	O
the	O
usage	O
variables	O
and	O
change	O
in	O
depression	O
between	O
baseline	O
and	O
end	O
of	O
treatment	O
.	O

Bivariate	O
correlations	O
were	O
run	O
among	O
the	O
number	O
of	O
coaching	O
sessions	O
and	O
duration	O
of	O
calls	O
,	O
usage	O
variables	O
,	O
and	O
change	O
in	O
depression	O
between	O
baseline	O
and	O
end	O
of	O
treatment	O
(	O
week	O
6	O
)	O
.	O

All	O
analyses	O
were	O
run	O
in	O
IBM	O
SPSS	O
Statistics	O
(	O
v23	O
)	O
,	O
at	O
the	O
nominal	O
0	O
.	O
05	O
type	O
I	O
error	O
rate	O
.	O

Post	O
hoc	O
tests	O
were	O
run	O
using	O
a	O
Bonferroni	O
correction	O
to	O
prevent	O
inflation	O
of	O
the	O
overall	O
type	O
I	O
error	O
rate	O
.	O

According	O
to	O
the	O
policy	O
notice	O
,	O
VHA	O
medical	O
centres	O
are	O
required	O
to	O
review	O
the	O
cases	O
of	O
very	O
high	O
-	O
risk	O
patients	O
.	O

Half	O
of	O
facilities	O
(	O
randomly	O
assigned	O
)	O
will	O
be	O
asked	O
to	O
complete	O
an	O
action	O
plan	O
and	O
receive	O
additional	O
oversight	O
and	O
facilitation	O
from	O
OMHSP	O
if	O
at	O
least	O
97	O
%	O
of	O
cases	O
are	O
not	O
reviewed	O
(	O
the	O
policy	O
treatment	O
group	O
)	O
.	O

Facilities	O
that	O
fail	O
to	O
meet	O
the	O
targeted	O
rate	O
for	O
completing	O
case	O
reviews	O
of	O
very	O
high	O
-	O
risk	O
patients	O
will	O
be	O
tasked	O
to	O
review	O
these	O
patients	O
and	O
report	O
quarterly	O
to	O
the	O
OMHSP	O
on	O
progress	O
towards	O
executing	O
an	O
action	O
plan	O
to	O
meet	O
the	O
metric	O
.	O

The	O
other	O
half	O
of	O
VHA	O
medical	O
centres	O
will	O
receive	O
a	O
version	O
of	O
the	O
notice	O
without	O
any	O
mention	O
of	O
action	O
plans	O
,	O
oversight	O
or	O
facilitation	O
(	O
the	O
policy	O
control	O
group	O
)	O
.	O

Within	O
the	O
policy	O
treatment	O
and	O
control	O
groups	O
,	O
separately	O
,	O
the	O
definition	O
of	O
very	O
high	O
-	O
risk	O
patients	O
will	O
be	O
altered	O
over	O
time	O
in	O
a	O
stepped	O
-	O
wedge	O
manner	O
.	O

This	O
will	O
allow	O
us	O
to	O
evaluate	O
the	O
effect	O
of	O
being	O
targeted	O
for	O
case	O
review	O
by	O
STORM	O
.	O

For	O
the	O
first	O
8	O
months	O
,	O
all	O
medical	O
centres	O
will	O
be	O
required	O
to	O
conduct	O
case	O
reviews	O
for	O
patients	O
in	O
the	O
top	O
1	O
%	O
of	O
risk	O
for	O
an	O
SAE	O
.	O

At	O
baseline	O
,	O
patients	O
with	O
risk	O
scores	O
between	O
1	O
%	O
and	O
5	O
%	O
are	O
not	O
displayed	O
in	O
STORM	O
(	O
control	O
group	O
)	O
.	O

At	O
month	O
9	O
,	O
half	O
of	O
the	O
policy	O
treatment	O
and	O
half	O
of	O
the	O
policy	O
control	O
facilities	O
will	O
be	O
randomly	O
assigned	O
to	O
review	O
patients	O
identified	O
as	O
high	O
risk	O
under	O
an	O
expanded	O
risk	O
threshold	O
(	O
up	O
to	O
5	O
%	O
)	O
.	O

At	O
month	O
15	O
,	O
all	O
facilities	O
will	O
be	O
required	O
to	O
review	O
patients	O
in	O
the	O
top	O
5	O
%	O
of	O
risk	O
.	O

This	O
stepped	O
-	O
wedge	O
design	O
creates	O
a	O
cohort	O
of	O
patients	O
who	O
have	O
opioid	O
prescriptions	O
and	O
are	O
between	O
the	O
top	O
1	O
%	O
and	O
top	O
5	O
%	O
of	O
SAE	O
risk	O
.	O

Half	O
of	O
these	O
patients	O
will	O
have	O
mandated	O
case	O
review	O
(	O
the	O
STORM	O
treatment	O
group	O
)	O
and	O
half	O
will	O
receive	O
usual	O
care	O
(	O
the	O
STORM	O
control	O
group	O
)	O
.	O

Figure	O
2	O
presents	O
the	O
two	O
interventions	O
and	O
timeline	O
.	O

Project	O
timeline	O
.	O

STORM	O
,	O
Stratification	O
Tool	O
for	O
Opioid	O
Risk	O
Mitigation	O
;	O
VHA	O
,	O
Veterans	O
Health	O
Administration	O
.	O

Randomisation	O
was	O
conducted	O
in	O
two	O
steps	O
,	O
using	O
permuted	O
block	O
randomisation	O
.	O

Permuted	O
block	O
randomisation	O
allowed	O
us	O
to	O
create	O
groups	O
with	O
an	O
even	O
number	O
of	O
facilities	O
.	O

First	O
,	O
the	O
140	O
VHA	O
medical	O
centres	O
were	O
split	O
into	O
two	O
groups	O
with	O
70	O
medical	O
centres	O
each	O
in	O
the	O
policy	O
treatment	O
and	O
policy	O
control	O
groups	O
.	O

Then	O
,	O
to	O
apply	O
the	O
stepped	O
-	O
wedge	O
design	O
for	O
analysis	O
of	O
STORM	O
treatment	O
versus	O
control	O
,	O
the	O
70	O
medical	O
centres	O
in	O
each	O
group	O
were	O
split	O
into	O
two	O
groups	O
of	O
35	O
hospitals	O
using	O
permuted	O
block	O
randomisation	O
.	O

The	O
STORM	O
dashboard	O
will	O
label	O
patients	O
as	O
‘very	O
high	O
risk’	O
using	O
the	O
respective	O
risk	O
score	O
cut	O
-	O
offs	O
(	O
top	O
1	O
%	O
and	O
top	O
5	O
%	O
)	O
at	O
each	O
VHA	O
medical	O
centre	O
.	O

The	O
risk	O
scores	O
will	O
not	O
be	O
displayed	O
,	O
and	O
providers	O
will	O
be	O
blinded	O
to	O
changes	O
in	O
the	O
risk	O
score	O
threshold	O
that	O
defines	O
‘very	O
high	O
risk’	O
.	O

Our	O
analytical	O
cohort	O
will	O
include	O
approximately	O
100	O
000	O
VHA	O
patients	O
with	O
an	O
opioid	O
prescription	O
in	O
the	O
top	O
10	O
%	O
of	O
risk	O
scores	O
.	O

Patients	O
are	O
eligible	O
for	O
inclusion	O
in	O
the	O
study	O
cohort	O
for	O
the	O
first	O
18	O
months	O
of	O
the	O
study	O
.	O

If	O
a	O
patient	O
has	O
an	O
active	O
opioid	O
prescription	O
on	O
the	O
day	O
the	O
policy	O
notice	O
is	O
released	O
and	O
has	O
a	O
risk	O
score	O
in	O
the	O
top	O
10	O
%	O
of	O
risk	O
,	O
he	O
or	O
she	O
will	O
automatically	O
enter	O
the	O
study	O
.	O

Other	O
patients	O
will	O
enter	O
the	O
cohort	O
on	O
the	O
date	O
of	O
their	O
first	O
prescription	O
that	O
exceeds	O
the	O
10	O
%	O
risk	O
threshold	O
.	O

Patients	O
will	O
be	O
followed	O
for	O
a	O
minimum	O
of	O
3	O
months	O
after	O
they	O
are	O
first	O
prescribed	O
an	O
opioid	O
.	O

Follow	O
-	O
up	O
will	O
continue	O
until	O
the	O
last	O
day	O
of	O
the	O
project	O
(	O
30	O
September	O
2019	O
)	O
or	O
date	O
of	O
death	O
.	O

Our	O
primary	O
analyses	O
of	O
the	O
effect	O
of	O
policy	O
language	O
will	O
focus	O
on	O
patients	O
in	O
the	O
top	O
1	O
%	O
of	O
risk	O
,	O
and	O
our	O
primary	O
analyses	O
of	O
the	O
effect	O
of	O
STORM	O
will	O
be	O
focused	O
on	O
patients	O
between	O
the	O
top	O
5	O
%	O
and	O
top	O
1	O
%	O
of	O
risk	O
scores	O
.	O

Over	O
the	O
course	O
of	O
this	O
study	O
,	O
we	O
anticipate	O
over	O
50	O
000	O
patients	O
will	O
have	O
risk	O
scores	O
in	O
the	O
top	O
5	O
%	O
of	O
risk	O
.	O

Our	O
primary	O
outcome	O
of	O
interest	O
is	O
opioid	B-phenotype
-	I-phenotype
related	I-phenotype
SAEs	I-phenotype
(	I-phenotype
eg	I-phenotype
,	I-phenotype
opioid	I-phenotype
overdose	I-phenotype
,	I-phenotype
accidental	I-phenotype
falls	I-phenotype
,	I-phenotype
and	I-phenotype
possible	I-phenotype
and	I-phenotype
confirmed	I-phenotype
suicide	I-phenotype
attempts	I-phenotype
,	I-phenotype
etc	I-phenotype
(	O
see	O
online	O
supplementary	O
A	O
for	O
International	B-coding_system
Classification	I-coding_system
of	I-coding_system
Diseases	I-coding_system
(	I-coding_system
ICD	I-coding_system
)	I-coding_system
-	I-coding_system
9	I-coding_system
and	O
ICD	B-coding_system
-	I-coding_system
10	I-coding_system
codes	O
)	O
)	O
.	O

The	O
outcome	O
measure	O
is	O
censored	O
by	O
death	O
or	O
end	O
of	O
study	O
.	O

The	O
STORM	O
risk	O
score	O
that	O
a	O
patient	O
receives	O
when	O
he	O
or	O
she	O
first	O
enters	O
the	O
study	O
(	O
baseline	O
risk	O
score	O
)	O
will	O
be	O
used	O
as	O
a	O
control	O
variable	O
,	O
since	O
it	O
reflects	O
the	O
probability	O
that	O
the	O
patient	O
will	O
have	O
an	O
opioid	O
-	O
related	O
SAE	O
outcome	O
.	O

The	O
risk	O
score	O
also	O
captures	O
the	O
risk	O
associated	O
with	O
general	O
demographic	O
characteristics	O
(	O
ie	O
,	O
age	O
,	O
race	O
,	O
gender	O
)	O
and	O
comorbidities	O
(	O
ie	O
,	O
prior	O
and	O
current	O
history	O
of	O
disease	O
)	O
.	O

In	O
addition	O
,	O
facility	O
indicators	O
and	O
time	O
in	O
study	O
(	O
indicators	O
for	O
current	O
and	O
past	O
months	O
)	O
will	O
be	O
used	O
as	O
control	O
variables	O
.	O

Although	O
case	O
review	O
is	O
mandated	O
,	O
it	O
is	O
unlikely	O
that	O
all	O
providers	O
will	O
review	O
all	O
identified	O
cases	O
.	O

In	O
addition	O
,	O
the	O
risk	O
mitigation	O
strategies	O
suggested	O
in	O
the	O
STORM	O
dashboard	O
are	O
optional	O
.	O

If	O
lower	O
SAE	O
rates	O
in	O
treatment	O
facilities	O
are	O
achieved	O
,	O
this	O
could	O
be	O
due	O
to	O
higher	O
case	O
review	O
rates	O
or	O
to	O
greater	O
use	O
of	O
risk	O
mitigation	O
strategies	O
.	O

That	O
is	O
,	O
the	O
case	O
review	O
rate	O
acts	O
as	O
a	O
mediator	O
of	O
the	O
relationship	O
between	O
risk	O
identification	O
and	O
opioid	O
-	O
related	O
SAEs	O
.	O

In	O
addition	O
,	O
risk	O
mitigation	O
strategies	O
are	O
intended	O
to	O
reduce	O
risk	O
of	O
adverse	O
outcomes	O
.	O

Thus	O
,	O
the	O
SAE	O
rates	O
should	O
be	O
lower	O
if	O
risk	O
mitigation	O
strategies	O
are	O
more	O
frequently	O
implemented	O
.	O

We	O
will	O
test	O
whether	O
facility	O
-	O
level	O
rates	O
of	O
case	O
review	O
and	O
patient	O
-	O
level	O
risk	O
mitigation	O
strategies	O
implemented	O
are	O
mediators	O
of	O
the	O
primary	O
outcome	O
.	O

STORM	O
risk	O
scores	O
are	O
calculated	O
and	O
updated	O
on	O
a	O
daily	O
basis	O
.	O

On	O
a	O
patient’s	O
entry	O
into	O
the	O
study	O
cohort	O
(	O
ie	O
,	O
at	O
the	O
date	O
of	O
the	O
first	O
opioid	O
prescription	O
on	O
or	O
after	O
the	O
release	O
of	O
the	O
policy	O
notice	O
)	O
,	O
his	O
or	O
her	O
risk	O
score	O
will	O
be	O
recorded	O
.	O

VHA	O
has	O
a	O
centralised	O
corporate	O
data	O
warehouse	O
(	O
CDW	O
)	O
where	O
all	O
patient	O
data	O
,	O
including	O
demographics	O
,	O
appointments	O
,	O
visits	O
,	O
diagnoses	O
and	O
prescriptions	O
are	O
stored	O
.	O

From	O
these	O
data	O
,	O
any	O
opioid	O
-	O
related	O
SAEs	O
for	O
study	O
patients	O
will	O
be	O
identified	O
.	O

The	O
case	O
review	O
notes	O
and	O
case	O
review	O
date	O
,	O
along	O
with	O
risk	O
mitigation	O
strategies	O
implemented	O
for	O
each	O
patient	O
,	O
will	O
also	O
be	O
collected	O
in	O
CDW	O
.	O

Sample	O
size	O
was	O
calculated	O
using	O
the	O
data	O
that	O
informed	O
the	O
original	O
STORM	O
model	O
.	O

7	O
That	O
dataset	O
included	O
1	O
135	O
600	O
patients	O
with	O
an	O
opioid	O
prescription	O
from	O
VHA	O
anytime	O
in	O
2010	O
.	O

The	O
sample	O
size	O
calculation	O
for	O
the	O
effectiveness	O
of	O
policy	O
was	O
completed	O
using	O
a	O
baseline	O
SAE	O
rate	O
of	O
0	O
.	O
029	O
per	O
person	O
-	O
month	O
for	O
the	O
policy	O
control	O
group	O
,	O
140	O
medical	O
centres	O
with	O
an	O
average	O
of	O
2112	O
patient	O
-	O
months	O
and	O
an	O
intraclass	O
correlation	O
coefficient	O
(	O
ICC	O
)	O
of	O
0	O
.	O
01	O
in	O
Stata’s	O
clustersampsi	O
function	O
.	O

11	O
For	O
the	O
effectiveness	O
of	O
STORM	O
,	O
Stata’s	O
stepped	O
-	O
wedge	O
function	O
was	O
used	O
to	O
account	O
for	O
the	O
changes	O
in	O
medical	O
centres	O
and	O
patients	O
included	O
in	O
the	O
treatment	O
group	O
over	O
time	O
.	O

12	O
To	O
calculate	O
sample	O
size	O
,	O
we	O
used	O
an	O
expected	O
baseline	O
SAE	O
rate	O
of	O
0	O
.	O
01	O
per	O
person	O
-	O
month	O
for	O
the	O
STORM	O
control	O
group	O
with	O
an	O
average	O
of	O
352	O
patients	O
per	O
medical	O
centre	O
in	O
the	O
1	O
%	O
–5	O
%	O
risk	O
group	O
,	O
and	O
we	O
assumed	O
an	O
ICC	O
of	O
0	O
.	O
01	O
.	O

Based	O
on	O
these	O
baseline	O
rates	O
,	O
with	O
an	O
alpha	O
of	O
0	O
.	O
05	O
,	O
we	O
can	O
detect	O
a	O
difference	O
between	O
the	O
policy	O
treatment	O
and	O
control	O
groups	O
of	O
28	O
%	O
(	O
ie	O
,	O
an	O
SAE	O
rate	O
difference	O
at	O
least	O
as	O
large	O
as	O
0	O
.	O
037	O
or	O
at	O
least	O
as	O
small	O
as	O
0	O
.	O
021	O
)	O
with	O
80	O
%	O
power	O
.	O

The	O
evaluation	O
can	O
also	O
detect	O
a	O
difference	O
of	O
15	O
%	O
between	O
the	O
STORM	O
treatment	O
and	O
control	O
groups	O
with	O
80	O
%	O
power	O
(	O
ie	O
,	O
an	O
SAE	O
rate	O
difference	O
at	O
least	O
as	O
large	O
as	O
0	O
.	O
012	O
or	O
at	O
least	O
as	O
small	O
as	O
0	O
.	O
009	O
)	O
.	O

The	O
data	O
will	O
be	O
analysed	O
using	O
an	O
intention	O
-	O
to	O
-	O
treat	O
approach	O
with	O
patient	O
-	O
month	O
-	O
level	O
Cox	O
proportional	O
hazards	O
models	O
for	O
both	O
interventions	O
:	O
(	O
1	O
)	O
effectiveness	O
of	O
policy	O
and	O
(	O
2	O
)	O
effectiveness	O
of	O
STORM	O
.	O

For	O
the	O
effectiveness	O
of	O
policy	O
analysis	O
,	O
a	O
patient	O
-	O
level	O
time	O
-	O
to	O
-	O
event	O
Cox	O
proportional	O
hazards	O
model	O
will	O
be	O
used	O
to	O
evaluate	O
the	O
difference	O
between	O
facilities	O
with	O
and	O
without	O
facilitation	O
language	O
in	O
the	O
notice	O
,	O
controlling	O
for	O
the	O
different	O
targeted	O
risk	O
group	O
at	O
different	O
times	O
and	O
facility	O
fixed	O
effects	O
.	O

Similarly	O
,	O
for	O
the	O
effectiveness	O
of	O
STORM	O
analysis	O
,	O
the	O
primary	O
outcome	O
will	O
be	O
modelled	O
with	O
a	O
patient	O
-	O
level	O
time	O
-	O
to	O
-	O
event	O
Cox	O
proportional	O
hazards	O
model	O
to	O
evaluate	O
the	O
difference	O
between	O
the	O
STORM	O
treatment	O
and	O
control	O
groups	O
,	O
controlling	O
for	O
difference	O
in	O
policy	O
and	O
facility	O
fixed	O
effects	O
.	O

We	O
will	O
estimate	O
the	O
effect	O
of	O
the	O
intervention	O
during	O
a	O
single	O
month	O
as	O
well	O
as	O
the	O
cumulative	O
effect	O
of	O
the	O
intervention	O
.	O

In	O
order	O
to	O
account	O
for	O
diminishing	O
returns	O
of	O
additional	O
months	O
of	O
exposure	O
to	O
time	O
in	O
STORM	O
,	O
we	O
estimate	O
separate	O
effects	O
for	O
1	O
month	O
before	O
treatment	O
,	O
2	O
months	O
before	O
treatment	O
and	O
so	O
on	O
.	O

Equations	O
1	O
and	O
2	O
represent	O
the	O
planned	O
analyses	O
for	O
effectiveness	O
of	O
policy	O
and	O
effectiveness	O
of	O
STORM	O
,	O
respectively	O
.	O

(	O
1	O
)	O
O	O
u	O
t	O
c	O
o	O
m	O
e	O
i	O
t	O
k	O
=	O
i	O
n	O
t	O
e	O
r	O
c	O
e	O
p	O
t	O
+	O
∝	O
i	O
+	O
β	O
t	O
+	O
P	O
i	O
γ	O
+	O
x	O
k	O
ɸ	O
+	O
ε	O
i	O
t	O
k	O
O	O
u	O
t	O
c	O
o	O
m	O
e	O
i	O
t	O
k	O
=	O
i	O
n	O
t	O
e	O
r	O
c	O
e	O
p	O
t	O
+	O
∝	O
i	O
+	O
β	O
t	O
+	O
P	O
i	O
γ	O
+	O
R	O
i	O
t	O
θ	O
t	O
(	O
2	O
)	O
+	O
R	O
i	O
t	O
−	O
1	O
θ	O
−	O
1	O
+	O
R	O
i	O
t	O
−	O
2	O
θ	O
−	O
2	O
+	O
…	O
+	O
R	O
i	O
t	O
−	O
n	O
θ	O
−	O
n	O
+	O
x	O
k	O
ɸ	O
+	O
ε	O
i	O
t	O
k	O

In	O
these	O
equations	O
,	O
i	O
represents	O
medical	O
centres	O
,	O
t	O
is	O
time	O
points	O
(	O
ie	O
,	O
months	O
)	O
,	O
n	O
is	O
months	O
before	O
month	O
t	O
,	O
and	O
k	O
is	O
individuals	O
.	O

In	O
addition	O
,	O
∝	O
is	O
a	O
random	O
medical	O
centre	O
effect	O
,	O
β	O
is	O
a	O
vector	O
of	O
fixed	O
time	O
effects	O
,	O
P	O
is	O
a	O
policy	O
indicator	O
(	O
P	O
=1	O
if	O
policy	O
treatment	O
medical	O
centre	O
,	O
0	O
if	O
policy	O
control	O
medical	O
centre	O
)	O
,	O
γ	O
is	O
a	O
fixed	O
effect	O
for	O
policy	O
,	O
R	O
is	O
a	O
risk	O
targeting	O
indicator	O
(	O
1	O
if	O
patient	O
in	O
the	O
1	O
%	O
-	O
5	O
%	O
risk	O
stratum	O
in	O
the	O
treatment	O
medical	O
centre	O
i	O
at	O
time	O
t	O
,	O
0	O
otherwise	O
)	O
,	O
θ	O
t	O
is	O
a	O
fixed	O
risk	O
targeting	O
effect	O
at	O
time	O
t	O
,	O
θ	O
−	O
n	O
represents	O
lagged	O
risk	O
targeting	O
effects	O
from	O
targeting	O
at	O
time	O
t	O
−	O
n	O
,	O
x	O
k	O
represents	O
baseline	O

covariates	O
,	O
represents	O
fixed	O
effects	O
for	O
baseline	O
covariates	O
and	O
ε	O
is	O
residual	O
error	O
.	O

In	O
equation	O
1	O
,	O
we	O
are	O
interested	O
in	O
estimates	O
of	O
γ	O
,	O
the	O
policy	O
treatment	O
effect	O
.	O

In	O
equation	O
2	O
,	O
we	O
are	O
interested	O
in	O
estimates	O
of	O
θ	O
,	O
the	O
risk	O
targeting	O
effect	O
at	O
month	O
t	O
,	O
as	O
well	O
as	O
in	O
estimates	O
of	O
θ	O
+	O
θ	O
−	O
1	O
+	O
θ	O
−	O
n	O
,	O
the	O
cumulative	O
effect	O
of	O
months	O
of	O
risk	O
targeting	O
experienced	O
prior	O
to	O
and	O
including	O
month	O
t	O
.	O

A	O
statistically	O
significant	O
difference	O
between	O
the	O
two	O
policy	O
groups	O
(	O
γ	O
)	O
suggests	O
that	O
the	O
threat	O
of	O
facilitation	O
modifies	O
VHA	O
providers’	O
behaviour	O
to	O
increase	O
surveillance	O
on	O
very	O
high	O
-	O
risk	O
opioid	O
-	O
prescribed	O
patients	O
and	O
to	O
apply	O
SAE	O
risk	O
mitigation	O
strategies	O
.	O

A	O
statistically	O
significant	O
effect	O
of	O
the	O
STORM	O
treatment	O
group	O
(	O
θ	O
)	O
indicates	O
that	O
when	O
opioid	O
-	O
prescribed	O
patients	O
are	O
required	O
to	O
be	O
case	O
reviewed	O
,	O
they	O
are	O
less	O
likely	O
to	O
experience	O
opioid	O
-	O
related	O
SAEs	O
.	O

Our	O
intention	O
-	O
to	O
-	O
treat	O
analysis	O
assumes	O
that	O
patients’	O
risk	O
scores	O
are	O
relatively	O
stable	O
over	O
the	O
study	O
period	O
,	O
and	O
that	O
baseline	O
risk	O
closely	O
approximates	O
the	O
risk	O
level	O
of	O
a	O
patient	O
at	O
the	O
time	O
their	O
facility	O
is	O
randomised	O
to	O
target	O
an	O
expanded	O
risk	O
threshold	O
.	O

However	O
,	O
it	O
is	O
possible	O
that	O
risk	O
scores	O
may	O
change	O
over	O
time	O
for	O
patients	O
who	O
receive	O
long	O
-	O
term	O
opioid	O
therapy	O
and	O
/	O
or	O
frequent	O
short	O
-	O
term	O
opioid	O
therapy	O
.	O

Risk	O
scores	O
at	O
baseline	O
may	O
simultaneously	O
predict	O
prospective	O
risk	O
scores	O
,	O
likelihood	O
of	O
exposure	O
to	O
the	O
intervention	O
and	O
risk	O
of	O
SAEs	O
.	O

In	O
addition	O
,	O
a	O
patient’s	O
risk	O
score	O
at	O
a	O
given	O
month	O
may	O
be	O
affected	O
by	O
the	O
version	O
of	O
policy	O
or	O
level	O
of	O
risk	O
threshold	O
in	O
place	O
at	O
a	O
facility	O
in	O
previous	O
months	O
.	O

To	O
account	O
for	O
this	O
potential	O
endogeneity	O
,	O
we	O
plan	O
to	O
conduct	O
a	O
secondary	O
survival	O
analysis	O
that	O
treats	O
the	O
facility	O
treatment	O
indicator	O
and	O
interaction	O
between	O
baseline	O
risk	O
score	O
and	O
facility	O
treatment	O
as	O
instrumental	O
variables	O
.	O

We	O
will	O
conduct	O
a	O
sensitivity	O
analysis	O
to	O
evaluate	O
the	O
effect	O
of	O
facilitation	O
during	O
the	O
study	O
period	O
on	O
the	O
policy	O
treatment	O
group	O
.	O

The	O
time	O
when	O
each	O
medical	O
centre	O
is	O
notified	O
that	O
they	O
failed	O
to	O
meet	O
the	O
targeted	O
case	O
review	O
rate	O
will	O
be	O
tracked	O
and	O
the	O
cohort	O
will	O
be	O
stratified	O
into	O
three	O
groups	O
:	O
policy	O
control	O
,	O
policy	O
treatment	O
with	O
facilitation	O
and	O
policy	O
treatment	O
without	O
facilitation	O
.	O

A	O
statistically	O
significant	O
effect	O
of	O
treatment	O
with	O
facilitation	O
compared	O
with	O
treatment	O
without	O
facilitation	O
indicates	O
facilitation	O
may	O
lead	O
to	O
greater	O
reduction	O
in	O
patients’	O
risk	O
of	O
opioid	O
-	O
related	O
SAEs	O
.	O

We	O
also	O
will	O
evaluate	O
whether	O
the	O
effect	O
of	O
the	O
threat	O
of	O
but	O
not	O
actual	O
facilitation	O
is	O
associated	O
with	O
reduced	O
risk	O
of	O
opioid	O
-	O
related	O
SAEs	O
.	O

Patients	O
and	O
public	O
were	O
not	O
involved	O
in	O
the	O
development	O
,	O
design	O
,	O
recruitment	O
and	O
randomisation	O
of	O
this	O
study	O
.	O

Randomised	O
roll	O
-	O
out	O
of	O
STORM	O
to	O
medical	O
centres	O
is	O
occurring	O
as	O
part	O
of	O
the	O
OMHSP’s	O
activities	O
and	O
does	O
not	O
require	O
IRB	O
approval	O
.	O

This	O
trial	O
has	O
been	O
registered	O
at	O
ISRCTN	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
isrctn	O
.	O
com	O
/	O
ISRCTN16012111	O
)	O
.	O

In	O
addition	O
,	O
our	O
partner	O
at	O
the	O
VHA	O
Center	O
for	O
Health	O
Equity	O
Research	O
and	O
Promotion	O
is	O
conducting	O
a	O
complementary	O
evaluation	O
to	O
identify	O
strategies	O
used	O
to	O
implement	O
STORM	O
across	O
the	O
two	O
policy	O
groups	O
as	O
well	O
as	O
barriers	O
and	O
facilitators	O
to	O
STORM	O
implementation	O
(	O
https	O
:	O
/	O
/	O
www	O
.	O
hsrd	O
.	O
research	O
.	O
va	O
.	O
gov	O
/	O
research	O
/	O
abstracts	O
.	O
cfm	O
?	O
Project	O
_	O
ID=2141704557	O
)	O
.	O

PEPReC’s	O
protocol	O
has	O
been	O
presented	O
at	O
the	O
2017	O
AcademyHealth	O
National	O
Health	O
Policy	O
Conference	O
and	O
a	O
VHA	O
cyberseminar	O
.	O

We	O
are	O
submitting	O
abstracts	O
about	O
this	O
protocol	O
and	O
randomised	O
programme	O
evaluations	O
to	O
other	O
national	O
conferences	O
.	O

Once	O
the	O
study	O
is	O
completed	O
,	O
the	O
following	O
two	O
papers	O
will	O
be	O
prepared	O
and	O
submitted	O
to	O
peer	O
-	O
reviewed	O
journals	O
;	O
(	O
1	O
)	O
Reduction	O
of	O
opioid	O
-	O
related	O
SAEs	O
in	O
VHA	O
medical	O
centres	O
with	O
and	O
without	O
facilitation	O
and	O
(	O
2	O
)	O
Effect	O
of	O
identification	O
of	O
high	O
-	O
risk	O
patients	O
via	O
the	O
STORM	O
dashboard	O
on	O
opioid	O
-	O
related	O
SAEs	O
.	O

Beyond	O
providing	O
rigorous	O
evidence	O
of	O
the	O
impact	O
of	O
STORM	O
on	O
patient	O
outcomes	O
,	O
this	O
study	O
will	O
provide	O
insight	O
to	O
OMHSP	O
and	O
VHA	O
leadership	O
about	O
how	O
to	O
optimise	O
the	O
STORM	O
dashboard	O
to	O
reduce	O
SAEs	O
among	O
high	O
-	O
risk	O
patients	O
.	O

We	O
followed	O
the	O
American	O
Society	O
for	O
Addiction	O
Medicine’s	O
(	O
ASAM	O
)	O
specifications	O
for	O
opioid	O
use	O
disorder	O
diagnosis	O
using	O
International	B-coding_system
Classifications	I-coding_system
of	I-coding_system
Diseases	I-coding_system
−10	I-coding_system
th	I-coding_system
(	I-coding_system
ICD	I-coding_system
-	I-coding_system
10	I-coding_system
)	I-coding_system
Edition	I-coding_system
-	I-coding_system
CM	I-coding_system
codes	O
(	O
Harris	O
,	O
Weisner	O
,	O
et	O
al	O
.	O
,	O
2016	O
)	O
.	O

Using	O
national	O
VHA	O
outpatient	O
and	O
inpatient	O
clinical	O
records	O
,	O
we	O
identified	O
veteran	O
patients	O
who	O
received	O
an	O
opioid	O
use	O
disorder	O
diagnosis	O
during	O
an	O
outpatient	O
visit	O
or	O
inpatient	O
stay	O
in	O
FY16	O
(	O
October	O
1	O
,	O
2015	O
through	O
September	O
30	O
,	O
2016	O
)	O
and	O
FY17	O
(	O
October	O
1	O
,	O
2016	O
through	O
September	O
30	O
,	O
2017	O
)	O
.	O

Opioid	B-phenotype
disorder	I-phenotype
diagnosis	I-phenotype
ICD	B-coding_system
-	I-coding_system
10	I-coding_system
codes	O
included	O
F11	B-code
.	I-code
20	I-code
,	O
F11	B-code
.	I-code
10	I-code
,	O
F11	B-code
.	I-code
122	I-code
,	O
F11	B-code
.	I-code
222	I-code
,	O
F11	B-code
.	I-code
120	I-code
,	O
F11	B-code
.	I-code
129	I-code
,	O
F11	B-code
.	I-code
229	I-code
,	O
F11	B-code
.	I-code
23	I-code
,	O
F11	B-code
.	I-code
99	I-code
,	O
F11	B-code
.	I-code
14	I-code
,	O
F11	B-code
.	I-code
188	I-code
,	O
F11	B-code
.	I-code
159	I-code
,	O
F11	B-code
.	I-code
150	I-code
,	O
F11	B-code
.	I-code
151	I-code
,	O
F11	B-code
.	I-code
181	I-code
,	O
F11	B-code
.	I-code
182	I-code
,	O
F11	B-code
.	I-code
19	I-code
.	O

Our	O
sample	O
was	O
selected	O
based	O
on	O
opioid	O
abuse	O
and	O
opioid	O
dependence	O
diagnosis	O
codes	O
,	O
included	O
veterans	O
with	O
a	O
new	O
or	O
reoccurring	O
/	O
stable	O
diagnosis	O
,	O
and	O
excluded	O
veterans	O
with	O
an	O
in	O
-	O
remission	O
diagnosis	O
.	O

This	O
study	O
was	O
approved	O
by	O
the	O
Stanford	O
University	O
Institutional	O
Review	O
Board	O
and	O
the	O
VA	O
Palo	O
Alto	O
Research	O
&	O
Development	O
Committee	O
.	O

Receipt	O
of	O
pharmacotherapy	O
for	O
opioid	O
use	O
disorder	O
was	O
calculated	O
for	O
each	O
FY	O
.	O

Following	O
version	O
2	O
of	O
the	O
ASAM	O
specifications	O
(	O
Harris	O
,	O
Weisner	O
,	O
et	O
al	O
.	O
,	O
2016	O
)	O
,	O
patients	O
who	O
had	O
at	O
least	O
one	O
visit	O
to	O
a	O
VA	O
methadone	O
clinic	O
in	O
their	O
outpatient	O
records	O
and	O
/	O
or	O
who	O
filled	O
at	O
least	O
one	O
prescription	O
for	O
buprenorphine	O
(	O
i	O
.	O
e	O
.	O

,	O
Suboxone	O
,	O
Subutex	O
,	O
excluding	O
patches	O
and	O
intravenous	O
medications	O
)	O
or	O
naltrexone	O
(	O
oral	O
or	O
injection	O
)	O
in	O
their	O
pharmacy	O
records	O
were	O
counted	O
as	O
having	O
received	O
pharmacotherapy	O
for	O
opioid	O
use	O
disorder	O
.	O

We	O
limited	O
our	O
analyses	O
to	O
facilities	O
that	O
had	O
patients	O
who	O
were	O
diagnosed	O
with	O
opioid	O
use	O
disorder	O
during	O
FY16	O
and	O
FY17	O
.	O

For	O
each	O
of	O
the	O
remaining	O
129	O
facilities	O
(	O
out	O
of	O
130	O
,	O
one	O
facility	O
did	O
not	O
have	O
patients	O
diagnosed	O
with	O
opioid	O
use	O
disorder	O
in	O
both	O
FYs	O
)	O
,	O
we	O
calculated	O
quality	O
measure	O
performance	O
as	O
the	O
number	O
of	O
patients	O
who	O
received	O
pharmacotherapy	O
for	O
opioid	O
use	O
disorder	O
divided	O
by	O
number	O
of	O
patients	O
diagnosed	O
with	O
a	O
non	O
-	O
remitted	O
opioid	O
use	O
disorder	O
.	O

We	O
calculated	O
the	O
overall	O
average	O
and	O
range	O
in	O
receipt	O
of	O
pharmacotherapy	O
for	O
each	O
FY	O
.	O

For	O
each	O
facility	O
,	O
we	O
subtracted	O
the	O
FY16	O
rate	O
of	O
receipt	O
from	O
the	O
FY17	O
rate	O
of	O
receipt	O
to	O
calculate	O
the	O
change	O
in	O
performance	O
over	O
the	O
two	O
FYs	O
.	O

We	O
chose	O
the	O
absolute	O
change	O
in	O
percent	O
for	O
the	O
primary	O
analyses	O
but	O
included	O
relative	O
change	O
in	O
percent	O
in	O
the	O
supplemental	O
appendix	O
as	O
it	O
provides	O
another	O
useful	O
view	O
of	O
the	O
data	O
.	O

Facilities	O
with	O
a	O
1	O
%	O
or	O
greater	O
change	O
from	O
FY16	O
to	O
FY17	O
were	O
considered	O
increasing	O
facilities	O
.	O

Facilities	O
with	O
a	O
0	O
%	O
change	O
were	O
no	O
change	O
facilities	O
,	O
and	O
facilities	O
with	O
a	O
−1	O
%	O
change	O
or	O
greater	O
were	O
considered	O
decreasing	O
facilities	O
.	O

We	O
examined	O
the	O
overall	O
and	O
facility	O
-	O
level	O
distribution	O
in	O
change	O
in	O
performance	O
over	O
the	O
two	O
FYs	O
.	O

A	O
retrospective	O
cohort	O
study	O
was	O
conducted	O
using	O
data	O
collected	O
from	O
Taiwan’s	O
National	O
Health	O
Insurance	O
Research	O
Database	O
(	O
NHIRD	O
)	O
,	O
an	O
insurance	O
claims	O
database	O
managed	O
by	O
Taiwan’s	O
National	O
Health	O
Research	O
Institute	O
(	O
NHRI	O
)	O
for	O
research	O
purposes	O
.	O

It	O
contains	O
demographic	O
information	O
,	O
diagnoses	O
,	O
health	O
services	O
provided	O
,	O
and	O
healthcare	O
costs	O
and	O
prescription	O
data	O
for	O
almost	O
all	O
outpatients	O
and	O
inpatients	O
as	O
well	O
as	O
patients	O
receiving	O
dental	O
services	O
in	O
Taiwan	O
.	O

Implemented	O
in	O
1995	O
,	O
the	O
National	O
Health	O
Insurance	O
(	O
NHI	O
)	O
program	O
provides	O
compulsory	O
universal	O
health	O
insurance	O
,	O
covering	O
the	O
delivery	O
of	O
virtually	O
all	O
health	O
care	O
(	O
98	O
%	O
)	O
to	O
the	O
entire	O
population	O
.	O

In	O
cooperation	O
with	O
the	O
Bureau	O
of	O
the	O
NHI	O
,	O
Taiwan’s	O
NHRI	O
extracted	O
a	O
randomly	O
sampled	O
set	O
of	O
representative	O
data	O
for	O
one	O
million	O
people	O
from	O
the	O
2005	O
registry	O
of	O
all	O
NHI	O
enrollees	O
to	O
create	O
a	O
subset	O
of	O
the	O
NHIRD	O
for	O
research	O
purposes	O
.	O

The	O
enrollees	O
in	O
this	O
subset	O
,	O
known	O
as	O
the	O
Longitudinal	O
Health	O
Insurance	O
Database	O
(	O
LHID	O
)	O
,	O
are	O
not	O
significantly	O
different	O
from	O
all	O
NHI	O
enrollees	O
with	O
regard	O
to	O
age	O
,	O
sex	O
,	O
or	O
health	O
care	O
costs	O
16	O
.	O

CRS	O
was	O
identified	O
in	O
this	O
study	O
by	O
the	O
claims	O
records	O
showing	O
a	O
primary	O
diagnosis	O
of	O
CRS	O
designated	O
with	O
the	O
use	O
of	O
the	O
International	B-coding_system
Classification	I-coding_system
of	I-coding_system
Diseases	I-coding_system
,	I-coding_system
Ninth	I-coding_system
Revision	I-coding_system
(	I-coding_system
ICD	I-coding_system
-	I-coding_system
9	I-coding_system
)	I-coding_system
codes	O
CRS	B-phenotype
15	O
17	O
(	O
ICD	B-coding_system
-	I-coding_system
9	I-coding_system
codes	O
:	O
473	B-code
,	O
473	B-code
.	I-code
0	I-code
,	O
473	B-code
.	I-code
1	I-code
,	O
473	B-code
.	I-code
2	I-code
,	O
473	B-code
.	I-code
3	I-code
,	O
473	B-code
.	I-code
8	I-code
,	O
and	O
473	B-code
.	I-code
9	I-code
)	O
from	O
1996	O
to	O
2007	O
.	O

Date	O
of	O
diagnosis	O
was	O
set	O
as	O
the	O
index	O
date	O
.	O

Nasal	O
polyps	O
(	O
NP	O
)	O
were	O
identified	O
by	O
a	O
diagnosis	O
of	O
NP	B-phenotype
ICD	B-coding_system
-	I-coding_system
9	I-coding_system
codes	O
:	O
471	B-code
,	O
471	B-code
.	I-code
0	I-code
,	O
471	B-code
.	I-code
1	I-code
,	O
471	B-code
.	I-code
8	I-code
,	O
and	O
471	B-code
.	I-code
9	I-code
.	O

CRS	O
without	O
NP	O
(	O
CRSsNP	O
)	O
was	O
defined	O
in	O
subjects	O
who	O
had	O
CRS	O
but	O
no	O
NP	O
.	O

CRS	O
with	O
NP	O
(	O
CRSwNP	O
)	O
was	O
defined	O
in	O
subjects	O
who	O
had	O
CRS	O
with	O
comorbid	O
NP	O
.	O

The	O
comparison	O
cohort	O
consisted	O
of	O
individuals	O
who	O
had	O
no	O
diagnosis	O
of	O
CRS	O
in	O
the	O
LHID	O
.	O

These	O
individuals	O
were	O
randomly	O
frequency	O
matched	O
with	O
the	O
cases	O
by	O
age	O
and	O
sex	O
at	O
a	O
ratio	O
of	O
1	O
:	O
10	O
.	O

Their	O
index	O
dates	O
were	O
randomly	O
assigned	O
to	O
months	O
and	O
days	O
within	O
the	O
same	O
year	O
of	O
the	O
index	O
date	O
of	O
the	O
patients	O
in	O
the	O
CRS	O
cohort	O
.	O

We	O
excluded	O
subjects	O
with	O
pre	B-phenotype
-	I-phenotype
existing	I-phenotype
ED	I-phenotype
(	O
ICD	B-coding_system
-	I-coding_system
9	I-coding_system
code	O
:	O
607	B-code
.	I-code
84	I-code
)	O
in	O
both	O
groups	O
.	O

Both	O
CRS	O
cases	O
and	O
controls	O
were	O
followed	O
up	O
until	O
they	O
were	O
diagnosed	O
with	O
ED	O
,	O
our	O
outcome	O
.	O

ED	O
cases	O
were	O
identified	O
based	O
on	O
a	O
recorded	O
diagnosis	O
of	O
ED	B-phenotype
ICD	B-coding_system
-	I-coding_system
9	I-coding_system
code	O
607	B-code
.	I-code
84	I-code
.	O

All	O
medical	O
claims	O
containing	O
this	O
diagnostic	O
code	O
between	O
1996	O
and	O
2007	O
were	O
collected	O
from	O
the	O
NHIRD	O
for	O
further	O
analysis	O
.	O

To	O
improve	O
the	O
diagnostic	O
validity	O
of	O
ED	O
,	O
only	O
those	O
patients	O
who	O
had	O
been	O
diagnosed	O
with	O
ED	O
at	O
least	O
twice	O
in	O
an	O
outpatient	O
service	O
or	O
once	O
in	O
an	O
inpatient	O
service	O
by	O
urologists	O
were	O
included	O
in	O
the	O
analysis	O
.	O

Physicians	O
in	O
Taiwan	O
generally	O
adhere	O
to	O
standardized	O
CRS	O
definitions	O
and	O
management	O
guidelines	O
,	O
such	O
as	O
those	O
provided	O
by	O
the	O
Rhinosinusitis	O
Task	O
Force	O
18	O
and	O
Clinical	O
Practice	O
Guidelines	O
:	O
Adult	O
Sinusitis	O
19	O
.	O

The	O
diagnosis	O
of	O
ED	O
in	O
Taiwan	O
is	O
based	O
on	O
criteria	O
established	O
by	O
the	O
American	O
Urological	O
Association	O
20	O
21	O
.	O

The	O
covariates	O
considered	O
in	O
this	O
analysis	O
were	O
sex	O
,	O
age	O
,	O
insurance	O
premium	O
,	O
area	O
of	O
residence	O
(	O
metropolitan	O
,	O
class	O
I	O
cities	O
,	O
class	O
II	O
cities	O
,	O
class	O
I	O
counties	O
,	O
class	O
II	O
counties	O
,	O
and	O
unclassified	O
)	O
,	O
hypertension	O
,	O
hyperlipidemia	O
,	O
diabetes	O
,	O
obesity	O
,	O
coronary	O
heart	O
disease	O
,	O
chronic	O
kidney	O
disease	O
(	O
CKD	O
)	O
,	O
chronic	O
obstructive	O
pulmonary	O
disease	O
(	O
COPD	O
)	O
,	O
asthma	O
,	O
allergic	O
rhinitis	O
,	O
arrhythmia	O
,	O
ischemic	O
stroke	O
,	O
intracerebral	O
hemorrhage	O
,	O
and	O
medications	O
[	O
angiotensin	O
-	O
converting	O
enzyme	O
inhibitors	O
(	O
ACEIs	O
)	O
,	O
beta	O
-	O
adrenergic	O

blockers	O
,	O
statins	O
,	O
and	O
steroid	O
]	O
.	O

The	O
insurance	O
premium	O
served	O
as	O
an	O
indicator	O
of	O
economic	O
status	O
and	O
subjects	O
were	O
classified	O
into	O
1	O
of	O
3	O
categories	O
:	O
fixed	O
premium	O
and	O
dependent	O
,	O
NTD20	O
,	O
000	O
(	O
income	O
per	O
month	O
)	O
or	O
less	O
,	O
and	O
more	O
than	O
NTD20	O
,	O
000	O
(	O
US$1	O
=	O
NTD32	O
.	O
8	O
in	O
2007	O
)	O
.	O

This	O
study	O
was	O
exempt	O
from	O
full	O
review	O
by	O
the	O
Institutional	O
Review	O
Board	O
of	O
Kaohsiung	O
Medical	O
University	O
Hospital	O
because	O
the	O
NHIRD	O
only	O
contains	O
de	O
-	O
identified	O
secondary	O
data	O
released	O
to	O
the	O
public	O
for	O
research	O
purposes	O
(	O
KMUHIRB	O
-	O
EXEMPT	O
-	O
20150003	O
)	O
.	O

The	O
baseline	O
characteristics	O
and	O
comorbidities	O
of	O
the	O
CRS	O
cohort	O
and	O
non	O
-	O
CRS	O
cohort	O
were	O
analyzed	O
descriptively	O
.	O

All	O
data	O
were	O
expressed	O
as	O
mean	O
±	O
standard	O
deviation	O
(	O
SD	O
)	O
or	O
percentage	O
.	O

Chi	O
-	O
square	O
and	O
t	O
-	O
tests	O
were	O
used	O
to	O
test	O
differences	O
in	O
categorical	O
and	O
continuous	O
variables	O
between	O
the	O
two	O
cohorts	O
.	O

Univariate	O
and	O
multivariable	O
Cox	O
proportional	O
hazards	O
regression	O
were	O
used	O
to	O
assess	O
the	O
hazard	O
ratio	O
(	O
HR	O
)	O
and	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
of	O
ED	O
associated	O
with	O
CRS	O
,	O
compared	O
with	O
the	O
non	O
-	O
CRS	O
cohort	O
.	O

The	O
multivariable	O
analysis	O
model	O
was	O
adjusted	O
for	O
sex	O
,	O
age	O
,	O
insurance	O
premium	O
,	O
residence	O
,	O
hypertension	O
,	O
hyperlipidemia	O
,	O
diabetes	O
,	O
obesity	O
,	O
coronary	O
heart	O
disease	O
,	O
chronic	O
kidney	O
disease	O
(	O
CKD	O
)	O
,	O
chronic	O
obstructive	O
pulmonary	O
disease	O
(	O
COPD	O
)	O
,	O
asthma	O
,	O
allergic	O
rhinitis	O
,	O
arrhythmia	O
,	O
ischemic	O
stroke	O
,	O
intracerebral	O
hemorrhage	O
,	O
and	O
medications	O
of	O
ACEIs	O
,	O
beta	O
-	O
adrenergic	O
blockers	O
,	O
statins	O
,	O
and	O
steroid	O
.	O

This	O
study	O
also	O
investigated	O
the	O
relationship	O
between	O
CRS	O
w	O
/	O
s	O
NP	O
and	O
ED	O
as	O
well	O
as	O
CRS	O
and	O
ED	O
.	O

To	O
find	O
out	O
if	O
CRS	O
is	O
an	O
age	O
-	O
dependent	O
risk	O
factor	O
for	O
ED	O
,	O
we	O
also	O
analyzed	O
the	O
effect	O
of	O
CRS	O
on	O
ED	O
stratified	O
by	O
age	O
group	O
.	O

The	O
cumulative	O
incidence	O
of	O
ED	O
between	O
the	O
CRS	O
cohort	O
and	O
the	O
non	O
-	O
CRS	O
cohort	O
was	O
analyzed	O
using	O
the	O
Kaplan–Meier	O
method	O
,	O
and	O
the	O
difference	O
was	O
examined	O
by	O
log	O
-	O
rank	O
test	O
.	O

SAS	O
software	O
(	O
version	O
9	O
.	O
3	O
for	O
Windows	O
;	O
SAS	O
Institute	O
Inc	O
.	O
,	O
Cary	O
,	O
NC	O
)	O
was	O
used	O
for	O
all	O
statistical	O
operations	O
.	O

A	O
P	O
value	O
<	O
0	O
.	O
05	O
was	O
considered	O
significant	O
.	O

We	O
performed	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
study	O
from	O
February	O
to	O
July	O
2015	O
at	O
the	O
Menopause	O
Clinic	O
of	O
Tokyo	O
Medical	O
and	O
Dental	O
University	O
.	O

The	O
study	O
protocol	O
was	O
reviewed	O
and	O
approved	O
by	O
the	O
Tokyo	O
Medical	O
and	O
Dental	O
University	O
Review	O
Board	O
,	O
and	O
written	O
informed	O
consent	O
was	O
obtained	O
from	O
all	O
the	O
participants	O
.	O

The	O
present	O
study	O
was	O
conducted	O
in	O
accordance	O
with	O
the	O
Declaration	O
of	O
Helsinki	O
.	O

Ninety	O
-	O
six	O
Japanese	O
women	O
aged	O
40	O
to	O
59	O
years	O
who	O
complained	O
of	O
fatigue	O
participated	O
in	O
this	O
study	O
.	O

Fatigue	O
was	O
evaluated	O
using	O
the	O
item	O
about	O
fatigue	O
in	O
the	O
Menopausal	O
Health	O
-	O
Related	O
Quality	O
of	O
Life	O
(	O
MHR	O
-	O
QOL	O
)	O
questionnaire	O
.	O

The	O
participants	O
were	O
recruited	O
through	O
advertisements	O
posted	O
in	O
our	O
hospital	O
and	O
in	O
the	O
patients’	O
social	O
network	O
.	O

Those	O
who	O
were	O
receiving	O
menopausal	O
hormone	O
therapy	O
,	O
herbal	O
medicine	O
,	O
or	O
psychotropic	O
drugs	O
were	O
excluded	O
.	O

Collected	O
data	O
included	O
age	O
,	O
menopausal	O
status	O
,	O
lifestyle	O
factors	O
,	O
physical	O
and	O
psychological	O
symptoms	O
of	O
menopause	O
,	O
subjective	O
symptoms	O
of	O
insomnia	O
and	O
fatigue	O
,	O
body	O
composition	O
,	O
cardiovascular	O
parameters	O
,	O
and	O
physical	O
activities	O
and	O
objective	O
sleep	O
states	O
obtained	O
from	O
actigraphy	O
.	O

The	O
data	O
were	O
evaluated	O
before	O
and	O
4	O
and	O
8	O
weeks	O
after	O
treatment	O
.	O

Regarding	O
menopausal	O
status	O
,	O
participants	O
were	O
classified	O
as	O
follows	O
:	O
premenopausal	O
(	O
regular	O
menstrual	O
cycles	O
in	O
the	O
past	O
3	O
months	O
)	O
,	O
perimenopausal	O
(	O
a	O
menstrual	O
period	O
within	O
the	O
past	O
12	O
months	O
but	O
a	O
missed	O
period	O
or	O
irregular	O
cycles	O
in	O
the	O
past	O
3	O
months	O
)	O
,	O
postmenopausal	O
(	O
no	O
menstrual	O
period	O
in	O
the	O
past	O
12	O
months	O
)	O
,	O
or	O
surgically	O
induced	O
menopause	O
(	O
hysterectomy	O
)	O
.	O

The	O
participants	O
were	O
randomized	O
into	O
1	O
of	O
3	O
groups	O
to	O
receive	O
active	O
tablets	O
containing	O
high	O
-	O
dose	O
(	O
1200	O
mg	O
/	O
day	O
;	O
n	O
=	O
32	O
)	O
or	O
low	O
-	O
dose	O
(	O
600	O
mg	O
/	O
day	O
;	O
n	O
=	O
32	O
)	O
soy	O
lecithin	O
,	O
or	O
placebo	O
(	O
n	O
=	O
32	O
)	O
for	O
8	O
weeks	O
.	O

The	O
high	O
-	O
dose	O
and	O
low	O
-	O
dose	O
soy	O
lecithin	O
and	O
placebo	O
tablets	O
,	O
indistinguishable	O
in	O
shape	O
,	O
weight	O
,	O
and	O
color	O
,	O
were	O
manufactured	O
and	O
packaged	O
by	O
Kikkoman	O
Corporation	O
(	O
Noda	O
,	O
Japan	O
)	O
.	O

The	O
tablet	O
contained	O
phospholipids	O
in	O
the	O
form	O
of	O
phosphatidylcholine	O
,	O
24	O
%	O
;	O
phosphatidylethanolamine	O
,	O
20	O
%	O
;	O
and	O
phosphatidylinositol	O
,	O
12	O
%	O
.	O

The	O
women	O
were	O
instructed	O
to	O
take	O
six	O
tablets	O
per	O
day	O
after	O
breakfast	O
.	O

Medication	O
adherence	O
was	O
evaluated	O
by	O
collecting	O
the	O
packages	O
of	O
the	O
supplements	O
from	O
participants	O
.	O

The	O
participants	O
were	O
sequentially	O
numbered	O
,	O
and	O
received	O
supplement	O
packages	O
with	O
the	O
corresponding	O
number	O
.	O

The	O
content	O
of	O
each	O
package	O
,	O
namely	O
high	O
-	O
dose	O
or	O
low	O
-	O
dose	O
soy	O
lecithin	O
,	O
or	O
placebo	O
,	O
was	O
known	O
only	O
by	O
the	O
manufacturers	O
.	O

Thus	O
,	O
allocation	O
was	O
concealed	O
from	O
both	O
the	O
participants	O
and	O
the	O
investigators	O
.	O

Safety	O
was	O
assessed	O
by	O
patient	O
-	O
reported	O
treatment	O
-	O
emergent	O
adverse	O
events	O
.	O

Menopausal	O
symptoms	O
were	O
evaluated	O
using	O
the	O
Menopausal	O
Health	O
-	O
Related	O
Quality	O
of	O
Life	O
(	O
MHR	O
-	O
QOL	O
)	O
questionnaire	O
,	O
Hospital	O
Anxiety	O
and	O
Depression	O
Scale	O
(	O
HADS	O
)	O
,	O
and	O
Athens	O
Insomnia	O
Scale	O
(	O
AIS	O
)	O
.	O

The	O
MHR	O
-	O
QOL	O
questionnaire	O
,	O
developed	O
and	O
validated	O
at	O
our	O
clinic	O
[	O
8	O
,	O
9	O
]	O
,	O
is	O
a	O
modification	O
of	O
the	O
Women’s	O
Health	O
Questionnaire	O
[	O
10	O
,	O
11	O
]	O
,	O
and	O
contains	O
38	O
items	O
scored	O
on	O
a	O
4	O
-	O
point	O
or	O
binary	O
scale	O
covering	O
four	O
major	O
domains	O
(	O
physical	O
symptoms	O
,	O
psychological	O
symptoms	O
,	O
life	O
satisfaction	O
,	O
and	O
social	O
involvement	O
)	O
of	O
a	O
woman’s	O
health	O
during	O
menopause	O
.	O

The	O
HADS	O
[	O
12	O
]	O
is	O
a	O
reliable	O
instrument	O
for	O
screening	O
clinically	O
significant	O
anxiety	O
and	O
depression	O
in	O
women	O
visiting	O
a	O
general	O
medicine	O
clinic	O
.	O

The	O
translated	O
Japanese	O
version	O
of	O
the	O
HADS	O
[	O
13	O
]	O
was	O
used	O
in	O
the	O
present	O
study	O
.	O

The	O
AIS	O
was	O
developed	O
as	O
a	O
brief	O
and	O
easy	O
-	O
to	O
-	O
administer	O
self	O
-	O
assessment	O
questionnaire	O
for	O
determining	O
the	O
severity	O
of	O
insomnia	B-phenotype
defined	O
according	O
to	O
the	O
International	B-coding_system
Classification	I-coding_system
of	I-coding_system
Diseases	I-coding_system
10th	I-coding_system
Revision	I-coding_system
.	O

The	O
internal	O
consistency	O
and	O
test	O
-	O
retest	O
reliability	O
of	O
the	O
AIS	O
have	O
been	O
confirmed	O
previously	O
[	O
14	O
]	O
.	O

Detailed	O
information	O
about	O
the	O
MHR	O
-	O
QOL	O
questionnaire	O
,	O
HADS	O
,	O
and	O
AIS	O
is	O
provided	O
elsewhere	O
[	O
8	O
]	O
.	O

Fatigue	O
and	O
mood	O
states	O
were	O
evaluated	O
by	O
the	O
Profile	O
of	O
Mood	O
States	O
(	O
POMS	O
)	O
-	O
brief	O
,	O
Chalder	O
Fatigue	O
Scale	O
(	O
CFS	O
)	O
,	O
and	O
Brief	O
Fatigue	O
Inventory	O
(	O
BFI	O
)	O
.	O

The	O
POMS	O
is	O
a	O
psychological	O
rating	O
scale	O
used	O
to	O
assess	O
feelings	O
and	O
mood	O
states	O
.	O

The	O
original	O
version	O
of	O
the	O
POMS	O
consists	O
of	O
65	O
items	O
,	O
while	O
the	O
POMS	O
-	O
brief	O
,	O
a	O
shortened	O
version	O
,	O
includes	O
30	O
items	O
covering	O
six	O
major	O
domains	O
(	O
tension	O
,	O
depression	O
,	O
anger	O
,	O
vigor	O
,	O
fatigue	O
,	O
and	O
confusion	O
)	O
.	O

Because	O
the	O
latter	O
is	O
easier	O
to	O
complete	O
and	O
its	O
validity	O
has	O
been	O
demonstrated	O
[	O
15	O
]	O
,	O
it	O
is	O
now	O
more	O
widely	O
used	O
than	O
the	O
original	O
form	O
.	O

The	O
POMS	O
-	O
brief	O
was	O
translated	O
into	O
Japanese	O
,	O
and	O
its	O
reliability	O
and	O
validity	O
were	O
confirmed	O
previously	O
[	O
16	O
]	O
.	O

The	O
CFS	O
is	O
a	O
self	O
-	O
administered	O
questionnaire	O
with	O
14	O
items	O
which	O
evaluates	O
fatigue	O
-	O
related	O
symptoms	O
by	O
using	O
a	O
4	O
-	O
point	O
Likert	O
scale	O
for	O
the	O
extent	O
or	O
frequency	O
of	O
the	O
symptoms	O
[	O
17	O
]	O
.	O

Although	O
originally	O
developed	O
to	O
measure	O
fatigue	O
symptoms	O
in	O
clinical	O
settings	O
,	O
the	O
scale	O
is	O
now	O
more	O
widely	O
used	O
[	O
18	O
]	O
.	O

The	O
BFI	O
,	O
a	O
self	O
-	O
rating	O
assessment	O
composed	O
of	O
9	O
items	O
using	O
a	O
numerical	O
scale	O
of	O
0	O
to	O
10	O
,	O
was	O
developed	O
for	O
the	O
rapid	O
assessment	O
of	O
fatigue	O
severity	O
in	O
cancer	O
patients	O
[	O
19	O
]	O
.	O

It	O
was	O
translated	O
into	O
Japanese	O
,	O
and	O
its	O
reliability	O
and	O
validity	O
were	O
confirmed	O
previously	O
[	O
20	O
]	O
.	O

Height	O
,	O
weight	O
,	O
body	O
mass	O
index	O
,	O
and	O
body	O
composition	O
including	O
fat	O
mass	O
,	O
and	O
fat	O
free	O
mass	O
,	O
was	O
assessed	O
using	O
a	O
body	O
composition	O
analyzer	O
(	O
MC190	O
-	O
EM	O
;	O
Tanita	O
,	O
Tokyo	O
,	O
Japan	O
)	O
.	O

Cardiovascular	O
parameters	O
,	O
including	O
systolic	O
and	O
diastolic	O
blood	O
pressure	O
,	O
heart	O
rate	O
,	O
and	O
the	O
cardio	O
-	O
ankle	O
vascular	O
index	O
(	O
CAVI	O
)	O
,	O
were	O
measured	O
using	O
a	O
vascular	O
screening	O
system	O
(	O
VS	O
-	O
1000	O
;	O
Fukuda	O
Denshi	O
Co	O
.	O
,	O
Tokyo	O
,	O
Japan	O
)	O
.	O

We	O
investigated	O
physical	O
activities	O
and	O
objective	O
sleep	O
states	O
using	O
the	O
actigraphy	O
system	O
that	O
is	O
loaded	O
with	O
a	O
miniature	O
triaxial	O
acceleration	O
sensor	O
(	O
Wrist	O
-	O
worn	O
Accelerometers	O
;	O
Hitachi	O
Ltd	O
.	O
,	O
Tokyo	O
,	O
Japan	O
)	O
.	O

It	O
measured	O
motion	O
with	O
accelerometers	O
and	O
sleep–wake	O
identification	O
was	O
automatically	O
performed	O
by	O
using	O
the	O
Cole–Kripke	O
algorithm	O
.	O

The	O
outcome	O
measures	O
included	O
zero	O
-	O
crossing	O
(	O
ZC	O
)	O
and	O
metabolic	O
equivalents	O
(	O
METs	O
)	O
during	O
the	O
awake	O
and	O
sleep	O
phase	O
,	O
total	O
sleep	O
time	O
,	O
day	O
-	O
to	O
-	O
day	O
variation	O
of	O
sleep	O
time	O
,	O
episodes	O
of	O
nocturnal	O
awakening	O
,	O
sleep	O
latency	O
,	O
and	O
sleep	O
efficiency	O
.	O

ZC	O
is	O
the	O
rate	O
of	O
signal	O
changes	O
from	O
the	O
triaxial	O
acceleration	O
sensor	O
,	O
representing	O
the	O
frequency	O
of	O
wrist	O
motion	O
.	O

METs	O
are	O
calculated	O
as	O
the	O
ratio	O
of	O
metabolic	O
rate	O
relative	O
to	O
that	O
in	O
resting	O
,	O
representing	O
the	O
intensity	O
of	O
exercise	O
.	O

We	O
define	O
sleep	O
latency	O
as	O
the	O
time	O
from	O
time	O
in	O
bed	O
to	O
the	O
start	O
of	O
identification	O
of	O
sleep	O
.	O

Sleep	O
efficiency	O
is	O
calculated	O
as	O
pure	O
sleep	O
time	O
(	O
time	O
in	O
bed	O
minus	O
awake	O
time	O
)	O
divided	O
by	O
time	O
in	O
bed	O
.	O

Participants	O
were	O
requested	O
to	O
wear	O
a	O
wrist	O
actigraph	O
device	O
for	O
72	O
h	O
on	O
their	O
non	O
-	O
dominant	O
arms	O
except	O
during	O
bathing	O
time	O
.	O

The	O
analysis	O
of	O
the	O
actigraphy	O
data	O
was	O
performed	O
at	O
‘blinded	O
for	O
peer	O
review’	O
.	O

The	O
baseline	O
characteristics	O
of	O
the	O
participants	O
who	O
completed	O
the	O
8	O
-	O
week	O
treatment	O
were	O
compared	O
using	O
one	O
-	O
way	O
analysis	O
of	O
variance	O
,	O
χ2	O
test	O
,	O
and	O
Kruskal	O
-	O
Wallis	O
test	O
.	O

Then	O
,	O
the	O
changes	O
from	O
baseline	O
to	O
8	O
weeks	O
of	O
treatment	O
in	O
all	O
of	O
the	O
collected	O
data	O
were	O
evaluated	O
using	O
Mann	O
-	O
Whitney	O
test	O
and	O
unpaired	O
t	O
-	O
test	O
.	O

All	O
statistical	O
analyses	O
were	O
performed	O
with	O
GraphPad	O
Prism	O
version	O
5	O
.	O
02	O
(	O
GraphPad	O
Software	O
Incorporated	O
,	O
CA	O
,	O
USA	O
)	O
.	O

A	O
P	O
-	O
value	O
<	O
0	O
.	O
05	O
was	O
considered	O
statistically	O
significant	O
.	O

The	O
study	O
is	O
designed	O
as	O
a	O
two	O
-	O
armed	O
,	O
single	O
-	O
blind	O
,	O
parallel	O
group	O
RCT	O
.	O

The	O
trial	O
was	O
registered	O
on	O
the	O
ClinicalTrial	O
.	O
gov	O
database	O
as	O
NCT02758418	O
,	O
and	O
it	O
will	O
be	O
conducted	O
following	O
the	O
Consolidated	O
Standards	O
of	O
Reporting	O
Trials	O
(	O
CONSORT	O
)	O
[	O
33	O
]	O
,	O
the	O
CONSORT	O
extension	O
for	O
Electronic	O
and	O
mobile	O
Health	O
Applications	O
and	O
onLine	O
TeleHealth	O
interventions	O
(	O
CONSORT	O
-	O
EHELTH	O
)	O
[	O
34	O
]	O
,	O
and	O
the	O
SPIRIT	O
guidelines	O
(	O
Standard	O
Protocol	O
Items	O
:	O
Recommendations	O
for	O
Intervention	O
Trials	O
)	O
[	O
35	O
,	O
36	O
]	O
.	O

All	O
suitable	O
participants	O
for	O
the	O
trial	O
will	O
be	O
randomly	O
allocated	O
to	O
the	O
intervention	O
group	O
(	O
ICBT	O
)	O
or	O
the	O
Waiting	O
List	O
Control	O
Group	O
(	O
WL	O
)	O
.	O

The	O
online	O
informed	O
consent	O
form	O
will	O
be	O
signed	O
before	O
the	O
randomization	O
.	O

Outcome	O
measures	O
will	O
be	O
assessed	O
at	O
baseline	O
,	O
post	O
-	O
intervention	O
,	O
and	O
3	O
-	O
,	O
6	O
-	O
,	O
and	O
12	O
-	O
month	O
follow	O
-	O
ups	O
,	O
in	O
order	O
to	O
provide	O
data	O
on	O
intervention	O
effectiveness	O
and	O
maintenance	O
of	O
the	O
improvements	O
achieved	O
.	O

Fig	O
.	O

1	O
displays	O
the	O
flow	O
chart	O
of	O
the	O
study	O
design	O
.	O

Fig	O
.	O

1	O
Flowchart	O
of	O
participants	O

Flowchart	O
of	O
participants	O

The	O
trial	O
will	O
be	O
announced	O
on	O
local	O
media	O
(	O
radio	O
,	O
TV	O
,	O
newspaper…	O
)	O
and	O
the	O
website	O
of	O
Universitat	O
Jaume	O
I	O
,	O
and	O
disseminated	O
through	O
social	O
networks	O
(	O
i	O
.	O
e	O
.	O

,	O
Facebook	O
and	O
Twitter	O
)	O
.	O

The	O
advertisement	O
will	O
be	O
published	O
in	O
newspapers	O
,	O
and	O
information	O
brochures	O
will	O
be	O
placed	O
on	O
noticeboards	O
at	O
local	O
universities	O
(	O
Universitat	O
Jaume	O
I	O
and	O
Universitat	O
de	O
València	O
)	O
and	O
nearby	O
towns	O
.	O

People	O
interested	O
in	O
the	O
study	O
will	O
be	O
encouraged	O
to	O
send	O
an	O
e	O
-	O
mail	O
to	O
tao	O
@	O
uji	O
.	O
es	O
.	O

The	O
clinical	O
team	O
involved	O
in	O
the	O
study	O
will	O
respond	O
to	O
all	O
e	O
-	O
mails	O
within	O
24	O
h	O
and	O
arrange	O
a	O
telephone	O
interview	O
.	O

The	O
interview	O
will	O
last	O
about	O
40–60	O
min	O
,	O
and	O
its	O
purpose	O
will	O
be	O
to	O
explain	O
the	O
terms	O
of	O
the	O
clinical	O
trial	O
and	O
check	O
the	O
fulfillment	O
of	O
eligibility	O
criteria	O
.	O

The	O
diagnostic	O
interview	O
will	O
be	O
administered	O
to	O
potential	O
participants	O
during	O
this	O
telephone	O
call	O
.	O

In	O
order	O
to	O
be	O
included	O
in	O
the	O
trial	O
,	O
participants	O
must	O
meet	O
the	O
following	O
inclusion	O
criteria	O
:	O
(	O
1	O
)	O
be	O
18	O
years	O
old	O
or	O
more	O
;	O
(	O
2	O
)	O
meet	O
DSM	B-coding_system
-	I-coding_system
5	I-coding_system
[	O
1	O
]	O
criteria	O
for	O
AjD	B-phenotype
;	O
(	O
3	O
)	O
be	O
able	O
to	O
understand	O
and	O
read	O
Spanish	O
;	O
(	O
4	O
)	O
be	O
able	O
to	O
use	O
a	O
computer	O
and	O
have	O
access	O
to	O
the	O
Internet	O
;	O
(	O
5	O
)	O
have	O
an	O
e	O
-	O
mail	O
address	O
.	O

On	O
the	O
other	O
hand	O
,	O
assessed	O
participants	O
who	O
meet	O
any	O
of	O
the	O
following	O
criteria	O
will	O
be	O
excluded	O
from	O
the	O
trial	O
:	O
(	O
1	O
)	O
receiving	O
another	O
psychological	O
treatment	O
for	O
AjD	O
;	O
(	O
2	O
)	O
meet	O
criteria	O
for	O
another	O
severe	O
mental	O
disorder	O
:	O
alcohol	O
or	O
other	O
substance	O
abuse	O
or	O
dependence	O
,	O
psychotic	O
disorder	O
,	O
dementia	O
,	O
or	O
bipolar	O
disorder	O
;	O
(	O
3	O
)	O
meet	O
criteria	O
for	O
a	O
severe	O
personality	O
disorder	O
or	O
illness	O
;	O
(	O
4	O
)	O
presence	O
of	O
risk	O
of	O
suicide	O
or	O
self	O
-	O
destructive	O
behaviors	O
.	O

Undergoing	O
pharmacological	O
treatment	O
is	O
not	O
an	O
exclusion	O
criterion	O
during	O
the	O
study	O
period	O
,	O
but	O
any	O
increase	O
and	O
/	O
or	O
change	O
in	O
the	O
medication	O
during	O
the	O
study	O
period	O
will	O
imply	O
the	O
participant’s	O
exclusion	O
from	O
subsequent	O
analyses	O
.	O

A	O
decrease	O
in	O
pharmacological	O
treatment	O
is	O
accepted	O
.	O

The	O
decision	O
about	O
each	O
participant’s	O
inclusion	O
or	O
non	O
-	O
inclusion	O
will	O
be	O
made	O
by	O
the	O
entire	O
clinical	O
team	O
,	O
ensuring	O
a	O
more	O
objective	O
and	O
reliable	O
diagnosis	O
.	O

The	O
telephone	O
interviews	O
will	O
also	O
be	O
recorded	O
,	O
with	O
the	O
patient’s	O
agreement	O
,	O
making	O
independent	O
inter	O
-	O
judge	O
assessment	O
possible	O
.	O

Participants	O
included	O
in	O
the	O
study	O
will	O
have	O
to	O
sign	O
the	O
participation	O
agreement	O
without	O
having	O
a	O
priori	O
knowledge	O
about	O
their	O
group	O
assignment	O
.	O

Study	O
researchers	O
will	O
also	O
be	O
blind	O
to	O
the	O
group	O
to	O
which	O
the	O
assessed	O
participants	O
will	O
belong	O
.	O

Once	O
the	O
online	O
informed	O
consent	O
has	O
been	O
signed	O
,	O
an	O
independent	O
researcher	O
will	O
perform	O
a	O
“blocked	O
randomization”	O
,	O
guaranteeing	O
that	O
the	O
same	O
number	O
of	O
participants	O
are	O
allocated	O
to	O
each	O
condition	O
(	O
ICBT	O
or	O
WL	O
)	O
.	O

This	O
allocation	O
will	O
be	O
performed	O
following	O
a	O
random	O
number	O
sequence	O
generated	O
by	O
the	O
Epidat	O
4	O
.	O
1	O
program	O
.	O

The	O
sample	O
size	O
for	O
the	O
trial	O
was	O
calculated	O
following	O
the	O
method	O
described	O
by	O
Campbell	O
,	O
Julious	O
,	O
and	O
Altman	O
[	O
37	O
]	O
,	O
and	O
Freiman	O
,	O
Chalmers	O
,	O
Smith	O
,	O
and	O
Kuebler	O
[	O
38	O
]	O
.	O

G	O
*	O
Power	O
3	O
software	O
[	O
39	O
]	O
was	O
used	O
to	O
facilitate	O
power	O
analysis	O
.	O

Because	O
there	O
is	O
no	O
published	O
research	O
on	O
the	O
effectiveness	O
of	O
ICBT	O
for	O
the	O
treatment	O
of	O
AjD	O
,	O
the	O
sample	O
size	O
was	O
calculated	O
taking	O
into	O
account	O
outcomes	O
found	O
in	O
trials	O
that	O
used	O
the	O
BAI	O
and	O
BDI	O
-	O
II	O
as	O
measures	O
of	O
clinical	O
change	O
after	O
an	O
ICBT	O
intervention	O
in	O
patients	O
with	O
clinical	O
depression	O
or	O
anxiety	O
disorder	O
[	O
40	O
–	O
42	O
]	O
.	O

After	O
reviewing	O
the	O
literature	O
and	O
adopting	O
a	O
more	O
conservative	O
approach	O
,	O
an	O
effect	O
size	O
of	O
.	O
70	O
was	O
assumed	O
in	O
the	O
present	O
study	O
.	O

Considering	O
a	O
significance	O
level	O
of	O
5	O
%	O
and	O
a	O
power	O
of	O
80	O
%	O
,	O
26	O
participants	O
in	O
each	O
group	O
would	O
be	O
enough	O
to	O
detect	O
the	O
assumed	O
difference	O
.	O

However	O
,	O
because	O
the	O
literature	O
reveals	O
dropout	O
rates	O
from	O
ICBTs	O
of	O
around	O
30	O
%	O
[	O
43	O
]	O
,	O
a	O
sample	O
of	O
68	O
participants	O
will	O
be	O
recruited	O
(	O
34	O
per	O
group	O
)	O
.	O

The	O
protocol	O
for	O
this	O
study	O
has	O
been	O
approved	O
by	O
the	O
Ethics	O
Committee	O
of	O
Universitat	O
Jaume	O
I	O
(	O
Castellón	O
,	O
Spain	O
)	O
,	O
and	O
the	O
study	O
will	O
be	O
conducted	O
in	O
compliance	O
with	O
the	O
Declaration	O
of	O
Helsinki	O
and	O
good	O
clinical	O
practice	O
.	O

Participation	O
will	O
be	O
completely	O
voluntary	O
.	O

Participants	O
will	O
also	O
be	O
informed	O
that	O
they	O
may	O
leave	O
the	O
study	O
at	O
any	O
time	O
.	O

The	O
RCT	O
will	O
be	O
carried	O
out	O
in	O
accordance	O
with	O
current	O
EU	O
and	O
Spanish	O
legislation	O
on	O
privacy	O
and	O
data	O
protection	O
.	O

In	O
order	O
to	O
protect	O
the	O
privacy	O
of	O
the	O
participants	O
,	O
all	O
personally	O
identifiable	O
information	O
will	O
be	O
replaced	O
by	O
a	O
randomly	O
assigned	O
username	O
and	O
only	O
made	O
available	O
to	O
the	O
researchers	O
responsible	O
for	O
its	O
supervision	O
.	O

All	O
data	O
from	O
outcome	O
measures	O
and	O
post	O
-	O
module	O
assessments	O
will	O
be	O
stored	O
separately	O
from	O
the	O
personal	O
information	O
and	O
protected	O
according	O
to	O
AES	O
(	O
Advanced	O
Encryptation	O
Standard	O
)	O
.	O

Adjustment	O
Disorders	O
Online	O
(	O
TAO	O
)	O
is	O
an	O
ICBT	O
based	O
on	O
a	O
manualized	O
protocol	O
for	O
the	O
treatment	O
of	O
AjD	O
,	O
structured	O
in	O
a	O
therapist	O
handbook	O
and	O
a	O
patient	O
handbook	O
.	O

TAO	O
comprises	O
the	O
following	O
therapeutic	O
components	O
:	O
psychoeducation	O
,	O
techniques	O
to	O
manage	O
negative	O
emotions	O
,	O
exposure	O
,	O
problem	O
-	O
solving	O
techniques	O
,	O
mindfulness	O
,	O
acceptance	O
and	O
elaboration	O
of	O
the	O
stressful	O
event	O
,	O
positive	O
psychology	O
strategies	O
,	O
and	O
relapse	O
prevention	O
.	O

It	O
is	O
the	O
optimized	O
version	O
of	O
the	O
original	O
intervention	O
protocol	O
for	O
AjD	O
developed	O
by	O
Botella	O
et	O
al	O
.	O
[	O
31	O
]	O
.	O

More	O
specifically	O
,	O
TAO	O
also	O
includes	O
behavioral	O
activation	O
for	O
mood	O
disturbance	O
,	O
problem	O
-	O
solving	O
techniques	O
to	O
improve	O
the	O
capacity	O
to	O
deal	O
with	O
everyday	O
challenges	O
,	O
and	O
mindfulness	O
to	O
become	O
aware	O
of	O
the	O
thoughts	O
and	O
feelings	O
related	O
to	O
the	O
stressful	O
event	O
instead	O
of	O
trying	O
to	O
escape	O
from	O
them	O
.	O

The	O
intervention	O
is	O
easily	O
accessible	O
over	O
the	O
internet	O
at	O
https	O
:	O
/	O
/	O
www	O
.	O
psicologiaytecnologia	O
.	O
com	O
/	O
.	O

In	O
order	O
to	O
provide	O
a	O
more	O
enjoyable	O
experience	O
,	O
the	O
program	O
content	O
is	O
presented	O
through	O
texts	O
,	O
videos	O
,	O
pictures	O
,	O
vignettes	O
,	O
and	O
interactive	O
exercises	O
.	O

Different	O
contents	O
can	O
also	O
be	O
downloaded	O
as	O
PDF	O
files	O
so	O
that	O
users	O
can	O
review	O
them	O
offline	O
.	O

TAO	O
is	O
organized	O
into	O
seven	O
sequential	O
modules	O
(	O
see	O
Table	O
1	O
)	O
,	O
and	O
it	O
takes	O
about	O
7	O
to	O
10	O
weeks	O
to	O
complete	O
it	O
.	O

Although	O
users	O
are	O
encouraged	O
to	O
advance	O
one	O
module	O
per	O
week	O
,	O
some	O
modules	O
may	O
require	O
more	O
time	O
.	O

Therefore	O
,	O
the	O
program	O
also	O
emphasizes	O
that	O
everyone	O
should	O
progress	O
at	O
their	O
own	O
pace	O
,	O
dedicating	O
enough	O
time	O
to	O
understand	O
the	O
module	O
contents	O
and	O
carry	O
out	O
the	O
proposed	O
activities	O
.	O

Table	O
1	O
TAO	O
content	O
Module	O
Aims	O
of	O
the	O
module	O
Contents	O
0	O
.	O

Welcome	O
module	O
:	O
starting	O
this	O
program	O
.	O

-	O
Providing	O
information	O
about	O
TAO	O
.	O

-	O
Promoting	O
the	O
adherence	O
to	O
the	O
program	O
.	O

-	O
Enhancing	O
motivation	O
for	O
change	O
.	O

-	O
Information	O
about	O
the	O
contents	O
of	O
each	O
module	O
.	O

-	O
Recommendations	O
to	O
get	O
the	O
maximum	O
benefit	O
from	O
the	O
program	O
.	O

-	O
Meditation	O
on	O
reasons	O
to	O
change	O
.	O

-	O
Goal	O
setting	O
.	O

1	O
.	O

Understanding	O
emotional	O
reactions	O
.	O

-	O
Providing	O
information	O
about	O
AjD	O
and	O
common	O
reactions	O
to	O
stressful	O
events	O
.	O

-	O
Learning	O
of	O
strategies	O
to	O
manage	O
negative	O
emotions	O
.	O

-	O
Psychoeducation	O
.	O

-	O
Behavior	O
activation	O
.	O

-	O
Slow	O
breathing	O
technique	O
.	O

2	O
.	O

Learning	O
to	O
deal	O
with	O
negative	O
emotions	O
.	O

-	O
Facing	O
avoided	O
situations	O
that	O
contribute	O
to	O
the	O
maintenance	O
of	O
the	O
problem	O
.	O

-	O
Improving	O
the	O
ability	O
to	O
deal	O
with	O
everyday	O
challenges	O
.	O

-	O
Exposure	O
.	O

-	O
Problem	O
solving	O
technique	O
.	O

3	O
.	O

Accepting	O
problems	O
.	O

-	O
Becoming	O
aware	O
of	O
the	O
personal	O
experiences	O
related	O
to	O
the	O
stressful	O
event	O
.	O

-	O
Elaborating	O
and	O
processing	O
the	O
stressful	O
event	O
through	O
the	O
acceptance	O
of	O
the	O
problematic	O
situation	O
.	O

-	O
Mindfulness	O
.	O

-	O
The	O
Book	O
of	O
Life	O
:	O
Acceptance	O
.	O

-	O
Elaboration	O
of	O
a	O
metaphorical	O
meaning	O
for	O
the	O
stressful	O
event	O
.	O

4	O
.	O

Learning	O
form	O
problems	O
.	O

-	O
Starting	O
to	O
see	O
problems	O
as	O
opportunities	O
to	O
grow	O
and	O
learn	O
.	O

-	O
Elaborating	O
and	O
processing	O
the	O
stressful	O
event	O
through	O
the	O
confrontation	O
of	O
the	O
problematic	O
situation	O
.	O

-	O
Promoting	O
personal	O
growth	O
.	O

-	O
Psychoeducation	O
on	O
the	O
positive	O
contribution	O
of	O
problems	O
.	O

-	O
The	O
Book	O
of	O
Life	O
:	O
Confrontation	O
.	O

-	O
Development	O
of	O
personal	O
strengths	O
.	O

5	O
.	O

Changing	O
the	O
meaning	O
of	O
problems	O
.	O

-	O
Elaborating	O
and	O
processing	O
the	O
stressful	O
event	O
through	O
the	O
development	O
of	O
a	O
new	O
meaning	O
for	O
the	O
problematic	O
situation	O
.	O

-	O
Developing	O
a	O
new	O
attitude	O
towards	O
problems	O
.	O

-	O
Elaboration	O
of	O
a	O
new	O
metaphorical	O
meaning	O
for	O
the	O
stressful	O
event	O
.	O

-	O
The	O
Book	O
of	O
Life	O
:	O
Change	O
the	O
meaning	O
.	O

-	O
Letter	O
of	O
projection	O
towards	O
the	O
future	O
.	O

-	O
Choice	O
of	O
a	O
personal	O
life	O
motto	O
.	O

6	O
.	O

Relapse	O
prevention	O
.	O

-	O
Assessing	O
achievements	O
accomplished	O
so	O
far	O
.	O

-	O
Reviewing	O
of	O
leaned	O
techniques	O
.	O

-	O
Identifying	O
problematic	O
situations	O
an	O
developing	O
a	O
plan	O
to	O
deal	O
with	O
them	O
.	O

-	O
Review	O
of	O
the	O
therapeutic	O
achievements	O
.	O

-	O
Action	O
plan	O
to	O
deal	O
with	O
future	O
problems	O
.	O

TAO	O
content	O

All	O
the	O
modules	O
present	O
the	O
same	O
structure	O
:	O
1	O
)	O
module	O
agenda	O
;	O
2	O
)	O
therapeutic	O
contents	O
of	O
the	O
module	O
;	O
3	O
)	O
exercises	O
and	O
activities	O
to	O
put	O
the	O
psychological	O
techniques	O
learned	O
in	O
the	O
module	O
into	O
practice	O
;	O
4	O
)	O
assessment	O
of	O
the	O
knowledge	O
acquired	O
during	O
the	O
module	O
;	O
5	O
)	O
tasks	O
to	O
be	O
completed	O
before	O
advancing	O
to	O
the	O
next	O
module	O
;	O
and	O
6	O
)	O
summary	O
of	O
the	O
module	O
.	O

An	O
effort	O
was	O
made	O
to	O
simplify	O
the	O
language	O
used	O
in	O
TAO	O
to	O
make	O
it	O
easily	O
understood	O
by	O
users	O
,	O
regardless	O
of	O
their	O
socio	O
-	O
demographic	O
features	O
.	O

Regarding	O
the	O
ease	O
of	O
use	O
of	O
TAO	O
,	O
preliminary	O
results	O
obtained	O
in	O
an	O
acceptance	O
and	O
usability	O
study	O
performed	O
with	O
clinical	O
psychologists	O
and	O
patients	O
with	O
AjD	O
showed	O
that	O
the	O
program	O
interface	O
is	O
highly	O
intuitive	O
and	O
user	O
-	O
friendly	O
and	O
does	O
not	O
require	O
any	O
previous	O
training	O
[	O
44	O
]	O
.	O

Participants	O
on	O
the	O
waiting	O
list	O
group	O
will	O
be	O
assessed	O
before	O
and	O
after	O
a	O
period	O
of	O
7	O
weeks	O
.	O

After	O
completing	O
a	O
post	O
-	O
waiting	O
period	O
assessment	O
,	O
they	O
will	O
be	O
offered	O
the	O
TAO	O
program	O
.	O

Because	O
the	O
literature	O
shows	O
that	O
guided	O
ICBT	O
provides	O
better	O
results	O
than	O
completely	O
unguided	O
interventions	O
[	O
45	O
]	O
,	O
all	O
the	O
participants	O
will	O
receive	O
weekly	O
phone	O
support	O
.	O

This	O
support	O
will	O
consist	O
of	O
a	O
short	O
phone	O
call	O
(	O
maximum	O
10	O
min	O
)	O
during	O
the	O
intervention	O
stage	O
.	O

The	O
aim	O
of	O
these	O
phone	O
calls	O
will	O
be	O
:	O
1	O
)	O
to	O
clarify	O
doubts	O
about	O
the	O
use	O
and	O
functioning	O
of	O
TAO	O
;	O
2	O
)	O
to	O
remind	O
them	O
of	O
the	O
importance	O
of	O
continuing	O
to	O
work	O
on	O
the	O
program	O
contents	O
;	O
and	O
3	O
)	O
to	O
congratulate	O
them	O
for	O
their	O
effort	O
and	O
achievements	O
.	O

Patients	O
will	O
receive	O
up	O
to	O
10	O
telephone	O
calls	O
over	O
a	O
7–10	O
week	O
period	O
,	O
and	O
so	O
they	O
will	O
have	O
a	O
maximum	O
of	O
100	O
min	O
of	O
therapeutic	O
support	O
.	O

No	O
additional	O
clinical	O
content	O
will	O
be	O
provided	O
during	O
the	O
phone	O
calls	O
.	O

The	O
support	O
will	O
be	O
provided	O
by	O
experienced	O
psychologists	O
who	O
will	O
have	O
at	O
least	O
a	O
Master’s	O
degree	O
in	O
Clinical	O
Psychology	O
.	O

Before	O
taking	O
part	O
in	O
the	O
trial	O
,	O
they	O
will	O
receive	O
training	O
in	O
order	O
to	O
ensure	O
that	O
everyone	O
provides	O
the	O
same	O
support	O
.	O

Measurements	O
will	O
be	O
taken	O
at	O
five	O
different	O
moments	O
:	O
baseline	O
,	O
post	O
-	O
intervention	O
,	O
and	O
three	O
follow	O
-	O
up	O
periods	O
(	O
3	O
-	O
,	O
6	O
-	O
and	O
12	O
-	O
month	O
)	O
.	O

The	O
diagnostic	O
interviews	O
will	O
be	O
administered	O
by	O
a	O
trained	O
clinician	O
by	O
phone	O
.	O

Moreover	O
,	O
all	O
interviewers	O
engaged	O
in	O
the	O
assessment	O
of	O
potential	O
participants	O
will	O
be	O
supervised	O
by	O
a	O
clinical	O
team	O
composed	O
of	O
mental	O
health	O
professionals	O
with	O
extensive	O
experience	O
in	O
the	O
diagnosis	O
and	O
treatment	O
of	O
stress	O
-	O
related	O
disorders	O
.	O

Questionnaires	O
will	O
be	O
self	O
-	O
administered	O
online	O
via	O
the	O
same	O
virtual	O
platform	O
as	O
the	O
intervention	O
program	O
.	O

Table	O
2	O
provides	O
an	O
overview	O
of	O
the	O
measures	O
used	O
at	O
each	O
time	O
point	O
.	O

Table	O
2	O
Study	O
measures	O
and	O
assessment	O
times	O
Assessment	O
moment	O
Telephone	O
assessment	O
performed	O
by	O
a	O
therapist	O
Automatic	O
online	O
assessment	O
BL	O
Diagnostic	O
Interview	O
for	O
Adjustment	O
Disorders	O
,	O
ADIS	O
-	O
IV	O
-	O
L	O
*	O
BDI	O
,	O
Suicide	O
item	O
,	O
BAI	O
,	O
ISL	O
,	O
PTGI	O
,	O
PANAS	O
,	O
MQLI	O
Post	O
-	O
M	O
–	O
Post	O
-	O
module	O
assessment	O
scale	O
,	O
suicide	O
item	O
Post	O
-	O
M1	O
–	O
Post	O
-	O
module	O
assessment	O
scale	O
,	O
suicide	O
item	O
,	O
Expectation	O
of	O
treatment	O
scale	O
Post	O
-	O
T	O
Diagnostic	O
Interview	O
for	O
Adjustment	O
Disorders	O
BDI	O
,	O
Suicide	O
item	O
,	O
BAI	O
,	O
ISL	O
,	O
PTGI	O
,	O
PANAS	O
,	O
MQLI	O
,	O
Opinion	O
of	O
treatment	O

scale	O
FU	O
Diagnostic	O
Interview	O
for	O
Adjustment	O
Disorders	O
BDI	O
,	O
Suicide	O
item	O
,	O
BAI	O
,	O
ISL	O
,	O
PTGI	O
,	O
PANAS	O
,	O
MQLI	O
BL	O
,	O
Baseline	O
;	O
Post	O
-	O
M	O
,	O
post	O
-	O
module	O
;	O
Post	O
-	O
M1	O
,	O
post	O
-	O
module	O
1	O
;	O
Post	O
-	O
T	O
,	O
post	O
-	O
treatment	O
;	O
FU	O
,	O
follow	O
-	O
ups	O
;	O
ADIS	O
-	O
IV	O
-	O
L	O
,	O
Anxiety	O
Disorders	O
Interview	O
Schedule	O
for	O
DSM	B-coding_system
-	I-coding_system
IV	I-coding_system
:	O
Lifetime	O
Version	O
;	O
BDI	O
,	O
Beck	O
Depression	O
Inventory	O
-	O
Second	O
Edition	O
;	O
BAI	O
,	O
Beck	O
Anxiety	O
Inventory	O
;	O
ISL	O
,	O
Inventory	O
of	O
Stress	O
and	O
Loss	O
;	O
PTGI	O
,	O
Posttraumatic	O
Growth	O
Inventory	O
;	O
PANAS	O
,	O
Positive	O
and	O
Negative	O
Affect	O
Scale	O
;	O
MQLI	O
,	O
Multidimensional	O
Quality	O

of	O
Life	O
Questionnaire	O
;	O
*	O
used	O
only	O
when	O
differential	O
diagnosis	O
is	O
needed	O

Study	O
measures	O
and	O
assessment	O
times	O

BL	O
,	O
Baseline	O
;	O
Post	O
-	O
M	O
,	O
post	O
-	O
module	O
;	O
Post	O
-	O
M1	O
,	O
post	O
-	O
module	O
1	O
;	O
Post	O
-	O
T	O
,	O
post	O
-	O
treatment	O
;	O
FU	O
,	O
follow	O
-	O
ups	O
;	O
ADIS	O
-	O
IV	O
-	O
L	O
,	O
Anxiety	O
Disorders	O
Interview	O
Schedule	O
for	O
DSM	B-coding_system
-	I-coding_system
IV	I-coding_system
:	O
Lifetime	O
Version	O
;	O
BDI	O
,	O
Beck	O
Depression	O
Inventory	O
-	O
Second	O
Edition	O
;	O
BAI	O
,	O
Beck	O
Anxiety	O
Inventory	O
;	O
ISL	O
,	O
Inventory	O
of	O
Stress	O
and	O
Loss	O
;	O
PTGI	O
,	O
Posttraumatic	O
Growth	O
Inventory	O
;	O
PANAS	O
,	O
Positive	O
and	O
Negative	O
Affect	O
Scale	O
;	O
MQLI	O
,	O
Multidimensional	O
Quality	O
of	O
Life	O
Questionnaire	O
;	O
*	O
used	O
only	O
when	O
differential	O
diagnosis	O
is	O
needed	O

This	O
interview	O
will	O
be	O
used	O
for	O
the	O
diagnosis	O
of	O
AjD	O
and	O
to	O
check	O
the	O
fulfillment	O
of	O
inclusion	O
/	O
exclusion	O
criteria	O
.	O

It	O
is	O
a	O
semi	O
-	O
structured	O
interview	O
developed	O
by	O
our	O
research	O
group	O
,	O
taking	O
into	O
consideration	O
the	O
diagnostic	O
criteria	O
for	O
AjD	B-phenotype
included	O
in	O
the	O
DSM	B-coding_system
-	I-coding_system
IV	I-coding_system
-	I-coding_system
TR	I-coding_system
[	O
46	O
]	O
,	O
the	O
ICD	B-coding_system
-	I-coding_system
10	I-coding_system
[	O
47	O
]	O
,	O
and	O
the	O
Structured	B-coding_system
Clinical	I-coding_system
Interview	I-coding_system
for	I-coding_system
DSM	I-coding_system
-	I-coding_system
IV	I-coding_system
(	I-coding_system
SCID	I-coding_system
-	I-coding_system
CV	I-coding_system
)	I-coding_system
[	O
48	O
]	O
.	O

The	O
first	O
part	O
of	O
the	O
interview	O
aims	O
to	O
explore	O
the	O
presence	O
of	O
a	O
stressful	O
event	O
(	O
current	O
or	O
past	O
)	O
.	O

In	O
order	O
to	O
make	O
the	O
interview	O
easier	O
,	O
a	O
list	O
of	O
46	O
possible	O
stressors	O
is	O
included	O
.	O

The	O
second	O
part	O
includes	O
28	O
symptoms	O
related	O
to	O
AjD	O
.	O

The	O
presence	O
and	O
severity	O
of	O
these	O
symptoms	O
is	O
rated	O
on	O
a	O
9	O
-	O
point	O
scale	O
(	O
0	O
=	O
Not	O
at	O
all	O
;	O
8	O
=	O
Very	O
severe	O
)	O
.	O

The	O
validation	O
of	O
this	O
instrument	O
is	O
currently	O
in	O
process	O
.	O

Lifetime	O
Version	O
(	O
ADIS	O
-	O
IV	O
-	O
L	O
)	O
[	O
49	O
]	O
.	O

This	O
semi	O
-	O
structured	O
interview	O
will	O
be	O
used	O
only	O
when	O
differential	O
diagnoses	O
with	O
Generalized	O
Anxiety	O
Disorder	O
and	O
/	O
or	O
a	O
Major	O
Depressive	O
Episode	O
are	O
needed	O
.	O

The	O
ADIS	O
-	O
IV	O
-	O
L	O
allows	O
a	O
reliable	O
diagnosis	O
of	O
current	O
and	O
lifetime	O
anxiety	O
,	O
mood	O
,	O
somatoform	O
,	O
and	O
substance	O
use	O
disorders	O
.	O

Beck	O
Depression	O
Inventory	O
-	O
Second	O
Edition	O
(	O
BDI	O
-	O
II	O
)	O
[	O
50	O
]	O
,	O
validated	O
in	O
the	O
Spanish	O
population	O
[	O
51	O
]	O
.	O

The	O
BDI	O
-	O
II	O
is	O
a	O
widely	O
used	O
self	O
-	O
report	O
inventory	O
that	O
measures	O
characteristic	O
attitudes	O
and	O
symptoms	O
of	O
depression	O
.	O

The	O
total	O
score	O
is	O
obtained	O
by	O
adding	O
the	O
scores	O
on	O
the	O
21	O
items	O
that	O
make	O
up	O
the	O
instrument	O
,	O
with	O
a	O
maximum	O
of	O
63	O
points	O
.	O

The	O
instrument	O
has	O
good	O
internal	O
consistency	O
(	O
Cronbach’s	O
alpha	O
of	O
0	O
.	O
76	O
to	O
0	O
.	O
95	O
)	O
and	O
test	O
-	O
retest	O
reliability	O
of	O
around	O
0	O
.	O
8	O
.	O

Beck	O
Anxiety	O
Inventory	O
(	O
BAI	O
)	O
[	O
52	O
]	O
,	O
validated	O
in	O
the	O
Spanish	O
population	O
[	O
53	O
]	O
.	O

The	O
BAI	O
measures	O
the	O
severity	O
of	O
both	O
physiological	O
and	O
cognitive	O
symptoms	O
of	O
anxiety	O
.	O

The	O
21	O
items	O
are	O
rated	O
on	O
a	O
4	O
-	O
point	O
Likert	O
-	O
type	O
scale	O
(	O
from	O
0	O
to	O
3	O
)	O
,	O
and	O
the	O
total	O
score	O
,	O
which	O
ranges	O
between	O
0	O
and	O
63	O
,	O
is	O
obtained	O
after	O
directly	O
adding	O
together	O
the	O
scores	O
on	O
all	O
the	O
items	O
.	O

Psychometric	O
analyses	O
carried	O
out	O
so	O
far	O
show	O
excellent	O
internal	O
consistency	O
(	O
Cronbach’s	O
alpha	O
≥0	O
.	O
85	O
)	O
.	O

This	O
inventory	O
is	O
an	O
adaptation	O
of	O
the	O
Complicated	O
Grief	O
Inventory	O
[	O
54	O
]	O
.	O

It	O
consists	O
of	O
17	O
first	O
-	O
person	O
statements	O
about	O
the	O
degree	O
to	O
which	O
the	O
lost	O
person	O
/	O
situation	O
interferes	O
in	O
the	O
individual’s	O
life	O
.	O

There	O
are	O
5	O
response	O
options	O
,	O
ranging	O
from	O
0	O
(	O
“Never”	O
)	O
to	O
4	O
(	O
“Always”	O
)	O
.	O

The	O
validation	O
of	O
the	O
instrument	O
is	O
currently	O
in	O
process	O
.	O

However	O
,	O
preliminary	O
validation	O
data	O
[	O
55	O
]	O
show	O
excellent	O
Cronbach	O
coefficients	O
in	O
both	O
general	O
(	O
0	O
.	O
91	O
)	O
and	O
clinical	O
AD	O
(	O
0	O
.	O
86	O
)	O
Spanish	O
populations	O
.	O

Test	O
-	O
retest	O
reliability	O
was	O
also	O
excellent	O
(	O
0	O
.	O
90	O
)	O
.	O

The	O
PTGI	O
is	O
a	O
21	O
-	O
item	O
instrument	O
that	O
assesses	O
positive	O
outcomes	O
reported	O
by	O
individuals	O
who	O
have	O
experienced	O
traumatic	O
events	O
.	O

A	O
6	O
-	O
point	O
Likert	O
response	O
format	O
is	O
used	O
,	O
so	O
that	O
each	O
statement	O
is	O
rated	O
from	O
“I	O
did	O
not	O
experience	O
this	O
change	O
as	O
a	O
result	O
of	O
my	O
crisis”	O
(	O
scored	O
0	O
)	O
,	O
to	O
“I	O
experienced	O
this	O
change	O
to	O
a	O
large	O
degree	O
as	O
a	O
result	O
of	O
my	O
crisis”	O
(	O
scored	O
5	O
)	O
.	O

The	O
instrument	O
has	O
excellent	O
internal	O
consistency	O
(	O
Cronbach’s	O
alpha	O
of	O
0	O
.	O
90	O
)	O
and	O
acceptable	O
test	O
-	O
retest	O
reliability	O
of	O
around	O
0	O
.	O
71	O
.	O

The	O
PANAS	O
consists	O
of	O
20	O
items	O
that	O
evaluate	O
two	O
independent	O
dimensions	O
:	O
positive	O
affect	O
(	O
PA	O
)	O
and	O
negative	O
affect	O
(	O
NA	O
)	O
.	O

The	O
range	O
for	O
each	O
scale	O
(	O
10	O
items	O
on	O
each	O
)	O
is	O
from	O
10	O
to	O
50	O
.	O

The	O
Spanish	O
version	O
has	O
demonstrated	O
high	O
internal	O
consistency	O
(	O
0	O
.	O
89	O
to	O
0	O
.	O
91	O
for	O
PA	O
and	O
NA	O
,	O
respectively	O
,	O
in	O
women	O
,	O
and	O
0	O
.	O
87	O
and	O
0	O
.	O
89	O
for	O
PA	O
and	O
NA	O
,	O
respectively	O
,	O
in	O
men	O
)	O
in	O
college	O
students	O
.	O

This	O
is	O
a	O
10	O
-	O
item	O
self	O
-	O
report	O
instrument	O
that	O
assesses	O
physical	O
and	O
emotional	O
well	O
-	O
being	O
,	O
self	O
-	O
care	O
,	O
occupational	O
and	O
interpersonal	O
functioning	O
,	O
community	O
and	O
services	O
support	O
,	O
personal	O
and	O
spiritual	O
fulfillment	O
,	O
and	O
the	O
overall	O
perception	O
of	O
quality	O
of	O
life	O
.	O

Satisfaction	O
in	O
each	O
of	O
these	O
areas	O
is	O
measured	O
using	O
a	O
10	O
-	O
point	O
Likert	O
rating	O
scale	O
.	O

The	O
MQLI	O
is	O
brief	O
and	O
easy	O
to	O
administer	O
.	O

It	O
also	O
presents	O
good	O
internal	O
consistency	O
(	O
Cronbach’s	O
alpha	O
of	O
0	O
.	O
79	O
)	O
and	O
a	O
test	O
-	O
retest	O
reliability	O
index	O
of	O
0	O
.	O
89	O
.	O

This	O
self	O
-	O
report	O
inventory	O
measures	O
patients’	O
expectations	O
before	O
they	O
start	O
the	O
treatment	O
and	O
their	O
satisfaction	O
when	O
they	O
complete	O
the	O
treatment	O
.	O

The	O
6	O
items	O
are	O
rated	O
from	O
1	O
(	O
“Not	O
at	O
all”	O
)	O
to	O
10	O
(	O
“Highly”	O
)	O
and	O
provide	O
information	O
about	O
the	O
extent	O
to	O
which	O
:	O
1	O
)	O
the	O
treatment	O
is	O
perceived	O
as	O
logical	O
;	O
2	O
)	O
patients	O
are	O
satisfied	O
with	O
the	O
treatment	O
;	O
3	O
)	O
the	O
treatment	O
would	O
be	O
recommended	O
to	O
a	O
friend	O
with	O
the	O
same	O
problem	O
;	O
4	O
)	O
the	O
treatment	O
would	O
be	O
useful	O
to	O
treat	O
other	O
psychological	O
problems	O
;	O
5	O
)	O
patients	O
perceive	O
the	O
treatment	O
as	O
useful	O
for	O
their	O
particular	O
problem	O
;	O
and	O
6	O
)	O
the	O
treatment	O
is	O
perceived	O
as	O
aversive	O
.	O

Participants	O
will	O
answer	O
the	O
Expectations	O
scale	O
after	O
the	O
therapist	O
explains	O
the	O
rationale	O
for	O
the	O
treatment	O
they	O
will	O
receive	O
and	O
before	O
beginning	O
the	O
treatment	O
.	O

The	O
Satisfaction	O
scale	O
will	O
be	O
completed	O
once	O
the	O
treatment	O
ends	O
.	O

This	O
adaptation	O
has	O
been	O
used	O
in	O
previous	O
studies	O
[	O
60	O
–	O
62	O
]	O
.	O

This	O
8	O
-	O
item	O
instrument	O
was	O
developed	O
specifically	O
for	O
this	O
trial	O
in	O
order	O
to	O
get	O
more	O
feedback	O
about	O
the	O
participants’	O
opinions	O
about	O
TAO	O
.	O

Four	O
of	O
the	O
items	O
are	O
answered	O
using	O
an	O
11	O
-	O
point	O
response	O
scale	O
,	O
rating	O
different	O
statements	O
from	O
0	O
(	O
“Not	O
at	O
all”	O
)	O
to	O
10	O
(	O
“Very	O
much”	O
)	O
:	O
(	O
1	O
)	O
usefulness	O
;	O
(	O
2	O
)	O
attractiveness	O
;	O
(	O
3	O
)	O
convenience	O
;	O
(	O
4	O
)	O
recommendation	O
.	O

Then	O
,	O
four	O
short	O
-	O
answer	O
questions	O
are	O
included	O
to	O
collect	O
qualitative	O
data	O
about	O
:	O
(	O
1	O
)	O
the	O
most	O
useful	O
module	O
;	O
(	O
2	O
)	O
positive	O
features	O
of	O
the	O
intervention	O
;	O
(	O
3	O
)	O
negative	O
features	O
of	O
the	O
intervention	O
;	O
and	O
(	O
4	O
)	O
the	O
overall	O
opinion	O
.	O

This	O
scale	O
will	O
be	O
filled	O
out	O
at	O
post	O
-	O
intervention	O
.	O

The	O
presence	O
,	O
frequency	O
,	O
and	O
severity	O
of	O
suicidal	O
thoughts	O
will	O
be	O
assessed	O
during	O
the	O
Diagnostic	O
Interview	O
for	O
Adjustment	O
Disorders	O
administered	O
by	O
phone	O
.	O

The	O
inclusion	O
of	O
a	O
suicide	O
item	O
after	O
each	O
program	O
module	O
,	O
at	O
post	O
-	O
intervention	O
,	O
and	O
at	O
follow	O
-	O
up	O
assessments	O
will	O
make	O
it	O
possible	O
to	O
detect	O
participants	O
who	O
are	O
at	O
risk	O
of	O
suicide	O
during	O
the	O
intervention	O
and	O
once	O
the	O
intervention	O
is	O
over	O
.	O

The	O
post	O
-	O
module	O
assessment	O
will	O
be	O
performed	O
using	O
a	O
short	O
scale	O
developed	O
by	O
the	O
clinical	O
team	O
involved	O
in	O
the	O
present	O
trial	O
.	O

In	O
addition	O
to	O
suicidal	O
risk	O
,	O
the	O
following	O
variables	O
will	O
also	O
be	O
assessed	O
:	O
the	O
general	O
mood	O
using	O
a	O
7	O
-	O
point	O
face	O
rating	O
scale	O
,	O
and	O
the	O
intensity	O
of	O
several	O
emotions	O
(	O
joy	O
,	O
sadness	O
,	O
anger	O
,	O
hope	O
,	O
anxiety	O
,	O
relaxation	O
,	O
pride	O
,	O
and	O
guilt	O
)	O
on	O
a	O
7	O
-	O
point	O
numeric	O
scale	O
.	O

Finally	O
,	O
10	O
-	O
point	O
numeric	O
scales	O
will	O
explore	O
:	O
(	O
1	O
)	O
the	O
feeling	O
of	O
self	O
-	O
efficacy	O
to	O
deal	O
with	O
the	O
stressful	O
event	O
that	O
caused	O
the	O
AjD	O
;	O
(	O
2	O
)	O
acceptance	O
of	O
negative	O
events	O
;	O
(	O
3	O
)	O
openness	O
to	O
new	O
experiences	O
;	O
and	O
(	O
4	O
)	O
satisfaction	O
with	O
the	O
TAO	O
module	O
.	O

The	O
statistical	O
package	O
IBM	O
SPSS	O
Statistics	O
version	O
22	O
.	O
0	O
for	O
Windows	O
will	O
be	O
used	O
for	O
data	O
analyses	O
.	O

Baseline	O
differences	O
between	O
groups	O
will	O
be	O
explored	O
for	O
continuous	O
and	O
categorical	O
measures	O
using	O
both	O
t	O
-	O
tests	O
and	O
chi	O
-	O
square	O
tests	O
.	O

Repeated	O
-	O
measures	O
ANOVAs	O
will	O
be	O
used	O
to	O
assess	O
within	O
-	O
group	O
changes	O
over	O
time	O
in	O
primary	O
and	O
secondary	O
outcome	O
measures	O
.	O

Effect	O
sizes	O
will	O
be	O
estimated	O
using	O
Cohen’s	O
d	O
.	O

Linear	O
regression	O
models	O
will	O
be	O
used	O
to	O
study	O
the	O
effect	O
of	O
different	O
variables	O
(	O
e	O
.	O
g	O
.	O
,	O
gender	O
,	O
age	O
,	O
and	O
treatment	O
expectations	O
)	O
on	O
adherence	O
and	O
response	O
to	O
the	O
intervention	O
.	O

Any	O
participants	O
who	O
do	O
not	O
complete	O
the	O
post	O
-	O
intervention	O
assessment	O
will	O
be	O
considered	O
drop	O
-	O
outs	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
number	O
of	O
times	O
each	O
patient	O
uses	O
the	O
program	O
will	O
be	O
used	O
as	O
the	O
measure	O
of	O
adherence	O
.	O

Before	O
analyzing	O
the	O
data	O
,	O
a	O
review	O
of	O
state	O
-	O
of	O
-	O
the	O
-	O
art	O
analytic	O
methodology	O
for	O
RCT	O
will	O
be	O
carried	O
out	O
in	O
order	O
to	O
ensure	O
the	O
use	O
of	O
the	O
most	O
suitable	O
statistical	O
analyses	O
.	O

Finally	O
,	O
following	O
SPIRIT	O
and	O
CONSORT	O
guideline	O
recommendations	O
,	O
both	O
intention	O
-	O
to	O
-	O
treat	O
and	O
per	O
-	O
protocol	O
analyses	O
will	O
be	O
reported	O
[	O
34	O
,	O
36	O
]	O
.	O

AESOP	O
is	O
a	O
multi	O
-	O
centre	O
incidence	O
and	O
case	O
-	O
control	O
study	O
of	O
first	O
-	O
episode	O
psychosis	O
.	O

Full	O
details	O
of	O
the	O
methods	O
are	O
provided	O
in	O
previous	O
reports	O
(	O
Morgan	O
et	O
al	O
.	O
,	O
2006	O
)	O
.	O

The	O
sample	O
comprises	O
cases	O
with	O
a	O
first	O
episode	O
of	O
psychosis	O
and	O
population	O
-	O
based	O
controls	O
.	O

The	O
inclusion	O
criteria	O
for	O
cases	O
were	O
:	O
age	O
16	O
-	O
64	O
;	O
resident	O
within	O
defined	O
catchment	O
areas	O
in	O
south	O
-	O
east	O
London	O
and	O
Nottingham	O
,	O
UK	O
;	O
presence	O
of	O
a	O
first	O
episode	O
of	O
psychosis	O
within	O
the	O
time	O
frame	O
of	O
the	O
study	O
;	O
and	O
no	O
previous	O
contact	O
with	O
health	O
services	O
for	O
psychosis	O
.	O

Exclusion	O
criteria	O
were	O
:	O
evidence	O
of	O
psychotic	O
symptoms	O
precipitated	O
by	O
an	O
organic	O
cause	O
;	O
and	O
transient	B-phenotype
psychotic	I-phenotype
symptoms	I-phenotype
resulting	I-phenotype
from	I-phenotype
acute	I-phenotype
intoxication	I-phenotype
as	O
defined	O
by	O
ICD	B-coding_system
-	I-coding_system
10	I-coding_system
.	O

Each	O
patient	O
meeting	O
inclusion	O
criteria	O
was	O
approached	O
and	O
informed	O
consent	O
sought	O
.	O

During	O
the	O
same	O
period	O
,	O
a	O
random	O
sample	O
of	O
population	O
-	O
based	O
controls	O
with	O
no	O
history	O
of	O
psychosis	O
aged	O
16	O
-	O
64	O
was	O
recruited	O
from	O
the	O
same	O
catchment	O
areas	O
.	O

The	O
study	O
received	O
approval	O
from	O
the	O
relevant	O
local	O
research	O
ethics	O
committees	O
and	O
all	O
participants	O
provided	O
informed	O
consent	O
.	O

Detailed	O
information	O
on	O
markers	O
of	O
adversity	O
in	O
childhood	O
and	O
adulthood	O
was	O
collected	O
from	O
cases	O
and	O
controls	O
using	O
the	O
MRC	O
Sociodemographic	O
Schedule	O
.	O

The	O
primary	O
markers	O
of	O
childhood	O
adversity	O
used	O
for	O
the	O
analyses	O
presented	O
in	O
this	O
paper	O
were	O
1	O
)	O
separation	O
from	O
a	O
parent	O
before	O
the	O
age	O
of	O
16	O
(	O
with	O
separation	O
defined	O
as	O
not	O
living	O
in	O
same	O
household	O
as	O
one	O
or	O
both	O
parents	O
for	O
one	O
-	O
year	O
or	O
more	O
because	O
of	O
family	O
breakdown	O
)	O
;	O
and	O
2	O
)	O
death	O
of	O
a	O
parent	O
before	O
the	O
age	O
of	O
16	O
(	O
Morgan	O
et	O
al	O
.	O
,	O
2007	O
)	O
.	O

With	O
regard	O
to	O
current	O
and	O
long	O
-	O
term	O
(	O
i	O
.	O
e	O
.	O
,	O
one	O
year	O
prior	O
to	O
assessment	O
)	O
adult	O
disadvantage	O
and	O
isolation	O
we	O
considered	O
,	O
where	O
possible	O
,	O
five	O
indicators	O
:	O
1	O
)	O
unemployed	O
;	O
2	O
)	O
living	O
alone	O
;	O
3	O
)	O
rented	O
housing	O
;	O
4	O
)	O
no	O
relationship	O
;	O
and	O
5	O
)	O
limited	O
social	O
networks	O
(	O
Morgan	O
et	O
al	O
.	O
,	O
2008	O
)	O
.	O

To	O
assess	O
the	O
impact	O
of	O
linked	O
and	O
cumulative	O
disadvantage	O
we	O
created	O
current	O
and	O
long	O
-	O
term	O
indices	O
by	O
dichotomising	O
each	O
variable	O
to	O
indicate	O
the	O
presence	O
or	O
absence	O
of	O
an	O
indicator	O
,	O
with	O
a	O
score	O
of	O
1	O
for	O
present	O
(	O
e	O
.	O
g	O
.	O
unemployed	O
)	O
and	O
0	O
for	O
absent	O
.	O

This	O
produced	O
a	O
potential	O
range	O
on	O
the	O
current	O
index	O
of	O
0	O
to	O
5	O
and	O
on	O
the	O
long	O
-	O
term	O
index	O
of	O
0	O
to	O
3	O
.	O

(	O
Long	O
-	O
term	O
data	O
were	O
available	O
for	O
three	O
markers	O
only	O
:	O
unemployment	O
,	O
living	O
alone	O
,	O
no	O
relationship	O
.	O
)	O
Poor	O
educational	O
achievement	O
was	O
operationalised	O
as	O
not	O
having	O
achieved	O
any	O
formal	O
educational	O
qualifications	O
.	O

Self	O
-	O
esteem	O
was	O
assessed	O
with	O
the	O
Rosenberg	O
Self	O
-	O
Esteem	O
Scale	O
(	O
Rosenberg	O
,	O
1989	O
)	O
.	O

The	O
questionnaire	O
comprises	O
10	O
-	O
items	O
(	O
e	O
.	O
g	O
.	O
,	O
‘on	O
the	O
whole	O
I	O
am	O
satisfied	O
with	O
myself’	O
)	O
on	O
a	O
five	O
-	O
point	O
scale	O
.	O

Total	O
scores	O
range	O
from	O
10	O
to	O
50	O
,	O
with	O
a	O
higher	O
score	O
indicating	O
more	O
positive	O
evaluations	O
of	O
the	O
self	O
.	O

Data	O
on	O
ethnicity	O
,	O
gender	O
,	O
and	O
age	O
were	O
collected	O
using	O
the	O
MRC	O
Sociodemographic	O
Schedule	O
.	O

Symptom	O
data	O
were	O
collected	O
using	O
the	O
Schedules	O
for	O
Clinical	O
Assessment	O
in	O
Neuropsychiatry	O
(	O
SCAN	O
)	O
(	O
WHO	O
,	O
1992	O
)	O
.	O

ICD	B-coding_system
-	I-coding_system
10	I-coding_system
diagnoses	O
were	O
determined	O
by	O
consensus	O
.	O

Premorbid	O
IQ	O
was	O
estimated	O
using	O
the	O
National	O
Adult	O
Reading	O
Test	O
and	O
a	O
parental	O
history	O
of	O
psychosis	O
was	O
established	O
using	O
the	O
Family	O
Interview	O
for	O
Genetic	O
Studies	O
.	O

To	O
test	O
our	O
hypotheses	O
we	O
first	O
examined	O
whether	O
there	O
was	O
evidence	O
that	O
the	O
effects	O
of	O
a	O
)	O
parental	O
separation	O
and	O
b	O
)	O
parental	O
death	O
before	O
the	O
age	O
of	O
16	O
on	O
case	O
-	O
control	O
status	O
were	O
mediated	O
through	O
poor	O
education	O
and	O
adult	O
disadvantage	O
and	O
self	O
-	O
esteem	O
using	O
multiple	O
mediation	O
analysis	O
(	O
MacKinnon	O
,	O
2008	O
)	O
.	O

In	O
line	O
with	O
Preacher	O
&	O
Hayes	O
(	O
2008	O
)	O
,	O
the	O
total	O
effect	O
of	O
parental	O
separation	O
(	O
and	O
of	O
parental	O
death	O
)	O
on	O
case	O
-	O
control	O
status	O
was	O
apportioned	O
into	O
a	O
direct	O
effect	O
and	O
mediating	O
or	O
,	O
synonymously	O
,	O
indirect	O
effects	O
through	O
poor	O
education	O
and	O
adult	O
disadvantage	O
and	O
self	O
-	O
esteem	O
.	O

The	O
total	O
indirect	O
effect	O
was	O
computed	O
as	O
the	O
sum	O
of	O
specific	O
indirect	O
effects	O
.	O

Logit	O
coefficients	O
and	O
odds	O
ratios	O
for	O
total	O
and	O
specific	O
indirect	O
effects	O
of	O
parental	O
separation	O
and	O
parental	O
death	O
through	O
the	O
hypothesised	O
mediators	O
on	O
case	O
-	O
control	O
status	O
were	O
estimated	O
using	O
maximum	O
likelihood	O
(	O
ML	O
)	O
estimation	O
in	O
MPlus	O
,	O
Version	O
6	O
.	O
1	O
(	O
Muthen	O
and	O
Muthen	O
,	O
1998	O
-	O
2012	O
)	O
.	O

All	O
mediation	O
analyses	O
were	O
repeated	O
using	O
the	O
robust	O
weighted	O
least	O
squares	O
means	O
and	O
variance	O
adjusted	O
estimator	O
(	O
WLSMV	O
)	O
to	O
compute	O
probit	O
coefficients	O
,	O
as	O
this	O
approach	O
provides	O
more	O
accurate	O
estimates	O
of	O
direct	O
,	O
indirect	O
,	O
and	O
total	O
effects	O
and	O
allows	O
for	O
use	O
of	O
bias	O
-	O
corrected	O
bootstrapping	O
.	O

29	O
,	O
30	O
Findings	O
from	O
these	O
analyses	O
(	O
see	O
supplementary	O
materials	O
)	O
were	O
in	O
line	O
with	O
those	O
produced	O
using	O
logit	O
coefficients	O
and	O
odds	O
ratios	O
,	O
which	O
are	O
presented	O
in	O
preference	O
in	O
the	O
main	O
body	O
of	O
the	O
paper	O
because	O
they	O
are	O
more	O
readily	O
interpretable	O
.	O

Data	O
were	O
assumed	O
to	O
be	O
missing	O
at	O
random	O
,	O
which	O
allowed	O
for	O
inclusion	O
of	O
the	O
full	O
sample	O
using	O
WLSMV	O
and	O
ML	O
estimators	O
.	O

Next	O
,	O
we	O
examined	O
whether	O
there	O
was	O
evidence	O
that	O
childhood	O
adversity	O
(	O
i	O
.	O
e	O
.	O
,	O
a	O
)	O
separation	O
from	O
a	O
parent	O
;	O
b	O
)	O
death	O
of	O
a	O
parent	O
)	O
combined	O
synergistically	O
with	O
poor	O
education	O
and	O
/	O
or	O
adult	O
disadvantage	O
by	O
testing	O
for	O
interaction	O
on	O
an	O
additive	O
scale	O
(	O
i	O
.	O
e	O
.	O
,	O
for	O
departure	O
from	O
additivity	O
)	O
using	O
interaction	O
contrast	O
ratios	O
(	O
ICR	O
)	O
,	O
as	O
described	O
by	O
Schwartz	O
et	O
al	O
23	O
.	O

Under	O
the	O
assumption	O
that	O
when	O
the	O
disorder	O
is	O
rare	O
odds	O
ratios	O
approximate	O
risk	O
ratios	O
,	O
this	O
approach	O
uses	O
odds	O
ratios	O
to	O
estimate	O
the	O
relative	O
excess	O
risk	O
due	O
to	O
interaction	O
(	O
i	O
.	O
e	O
.	O

,	O
ICR	O
=	O
OR	O
exposure	O
A	O
&	O
exposure	O
B	O
-	O
OR	O
exposure	O
A	O
only	O
-	O
OR	O
exposure	O
B	O
only	O
+	O
1	O
)	O
.	O

In	O
this	O
model	O
,	O
deviation	O
from	O
additivity	O
(	O
i	O
.	O
e	O
.	O
,	O
interaction	O
)	O
is	O
indexed	O
by	O
an	O
ICR	O
greater	O
than	O
0	O
.	O

Confidence	O
intervals	O
and	O
p	O
-	O
values	O
for	O
ICRs	O
were	O
generated	O
using	O
the	O
nlcom	O
procedure	O
in	O
STATA	O
.	O

Analyses	O
were	O
conducted	O
using	O
STATA	O
Version	O
12	O
and	O
MPlus	O
Version	O
6	O
.	O
1	O
.	O

Data	O
for	O
this	O
study	O
were	O
collected	O
retrospectively	O
at	O
a	O
single	O
time	O
point	O
,	O
which	O
inevitably	O
limits	O
the	O
inferences	O
that	O
can	O
be	O
drawn	O
regarding	O
causal	O
pathways	O
.	O

We	O
did	O
,	O
however	O
,	O
select	O
variables	O
that	O
are	O
temporally	O
sequential	O
such	O
that	O
it	O
is	O
reasonable	O
to	O
assume	O
in	O
most	O
cases	O
that	O
parental	O
separation	O
prior	O
to	O
age	O
16	O
years	O
preceded	O
educational	O
level	O
(	O
i	O
.	O
e	O
.	O
,	O
no	O
qualifications	O
on	O
leaving	O
school	O
at	O
16	O
years	O
or	O
subsequently	O
)	O
,	O
which	O
in	O
turn	O
preceded	O
disadvantage	O
and	O
self	O
-	O
esteem	O
(	O
determined	O
at	O
point	O
of	O
assessment	O
,	O
i	O
.	O
e	O
.	O
after	O
age	O
16	O
years	O
)	O
.	O

Perhaps	O
more	O
problematically	O
,	O
as	O
disadvantage	O
and	O
self	O
-	O
esteem	O
were	O
assessed	O
after	O
onset	O
of	O
disorder	O
,	O
we	O
cannot	O
determine	O
the	O
direction	O
of	O
causation	O
between	O
these	O
and	O
psychosis	O
.	O

However	O
,	O
we	O
have	O
shown	O
in	O
previous	O
analyses	O
that	O
associations	O
between	O
case	O
-	O
control	O
status	O
and	O
markers	O
of	O
disadvantage	O
held	O
when	O
the	O
sample	O
was	O
restricted	O
to	O
those	O
with	O
a	O
very	O
short	O
DUP	O
(	O
<	O
1	O
month	O
)	O
and	O
when	O
long	O
-	O
term	O
indicators	O
of	O
social	O
disadvantage	O
were	O
considered	O
,	O
which	O
suggests	O
high	O
levels	O
of	O
disadvantage	O
in	O
the	O
case	O
sample	O
are	O
not	O
simply	O
a	O
consequence	O
of	O
disorder	O
(	O
Morgan	O
et	O
al	O
.	O
,	O
2008	O
)	O
.	O

In	O
a	O
more	O
recent	O
study	O
,	O
we	O
replicated	O
these	O
findings	O
and	O
further	O
showed	O
that	O
markers	O
of	O
disadvantage	O
were	O
present	O
5	O
years	O
prior	O
to	O
onset	O
(	O
Stilo	O
et	O
al	O
.	O
,	O
2012	O
)	O
.	O

Similarly	O
,	O
in	O
the	O
analyses	O
presented	O
in	O
this	O
paper	O
,	O
when	O
we	O
both	O
restricted	O
the	O
sample	O
to	O
those	O
with	O
a	O
short	O
DUP	O
and	O
repeated	O
analyses	O
using	O
the	O
long	O
-	O
term	O
index	O
of	O
social	O
disadvantage	O
the	O
findings	O
were	O
the	O
same	O
.	O

We	O
were	O
able	O
to	O
adjust	O
for	O
a	O
parental	O
history	O
of	O
psychosis	O
and	O
,	O
in	O
a	O
sub	O
-	O
sample	O
,	O
for	O
estimated	O
premorbid	O
IQ	O
,	O
and	O
the	O
findings	O
remained	O
largely	O
robust	O
.	O

Parental	O
history	O
,	O
however	O
,	O
is	O
a	O
limited	O
proxy	O
for	O
genetic	O
risk	O
and	O
we	O
cannot	O
entirely	O
rule	O
out	O
the	O
possibility	O
that	O
some	O
of	O
the	O
observed	O
effects	O
are	O
a	O
consequence	O
of	O
underlying	O
genetic	O
susceptibility	O
.	O

Polygenic	O
risk	O
scores	O
may	O
provide	O
more	O
useful	O
summaries	O
of	O
total	O
genetic	O
risk	O
that	O
can	O
be	O
employed	O
in	O
future	O
studies	O
(	O
Purcell	O
et	O
al	O
.	O
,	O
2009	O
)	O
.	O

In	O
addition	O
,	O
we	O
cannot	O
rule	O
out	O
confounding	O
by	O
unmeasured	O
factors	O
such	O
as	O
substance	O
use	O
.	O

What	O
this	O
indicates	O
is	O
that	O
the	O
models	O
we	O
have	O
tested	O
are	O
inevitably	O
partial	O
.	O

Our	O
finding	O
of	O
evidence	O
for	O
synergistic	O
effects	O
on	O
an	O
additive	O
scale	O
should	O
be	O
interpreted	O
with	O
caution	O
.	O

As	O
has	O
been	O
discussed	O
in	O
relation	O
to	O
gene	O
-	O
environment	O
interactions	O
,	O
models	O
are	O
scale	O
dependent	O
(	O
Zammit	O
et	O
al	O
.	O
,	O
2010a	O
)	O
.	O

Recent	O
critiques	O
of	O
interaction	O
analyses	O
,	O
particularly	O
of	O
additive	O
models	O
,	O
emphasise	O
the	O
need	O
to	O
determine	O
analyses	O
and	O
scale	O
for	O
interaction	O
a	O
priori	O
,	O
especially	O
given	O
the	O
high	O
probability	O
of	O
Type	O
I	O
error	O
(	O
Zammit	O
et	O
al	O
.	O
,	O
2010a	O
)	O
.	O

Our	O
decision	O
to	O
model	O
interactions	O
on	O
an	O
additive	O
scale	O
was	O
made	O
because	O
,	O
within	O
a	O
minimum	O
sufficient	O
causes	O
framework	O
,	O
additive	O
models	O
provide	O
the	O
best	O
representation	O
of	O
synergy	O
(	O
Rothman	O
et	O
al	O
.	O
,	O
1980	O
,	O
Schwartz	O
,	O
2006	O
)	O
.	O

In	O
addition	O
,	O
as	O
others	O
have	O
noted	O
,	O
multiplicative	O
models	O
are	O
more	O
complex	O
and	O
prone	O
to	O
error	O
and	O
,	O
from	O
a	O
public	O
health	O
perspective	O
,	O
they	O
are	O
not	O
as	O
informative	O
as	O
additive	O
models	O
,	O
which	O
provide	O
more	O
readily	O
interpretable	O
information	O
on	O
the	O
combined	O
impact	O
of	O
two	O
risk	O
factors	O
over	O
and	O
above	O
what	O
would	O
be	O
expected	O
from	O
each	O
one	O
alone	O
(	O
Kendler	O
and	O
Gardner	O
,	O
2010	O
)	O
.	O

It	O
further	O
bears	O
noting	O
that	O
our	O
key	O
exposure	O
variables	O
are	O
perhaps	O
most	O
usefully	O
considered	O
risk	O
indicators	O
that	O
probably	O
index	O
exposure	O
,	O
in	O
some	O
but	O
not	O
all	O
,	O
to	O
risk	O
factors	O
that	O
are	O
more	O
common	O
among	O
those	O
who	O
are	O
separated	O
and	O
who	O
are	O
unemployed	O
,	O
living	O
alone	O
and	O
so	O
on	O
.	O

That	O
there	O
are	O
multiple	O
effects	O
of	O
separation	O
on	O
risk	O
further	O
hints	O
at	O
this	O
.	O

The	O
meaning	O
and	O
impact	O
of	O
separation	O
,	O
for	O
example	O
,	O
is	O
probably	O
diffuse	O
;	O
indeed	O
,	O
our	O
findings	O
suggest	O
separation	O
indicate	O
exposure	O
to	O
processes	O
that	O
impact	O
on	O
risk	O
of	O
psychosis	O
both	O
directly	O
(	O
e	O
.	O
g	O
.	O
,	O
disrupted	O
attachments	O
,	O
intra	O
-	O
familial	O
conflict	O
and	O
neglect	O
)	O
,	O
which	O
in	O
turn	O
may	O
combine	O
synergistically	O
with	O
subsequent	O
exposures	O
,	O
and	O
indirectly	O
via	O
other	O
variables	O
,	O
e	O
.	O
g	O
.	O
education	O
and	O
subsequent	O
disadvantage	O
.	O

What	O
is	O
more	O
,	O
this	O
may	O
explain	O
why	O
the	O
same	O
exposures	O
are	O
often	O
associated	O
with	O
a	O
heterogeneous	O
range	O
of	O
outcomes	O
;	O
that	O
is	O
,	O
specificity	O
may	O
lie	O
in	O
the	O
particular	O
paths	O
that	O
follow	O
initial	O
exposures	O
,	O
and	O
this	O
points	O
strongly	O
to	O
a	O
need	O
for	O
more	O
detailed	O
and	O
robust	O
measures	O
of	O
social	O
exposures	O
.	O

The	O
above	O
limitations	O
noted	O
,	O
the	O
analyses	O
reported	O
here	O
both	O
illustrate	O
how	O
multiple	O
(	O
social	O
)	O
risk	O
factors	O
can	O
be	O
simultaneously	O
modelled	O
to	O
provide	O
clues	O
on	O
how	O
they	O
combine	O
in	O
developmental	O
trajectories	O
to	O
psychosis	O
and	O
provide	O
initial	O
evidence	O
in	O
relation	O
to	O
childhood	O
adversity	O
,	O
subsequent	O
disadvantage	O
and	O
(	O
tentatively	O
)	O
self	O
-	O
esteem	O
.	O

Our	O
analyses	O
tie	O
in	O
with	O
a	O
developing	O
literature	O
considering	O
how	O
social	O
and	O
non	O
-	O
social	O
environmental	O
factors	O
combine	O
and	O
interact	O
over	O
time	O
to	O
increase	O
risk	O
of	O
psychosis	O
.	O

There	O
is	O
,	O
for	O
example	O
,	O
increasing	O
evidence	O
for	O
cross	O
-	O
level	O
social	O
environment	O
-	O
environment	O
interactions	O
,	O
such	O
that	O
the	O
effects	O
of	O
individual	O
-	O
level	O
exposures	O
(	O
e	O
.	O
g	O
.	O
,	O
being	O
single	O
)	O
often	O
depend	O
on	O
area	O
-	O
level	O
exposures	O
(	O
e	O
.	O
g	O
.	O
,	O
living	O
in	O
area	O
with	O
few	O
single	O
people	O
)	O
(	O
van	O
Os	O
et	O
al	O
.	O
,	O
2000	O
)	O
.	O

In	O
relation	O
to	O
non	O
-	O
social	O
environmental	O
factors	O
,	O
Clarke	O
et	O
al	O
(	O
2011	O
)	O
found	O
evidence	O
for	O
interaction	O
between	O
obstetric	O
complications	O
and	O
delayed	O
developmental	O
milestones	O
in	O
risk	O
for	O
schizophrenia	O
using	O
data	O
from	O
population	O
records	O
in	O
Helsinki	O
,	O
Finland	O
.	O

With	O
regard	O
to	O
causal	O
paths	O
,	O
Bebbington	O
et	O
al	O
(	O
2011	O
)	O
found	O
evidence	O
consistent	O
with	O
a	O
pathway	O
from	O
childhood	O
sexual	O
abuse	O
to	O
psychosis	O
via	O
anxiety	O
and	O
depression	O
in	O
their	O
analyses	O
of	O
data	O
from	O
the	O
2007	O
Adult	O
Psychiatric	O
Morbidity	O
Survey	O
in	O
England	O
(	O
n	O
in	O
analysis	O
=	O
7353	O
)	O
.	O

More	O
recently	O
,	O
Fisher	O
et	O
al	O
(	O
2012	O
)	O
in	O
analyses	O
of	O
data	O
from	O
the	O
ALSPAC	O
birth	O
cohort	O
(	O
n	O
in	O
analyses	O
=	O
6692	O
)	O
,	O
found	O
that	O
the	O
effects	O
of	O
harsh	O
parenting	O
and	O
bullying	O
prior	O
to	O
8	O
.	O
5	O
years	O
old	O
on	O
risk	O
of	O
psychotic	O
experiences	O
at	O
age	O
13	O
years	O
were	O
fully	O
or	O
partially	O
mediated	O
by	O
anxiety	O
,	O
depressive	O
symptoms	O
,	O
external	O
locus	O
of	O
control	O
and	O
low	O
self	O
-	O
esteem	O
.	O

Our	O
findings	O
are	O
consistent	O
with	O
and	O
add	O
to	O
this	O
developing	O
literature	O
and	O
further	O
extend	O
it	O
by	O
modelling	O
paths	O
and	O
interactions	O
within	O
the	O
same	O
analyses	O
.	O

There	O
is	O
,	O
however	O
,	O
some	O
way	O
to	O
go	O
before	O
our	O
models	O
capture	O
the	O
complexity	O
that	O
undoubtedly	O
underlies	O
developmental	O
trajectories	O
to	O
psychosis	O
.	O

In	O
this	O
respect	O
,	O
models	O
of	O
the	O
environmental	O
antecedents	O
of	O
psychosis	O
are	O
currently	O
less	O
well	O
developed	O
and	O
empirically	O
supported	O
than	O
those	O
for	O
other	O
disorders	O
(	O
e	O
.	O
g	O
.	O
,	O
depression	O
(	O
Brown	O
et	O
al	O
.	O
,	O
2007	O
)	O
)	O
;	O
this	O
wider	O
literature	O
points	O
a	O
way	O
forward	O
for	O
studies	O
of	O
psychosis	O
.	O

In	O
relation	O
to	O
socio	O
-	O
environmental	O
factors	O
,	O
it	O
is	O
important	O
to	O
note	O
that	O
there	O
is	O
now	O
evidence	O
for	O
plausible	O
mechanisms	O
that	O
may	O
account	O
for	O
how	O
external	O
social	O
experiences	O
impact	O
on	O
individuals	O
in	O
such	O
a	O
way	O
as	O
to	O
increase	O
risk	O
of	O
psychosis	O
(	O
e	O
.	O
g	O
.	O
,	O
via	O
effects	O
of	O
stress	O
on	O
dopamine	O
(	O
Howes	O
and	O
Kapur	O
,	O
2009	O
)	O
,	O
the	O
HPA	O
axis	O
(	O
Mondelli	O
et	O
al	O
.	O
,	O
2010	O
)	O
,	O
neural	O
function	O
(	O
Lederbogen	O
et	O
al	O
.	O
,	O
2011	O
)	O
and	O
cognition	O
and	O
affect	O
(	O
Fowler	O
et	O
al	O
.	O
,	O
2012	O
)	O
)	O
.	O

These	O
findings	O
,	O
in	O
turn	O
,	O
validate	O
the	O
importance	O
of	O
environmental	O
factors	O
and	O
provide	O
further	O
impetus	O
to	O
research	O
on	O
how	O
such	O
factors	O
combine	O
and	O
interact	O
with	O
each	O
other	O
to	O
increase	O
risk	O
of	O
disorder	O
.	O

Social	O
disadvantage	O
,	O
broadly	O
defined	O
,	O
frequently	O
persists	O
over	O
time	O
and	O
is	O
often	O
associated	O
with	O
poor	O
outcomes	O
in	O
a	O
number	O
of	O
domains	O
(	O
e	O
.	O
g	O
.	O
,	O
education	O
,	O
health	O
,	O
housing	O
,	O
etc	O
.	O
)	O
;	O
these	O
poor	O
outcomes	O
in	O
turn	O
further	O
entrench	O
and	O
amplify	O
disadvantage	O
,	O
creating	O
for	O
many	O
a	O
vicious	O
downward	O
cycle	O
of	O
poverty	O
and	O
exclusion	O
(	O
Pantazis	O
et	O
al	O
.	O
,	O
2006	O
)	O
.	O

Given	O
this	O
,	O
it	O
is	O
plausible	O
that	O
one	O
pathway	O
from	O
adversity	O
in	O
childhood	O
to	O
psychosis	O
is	O
via	O
persistent	O
exposure	O
to	O
disadvantage	O
in	O
adulthood	O
and	O
consequent	O
low	O
self	O
-	O
esteem	O
.	O

With	O
this	O
in	O
mind	O
,	O
we	O
have	O
previously	O
proposed	O
a	O
predominantly	O
socio	O
-	O
developmental	O
pathway	O
to	O
psychosis	O
,	O
in	O
which	O
,	O
for	O
some	O
,	O
adverse	O
social	O
experiences	O
in	O
childhood	O
link	O
to	O
psychosis	O
via	O
and	O
in	O
interaction	O
with	O
further	O
cumulative	O
stressors	O
in	O
adulthood	O
(	O
and	O
indeed	O
other	O
factors	O
,	O
e	O
.	O
g	O
.	O
,	O
substance	O
use	O
)	O
(	O
Morgan	O
et	O
al	O
.	O
,	O
2010	O
)	O
.	O

The	O
analyses	O
presented	O
here	O
are	O
,	O
put	O
cautiously	O
,	O
consistent	O
with	O
this	O
.	O

Further	O
,	O
this	O
model	O
was	O
proposed	O
primarily	O
to	O
explain	O
the	O
high	O
rates	O
of	O
psychosis	O
observed	O
in	O
some	O
minority	O
ethnic	O
populations	O
,	O
particularly	O
the	O
black	O
Caribbean	O
in	O
the	O
UK	O
,	O
in	O
which	O
there	O
are	O
very	O
high	O
levels	O
of	O
social	O
disadvantage	O
across	O
the	O
life	O
course	O
.	O

The	O
data	O
are	O
,	O
again	O
put	O
cautiously	O
,	O
consistent	O
with	O
this	O
(	O
i	O
.	O
e	O
.	O
,	O
similar	O
effect	O
sizes	O
among	O
populations	O
,	O
higher	O
prevalence	O
of	O
exposure	O
in	O
one	O
population	O
)	O
.	O

Unraveling	O
these	O
complex	O
connections	O
is	O
of	O
potential	O
public	O
health	O
importance	O
.	O

Put	O
simply	O
,	O
if	O
initial	O
disadvantage	O
in	O
childhood	O
is	O
not	O
followed	O
by	O
later	O
disadvantage	O
,	O
the	O
overall	O
effect	O
of	O
,	O
say	O
,	O
separation	O
from	O
a	O
parent	O
on	O
risk	O
may	O
be	O
reduced	O
,	O
a	O
possibility	O
with	O
tangible	O
public	O
health	O
implications	O
.	O

Related	O
to	O
this	O
,	O
there	O
is	O
emerging	O
interest	O
in	O
the	O
role	O
of	O
protective	O
factors	O
and	O
resilience	O
in	O
mitigating	O
the	O
effect	O
of	O
social	O
adversities	O
on	O
risk	O
of	O
psychosis	O
(	O
Gayer	O
-	O
Anderson	O
and	O
Morgan	O
,	O
2012	O
)	O
.	O

It	O
may	O
be	O
,	O
then	O
,	O
that	O
by	O
identifying	O
how	O
social	O
(	O
and	O
other	O
)	O
factors	O
that	O
may	O
be	O
amendable	O
to	O
change	O
connect	O
over	O
time	O
in	O
complex	O
causal	O
webs	O
,	O
we	O
can	O
gain	O
further	O
traction	O
on	O
when	O
and	O
how	O
to	O
intervene	O
to	O
reduce	O
risk	O
.	O

